<!DOCTYPE html>

<html xmlns="http://www.w3.org/1999/xhtml">

<head>

<meta charset="utf-8" />
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />




<title>Clean script</title>

<script src="data:application/x-javascript;base64,/*! jQuery v1.11.3 | (c) 2005, 2015 jQuery Foundation, Inc. | jquery.org/license */
!function(a,b){"object"==typeof module&&"object"==typeof module.exports?module.exports=a.document?b(a,!0):function(a){if(!a.document)throw new Error("jQuery requires a window with a document");return b(a)}:b(a)}("undefined"!=typeof window?window:this,function(a,b){var c=[],d=c.slice,e=c.concat,f=c.push,g=c.indexOf,h={},i=h.toString,j=h.hasOwnProperty,k={},l="1.11.3",m=function(a,b){return new m.fn.init(a,b)},n=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g,o=/^-ms-/,p=/-([\da-z])/gi,q=function(a,b){return b.toUpperCase()};m.fn=m.prototype={jquery:l,constructor:m,selector:"",length:0,toArray:function(){return d.call(this)},get:function(a){return null!=a?0>a?this[a+this.length]:this[a]:d.call(this)},pushStack:function(a){var b=m.merge(this.constructor(),a);return b.prevObject=this,b.context=this.context,b},each:function(a,b){return m.each(this,a,b)},map:function(a){return this.pushStack(m.map(this,function(b,c){return a.call(b,c,b)}))},slice:function(){return this.pushStack(d.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},eq:function(a){var b=this.length,c=+a+(0>a?b:0);return this.pushStack(c>=0&&b>c?[this[c]]:[])},end:function(){return this.prevObject||this.constructor(null)},push:f,sort:c.sort,splice:c.splice},m.extend=m.fn.extend=function(){var a,b,c,d,e,f,g=arguments[0]||{},h=1,i=arguments.length,j=!1;for("boolean"==typeof g&&(j=g,g=arguments[h]||{},h++),"object"==typeof g||m.isFunction(g)||(g={}),h===i&&(g=this,h--);i>h;h++)if(null!=(e=arguments[h]))for(d in e)a=g[d],c=e[d],g!==c&&(j&&c&&(m.isPlainObject(c)||(b=m.isArray(c)))?(b?(b=!1,f=a&&m.isArray(a)?a:[]):f=a&&m.isPlainObject(a)?a:{},g[d]=m.extend(j,f,c)):void 0!==c&&(g[d]=c));return g},m.extend({expando:"jQuery"+(l+Math.random()).replace(/\D/g,""),isReady:!0,error:function(a){throw new Error(a)},noop:function(){},isFunction:function(a){return"function"===m.type(a)},isArray:Array.isArray||function(a){return"array"===m.type(a)},isWindow:function(a){return null!=a&&a==a.window},isNumeric:function(a){return!m.isArray(a)&&a-parseFloat(a)+1>=0},isEmptyObject:function(a){var b;for(b in a)return!1;return!0},isPlainObject:function(a){var b;if(!a||"object"!==m.type(a)||a.nodeType||m.isWindow(a))return!1;try{if(a.constructor&&!j.call(a,"constructor")&&!j.call(a.constructor.prototype,"isPrototypeOf"))return!1}catch(c){return!1}if(k.ownLast)for(b in a)return j.call(a,b);for(b in a);return void 0===b||j.call(a,b)},type:function(a){return null==a?a+"":"object"==typeof a||"function"==typeof a?h[i.call(a)]||"object":typeof a},globalEval:function(b){b&&m.trim(b)&&(a.execScript||function(b){a.eval.call(a,b)})(b)},camelCase:function(a){return a.replace(o,"ms-").replace(p,q)},nodeName:function(a,b){return a.nodeName&&a.nodeName.toLowerCase()===b.toLowerCase()},each:function(a,b,c){var d,e=0,f=a.length,g=r(a);if(c){if(g){for(;f>e;e++)if(d=b.apply(a[e],c),d===!1)break}else for(e in a)if(d=b.apply(a[e],c),d===!1)break}else if(g){for(;f>e;e++)if(d=b.call(a[e],e,a[e]),d===!1)break}else for(e in a)if(d=b.call(a[e],e,a[e]),d===!1)break;return a},trim:function(a){return null==a?"":(a+"").replace(n,"")},makeArray:function(a,b){var c=b||[];return null!=a&&(r(Object(a))?m.merge(c,"string"==typeof a?[a]:a):f.call(c,a)),c},inArray:function(a,b,c){var d;if(b){if(g)return g.call(b,a,c);for(d=b.length,c=c?0>c?Math.max(0,d+c):c:0;d>c;c++)if(c in b&&b[c]===a)return c}return-1},merge:function(a,b){var c=+b.length,d=0,e=a.length;while(c>d)a[e++]=b[d++];if(c!==c)while(void 0!==b[d])a[e++]=b[d++];return a.length=e,a},grep:function(a,b,c){for(var d,e=[],f=0,g=a.length,h=!c;g>f;f++)d=!b(a[f],f),d!==h&&e.push(a[f]);return e},map:function(a,b,c){var d,f=0,g=a.length,h=r(a),i=[];if(h)for(;g>f;f++)d=b(a[f],f,c),null!=d&&i.push(d);else for(f in a)d=b(a[f],f,c),null!=d&&i.push(d);return e.apply([],i)},guid:1,proxy:function(a,b){var c,e,f;return"string"==typeof b&&(f=a[b],b=a,a=f),m.isFunction(a)?(c=d.call(arguments,2),e=function(){return a.apply(b||this,c.concat(d.call(arguments)))},e.guid=a.guid=a.guid||m.guid++,e):void 0},now:function(){return+new Date},support:k}),m.each("Boolean Number String Function Array Date RegExp Object Error".split(" "),function(a,b){h["[object "+b+"]"]=b.toLowerCase()});function r(a){var b="length"in a&&a.length,c=m.type(a);return"function"===c||m.isWindow(a)?!1:1===a.nodeType&&b?!0:"array"===c||0===b||"number"==typeof b&&b>0&&b-1 in a}var s=function(a){var b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u="sizzle"+1*new Date,v=a.document,w=0,x=0,y=ha(),z=ha(),A=ha(),B=function(a,b){return a===b&&(l=!0),0},C=1<<31,D={}.hasOwnProperty,E=[],F=E.pop,G=E.push,H=E.push,I=E.slice,J=function(a,b){for(var c=0,d=a.length;d>c;c++)if(a[c]===b)return c;return-1},K="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",L="[\\x20\\t\\r\\n\\f]",M="(?:\\\\.|[\\w-]|[^\\x00-\\xa0])+",N=M.replace("w","w#"),O="\\["+L+"*("+M+")(?:"+L+"*([*^$|!~]?=)"+L+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+N+"))|)"+L+"*\\]",P=":("+M+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+O+")*)|.*)\\)|)",Q=new RegExp(L+"+","g"),R=new RegExp("^"+L+"+|((?:^|[^\\\\])(?:\\\\.)*)"+L+"+$","g"),S=new RegExp("^"+L+"*,"+L+"*"),T=new RegExp("^"+L+"*([>+~]|"+L+")"+L+"*"),U=new RegExp("="+L+"*([^\\]'\"]*?)"+L+"*\\]","g"),V=new RegExp(P),W=new RegExp("^"+N+"$"),X={ID:new RegExp("^#("+M+")"),CLASS:new RegExp("^\\.("+M+")"),TAG:new RegExp("^("+M.replace("w","w*")+")"),ATTR:new RegExp("^"+O),PSEUDO:new RegExp("^"+P),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+L+"*(even|odd|(([+-]|)(\\d*)n|)"+L+"*(?:([+-]|)"+L+"*(\\d+)|))"+L+"*\\)|)","i"),bool:new RegExp("^(?:"+K+")$","i"),needsContext:new RegExp("^"+L+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+L+"*((?:-\\d)?\\d*)"+L+"*\\)|)(?=[^-]|$)","i")},Y=/^(?:input|select|textarea|button)$/i,Z=/^h\d$/i,$=/^[^{]+\{\s*\[native \w/,_=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,aa=/[+~]/,ba=/'|\\/g,ca=new RegExp("\\\\([\\da-f]{1,6}"+L+"?|("+L+")|.)","ig"),da=function(a,b,c){var d="0x"+b-65536;return d!==d||c?b:0>d?String.fromCharCode(d+65536):String.fromCharCode(d>>10|55296,1023&d|56320)},ea=function(){m()};try{H.apply(E=I.call(v.childNodes),v.childNodes),E[v.childNodes.length].nodeType}catch(fa){H={apply:E.length?function(a,b){G.apply(a,I.call(b))}:function(a,b){var c=a.length,d=0;while(a[c++]=b[d++]);a.length=c-1}}}function ga(a,b,d,e){var f,h,j,k,l,o,r,s,w,x;if((b?b.ownerDocument||b:v)!==n&&m(b),b=b||n,d=d||[],k=b.nodeType,"string"!=typeof a||!a||1!==k&&9!==k&&11!==k)return d;if(!e&&p){if(11!==k&&(f=_.exec(a)))if(j=f[1]){if(9===k){if(h=b.getElementById(j),!h||!h.parentNode)return d;if(h.id===j)return d.push(h),d}else if(b.ownerDocument&&(h=b.ownerDocument.getElementById(j))&&t(b,h)&&h.id===j)return d.push(h),d}else{if(f[2])return H.apply(d,b.getElementsByTagName(a)),d;if((j=f[3])&&c.getElementsByClassName)return H.apply(d,b.getElementsByClassName(j)),d}if(c.qsa&&(!q||!q.test(a))){if(s=r=u,w=b,x=1!==k&&a,1===k&&"object"!==b.nodeName.toLowerCase()){o=g(a),(r=b.getAttribute("id"))?s=r.replace(ba,"\\$&"):b.setAttribute("id",s),s="[id='"+s+"'] ",l=o.length;while(l--)o[l]=s+ra(o[l]);w=aa.test(a)&&pa(b.parentNode)||b,x=o.join(",")}if(x)try{return H.apply(d,w.querySelectorAll(x)),d}catch(y){}finally{r||b.removeAttribute("id")}}}return i(a.replace(R,"$1"),b,d,e)}function ha(){var a=[];function b(c,e){return a.push(c+" ")>d.cacheLength&&delete b[a.shift()],b[c+" "]=e}return b}function ia(a){return a[u]=!0,a}function ja(a){var b=n.createElement("div");try{return!!a(b)}catch(c){return!1}finally{b.parentNode&&b.parentNode.removeChild(b),b=null}}function ka(a,b){var c=a.split("|"),e=a.length;while(e--)d.attrHandle[c[e]]=b}function la(a,b){var c=b&&a,d=c&&1===a.nodeType&&1===b.nodeType&&(~b.sourceIndex||C)-(~a.sourceIndex||C);if(d)return d;if(c)while(c=c.nextSibling)if(c===b)return-1;return a?1:-1}function ma(a){return function(b){var c=b.nodeName.toLowerCase();return"input"===c&&b.type===a}}function na(a){return function(b){var c=b.nodeName.toLowerCase();return("input"===c||"button"===c)&&b.type===a}}function oa(a){return ia(function(b){return b=+b,ia(function(c,d){var e,f=a([],c.length,b),g=f.length;while(g--)c[e=f[g]]&&(c[e]=!(d[e]=c[e]))})})}function pa(a){return a&&"undefined"!=typeof a.getElementsByTagName&&a}c=ga.support={},f=ga.isXML=function(a){var b=a&&(a.ownerDocument||a).documentElement;return b?"HTML"!==b.nodeName:!1},m=ga.setDocument=function(a){var b,e,g=a?a.ownerDocument||a:v;return g!==n&&9===g.nodeType&&g.documentElement?(n=g,o=g.documentElement,e=g.defaultView,e&&e!==e.top&&(e.addEventListener?e.addEventListener("unload",ea,!1):e.attachEvent&&e.attachEvent("onunload",ea)),p=!f(g),c.attributes=ja(function(a){return a.className="i",!a.getAttribute("className")}),c.getElementsByTagName=ja(function(a){return a.appendChild(g.createComment("")),!a.getElementsByTagName("*").length}),c.getElementsByClassName=$.test(g.getElementsByClassName),c.getById=ja(function(a){return o.appendChild(a).id=u,!g.getElementsByName||!g.getElementsByName(u).length}),c.getById?(d.find.ID=function(a,b){if("undefined"!=typeof b.getElementById&&p){var c=b.getElementById(a);return c&&c.parentNode?[c]:[]}},d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){return a.getAttribute("id")===b}}):(delete d.find.ID,d.filter.ID=function(a){var b=a.replace(ca,da);return function(a){var c="undefined"!=typeof a.getAttributeNode&&a.getAttributeNode("id");return c&&c.value===b}}),d.find.TAG=c.getElementsByTagName?function(a,b){return"undefined"!=typeof b.getElementsByTagName?b.getElementsByTagName(a):c.qsa?b.querySelectorAll(a):void 0}:function(a,b){var c,d=[],e=0,f=b.getElementsByTagName(a);if("*"===a){while(c=f[e++])1===c.nodeType&&d.push(c);return d}return f},d.find.CLASS=c.getElementsByClassName&&function(a,b){return p?b.getElementsByClassName(a):void 0},r=[],q=[],(c.qsa=$.test(g.querySelectorAll))&&(ja(function(a){o.appendChild(a).innerHTML="<a id='"+u+"'></a><select id='"+u+"-\f]' msallowcapture=''><option selected=''></option></select>",a.querySelectorAll("[msallowcapture^='']").length&&q.push("[*^$]="+L+"*(?:''|\"\")"),a.querySelectorAll("[selected]").length||q.push("\\["+L+"*(?:value|"+K+")"),a.querySelectorAll("[id~="+u+"-]").length||q.push("~="),a.querySelectorAll(":checked").length||q.push(":checked"),a.querySelectorAll("a#"+u+"+*").length||q.push(".#.+[+~]")}),ja(function(a){var b=g.createElement("input");b.setAttribute("type","hidden"),a.appendChild(b).setAttribute("name","D"),a.querySelectorAll("[name=d]").length&&q.push("name"+L+"*[*^$|!~]?="),a.querySelectorAll(":enabled").length||q.push(":enabled",":disabled"),a.querySelectorAll("*,:x"),q.push(",.*:")})),(c.matchesSelector=$.test(s=o.matches||o.webkitMatchesSelector||o.mozMatchesSelector||o.oMatchesSelector||o.msMatchesSelector))&&ja(function(a){c.disconnectedMatch=s.call(a,"div"),s.call(a,"[s!='']:x"),r.push("!=",P)}),q=q.length&&new RegExp(q.join("|")),r=r.length&&new RegExp(r.join("|")),b=$.test(o.compareDocumentPosition),t=b||$.test(o.contains)?function(a,b){var c=9===a.nodeType?a.documentElement:a,d=b&&b.parentNode;return a===d||!(!d||1!==d.nodeType||!(c.contains?c.contains(d):a.compareDocumentPosition&&16&a.compareDocumentPosition(d)))}:function(a,b){if(b)while(b=b.parentNode)if(b===a)return!0;return!1},B=b?function(a,b){if(a===b)return l=!0,0;var d=!a.compareDocumentPosition-!b.compareDocumentPosition;return d?d:(d=(a.ownerDocument||a)===(b.ownerDocument||b)?a.compareDocumentPosition(b):1,1&d||!c.sortDetached&&b.compareDocumentPosition(a)===d?a===g||a.ownerDocument===v&&t(v,a)?-1:b===g||b.ownerDocument===v&&t(v,b)?1:k?J(k,a)-J(k,b):0:4&d?-1:1)}:function(a,b){if(a===b)return l=!0,0;var c,d=0,e=a.parentNode,f=b.parentNode,h=[a],i=[b];if(!e||!f)return a===g?-1:b===g?1:e?-1:f?1:k?J(k,a)-J(k,b):0;if(e===f)return la(a,b);c=a;while(c=c.parentNode)h.unshift(c);c=b;while(c=c.parentNode)i.unshift(c);while(h[d]===i[d])d++;return d?la(h[d],i[d]):h[d]===v?-1:i[d]===v?1:0},g):n},ga.matches=function(a,b){return ga(a,null,null,b)},ga.matchesSelector=function(a,b){if((a.ownerDocument||a)!==n&&m(a),b=b.replace(U,"='$1']"),!(!c.matchesSelector||!p||r&&r.test(b)||q&&q.test(b)))try{var d=s.call(a,b);if(d||c.disconnectedMatch||a.document&&11!==a.document.nodeType)return d}catch(e){}return ga(b,n,null,[a]).length>0},ga.contains=function(a,b){return(a.ownerDocument||a)!==n&&m(a),t(a,b)},ga.attr=function(a,b){(a.ownerDocument||a)!==n&&m(a);var e=d.attrHandle[b.toLowerCase()],f=e&&D.call(d.attrHandle,b.toLowerCase())?e(a,b,!p):void 0;return void 0!==f?f:c.attributes||!p?a.getAttribute(b):(f=a.getAttributeNode(b))&&f.specified?f.value:null},ga.error=function(a){throw new Error("Syntax error, unrecognized expression: "+a)},ga.uniqueSort=function(a){var b,d=[],e=0,f=0;if(l=!c.detectDuplicates,k=!c.sortStable&&a.slice(0),a.sort(B),l){while(b=a[f++])b===a[f]&&(e=d.push(f));while(e--)a.splice(d[e],1)}return k=null,a},e=ga.getText=function(a){var b,c="",d=0,f=a.nodeType;if(f){if(1===f||9===f||11===f){if("string"==typeof a.textContent)return a.textContent;for(a=a.firstChild;a;a=a.nextSibling)c+=e(a)}else if(3===f||4===f)return a.nodeValue}else while(b=a[d++])c+=e(b);return c},d=ga.selectors={cacheLength:50,createPseudo:ia,match:X,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(a){return a[1]=a[1].replace(ca,da),a[3]=(a[3]||a[4]||a[5]||"").replace(ca,da),"~="===a[2]&&(a[3]=" "+a[3]+" "),a.slice(0,4)},CHILD:function(a){return a[1]=a[1].toLowerCase(),"nth"===a[1].slice(0,3)?(a[3]||ga.error(a[0]),a[4]=+(a[4]?a[5]+(a[6]||1):2*("even"===a[3]||"odd"===a[3])),a[5]=+(a[7]+a[8]||"odd"===a[3])):a[3]&&ga.error(a[0]),a},PSEUDO:function(a){var b,c=!a[6]&&a[2];return X.CHILD.test(a[0])?null:(a[3]?a[2]=a[4]||a[5]||"":c&&V.test(c)&&(b=g(c,!0))&&(b=c.indexOf(")",c.length-b)-c.length)&&(a[0]=a[0].slice(0,b),a[2]=c.slice(0,b)),a.slice(0,3))}},filter:{TAG:function(a){var b=a.replace(ca,da).toLowerCase();return"*"===a?function(){return!0}:function(a){return a.nodeName&&a.nodeName.toLowerCase()===b}},CLASS:function(a){var b=y[a+" "];return b||(b=new RegExp("(^|"+L+")"+a+"("+L+"|$)"))&&y(a,function(a){return b.test("string"==typeof a.className&&a.className||"undefined"!=typeof a.getAttribute&&a.getAttribute("class")||"")})},ATTR:function(a,b,c){return function(d){var e=ga.attr(d,a);return null==e?"!="===b:b?(e+="","="===b?e===c:"!="===b?e!==c:"^="===b?c&&0===e.indexOf(c):"*="===b?c&&e.indexOf(c)>-1:"$="===b?c&&e.slice(-c.length)===c:"~="===b?(" "+e.replace(Q," ")+" ").indexOf(c)>-1:"|="===b?e===c||e.slice(0,c.length+1)===c+"-":!1):!0}},CHILD:function(a,b,c,d,e){var f="nth"!==a.slice(0,3),g="last"!==a.slice(-4),h="of-type"===b;return 1===d&&0===e?function(a){return!!a.parentNode}:function(b,c,i){var j,k,l,m,n,o,p=f!==g?"nextSibling":"previousSibling",q=b.parentNode,r=h&&b.nodeName.toLowerCase(),s=!i&&!h;if(q){if(f){while(p){l=b;while(l=l[p])if(h?l.nodeName.toLowerCase()===r:1===l.nodeType)return!1;o=p="only"===a&&!o&&"nextSibling"}return!0}if(o=[g?q.firstChild:q.lastChild],g&&s){k=q[u]||(q[u]={}),j=k[a]||[],n=j[0]===w&&j[1],m=j[0]===w&&j[2],l=n&&q.childNodes[n];while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if(1===l.nodeType&&++m&&l===b){k[a]=[w,n,m];break}}else if(s&&(j=(b[u]||(b[u]={}))[a])&&j[0]===w)m=j[1];else while(l=++n&&l&&l[p]||(m=n=0)||o.pop())if((h?l.nodeName.toLowerCase()===r:1===l.nodeType)&&++m&&(s&&((l[u]||(l[u]={}))[a]=[w,m]),l===b))break;return m-=e,m===d||m%d===0&&m/d>=0}}},PSEUDO:function(a,b){var c,e=d.pseudos[a]||d.setFilters[a.toLowerCase()]||ga.error("unsupported pseudo: "+a);return e[u]?e(b):e.length>1?(c=[a,a,"",b],d.setFilters.hasOwnProperty(a.toLowerCase())?ia(function(a,c){var d,f=e(a,b),g=f.length;while(g--)d=J(a,f[g]),a[d]=!(c[d]=f[g])}):function(a){return e(a,0,c)}):e}},pseudos:{not:ia(function(a){var b=[],c=[],d=h(a.replace(R,"$1"));return d[u]?ia(function(a,b,c,e){var f,g=d(a,null,e,[]),h=a.length;while(h--)(f=g[h])&&(a[h]=!(b[h]=f))}):function(a,e,f){return b[0]=a,d(b,null,f,c),b[0]=null,!c.pop()}}),has:ia(function(a){return function(b){return ga(a,b).length>0}}),contains:ia(function(a){return a=a.replace(ca,da),function(b){return(b.textContent||b.innerText||e(b)).indexOf(a)>-1}}),lang:ia(function(a){return W.test(a||"")||ga.error("unsupported lang: "+a),a=a.replace(ca,da).toLowerCase(),function(b){var c;do if(c=p?b.lang:b.getAttribute("xml:lang")||b.getAttribute("lang"))return c=c.toLowerCase(),c===a||0===c.indexOf(a+"-");while((b=b.parentNode)&&1===b.nodeType);return!1}}),target:function(b){var c=a.location&&a.location.hash;return c&&c.slice(1)===b.id},root:function(a){return a===o},focus:function(a){return a===n.activeElement&&(!n.hasFocus||n.hasFocus())&&!!(a.type||a.href||~a.tabIndex)},enabled:function(a){return a.disabled===!1},disabled:function(a){return a.disabled===!0},checked:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&!!a.checked||"option"===b&&!!a.selected},selected:function(a){return a.parentNode&&a.parentNode.selectedIndex,a.selected===!0},empty:function(a){for(a=a.firstChild;a;a=a.nextSibling)if(a.nodeType<6)return!1;return!0},parent:function(a){return!d.pseudos.empty(a)},header:function(a){return Z.test(a.nodeName)},input:function(a){return Y.test(a.nodeName)},button:function(a){var b=a.nodeName.toLowerCase();return"input"===b&&"button"===a.type||"button"===b},text:function(a){var b;return"input"===a.nodeName.toLowerCase()&&"text"===a.type&&(null==(b=a.getAttribute("type"))||"text"===b.toLowerCase())},first:oa(function(){return[0]}),last:oa(function(a,b){return[b-1]}),eq:oa(function(a,b,c){return[0>c?c+b:c]}),even:oa(function(a,b){for(var c=0;b>c;c+=2)a.push(c);return a}),odd:oa(function(a,b){for(var c=1;b>c;c+=2)a.push(c);return a}),lt:oa(function(a,b,c){for(var d=0>c?c+b:c;--d>=0;)a.push(d);return a}),gt:oa(function(a,b,c){for(var d=0>c?c+b:c;++d<b;)a.push(d);return a})}},d.pseudos.nth=d.pseudos.eq;for(b in{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})d.pseudos[b]=ma(b);for(b in{submit:!0,reset:!0})d.pseudos[b]=na(b);function qa(){}qa.prototype=d.filters=d.pseudos,d.setFilters=new qa,g=ga.tokenize=function(a,b){var c,e,f,g,h,i,j,k=z[a+" "];if(k)return b?0:k.slice(0);h=a,i=[],j=d.preFilter;while(h){(!c||(e=S.exec(h)))&&(e&&(h=h.slice(e[0].length)||h),i.push(f=[])),c=!1,(e=T.exec(h))&&(c=e.shift(),f.push({value:c,type:e[0].replace(R," ")}),h=h.slice(c.length));for(g in d.filter)!(e=X[g].exec(h))||j[g]&&!(e=j[g](e))||(c=e.shift(),f.push({value:c,type:g,matches:e}),h=h.slice(c.length));if(!c)break}return b?h.length:h?ga.error(a):z(a,i).slice(0)};function ra(a){for(var b=0,c=a.length,d="";c>b;b++)d+=a[b].value;return d}function sa(a,b,c){var d=b.dir,e=c&&"parentNode"===d,f=x++;return b.first?function(b,c,f){while(b=b[d])if(1===b.nodeType||e)return a(b,c,f)}:function(b,c,g){var h,i,j=[w,f];if(g){while(b=b[d])if((1===b.nodeType||e)&&a(b,c,g))return!0}else while(b=b[d])if(1===b.nodeType||e){if(i=b[u]||(b[u]={}),(h=i[d])&&h[0]===w&&h[1]===f)return j[2]=h[2];if(i[d]=j,j[2]=a(b,c,g))return!0}}}function ta(a){return a.length>1?function(b,c,d){var e=a.length;while(e--)if(!a[e](b,c,d))return!1;return!0}:a[0]}function ua(a,b,c){for(var d=0,e=b.length;e>d;d++)ga(a,b[d],c);return c}function va(a,b,c,d,e){for(var f,g=[],h=0,i=a.length,j=null!=b;i>h;h++)(f=a[h])&&(!c||c(f,d,e))&&(g.push(f),j&&b.push(h));return g}function wa(a,b,c,d,e,f){return d&&!d[u]&&(d=wa(d)),e&&!e[u]&&(e=wa(e,f)),ia(function(f,g,h,i){var j,k,l,m=[],n=[],o=g.length,p=f||ua(b||"*",h.nodeType?[h]:h,[]),q=!a||!f&&b?p:va(p,m,a,h,i),r=c?e||(f?a:o||d)?[]:g:q;if(c&&c(q,r,h,i),d){j=va(r,n),d(j,[],h,i),k=j.length;while(k--)(l=j[k])&&(r[n[k]]=!(q[n[k]]=l))}if(f){if(e||a){if(e){j=[],k=r.length;while(k--)(l=r[k])&&j.push(q[k]=l);e(null,r=[],j,i)}k=r.length;while(k--)(l=r[k])&&(j=e?J(f,l):m[k])>-1&&(f[j]=!(g[j]=l))}}else r=va(r===g?r.splice(o,r.length):r),e?e(null,g,r,i):H.apply(g,r)})}function xa(a){for(var b,c,e,f=a.length,g=d.relative[a[0].type],h=g||d.relative[" "],i=g?1:0,k=sa(function(a){return a===b},h,!0),l=sa(function(a){return J(b,a)>-1},h,!0),m=[function(a,c,d){var e=!g&&(d||c!==j)||((b=c).nodeType?k(a,c,d):l(a,c,d));return b=null,e}];f>i;i++)if(c=d.relative[a[i].type])m=[sa(ta(m),c)];else{if(c=d.filter[a[i].type].apply(null,a[i].matches),c[u]){for(e=++i;f>e;e++)if(d.relative[a[e].type])break;return wa(i>1&&ta(m),i>1&&ra(a.slice(0,i-1).concat({value:" "===a[i-2].type?"*":""})).replace(R,"$1"),c,e>i&&xa(a.slice(i,e)),f>e&&xa(a=a.slice(e)),f>e&&ra(a))}m.push(c)}return ta(m)}function ya(a,b){var c=b.length>0,e=a.length>0,f=function(f,g,h,i,k){var l,m,o,p=0,q="0",r=f&&[],s=[],t=j,u=f||e&&d.find.TAG("*",k),v=w+=null==t?1:Math.random()||.1,x=u.length;for(k&&(j=g!==n&&g);q!==x&&null!=(l=u[q]);q++){if(e&&l){m=0;while(o=a[m++])if(o(l,g,h)){i.push(l);break}k&&(w=v)}c&&((l=!o&&l)&&p--,f&&r.push(l))}if(p+=q,c&&q!==p){m=0;while(o=b[m++])o(r,s,g,h);if(f){if(p>0)while(q--)r[q]||s[q]||(s[q]=F.call(i));s=va(s)}H.apply(i,s),k&&!f&&s.length>0&&p+b.length>1&&ga.uniqueSort(i)}return k&&(w=v,j=t),r};return c?ia(f):f}return h=ga.compile=function(a,b){var c,d=[],e=[],f=A[a+" "];if(!f){b||(b=g(a)),c=b.length;while(c--)f=xa(b[c]),f[u]?d.push(f):e.push(f);f=A(a,ya(e,d)),f.selector=a}return f},i=ga.select=function(a,b,e,f){var i,j,k,l,m,n="function"==typeof a&&a,o=!f&&g(a=n.selector||a);if(e=e||[],1===o.length){if(j=o[0]=o[0].slice(0),j.length>2&&"ID"===(k=j[0]).type&&c.getById&&9===b.nodeType&&p&&d.relative[j[1].type]){if(b=(d.find.ID(k.matches[0].replace(ca,da),b)||[])[0],!b)return e;n&&(b=b.parentNode),a=a.slice(j.shift().value.length)}i=X.needsContext.test(a)?0:j.length;while(i--){if(k=j[i],d.relative[l=k.type])break;if((m=d.find[l])&&(f=m(k.matches[0].replace(ca,da),aa.test(j[0].type)&&pa(b.parentNode)||b))){if(j.splice(i,1),a=f.length&&ra(j),!a)return H.apply(e,f),e;break}}}return(n||h(a,o))(f,b,!p,e,aa.test(a)&&pa(b.parentNode)||b),e},c.sortStable=u.split("").sort(B).join("")===u,c.detectDuplicates=!!l,m(),c.sortDetached=ja(function(a){return 1&a.compareDocumentPosition(n.createElement("div"))}),ja(function(a){return a.innerHTML="<a href='#'></a>","#"===a.firstChild.getAttribute("href")})||ka("type|href|height|width",function(a,b,c){return c?void 0:a.getAttribute(b,"type"===b.toLowerCase()?1:2)}),c.attributes&&ja(function(a){return a.innerHTML="<input/>",a.firstChild.setAttribute("value",""),""===a.firstChild.getAttribute("value")})||ka("value",function(a,b,c){return c||"input"!==a.nodeName.toLowerCase()?void 0:a.defaultValue}),ja(function(a){return null==a.getAttribute("disabled")})||ka(K,function(a,b,c){var d;return c?void 0:a[b]===!0?b.toLowerCase():(d=a.getAttributeNode(b))&&d.specified?d.value:null}),ga}(a);m.find=s,m.expr=s.selectors,m.expr[":"]=m.expr.pseudos,m.unique=s.uniqueSort,m.text=s.getText,m.isXMLDoc=s.isXML,m.contains=s.contains;var t=m.expr.match.needsContext,u=/^<(\w+)\s*\/?>(?:<\/\1>|)$/,v=/^.[^:#\[\.,]*$/;function w(a,b,c){if(m.isFunction(b))return m.grep(a,function(a,d){return!!b.call(a,d,a)!==c});if(b.nodeType)return m.grep(a,function(a){return a===b!==c});if("string"==typeof b){if(v.test(b))return m.filter(b,a,c);b=m.filter(b,a)}return m.grep(a,function(a){return m.inArray(a,b)>=0!==c})}m.filter=function(a,b,c){var d=b[0];return c&&(a=":not("+a+")"),1===b.length&&1===d.nodeType?m.find.matchesSelector(d,a)?[d]:[]:m.find.matches(a,m.grep(b,function(a){return 1===a.nodeType}))},m.fn.extend({find:function(a){var b,c=[],d=this,e=d.length;if("string"!=typeof a)return this.pushStack(m(a).filter(function(){for(b=0;e>b;b++)if(m.contains(d[b],this))return!0}));for(b=0;e>b;b++)m.find(a,d[b],c);return c=this.pushStack(e>1?m.unique(c):c),c.selector=this.selector?this.selector+" "+a:a,c},filter:function(a){return this.pushStack(w(this,a||[],!1))},not:function(a){return this.pushStack(w(this,a||[],!0))},is:function(a){return!!w(this,"string"==typeof a&&t.test(a)?m(a):a||[],!1).length}});var x,y=a.document,z=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]*))$/,A=m.fn.init=function(a,b){var c,d;if(!a)return this;if("string"==typeof a){if(c="<"===a.charAt(0)&&">"===a.charAt(a.length-1)&&a.length>=3?[null,a,null]:z.exec(a),!c||!c[1]&&b)return!b||b.jquery?(b||x).find(a):this.constructor(b).find(a);if(c[1]){if(b=b instanceof m?b[0]:b,m.merge(this,m.parseHTML(c[1],b&&b.nodeType?b.ownerDocument||b:y,!0)),u.test(c[1])&&m.isPlainObject(b))for(c in b)m.isFunction(this[c])?this[c](b[c]):this.attr(c,b[c]);return this}if(d=y.getElementById(c[2]),d&&d.parentNode){if(d.id!==c[2])return x.find(a);this.length=1,this[0]=d}return this.context=y,this.selector=a,this}return a.nodeType?(this.context=this[0]=a,this.length=1,this):m.isFunction(a)?"undefined"!=typeof x.ready?x.ready(a):a(m):(void 0!==a.selector&&(this.selector=a.selector,this.context=a.context),m.makeArray(a,this))};A.prototype=m.fn,x=m(y);var B=/^(?:parents|prev(?:Until|All))/,C={children:!0,contents:!0,next:!0,prev:!0};m.extend({dir:function(a,b,c){var d=[],e=a[b];while(e&&9!==e.nodeType&&(void 0===c||1!==e.nodeType||!m(e).is(c)))1===e.nodeType&&d.push(e),e=e[b];return d},sibling:function(a,b){for(var c=[];a;a=a.nextSibling)1===a.nodeType&&a!==b&&c.push(a);return c}}),m.fn.extend({has:function(a){var b,c=m(a,this),d=c.length;return this.filter(function(){for(b=0;d>b;b++)if(m.contains(this,c[b]))return!0})},closest:function(a,b){for(var c,d=0,e=this.length,f=[],g=t.test(a)||"string"!=typeof a?m(a,b||this.context):0;e>d;d++)for(c=this[d];c&&c!==b;c=c.parentNode)if(c.nodeType<11&&(g?g.index(c)>-1:1===c.nodeType&&m.find.matchesSelector(c,a))){f.push(c);break}return this.pushStack(f.length>1?m.unique(f):f)},index:function(a){return a?"string"==typeof a?m.inArray(this[0],m(a)):m.inArray(a.jquery?a[0]:a,this):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(a,b){return this.pushStack(m.unique(m.merge(this.get(),m(a,b))))},addBack:function(a){return this.add(null==a?this.prevObject:this.prevObject.filter(a))}});function D(a,b){do a=a[b];while(a&&1!==a.nodeType);return a}m.each({parent:function(a){var b=a.parentNode;return b&&11!==b.nodeType?b:null},parents:function(a){return m.dir(a,"parentNode")},parentsUntil:function(a,b,c){return m.dir(a,"parentNode",c)},next:function(a){return D(a,"nextSibling")},prev:function(a){return D(a,"previousSibling")},nextAll:function(a){return m.dir(a,"nextSibling")},prevAll:function(a){return m.dir(a,"previousSibling")},nextUntil:function(a,b,c){return m.dir(a,"nextSibling",c)},prevUntil:function(a,b,c){return m.dir(a,"previousSibling",c)},siblings:function(a){return m.sibling((a.parentNode||{}).firstChild,a)},children:function(a){return m.sibling(a.firstChild)},contents:function(a){return m.nodeName(a,"iframe")?a.contentDocument||a.contentWindow.document:m.merge([],a.childNodes)}},function(a,b){m.fn[a]=function(c,d){var e=m.map(this,b,c);return"Until"!==a.slice(-5)&&(d=c),d&&"string"==typeof d&&(e=m.filter(d,e)),this.length>1&&(C[a]||(e=m.unique(e)),B.test(a)&&(e=e.reverse())),this.pushStack(e)}});var E=/\S+/g,F={};function G(a){var b=F[a]={};return m.each(a.match(E)||[],function(a,c){b[c]=!0}),b}m.Callbacks=function(a){a="string"==typeof a?F[a]||G(a):m.extend({},a);var b,c,d,e,f,g,h=[],i=!a.once&&[],j=function(l){for(c=a.memory&&l,d=!0,f=g||0,g=0,e=h.length,b=!0;h&&e>f;f++)if(h[f].apply(l[0],l[1])===!1&&a.stopOnFalse){c=!1;break}b=!1,h&&(i?i.length&&j(i.shift()):c?h=[]:k.disable())},k={add:function(){if(h){var d=h.length;!function f(b){m.each(b,function(b,c){var d=m.type(c);"function"===d?a.unique&&k.has(c)||h.push(c):c&&c.length&&"string"!==d&&f(c)})}(arguments),b?e=h.length:c&&(g=d,j(c))}return this},remove:function(){return h&&m.each(arguments,function(a,c){var d;while((d=m.inArray(c,h,d))>-1)h.splice(d,1),b&&(e>=d&&e--,f>=d&&f--)}),this},has:function(a){return a?m.inArray(a,h)>-1:!(!h||!h.length)},empty:function(){return h=[],e=0,this},disable:function(){return h=i=c=void 0,this},disabled:function(){return!h},lock:function(){return i=void 0,c||k.disable(),this},locked:function(){return!i},fireWith:function(a,c){return!h||d&&!i||(c=c||[],c=[a,c.slice?c.slice():c],b?i.push(c):j(c)),this},fire:function(){return k.fireWith(this,arguments),this},fired:function(){return!!d}};return k},m.extend({Deferred:function(a){var b=[["resolve","done",m.Callbacks("once memory"),"resolved"],["reject","fail",m.Callbacks("once memory"),"rejected"],["notify","progress",m.Callbacks("memory")]],c="pending",d={state:function(){return c},always:function(){return e.done(arguments).fail(arguments),this},then:function(){var a=arguments;return m.Deferred(function(c){m.each(b,function(b,f){var g=m.isFunction(a[b])&&a[b];e[f[1]](function(){var a=g&&g.apply(this,arguments);a&&m.isFunction(a.promise)?a.promise().done(c.resolve).fail(c.reject).progress(c.notify):c[f[0]+"With"](this===d?c.promise():this,g?[a]:arguments)})}),a=null}).promise()},promise:function(a){return null!=a?m.extend(a,d):d}},e={};return d.pipe=d.then,m.each(b,function(a,f){var g=f[2],h=f[3];d[f[1]]=g.add,h&&g.add(function(){c=h},b[1^a][2].disable,b[2][2].lock),e[f[0]]=function(){return e[f[0]+"With"](this===e?d:this,arguments),this},e[f[0]+"With"]=g.fireWith}),d.promise(e),a&&a.call(e,e),e},when:function(a){var b=0,c=d.call(arguments),e=c.length,f=1!==e||a&&m.isFunction(a.promise)?e:0,g=1===f?a:m.Deferred(),h=function(a,b,c){return function(e){b[a]=this,c[a]=arguments.length>1?d.call(arguments):e,c===i?g.notifyWith(b,c):--f||g.resolveWith(b,c)}},i,j,k;if(e>1)for(i=new Array(e),j=new Array(e),k=new Array(e);e>b;b++)c[b]&&m.isFunction(c[b].promise)?c[b].promise().done(h(b,k,c)).fail(g.reject).progress(h(b,j,i)):--f;return f||g.resolveWith(k,c),g.promise()}});var H;m.fn.ready=function(a){return m.ready.promise().done(a),this},m.extend({isReady:!1,readyWait:1,holdReady:function(a){a?m.readyWait++:m.ready(!0)},ready:function(a){if(a===!0?!--m.readyWait:!m.isReady){if(!y.body)return setTimeout(m.ready);m.isReady=!0,a!==!0&&--m.readyWait>0||(H.resolveWith(y,[m]),m.fn.triggerHandler&&(m(y).triggerHandler("ready"),m(y).off("ready")))}}});function I(){y.addEventListener?(y.removeEventListener("DOMContentLoaded",J,!1),a.removeEventListener("load",J,!1)):(y.detachEvent("onreadystatechange",J),a.detachEvent("onload",J))}function J(){(y.addEventListener||"load"===event.type||"complete"===y.readyState)&&(I(),m.ready())}m.ready.promise=function(b){if(!H)if(H=m.Deferred(),"complete"===y.readyState)setTimeout(m.ready);else if(y.addEventListener)y.addEventListener("DOMContentLoaded",J,!1),a.addEventListener("load",J,!1);else{y.attachEvent("onreadystatechange",J),a.attachEvent("onload",J);var c=!1;try{c=null==a.frameElement&&y.documentElement}catch(d){}c&&c.doScroll&&!function e(){if(!m.isReady){try{c.doScroll("left")}catch(a){return setTimeout(e,50)}I(),m.ready()}}()}return H.promise(b)};var K="undefined",L;for(L in m(k))break;k.ownLast="0"!==L,k.inlineBlockNeedsLayout=!1,m(function(){var a,b,c,d;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="display:inline;margin:0;border:0;padding:1px;width:1px;zoom:1",k.inlineBlockNeedsLayout=a=3===b.offsetWidth,a&&(c.style.zoom=1)),c.removeChild(d))}),function(){var a=y.createElement("div");if(null==k.deleteExpando){k.deleteExpando=!0;try{delete a.test}catch(b){k.deleteExpando=!1}}a=null}(),m.acceptData=function(a){var b=m.noData[(a.nodeName+" ").toLowerCase()],c=+a.nodeType||1;return 1!==c&&9!==c?!1:!b||b!==!0&&a.getAttribute("classid")===b};var M=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,N=/([A-Z])/g;function O(a,b,c){if(void 0===c&&1===a.nodeType){var d="data-"+b.replace(N,"-$1").toLowerCase();if(c=a.getAttribute(d),"string"==typeof c){try{c="true"===c?!0:"false"===c?!1:"null"===c?null:+c+""===c?+c:M.test(c)?m.parseJSON(c):c}catch(e){}m.data(a,b,c)}else c=void 0}return c}function P(a){var b;for(b in a)if(("data"!==b||!m.isEmptyObject(a[b]))&&"toJSON"!==b)return!1;

return!0}function Q(a,b,d,e){if(m.acceptData(a)){var f,g,h=m.expando,i=a.nodeType,j=i?m.cache:a,k=i?a[h]:a[h]&&h;if(k&&j[k]&&(e||j[k].data)||void 0!==d||"string"!=typeof b)return k||(k=i?a[h]=c.pop()||m.guid++:h),j[k]||(j[k]=i?{}:{toJSON:m.noop}),("object"==typeof b||"function"==typeof b)&&(e?j[k]=m.extend(j[k],b):j[k].data=m.extend(j[k].data,b)),g=j[k],e||(g.data||(g.data={}),g=g.data),void 0!==d&&(g[m.camelCase(b)]=d),"string"==typeof b?(f=g[b],null==f&&(f=g[m.camelCase(b)])):f=g,f}}function R(a,b,c){if(m.acceptData(a)){var d,e,f=a.nodeType,g=f?m.cache:a,h=f?a[m.expando]:m.expando;if(g[h]){if(b&&(d=c?g[h]:g[h].data)){m.isArray(b)?b=b.concat(m.map(b,m.camelCase)):b in d?b=[b]:(b=m.camelCase(b),b=b in d?[b]:b.split(" ")),e=b.length;while(e--)delete d[b[e]];if(c?!P(d):!m.isEmptyObject(d))return}(c||(delete g[h].data,P(g[h])))&&(f?m.cleanData([a],!0):k.deleteExpando||g!=g.window?delete g[h]:g[h]=null)}}}m.extend({cache:{},noData:{"applet ":!0,"embed ":!0,"object ":"clsid:D27CDB6E-AE6D-11cf-96B8-444553540000"},hasData:function(a){return a=a.nodeType?m.cache[a[m.expando]]:a[m.expando],!!a&&!P(a)},data:function(a,b,c){return Q(a,b,c)},removeData:function(a,b){return R(a,b)},_data:function(a,b,c){return Q(a,b,c,!0)},_removeData:function(a,b){return R(a,b,!0)}}),m.fn.extend({data:function(a,b){var c,d,e,f=this[0],g=f&&f.attributes;if(void 0===a){if(this.length&&(e=m.data(f),1===f.nodeType&&!m._data(f,"parsedAttrs"))){c=g.length;while(c--)g[c]&&(d=g[c].name,0===d.indexOf("data-")&&(d=m.camelCase(d.slice(5)),O(f,d,e[d])));m._data(f,"parsedAttrs",!0)}return e}return"object"==typeof a?this.each(function(){m.data(this,a)}):arguments.length>1?this.each(function(){m.data(this,a,b)}):f?O(f,a,m.data(f,a)):void 0},removeData:function(a){return this.each(function(){m.removeData(this,a)})}}),m.extend({queue:function(a,b,c){var d;return a?(b=(b||"fx")+"queue",d=m._data(a,b),c&&(!d||m.isArray(c)?d=m._data(a,b,m.makeArray(c)):d.push(c)),d||[]):void 0},dequeue:function(a,b){b=b||"fx";var c=m.queue(a,b),d=c.length,e=c.shift(),f=m._queueHooks(a,b),g=function(){m.dequeue(a,b)};"inprogress"===e&&(e=c.shift(),d--),e&&("fx"===b&&c.unshift("inprogress"),delete f.stop,e.call(a,g,f)),!d&&f&&f.empty.fire()},_queueHooks:function(a,b){var c=b+"queueHooks";return m._data(a,c)||m._data(a,c,{empty:m.Callbacks("once memory").add(function(){m._removeData(a,b+"queue"),m._removeData(a,c)})})}}),m.fn.extend({queue:function(a,b){var c=2;return"string"!=typeof a&&(b=a,a="fx",c--),arguments.length<c?m.queue(this[0],a):void 0===b?this:this.each(function(){var c=m.queue(this,a,b);m._queueHooks(this,a),"fx"===a&&"inprogress"!==c[0]&&m.dequeue(this,a)})},dequeue:function(a){return this.each(function(){m.dequeue(this,a)})},clearQueue:function(a){return this.queue(a||"fx",[])},promise:function(a,b){var c,d=1,e=m.Deferred(),f=this,g=this.length,h=function(){--d||e.resolveWith(f,[f])};"string"!=typeof a&&(b=a,a=void 0),a=a||"fx";while(g--)c=m._data(f[g],a+"queueHooks"),c&&c.empty&&(d++,c.empty.add(h));return h(),e.promise(b)}});var S=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,T=["Top","Right","Bottom","Left"],U=function(a,b){return a=b||a,"none"===m.css(a,"display")||!m.contains(a.ownerDocument,a)},V=m.access=function(a,b,c,d,e,f,g){var h=0,i=a.length,j=null==c;if("object"===m.type(c)){e=!0;for(h in c)m.access(a,b,h,c[h],!0,f,g)}else if(void 0!==d&&(e=!0,m.isFunction(d)||(g=!0),j&&(g?(b.call(a,d),b=null):(j=b,b=function(a,b,c){return j.call(m(a),c)})),b))for(;i>h;h++)b(a[h],c,g?d:d.call(a[h],h,b(a[h],c)));return e?a:j?b.call(a):i?b(a[0],c):f},W=/^(?:checkbox|radio)$/i;!function(){var a=y.createElement("input"),b=y.createElement("div"),c=y.createDocumentFragment();if(b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",k.leadingWhitespace=3===b.firstChild.nodeType,k.tbody=!b.getElementsByTagName("tbody").length,k.htmlSerialize=!!b.getElementsByTagName("link").length,k.html5Clone="<:nav></:nav>"!==y.createElement("nav").cloneNode(!0).outerHTML,a.type="checkbox",a.checked=!0,c.appendChild(a),k.appendChecked=a.checked,b.innerHTML="<textarea>x</textarea>",k.noCloneChecked=!!b.cloneNode(!0).lastChild.defaultValue,c.appendChild(b),b.innerHTML="<input type='radio' checked='checked' name='t'/>",k.checkClone=b.cloneNode(!0).cloneNode(!0).lastChild.checked,k.noCloneEvent=!0,b.attachEvent&&(b.attachEvent("onclick",function(){k.noCloneEvent=!1}),b.cloneNode(!0).click()),null==k.deleteExpando){k.deleteExpando=!0;try{delete b.test}catch(d){k.deleteExpando=!1}}}(),function(){var b,c,d=y.createElement("div");for(b in{submit:!0,change:!0,focusin:!0})c="on"+b,(k[b+"Bubbles"]=c in a)||(d.setAttribute(c,"t"),k[b+"Bubbles"]=d.attributes[c].expando===!1);d=null}();var X=/^(?:input|select|textarea)$/i,Y=/^key/,Z=/^(?:mouse|pointer|contextmenu)|click/,$=/^(?:focusinfocus|focusoutblur)$/,_=/^([^.]*)(?:\.(.+)|)$/;function aa(){return!0}function ba(){return!1}function ca(){try{return y.activeElement}catch(a){}}m.event={global:{},add:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m._data(a);if(r){c.handler&&(i=c,c=i.handler,e=i.selector),c.guid||(c.guid=m.guid++),(g=r.events)||(g=r.events={}),(k=r.handle)||(k=r.handle=function(a){return typeof m===K||a&&m.event.triggered===a.type?void 0:m.event.dispatch.apply(k.elem,arguments)},k.elem=a),b=(b||"").match(E)||[""],h=b.length;while(h--)f=_.exec(b[h])||[],o=q=f[1],p=(f[2]||"").split(".").sort(),o&&(j=m.event.special[o]||{},o=(e?j.delegateType:j.bindType)||o,j=m.event.special[o]||{},l=m.extend({type:o,origType:q,data:d,handler:c,guid:c.guid,selector:e,needsContext:e&&m.expr.match.needsContext.test(e),namespace:p.join(".")},i),(n=g[o])||(n=g[o]=[],n.delegateCount=0,j.setup&&j.setup.call(a,d,p,k)!==!1||(a.addEventListener?a.addEventListener(o,k,!1):a.attachEvent&&a.attachEvent("on"+o,k))),j.add&&(j.add.call(a,l),l.handler.guid||(l.handler.guid=c.guid)),e?n.splice(n.delegateCount++,0,l):n.push(l),m.event.global[o]=!0);a=null}},remove:function(a,b,c,d,e){var f,g,h,i,j,k,l,n,o,p,q,r=m.hasData(a)&&m._data(a);if(r&&(k=r.events)){b=(b||"").match(E)||[""],j=b.length;while(j--)if(h=_.exec(b[j])||[],o=q=h[1],p=(h[2]||"").split(".").sort(),o){l=m.event.special[o]||{},o=(d?l.delegateType:l.bindType)||o,n=k[o]||[],h=h[2]&&new RegExp("(^|\\.)"+p.join("\\.(?:.*\\.|)")+"(\\.|$)"),i=f=n.length;while(f--)g=n[f],!e&&q!==g.origType||c&&c.guid!==g.guid||h&&!h.test(g.namespace)||d&&d!==g.selector&&("**"!==d||!g.selector)||(n.splice(f,1),g.selector&&n.delegateCount--,l.remove&&l.remove.call(a,g));i&&!n.length&&(l.teardown&&l.teardown.call(a,p,r.handle)!==!1||m.removeEvent(a,o,r.handle),delete k[o])}else for(o in k)m.event.remove(a,o+b[j],c,d,!0);m.isEmptyObject(k)&&(delete r.handle,m._removeData(a,"events"))}},trigger:function(b,c,d,e){var f,g,h,i,k,l,n,o=[d||y],p=j.call(b,"type")?b.type:b,q=j.call(b,"namespace")?b.namespace.split("."):[];if(h=l=d=d||y,3!==d.nodeType&&8!==d.nodeType&&!$.test(p+m.event.triggered)&&(p.indexOf(".")>=0&&(q=p.split("."),p=q.shift(),q.sort()),g=p.indexOf(":")<0&&"on"+p,b=b[m.expando]?b:new m.Event(p,"object"==typeof b&&b),b.isTrigger=e?2:3,b.namespace=q.join("."),b.namespace_re=b.namespace?new RegExp("(^|\\.)"+q.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,b.result=void 0,b.target||(b.target=d),c=null==c?[b]:m.makeArray(c,[b]),k=m.event.special[p]||{},e||!k.trigger||k.trigger.apply(d,c)!==!1)){if(!e&&!k.noBubble&&!m.isWindow(d)){for(i=k.delegateType||p,$.test(i+p)||(h=h.parentNode);h;h=h.parentNode)o.push(h),l=h;l===(d.ownerDocument||y)&&o.push(l.defaultView||l.parentWindow||a)}n=0;while((h=o[n++])&&!b.isPropagationStopped())b.type=n>1?i:k.bindType||p,f=(m._data(h,"events")||{})[b.type]&&m._data(h,"handle"),f&&f.apply(h,c),f=g&&h[g],f&&f.apply&&m.acceptData(h)&&(b.result=f.apply(h,c),b.result===!1&&b.preventDefault());if(b.type=p,!e&&!b.isDefaultPrevented()&&(!k._default||k._default.apply(o.pop(),c)===!1)&&m.acceptData(d)&&g&&d[p]&&!m.isWindow(d)){l=d[g],l&&(d[g]=null),m.event.triggered=p;try{d[p]()}catch(r){}m.event.triggered=void 0,l&&(d[g]=l)}return b.result}},dispatch:function(a){a=m.event.fix(a);var b,c,e,f,g,h=[],i=d.call(arguments),j=(m._data(this,"events")||{})[a.type]||[],k=m.event.special[a.type]||{};if(i[0]=a,a.delegateTarget=this,!k.preDispatch||k.preDispatch.call(this,a)!==!1){h=m.event.handlers.call(this,a,j),b=0;while((f=h[b++])&&!a.isPropagationStopped()){a.currentTarget=f.elem,g=0;while((e=f.handlers[g++])&&!a.isImmediatePropagationStopped())(!a.namespace_re||a.namespace_re.test(e.namespace))&&(a.handleObj=e,a.data=e.data,c=((m.event.special[e.origType]||{}).handle||e.handler).apply(f.elem,i),void 0!==c&&(a.result=c)===!1&&(a.preventDefault(),a.stopPropagation()))}return k.postDispatch&&k.postDispatch.call(this,a),a.result}},handlers:function(a,b){var c,d,e,f,g=[],h=b.delegateCount,i=a.target;if(h&&i.nodeType&&(!a.button||"click"!==a.type))for(;i!=this;i=i.parentNode||this)if(1===i.nodeType&&(i.disabled!==!0||"click"!==a.type)){for(e=[],f=0;h>f;f++)d=b[f],c=d.selector+" ",void 0===e[c]&&(e[c]=d.needsContext?m(c,this).index(i)>=0:m.find(c,this,null,[i]).length),e[c]&&e.push(d);e.length&&g.push({elem:i,handlers:e})}return h<b.length&&g.push({elem:this,handlers:b.slice(h)}),g},fix:function(a){if(a[m.expando])return a;var b,c,d,e=a.type,f=a,g=this.fixHooks[e];g||(this.fixHooks[e]=g=Z.test(e)?this.mouseHooks:Y.test(e)?this.keyHooks:{}),d=g.props?this.props.concat(g.props):this.props,a=new m.Event(f),b=d.length;while(b--)c=d[b],a[c]=f[c];return a.target||(a.target=f.srcElement||y),3===a.target.nodeType&&(a.target=a.target.parentNode),a.metaKey=!!a.metaKey,g.filter?g.filter(a,f):a},props:"altKey bubbles cancelable ctrlKey currentTarget eventPhase metaKey relatedTarget shiftKey target timeStamp view which".split(" "),fixHooks:{},keyHooks:{props:"char charCode key keyCode".split(" "),filter:function(a,b){return null==a.which&&(a.which=null!=b.charCode?b.charCode:b.keyCode),a}},mouseHooks:{props:"button buttons clientX clientY fromElement offsetX offsetY pageX pageY screenX screenY toElement".split(" "),filter:function(a,b){var c,d,e,f=b.button,g=b.fromElement;return null==a.pageX&&null!=b.clientX&&(d=a.target.ownerDocument||y,e=d.documentElement,c=d.body,a.pageX=b.clientX+(e&&e.scrollLeft||c&&c.scrollLeft||0)-(e&&e.clientLeft||c&&c.clientLeft||0),a.pageY=b.clientY+(e&&e.scrollTop||c&&c.scrollTop||0)-(e&&e.clientTop||c&&c.clientTop||0)),!a.relatedTarget&&g&&(a.relatedTarget=g===a.target?b.toElement:g),a.which||void 0===f||(a.which=1&f?1:2&f?3:4&f?2:0),a}},special:{load:{noBubble:!0},focus:{trigger:function(){if(this!==ca()&&this.focus)try{return this.focus(),!1}catch(a){}},delegateType:"focusin"},blur:{trigger:function(){return this===ca()&&this.blur?(this.blur(),!1):void 0},delegateType:"focusout"},click:{trigger:function(){return m.nodeName(this,"input")&&"checkbox"===this.type&&this.click?(this.click(),!1):void 0},_default:function(a){return m.nodeName(a.target,"a")}},beforeunload:{postDispatch:function(a){void 0!==a.result&&a.originalEvent&&(a.originalEvent.returnValue=a.result)}}},simulate:function(a,b,c,d){var e=m.extend(new m.Event,c,{type:a,isSimulated:!0,originalEvent:{}});d?m.event.trigger(e,null,b):m.event.dispatch.call(b,e),e.isDefaultPrevented()&&c.preventDefault()}},m.removeEvent=y.removeEventListener?function(a,b,c){a.removeEventListener&&a.removeEventListener(b,c,!1)}:function(a,b,c){var d="on"+b;a.detachEvent&&(typeof a[d]===K&&(a[d]=null),a.detachEvent(d,c))},m.Event=function(a,b){return this instanceof m.Event?(a&&a.type?(this.originalEvent=a,this.type=a.type,this.isDefaultPrevented=a.defaultPrevented||void 0===a.defaultPrevented&&a.returnValue===!1?aa:ba):this.type=a,b&&m.extend(this,b),this.timeStamp=a&&a.timeStamp||m.now(),void(this[m.expando]=!0)):new m.Event(a,b)},m.Event.prototype={isDefaultPrevented:ba,isPropagationStopped:ba,isImmediatePropagationStopped:ba,preventDefault:function(){var a=this.originalEvent;this.isDefaultPrevented=aa,a&&(a.preventDefault?a.preventDefault():a.returnValue=!1)},stopPropagation:function(){var a=this.originalEvent;this.isPropagationStopped=aa,a&&(a.stopPropagation&&a.stopPropagation(),a.cancelBubble=!0)},stopImmediatePropagation:function(){var a=this.originalEvent;this.isImmediatePropagationStopped=aa,a&&a.stopImmediatePropagation&&a.stopImmediatePropagation(),this.stopPropagation()}},m.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(a,b){m.event.special[a]={delegateType:b,bindType:b,handle:function(a){var c,d=this,e=a.relatedTarget,f=a.handleObj;return(!e||e!==d&&!m.contains(d,e))&&(a.type=f.origType,c=f.handler.apply(this,arguments),a.type=b),c}}}),k.submitBubbles||(m.event.special.submit={setup:function(){return m.nodeName(this,"form")?!1:void m.event.add(this,"click._submit keypress._submit",function(a){var b=a.target,c=m.nodeName(b,"input")||m.nodeName(b,"button")?b.form:void 0;c&&!m._data(c,"submitBubbles")&&(m.event.add(c,"submit._submit",function(a){a._submit_bubble=!0}),m._data(c,"submitBubbles",!0))})},postDispatch:function(a){a._submit_bubble&&(delete a._submit_bubble,this.parentNode&&!a.isTrigger&&m.event.simulate("submit",this.parentNode,a,!0))},teardown:function(){return m.nodeName(this,"form")?!1:void m.event.remove(this,"._submit")}}),k.changeBubbles||(m.event.special.change={setup:function(){return X.test(this.nodeName)?(("checkbox"===this.type||"radio"===this.type)&&(m.event.add(this,"propertychange._change",function(a){"checked"===a.originalEvent.propertyName&&(this._just_changed=!0)}),m.event.add(this,"click._change",function(a){this._just_changed&&!a.isTrigger&&(this._just_changed=!1),m.event.simulate("change",this,a,!0)})),!1):void m.event.add(this,"beforeactivate._change",function(a){var b=a.target;X.test(b.nodeName)&&!m._data(b,"changeBubbles")&&(m.event.add(b,"change._change",function(a){!this.parentNode||a.isSimulated||a.isTrigger||m.event.simulate("change",this.parentNode,a,!0)}),m._data(b,"changeBubbles",!0))})},handle:function(a){var b=a.target;return this!==b||a.isSimulated||a.isTrigger||"radio"!==b.type&&"checkbox"!==b.type?a.handleObj.handler.apply(this,arguments):void 0},teardown:function(){return m.event.remove(this,"._change"),!X.test(this.nodeName)}}),k.focusinBubbles||m.each({focus:"focusin",blur:"focusout"},function(a,b){var c=function(a){m.event.simulate(b,a.target,m.event.fix(a),!0)};m.event.special[b]={setup:function(){var d=this.ownerDocument||this,e=m._data(d,b);e||d.addEventListener(a,c,!0),m._data(d,b,(e||0)+1)},teardown:function(){var d=this.ownerDocument||this,e=m._data(d,b)-1;e?m._data(d,b,e):(d.removeEventListener(a,c,!0),m._removeData(d,b))}}}),m.fn.extend({on:function(a,b,c,d,e){var f,g;if("object"==typeof a){"string"!=typeof b&&(c=c||b,b=void 0);for(f in a)this.on(f,b,c,a[f],e);return this}if(null==c&&null==d?(d=b,c=b=void 0):null==d&&("string"==typeof b?(d=c,c=void 0):(d=c,c=b,b=void 0)),d===!1)d=ba;else if(!d)return this;return 1===e&&(g=d,d=function(a){return m().off(a),g.apply(this,arguments)},d.guid=g.guid||(g.guid=m.guid++)),this.each(function(){m.event.add(this,a,d,c,b)})},one:function(a,b,c,d){return this.on(a,b,c,d,1)},off:function(a,b,c){var d,e;if(a&&a.preventDefault&&a.handleObj)return d=a.handleObj,m(a.delegateTarget).off(d.namespace?d.origType+"."+d.namespace:d.origType,d.selector,d.handler),this;if("object"==typeof a){for(e in a)this.off(e,b,a[e]);return this}return(b===!1||"function"==typeof b)&&(c=b,b=void 0),c===!1&&(c=ba),this.each(function(){m.event.remove(this,a,c,b)})},trigger:function(a,b){return this.each(function(){m.event.trigger(a,b,this)})},triggerHandler:function(a,b){var c=this[0];return c?m.event.trigger(a,b,c,!0):void 0}});function da(a){var b=ea.split("|"),c=a.createDocumentFragment();if(c.createElement)while(b.length)c.createElement(b.pop());return c}var ea="abbr|article|aside|audio|bdi|canvas|data|datalist|details|figcaption|figure|footer|header|hgroup|mark|meter|nav|output|progress|section|summary|time|video",fa=/ jQuery\d+="(?:null|\d+)"/g,ga=new RegExp("<(?:"+ea+")[\\s/>]","i"),ha=/^\s+/,ia=/<(?!area|br|col|embed|hr|img|input|link|meta|param)(([\w:]+)[^>]*)\/>/gi,ja=/<([\w:]+)/,ka=/<tbody/i,la=/<|&#?\w+;/,ma=/<(?:script|style|link)/i,na=/checked\s*(?:[^=]|=\s*.checked.)/i,oa=/^$|\/(?:java|ecma)script/i,pa=/^true\/(.*)/,qa=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g,ra={option:[1,"<select multiple='multiple'>","</select>"],legend:[1,"<fieldset>","</fieldset>"],area:[1,"<map>","</map>"],param:[1,"<object>","</object>"],thead:[1,"<table>","</table>"],tr:[2,"<table><tbody>","</tbody></table>"],col:[2,"<table><tbody></tbody><colgroup>","</colgroup></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:k.htmlSerialize?[0,"",""]:[1,"X<div>","</div>"]},sa=da(y),ta=sa.appendChild(y.createElement("div"));ra.optgroup=ra.option,ra.tbody=ra.tfoot=ra.colgroup=ra.caption=ra.thead,ra.th=ra.td;function ua(a,b){var c,d,e=0,f=typeof a.getElementsByTagName!==K?a.getElementsByTagName(b||"*"):typeof a.querySelectorAll!==K?a.querySelectorAll(b||"*"):void 0;if(!f)for(f=[],c=a.childNodes||a;null!=(d=c[e]);e++)!b||m.nodeName(d,b)?f.push(d):m.merge(f,ua(d,b));return void 0===b||b&&m.nodeName(a,b)?m.merge([a],f):f}function va(a){W.test(a.type)&&(a.defaultChecked=a.checked)}function wa(a,b){return m.nodeName(a,"table")&&m.nodeName(11!==b.nodeType?b:b.firstChild,"tr")?a.getElementsByTagName("tbody")[0]||a.appendChild(a.ownerDocument.createElement("tbody")):a}function xa(a){return a.type=(null!==m.find.attr(a,"type"))+"/"+a.type,a}function ya(a){var b=pa.exec(a.type);return b?a.type=b[1]:a.removeAttribute("type"),a}function za(a,b){for(var c,d=0;null!=(c=a[d]);d++)m._data(c,"globalEval",!b||m._data(b[d],"globalEval"))}function Aa(a,b){if(1===b.nodeType&&m.hasData(a)){var c,d,e,f=m._data(a),g=m._data(b,f),h=f.events;if(h){delete g.handle,g.events={};for(c in h)for(d=0,e=h[c].length;e>d;d++)m.event.add(b,c,h[c][d])}g.data&&(g.data=m.extend({},g.data))}}function Ba(a,b){var c,d,e;if(1===b.nodeType){if(c=b.nodeName.toLowerCase(),!k.noCloneEvent&&b[m.expando]){e=m._data(b);for(d in e.events)m.removeEvent(b,d,e.handle);b.removeAttribute(m.expando)}"script"===c&&b.text!==a.text?(xa(b).text=a.text,ya(b)):"object"===c?(b.parentNode&&(b.outerHTML=a.outerHTML),k.html5Clone&&a.innerHTML&&!m.trim(b.innerHTML)&&(b.innerHTML=a.innerHTML)):"input"===c&&W.test(a.type)?(b.defaultChecked=b.checked=a.checked,b.value!==a.value&&(b.value=a.value)):"option"===c?b.defaultSelected=b.selected=a.defaultSelected:("input"===c||"textarea"===c)&&(b.defaultValue=a.defaultValue)}}m.extend({clone:function(a,b,c){var d,e,f,g,h,i=m.contains(a.ownerDocument,a);if(k.html5Clone||m.isXMLDoc(a)||!ga.test("<"+a.nodeName+">")?f=a.cloneNode(!0):(ta.innerHTML=a.outerHTML,ta.removeChild(f=ta.firstChild)),!(k.noCloneEvent&&k.noCloneChecked||1!==a.nodeType&&11!==a.nodeType||m.isXMLDoc(a)))for(d=ua(f),h=ua(a),g=0;null!=(e=h[g]);++g)d[g]&&Ba(e,d[g]);if(b)if(c)for(h=h||ua(a),d=d||ua(f),g=0;null!=(e=h[g]);g++)Aa(e,d[g]);else Aa(a,f);return d=ua(f,"script"),d.length>0&&za(d,!i&&ua(a,"script")),d=h=e=null,f},buildFragment:function(a,b,c,d){for(var e,f,g,h,i,j,l,n=a.length,o=da(b),p=[],q=0;n>q;q++)if(f=a[q],f||0===f)if("object"===m.type(f))m.merge(p,f.nodeType?[f]:f);else if(la.test(f)){h=h||o.appendChild(b.createElement("div")),i=(ja.exec(f)||["",""])[1].toLowerCase(),l=ra[i]||ra._default,h.innerHTML=l[1]+f.replace(ia,"<$1></$2>")+l[2],e=l[0];while(e--)h=h.lastChild;if(!k.leadingWhitespace&&ha.test(f)&&p.push(b.createTextNode(ha.exec(f)[0])),!k.tbody){f="table"!==i||ka.test(f)?"<table>"!==l[1]||ka.test(f)?0:h:h.firstChild,e=f&&f.childNodes.length;while(e--)m.nodeName(j=f.childNodes[e],"tbody")&&!j.childNodes.length&&f.removeChild(j)}m.merge(p,h.childNodes),h.textContent="";while(h.firstChild)h.removeChild(h.firstChild);h=o.lastChild}else p.push(b.createTextNode(f));h&&o.removeChild(h),k.appendChecked||m.grep(ua(p,"input"),va),q=0;while(f=p[q++])if((!d||-1===m.inArray(f,d))&&(g=m.contains(f.ownerDocument,f),h=ua(o.appendChild(f),"script"),g&&za(h),c)){e=0;while(f=h[e++])oa.test(f.type||"")&&c.push(f)}return h=null,o},cleanData:function(a,b){for(var d,e,f,g,h=0,i=m.expando,j=m.cache,l=k.deleteExpando,n=m.event.special;null!=(d=a[h]);h++)if((b||m.acceptData(d))&&(f=d[i],g=f&&j[f])){if(g.events)for(e in g.events)n[e]?m.event.remove(d,e):m.removeEvent(d,e,g.handle);j[f]&&(delete j[f],l?delete d[i]:typeof d.removeAttribute!==K?d.removeAttribute(i):d[i]=null,c.push(f))}}}),m.fn.extend({text:function(a){return V(this,function(a){return void 0===a?m.text(this):this.empty().append((this[0]&&this[0].ownerDocument||y).createTextNode(a))},null,a,arguments.length)},append:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.appendChild(a)}})},prepend:function(){return this.domManip(arguments,function(a){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var b=wa(this,a);b.insertBefore(a,b.firstChild)}})},before:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this)})},after:function(){return this.domManip(arguments,function(a){this.parentNode&&this.parentNode.insertBefore(a,this.nextSibling)})},remove:function(a,b){for(var c,d=a?m.filter(a,this):this,e=0;null!=(c=d[e]);e++)b||1!==c.nodeType||m.cleanData(ua(c)),c.parentNode&&(b&&m.contains(c.ownerDocument,c)&&za(ua(c,"script")),c.parentNode.removeChild(c));return this},empty:function(){for(var a,b=0;null!=(a=this[b]);b++){1===a.nodeType&&m.cleanData(ua(a,!1));while(a.firstChild)a.removeChild(a.firstChild);a.options&&m.nodeName(a,"select")&&(a.options.length=0)}return this},clone:function(a,b){return a=null==a?!1:a,b=null==b?a:b,this.map(function(){return m.clone(this,a,b)})},html:function(a){return V(this,function(a){var b=this[0]||{},c=0,d=this.length;if(void 0===a)return 1===b.nodeType?b.innerHTML.replace(fa,""):void 0;if(!("string"!=typeof a||ma.test(a)||!k.htmlSerialize&&ga.test(a)||!k.leadingWhitespace&&ha.test(a)||ra[(ja.exec(a)||["",""])[1].toLowerCase()])){a=a.replace(ia,"<$1></$2>");try{for(;d>c;c++)b=this[c]||{},1===b.nodeType&&(m.cleanData(ua(b,!1)),b.innerHTML=a);b=0}catch(e){}}b&&this.empty().append(a)},null,a,arguments.length)},replaceWith:function(){var a=arguments[0];return this.domManip(arguments,function(b){a=this.parentNode,m.cleanData(ua(this)),a&&a.replaceChild(b,this)}),a&&(a.length||a.nodeType)?this:this.remove()},detach:function(a){return this.remove(a,!0)},domManip:function(a,b){a=e.apply([],a);var c,d,f,g,h,i,j=0,l=this.length,n=this,o=l-1,p=a[0],q=m.isFunction(p);if(q||l>1&&"string"==typeof p&&!k.checkClone&&na.test(p))return this.each(function(c){var d=n.eq(c);q&&(a[0]=p.call(this,c,d.html())),d.domManip(a,b)});if(l&&(i=m.buildFragment(a,this[0].ownerDocument,!1,this),c=i.firstChild,1===i.childNodes.length&&(i=c),c)){for(g=m.map(ua(i,"script"),xa),f=g.length;l>j;j++)d=i,j!==o&&(d=m.clone(d,!0,!0),f&&m.merge(g,ua(d,"script"))),b.call(this[j],d,j);if(f)for(h=g[g.length-1].ownerDocument,m.map(g,ya),j=0;f>j;j++)d=g[j],oa.test(d.type||"")&&!m._data(d,"globalEval")&&m.contains(h,d)&&(d.src?m._evalUrl&&m._evalUrl(d.src):m.globalEval((d.text||d.textContent||d.innerHTML||"").replace(qa,"")));i=c=null}return this}}),m.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(a,b){m.fn[a]=function(a){for(var c,d=0,e=[],g=m(a),h=g.length-1;h>=d;d++)c=d===h?this:this.clone(!0),m(g[d])[b](c),f.apply(e,c.get());return this.pushStack(e)}});var Ca,Da={};function Ea(b,c){var d,e=m(c.createElement(b)).appendTo(c.body),f=a.getDefaultComputedStyle&&(d=a.getDefaultComputedStyle(e[0]))?d.display:m.css(e[0],"display");return e.detach(),f}function Fa(a){var b=y,c=Da[a];return c||(c=Ea(a,b),"none"!==c&&c||(Ca=(Ca||m("<iframe frameborder='0' width='0' height='0'/>")).appendTo(b.documentElement),b=(Ca[0].contentWindow||Ca[0].contentDocument).document,b.write(),b.close(),c=Ea(a,b),Ca.detach()),Da[a]=c),c}!function(){var a;k.shrinkWrapBlocks=function(){if(null!=a)return a;a=!1;var b,c,d;return c=y.getElementsByTagName("body")[0],c&&c.style?(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),typeof b.style.zoom!==K&&(b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:1px;width:1px;zoom:1",b.appendChild(y.createElement("div")).style.width="5px",a=3!==b.offsetWidth),c.removeChild(d),a):void 0}}();var Ga=/^margin/,Ha=new RegExp("^("+S+")(?!px)[a-z%]+$","i"),Ia,Ja,Ka=/^(top|right|bottom|left)$/;a.getComputedStyle?(Ia=function(b){return b.ownerDocument.defaultView.opener?b.ownerDocument.defaultView.getComputedStyle(b,null):a.getComputedStyle(b,null)},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c.getPropertyValue(b)||c[b]:void 0,c&&(""!==g||m.contains(a.ownerDocument,a)||(g=m.style(a,b)),Ha.test(g)&&Ga.test(b)&&(d=h.width,e=h.minWidth,f=h.maxWidth,h.minWidth=h.maxWidth=h.width=g,g=c.width,h.width=d,h.minWidth=e,h.maxWidth=f)),void 0===g?g:g+""}):y.documentElement.currentStyle&&(Ia=function(a){return a.currentStyle},Ja=function(a,b,c){var d,e,f,g,h=a.style;return c=c||Ia(a),g=c?c[b]:void 0,null==g&&h&&h[b]&&(g=h[b]),Ha.test(g)&&!Ka.test(b)&&(d=h.left,e=a.runtimeStyle,f=e&&e.left,f&&(e.left=a.currentStyle.left),h.left="fontSize"===b?"1em":g,g=h.pixelLeft+"px",h.left=d,f&&(e.left=f)),void 0===g?g:g+""||"auto"});function La(a,b){return{get:function(){var c=a();if(null!=c)return c?void delete this.get:(this.get=b).apply(this,arguments)}}}!function(){var b,c,d,e,f,g,h;if(b=y.createElement("div"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=d&&d.style){c.cssText="float:left;opacity:.5",k.opacity="0.5"===c.opacity,k.cssFloat=!!c.cssFloat,b.style.backgroundClip="content-box",b.cloneNode(!0).style.backgroundClip="",k.clearCloneStyle="content-box"===b.style.backgroundClip,k.boxSizing=""===c.boxSizing||""===c.MozBoxSizing||""===c.WebkitBoxSizing,m.extend(k,{reliableHiddenOffsets:function(){return null==g&&i(),g},boxSizingReliable:function(){return null==f&&i(),f},pixelPosition:function(){return null==e&&i(),e},reliableMarginRight:function(){return null==h&&i(),h}});function i(){var b,c,d,i;c=y.getElementsByTagName("body")[0],c&&c.style&&(b=y.createElement("div"),d=y.createElement("div"),d.style.cssText="position:absolute;border:0;width:0;height:0;top:0;left:-9999px",c.appendChild(d).appendChild(b),b.style.cssText="-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;display:block;margin-top:1%;top:1%;border:1px;padding:1px;width:4px;position:absolute",e=f=!1,h=!0,a.getComputedStyle&&(e="1%"!==(a.getComputedStyle(b,null)||{}).top,f="4px"===(a.getComputedStyle(b,null)||{width:"4px"}).width,i=b.appendChild(y.createElement("div")),i.style.cssText=b.style.cssText="-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;display:block;margin:0;border:0;padding:0",i.style.marginRight=i.style.width="0",b.style.width="1px",h=!parseFloat((a.getComputedStyle(i,null)||{}).marginRight),b.removeChild(i)),b.innerHTML="<table><tr><td></td><td>t</td></tr></table>",i=b.getElementsByTagName("td"),i[0].style.cssText="margin:0;border:0;padding:0;display:none",g=0===i[0].offsetHeight,g&&(i[0].style.display="",i[1].style.display="none",g=0===i[0].offsetHeight),c.removeChild(d))}}}(),m.swap=function(a,b,c,d){var e,f,g={};for(f in b)g[f]=a.style[f],a.style[f]=b[f];e=c.apply(a,d||[]);for(f in b)a.style[f]=g[f];return e};var Ma=/alpha\([^)]*\)/i,Na=/opacity\s*=\s*([^)]*)/,Oa=/^(none|table(?!-c[ea]).+)/,Pa=new RegExp("^("+S+")(.*)$","i"),Qa=new RegExp("^([+-])=("+S+")","i"),Ra={position:"absolute",visibility:"hidden",display:"block"},Sa={letterSpacing:"0",fontWeight:"400"},Ta=["Webkit","O","Moz","ms"];function Ua(a,b){if(b in a)return b;var c=b.charAt(0).toUpperCase()+b.slice(1),d=b,e=Ta.length;while(e--)if(b=Ta[e]+c,b in a)return b;return d}function Va(a,b){for(var c,d,e,f=[],g=0,h=a.length;h>g;g++)d=a[g],d.style&&(f[g]=m._data(d,"olddisplay"),c=d.style.display,b?(f[g]||"none"!==c||(d.style.display=""),""===d.style.display&&U(d)&&(f[g]=m._data(d,"olddisplay",Fa(d.nodeName)))):(e=U(d),(c&&"none"!==c||!e)&&m._data(d,"olddisplay",e?c:m.css(d,"display"))));for(g=0;h>g;g++)d=a[g],d.style&&(b&&"none"!==d.style.display&&""!==d.style.display||(d.style.display=b?f[g]||"":"none"));return a}function Wa(a,b,c){var d=Pa.exec(b);return d?Math.max(0,d[1]-(c||0))+(d[2]||"px"):b}function Xa(a,b,c,d,e){for(var f=c===(d?"border":"content")?4:"width"===b?1:0,g=0;4>f;f+=2)"margin"===c&&(g+=m.css(a,c+T[f],!0,e)),d?("content"===c&&(g-=m.css(a,"padding"+T[f],!0,e)),"margin"!==c&&(g-=m.css(a,"border"+T[f]+"Width",!0,e))):(g+=m.css(a,"padding"+T[f],!0,e),"padding"!==c&&(g+=m.css(a,"border"+T[f]+"Width",!0,e)));return g}function Ya(a,b,c){var d=!0,e="width"===b?a.offsetWidth:a.offsetHeight,f=Ia(a),g=k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,f);if(0>=e||null==e){if(e=Ja(a,b,f),(0>e||null==e)&&(e=a.style[b]),Ha.test(e))return e;d=g&&(k.boxSizingReliable()||e===a.style[b]),e=parseFloat(e)||0}return e+Xa(a,b,c||(g?"border":"content"),d,f)+"px"}m.extend({cssHooks:{opacity:{get:function(a,b){if(b){var c=Ja(a,"opacity");return""===c?"1":c}}}},cssNumber:{columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{"float":k.cssFloat?"cssFloat":"styleFloat"},style:function(a,b,c,d){if(a&&3!==a.nodeType&&8!==a.nodeType&&a.style){var e,f,g,h=m.camelCase(b),i=a.style;if(b=m.cssProps[h]||(m.cssProps[h]=Ua(i,h)),g=m.cssHooks[b]||m.cssHooks[h],void 0===c)return g&&"get"in g&&void 0!==(e=g.get(a,!1,d))?e:i[b];if(f=typeof c,"string"===f&&(e=Qa.exec(c))&&(c=(e[1]+1)*e[2]+parseFloat(m.css(a,b)),f="number"),null!=c&&c===c&&("number"!==f||m.cssNumber[h]||(c+="px"),k.clearCloneStyle||""!==c||0!==b.indexOf("background")||(i[b]="inherit"),!(g&&"set"in g&&void 0===(c=g.set(a,c,d)))))try{i[b]=c}catch(j){}}},css:function(a,b,c,d){var e,f,g,h=m.camelCase(b);return b=m.cssProps[h]||(m.cssProps[h]=Ua(a.style,h)),g=m.cssHooks[b]||m.cssHooks[h],g&&"get"in g&&(f=g.get(a,!0,c)),void 0===f&&(f=Ja(a,b,d)),"normal"===f&&b in Sa&&(f=Sa[b]),""===c||c?(e=parseFloat(f),c===!0||m.isNumeric(e)?e||0:f):f}}),m.each(["height","width"],function(a,b){m.cssHooks[b]={get:function(a,c,d){return c?Oa.test(m.css(a,"display"))&&0===a.offsetWidth?m.swap(a,Ra,function(){return Ya(a,b,d)}):Ya(a,b,d):void 0},set:function(a,c,d){var e=d&&Ia(a);return Wa(a,c,d?Xa(a,b,d,k.boxSizing&&"border-box"===m.css(a,"boxSizing",!1,e),e):0)}}}),k.opacity||(m.cssHooks.opacity={get:function(a,b){return Na.test((b&&a.currentStyle?a.currentStyle.filter:a.style.filter)||"")?.01*parseFloat(RegExp.$1)+"":b?"1":""},set:function(a,b){var c=a.style,d=a.currentStyle,e=m.isNumeric(b)?"alpha(opacity="+100*b+")":"",f=d&&d.filter||c.filter||"";c.zoom=1,(b>=1||""===b)&&""===m.trim(f.replace(Ma,""))&&c.removeAttribute&&(c.removeAttribute("filter"),""===b||d&&!d.filter)||(c.filter=Ma.test(f)?f.replace(Ma,e):f+" "+e)}}),m.cssHooks.marginRight=La(k.reliableMarginRight,function(a,b){return b?m.swap(a,{display:"inline-block"},Ja,[a,"marginRight"]):void 0}),m.each({margin:"",padding:"",border:"Width"},function(a,b){m.cssHooks[a+b]={expand:function(c){for(var d=0,e={},f="string"==typeof c?c.split(" "):[c];4>d;d++)e[a+T[d]+b]=f[d]||f[d-2]||f[0];return e}},Ga.test(a)||(m.cssHooks[a+b].set=Wa)}),m.fn.extend({css:function(a,b){return V(this,function(a,b,c){var d,e,f={},g=0;if(m.isArray(b)){for(d=Ia(a),e=b.length;e>g;g++)f[b[g]]=m.css(a,b[g],!1,d);return f}return void 0!==c?m.style(a,b,c):m.css(a,b)},a,b,arguments.length>1)},show:function(){return Va(this,!0)},hide:function(){return Va(this)},toggle:function(a){return"boolean"==typeof a?a?this.show():this.hide():this.each(function(){U(this)?m(this).show():m(this).hide()})}});function Za(a,b,c,d,e){
return new Za.prototype.init(a,b,c,d,e)}m.Tween=Za,Za.prototype={constructor:Za,init:function(a,b,c,d,e,f){this.elem=a,this.prop=c,this.easing=e||"swing",this.options=b,this.start=this.now=this.cur(),this.end=d,this.unit=f||(m.cssNumber[c]?"":"px")},cur:function(){var a=Za.propHooks[this.prop];return a&&a.get?a.get(this):Za.propHooks._default.get(this)},run:function(a){var b,c=Za.propHooks[this.prop];return this.options.duration?this.pos=b=m.easing[this.easing](a,this.options.duration*a,0,1,this.options.duration):this.pos=b=a,this.now=(this.end-this.start)*b+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),c&&c.set?c.set(this):Za.propHooks._default.set(this),this}},Za.prototype.init.prototype=Za.prototype,Za.propHooks={_default:{get:function(a){var b;return null==a.elem[a.prop]||a.elem.style&&null!=a.elem.style[a.prop]?(b=m.css(a.elem,a.prop,""),b&&"auto"!==b?b:0):a.elem[a.prop]},set:function(a){m.fx.step[a.prop]?m.fx.step[a.prop](a):a.elem.style&&(null!=a.elem.style[m.cssProps[a.prop]]||m.cssHooks[a.prop])?m.style(a.elem,a.prop,a.now+a.unit):a.elem[a.prop]=a.now}}},Za.propHooks.scrollTop=Za.propHooks.scrollLeft={set:function(a){a.elem.nodeType&&a.elem.parentNode&&(a.elem[a.prop]=a.now)}},m.easing={linear:function(a){return a},swing:function(a){return.5-Math.cos(a*Math.PI)/2}},m.fx=Za.prototype.init,m.fx.step={};var $a,_a,ab=/^(?:toggle|show|hide)$/,bb=new RegExp("^(?:([+-])=|)("+S+")([a-z%]*)$","i"),cb=/queueHooks$/,db=[ib],eb={"*":[function(a,b){var c=this.createTween(a,b),d=c.cur(),e=bb.exec(b),f=e&&e[3]||(m.cssNumber[a]?"":"px"),g=(m.cssNumber[a]||"px"!==f&&+d)&&bb.exec(m.css(c.elem,a)),h=1,i=20;if(g&&g[3]!==f){f=f||g[3],e=e||[],g=+d||1;do h=h||".5",g/=h,m.style(c.elem,a,g+f);while(h!==(h=c.cur()/d)&&1!==h&&--i)}return e&&(g=c.start=+g||+d||0,c.unit=f,c.end=e[1]?g+(e[1]+1)*e[2]:+e[2]),c}]};function fb(){return setTimeout(function(){$a=void 0}),$a=m.now()}function gb(a,b){var c,d={height:a},e=0;for(b=b?1:0;4>e;e+=2-b)c=T[e],d["margin"+c]=d["padding"+c]=a;return b&&(d.opacity=d.width=a),d}function hb(a,b,c){for(var d,e=(eb[b]||[]).concat(eb["*"]),f=0,g=e.length;g>f;f++)if(d=e[f].call(c,b,a))return d}function ib(a,b,c){var d,e,f,g,h,i,j,l,n=this,o={},p=a.style,q=a.nodeType&&U(a),r=m._data(a,"fxshow");c.queue||(h=m._queueHooks(a,"fx"),null==h.unqueued&&(h.unqueued=0,i=h.empty.fire,h.empty.fire=function(){h.unqueued||i()}),h.unqueued++,n.always(function(){n.always(function(){h.unqueued--,m.queue(a,"fx").length||h.empty.fire()})})),1===a.nodeType&&("height"in b||"width"in b)&&(c.overflow=[p.overflow,p.overflowX,p.overflowY],j=m.css(a,"display"),l="none"===j?m._data(a,"olddisplay")||Fa(a.nodeName):j,"inline"===l&&"none"===m.css(a,"float")&&(k.inlineBlockNeedsLayout&&"inline"!==Fa(a.nodeName)?p.zoom=1:p.display="inline-block")),c.overflow&&(p.overflow="hidden",k.shrinkWrapBlocks()||n.always(function(){p.overflow=c.overflow[0],p.overflowX=c.overflow[1],p.overflowY=c.overflow[2]}));for(d in b)if(e=b[d],ab.exec(e)){if(delete b[d],f=f||"toggle"===e,e===(q?"hide":"show")){if("show"!==e||!r||void 0===r[d])continue;q=!0}o[d]=r&&r[d]||m.style(a,d)}else j=void 0;if(m.isEmptyObject(o))"inline"===("none"===j?Fa(a.nodeName):j)&&(p.display=j);else{r?"hidden"in r&&(q=r.hidden):r=m._data(a,"fxshow",{}),f&&(r.hidden=!q),q?m(a).show():n.done(function(){m(a).hide()}),n.done(function(){var b;m._removeData(a,"fxshow");for(b in o)m.style(a,b,o[b])});for(d in o)g=hb(q?r[d]:0,d,n),d in r||(r[d]=g.start,q&&(g.end=g.start,g.start="width"===d||"height"===d?1:0))}}function jb(a,b){var c,d,e,f,g;for(c in a)if(d=m.camelCase(c),e=b[d],f=a[c],m.isArray(f)&&(e=f[1],f=a[c]=f[0]),c!==d&&(a[d]=f,delete a[c]),g=m.cssHooks[d],g&&"expand"in g){f=g.expand(f),delete a[d];for(c in f)c in a||(a[c]=f[c],b[c]=e)}else b[d]=e}function kb(a,b,c){var d,e,f=0,g=db.length,h=m.Deferred().always(function(){delete i.elem}),i=function(){if(e)return!1;for(var b=$a||fb(),c=Math.max(0,j.startTime+j.duration-b),d=c/j.duration||0,f=1-d,g=0,i=j.tweens.length;i>g;g++)j.tweens[g].run(f);return h.notifyWith(a,[j,f,c]),1>f&&i?c:(h.resolveWith(a,[j]),!1)},j=h.promise({elem:a,props:m.extend({},b),opts:m.extend(!0,{specialEasing:{}},c),originalProperties:b,originalOptions:c,startTime:$a||fb(),duration:c.duration,tweens:[],createTween:function(b,c){var d=m.Tween(a,j.opts,b,c,j.opts.specialEasing[b]||j.opts.easing);return j.tweens.push(d),d},stop:function(b){var c=0,d=b?j.tweens.length:0;if(e)return this;for(e=!0;d>c;c++)j.tweens[c].run(1);return b?h.resolveWith(a,[j,b]):h.rejectWith(a,[j,b]),this}}),k=j.props;for(jb(k,j.opts.specialEasing);g>f;f++)if(d=db[f].call(j,a,k,j.opts))return d;return m.map(k,hb,j),m.isFunction(j.opts.start)&&j.opts.start.call(a,j),m.fx.timer(m.extend(i,{elem:a,anim:j,queue:j.opts.queue})),j.progress(j.opts.progress).done(j.opts.done,j.opts.complete).fail(j.opts.fail).always(j.opts.always)}m.Animation=m.extend(kb,{tweener:function(a,b){m.isFunction(a)?(b=a,a=["*"]):a=a.split(" ");for(var c,d=0,e=a.length;e>d;d++)c=a[d],eb[c]=eb[c]||[],eb[c].unshift(b)},prefilter:function(a,b){b?db.unshift(a):db.push(a)}}),m.speed=function(a,b,c){var d=a&&"object"==typeof a?m.extend({},a):{complete:c||!c&&b||m.isFunction(a)&&a,duration:a,easing:c&&b||b&&!m.isFunction(b)&&b};return d.duration=m.fx.off?0:"number"==typeof d.duration?d.duration:d.duration in m.fx.speeds?m.fx.speeds[d.duration]:m.fx.speeds._default,(null==d.queue||d.queue===!0)&&(d.queue="fx"),d.old=d.complete,d.complete=function(){m.isFunction(d.old)&&d.old.call(this),d.queue&&m.dequeue(this,d.queue)},d},m.fn.extend({fadeTo:function(a,b,c,d){return this.filter(U).css("opacity",0).show().end().animate({opacity:b},a,c,d)},animate:function(a,b,c,d){var e=m.isEmptyObject(a),f=m.speed(b,c,d),g=function(){var b=kb(this,m.extend({},a),f);(e||m._data(this,"finish"))&&b.stop(!0)};return g.finish=g,e||f.queue===!1?this.each(g):this.queue(f.queue,g)},stop:function(a,b,c){var d=function(a){var b=a.stop;delete a.stop,b(c)};return"string"!=typeof a&&(c=b,b=a,a=void 0),b&&a!==!1&&this.queue(a||"fx",[]),this.each(function(){var b=!0,e=null!=a&&a+"queueHooks",f=m.timers,g=m._data(this);if(e)g[e]&&g[e].stop&&d(g[e]);else for(e in g)g[e]&&g[e].stop&&cb.test(e)&&d(g[e]);for(e=f.length;e--;)f[e].elem!==this||null!=a&&f[e].queue!==a||(f[e].anim.stop(c),b=!1,f.splice(e,1));(b||!c)&&m.dequeue(this,a)})},finish:function(a){return a!==!1&&(a=a||"fx"),this.each(function(){var b,c=m._data(this),d=c[a+"queue"],e=c[a+"queueHooks"],f=m.timers,g=d?d.length:0;for(c.finish=!0,m.queue(this,a,[]),e&&e.stop&&e.stop.call(this,!0),b=f.length;b--;)f[b].elem===this&&f[b].queue===a&&(f[b].anim.stop(!0),f.splice(b,1));for(b=0;g>b;b++)d[b]&&d[b].finish&&d[b].finish.call(this);delete c.finish})}}),m.each(["toggle","show","hide"],function(a,b){var c=m.fn[b];m.fn[b]=function(a,d,e){return null==a||"boolean"==typeof a?c.apply(this,arguments):this.animate(gb(b,!0),a,d,e)}}),m.each({slideDown:gb("show"),slideUp:gb("hide"),slideToggle:gb("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(a,b){m.fn[a]=function(a,c,d){return this.animate(b,a,c,d)}}),m.timers=[],m.fx.tick=function(){var a,b=m.timers,c=0;for($a=m.now();c<b.length;c++)a=b[c],a()||b[c]!==a||b.splice(c--,1);b.length||m.fx.stop(),$a=void 0},m.fx.timer=function(a){m.timers.push(a),a()?m.fx.start():m.timers.pop()},m.fx.interval=13,m.fx.start=function(){_a||(_a=setInterval(m.fx.tick,m.fx.interval))},m.fx.stop=function(){clearInterval(_a),_a=null},m.fx.speeds={slow:600,fast:200,_default:400},m.fn.delay=function(a,b){return a=m.fx?m.fx.speeds[a]||a:a,b=b||"fx",this.queue(b,function(b,c){var d=setTimeout(b,a);c.stop=function(){clearTimeout(d)}})},function(){var a,b,c,d,e;b=y.createElement("div"),b.setAttribute("className","t"),b.innerHTML="  <link/><table></table><a href='/a'>a</a><input type='checkbox'/>",d=b.getElementsByTagName("a")[0],c=y.createElement("select"),e=c.appendChild(y.createElement("option")),a=b.getElementsByTagName("input")[0],d.style.cssText="top:1px",k.getSetAttribute="t"!==b.className,k.style=/top/.test(d.getAttribute("style")),k.hrefNormalized="/a"===d.getAttribute("href"),k.checkOn=!!a.value,k.optSelected=e.selected,k.enctype=!!y.createElement("form").enctype,c.disabled=!0,k.optDisabled=!e.disabled,a=y.createElement("input"),a.setAttribute("value",""),k.input=""===a.getAttribute("value"),a.value="t",a.setAttribute("type","radio"),k.radioValue="t"===a.value}();var lb=/\r/g;m.fn.extend({val:function(a){var b,c,d,e=this[0];{if(arguments.length)return d=m.isFunction(a),this.each(function(c){var e;1===this.nodeType&&(e=d?a.call(this,c,m(this).val()):a,null==e?e="":"number"==typeof e?e+="":m.isArray(e)&&(e=m.map(e,function(a){return null==a?"":a+""})),b=m.valHooks[this.type]||m.valHooks[this.nodeName.toLowerCase()],b&&"set"in b&&void 0!==b.set(this,e,"value")||(this.value=e))});if(e)return b=m.valHooks[e.type]||m.valHooks[e.nodeName.toLowerCase()],b&&"get"in b&&void 0!==(c=b.get(e,"value"))?c:(c=e.value,"string"==typeof c?c.replace(lb,""):null==c?"":c)}}}),m.extend({valHooks:{option:{get:function(a){var b=m.find.attr(a,"value");return null!=b?b:m.trim(m.text(a))}},select:{get:function(a){for(var b,c,d=a.options,e=a.selectedIndex,f="select-one"===a.type||0>e,g=f?null:[],h=f?e+1:d.length,i=0>e?h:f?e:0;h>i;i++)if(c=d[i],!(!c.selected&&i!==e||(k.optDisabled?c.disabled:null!==c.getAttribute("disabled"))||c.parentNode.disabled&&m.nodeName(c.parentNode,"optgroup"))){if(b=m(c).val(),f)return b;g.push(b)}return g},set:function(a,b){var c,d,e=a.options,f=m.makeArray(b),g=e.length;while(g--)if(d=e[g],m.inArray(m.valHooks.option.get(d),f)>=0)try{d.selected=c=!0}catch(h){d.scrollHeight}else d.selected=!1;return c||(a.selectedIndex=-1),e}}}}),m.each(["radio","checkbox"],function(){m.valHooks[this]={set:function(a,b){return m.isArray(b)?a.checked=m.inArray(m(a).val(),b)>=0:void 0}},k.checkOn||(m.valHooks[this].get=function(a){return null===a.getAttribute("value")?"on":a.value})});var mb,nb,ob=m.expr.attrHandle,pb=/^(?:checked|selected)$/i,qb=k.getSetAttribute,rb=k.input;m.fn.extend({attr:function(a,b){return V(this,m.attr,a,b,arguments.length>1)},removeAttr:function(a){return this.each(function(){m.removeAttr(this,a)})}}),m.extend({attr:function(a,b,c){var d,e,f=a.nodeType;if(a&&3!==f&&8!==f&&2!==f)return typeof a.getAttribute===K?m.prop(a,b,c):(1===f&&m.isXMLDoc(a)||(b=b.toLowerCase(),d=m.attrHooks[b]||(m.expr.match.bool.test(b)?nb:mb)),void 0===c?d&&"get"in d&&null!==(e=d.get(a,b))?e:(e=m.find.attr(a,b),null==e?void 0:e):null!==c?d&&"set"in d&&void 0!==(e=d.set(a,c,b))?e:(a.setAttribute(b,c+""),c):void m.removeAttr(a,b))},removeAttr:function(a,b){var c,d,e=0,f=b&&b.match(E);if(f&&1===a.nodeType)while(c=f[e++])d=m.propFix[c]||c,m.expr.match.bool.test(c)?rb&&qb||!pb.test(c)?a[d]=!1:a[m.camelCase("default-"+c)]=a[d]=!1:m.attr(a,c,""),a.removeAttribute(qb?c:d)},attrHooks:{type:{set:function(a,b){if(!k.radioValue&&"radio"===b&&m.nodeName(a,"input")){var c=a.value;return a.setAttribute("type",b),c&&(a.value=c),b}}}}}),nb={set:function(a,b,c){return b===!1?m.removeAttr(a,c):rb&&qb||!pb.test(c)?a.setAttribute(!qb&&m.propFix[c]||c,c):a[m.camelCase("default-"+c)]=a[c]=!0,c}},m.each(m.expr.match.bool.source.match(/\w+/g),function(a,b){var c=ob[b]||m.find.attr;ob[b]=rb&&qb||!pb.test(b)?function(a,b,d){var e,f;return d||(f=ob[b],ob[b]=e,e=null!=c(a,b,d)?b.toLowerCase():null,ob[b]=f),e}:function(a,b,c){return c?void 0:a[m.camelCase("default-"+b)]?b.toLowerCase():null}}),rb&&qb||(m.attrHooks.value={set:function(a,b,c){return m.nodeName(a,"input")?void(a.defaultValue=b):mb&&mb.set(a,b,c)}}),qb||(mb={set:function(a,b,c){var d=a.getAttributeNode(c);return d||a.setAttributeNode(d=a.ownerDocument.createAttribute(c)),d.value=b+="","value"===c||b===a.getAttribute(c)?b:void 0}},ob.id=ob.name=ob.coords=function(a,b,c){var d;return c?void 0:(d=a.getAttributeNode(b))&&""!==d.value?d.value:null},m.valHooks.button={get:function(a,b){var c=a.getAttributeNode(b);return c&&c.specified?c.value:void 0},set:mb.set},m.attrHooks.contenteditable={set:function(a,b,c){mb.set(a,""===b?!1:b,c)}},m.each(["width","height"],function(a,b){m.attrHooks[b]={set:function(a,c){return""===c?(a.setAttribute(b,"auto"),c):void 0}}})),k.style||(m.attrHooks.style={get:function(a){return a.style.cssText||void 0},set:function(a,b){return a.style.cssText=b+""}});var sb=/^(?:input|select|textarea|button|object)$/i,tb=/^(?:a|area)$/i;m.fn.extend({prop:function(a,b){return V(this,m.prop,a,b,arguments.length>1)},removeProp:function(a){return a=m.propFix[a]||a,this.each(function(){try{this[a]=void 0,delete this[a]}catch(b){}})}}),m.extend({propFix:{"for":"htmlFor","class":"className"},prop:function(a,b,c){var d,e,f,g=a.nodeType;if(a&&3!==g&&8!==g&&2!==g)return f=1!==g||!m.isXMLDoc(a),f&&(b=m.propFix[b]||b,e=m.propHooks[b]),void 0!==c?e&&"set"in e&&void 0!==(d=e.set(a,c,b))?d:a[b]=c:e&&"get"in e&&null!==(d=e.get(a,b))?d:a[b]},propHooks:{tabIndex:{get:function(a){var b=m.find.attr(a,"tabindex");return b?parseInt(b,10):sb.test(a.nodeName)||tb.test(a.nodeName)&&a.href?0:-1}}}}),k.hrefNormalized||m.each(["href","src"],function(a,b){m.propHooks[b]={get:function(a){return a.getAttribute(b,4)}}}),k.optSelected||(m.propHooks.selected={get:function(a){var b=a.parentNode;return b&&(b.selectedIndex,b.parentNode&&b.parentNode.selectedIndex),null}}),m.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){m.propFix[this.toLowerCase()]=this}),k.enctype||(m.propFix.enctype="encoding");var ub=/[\t\r\n\f]/g;m.fn.extend({addClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j="string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).addClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):" ")){f=0;while(e=b[f++])d.indexOf(" "+e+" ")<0&&(d+=e+" ");g=m.trim(d),c.className!==g&&(c.className=g)}return this},removeClass:function(a){var b,c,d,e,f,g,h=0,i=this.length,j=0===arguments.length||"string"==typeof a&&a;if(m.isFunction(a))return this.each(function(b){m(this).removeClass(a.call(this,b,this.className))});if(j)for(b=(a||"").match(E)||[];i>h;h++)if(c=this[h],d=1===c.nodeType&&(c.className?(" "+c.className+" ").replace(ub," "):"")){f=0;while(e=b[f++])while(d.indexOf(" "+e+" ")>=0)d=d.replace(" "+e+" "," ");g=a?m.trim(d):"",c.className!==g&&(c.className=g)}return this},toggleClass:function(a,b){var c=typeof a;return"boolean"==typeof b&&"string"===c?b?this.addClass(a):this.removeClass(a):this.each(m.isFunction(a)?function(c){m(this).toggleClass(a.call(this,c,this.className,b),b)}:function(){if("string"===c){var b,d=0,e=m(this),f=a.match(E)||[];while(b=f[d++])e.hasClass(b)?e.removeClass(b):e.addClass(b)}else(c===K||"boolean"===c)&&(this.className&&m._data(this,"__className__",this.className),this.className=this.className||a===!1?"":m._data(this,"__className__")||"")})},hasClass:function(a){for(var b=" "+a+" ",c=0,d=this.length;d>c;c++)if(1===this[c].nodeType&&(" "+this[c].className+" ").replace(ub," ").indexOf(b)>=0)return!0;return!1}}),m.each("blur focus focusin focusout load resize scroll unload click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup error contextmenu".split(" "),function(a,b){m.fn[b]=function(a,c){return arguments.length>0?this.on(b,null,a,c):this.trigger(b)}}),m.fn.extend({hover:function(a,b){return this.mouseenter(a).mouseleave(b||a)},bind:function(a,b,c){return this.on(a,null,b,c)},unbind:function(a,b){return this.off(a,null,b)},delegate:function(a,b,c,d){return this.on(b,a,c,d)},undelegate:function(a,b,c){return 1===arguments.length?this.off(a,"**"):this.off(b,a||"**",c)}});var vb=m.now(),wb=/\?/,xb=/(,)|(\[|{)|(}|])|"(?:[^"\\\r\n]|\\["\\\/bfnrt]|\\u[\da-fA-F]{4})*"\s*:?|true|false|null|-?(?!0\d)\d+(?:\.\d+|)(?:[eE][+-]?\d+|)/g;m.parseJSON=function(b){if(a.JSON&&a.JSON.parse)return a.JSON.parse(b+"");var c,d=null,e=m.trim(b+"");return e&&!m.trim(e.replace(xb,function(a,b,e,f){return c&&b&&(d=0),0===d?a:(c=e||b,d+=!f-!e,"")}))?Function("return "+e)():m.error("Invalid JSON: "+b)},m.parseXML=function(b){var c,d;if(!b||"string"!=typeof b)return null;try{a.DOMParser?(d=new DOMParser,c=d.parseFromString(b,"text/xml")):(c=new ActiveXObject("Microsoft.XMLDOM"),c.async="false",c.loadXML(b))}catch(e){c=void 0}return c&&c.documentElement&&!c.getElementsByTagName("parsererror").length||m.error("Invalid XML: "+b),c};var yb,zb,Ab=/#.*$/,Bb=/([?&])_=[^&]*/,Cb=/^(.*?):[ \t]*([^\r\n]*)\r?$/gm,Db=/^(?:about|app|app-storage|.+-extension|file|res|widget):$/,Eb=/^(?:GET|HEAD)$/,Fb=/^\/\//,Gb=/^([\w.+-]+:)(?:\/\/(?:[^\/?#]*@|)([^\/?#:]*)(?::(\d+)|)|)/,Hb={},Ib={},Jb="*/".concat("*");try{zb=location.href}catch(Kb){zb=y.createElement("a"),zb.href="",zb=zb.href}yb=Gb.exec(zb.toLowerCase())||[];function Lb(a){return function(b,c){"string"!=typeof b&&(c=b,b="*");var d,e=0,f=b.toLowerCase().match(E)||[];if(m.isFunction(c))while(d=f[e++])"+"===d.charAt(0)?(d=d.slice(1)||"*",(a[d]=a[d]||[]).unshift(c)):(a[d]=a[d]||[]).push(c)}}function Mb(a,b,c,d){var e={},f=a===Ib;function g(h){var i;return e[h]=!0,m.each(a[h]||[],function(a,h){var j=h(b,c,d);return"string"!=typeof j||f||e[j]?f?!(i=j):void 0:(b.dataTypes.unshift(j),g(j),!1)}),i}return g(b.dataTypes[0])||!e["*"]&&g("*")}function Nb(a,b){var c,d,e=m.ajaxSettings.flatOptions||{};for(d in b)void 0!==b[d]&&((e[d]?a:c||(c={}))[d]=b[d]);return c&&m.extend(!0,a,c),a}function Ob(a,b,c){var d,e,f,g,h=a.contents,i=a.dataTypes;while("*"===i[0])i.shift(),void 0===e&&(e=a.mimeType||b.getResponseHeader("Content-Type"));if(e)for(g in h)if(h[g]&&h[g].test(e)){i.unshift(g);break}if(i[0]in c)f=i[0];else{for(g in c){if(!i[0]||a.converters[g+" "+i[0]]){f=g;break}d||(d=g)}f=f||d}return f?(f!==i[0]&&i.unshift(f),c[f]):void 0}function Pb(a,b,c,d){var e,f,g,h,i,j={},k=a.dataTypes.slice();if(k[1])for(g in a.converters)j[g.toLowerCase()]=a.converters[g];f=k.shift();while(f)if(a.responseFields[f]&&(c[a.responseFields[f]]=b),!i&&d&&a.dataFilter&&(b=a.dataFilter(b,a.dataType)),i=f,f=k.shift())if("*"===f)f=i;else if("*"!==i&&i!==f){if(g=j[i+" "+f]||j["* "+f],!g)for(e in j)if(h=e.split(" "),h[1]===f&&(g=j[i+" "+h[0]]||j["* "+h[0]])){g===!0?g=j[e]:j[e]!==!0&&(f=h[0],k.unshift(h[1]));break}if(g!==!0)if(g&&a["throws"])b=g(b);else try{b=g(b)}catch(l){return{state:"parsererror",error:g?l:"No conversion from "+i+" to "+f}}}return{state:"success",data:b}}m.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:zb,type:"GET",isLocal:Db.test(yb[1]),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Jb,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/xml/,html:/html/,json:/json/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":m.parseJSON,"text xml":m.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(a,b){return b?Nb(Nb(a,m.ajaxSettings),b):Nb(m.ajaxSettings,a)},ajaxPrefilter:Lb(Hb),ajaxTransport:Lb(Ib),ajax:function(a,b){"object"==typeof a&&(b=a,a=void 0),b=b||{};var c,d,e,f,g,h,i,j,k=m.ajaxSetup({},b),l=k.context||k,n=k.context&&(l.nodeType||l.jquery)?m(l):m.event,o=m.Deferred(),p=m.Callbacks("once memory"),q=k.statusCode||{},r={},s={},t=0,u="canceled",v={readyState:0,getResponseHeader:function(a){var b;if(2===t){if(!j){j={};while(b=Cb.exec(f))j[b[1].toLowerCase()]=b[2]}b=j[a.toLowerCase()]}return null==b?null:b},getAllResponseHeaders:function(){return 2===t?f:null},setRequestHeader:function(a,b){var c=a.toLowerCase();return t||(a=s[c]=s[c]||a,r[a]=b),this},overrideMimeType:function(a){return t||(k.mimeType=a),this},statusCode:function(a){var b;if(a)if(2>t)for(b in a)q[b]=[q[b],a[b]];else v.always(a[v.status]);return this},abort:function(a){var b=a||u;return i&&i.abort(b),x(0,b),this}};if(o.promise(v).complete=p.add,v.success=v.done,v.error=v.fail,k.url=((a||k.url||zb)+"").replace(Ab,"").replace(Fb,yb[1]+"//"),k.type=b.method||b.type||k.method||k.type,k.dataTypes=m.trim(k.dataType||"*").toLowerCase().match(E)||[""],null==k.crossDomain&&(c=Gb.exec(k.url.toLowerCase()),k.crossDomain=!(!c||c[1]===yb[1]&&c[2]===yb[2]&&(c[3]||("http:"===c[1]?"80":"443"))===(yb[3]||("http:"===yb[1]?"80":"443")))),k.data&&k.processData&&"string"!=typeof k.data&&(k.data=m.param(k.data,k.traditional)),Mb(Hb,k,b,v),2===t)return v;h=m.event&&k.global,h&&0===m.active++&&m.event.trigger("ajaxStart"),k.type=k.type.toUpperCase(),k.hasContent=!Eb.test(k.type),e=k.url,k.hasContent||(k.data&&(e=k.url+=(wb.test(e)?"&":"?")+k.data,delete k.data),k.cache===!1&&(k.url=Bb.test(e)?e.replace(Bb,"$1_="+vb++):e+(wb.test(e)?"&":"?")+"_="+vb++)),k.ifModified&&(m.lastModified[e]&&v.setRequestHeader("If-Modified-Since",m.lastModified[e]),m.etag[e]&&v.setRequestHeader("If-None-Match",m.etag[e])),(k.data&&k.hasContent&&k.contentType!==!1||b.contentType)&&v.setRequestHeader("Content-Type",k.contentType),v.setRequestHeader("Accept",k.dataTypes[0]&&k.accepts[k.dataTypes[0]]?k.accepts[k.dataTypes[0]]+("*"!==k.dataTypes[0]?", "+Jb+"; q=0.01":""):k.accepts["*"]);for(d in k.headers)v.setRequestHeader(d,k.headers[d]);if(k.beforeSend&&(k.beforeSend.call(l,v,k)===!1||2===t))return v.abort();u="abort";for(d in{success:1,error:1,complete:1})v[d](k[d]);if(i=Mb(Ib,k,b,v)){v.readyState=1,h&&n.trigger("ajaxSend",[v,k]),k.async&&k.timeout>0&&(g=setTimeout(function(){v.abort("timeout")},k.timeout));try{t=1,i.send(r,x)}catch(w){if(!(2>t))throw w;x(-1,w)}}else x(-1,"No Transport");function x(a,b,c,d){var j,r,s,u,w,x=b;2!==t&&(t=2,g&&clearTimeout(g),i=void 0,f=d||"",v.readyState=a>0?4:0,j=a>=200&&300>a||304===a,c&&(u=Ob(k,v,c)),u=Pb(k,u,v,j),j?(k.ifModified&&(w=v.getResponseHeader("Last-Modified"),w&&(m.lastModified[e]=w),w=v.getResponseHeader("etag"),w&&(m.etag[e]=w)),204===a||"HEAD"===k.type?x="nocontent":304===a?x="notmodified":(x=u.state,r=u.data,s=u.error,j=!s)):(s=x,(a||!x)&&(x="error",0>a&&(a=0))),v.status=a,v.statusText=(b||x)+"",j?o.resolveWith(l,[r,x,v]):o.rejectWith(l,[v,x,s]),v.statusCode(q),q=void 0,h&&n.trigger(j?"ajaxSuccess":"ajaxError",[v,k,j?r:s]),p.fireWith(l,[v,x]),h&&(n.trigger("ajaxComplete",[v,k]),--m.active||m.event.trigger("ajaxStop")))}return v},getJSON:function(a,b,c){return m.get(a,b,c,"json")},getScript:function(a,b){return m.get(a,void 0,b,"script")}}),m.each(["get","post"],function(a,b){m[b]=function(a,c,d,e){return m.isFunction(c)&&(e=e||d,d=c,c=void 0),m.ajax({url:a,type:b,dataType:e,data:c,success:d})}}),m._evalUrl=function(a){return m.ajax({url:a,type:"GET",dataType:"script",async:!1,global:!1,"throws":!0})},m.fn.extend({wrapAll:function(a){if(m.isFunction(a))return this.each(function(b){m(this).wrapAll(a.call(this,b))});if(this[0]){var b=m(a,this[0].ownerDocument).eq(0).clone(!0);this[0].parentNode&&b.insertBefore(this[0]),b.map(function(){var a=this;while(a.firstChild&&1===a.firstChild.nodeType)a=a.firstChild;return a}).append(this)}return this},wrapInner:function(a){return this.each(m.isFunction(a)?function(b){m(this).wrapInner(a.call(this,b))}:function(){var b=m(this),c=b.contents();c.length?c.wrapAll(a):b.append(a)})},wrap:function(a){var b=m.isFunction(a);return this.each(function(c){m(this).wrapAll(b?a.call(this,c):a)})},unwrap:function(){return this.parent().each(function(){m.nodeName(this,"body")||m(this).replaceWith(this.childNodes)}).end()}}),m.expr.filters.hidden=function(a){return a.offsetWidth<=0&&a.offsetHeight<=0||!k.reliableHiddenOffsets()&&"none"===(a.style&&a.style.display||m.css(a,"display"))},m.expr.filters.visible=function(a){return!m.expr.filters.hidden(a)};var Qb=/%20/g,Rb=/\[\]$/,Sb=/\r?\n/g,Tb=/^(?:submit|button|image|reset|file)$/i,Ub=/^(?:input|select|textarea|keygen)/i;function Vb(a,b,c,d){var e;if(m.isArray(b))m.each(b,function(b,e){c||Rb.test(a)?d(a,e):Vb(a+"["+("object"==typeof e?b:"")+"]",e,c,d)});else if(c||"object"!==m.type(b))d(a,b);else for(e in b)Vb(a+"["+e+"]",b[e],c,d)}m.param=function(a,b){var c,d=[],e=function(a,b){b=m.isFunction(b)?b():null==b?"":b,d[d.length]=encodeURIComponent(a)+"="+encodeURIComponent(b)};if(void 0===b&&(b=m.ajaxSettings&&m.ajaxSettings.traditional),m.isArray(a)||a.jquery&&!m.isPlainObject(a))m.each(a,function(){e(this.name,this.value)});else for(c in a)Vb(c,a[c],b,e);return d.join("&").replace(Qb,"+")},m.fn.extend({serialize:function(){return m.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var a=m.prop(this,"elements");return a?m.makeArray(a):this}).filter(function(){var a=this.type;return this.name&&!m(this).is(":disabled")&&Ub.test(this.nodeName)&&!Tb.test(a)&&(this.checked||!W.test(a))}).map(function(a,b){var c=m(this).val();return null==c?null:m.isArray(c)?m.map(c,function(a){return{name:b.name,value:a.replace(Sb,"\r\n")}}):{name:b.name,value:c.replace(Sb,"\r\n")}}).get()}}),m.ajaxSettings.xhr=void 0!==a.ActiveXObject?function(){return!this.isLocal&&/^(get|post|head|put|delete|options)$/i.test(this.type)&&Zb()||$b()}:Zb;var Wb=0,Xb={},Yb=m.ajaxSettings.xhr();a.attachEvent&&a.attachEvent("onunload",function(){for(var a in Xb)Xb[a](void 0,!0)}),k.cors=!!Yb&&"withCredentials"in Yb,Yb=k.ajax=!!Yb,Yb&&m.ajaxTransport(function(a){if(!a.crossDomain||k.cors){var b;return{send:function(c,d){var e,f=a.xhr(),g=++Wb;if(f.open(a.type,a.url,a.async,a.username,a.password),a.xhrFields)for(e in a.xhrFields)f[e]=a.xhrFields[e];a.mimeType&&f.overrideMimeType&&f.overrideMimeType(a.mimeType),a.crossDomain||c["X-Requested-With"]||(c["X-Requested-With"]="XMLHttpRequest");for(e in c)void 0!==c[e]&&f.setRequestHeader(e,c[e]+"");f.send(a.hasContent&&a.data||null),b=function(c,e){var h,i,j;if(b&&(e||4===f.readyState))if(delete Xb[g],b=void 0,f.onreadystatechange=m.noop,e)4!==f.readyState&&f.abort();else{j={},h=f.status,"string"==typeof f.responseText&&(j.text=f.responseText);try{i=f.statusText}catch(k){i=""}h||!a.isLocal||a.crossDomain?1223===h&&(h=204):h=j.text?200:404}j&&d(h,i,j,f.getAllResponseHeaders())},a.async?4===f.readyState?setTimeout(b):f.onreadystatechange=Xb[g]=b:b()},abort:function(){b&&b(void 0,!0)}}}});function Zb(){try{return new a.XMLHttpRequest}catch(b){}}function $b(){try{return new a.ActiveXObject("Microsoft.XMLHTTP")}catch(b){}}m.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/(?:java|ecma)script/},converters:{"text script":function(a){return m.globalEval(a),a}}}),m.ajaxPrefilter("script",function(a){void 0===a.cache&&(a.cache=!1),a.crossDomain&&(a.type="GET",a.global=!1)}),m.ajaxTransport("script",function(a){if(a.crossDomain){var b,c=y.head||m("head")[0]||y.documentElement;return{send:function(d,e){b=y.createElement("script"),b.async=!0,a.scriptCharset&&(b.charset=a.scriptCharset),b.src=a.url,b.onload=b.onreadystatechange=function(a,c){(c||!b.readyState||/loaded|complete/.test(b.readyState))&&(b.onload=b.onreadystatechange=null,b.parentNode&&b.parentNode.removeChild(b),b=null,c||e(200,"success"))},c.insertBefore(b,c.firstChild)},abort:function(){b&&b.onload(void 0,!0)}}}});var _b=[],ac=/(=)\?(?=&|$)|\?\?/;m.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var a=_b.pop()||m.expando+"_"+vb++;return this[a]=!0,a}}),m.ajaxPrefilter("json jsonp",function(b,c,d){var e,f,g,h=b.jsonp!==!1&&(ac.test(b.url)?"url":"string"==typeof b.data&&!(b.contentType||"").indexOf("application/x-www-form-urlencoded")&&ac.test(b.data)&&"data");return h||"jsonp"===b.dataTypes[0]?(e=b.jsonpCallback=m.isFunction(b.jsonpCallback)?b.jsonpCallback():b.jsonpCallback,h?b[h]=b[h].replace(ac,"$1"+e):b.jsonp!==!1&&(b.url+=(wb.test(b.url)?"&":"?")+b.jsonp+"="+e),b.converters["script json"]=function(){return g||m.error(e+" was not called"),g[0]},b.dataTypes[0]="json",f=a[e],a[e]=function(){g=arguments},d.always(function(){a[e]=f,b[e]&&(b.jsonpCallback=c.jsonpCallback,_b.push(e)),g&&m.isFunction(f)&&f(g[0]),g=f=void 0}),"script"):void 0}),m.parseHTML=function(a,b,c){if(!a||"string"!=typeof a)return null;"boolean"==typeof b&&(c=b,b=!1),b=b||y;var d=u.exec(a),e=!c&&[];return d?[b.createElement(d[1])]:(d=m.buildFragment([a],b,e),e&&e.length&&m(e).remove(),m.merge([],d.childNodes))};var bc=m.fn.load;m.fn.load=function(a,b,c){if("string"!=typeof a&&bc)return bc.apply(this,arguments);var d,e,f,g=this,h=a.indexOf(" ");return h>=0&&(d=m.trim(a.slice(h,a.length)),a=a.slice(0,h)),m.isFunction(b)?(c=b,b=void 0):b&&"object"==typeof b&&(f="POST"),g.length>0&&m.ajax({url:a,type:f,dataType:"html",data:b}).done(function(a){e=arguments,g.html(d?m("<div>").append(m.parseHTML(a)).find(d):a)}).complete(c&&function(a,b){g.each(c,e||[a.responseText,b,a])}),this},m.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(a,b){m.fn[b]=function(a){return this.on(b,a)}}),m.expr.filters.animated=function(a){return m.grep(m.timers,function(b){return a===b.elem}).length};var cc=a.document.documentElement;function dc(a){return m.isWindow(a)?a:9===a.nodeType?a.defaultView||a.parentWindow:!1}m.offset={setOffset:function(a,b,c){var d,e,f,g,h,i,j,k=m.css(a,"position"),l=m(a),n={};"static"===k&&(a.style.position="relative"),h=l.offset(),f=m.css(a,"top"),i=m.css(a,"left"),j=("absolute"===k||"fixed"===k)&&m.inArray("auto",[f,i])>-1,j?(d=l.position(),g=d.top,e=d.left):(g=parseFloat(f)||0,e=parseFloat(i)||0),m.isFunction(b)&&(b=b.call(a,c,h)),null!=b.top&&(n.top=b.top-h.top+g),null!=b.left&&(n.left=b.left-h.left+e),"using"in b?b.using.call(a,n):l.css(n)}},m.fn.extend({offset:function(a){if(arguments.length)return void 0===a?this:this.each(function(b){m.offset.setOffset(this,a,b)});var b,c,d={top:0,left:0},e=this[0],f=e&&e.ownerDocument;if(f)return b=f.documentElement,m.contains(b,e)?(typeof e.getBoundingClientRect!==K&&(d=e.getBoundingClientRect()),c=dc(f),{top:d.top+(c.pageYOffset||b.scrollTop)-(b.clientTop||0),left:d.left+(c.pageXOffset||b.scrollLeft)-(b.clientLeft||0)}):d},position:function(){if(this[0]){var a,b,c={top:0,left:0},d=this[0];return"fixed"===m.css(d,"position")?b=d.getBoundingClientRect():(a=this.offsetParent(),b=this.offset(),m.nodeName(a[0],"html")||(c=a.offset()),c.top+=m.css(a[0],"borderTopWidth",!0),c.left+=m.css(a[0],"borderLeftWidth",!0)),{top:b.top-c.top-m.css(d,"marginTop",!0),left:b.left-c.left-m.css(d,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var a=this.offsetParent||cc;while(a&&!m.nodeName(a,"html")&&"static"===m.css(a,"position"))a=a.offsetParent;return a||cc})}}),m.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(a,b){var c=/Y/.test(b);m.fn[a]=function(d){return V(this,function(a,d,e){var f=dc(a);return void 0===e?f?b in f?f[b]:f.document.documentElement[d]:a[d]:void(f?f.scrollTo(c?m(f).scrollLeft():e,c?e:m(f).scrollTop()):a[d]=e)},a,d,arguments.length,null)}}),m.each(["top","left"],function(a,b){m.cssHooks[b]=La(k.pixelPosition,function(a,c){return c?(c=Ja(a,b),Ha.test(c)?m(a).position()[b]+"px":c):void 0})}),m.each({Height:"height",Width:"width"},function(a,b){m.each({padding:"inner"+a,content:b,"":"outer"+a},function(c,d){m.fn[d]=function(d,e){var f=arguments.length&&(c||"boolean"!=typeof d),g=c||(d===!0||e===!0?"margin":"border");return V(this,function(b,c,d){var e;return m.isWindow(b)?b.document.documentElement["client"+a]:9===b.nodeType?(e=b.documentElement,Math.max(b.body["scroll"+a],e["scroll"+a],b.body["offset"+a],e["offset"+a],e["client"+a])):void 0===d?m.css(b,c,g):m.style(b,c,d,g)},b,f?d:void 0,f,null)}})}),m.fn.size=function(){return this.length},m.fn.andSelf=m.fn.addBack,"function"==typeof define&&define.amd&&define("jquery",[],function(){return m});var ec=a.jQuery,fc=a.$;return m.noConflict=function(b){return a.$===m&&(a.$=fc),b&&a.jQuery===m&&(a.jQuery=ec),m},typeof b===K&&(a.jQuery=a.$=m),m});
"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="data:text/css;charset=utf-8,html%7Bfont%2Dfamily%3Asans%2Dserif%3B%2Dwebkit%2Dtext%2Dsize%2Dadjust%3A100%25%3B%2Dms%2Dtext%2Dsize%2Dadjust%3A100%25%7Dbody%7Bmargin%3A0%7Darticle%2Caside%2Cdetails%2Cfigcaption%2Cfigure%2Cfooter%2Cheader%2Chgroup%2Cmain%2Cmenu%2Cnav%2Csection%2Csummary%7Bdisplay%3Ablock%7Daudio%2Ccanvas%2Cprogress%2Cvideo%7Bdisplay%3Ainline%2Dblock%3Bvertical%2Dalign%3Abaseline%7Daudio%3Anot%28%5Bcontrols%5D%29%7Bdisplay%3Anone%3Bheight%3A0%7D%5Bhidden%5D%2Ctemplate%7Bdisplay%3Anone%7Da%7Bbackground%2Dcolor%3Atransparent%7Da%3Aactive%2Ca%3Ahover%7Boutline%3A0%7Dabbr%5Btitle%5D%7Bborder%2Dbottom%3A1px%20dotted%7Db%2Cstrong%7Bfont%2Dweight%3A700%7Ddfn%7Bfont%2Dstyle%3Aitalic%7Dh1%7Bmargin%3A%2E67em%200%3Bfont%2Dsize%3A2em%7Dmark%7Bcolor%3A%23000%3Bbackground%3A%23ff0%7Dsmall%7Bfont%2Dsize%3A80%25%7Dsub%2Csup%7Bposition%3Arelative%3Bfont%2Dsize%3A75%25%3Bline%2Dheight%3A0%3Bvertical%2Dalign%3Abaseline%7Dsup%7Btop%3A%2D%2E5em%7Dsub%7Bbottom%3A%2D%2E25em%7Dimg%7Bborder%3A0%7Dsvg%3Anot%28%3Aroot%29%7Boverflow%3Ahidden%7Dfigure%7Bmargin%3A1em%2040px%7Dhr%7Bheight%3A0%3B%2Dwebkit%2Dbox%2Dsizing%3Acontent%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Acontent%2Dbox%3Bbox%2Dsizing%3Acontent%2Dbox%7Dpre%7Boverflow%3Aauto%7Dcode%2Ckbd%2Cpre%2Csamp%7Bfont%2Dfamily%3Amonospace%2Cmonospace%3Bfont%2Dsize%3A1em%7Dbutton%2Cinput%2Coptgroup%2Cselect%2Ctextarea%7Bmargin%3A0%3Bfont%3Ainherit%3Bcolor%3Ainherit%7Dbutton%7Boverflow%3Avisible%7Dbutton%2Cselect%7Btext%2Dtransform%3Anone%7Dbutton%2Chtml%20input%5Btype%3Dbutton%5D%2Cinput%5Btype%3Dreset%5D%2Cinput%5Btype%3Dsubmit%5D%7B%2Dwebkit%2Dappearance%3Abutton%3Bcursor%3Apointer%7Dbutton%5Bdisabled%5D%2Chtml%20input%5Bdisabled%5D%7Bcursor%3Adefault%7Dbutton%3A%3A%2Dmoz%2Dfocus%2Dinner%2Cinput%3A%3A%2Dmoz%2Dfocus%2Dinner%7Bpadding%3A0%3Bborder%3A0%7Dinput%7Bline%2Dheight%3Anormal%7Dinput%5Btype%3Dcheckbox%5D%2Cinput%5Btype%3Dradio%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%3Bpadding%3A0%7Dinput%5Btype%3Dnumber%5D%3A%3A%2Dwebkit%2Dinner%2Dspin%2Dbutton%2Cinput%5Btype%3Dnumber%5D%3A%3A%2Dwebkit%2Douter%2Dspin%2Dbutton%7Bheight%3Aauto%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Acontent%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Acontent%2Dbox%3Bbox%2Dsizing%3Acontent%2Dbox%3B%2Dwebkit%2Dappearance%3Atextfield%7Dinput%5Btype%3Dsearch%5D%3A%3A%2Dwebkit%2Dsearch%2Dcancel%2Dbutton%2Cinput%5Btype%3Dsearch%5D%3A%3A%2Dwebkit%2Dsearch%2Ddecoration%7B%2Dwebkit%2Dappearance%3Anone%7Dfieldset%7Bpadding%3A%2E35em%20%2E625em%20%2E75em%3Bmargin%3A0%202px%3Bborder%3A1px%20solid%20silver%7Dlegend%7Bpadding%3A0%3Bborder%3A0%7Dtextarea%7Boverflow%3Aauto%7Doptgroup%7Bfont%2Dweight%3A700%7Dtable%7Bborder%2Dspacing%3A0%3Bborder%2Dcollapse%3Acollapse%7Dtd%2Cth%7Bpadding%3A0%7D%40media%20print%7B%2A%2C%3Aafter%2C%3Abefore%7Bcolor%3A%23000%21important%3Btext%2Dshadow%3Anone%21important%3Bbackground%3A0%200%21important%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%21important%3Bbox%2Dshadow%3Anone%21important%7Da%2Ca%3Avisited%7Btext%2Ddecoration%3Aunderline%7Da%5Bhref%5D%3Aafter%7Bcontent%3A%22%20%28%22%20attr%28href%29%20%22%29%22%7Dabbr%5Btitle%5D%3Aafter%7Bcontent%3A%22%20%28%22%20attr%28title%29%20%22%29%22%7Da%5Bhref%5E%3D%22javascript%3A%22%5D%3Aafter%2Ca%5Bhref%5E%3D%22%23%22%5D%3Aafter%7Bcontent%3A%22%22%7Dblockquote%2Cpre%7Bborder%3A1px%20solid%20%23999%3Bpage%2Dbreak%2Dinside%3Aavoid%7Dthead%7Bdisplay%3Atable%2Dheader%2Dgroup%7Dimg%2Ctr%7Bpage%2Dbreak%2Dinside%3Aavoid%7Dimg%7Bmax%2Dwidth%3A100%25%21important%7Dh2%2Ch3%2Cp%7Borphans%3A3%3Bwidows%3A3%7Dh2%2Ch3%7Bpage%2Dbreak%2Dafter%3Aavoid%7D%2Enavbar%7Bdisplay%3Anone%7D%2Ebtn%3E%2Ecaret%2C%2Edropup%3E%2Ebtn%3E%2Ecaret%7Bborder%2Dtop%2Dcolor%3A%23000%21important%7D%2Elabel%7Bborder%3A1px%20solid%20%23000%7D%2Etable%7Bborder%2Dcollapse%3Acollapse%21important%7D%2Etable%20td%2C%2Etable%20th%7Bbackground%2Dcolor%3A%23fff%21important%7D%2Etable%2Dbordered%20td%2C%2Etable%2Dbordered%20th%7Bborder%3A1px%20solid%20%23ddd%21important%7D%7D%40font%2Dface%7Bfont%2Dfamily%3A%27Glyphicons%20Halflings%27%3Bsrc%3Aurl%28data%3Aapplication%2Fvnd%2Ems%2Dfontobject%3Bbase64%2Cn04AAEFNAAACAAIABAAAAAAABQAAAAAAAAABAJABAAAEAExQAAAAAAAAAAIAAAAAAAAAAAEAAAAAAAAAJxJ%2FLAAAAAAAAAAAAAAAAAAAAAAAACgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAAAADgBSAGUAZwB1AGwAYQByAAAAeABWAGUAcgBzAGkAbwBuACAAMQAuADAAMAA5ADsAUABTACAAMAAwADEALgAwADAAOQA7AGgAbwB0AGMAbwBuAHYAIAAxAC4AMAAuADcAMAA7AG0AYQBrAGUAbwB0AGYALgBsAGkAYgAyAC4ANQAuADUAOAAzADIAOQAAADgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzACAAUgBlAGcAdQBsAGEAcgAAAAAAQlNHUAAAAAAAAAAAAAAAAAAAAAADAKncAE0TAE0ZAEbuFM3pjM%2FSEdmjKHUbyow8ATBE40IvWA3vTu8LiABDQ%2BpexwUMcm1SMnNryctQSiI1K5ZnbOlXKmnVV5YvRe6RnNMFNCOs1KNVpn6yZhCJkRtVRNzEufeIq7HgSrcx4S8h%2Fv4vnrrKc6oCNxmSk2uKlZQHBii6iKFoH0746ThvkO1kJHlxjrkxs%2BLWORaDQBEtiYJIR5IB9Bi1UyL4Rmr0BNigNkMzlKQmnofBHviqVzUxwdMb3NdCn69hy%2BpRYVKGVS%2F1tnsqv4LL7wCCPZZAZPT4aCShHjHJVNuXbmMrY5LeQaGnvAkXlVrJgKRAUdFjrWEah9XebPeQMj7KS7DIBAFt8ycgC5PLGUOHSE3ErGZCiViNLL5ZARfywnCoZaKQCu6NuFX42AEeKtKUGnr%2FCm2Cy8tpFhBPMW5Fxi4Qm4TkDWh4IWFDClhU2hRWosUWqcKLlgyXB%2BlSHaWaHiWlBAR8SeSgSPCQxdVQgzUixWKSTrIQEbU94viDctkvX%2BVSjJuUmV8L4CXShI11esnp0pjWNZIyxKHS4wVQ2ime1P4RnhvGw0aDN1OLAXGERsB7buFpFGGBAre4QEQR0HOIO5oYH305G%2BKspT%2FFupEGGafCCwxSe6ZUa%2B073rXHnNdVXE6eWvibUS27XtRzkH838mYLMBmYysZTM0EM3A1fbpCBYFccN1B%2FEnCYu%2FTgCGmr7bMh8GfYL%2BBfcLvB0gRagC09w9elfldaIy%2FhNCBLRgBgtCC7jAF63wLSMAfbfAlEggYU0bUA7ACCJmTDpEmJtI78w4%2FBO7dN7JR7J7ZvbYaUbaILSQsRBiF3HGk5fEg6p9unwLvn98r%2BvnsV%2B372uf1xBLq4qU%2F45fTuqaAP%2BpssmCCCTF0mhEow8ZXZOS8D7Q85JsxZ%2BAzok7B7O%2Ff6J8AzYBySZQB%2FQHYUSA%2BEeQhEWiS6AIQzgcsDiER4MjgMBAWDV4AgQ3g1eBgIdweCQmCjJEMkJ%2BPKRWyFHHmg1Wi%2F6xzUgA0LREoKJChwnQa9B%2B5RQZRB3IlBlkAnxyQNaANwHMowzlYSMCBgnbpzvqpl0iTJNCQidDI9ZrSYNIRBhHtUa5YHMHxyGEik9hDE0AKj72AbTCaxtHPUaKZdAZSnQTyjGqGLsmBStCejApUhg4uBMU6mATujEl%2BKdDPbI6Ag4vLr%2BhjY6lbjBeoLKnZl0UZgRX8gTySOeynZVz1wOq7e1hFGYIq%2BMhrGxDLak0PrwYzSXtcuyhXEhwOYofiW%2BEcI%2Fjw8P6IY6ed%2BetAbuqKp5QIapT77LnAe505lMuqL79a0ut4rWexzFttsOsLDy7zvtQzcq3U1qabe7tB0wHWVXji%2BzDbo8x8HyIRUbXnwUcklFv51fvTymiV%2BMXLSmGH9d9%2BaXpD5X6lao41anWGig7IwIdnoBY2ht%2FpO9mClLo4NdXHAsefqWUKlXJkbqPOFhMoR4aiA1BXqhRNbB2Xwi%2B7u%2FjpAoOpKJ0UX24EsrzMfHXViakCNcKjBxuQX8BO0ZqjJ3xXzf%2B61t2VXOSgJ8xu65QKgtN6FibPmPYsXbJRHHqbgATcSZxBqGiDiU4NNNsYBsKD0MIP%2FOfKnlk%2FLkaid%2FO2NbKeuQrwOB2Gq3YHyr6ALgzym5wIBnsdC1ZkoBFZSQXChZvlesPqvK2c5oHHT3Q65jYpNxnQcGF0EHbvYqoFw60WNlXIHQF2HQB7zD6lWjZ9rVqUKBXUT6hrkZOle0RFYII0V5ZYGl1JAP0Ud1fZZMvSomBzJ710j4Me8mjQDwEre5Uv2wQfk1ifDwb5ksuJQQ3xt423lbuQjvoIQByQrNDh1JxGFkOdlJvu%2FgFtuW0wR4cgd%2BZKesSV7QkNE2kw6AV4hoIuC02LGmTomyf8PiO6CZzOTLTPQ%2BHW06H%2Btx%2BbQ8LmDYg1pTFrp2oJXgkZTyeRJZM0C8aE2LpFrNVDuhARsN543%2FFV6klQ6Tv1OoZGXLv0igKrl%2FCmJxRmX7JJbJ998VSIPQRyDBICzl4JJlYHbdql30NvYcOuZ7a10uWRrgoieOdgIm4rlq6vNOQBuqESLbXG5lzdJGHw2m0sDYmODXbYGTfSTGRKpssTO95fothJCjUGQgEL4yKoGAF%2F0SrpUDNn8CBgBcSDQByAeNkCXp4S4Ro2Xh4OeaGRgR66PVOsU8bc6TR5%2FxTcn4IVMLOkXSWiXxkZQCbvKfmoAvQaKjO3EDKwkwqHChCDEM5loQRPd5ACBki1TjF772oaQhQbQ5C0lcWXPFOzrfsDGUXGrpxasbG4iab6eByaQkQfm0VFlP0ZsDkvvqCL6QXMUwCjdMx1ZOyKhTJ7a1GWAdOUcJ8RSejxNVyGs31OKMyRyBVoZFjqIkmKlLQ5eHMeEL4MkUf23cQ%2F1SgRCJ1dk4UdBT7OoyuNgLs0oCd8RnrEIb6QdMxT2QjD4zMrJkfgx5aDMcA4orsTtKCqWb%2FVeyceqa5OGSmB28YwH4rFbkQaLoUN8OQQYnD3w2eXpI4ScQfbCUZiJ4yMOIKLyyTc7BQ4uXUw6Ee6%2FxM%2B4Y67ngNBknxIPwuppgIhFcwJyr6EIj%2BLzNj%2FmfR2vhhRlx0BILZoAYruF0caWQ7YxO66UmeguDREAFHYuC7HJviRgVO6ruJH59h%2FC%2FPkgSle8xNzZJULLWq9JMDTE2fjGE146a1Us6PZDGYle6ldWRqn%2FpdpgHKNGrGIdkRK%2BKPETT9nKT6kLyDI8xd9A1FgWmXWRAIHwZ37WyZHOVyCadJEmMVz0MadMjDrPho%2BEIochkVC2xgGiwwsQ6DMv2P7UXqT4x7CdcYGId2BJQQa85EQKmCmwcRejQ9Bm4oATENFPkxPXILHpMPUyWTI5rjNOsIlmEeMbcOCEqInpXACYQ9DDxmFo9vcmsDblcMtg4tqBerNngkIKaFJmrQAPnq1dEzsMXcwjcHdfdCibcAxxA%2Bq%2Fj9m3LM%2FO7WJka4tSidVCjsvo2lQ%2F2ewyoYyXwAYyr2PlRoR5MpgVmSUIrM3PQxXPbgjBOaDQFIyFMJvx3Pc5RSYj12ySVF9fwFPQu2e2KWVoL9q3Ayv3IzpGHUdvdPdrNUdicjsTQ2ISy7QU3DrEytIjvbzJnAkmANXjAFERA0MUoPF3%2F5KFmW14bBNOhwircYgMqoDpUMcDtCmBE82QM2YtdjVLB4kBuKho%2FbcwQdeboqfQartuU3CsCf%2BcXkgYAqp%2F0Ee3RorAZt0AvvOCSI4JICIlGlsV0bsSid%2FNIEALAAzb6HAgyWHBps6xAOwkJIGcB82CxRQq4sJf3FzA70A%2BTRqcqjEMETCoez3mkPcpnoALs0ugJY8kQwrC%2BJE5ik3w9rzrvDRjAQnqgEVvdGrNwlanR0SOKWzxOJOvLJhcd8Cl4AshACUkv9czdMkJCVQSQhp6kp7StAlpVRpK0t0SW6LHeBJnE2QchB5Ccu8kxRghZXGIgZIiSj7gEKMJDClcnX6hgoqJMwiQDigIXg3ioFLCgDgjPtYHYpsF5EiA4kcnN18MZtOrY866dEQAb0FB34OGKHGZQjwW%2FWDHA60cYFaI%2FPjpzquUqdaYGcIq%2BmLez3WLFFCtNBN2QJcrlcoELgiPku5R5dSlJFaCEqEZle1AQzAKC%2B1SotMcBNyQUFuRHRF6OlimSBgjZeTBCwLyc6A%2BP%2FoFRchXTz5ADknYJHxzrJ5pGuIKRQISU6WyKTBBjD8WozmVYWIsto1AS5rxzKlvJu4E%2FvwOiKxRtCWsDM%2BeTHUrmwrCK5BIfMzGkD%2B0Fk5LzBs0jMYXktNDblB06LMNJ09U8pzSLmo14MS0OMjcdrZ31pyQqxJJpRImlSvfYAK8inkYU52QY2FPEVsjoWewpwhRp5yAuNpkqhdb7ku9Seefl2D0B8SMTFD90xi4CSOwwZy9IKkpMtI3FmFUg3%2FkFutpQGNc3pCR7gvC4sgwbupDu3DyEN%2BW6YGLNM21jpB49irxy9BSlHrVDlnihGKHwPrbVFtc%2Bh1rVQKZduxIyojccZIIcOCmhEnC7UkY68WXKQgLi2JCDQkQWJRQuk60hZp0D3rtCTINSeY9Ej2kIKYfGxwOs4j9qMM7fYZiipzgcf7TamnehqdhsiMiCawXnz4xAbyCkLAx5EGbo3Ax1u3dUIKnTxIaxwQTHehPl3V491H0%2BbC5zgpGz7Io%2BmjdhKlPJ01EeMpM7UsRJMi1nGjmJg35i6bQBAAxjO%2FENJubU2mg3ONySEoWklCwdABETcs7ck3jgiuU9pcKKpbgn%2B3YlzV1FzIkB6pmEDOSSyDfPPlQskznctFji0kpgZjW5RZe6x9kYT4KJcXg0bNiCyif%2BpZACCyRMmYsfiKmN9tSO65F0R2OO6ytlEhY5Sj6uRKfFxw0ijJaAx%2Fk3QgnAFSq27%2F2i4GEBA%2BUvTJKK%2F9eISNvG46Em5RZfjTYLdeD8kdXHyrwId%2FDQZUaMCY4gGbke2C8vfjgV%2FY9kkRQOJIn%2FxM9INZSpiBnqX0Q9GlQPpPKAyO5y%2BW5NMPSRdBCUlmuxl40ZfMCnf2Cp044uI9WLFtCi4YVxKjuRCOBWIb4XbIsGdbo4qtMQnNOQz4XDSui7W%2FN6l54qOynCqD3DpWQ%2BmpD7C40D8BZEWGJX3tlAaZBMj1yjvDYKwCJBa201u6nBKE5UE%2B7QSEhCwrXfbRZylAaAkplhBWX50dumrElePyNMRYUrC99UmcSSNgImhFhDI4BXjMtiqkgizUGCrZ8iwFxU6fQ8GEHCFdLewwxYWxgScAYMdMLmcZR6b7rZl95eQVDGVoUKcRMM1ixXQtXNkBETZkVVPg8LoSrdetHzkuM7DjZRHP02tCxA1fmkXKF3VzfN1pc1cv%2F8lbTIkkYpqKM9VOhp65ktYk%2BQ46myFWBapDfyWUCnsnI00QTBQmuFjMZTcd0V2NQ768Fhpby04k2IzNR1wKabuGJqYWwSly6ocMFGTeeI%2BejsWDYgEvr66QgqdcIbFYDNgsm0x9UHY6SCd5%2B7tpsLpKdvhahIDyYmEJQCqMqtCF6UlrE5GXRmbu%2Bvtm3BFSxI6ND6UxIE7GsGMgWqghXxSnaRJuGFveTcK5ZVSPJyjUxe1dKgI6kNF7EZhIZs8y8FVqwEfbM0Xk2ltORVDKZZM40SD3qQoQe0orJEKwPfZwm3YPqwixhUMOndis6MhbmfvLBKjC8sKKIZKbJk8L11oNkCQzCgvjhyyEiQSuJcgCQSG4Mocfgc0Hkwcjal1UNgP0CBPikYqBIk9tONv4kLtBswH07vUCjEaHiFGlLf8MgXKzSgjp2HolRRccAOh0ILHz9qlGgIFkwAnzHJRjWFhlA7ROwINyB5HFj59PRZHFor6voq7l23EPNRwdWhgawqbivLSjRA4htEYUFkjESu67icTg5S0aW1sOkCiIysfJ9UnIWevOOLGpepcBxy1wEhd2WI3AZg7sr9WBmHWyasxMcvY%2FiOmsLtHSWNUWEGk9hScMPShasUA1AcHOtRZlqMeQ0OzYS9vQvYUjOLrzP07BUAFikcJNMi7gIxEw4pL1G54TcmmmoAQ5s7TGWErJZ2Io4yQ0ljRYhL8H5e62oDtLF8aDpnIvZ5R3GWJyAugdiiJW9hQAVTsnCBHhwu7rkBlBX6r3b7ejEY0k5GGeyKv66v%2B6dg7mcJTrWHbtMywbedYqCQ0FPwoytmSWsL8WTtChZCKKzEF7vP6De4x2BJkkniMgSdWhbeBSLtJZR9CTHetK1xb34AYIJ37OegYIoPVbXgJ%2FqDQK%2BbfCtxQRVKQu77WzOoM6SGL7MaZwCGJVk46aImai9fmam%2BWpHG%2B0BtQPWUgZ7RIAlPq6lkECUhZQ2gqWkMYKcYMYaIc4gYCDFHYa2d1nzp3%2BJ1eCBay8IYZ0wQRKGAqvCuZ%2FUgbQPyllosq%2BXtfKIZOzmeJqRazpmmoP%2F76YfkjzV2NlXTDSBYB04SVlNQsFTbGPk1t%2FI4Jktu0XSgifO2ozFOiwd%2F0SssJDn0dn4xqk4GDTTKX73%2FwQyBLdqgJ%2BWx6AQaba3BA9CKEzjtQYIfAsiYamapq80LAamYjinlKXUkxdpIDk0puXUEYzSalfRibAeDAKpNiqQ0FTwoxuGYzRnisyTotdVTclis1LHRQCy%2FqqL8oUaQzWRxilq5Mi0IJGtMY02cGLD69vGjkj3p6pGePKI8bkBv5evq8SjjyU04vJR2cQXQwSJyoinDsUJHCQ50jrFTT7yRdbdYQMB3MYCb6uBzJ9ewhXYPAIZSXfeEQBZZ3GPN3Nbhh%2FwkvAJLXnQMdi5NYYZ5GHE400GS5rXkOZSQsdZgIbzRnF9ueLnsfQ47wHAsirITnTlkCcuWWIUhJSbpM3wWhXNHvt2xUsKKMpdBSbJnBMcihkoDqAd1Zml%2FR4yrzow1Q2A5G%2Bkzo%2FRhRxQS2lCSDRV8LlYLBOOoo1bF4jwJAwKMK1tWLHlu9i0j4Ig8qVm6wE1DxXwAwQwsaBWUg2pOOol2dHxyt6npwJEdLDDVYyRc2D0HbcbLUJQj8gPevQBUBOUHXPrsAPBERICpnYESeu2OHotpXQxRGlCCtLdIsu23MhZVEoJg8Qumj%2FUMMc34IBqTKLDTp76WzL%2FdMjCxK7MjhiGjeYAC%2Fkj%2FjY%2FRde7hpSM1xChrog6yZ7OWTuD56xBJnGFE%2BpT2ElSyCnJcwVzCjkqeNLfMEJqKW0G7OFIp0G%2B9mh50I9o8k1tpCY0xYqFNIALgIfc2me4n1bmJnRZ89oepgLPT0NTMLNZsvSCZAc3TXaNB07vail36%2FdBySis4m9%2FDR8izaLJW6bWCkVgm5T%2Bius3ZXq4xI%2BGnbveLbdRwF2mNtsrE0JjYc1AXknCOrLSu7Te%2Fr4dPYMCl5qtiHNTn%2BTPbh1jCBHH%2BdMJNhwNgs3nT%2BOhQoQ0vYif56BMG6WowAcHR3DjQolxLzyVekHj00PBAaW7IIAF1EF%2BuRIWyXjQMAs2chdpaKPNaB%2BkSezYt0%2BCA04sOg5vx8Fr7Ofa9sUv87h7SLAUFSzbetCCZ9pmyLt6l6%2FTzoA1%2FZBG9bIUVHLAbi%2FkdBFgYGyGwRQGBpkqCEg2ah9UD6EedEcEL3j4y0BQQCiExEnocA3SZboh%2Bepgd3YsOkHskZwPuQ5OoyA0fTA5AXrHcUOQF%2BzkJHIA7PwCDk1gGVmGUZSSoPhNf%2BTklauz98QofOlCIQ%2FtCD4dosHYPqtPCXB3agggQQIqQJsSkB%2Bqn0rkQ1toJjON%2FOtCIB9RYv3PqRA4C4U68ZMlZn6BdgEvi2ziU%2BTQ6NIw3ej%2BAtDwMGEZk7e2IjxUWKdAxyaw9OCwSmeADTPPleyk6UhGDNXQb%2B%2BW6Uk4q6F7%2Frg6WVTo82IoCxSIsFDrav4EPHphD3u4hR53WKVvYZUwNCCeM4PMBWzK%2BEfIthZOkuAwPo5C5jgoZgn6dUdvx5rIDmd58cXXdKNfw3l%2BwM2UjgrDJeQHhbD7HW2QDoZMCujgIUkk5Fg8VCsdyjOtnGRx8wgKRPZN5dR0zPUyfGZFVihbFRniXZFOZGKPnEQzU3AnD1KfR6weHW2XS6KbPJxUkOTZsAB9vTVp3Le1F8q5l%2BDMcLiIq78jxAImD2pGFw0VHfRatScGlK6SMu8leTmhUSMy8Uhdd6xBiH3Gdman4tjQGLboJfqz6fL2WKHTmrfsKZRYX6BTDjDldKMosaSTLdQS7oDisJNqAUhw1PfTlnacCO8vl8706Km1FROgLDmudzxg%2BEWTiArtHgLsRrAXYWdB0NmToNCJdKm0KWycZQqb%2BMw76Qy29iQ5up%2FX7oyw8QZ75kP5F6iJAJz6KCmqxz8fEa%2FxnsMYcIO%2FvEkGRuMckhr4rIeLrKaXnmIzlNLxbFspOphkcnJdnz%2FChp%2FVlpj2P7jJQmQRwGnltkTV5dbF9fE3%2FfxoSqTROgq9wFUlbuYzYcasE0ouzBo%2BdDCDzxKAfhbAZYxQiHrLzV2iVexnDX%2FQnT1fsT%2Fxuhu1ui5qIytgbGmRoQkeQooO8eJNNZsf0iALur8QxZFH0nCMnjerYQqG1pIfjyVZWxhVRznmmfLG00BcBWJE6hzQWRyFknuJnXuk8A5FRDCulwrWASSNoBtR%2BCtGdkPwYN2o7DOw%2FVGlCZPusRBFXODQdUM5zeHDIVuAJBLqbO%2Ff9Qua%2BpDqEPk230Sob9lEZ8BHiCorjVghuI0lI4JDgHGRDD%2FprQ84B1pVGkIpVUAHCG%2Biz3Bn3qm2AVrYcYWhock4jso5%2BJ7HfHVj4WMIQdGctq3psBCVVzupQOEioBGA2Bk%2BUILT7%2BVoX5mdxxA5fS42gISQVi%2FHTzrgMxu0fY6hE1ocUwwbsbWcezrY2n6S8%2F6cxXkOH4prpmPuFoikTzY7T85C4T2XYlbxLglSv2uLCgFv8Quk%2FwdesUdWPeHYIH0R729JIisN9Apdd4eB10aqwXrPt%2BSu9mA8k8n1sjMwnfsfF2j3jMUzXepSHmZ%2FBfqXvzgUNQQWOXO8YEuFBh4QTYCkOAPxywpYu1VxiDyJmKVcmJPGWk%2Fgc3Pov02StyYDahwmzw3E1gYC9wkupyWfDqDSUMpCTH5e5N8B%2F%2FlHiMuIkTNw4USHrJU67bjXGqNav6PBuQSoqTxc8avHoGmvqNtXzIaoyMIQIiiUHIM64cXieouplhNYln7qgc4wBVAYR104kO%2BCvKqsg4yIUlFNThVUAKZxZt1XA34h3TCUUiXVkZ0w8Hh2R0Z5L0b4LZvPd%2Fp1gi%2F07h8qfwHrByuSxglc9cI4QIg2oqvC%2Fqm0i7tjPLTgDhoWTAKDO2ONW5oe%2B%2FeKB9vZB8K6C25yCZ9RFVMnb6NRdRjyVK57CHHSkJBfnM2%2Fj4ODUwRkqrtBBCrDsDpt8jhZdXoy%2F1BCqw3sSGhgGGy0a5Jw6BP%2FTExoCmNFYjZl248A0osgPyGEmRA%2BfAsqPVaNAfytu0vuQJ7rk3J4kTDTR2AlCHJ5cls26opZM4w3jMULh2YXKpcqGBtuleAlOZnaZGbD6DHzMd6i2oFeJ8z9XYmalg1Szd%2FocZDc1C7Y6vcALJz2lYnTXiWEr2wawtoR4g3jvWUU2Ngjd1cewtFzEvM1NiHZPeLlIXFbBPawxNgMwwAlyNSuGF3zizVeOoC9bag1qRAQKQE%2FEZBWC2J8mnXAN2aTBboZ7HewnObE8CwROudZHmUM5oZ%2FUgd%2FJZQK8lvAm43uDRAbyW8gZ%2BZGq0EVerVGUKUSm%2FIdn8AQHdR4m7bue88WBwft9mSCeMOt1ncBwziOmJYI2ZR7ewNMPiCugmSsE4EyQ%2BQATJG6qORMGd4snEzc6B4shPIo4G1T7PgSm8PY5eUkPdF8JZ0VBtadbHXoJgnEhZQaODPj2gpODKJY5Yp4DOsLBFxWbvXN755KWylJm%2BoOd4zEL9Hpubuy2gyyfxh8oEfFutnYWdfB8PdESLWYvSqbElP9qo3u6KTmkhoacDauMNNjj0oy40DFV7Ql0aZj77xfGl7TJNHnIwgqOkenruYYNo6h724%2BzUQ7%2BvkCpZB%2BpGA562hYQiDxHVWOq0oDQl%2FQsoiY%2BcuI7iWq%2FZIBtHcXJ7kks%2Bh2fCNUPA82BzjnqktNts%2BRLdk1VSu%2BtqEn7QZCCsvEqk6FkfiOYkrsw092J8jsfIuEKypNjLxrKA9kiA19mxBD2suxQKCzwXGws7kEJvlhUiV9tArLIdZW0IORcxEzdzKmjtFhsjKy%2F44XYXdI5noQoRcvjZ1RMPACRqYg2V1%2BOwOepcOknRLLFdYgTkT5UApt%2FJhLM3jeFYprZV%2BZow2g8fP%2BU68hkKFWJj2yBbKqsrp25xkZX1DAjUw52IMYWaOhab8Kp05VrdNftqwRrymWF4OQSjbdfzmRZirK8FMJELEgER2PHjEAN9pGfLhCUiTJFbd5LBkOBMaxLr%2FA1SY9dXFz4RjzoU9ExfJCmx%2FI9FKEGT3n2cmzl2X42L3Jh%2BAbQq6sA%2BSs1kitoa4TAYgKHaoybHUDJ51oETdeI%2F9ThSmjWGkyLi5QAGWhL0BG1UsTyRGRJOldKBrYJeB8ljLJHfATWTEQBXBDnQexOHTB%2BUn44zExFE4vLytcu5NwpWrUxO%2F0ZICUGM7hGABXym0V6ZvDST0E370St9MIWQOTWngeoQHUTdCJUP04spMBMS8LSker9cReVQkULFDIZDFPrhTzBl6sed9wcZQTbL%2BBDqMyaN3RJPh%2Fanbx%2BIv%2BqgQdAa3M9Z5JmvYlh4qop%2BHo1F1W5gbOE9YKLgAnWytXElU4G8GtW47lhgFE6gaSs%2Bgs37sFvi0PPVvA5dnCBgILTwoKd%2F%2BDoL9F6inlM7H4rOTzD79KJgKlZO%2FZgt22UsKhrAaXU5ZcLrAglTVKJEmNJvORGN1vqrcfSMizfpsgbIe9zno%2BgBoKVXgIL%2FVI8dB1O5o%2FR3Suez%2FgD7M781ShjKpIIORM%2FnxG%2BjjhhgPwsn2IoXsPGPqYHXA63zJ07M2GPEykQwJBYLK808qYxuIew4frk52nhCsnCYmXiR6CuapvE1IwRB4%2FQftDbEn%2BAucIr1oxrLabRj9q4ae0%2BfXkHnteAJwXRbVkR0mctVSwEbqhJiMSZUp9DNbEDMmjX22m3ABpkrPQQTP3S1sib5pD2VRKRd%2BeNAjLYyT0hGrdjWJZy24OYXRoWQAIhGBZRxuBFMjjZQhpgrWo8SiFYbojcHO8V5DyscJpLTHyx9Fimassyo5U6WNtquUMYgccaHY5amgR3PQzq3ToNM5ABnoB9kuxsebqmYZm0R9qxJbFXCQ1UPyFIbxoUraTJFDpCk0Wk9GaYJKz%2F6oHwEP0Q14lMtlddQsOAU9zlYdMVHiT7RQP3XCmWYDcHCGbVRHGnHuwzScA0BaSBOGkz3lM8CArjrBsyEoV6Ys4qgDK3ykQQPZ3hCRGNXQTNNXbEb6tDiTDLKOyMzRhCFT%2BmAUmiYbV3YQVqFVp9dorv%2BTsLeCykS2b5yyu8AV7IS9cxcL8z4Kfwp%2BxJyYLv1OsxQCZwTB4a8BZ%2F5EdxTBJthApqyfd9u3ifr%2FWILTqq5VqgwMT9SOxbSGWLQJUUWCVi4k9tho9nEsbUh7U6NUsLmkYFXOhZ0kmamaJLRNJzSj%2Fqn4Mso6zb6iLLBXoaZ6AqeWCjHQm2lztnejYYM2eubnpBdKVLORZhudH3JF1waBJKA9%2BW8EhMj3Kzf0L4vi4k6RoHh3Z5YgmSZmk6ns4fjScjAoL8GoOECgqgYEBYUGFVO4FUv4%2FYtowhEmTs0vrvlD%2FCrisnoBNDAcUi%2FteY7OctFlmARQzjOItrrlKuPO6E2Ox93L4O%2F4DcgV%2FdZ7qR3VBwVQxP1GCieA4RIpweYJ5FoYrHxqRBdJjnqbsikA2Ictbb8vE1GYIo9dacK0REgDX4smy6GAkxlH1yCGGsk%2BtgiDhNKuKu3yNrMdxafmKTF632F8Vx4BNK57GvlFisrkjN9WDAtjsWA0ENT2e2nETUb%2Fn7qwhvGnrHuf5bX6Vh%2Fn3xffU3PeHdR%2BFA92i6ufT3AlyAREoNDh6chiMWTvjKjHDeRhOa9YkOQRq1vQXEMppAQVwHCuIcV2g5rBn6GmZZpTR7vnSD6ZmhdSl176gqKTXu5E%2BYbfL0adwNtHP7dT7t7b46DVZIkzaRJOM%2BS6KcrzYVg%2BT3wSRFRQashjfU18NutrKa%2F7PXbtuJvpIjbgPeqd%2BpjmRw6YKpnANFSQcpzTZgpSNJ6J7uiagAbir%2F8tNXJ%2FOsOnRh6iuIexxrmkIneAgz8QoLmiaJ8sLQrELVK2yn3wOHp57BAZJhDZjTBzyoRAuuZ4eoxHruY1pSb7qq79cIeAdOwin4GdgMeIMHeG%2BFZWYaiUQQyC5b50zKjYw97dFjAeY2I4Bnl105Iku1y0lMA1ZHolLx19uZnRdILcXKlZGQx%2FGdEqSsMRU1BIrFqRcV1qQOOHyxOLXEGcbRtAEsuAC2V4K3p5mFJ22IDWaEkk9ttf5Izb2LkD1MnrSwztXmmD%2FQi%2FEmVEFBfiKGmftsPwVaIoZanlKndMZsIBOskFYpDOq3QUs9aSbAAtL5Dbokus2G4%2FasthNMK5UQKCOhU97oaOYNGsTah%2BjfCKsZnTRn5TbhFX8ghg8CBYt%2FBjeYYYUrtUZ5jVij%2Fop7V5SsbA4mYTOwZ46hqdpbB6Qvq3AS2HHNkC15pTDIcDNGsMPXaBidXYPHc6PJAkRh29Vx8KcgX46LoUQBhRM%2B3SW6Opll%2FwgxxsPgKJKzr5QCmwkUxNbeg6Wj34SUnEzOemSuvS2OetRCO8Tyy%2BQbSKVJcqkia%2BGvDefFwMOmgnD7h81TUtMn%2BmRpyJJ349HhAnoWFTejhpYTL9G8N2nVg1qkXBeoS9Nw2fB27t7trm7d%2FQK7Cr4uoCeOQ7%2F8JfKT77KiDzLImESHw%2F0wf73QeHu74hxv7uihi4fTX%2BXEwAyQG3264dwv17aJ5N335Vt9sdrAXhPOAv8JFvzqyYXwfx8WYJaef1gMl98JRFyl5Mv5Uo%2FoVH5ww5OzLFsiTPDns7fS6EURSSWd%2F92BxMYQ8sBaH%2Bj%2BwthQPdVgDGpTfi%2BJQIWMD8xKqULliRH01rTeyF8x8q%2FGBEEEBrAJMPf25UQwi0b8tmqRXY7kIvNkzrkvRWLnxoGYEJsz8u4oOyMp8cHyaybb1HdMCaLApUE%2B%2F7xLIZGP6H9xuSEXp1zLIdjk5nBaMuV%2FyTDRRP8Y2ww5RO6d2D94o%2B6ucWIqUAvgHIHXhZsmDhjVLczmZ3ca0Cb3PpKwt2UtHVQ0BgFJsqqTsnzZPlKahRUkEu4qmkJt%2Bkqdae76ViWe3STan69yaF9%2BfESD2lcQshLHWVu4ovItXxO69bqC5p1nZLvI8NdQB9s9UNaJGlQ5mG947ipdDA0eTIw%2FA1zEdjWquIsQXXGIVEH0thC5M%2BW9pZe7IhAVnPJkYCCXN5a32HjN6nsvokEqRS44tGIs7s2LVTvcrHAF%2BRVmI8L4HUYk4x%2B67AxSMJKqCg8zrGOgvK9kNMdDrNiUtSWuHFpC8%2Fp5qIQrEo%2FH%2B1l%2F0cAwQ2nKmpWxKcMIuHY44Y6DlkpO48tRuUGBWT0FyHwSKO72Ud%2BtJUfdaZ4CWNijzZtlRa8%2BCkmO%2FEwHYfPZFU%2FhzjFWH7vnzHRMo%2BaF9u8qHSAiEkA2HjoNQPEwHsDKOt6hOoK3Ce%2F%2B%2F9boMWDa44I6FrQhdgS7OnNaSzwxWKZMcyHi6LN4WC6sSj0qm2PSOGBTvDs%2FGWJS6SwEN%2FULwpb4LQo9fYjUfSXRwZkynUazlSpvX9e%2BG2zor8l%2BYaMxSEomDdLHGcD6YVQPegTaA74H8%2BV4WvJkFUrjMLGLlvSZQWvi8%2FQA7yzQ8GPno%2F%2F5SJHRP%2FOqKObPCo81s%2F%2B6WgLqykYpGAgQZhVDEBPXWgU%2FWzFZjKUhSFInufPRiMAUULC6T11yL45ZrRoB4DzOyJShKXaAJIBS9wzLYIoCEcJKQW8GVCx4fihqJ6mshBUXSw3wWVj3grrHQlGNGhIDNNzsxQ3M%2BGWn6ASobIWC%2BLbYOC6UpahVO13Zs2zOzZC8z7FmA05JhUGyBsF4tsG0drcggIFzgg%2Fkpf3%2BCnAXKiMgIE8Jk%2FMhpkc8DUJEUzDSnWlQFme3d0sHZDrg7LavtsEX3cHwjCYA17pMTfx8Ajw9hHscN67hyo%2BRJQ4458RmPywXykkVcW688oVUrQhahpPRvTWPnuI0B%2BSkQu7dCyvLRyFYlC1LG1gRCIvn3rwQeINzZQC2KXq31FaR9UmVV2QeGVqBHjmE%2BVMd3b1fhCynD0pQNhCG6%2FWCDbKPyE7NRQzL3BzQAJ0g09aUzcQA6mUp9iZFK6Sbp%2FYbHjo%2B%2B7%2FWj8S4YNa%2BZdqAw1hDrKWFXv9%2BzaXpf8ZTDSbiqsxnwN%2FCzK5tPkOr4tRh2kY3Bn9JtalbIOI4b3F7F1vPQMfoDcdxMS8CW9m%2FNCW%2FHILTUVWQIPiD0j1A6bo8vsv6P1hCESl2abrSJWDrq5sSzUpwoxaCU9FtJyYH4QFMxDBpkkBR6kn0LMPO%2B5EJ7Z6bCiRoPedRZ%2FP0SSdii7ZnPAtVwwHUidcdyspwncz5uq6vvm4IEDbJVLUFCn%2FLvIHfooUBTkFO130FC7CmmcrKdgDJcid9mvVzsDSibOoXtIf9k6ABle3PmIxejodc4aob0QKS432srrCMndbfD454q52V01G4q913mC5HOsTzWF4h2No1av1VbcUgWAqyoZl%2B11PoFYnNv2HwAODeNRkHj%2B8SF1fcvVBu6MrehHAZK1Gm69ICcTKizykHgGFx7QdowTVAsYEF2tVc0Z6wLryz2FI1sc5By2znJAAmINndoJiB4sfPdPrTC8RnkW7KRCwxC6YvXg5ahMlQuMpoCSXjOlBy0Kij%2BbsCYPbGp8BdCBiLmLSAkEQRaieWo1SYvZIKJGj9Ur%2FeWHjiB7SOVdqMAVmpBvfRiebsFjger7DC%2B8kRFGtNrTrnnGD2GAJb8rQCWkUPYHhwXsjNBSkE6lGWUj5QNhK0DMNM2l%2BkXRZ0KLZaGsFSIdQz%2FHXDxf3%2FTE30%2BDgBKWGWdxElyLccJfEpjsnszECNoDGZpdwdRgCixeg9L4EPhH%2BRptvRMVRaahu4cySjS3P5wxAUCPkmn%2BrhyASpmiTaiDeggaIxYBmtLZDDhiWIJaBgzfCsAGUF1Q1SFZYyXDt9skCaxJsxK2Ms65dmdp5WAZyxik%2FzbrTQk5KmgxCg%2Ff45L0jywebOWUYFJQAJia7XzCV0x89rpp%2Ff3AVWhSPyTanqmik2SkD8A3Ml4NhIGLAjBXtPShwKYfi2eXtrDuKLk4QlSyTw1ftXgwqA2jUuopDl%2B5tfUWZNwBpEPXghzbBggYCw%2Fdhy0ntds2yeHCDKkF%2FYxQjNIL%2FF%2F37jLPHCKBO9ibwYCmuxImIo0ijV2Wbg3kSN2psoe8IsABv3RNFaF9uMyCtCYtqcD%2BqNOhwMlfARQUdJ2tUX%2BMNJqOwIciWalZsmEjt07tfa8ma4cji9sqz%2BQ9hWfmMoKEbIHPOQORbhQRHIsrTYlnVTNvcq1imqmmPDdVDkJgRcTgB8Sb6epCQVmFZe%2BjGDiNJQLWnfx%2BdrTKYjm0G8yH0ZAGMWzEJhUEQ4Maimgf%2Fbkvo8PLVBsZl152y5S8%2BHRDfZIMCbYZ1WDp4yrdchOJw8k6R%2B%2F2pHmydK4NIK2PHdFPHtoLmHxRDwLFb7eB%2BM4zNZcB9NrAgjVyzLM7xyYSY13ykWfIEEd2n5%2FiYp3ZdrCf7fL%2Ben%2BsIJu2W7E30MrAgZBD1rAAbZHPgeAMtKCg3NpSpYQUDWJu9bT3V7tOKv%2BNRiJc8JAKqqgCA%2FPNRBR7ChpiEulyQApMK1AyqcWnpSOmYh6yLiWkGJ2mklCSPIqN7UypWj3dGi5MvsHQ87MrB4VFgypJaFriaHivwcHIpmyi5LhNqtem4q0n8awM19Qk8BOS0EsqGscuuydYsIGsbT5GHnERUiMpKJl4ON7qjB4fEqlGN%2FhCky89232UQCiaeWpDYCJINXjT6xl4Gc7DxRCtgV0i1ma4RgWLsNtnEBRQFqZggCLiuyEydmFd7WlogpkCw5G1x4ft2psm3KAREwVwr1Gzl6RT7FDAqpVal34ewVm3VH4qn5mjGj%2BbYL1NgfLNeXDwtmYSpwzbruDKpTjOdgiIHDVQSb5%2FzBgSMbHLkxWWgghIh9QTFSDILixVwg0Eg1puooBiHAt7DzwJ7m8i8%2Fi%2BjHvKf0QDnnHVkVTIqMvIQImOrzCJwhSR7qYB5gSwL6aWL9hERHCZc4G2%2BJrpgHNB8eCCmcIWIQ6rSdyPCyftXkDlErUkHafHRlkOIjxGbAktz75bnh50dU7YHk%2BMz7wwstg6RFZb%2BTZuSOx1qqP5C66c0mptQmzIC2dlpte7vZrauAMm%2F7RfBYkGtXWGiaWTtwvAQiq2oD4YixPLXE2khB2FRaNRDTk%2B9sZ6K74Ia9VntCpN4BhJGJMT4Z5c5FhSepRCRWmBXqx%2BwhVZC4me4saDs2iNqXMuCl6iAZflH8fscC1sTsy4PHeC%2BXYuqMBMUun5YezKbRKmEPwuK%2BCLzijPEQgfhahQswBBLfg%2FGBgBiI4QwAqzJkkyYAWtjzSg2ILgMAgqxYfwERRo3zruBL9WOryUArSD8sQOcD7fvIODJxKFS615KFPsb68USBEPPj1orNzFY2xoTtNBVTyzBhPbhFH0PI5AtlJBl2aSgNPYzxYLw7XTDBDinmVoENwiGzmngrMo8OmnRP0Z0i0Zrln9DDFcnmOoBZjABaQIbPOJYZGqX%2BRCMlDDbElcjaROLDoualmUIQ88Kekk3iM4OQrADcxi3rJguS4MOIBIgKgXrjd1WkbCdqxJk%2F4efRIFsavZA7KvvJQqp3Iid5Z0NFc5aiMRzGN3vrpBzaMy4JYde3wr96PjN90AYOIbyp6T4zj8LoE66OGcX1Ef4Z3KoWLAUF4BTg7ug%2FAbkG5UNQXAMkQezujSHeir2uTThgd3gpyzDrbnEdDRH2W7U6PeRvBX1ZFMP5RM%2BZu6UUZZD8hDPHldVWntTCNk7To8IeOW9yn2wx0gmurwqC60AOde4r3ETi5pVMSDK8wxhoGAoEX9NLWHIR33VbrbMveii2jAJlrxwytTHbWNu8Y4N8vCCyZjAX%2FpcsfwXbLze2%2BD%2Bu33OGBoJyAAL3jn3RuEcdp5If8O%2Ba4NKWvxOTyDltG0IWoHhwVGe7dKkCWFT%2B%2Btm%2BhaBCikRUUMrMhYKZJKYoVuv%2FbsJzO8DwfVIInQq3g3BYypiz8baogH3r3GwqCwFtZnz4xMjAVOYnyOi5HWbFA8n0qz1OjSpHWFzpQOpvkNETZBGpxN8ybhtqV%2FDMUxd9uFZmBfKXMCn%2FSqkWJyKPnT6lq%2B4zBZni6fYRByJn6OK%2BOgPBGRAJluwGSk4wxjOOzyce%2FPKODwRlsgrVkdcsEiYrqYdXo0Er2GXi2GQZd0tNJT6c9pK1EEJG1zgDJBoTVuCXGAU8BKTvCO%2FcEQ1Wjk3Zzuy90JX4m3O5IlxVFhYkSUwuQB2up7jhvkm%2BbddRQu5F9s0XftGEJ9JSuSk%2BZachCbdU45fEqbugzTIUokwoAKvpUQF%2FCvLbWW5BNQFqFkJg2f30E%2F48StNe5QwBg8zz3YAJ82FZoXBxXSv4QDooDo79NixyglO9AembuBcx5Re3CwOKTHebOPhkmFC7wNaWtoBhFuV4AkEuJ0J%2B1pT0tLkvFVZaNzfhs%2FKd3%2BA9YsImlO4XK4vpCo%2FelHQi%2F9gkFg07xxnuXLt21unCIpDV%2BbbRxb7FC6nWYTsMFF8%2B1LUg4JFjVt3vqbuhHmDKbgQ4e%2BRGizRiO8ky05LQGMdL2IKLSNar0kNG7lHJMaXr5mLdG3nykgj6vB%2FKVijd1ARWkFEf3yiUw1v%2FWaQivVUpIDdSNrrKbjO5NPnxz6qTTGgYg03HgPhDrCFyYZTi3XQw3HXCva39mpLNFtz8AiEhxAJHpWX13gCTAwgm9YTvMeiqetdNQv6IU0hH0G%2BZManTqDLPjyrOse7WiiwOJCG%2BJ0pZYULhN8NILulmYYvmVcV2MjAfA39sGKqGdjpiPo86fecg65UPyXDIAOyOkCx5NQsLeD4gGVjTVDwOHWkbbBW0GeNjDkcSOn2Nq4cEssP54t9D749A7M1AIOBl0Fi0sSO5v3P7LCBrM6ZwFY6kp2FX6AcbGUdybnfChHPyu6WlRZ2Fwv9YM0RMI7kISRgR8HpQSJJOyTfXj%2F6gQKuihPtiUtlCQVPohUgzfezTg8o1b3n9pNZeco1QucaoXe40Fa5JYhqdTspFmxGtW9h5ezLFZs3j%2FN46f%2BS2rjYNC2JySXrnSAFhvAkz9a5L3pza8eYKHNoPrvBRESpxYPJdKVUxBE39nJ1chrAFpy4MMkf0qKgYALctGg1DQI1kIymyeS2AJNT4X240d3IFQb%2F0jQbaHJ2YRK8A%2Bls6WMhWmpCXYG5jqapGs5%2FeOJErxi2%2F2KWVHiPellTgh%2FfNl%2F2KYPKb7DUcAg%2BmCOPQFCiU9Mq%2FWLcU1xxC8aLePFZZlE%2BPCLzf7ey46INWRw2kcXySR9FDgByXzfxiNKwDFbUSMMhALPFSedyjEVM5442GZ4hTrsAEvZxIieSHGSgkwFh%2FnFNdrrFD4tBH4Il7fW6ur4J8Xaz7RW9jgtuPEXQsYk7gcMs2neu3zJwTyUerHKSh1iTBkj2YJh1SSOZL5pLuQbFFAvyO4k1Hxg2h99MTC6cTUkbONQIAnEfGsGkNFWRbuRyyaEZInM5pij73EA9rPIUfU4XoqQpHT9THZkW%2BoKFLvpyvTBMM69tN1Ydwv1LIEhHsC%2BueVG%2Bw%2BkyCPsvV3erRikcscHjZCkccx6VrBkBRusTDDd8847GA7p2Ucy0y0HdSRN6YIBciYa4vuXcAZbQAuSEmzw%2BH%2FAuOx%2BaH%2BtBL88H57D0MsqyiZxhOEQkF%2F8DR1d2hSPMj%2FsNOa5rxcUnBgH8ictv2J%2Bcb4BA4v3MCShdZ2vtK30vAwkobnEWh7rsSyhmos3WC93Gn9C4nnAd%2FPjMMtQfyDNZsOPd6XcAsnBE%2FmRHtHEyJMzJfZFLE9OvQa0i9kUmToJ0ZxknTgdl%2FXPV8xoh0K7wNHHsnBdvFH3sv52lU7UFteseLG%2FVanIvcwycVA7%2BBE1Ulyb20BvwUWZcMTKhaCcmY3ROpvonVMV4N7yBXTL7IDtHzQ4CCcqF66LjF3xUqgErKzolLyCG6Kb7irP%2FMVTCCwGRxfrPGpMMGvPLgJ881PHMNMIO09T5ig7AzZTX%2F5PLlwnJLDAPfuHynSGhV4tPqR3gJ4kg4c06c%2FF1AcjGytKm2Yb5jwMotF7vro4YDLWlnMIpmPg36NgAZsGA0W1spfLSue4xxat0Gdwd0lqDBOgIaMANykwwDKejt5YaNtJYIkrSgu0KjIg0pznY0SCd1qlC6R19g97UrWDoYJGlrvCE05J%2F5wkjpkre727p5PTRX5FGrSBIfJqhJE%2FIS876PaHFkx9pGTH3oaY3jJRvLX9Iy3Edoar7cFvJqyUlOhAEiOSAyYgVEGkzHdug%2BoRHIEOXAExMiTSKU9A6nmRC8mp8iYhwWdP2U%2F5EkFAdPrZw03YA3gSyNUtMZeh7dDCu8pF5x0VORCTgKp07ehy7NZqKTpIC4UJJ89lnboyAfy5OyXzXtuDRbtAFjZRSyGFTpFrXwkpjSLIQIG3N0Vj4BtzK3wdlkBJrO18MNsgseR4BysJilI0wI6ZahLhBFA0XBmV8d4LUzEcNVb0xbLjLTETYN8OEVqNxkt10W614dd1FlFFVTIgB7%2FBQQp1sWlNolpIu4ekxUTBV7NmxOFKEBmmN%2BnA7pvF78%2FRII5ZHA09OAiE%2F66MF6HQ%2BqVEJCHxwymukkNvzqHEh52dULPbVasfQMgTDyBZzx4007YiKdBuUauQOt27Gmy8ISclPmEUCIcuLbkb1mzQSqIa3iE0PJh7UMYQbkpe%2BhXjTJKdldyt2mVPwywoODGJtBV1lJTgMsuSQBlDMwhEKIfrvsxGQjHPCEfNfMAY2oxvyKcKPUbQySkKG6tj9AQyEW3Q5rpaDJ5Sns9ScLKeizPRbvWYAw4bXkrZdmB7CQopCH8NAmqbuciZChHN8lVGaDbCnmddnqO1PQ4ieMYfcSiBE5zzMz%2BJV%2F4eyzrzTEShvqSGzgWimkNxLvUj86iAwcZuIkqdB0VaIB7wncLRmzHkiUQpPBIXbDDLHBlq7vp9xwuC9AiNkIptAYlG7Biyuk8ILdynuUM1cHWJgeB%2BK3wBP%2FineogxkvBNNQ4AkW0hvpBOQGFfeptF2YTR75MexYDUy7Q%2F9uocGsx41O4IZhViw%2F2FvAEuGO5g2kyXBUijAggWM08bRhXg5ijgMwDJy40QeY%2FcQpUDZiIzmvskQpO5G1zyGZA8WByjIQU4jRoFJt56behxtHUUE%2Fom7Rj2psYXGmq3llVOCgGYKNMo4pzwntITtapDqjvQtqpjaJwjHmDzSVGLxMt12gEXAdLi%2FcaHSM3FPRGRf7dB7YC%2BcD2ho6oL2zGDCkjlf%2FDFoQVl8GS%2F56wur3rdV6ggtzZW60MRB3g%2BU1W8o8cvqIpMkctiGVMzXUFI7FacFLrgtdz4mTEr4aRAaQ2AFQaNeG7GX0yOJgMRYFziXdJf24kg%2FgBQIZMG%2FYcPEllRTVNoDYR6oSJ8wQNLuihfw81UpiKPm714bZX1KYjcXJdfclCUOOpvTxr9AAJevTY4HK%2FG7F3mUc3GOAKqh60zM0v34v%2BELyhJZqhkaMA8UMMOU90f8RKEJFj7EqepBVwsRiLbwMo1J2zrE2UYJnsgIAscDmjPjnzI8a719Wxp757wqmSJBjXowhc46QN4RwKIxqEE6E5218OeK7RfcpGjWG1jD7qND%2B%2FGTk6M56Ig4yMsU6LUW1EWE%2BfIYycVV1thldSlbP6ltdC01y3KUfkobkt2q01YYMmxpKRvh1Z48uNKzP%2FIoRIZ%2FF6buOymSnW8gICitpJjKWBscSb9JJKaWkvEkqinAJ2kowKoqkqZftRqfRQlLtKoqvTRDi2vg%2FRrPD%2Fd3a09J8JhGZlEkOM6znTsoMCsuvTmywxTCDhw5dd0GJOHCMPbsj3QLkTE3MInsZsimDQ3HkvthT7U9VA4s6G07sID0FW4SHJmRGwCl%2BMu4xf0ezqeXD2PtPDnwMPo86sbwDV%2B9PWcgFcARUVYm3hrFQrHcgMElFGbSM2A1zUYA3baWfheJp2AINmTJLuoyYD%2FOwA4a6V0ChBN97E8YtDBerUECv0u0TlxR5yhJCXvJxgyM73Bb6pyq0jTFJDZ4p1Am1SA6sh8nADd1hAcGBMfq4d%2FUfwnmBqe0Jun1n1LzrgKuZMAnxA3NtCN7Klf4BH%2B14B7ibBmgt0TGUafVzI4uKlpF7v8NmgNjg90D6QE3tbx8AjSAC%2BOA1YJvclyPKgT27QpIEgVYpbPYGBsnyCNrGz9XUsCHkW1QAHgL2STZk12QGqmvAB0NFteERkvBIH7INDsNW9KKaAYyDMdBEMzJiWaJHZALqDxQDWRntumSDPcplyFiI1oDpT8wbwe01AHhW6%2BvAUUBoGhY3CT2tgwehdPqU%2F4Q7ZLYvhRl%2FogOvR9O2%2BwkkPKW5vCTjD2fHRYXONCoIl4Jh1bZY0ZE1O94mMGn%2FdFSWBWzQ%2FVYk%2BGezi46RgiDv3EshoTmMSlioUK6MQEN8qeyK6FRninyX8ZPeUWjjbMJChn0n%2FyJvrq5bh5UcCAcBYSafTFg7p0jDgrXo2QWLb3WpSOET%2FHh4oSadBTvyDo10IufLzxiMLAnbZ1vcUmj3w7BQuIXjEZXifwukVxrGa9j%2BDXfpi12m1RbzYLg9J2wFergEwOxFyD0%2FJstNK06ZN2XdZSGWxcJODpQHOq4iKqjqkJUmPu1VczL5xTGUfCgLEYyNBCCbMBFT%2FcUP6pE%2FmujnHsSDeWxMbhrNilS5MyYR0nJyzanWXBeVcEQrRIhQeJA6Xt4f2eQESNeLwmC10WJVHqwx8SSyrtAAjpGjidcj1E2FYN0LObUcFQhafUKTiGmHWRHGsFCB%2BHEXgrzJEB5bp0QiF8ZHh11nFX8AboTD0PS4O1LqF8XBks2MpjsQnwKHF6HgaKCVLJtcr0XjqFMRGfKv8tmmykhLRzu%2BvqQ02%2BKpJBjaLt9ye1Ab%2BBbEBhy4EVdIJDrL2naV0o4wU8YZ2Lq04FG1mWCKC%2BUwkXOoAjneU%2FxHplMQo2cXUlrVNqJYczgYlaOEczVCs%2FOCgkyvLmTmdaBJc1iBLuKwmr6qtRnhowngsDxhzKFAi02tf8bmET8BO27ovJKF1plJwm3b0JpMh38%2BxsrXXg7U74QUM8ZCIMOpXujHntKdaRtsgyEZl5MClMVMMMZkZLNxH9%2Bb8fH6%2Bb8Lev30A9TuEVj9CqAdmwAAHBPbfOBFEATAPZ2CS0OH1Pj%2F0Q7PFUcC8hDrxESWdfgFRm%2B7vvWbkEppHB4T%2F1ApWnlTIqQwjcPl0VgS1yHSmD0OdsCVST8CQVwuiew1Y%2Bg3QGFjNMzwRB2DSsAk26cmA8lp2wIU4p93AUBiUHFGOxOajAqD7Gm6NezNDjYzwLOaSXRBYcWipTSONHjUDXCY4mMI8XoVCR%2FRrs%2FJLKXgEx%2BqkmeDlFOD1%2FyTQNDClRuiUyKYCllfMiQiyFkmuTz2vLsBNyRW%2Bxz%2B5FElFxWB28VjYIGZ0Yd%2B5wIjkcoMaggxswbT0pCmckRAErbRlIlcOGdBo4djTNO8FAgQ%2BlT6vPS60BwTRSUAM3ddkEAZiwtEyArrkiDRnS7LJ%2B2hwbzd2YDQagSgACpsovmjil5wfPuXq3GuH0CyE7FK3M4FgRaFoIkaodORrPx1%2BJpI9psyNYIFuJogZa0%2F1AhOWdlHQxdAgbwacsHqPZo8u%2FngAH2GmaTdhYnBfSDbBfh8CHq6Bx5bttP2%2BRdM%2BMAaYaZ0Y%2FADkbNCZuAyAVQa2OcXOeICmDn9Q%2FeFkDeFQg5MgHEDXq%2FtVjj%2Bjtd26nhaaolWxs1ixSUgOBwrDhRIGOLyOVk2%2FBc0UxvseQCO2pQ2i%2BKrfhu%2FWeBovNb5dJxQtJRUDv2mCwYVpNl2efQM9xQHnK0JwLYt%2FU0Wf%2BphiA4uw8G91slC832pmOTCAoZXohg1fewCZqLBhkOUBofBWpMPsqg7XEXgPfAlDo2U5WXjtFdS87PIqClCK5nW6adCeXPkUiTGx0emOIDQqw1yFYGHEVx20xKjJVYe0O8iLmnQr3FA9nSIQilUKtJ4ZAdcTm7%2BExseJauyqo30hs%2B1qSW211A1SFAOUgDlCGq7eTIcMAeyZkV1SQJ4j%2Fe1Smbq4HcjqgFbLAGLyKxlMDMgZavK5NAYH19Olz3la%2FQCTiVelFnU6O%2FGCvykqS%2FwZJDhKN9gBtSOp%2F1SP5VRgJcoVj%2Bkmf2wBgv4gjrgARBWiURYx8xENV3bEVUAAWWD3dYDKAIWk5opaCFCMR5ZjJExiCAw7gYiSZ2rkyTce4eNMY3lfGn%2B8p6%2BvBckGlKEXnA6Eota69OxDO9oOsJoy28BXOR0UoXNRaJD5ceKdlWMJlOFzDdZNpc05tkMGQtqeNF2lttZqNco1VtwXgRstLSQ6tSPChgqtGV5h2DcDReIQadaNRR6AsAYKL5gSFsCJMgfsaZ7DpKh8mg8Wz8V7H%2BgDnLuMxaWEIUPevIbClgap4dqmVWSrPgVYCzAoZHIa5z2Ocx1D%2FGvDOEqMOKLrMefWIbSWHZ6jbgA8qVBhYNHpx0P%2BjAgN5TB3haSifDcApp6yymEi6Ij%2FGsEpDYUgcHATJUYDUAmC1SCkJ4cuZXSAP2DEpQsGUjQmKJfJOvlC2x%2FpChkOyLW7KEoMYc5FDC4v2FGqSoRWiLsbPCiyg1U5yiHZVm1XLkHMMZL11%2Fyxyw0UnGig3MFdZklN5FI%2FqiT65T%2BjOXOdO7XbgWurOAZR6Cv9uu1cm5LjkXX4xi6mWn5r5NjBS0gTliHhMZI2WNqSiSphEtiCAwnafS11JhseDGHYQ5%2BbqWiAYiAv6Jsf79%2FVUs4cIl%2Bn6%2BWOjcgB%2F2l5TreoAV2717JzZbQIR0W1cl%2FdEqCy5kJ3ZSIHuU0vBoHooEpiHeQWVkkkOqRX27eD1FWw4BfO9CJDdKoSogQi3hAAwsPRFrN5RbX7bqLdBJ9JYMohWrgJKHSjVl1sy2xAG0E3sNyO0oCbSGOxCNBRRXTXenYKuwAoDLfnDcQaCwehUOIDiHAu5m5hMpKeKM4sIo3vxACakIxKoH2YWF2QM84e6F5C5hJU4g8uxuFOlAYnqtwxmHyNEawLW%2FPhoawJDrGAP0JYWHgAVUByo%2FbGdiv2T2EMg8gsS14%2FrAdzlOYazFE7w4OzxeKiWdm3nSOnQRRKXSlVo8HEAbBfyJMKqoq%2BSCcTSx5NDtbFwNlh8VhjGGDu7JG5%2FTAGAvniQSSUog0pNzTim8Owc6QTuSKSTXlQqwV3eiEnklS3LeSXYPXGK2VgeZBqNcHG6tZHvA3vTINhV0ELuQdp3t1y9%2BogD8Kk%2FW7QoRN1UWPqM4%2BxdygkFDPLoTaumKReKiLWoPHOfY54m3qPx4c%2B4pgY3MRKKbljG8w4wvz8pxk3AqKsy4GMAkAtmRjRMsCxbb4Q2Ds0Ia9ci8cMT6DmsJG00XaHCIS%2Bo3F8YVVeikw13w%2BOEDaCYYhC0ZE54kA4jpjruBr5STWeqQG6M74HHL6TZ3lXrd99ZX%2B%2B7LhNatQaZosuxEf5yRA15S9gPeHskBIq3Gcw81AGb9%2FO53DYi%2F5CsQ51EmEh8Rkg4vOciClpy4d04eYsfr6fyQkBmtD%2BP8sNh6e%2BXYHJXT%2FlkXxT4KXU5F2sGxYyzfniMMQkb9OjDN2C8tRRgTyL7GwozH14PrEUZc6oz05Emne3Ts5EG7WolDmU8OB1LDG3VrpQxp%2BpT0KYV5dGtknU64JhabdqcVQbGZiAxQAnvN1u70y1AnmvOSPgLI6uB4AuDGhmAu3ATkJSw7OtS%2F2ToPjqkaq62%2F7WFG8advGlRRqxB9diP07JrXowKR9tpRa%2BjGJ91zxNTT1h8I2PcSfoUPtd7NejVoH03EUcqSBuFZPkMZhegHyo2ZAITovmm3zAIdGFWxoNNORiMRShgwdYwFzkPw5PA4a5MIIQpmq%2Bnsp3YMuXt%2FGkXxLx%2FP6%2BZJS0lFyz4MunC3eWSGE8xlCQrKvhKUPXr0hjpAN9ZK4PfEDrPMfMbGNWcHDzjA7ngMxTPnT7GMHar%2BgMQQ3NwHCv4zH4BIMYvzsdiERi6gebRmerTsVwZJTRsL8dkZgxgRxmpbgRcud%2BYlCIRpPwHShlUSwuipZnx9QCsEWziVazdDeKSYU5CF7UVPAhLer3CgJOQXl%2Fzh575R5rsrmRnKAzq4POFdgbYBuEviM4%2BLVC15ssLNFghbTtHWerS1hDt5s4qkLUha%2FqpZXhWh1C6lTQAqCNQnaDjS7UGFBC6wTu8yFnKJnExCnAs3Ok9yj5KpfZESQ4lTy5pTGTnkAUpxI%2ByjEldJfSo4y0QhG4i4IwkRFGcjWY8%2BEzgYYJUK7BXQksLxAww%2FYYWBMhJILB9e8ePEJ4OP7z%2B4%2FwOQDl64iOYDp26DaONPxpKtBxq%2FaTzRGarm3VkPYTLJKx6Z%2FMw2YbBGseJhPMwhhNswrIkyvV2BYzrvZbxLpKwcWJhYmFtVZ%2BlPEq91FzVp1HlQY1bZVLqeNR9SAUn6n0E28k%2FUuGkNpP1DBI5ch%2FEehZfjUQ9aE41NhETExoPT2gGQz0IhWJbEOvTQ4wgcXCHHFBhewYUiFHuhRSAUVmEHeCRQHQkXGFwkAgyzREJCVN7TRnTon36Zw3tPhx4EALwNdwDv%2BJ41YSP4B2CQqz0EFgARZ4ESgBHQgROwAVn9GTI%2BHYexTUevLUeta4%2FDqKrbMVS%2BYqb8hUwYCrlgKtmAq1YCrFgKrd4qpXiqZcKn1oqdWipjYKpWwVPVYqW6xUpVipKqFR3QKjagVEtAqHpxUMTitsnFaJOKx2cVhswq35RVpyiq9lFVNIKnOQVMkgqtYxVNxiqQjFS7GKlSIVIsQqPIhUWwioigFQ%2B%2BKkN8VHr49HDw9Ebo9EDo9DTo9Crg9BDg9%2FWx7gWx7YWwlobYrOGxWPNisAaAHEyALpkAVDIAeWAArsABVXACYuAD5cAF6wAKFQAQqgAbVAAsoAAlQAUaYAfkwAvogBWQACOgAD9AAHSAAKT4GUdMiOvFngBTwCn2AZ7Dv6B6k%2F90B8%2ByRnkV144AIBoAMTQATGgAjNAA4YABgwABZgB%2FmQCwyAVlwCguASlwCEuAQFwB4uAMlwBYuAJlQAUVAAhUD2KgdpUDaJgaRMDFJgX5MC1JgWJEAokQCWRAHxEAWkQBMRADpEAMkQAYROAEecC484DRpwBDTnwNOdw05tjTmiNOYwtswhYFwLA7BYG4LA2BYGOLAwRYFuLAsxYFQJAohIEyJAMwkAwiQC0JAJgkAeiQBkJAFokAPCQA0JABwcD4Dgc4cDdDgaYcDIDgYgUC6CgWgUClCgUYUAVBQBOFAEYMALgwAgDA9QYAdIn8AZzeBB2L5EcWrenUT1KXienEsuJJ7x5U8XlTjc1NVzUyXFTGb1LlpUtWlTDIjqwE4LsagowoCi2gJLKAkpoBgJQNpAIhNqaEoneI6kiiqQ6Go%2Fn6j0cS%2Ba2gEU8gIHJ%2BBwfgZX4GL%2BBd%2FgW34FZ%2BBS%2FgUH4FN6BTegTvoEv6BJegRnYEF2A79gOvYDl2BdEjCkqkGtwXp0LNToIskOTXzh%2FF062yJ7AAAAEDAWAAABWhJ%2BKPEIJgBFxMVP7w2QJBGHASQnOBKXKFIdUK4igKA9IEaYJg%29%3Bsrc%3Aurl%28data%3Aapplication%2Fvnd%2Ems%2Dfontobject%3Bbase64%2Cn04AAEFNAAACAAIABAAAAAAABQAAAAAAAAABAJABAAAEAExQAAAAAAAAAAIAAAAAAAAAAAEAAAAAAAAAJxJ%2FLAAAAAAAAAAAAAAAAAAAAAAAACgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAAAADgBSAGUAZwB1AGwAYQByAAAAeABWAGUAcgBzAGkAbwBuACAAMQAuADAAMAA5ADsAUABTACAAMAAwADEALgAwADAAOQA7AGgAbwB0AGMAbwBuAHYAIAAxAC4AMAAuADcAMAA7AG0AYQBrAGUAbwB0AGYALgBsAGkAYgAyAC4ANQAuADUAOAAzADIAOQAAADgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzACAAUgBlAGcAdQBsAGEAcgAAAAAAQlNHUAAAAAAAAAAAAAAAAAAAAAADAKncAE0TAE0ZAEbuFM3pjM%2FSEdmjKHUbyow8ATBE40IvWA3vTu8LiABDQ%2BpexwUMcm1SMnNryctQSiI1K5ZnbOlXKmnVV5YvRe6RnNMFNCOs1KNVpn6yZhCJkRtVRNzEufeIq7HgSrcx4S8h%2Fv4vnrrKc6oCNxmSk2uKlZQHBii6iKFoH0746ThvkO1kJHlxjrkxs%2BLWORaDQBEtiYJIR5IB9Bi1UyL4Rmr0BNigNkMzlKQmnofBHviqVzUxwdMb3NdCn69hy%2BpRYVKGVS%2F1tnsqv4LL7wCCPZZAZPT4aCShHjHJVNuXbmMrY5LeQaGnvAkXlVrJgKRAUdFjrWEah9XebPeQMj7KS7DIBAFt8ycgC5PLGUOHSE3ErGZCiViNLL5ZARfywnCoZaKQCu6NuFX42AEeKtKUGnr%2FCm2Cy8tpFhBPMW5Fxi4Qm4TkDWh4IWFDClhU2hRWosUWqcKLlgyXB%2BlSHaWaHiWlBAR8SeSgSPCQxdVQgzUixWKSTrIQEbU94viDctkvX%2BVSjJuUmV8L4CXShI11esnp0pjWNZIyxKHS4wVQ2ime1P4RnhvGw0aDN1OLAXGERsB7buFpFGGBAre4QEQR0HOIO5oYH305G%2BKspT%2FFupEGGafCCwxSe6ZUa%2B073rXHnNdVXE6eWvibUS27XtRzkH838mYLMBmYysZTM0EM3A1fbpCBYFccN1B%2FEnCYu%2FTgCGmr7bMh8GfYL%2BBfcLvB0gRagC09w9elfldaIy%2FhNCBLRgBgtCC7jAF63wLSMAfbfAlEggYU0bUA7ACCJmTDpEmJtI78w4%2FBO7dN7JR7J7ZvbYaUbaILSQsRBiF3HGk5fEg6p9unwLvn98r%2BvnsV%2B372uf1xBLq4qU%2F45fTuqaAP%2BpssmCCCTF0mhEow8ZXZOS8D7Q85JsxZ%2BAzok7B7O%2Ff6J8AzYBySZQB%2FQHYUSA%2BEeQhEWiS6AIQzgcsDiER4MjgMBAWDV4AgQ3g1eBgIdweCQmCjJEMkJ%2BPKRWyFHHmg1Wi%2F6xzUgA0LREoKJChwnQa9B%2B5RQZRB3IlBlkAnxyQNaANwHMowzlYSMCBgnbpzvqpl0iTJNCQidDI9ZrSYNIRBhHtUa5YHMHxyGEik9hDE0AKj72AbTCaxtHPUaKZdAZSnQTyjGqGLsmBStCejApUhg4uBMU6mATujEl%2BKdDPbI6Ag4vLr%2BhjY6lbjBeoLKnZl0UZgRX8gTySOeynZVz1wOq7e1hFGYIq%2BMhrGxDLak0PrwYzSXtcuyhXEhwOYofiW%2BEcI%2Fjw8P6IY6ed%2BetAbuqKp5QIapT77LnAe505lMuqL79a0ut4rWexzFttsOsLDy7zvtQzcq3U1qabe7tB0wHWVXji%2BzDbo8x8HyIRUbXnwUcklFv51fvTymiV%2BMXLSmGH9d9%2BaXpD5X6lao41anWGig7IwIdnoBY2ht%2FpO9mClLo4NdXHAsefqWUKlXJkbqPOFhMoR4aiA1BXqhRNbB2Xwi%2B7u%2FjpAoOpKJ0UX24EsrzMfHXViakCNcKjBxuQX8BO0ZqjJ3xXzf%2B61t2VXOSgJ8xu65QKgtN6FibPmPYsXbJRHHqbgATcSZxBqGiDiU4NNNsYBsKD0MIP%2FOfKnlk%2FLkaid%2FO2NbKeuQrwOB2Gq3YHyr6ALgzym5wIBnsdC1ZkoBFZSQXChZvlesPqvK2c5oHHT3Q65jYpNxnQcGF0EHbvYqoFw60WNlXIHQF2HQB7zD6lWjZ9rVqUKBXUT6hrkZOle0RFYII0V5ZYGl1JAP0Ud1fZZMvSomBzJ710j4Me8mjQDwEre5Uv2wQfk1ifDwb5ksuJQQ3xt423lbuQjvoIQByQrNDh1JxGFkOdlJvu%2FgFtuW0wR4cgd%2BZKesSV7QkNE2kw6AV4hoIuC02LGmTomyf8PiO6CZzOTLTPQ%2BHW06H%2Btx%2BbQ8LmDYg1pTFrp2oJXgkZTyeRJZM0C8aE2LpFrNVDuhARsN543%2FFV6klQ6Tv1OoZGXLv0igKrl%2FCmJxRmX7JJbJ998VSIPQRyDBICzl4JJlYHbdql30NvYcOuZ7a10uWRrgoieOdgIm4rlq6vNOQBuqESLbXG5lzdJGHw2m0sDYmODXbYGTfSTGRKpssTO95fothJCjUGQgEL4yKoGAF%2F0SrpUDNn8CBgBcSDQByAeNkCXp4S4Ro2Xh4OeaGRgR66PVOsU8bc6TR5%2FxTcn4IVMLOkXSWiXxkZQCbvKfmoAvQaKjO3EDKwkwqHChCDEM5loQRPd5ACBki1TjF772oaQhQbQ5C0lcWXPFOzrfsDGUXGrpxasbG4iab6eByaQkQfm0VFlP0ZsDkvvqCL6QXMUwCjdMx1ZOyKhTJ7a1GWAdOUcJ8RSejxNVyGs31OKMyRyBVoZFjqIkmKlLQ5eHMeEL4MkUf23cQ%2F1SgRCJ1dk4UdBT7OoyuNgLs0oCd8RnrEIb6QdMxT2QjD4zMrJkfgx5aDMcA4orsTtKCqWb%2FVeyceqa5OGSmB28YwH4rFbkQaLoUN8OQQYnD3w2eXpI4ScQfbCUZiJ4yMOIKLyyTc7BQ4uXUw6Ee6%2FxM%2B4Y67ngNBknxIPwuppgIhFcwJyr6EIj%2BLzNj%2FmfR2vhhRlx0BILZoAYruF0caWQ7YxO66UmeguDREAFHYuC7HJviRgVO6ruJH59h%2FC%2FPkgSle8xNzZJULLWq9JMDTE2fjGE146a1Us6PZDGYle6ldWRqn%2FpdpgHKNGrGIdkRK%2BKPETT9nKT6kLyDI8xd9A1FgWmXWRAIHwZ37WyZHOVyCadJEmMVz0MadMjDrPho%2BEIochkVC2xgGiwwsQ6DMv2P7UXqT4x7CdcYGId2BJQQa85EQKmCmwcRejQ9Bm4oATENFPkxPXILHpMPUyWTI5rjNOsIlmEeMbcOCEqInpXACYQ9DDxmFo9vcmsDblcMtg4tqBerNngkIKaFJmrQAPnq1dEzsMXcwjcHdfdCibcAxxA%2Bq%2Fj9m3LM%2FO7WJka4tSidVCjsvo2lQ%2F2ewyoYyXwAYyr2PlRoR5MpgVmSUIrM3PQxXPbgjBOaDQFIyFMJvx3Pc5RSYj12ySVF9fwFPQu2e2KWVoL9q3Ayv3IzpGHUdvdPdrNUdicjsTQ2ISy7QU3DrEytIjvbzJnAkmANXjAFERA0MUoPF3%2F5KFmW14bBNOhwircYgMqoDpUMcDtCmBE82QM2YtdjVLB4kBuKho%2FbcwQdeboqfQartuU3CsCf%2BcXkgYAqp%2F0Ee3RorAZt0AvvOCSI4JICIlGlsV0bsSid%2FNIEALAAzb6HAgyWHBps6xAOwkJIGcB82CxRQq4sJf3FzA70A%2BTRqcqjEMETCoez3mkPcpnoALs0ugJY8kQwrC%2BJE5ik3w9rzrvDRjAQnqgEVvdGrNwlanR0SOKWzxOJOvLJhcd8Cl4AshACUkv9czdMkJCVQSQhp6kp7StAlpVRpK0t0SW6LHeBJnE2QchB5Ccu8kxRghZXGIgZIiSj7gEKMJDClcnX6hgoqJMwiQDigIXg3ioFLCgDgjPtYHYpsF5EiA4kcnN18MZtOrY866dEQAb0FB34OGKHGZQjwW%2FWDHA60cYFaI%2FPjpzquUqdaYGcIq%2BmLez3WLFFCtNBN2QJcrlcoELgiPku5R5dSlJFaCEqEZle1AQzAKC%2B1SotMcBNyQUFuRHRF6OlimSBgjZeTBCwLyc6A%2BP%2FoFRchXTz5ADknYJHxzrJ5pGuIKRQISU6WyKTBBjD8WozmVYWIsto1AS5rxzKlvJu4E%2FvwOiKxRtCWsDM%2BeTHUrmwrCK5BIfMzGkD%2B0Fk5LzBs0jMYXktNDblB06LMNJ09U8pzSLmo14MS0OMjcdrZ31pyQqxJJpRImlSvfYAK8inkYU52QY2FPEVsjoWewpwhRp5yAuNpkqhdb7ku9Seefl2D0B8SMTFD90xi4CSOwwZy9IKkpMtI3FmFUg3%2FkFutpQGNc3pCR7gvC4sgwbupDu3DyEN%2BW6YGLNM21jpB49irxy9BSlHrVDlnihGKHwPrbVFtc%2Bh1rVQKZduxIyojccZIIcOCmhEnC7UkY68WXKQgLi2JCDQkQWJRQuk60hZp0D3rtCTINSeY9Ej2kIKYfGxwOs4j9qMM7fYZiipzgcf7TamnehqdhsiMiCawXnz4xAbyCkLAx5EGbo3Ax1u3dUIKnTxIaxwQTHehPl3V491H0%2BbC5zgpGz7Io%2BmjdhKlPJ01EeMpM7UsRJMi1nGjmJg35i6bQBAAxjO%2FENJubU2mg3ONySEoWklCwdABETcs7ck3jgiuU9pcKKpbgn%2B3YlzV1FzIkB6pmEDOSSyDfPPlQskznctFji0kpgZjW5RZe6x9kYT4KJcXg0bNiCyif%2BpZACCyRMmYsfiKmN9tSO65F0R2OO6ytlEhY5Sj6uRKfFxw0ijJaAx%2Fk3QgnAFSq27%2F2i4GEBA%2BUvTJKK%2F9eISNvG46Em5RZfjTYLdeD8kdXHyrwId%2FDQZUaMCY4gGbke2C8vfjgV%2FY9kkRQOJIn%2FxM9INZSpiBnqX0Q9GlQPpPKAyO5y%2BW5NMPSRdBCUlmuxl40ZfMCnf2Cp044uI9WLFtCi4YVxKjuRCOBWIb4XbIsGdbo4qtMQnNOQz4XDSui7W%2FN6l54qOynCqD3DpWQ%2BmpD7C40D8BZEWGJX3tlAaZBMj1yjvDYKwCJBa201u6nBKE5UE%2B7QSEhCwrXfbRZylAaAkplhBWX50dumrElePyNMRYUrC99UmcSSNgImhFhDI4BXjMtiqkgizUGCrZ8iwFxU6fQ8GEHCFdLewwxYWxgScAYMdMLmcZR6b7rZl95eQVDGVoUKcRMM1ixXQtXNkBETZkVVPg8LoSrdetHzkuM7DjZRHP02tCxA1fmkXKF3VzfN1pc1cv%2F8lbTIkkYpqKM9VOhp65ktYk%2BQ46myFWBapDfyWUCnsnI00QTBQmuFjMZTcd0V2NQ768Fhpby04k2IzNR1wKabuGJqYWwSly6ocMFGTeeI%2BejsWDYgEvr66QgqdcIbFYDNgsm0x9UHY6SCd5%2B7tpsLpKdvhahIDyYmEJQCqMqtCF6UlrE5GXRmbu%2Bvtm3BFSxI6ND6UxIE7GsGMgWqghXxSnaRJuGFveTcK5ZVSPJyjUxe1dKgI6kNF7EZhIZs8y8FVqwEfbM0Xk2ltORVDKZZM40SD3qQoQe0orJEKwPfZwm3YPqwixhUMOndis6MhbmfvLBKjC8sKKIZKbJk8L11oNkCQzCgvjhyyEiQSuJcgCQSG4Mocfgc0Hkwcjal1UNgP0CBPikYqBIk9tONv4kLtBswH07vUCjEaHiFGlLf8MgXKzSgjp2HolRRccAOh0ILHz9qlGgIFkwAnzHJRjWFhlA7ROwINyB5HFj59PRZHFor6voq7l23EPNRwdWhgawqbivLSjRA4htEYUFkjESu67icTg5S0aW1sOkCiIysfJ9UnIWevOOLGpepcBxy1wEhd2WI3AZg7sr9WBmHWyasxMcvY%2FiOmsLtHSWNUWEGk9hScMPShasUA1AcHOtRZlqMeQ0OzYS9vQvYUjOLrzP07BUAFikcJNMi7gIxEw4pL1G54TcmmmoAQ5s7TGWErJZ2Io4yQ0ljRYhL8H5e62oDtLF8aDpnIvZ5R3GWJyAugdiiJW9hQAVTsnCBHhwu7rkBlBX6r3b7ejEY0k5GGeyKv66v%2B6dg7mcJTrWHbtMywbedYqCQ0FPwoytmSWsL8WTtChZCKKzEF7vP6De4x2BJkkniMgSdWhbeBSLtJZR9CTHetK1xb34AYIJ37OegYIoPVbXgJ%2FqDQK%2BbfCtxQRVKQu77WzOoM6SGL7MaZwCGJVk46aImai9fmam%2BWpHG%2B0BtQPWUgZ7RIAlPq6lkECUhZQ2gqWkMYKcYMYaIc4gYCDFHYa2d1nzp3%2BJ1eCBay8IYZ0wQRKGAqvCuZ%2FUgbQPyllosq%2BXtfKIZOzmeJqRazpmmoP%2F76YfkjzV2NlXTDSBYB04SVlNQsFTbGPk1t%2FI4Jktu0XSgifO2ozFOiwd%2F0SssJDn0dn4xqk4GDTTKX73%2FwQyBLdqgJ%2BWx6AQaba3BA9CKEzjtQYIfAsiYamapq80LAamYjinlKXUkxdpIDk0puXUEYzSalfRibAeDAKpNiqQ0FTwoxuGYzRnisyTotdVTclis1LHRQCy%2FqqL8oUaQzWRxilq5Mi0IJGtMY02cGLD69vGjkj3p6pGePKI8bkBv5evq8SjjyU04vJR2cQXQwSJyoinDsUJHCQ50jrFTT7yRdbdYQMB3MYCb6uBzJ9ewhXYPAIZSXfeEQBZZ3GPN3Nbhh%2FwkvAJLXnQMdi5NYYZ5GHE400GS5rXkOZSQsdZgIbzRnF9ueLnsfQ47wHAsirITnTlkCcuWWIUhJSbpM3wWhXNHvt2xUsKKMpdBSbJnBMcihkoDqAd1Zml%2FR4yrzow1Q2A5G%2Bkzo%2FRhRxQS2lCSDRV8LlYLBOOoo1bF4jwJAwKMK1tWLHlu9i0j4Ig8qVm6wE1DxXwAwQwsaBWUg2pOOol2dHxyt6npwJEdLDDVYyRc2D0HbcbLUJQj8gPevQBUBOUHXPrsAPBERICpnYESeu2OHotpXQxRGlCCtLdIsu23MhZVEoJg8Qumj%2FUMMc34IBqTKLDTp76WzL%2FdMjCxK7MjhiGjeYAC%2Fkj%2FjY%2FRde7hpSM1xChrog6yZ7OWTuD56xBJnGFE%2BpT2ElSyCnJcwVzCjkqeNLfMEJqKW0G7OFIp0G%2B9mh50I9o8k1tpCY0xYqFNIALgIfc2me4n1bmJnRZ89oepgLPT0NTMLNZsvSCZAc3TXaNB07vail36%2FdBySis4m9%2FDR8izaLJW6bWCkVgm5T%2Bius3ZXq4xI%2BGnbveLbdRwF2mNtsrE0JjYc1AXknCOrLSu7Te%2Fr4dPYMCl5qtiHNTn%2BTPbh1jCBHH%2BdMJNhwNgs3nT%2BOhQoQ0vYif56BMG6WowAcHR3DjQolxLzyVekHj00PBAaW7IIAF1EF%2BuRIWyXjQMAs2chdpaKPNaB%2BkSezYt0%2BCA04sOg5vx8Fr7Ofa9sUv87h7SLAUFSzbetCCZ9pmyLt6l6%2FTzoA1%2FZBG9bIUVHLAbi%2FkdBFgYGyGwRQGBpkqCEg2ah9UD6EedEcEL3j4y0BQQCiExEnocA3SZboh%2Bepgd3YsOkHskZwPuQ5OoyA0fTA5AXrHcUOQF%2BzkJHIA7PwCDk1gGVmGUZSSoPhNf%2BTklauz98QofOlCIQ%2FtCD4dosHYPqtPCXB3agggQQIqQJsSkB%2Bqn0rkQ1toJjON%2FOtCIB9RYv3PqRA4C4U68ZMlZn6BdgEvi2ziU%2BTQ6NIw3ej%2BAtDwMGEZk7e2IjxUWKdAxyaw9OCwSmeADTPPleyk6UhGDNXQb%2B%2BW6Uk4q6F7%2Frg6WVTo82IoCxSIsFDrav4EPHphD3u4hR53WKVvYZUwNCCeM4PMBWzK%2BEfIthZOkuAwPo5C5jgoZgn6dUdvx5rIDmd58cXXdKNfw3l%2BwM2UjgrDJeQHhbD7HW2QDoZMCujgIUkk5Fg8VCsdyjOtnGRx8wgKRPZN5dR0zPUyfGZFVihbFRniXZFOZGKPnEQzU3AnD1KfR6weHW2XS6KbPJxUkOTZsAB9vTVp3Le1F8q5l%2BDMcLiIq78jxAImD2pGFw0VHfRatScGlK6SMu8leTmhUSMy8Uhdd6xBiH3Gdman4tjQGLboJfqz6fL2WKHTmrfsKZRYX6BTDjDldKMosaSTLdQS7oDisJNqAUhw1PfTlnacCO8vl8706Km1FROgLDmudzxg%2BEWTiArtHgLsRrAXYWdB0NmToNCJdKm0KWycZQqb%2BMw76Qy29iQ5up%2FX7oyw8QZ75kP5F6iJAJz6KCmqxz8fEa%2FxnsMYcIO%2FvEkGRuMckhr4rIeLrKaXnmIzlNLxbFspOphkcnJdnz%2FChp%2FVlpj2P7jJQmQRwGnltkTV5dbF9fE3%2FfxoSqTROgq9wFUlbuYzYcasE0ouzBo%2BdDCDzxKAfhbAZYxQiHrLzV2iVexnDX%2FQnT1fsT%2Fxuhu1ui5qIytgbGmRoQkeQooO8eJNNZsf0iALur8QxZFH0nCMnjerYQqG1pIfjyVZWxhVRznmmfLG00BcBWJE6hzQWRyFknuJnXuk8A5FRDCulwrWASSNoBtR%2BCtGdkPwYN2o7DOw%2FVGlCZPusRBFXODQdUM5zeHDIVuAJBLqbO%2Ff9Qua%2BpDqEPk230Sob9lEZ8BHiCorjVghuI0lI4JDgHGRDD%2FprQ84B1pVGkIpVUAHCG%2Biz3Bn3qm2AVrYcYWhock4jso5%2BJ7HfHVj4WMIQdGctq3psBCVVzupQOEioBGA2Bk%2BUILT7%2BVoX5mdxxA5fS42gISQVi%2FHTzrgMxu0fY6hE1ocUwwbsbWcezrY2n6S8%2F6cxXkOH4prpmPuFoikTzY7T85C4T2XYlbxLglSv2uLCgFv8Quk%2FwdesUdWPeHYIH0R729JIisN9Apdd4eB10aqwXrPt%2BSu9mA8k8n1sjMwnfsfF2j3jMUzXepSHmZ%2FBfqXvzgUNQQWOXO8YEuFBh4QTYCkOAPxywpYu1VxiDyJmKVcmJPGWk%2Fgc3Pov02StyYDahwmzw3E1gYC9wkupyWfDqDSUMpCTH5e5N8B%2F%2FlHiMuIkTNw4USHrJU67bjXGqNav6PBuQSoqTxc8avHoGmvqNtXzIaoyMIQIiiUHIM64cXieouplhNYln7qgc4wBVAYR104kO%2BCvKqsg4yIUlFNThVUAKZxZt1XA34h3TCUUiXVkZ0w8Hh2R0Z5L0b4LZvPd%2Fp1gi%2F07h8qfwHrByuSxglc9cI4QIg2oqvC%2Fqm0i7tjPLTgDhoWTAKDO2ONW5oe%2B%2FeKB9vZB8K6C25yCZ9RFVMnb6NRdRjyVK57CHHSkJBfnM2%2Fj4ODUwRkqrtBBCrDsDpt8jhZdXoy%2F1BCqw3sSGhgGGy0a5Jw6BP%2FTExoCmNFYjZl248A0osgPyGEmRA%2BfAsqPVaNAfytu0vuQJ7rk3J4kTDTR2AlCHJ5cls26opZM4w3jMULh2YXKpcqGBtuleAlOZnaZGbD6DHzMd6i2oFeJ8z9XYmalg1Szd%2FocZDc1C7Y6vcALJz2lYnTXiWEr2wawtoR4g3jvWUU2Ngjd1cewtFzEvM1NiHZPeLlIXFbBPawxNgMwwAlyNSuGF3zizVeOoC9bag1qRAQKQE%2FEZBWC2J8mnXAN2aTBboZ7HewnObE8CwROudZHmUM5oZ%2FUgd%2FJZQK8lvAm43uDRAbyW8gZ%2BZGq0EVerVGUKUSm%2FIdn8AQHdR4m7bue88WBwft9mSCeMOt1ncBwziOmJYI2ZR7ewNMPiCugmSsE4EyQ%2BQATJG6qORMGd4snEzc6B4shPIo4G1T7PgSm8PY5eUkPdF8JZ0VBtadbHXoJgnEhZQaODPj2gpODKJY5Yp4DOsLBFxWbvXN755KWylJm%2BoOd4zEL9Hpubuy2gyyfxh8oEfFutnYWdfB8PdESLWYvSqbElP9qo3u6KTmkhoacDauMNNjj0oy40DFV7Ql0aZj77xfGl7TJNHnIwgqOkenruYYNo6h724%2BzUQ7%2BvkCpZB%2BpGA562hYQiDxHVWOq0oDQl%2FQsoiY%2BcuI7iWq%2FZIBtHcXJ7kks%2Bh2fCNUPA82BzjnqktNts%2BRLdk1VSu%2BtqEn7QZCCsvEqk6FkfiOYkrsw092J8jsfIuEKypNjLxrKA9kiA19mxBD2suxQKCzwXGws7kEJvlhUiV9tArLIdZW0IORcxEzdzKmjtFhsjKy%2F44XYXdI5noQoRcvjZ1RMPACRqYg2V1%2BOwOepcOknRLLFdYgTkT5UApt%2FJhLM3jeFYprZV%2BZow2g8fP%2BU68hkKFWJj2yBbKqsrp25xkZX1DAjUw52IMYWaOhab8Kp05VrdNftqwRrymWF4OQSjbdfzmRZirK8FMJELEgER2PHjEAN9pGfLhCUiTJFbd5LBkOBMaxLr%2FA1SY9dXFz4RjzoU9ExfJCmx%2FI9FKEGT3n2cmzl2X42L3Jh%2BAbQq6sA%2BSs1kitoa4TAYgKHaoybHUDJ51oETdeI%2F9ThSmjWGkyLi5QAGWhL0BG1UsTyRGRJOldKBrYJeB8ljLJHfATWTEQBXBDnQexOHTB%2BUn44zExFE4vLytcu5NwpWrUxO%2F0ZICUGM7hGABXym0V6ZvDST0E370St9MIWQOTWngeoQHUTdCJUP04spMBMS8LSker9cReVQkULFDIZDFPrhTzBl6sed9wcZQTbL%2BBDqMyaN3RJPh%2Fanbx%2BIv%2BqgQdAa3M9Z5JmvYlh4qop%2BHo1F1W5gbOE9YKLgAnWytXElU4G8GtW47lhgFE6gaSs%2Bgs37sFvi0PPVvA5dnCBgILTwoKd%2F%2BDoL9F6inlM7H4rOTzD79KJgKlZO%2FZgt22UsKhrAaXU5ZcLrAglTVKJEmNJvORGN1vqrcfSMizfpsgbIe9zno%2BgBoKVXgIL%2FVI8dB1O5o%2FR3Suez%2FgD7M781ShjKpIIORM%2FnxG%2BjjhhgPwsn2IoXsPGPqYHXA63zJ07M2GPEykQwJBYLK808qYxuIew4frk52nhCsnCYmXiR6CuapvE1IwRB4%2FQftDbEn%2BAucIr1oxrLabRj9q4ae0%2BfXkHnteAJwXRbVkR0mctVSwEbqhJiMSZUp9DNbEDMmjX22m3ABpkrPQQTP3S1sib5pD2VRKRd%2BeNAjLYyT0hGrdjWJZy24OYXRoWQAIhGBZRxuBFMjjZQhpgrWo8SiFYbojcHO8V5DyscJpLTHyx9Fimassyo5U6WNtquUMYgccaHY5amgR3PQzq3ToNM5ABnoB9kuxsebqmYZm0R9qxJbFXCQ1UPyFIbxoUraTJFDpCk0Wk9GaYJKz%2F6oHwEP0Q14lMtlddQsOAU9zlYdMVHiT7RQP3XCmWYDcHCGbVRHGnHuwzScA0BaSBOGkz3lM8CArjrBsyEoV6Ys4qgDK3ykQQPZ3hCRGNXQTNNXbEb6tDiTDLKOyMzRhCFT%2BmAUmiYbV3YQVqFVp9dorv%2BTsLeCykS2b5yyu8AV7IS9cxcL8z4Kfwp%2BxJyYLv1OsxQCZwTB4a8BZ%2F5EdxTBJthApqyfd9u3ifr%2FWILTqq5VqgwMT9SOxbSGWLQJUUWCVi4k9tho9nEsbUh7U6NUsLmkYFXOhZ0kmamaJLRNJzSj%2Fqn4Mso6zb6iLLBXoaZ6AqeWCjHQm2lztnejYYM2eubnpBdKVLORZhudH3JF1waBJKA9%2BW8EhMj3Kzf0L4vi4k6RoHh3Z5YgmSZmk6ns4fjScjAoL8GoOECgqgYEBYUGFVO4FUv4%2FYtowhEmTs0vrvlD%2FCrisnoBNDAcUi%2FteY7OctFlmARQzjOItrrlKuPO6E2Ox93L4O%2F4DcgV%2FdZ7qR3VBwVQxP1GCieA4RIpweYJ5FoYrHxqRBdJjnqbsikA2Ictbb8vE1GYIo9dacK0REgDX4smy6GAkxlH1yCGGsk%2BtgiDhNKuKu3yNrMdxafmKTF632F8Vx4BNK57GvlFisrkjN9WDAtjsWA0ENT2e2nETUb%2Fn7qwhvGnrHuf5bX6Vh%2Fn3xffU3PeHdR%2BFA92i6ufT3AlyAREoNDh6chiMWTvjKjHDeRhOa9YkOQRq1vQXEMppAQVwHCuIcV2g5rBn6GmZZpTR7vnSD6ZmhdSl176gqKTXu5E%2BYbfL0adwNtHP7dT7t7b46DVZIkzaRJOM%2BS6KcrzYVg%2BT3wSRFRQashjfU18NutrKa%2F7PXbtuJvpIjbgPeqd%2BpjmRw6YKpnANFSQcpzTZgpSNJ6J7uiagAbir%2F8tNXJ%2FOsOnRh6iuIexxrmkIneAgz8QoLmiaJ8sLQrELVK2yn3wOHp57BAZJhDZjTBzyoRAuuZ4eoxHruY1pSb7qq79cIeAdOwin4GdgMeIMHeG%2BFZWYaiUQQyC5b50zKjYw97dFjAeY2I4Bnl105Iku1y0lMA1ZHolLx19uZnRdILcXKlZGQx%2FGdEqSsMRU1BIrFqRcV1qQOOHyxOLXEGcbRtAEsuAC2V4K3p5mFJ22IDWaEkk9ttf5Izb2LkD1MnrSwztXmmD%2FQi%2FEmVEFBfiKGmftsPwVaIoZanlKndMZsIBOskFYpDOq3QUs9aSbAAtL5Dbokus2G4%2FasthNMK5UQKCOhU97oaOYNGsTah%2BjfCKsZnTRn5TbhFX8ghg8CBYt%2FBjeYYYUrtUZ5jVij%2Fop7V5SsbA4mYTOwZ46hqdpbB6Qvq3AS2HHNkC15pTDIcDNGsMPXaBidXYPHc6PJAkRh29Vx8KcgX46LoUQBhRM%2B3SW6Opll%2FwgxxsPgKJKzr5QCmwkUxNbeg6Wj34SUnEzOemSuvS2OetRCO8Tyy%2BQbSKVJcqkia%2BGvDefFwMOmgnD7h81TUtMn%2BmRpyJJ349HhAnoWFTejhpYTL9G8N2nVg1qkXBeoS9Nw2fB27t7trm7d%2FQK7Cr4uoCeOQ7%2F8JfKT77KiDzLImESHw%2F0wf73QeHu74hxv7uihi4fTX%2BXEwAyQG3264dwv17aJ5N335Vt9sdrAXhPOAv8JFvzqyYXwfx8WYJaef1gMl98JRFyl5Mv5Uo%2FoVH5ww5OzLFsiTPDns7fS6EURSSWd%2F92BxMYQ8sBaH%2Bj%2BwthQPdVgDGpTfi%2BJQIWMD8xKqULliRH01rTeyF8x8q%2FGBEEEBrAJMPf25UQwi0b8tmqRXY7kIvNkzrkvRWLnxoGYEJsz8u4oOyMp8cHyaybb1HdMCaLApUE%2B%2F7xLIZGP6H9xuSEXp1zLIdjk5nBaMuV%2FyTDRRP8Y2ww5RO6d2D94o%2B6ucWIqUAvgHIHXhZsmDhjVLczmZ3ca0Cb3PpKwt2UtHVQ0BgFJsqqTsnzZPlKahRUkEu4qmkJt%2Bkqdae76ViWe3STan69yaF9%2BfESD2lcQshLHWVu4ovItXxO69bqC5p1nZLvI8NdQB9s9UNaJGlQ5mG947ipdDA0eTIw%2FA1zEdjWquIsQXXGIVEH0thC5M%2BW9pZe7IhAVnPJkYCCXN5a32HjN6nsvokEqRS44tGIs7s2LVTvcrHAF%2BRVmI8L4HUYk4x%2B67AxSMJKqCg8zrGOgvK9kNMdDrNiUtSWuHFpC8%2Fp5qIQrEo%2FH%2B1l%2F0cAwQ2nKmpWxKcMIuHY44Y6DlkpO48tRuUGBWT0FyHwSKO72Ud%2BtJUfdaZ4CWNijzZtlRa8%2BCkmO%2FEwHYfPZFU%2FhzjFWH7vnzHRMo%2BaF9u8qHSAiEkA2HjoNQPEwHsDKOt6hOoK3Ce%2F%2B%2F9boMWDa44I6FrQhdgS7OnNaSzwxWKZMcyHi6LN4WC6sSj0qm2PSOGBTvDs%2FGWJS6SwEN%2FULwpb4LQo9fYjUfSXRwZkynUazlSpvX9e%2BG2zor8l%2BYaMxSEomDdLHGcD6YVQPegTaA74H8%2BV4WvJkFUrjMLGLlvSZQWvi8%2FQA7yzQ8GPno%2F%2F5SJHRP%2FOqKObPCo81s%2F%2B6WgLqykYpGAgQZhVDEBPXWgU%2FWzFZjKUhSFInufPRiMAUULC6T11yL45ZrRoB4DzOyJShKXaAJIBS9wzLYIoCEcJKQW8GVCx4fihqJ6mshBUXSw3wWVj3grrHQlGNGhIDNNzsxQ3M%2BGWn6ASobIWC%2BLbYOC6UpahVO13Zs2zOzZC8z7FmA05JhUGyBsF4tsG0drcggIFzgg%2Fkpf3%2BCnAXKiMgIE8Jk%2FMhpkc8DUJEUzDSnWlQFme3d0sHZDrg7LavtsEX3cHwjCYA17pMTfx8Ajw9hHscN67hyo%2BRJQ4458RmPywXykkVcW688oVUrQhahpPRvTWPnuI0B%2BSkQu7dCyvLRyFYlC1LG1gRCIvn3rwQeINzZQC2KXq31FaR9UmVV2QeGVqBHjmE%2BVMd3b1fhCynD0pQNhCG6%2FWCDbKPyE7NRQzL3BzQAJ0g09aUzcQA6mUp9iZFK6Sbp%2FYbHjo%2B%2B7%2FWj8S4YNa%2BZdqAw1hDrKWFXv9%2BzaXpf8ZTDSbiqsxnwN%2FCzK5tPkOr4tRh2kY3Bn9JtalbIOI4b3F7F1vPQMfoDcdxMS8CW9m%2FNCW%2FHILTUVWQIPiD0j1A6bo8vsv6P1hCESl2abrSJWDrq5sSzUpwoxaCU9FtJyYH4QFMxDBpkkBR6kn0LMPO%2B5EJ7Z6bCiRoPedRZ%2FP0SSdii7ZnPAtVwwHUidcdyspwncz5uq6vvm4IEDbJVLUFCn%2FLvIHfooUBTkFO130FC7CmmcrKdgDJcid9mvVzsDSibOoXtIf9k6ABle3PmIxejodc4aob0QKS432srrCMndbfD454q52V01G4q913mC5HOsTzWF4h2No1av1VbcUgWAqyoZl%2B11PoFYnNv2HwAODeNRkHj%2B8SF1fcvVBu6MrehHAZK1Gm69ICcTKizykHgGFx7QdowTVAsYEF2tVc0Z6wLryz2FI1sc5By2znJAAmINndoJiB4sfPdPrTC8RnkW7KRCwxC6YvXg5ahMlQuMpoCSXjOlBy0Kij%2BbsCYPbGp8BdCBiLmLSAkEQRaieWo1SYvZIKJGj9Ur%2FeWHjiB7SOVdqMAVmpBvfRiebsFjger7DC%2B8kRFGtNrTrnnGD2GAJb8rQCWkUPYHhwXsjNBSkE6lGWUj5QNhK0DMNM2l%2BkXRZ0KLZaGsFSIdQz%2FHXDxf3%2FTE30%2BDgBKWGWdxElyLccJfEpjsnszECNoDGZpdwdRgCixeg9L4EPhH%2BRptvRMVRaahu4cySjS3P5wxAUCPkmn%2BrhyASpmiTaiDeggaIxYBmtLZDDhiWIJaBgzfCsAGUF1Q1SFZYyXDt9skCaxJsxK2Ms65dmdp5WAZyxik%2FzbrTQk5KmgxCg%2Ff45L0jywebOWUYFJQAJia7XzCV0x89rpp%2Ff3AVWhSPyTanqmik2SkD8A3Ml4NhIGLAjBXtPShwKYfi2eXtrDuKLk4QlSyTw1ftXgwqA2jUuopDl%2B5tfUWZNwBpEPXghzbBggYCw%2Fdhy0ntds2yeHCDKkF%2FYxQjNIL%2FF%2F37jLPHCKBO9ibwYCmuxImIo0ijV2Wbg3kSN2psoe8IsABv3RNFaF9uMyCtCYtqcD%2BqNOhwMlfARQUdJ2tUX%2BMNJqOwIciWalZsmEjt07tfa8ma4cji9sqz%2BQ9hWfmMoKEbIHPOQORbhQRHIsrTYlnVTNvcq1imqmmPDdVDkJgRcTgB8Sb6epCQVmFZe%2BjGDiNJQLWnfx%2BdrTKYjm0G8yH0ZAGMWzEJhUEQ4Maimgf%2Fbkvo8PLVBsZl152y5S8%2BHRDfZIMCbYZ1WDp4yrdchOJw8k6R%2B%2F2pHmydK4NIK2PHdFPHtoLmHxRDwLFb7eB%2BM4zNZcB9NrAgjVyzLM7xyYSY13ykWfIEEd2n5%2FiYp3ZdrCf7fL%2Ben%2BsIJu2W7E30MrAgZBD1rAAbZHPgeAMtKCg3NpSpYQUDWJu9bT3V7tOKv%2BNRiJc8JAKqqgCA%2FPNRBR7ChpiEulyQApMK1AyqcWnpSOmYh6yLiWkGJ2mklCSPIqN7UypWj3dGi5MvsHQ87MrB4VFgypJaFriaHivwcHIpmyi5LhNqtem4q0n8awM19Qk8BOS0EsqGscuuydYsIGsbT5GHnERUiMpKJl4ON7qjB4fEqlGN%2FhCky89232UQCiaeWpDYCJINXjT6xl4Gc7DxRCtgV0i1ma4RgWLsNtnEBRQFqZggCLiuyEydmFd7WlogpkCw5G1x4ft2psm3KAREwVwr1Gzl6RT7FDAqpVal34ewVm3VH4qn5mjGj%2BbYL1NgfLNeXDwtmYSpwzbruDKpTjOdgiIHDVQSb5%2FzBgSMbHLkxWWgghIh9QTFSDILixVwg0Eg1puooBiHAt7DzwJ7m8i8%2Fi%2BjHvKf0QDnnHVkVTIqMvIQImOrzCJwhSR7qYB5gSwL6aWL9hERHCZc4G2%2BJrpgHNB8eCCmcIWIQ6rSdyPCyftXkDlErUkHafHRlkOIjxGbAktz75bnh50dU7YHk%2BMz7wwstg6RFZb%2BTZuSOx1qqP5C66c0mptQmzIC2dlpte7vZrauAMm%2F7RfBYkGtXWGiaWTtwvAQiq2oD4YixPLXE2khB2FRaNRDTk%2B9sZ6K74Ia9VntCpN4BhJGJMT4Z5c5FhSepRCRWmBXqx%2BwhVZC4me4saDs2iNqXMuCl6iAZflH8fscC1sTsy4PHeC%2BXYuqMBMUun5YezKbRKmEPwuK%2BCLzijPEQgfhahQswBBLfg%2FGBgBiI4QwAqzJkkyYAWtjzSg2ILgMAgqxYfwERRo3zruBL9WOryUArSD8sQOcD7fvIODJxKFS615KFPsb68USBEPPj1orNzFY2xoTtNBVTyzBhPbhFH0PI5AtlJBl2aSgNPYzxYLw7XTDBDinmVoENwiGzmngrMo8OmnRP0Z0i0Zrln9DDFcnmOoBZjABaQIbPOJYZGqX%2BRCMlDDbElcjaROLDoualmUIQ88Kekk3iM4OQrADcxi3rJguS4MOIBIgKgXrjd1WkbCdqxJk%2F4efRIFsavZA7KvvJQqp3Iid5Z0NFc5aiMRzGN3vrpBzaMy4JYde3wr96PjN90AYOIbyp6T4zj8LoE66OGcX1Ef4Z3KoWLAUF4BTg7ug%2FAbkG5UNQXAMkQezujSHeir2uTThgd3gpyzDrbnEdDRH2W7U6PeRvBX1ZFMP5RM%2BZu6UUZZD8hDPHldVWntTCNk7To8IeOW9yn2wx0gmurwqC60AOde4r3ETi5pVMSDK8wxhoGAoEX9NLWHIR33VbrbMveii2jAJlrxwytTHbWNu8Y4N8vCCyZjAX%2FpcsfwXbLze2%2BD%2Bu33OGBoJyAAL3jn3RuEcdp5If8O%2Ba4NKWvxOTyDltG0IWoHhwVGe7dKkCWFT%2B%2Btm%2BhaBCikRUUMrMhYKZJKYoVuv%2FbsJzO8DwfVIInQq3g3BYypiz8baogH3r3GwqCwFtZnz4xMjAVOYnyOi5HWbFA8n0qz1OjSpHWFzpQOpvkNETZBGpxN8ybhtqV%2FDMUxd9uFZmBfKXMCn%2FSqkWJyKPnT6lq%2B4zBZni6fYRByJn6OK%2BOgPBGRAJluwGSk4wxjOOzyce%2FPKODwRlsgrVkdcsEiYrqYdXo0Er2GXi2GQZd0tNJT6c9pK1EEJG1zgDJBoTVuCXGAU8BKTvCO%2FcEQ1Wjk3Zzuy90JX4m3O5IlxVFhYkSUwuQB2up7jhvkm%2BbddRQu5F9s0XftGEJ9JSuSk%2BZachCbdU45fEqbugzTIUokwoAKvpUQF%2FCvLbWW5BNQFqFkJg2f30E%2F48StNe5QwBg8zz3YAJ82FZoXBxXSv4QDooDo79NixyglO9AembuBcx5Re3CwOKTHebOPhkmFC7wNaWtoBhFuV4AkEuJ0J%2B1pT0tLkvFVZaNzfhs%2FKd3%2BA9YsImlO4XK4vpCo%2FelHQi%2F9gkFg07xxnuXLt21unCIpDV%2BbbRxb7FC6nWYTsMFF8%2B1LUg4JFjVt3vqbuhHmDKbgQ4e%2BRGizRiO8ky05LQGMdL2IKLSNar0kNG7lHJMaXr5mLdG3nykgj6vB%2FKVijd1ARWkFEf3yiUw1v%2FWaQivVUpIDdSNrrKbjO5NPnxz6qTTGgYg03HgPhDrCFyYZTi3XQw3HXCva39mpLNFtz8AiEhxAJHpWX13gCTAwgm9YTvMeiqetdNQv6IU0hH0G%2BZManTqDLPjyrOse7WiiwOJCG%2BJ0pZYULhN8NILulmYYvmVcV2MjAfA39sGKqGdjpiPo86fecg65UPyXDIAOyOkCx5NQsLeD4gGVjTVDwOHWkbbBW0GeNjDkcSOn2Nq4cEssP54t9D749A7M1AIOBl0Fi0sSO5v3P7LCBrM6ZwFY6kp2FX6AcbGUdybnfChHPyu6WlRZ2Fwv9YM0RMI7kISRgR8HpQSJJOyTfXj%2F6gQKuihPtiUtlCQVPohUgzfezTg8o1b3n9pNZeco1QucaoXe40Fa5JYhqdTspFmxGtW9h5ezLFZs3j%2FN46f%2BS2rjYNC2JySXrnSAFhvAkz9a5L3pza8eYKHNoPrvBRESpxYPJdKVUxBE39nJ1chrAFpy4MMkf0qKgYALctGg1DQI1kIymyeS2AJNT4X240d3IFQb%2F0jQbaHJ2YRK8A%2Bls6WMhWmpCXYG5jqapGs5%2FeOJErxi2%2F2KWVHiPellTgh%2FfNl%2F2KYPKb7DUcAg%2BmCOPQFCiU9Mq%2FWLcU1xxC8aLePFZZlE%2BPCLzf7ey46INWRw2kcXySR9FDgByXzfxiNKwDFbUSMMhALPFSedyjEVM5442GZ4hTrsAEvZxIieSHGSgkwFh%2FnFNdrrFD4tBH4Il7fW6ur4J8Xaz7RW9jgtuPEXQsYk7gcMs2neu3zJwTyUerHKSh1iTBkj2YJh1SSOZL5pLuQbFFAvyO4k1Hxg2h99MTC6cTUkbONQIAnEfGsGkNFWRbuRyyaEZInM5pij73EA9rPIUfU4XoqQpHT9THZkW%2BoKFLvpyvTBMM69tN1Ydwv1LIEhHsC%2BueVG%2Bw%2BkyCPsvV3erRikcscHjZCkccx6VrBkBRusTDDd8847GA7p2Ucy0y0HdSRN6YIBciYa4vuXcAZbQAuSEmzw%2BH%2FAuOx%2BaH%2BtBL88H57D0MsqyiZxhOEQkF%2F8DR1d2hSPMj%2FsNOa5rxcUnBgH8ictv2J%2Bcb4BA4v3MCShdZ2vtK30vAwkobnEWh7rsSyhmos3WC93Gn9C4nnAd%2FPjMMtQfyDNZsOPd6XcAsnBE%2FmRHtHEyJMzJfZFLE9OvQa0i9kUmToJ0ZxknTgdl%2FXPV8xoh0K7wNHHsnBdvFH3sv52lU7UFteseLG%2FVanIvcwycVA7%2BBE1Ulyb20BvwUWZcMTKhaCcmY3ROpvonVMV4N7yBXTL7IDtHzQ4CCcqF66LjF3xUqgErKzolLyCG6Kb7irP%2FMVTCCwGRxfrPGpMMGvPLgJ881PHMNMIO09T5ig7AzZTX%2F5PLlwnJLDAPfuHynSGhV4tPqR3gJ4kg4c06c%2FF1AcjGytKm2Yb5jwMotF7vro4YDLWlnMIpmPg36NgAZsGA0W1spfLSue4xxat0Gdwd0lqDBOgIaMANykwwDKejt5YaNtJYIkrSgu0KjIg0pznY0SCd1qlC6R19g97UrWDoYJGlrvCE05J%2F5wkjpkre727p5PTRX5FGrSBIfJqhJE%2FIS876PaHFkx9pGTH3oaY3jJRvLX9Iy3Edoar7cFvJqyUlOhAEiOSAyYgVEGkzHdug%2BoRHIEOXAExMiTSKU9A6nmRC8mp8iYhwWdP2U%2F5EkFAdPrZw03YA3gSyNUtMZeh7dDCu8pF5x0VORCTgKp07ehy7NZqKTpIC4UJJ89lnboyAfy5OyXzXtuDRbtAFjZRSyGFTpFrXwkpjSLIQIG3N0Vj4BtzK3wdlkBJrO18MNsgseR4BysJilI0wI6ZahLhBFA0XBmV8d4LUzEcNVb0xbLjLTETYN8OEVqNxkt10W614dd1FlFFVTIgB7%2FBQQp1sWlNolpIu4ekxUTBV7NmxOFKEBmmN%2BnA7pvF78%2FRII5ZHA09OAiE%2F66MF6HQ%2BqVEJCHxwymukkNvzqHEh52dULPbVasfQMgTDyBZzx4007YiKdBuUauQOt27Gmy8ISclPmEUCIcuLbkb1mzQSqIa3iE0PJh7UMYQbkpe%2BhXjTJKdldyt2mVPwywoODGJtBV1lJTgMsuSQBlDMwhEKIfrvsxGQjHPCEfNfMAY2oxvyKcKPUbQySkKG6tj9AQyEW3Q5rpaDJ5Sns9ScLKeizPRbvWYAw4bXkrZdmB7CQopCH8NAmqbuciZChHN8lVGaDbCnmddnqO1PQ4ieMYfcSiBE5zzMz%2BJV%2F4eyzrzTEShvqSGzgWimkNxLvUj86iAwcZuIkqdB0VaIB7wncLRmzHkiUQpPBIXbDDLHBlq7vp9xwuC9AiNkIptAYlG7Biyuk8ILdynuUM1cHWJgeB%2BK3wBP%2FineogxkvBNNQ4AkW0hvpBOQGFfeptF2YTR75MexYDUy7Q%2F9uocGsx41O4IZhViw%2F2FvAEuGO5g2kyXBUijAggWM08bRhXg5ijgMwDJy40QeY%2FcQpUDZiIzmvskQpO5G1zyGZA8WByjIQU4jRoFJt56behxtHUUE%2Fom7Rj2psYXGmq3llVOCgGYKNMo4pzwntITtapDqjvQtqpjaJwjHmDzSVGLxMt12gEXAdLi%2FcaHSM3FPRGRf7dB7YC%2BcD2ho6oL2zGDCkjlf%2FDFoQVl8GS%2F56wur3rdV6ggtzZW60MRB3g%2BU1W8o8cvqIpMkctiGVMzXUFI7FacFLrgtdz4mTEr4aRAaQ2AFQaNeG7GX0yOJgMRYFziXdJf24kg%2FgBQIZMG%2FYcPEllRTVNoDYR6oSJ8wQNLuihfw81UpiKPm714bZX1KYjcXJdfclCUOOpvTxr9AAJevTY4HK%2FG7F3mUc3GOAKqh60zM0v34v%2BELyhJZqhkaMA8UMMOU90f8RKEJFj7EqepBVwsRiLbwMo1J2zrE2UYJnsgIAscDmjPjnzI8a719Wxp757wqmSJBjXowhc46QN4RwKIxqEE6E5218OeK7RfcpGjWG1jD7qND%2B%2FGTk6M56Ig4yMsU6LUW1EWE%2BfIYycVV1thldSlbP6ltdC01y3KUfkobkt2q01YYMmxpKRvh1Z48uNKzP%2FIoRIZ%2FF6buOymSnW8gICitpJjKWBscSb9JJKaWkvEkqinAJ2kowKoqkqZftRqfRQlLtKoqvTRDi2vg%2FRrPD%2Fd3a09J8JhGZlEkOM6znTsoMCsuvTmywxTCDhw5dd0GJOHCMPbsj3QLkTE3MInsZsimDQ3HkvthT7U9VA4s6G07sID0FW4SHJmRGwCl%2BMu4xf0ezqeXD2PtPDnwMPo86sbwDV%2B9PWcgFcARUVYm3hrFQrHcgMElFGbSM2A1zUYA3baWfheJp2AINmTJLuoyYD%2FOwA4a6V0ChBN97E8YtDBerUECv0u0TlxR5yhJCXvJxgyM73Bb6pyq0jTFJDZ4p1Am1SA6sh8nADd1hAcGBMfq4d%2FUfwnmBqe0Jun1n1LzrgKuZMAnxA3NtCN7Klf4BH%2B14B7ibBmgt0TGUafVzI4uKlpF7v8NmgNjg90D6QE3tbx8AjSAC%2BOA1YJvclyPKgT27QpIEgVYpbPYGBsnyCNrGz9XUsCHkW1QAHgL2STZk12QGqmvAB0NFteERkvBIH7INDsNW9KKaAYyDMdBEMzJiWaJHZALqDxQDWRntumSDPcplyFiI1oDpT8wbwe01AHhW6%2BvAUUBoGhY3CT2tgwehdPqU%2F4Q7ZLYvhRl%2FogOvR9O2%2BwkkPKW5vCTjD2fHRYXONCoIl4Jh1bZY0ZE1O94mMGn%2FdFSWBWzQ%2FVYk%2BGezi46RgiDv3EshoTmMSlioUK6MQEN8qeyK6FRninyX8ZPeUWjjbMJChn0n%2FyJvrq5bh5UcCAcBYSafTFg7p0jDgrXo2QWLb3WpSOET%2FHh4oSadBTvyDo10IufLzxiMLAnbZ1vcUmj3w7BQuIXjEZXifwukVxrGa9j%2BDXfpi12m1RbzYLg9J2wFergEwOxFyD0%2FJstNK06ZN2XdZSGWxcJODpQHOq4iKqjqkJUmPu1VczL5xTGUfCgLEYyNBCCbMBFT%2FcUP6pE%2FmujnHsSDeWxMbhrNilS5MyYR0nJyzanWXBeVcEQrRIhQeJA6Xt4f2eQESNeLwmC10WJVHqwx8SSyrtAAjpGjidcj1E2FYN0LObUcFQhafUKTiGmHWRHGsFCB%2BHEXgrzJEB5bp0QiF8ZHh11nFX8AboTD0PS4O1LqF8XBks2MpjsQnwKHF6HgaKCVLJtcr0XjqFMRGfKv8tmmykhLRzu%2BvqQ02%2BKpJBjaLt9ye1Ab%2BBbEBhy4EVdIJDrL2naV0o4wU8YZ2Lq04FG1mWCKC%2BUwkXOoAjneU%2FxHplMQo2cXUlrVNqJYczgYlaOEczVCs%2FOCgkyvLmTmdaBJc1iBLuKwmr6qtRnhowngsDxhzKFAi02tf8bmET8BO27ovJKF1plJwm3b0JpMh38%2BxsrXXg7U74QUM8ZCIMOpXujHntKdaRtsgyEZl5MClMVMMMZkZLNxH9%2Bb8fH6%2Bb8Lev30A9TuEVj9CqAdmwAAHBPbfOBFEATAPZ2CS0OH1Pj%2F0Q7PFUcC8hDrxESWdfgFRm%2B7vvWbkEppHB4T%2F1ApWnlTIqQwjcPl0VgS1yHSmD0OdsCVST8CQVwuiew1Y%2Bg3QGFjNMzwRB2DSsAk26cmA8lp2wIU4p93AUBiUHFGOxOajAqD7Gm6NezNDjYzwLOaSXRBYcWipTSONHjUDXCY4mMI8XoVCR%2FRrs%2FJLKXgEx%2BqkmeDlFOD1%2FyTQNDClRuiUyKYCllfMiQiyFkmuTz2vLsBNyRW%2Bxz%2B5FElFxWB28VjYIGZ0Yd%2B5wIjkcoMaggxswbT0pCmckRAErbRlIlcOGdBo4djTNO8FAgQ%2BlT6vPS60BwTRSUAM3ddkEAZiwtEyArrkiDRnS7LJ%2B2hwbzd2YDQagSgACpsovmjil5wfPuXq3GuH0CyE7FK3M4FgRaFoIkaodORrPx1%2BJpI9psyNYIFuJogZa0%2F1AhOWdlHQxdAgbwacsHqPZo8u%2FngAH2GmaTdhYnBfSDbBfh8CHq6Bx5bttP2%2BRdM%2BMAaYaZ0Y%2FADkbNCZuAyAVQa2OcXOeICmDn9Q%2FeFkDeFQg5MgHEDXq%2FtVjj%2Bjtd26nhaaolWxs1ixSUgOBwrDhRIGOLyOVk2%2FBc0UxvseQCO2pQ2i%2BKrfhu%2FWeBovNb5dJxQtJRUDv2mCwYVpNl2efQM9xQHnK0JwLYt%2FU0Wf%2BphiA4uw8G91slC832pmOTCAoZXohg1fewCZqLBhkOUBofBWpMPsqg7XEXgPfAlDo2U5WXjtFdS87PIqClCK5nW6adCeXPkUiTGx0emOIDQqw1yFYGHEVx20xKjJVYe0O8iLmnQr3FA9nSIQilUKtJ4ZAdcTm7%2BExseJauyqo30hs%2B1qSW211A1SFAOUgDlCGq7eTIcMAeyZkV1SQJ4j%2Fe1Smbq4HcjqgFbLAGLyKxlMDMgZavK5NAYH19Olz3la%2FQCTiVelFnU6O%2FGCvykqS%2FwZJDhKN9gBtSOp%2F1SP5VRgJcoVj%2Bkmf2wBgv4gjrgARBWiURYx8xENV3bEVUAAWWD3dYDKAIWk5opaCFCMR5ZjJExiCAw7gYiSZ2rkyTce4eNMY3lfGn%2B8p6%2BvBckGlKEXnA6Eota69OxDO9oOsJoy28BXOR0UoXNRaJD5ceKdlWMJlOFzDdZNpc05tkMGQtqeNF2lttZqNco1VtwXgRstLSQ6tSPChgqtGV5h2DcDReIQadaNRR6AsAYKL5gSFsCJMgfsaZ7DpKh8mg8Wz8V7H%2BgDnLuMxaWEIUPevIbClgap4dqmVWSrPgVYCzAoZHIa5z2Ocx1D%2FGvDOEqMOKLrMefWIbSWHZ6jbgA8qVBhYNHpx0P%2BjAgN5TB3haSifDcApp6yymEi6Ij%2FGsEpDYUgcHATJUYDUAmC1SCkJ4cuZXSAP2DEpQsGUjQmKJfJOvlC2x%2FpChkOyLW7KEoMYc5FDC4v2FGqSoRWiLsbPCiyg1U5yiHZVm1XLkHMMZL11%2Fyxyw0UnGig3MFdZklN5FI%2FqiT65T%2BjOXOdO7XbgWurOAZR6Cv9uu1cm5LjkXX4xi6mWn5r5NjBS0gTliHhMZI2WNqSiSphEtiCAwnafS11JhseDGHYQ5%2BbqWiAYiAv6Jsf79%2FVUs4cIl%2Bn6%2BWOjcgB%2F2l5TreoAV2717JzZbQIR0W1cl%2FdEqCy5kJ3ZSIHuU0vBoHooEpiHeQWVkkkOqRX27eD1FWw4BfO9CJDdKoSogQi3hAAwsPRFrN5RbX7bqLdBJ9JYMohWrgJKHSjVl1sy2xAG0E3sNyO0oCbSGOxCNBRRXTXenYKuwAoDLfnDcQaCwehUOIDiHAu5m5hMpKeKM4sIo3vxACakIxKoH2YWF2QM84e6F5C5hJU4g8uxuFOlAYnqtwxmHyNEawLW%2FPhoawJDrGAP0JYWHgAVUByo%2FbGdiv2T2EMg8gsS14%2FrAdzlOYazFE7w4OzxeKiWdm3nSOnQRRKXSlVo8HEAbBfyJMKqoq%2BSCcTSx5NDtbFwNlh8VhjGGDu7JG5%2FTAGAvniQSSUog0pNzTim8Owc6QTuSKSTXlQqwV3eiEnklS3LeSXYPXGK2VgeZBqNcHG6tZHvA3vTINhV0ELuQdp3t1y9%2BogD8Kk%2FW7QoRN1UWPqM4%2BxdygkFDPLoTaumKReKiLWoPHOfY54m3qPx4c%2B4pgY3MRKKbljG8w4wvz8pxk3AqKsy4GMAkAtmRjRMsCxbb4Q2Ds0Ia9ci8cMT6DmsJG00XaHCIS%2Bo3F8YVVeikw13w%2BOEDaCYYhC0ZE54kA4jpjruBr5STWeqQG6M74HHL6TZ3lXrd99ZX%2B%2B7LhNatQaZosuxEf5yRA15S9gPeHskBIq3Gcw81AGb9%2FO53DYi%2F5CsQ51EmEh8Rkg4vOciClpy4d04eYsfr6fyQkBmtD%2BP8sNh6e%2BXYHJXT%2FlkXxT4KXU5F2sGxYyzfniMMQkb9OjDN2C8tRRgTyL7GwozH14PrEUZc6oz05Emne3Ts5EG7WolDmU8OB1LDG3VrpQxp%2BpT0KYV5dGtknU64JhabdqcVQbGZiAxQAnvN1u70y1AnmvOSPgLI6uB4AuDGhmAu3ATkJSw7OtS%2F2ToPjqkaq62%2F7WFG8advGlRRqxB9diP07JrXowKR9tpRa%2BjGJ91zxNTT1h8I2PcSfoUPtd7NejVoH03EUcqSBuFZPkMZhegHyo2ZAITovmm3zAIdGFWxoNNORiMRShgwdYwFzkPw5PA4a5MIIQpmq%2Bnsp3YMuXt%2FGkXxLx%2FP6%2BZJS0lFyz4MunC3eWSGE8xlCQrKvhKUPXr0hjpAN9ZK4PfEDrPMfMbGNWcHDzjA7ngMxTPnT7GMHar%2BgMQQ3NwHCv4zH4BIMYvzsdiERi6gebRmerTsVwZJTRsL8dkZgxgRxmpbgRcud%2BYlCIRpPwHShlUSwuipZnx9QCsEWziVazdDeKSYU5CF7UVPAhLer3CgJOQXl%2Fzh575R5rsrmRnKAzq4POFdgbYBuEviM4%2BLVC15ssLNFghbTtHWerS1hDt5s4qkLUha%2FqpZXhWh1C6lTQAqCNQnaDjS7UGFBC6wTu8yFnKJnExCnAs3Ok9yj5KpfZESQ4lTy5pTGTnkAUpxI%2ByjEldJfSo4y0QhG4i4IwkRFGcjWY8%2BEzgYYJUK7BXQksLxAww%2FYYWBMhJILB9e8ePEJ4OP7z%2B4%2FwOQDl64iOYDp26DaONPxpKtBxq%2FaTzRGarm3VkPYTLJKx6Z%2FMw2YbBGseJhPMwhhNswrIkyvV2BYzrvZbxLpKwcWJhYmFtVZ%2BlPEq91FzVp1HlQY1bZVLqeNR9SAUn6n0E28k%2FUuGkNpP1DBI5ch%2FEehZfjUQ9aE41NhETExoPT2gGQz0IhWJbEOvTQ4wgcXCHHFBhewYUiFHuhRSAUVmEHeCRQHQkXGFwkAgyzREJCVN7TRnTon36Zw3tPhx4EALwNdwDv%2BJ41YSP4B2CQqz0EFgARZ4ESgBHQgROwAVn9GTI%2BHYexTUevLUeta4%2FDqKrbMVS%2BYqb8hUwYCrlgKtmAq1YCrFgKrd4qpXiqZcKn1oqdWipjYKpWwVPVYqW6xUpVipKqFR3QKjagVEtAqHpxUMTitsnFaJOKx2cVhswq35RVpyiq9lFVNIKnOQVMkgqtYxVNxiqQjFS7GKlSIVIsQqPIhUWwioigFQ%2B%2BKkN8VHr49HDw9Ebo9EDo9DTo9Crg9BDg9%2FWx7gWx7YWwlobYrOGxWPNisAaAHEyALpkAVDIAeWAArsABVXACYuAD5cAF6wAKFQAQqgAbVAAsoAAlQAUaYAfkwAvogBWQACOgAD9AAHSAAKT4GUdMiOvFngBTwCn2AZ7Dv6B6k%2F90B8%2ByRnkV144AIBoAMTQATGgAjNAA4YABgwABZgB%2FmQCwyAVlwCguASlwCEuAQFwB4uAMlwBYuAJlQAUVAAhUD2KgdpUDaJgaRMDFJgX5MC1JgWJEAokQCWRAHxEAWkQBMRADpEAMkQAYROAEecC484DRpwBDTnwNOdw05tjTmiNOYwtswhYFwLA7BYG4LA2BYGOLAwRYFuLAsxYFQJAohIEyJAMwkAwiQC0JAJgkAeiQBkJAFokAPCQA0JABwcD4Dgc4cDdDgaYcDIDgYgUC6CgWgUClCgUYUAVBQBOFAEYMALgwAgDA9QYAdIn8AZzeBB2L5EcWrenUT1KXienEsuJJ7x5U8XlTjc1NVzUyXFTGb1LlpUtWlTDIjqwE4LsagowoCi2gJLKAkpoBgJQNpAIhNqaEoneI6kiiqQ6Go%2Fn6j0cS%2Ba2gEU8gIHJ%2BBwfgZX4GL%2BBd%2FgW34FZ%2BBS%2FgUH4FN6BTegTvoEv6BJegRnYEF2A79gOvYDl2BdEjCkqkGtwXp0LNToIskOTXzh%2FF062yJ7AAAAEDAWAAABWhJ%2BKPEIJgBFxMVP7w2QJBGHASQnOBKXKFIdUK4igKA9IEaYJg%29%20format%28%27embedded%2Dopentype%27%29%2Curl%28data%3Aapplication%2Ffont%2Dwoff%3Bbase64%2Cd09GRgABAAAAAFuAAA8AAAAAsVwAAQAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAABWAAAABwAAAAcbSqX3EdERUYAAAF0AAAAHwAAACABRAAET1MvMgAAAZQAAABFAAAAYGe5a4ljbWFwAAAB3AAAAsAAAAZy2q3jgWN2dCAAAAScAAAABAAAAAQAKAL4Z2FzcAAABKAAAAAIAAAACP%2F%2FAANnbHlmAAAEqAAATRcAAJSkfV3Cb2hlYWQAAFHAAAAANAAAADYFTS%2FYaGhlYQAAUfQAAAAcAAAAJApEBBFobXR4AABSEAAAAU8AAAN00scgYGxvY2EAAFNgAAACJwAAAjBv%2B5XObWF4cAAAVYgAAAAgAAAAIAFqANhuYW1lAABVqAAAAZ4AAAOisyygm3Bvc3QAAFdIAAAELQAACtG6o%2BU1d2ViZgAAW3gAAAAGAAAABsMYVFAAAAABAAAAAMw9os8AAAAA0HaBdQAAAADQdnOXeNpjYGRgYOADYgkGEGBiYGRgZBQDkixgHgMABUgASgB42mNgZulmnMDAysDCzMN0gYGBIQpCMy5hMGLaAeQDpRCACYkd6h3ux%2BDAoPD%2FP%2FOB%2FwJAdSIM1UBhRiQlCgyMADGWCwwAAAB42u2UP2hTQRzHf5ekaVPExv6JjW3fvTQ0sa3QLA5xylBLgyBx0gzSWEUaXbIoBBQyCQGHLqXUqYNdtIIgIg5FHJxEtwqtpbnfaV1E1KFaSvX5vVwGEbW6OPngk8%2FvvXfv7pt3v4SImojIDw6BViKxRgIVBaZwVdSv%2BxvXA%2BIuzqcog2cOkkvDNE8Lbqs74k64i%2B5Sf3u8Z2AnIRLbyVCyTflVSEXVoEqrrMqrgiqqsqqqWQ5xlAc5zWOc5TwXucxVnuE5HdQhHdFRHdNJndZZndeFLc%2FzsKJLQ%2FWV6BcrCdWkwspVKZVROaw0qUqqoqZZcJhdTnGGxznHBS5xhad5VhNWCuturBTXKZ3RObuS98pb9c57k6ql9rp2v1as5deb1r6s9q1GV2IrHSt73T631424YXzjgPwqt%2BRn%2BVG%2BlRvyirwsS%2FKCPCfPytPypDwhj8mjctRZd9acF86y89x55jxxHjkPnXstXfbt%2FpNjj%2FnwXW%2BcHa6%2FSYvZ7yEwbDYazDcIgoUGzY3h2HtqgUcs1AFPWKgTXrRQF7xkoQhRf7uF9hPFeyzUTTSwY6EoUUJY6AC8bSGMS4Ys1Au3WaiPSGGsMtkdGH2rzJgYHAaYjxIwQqtB1CnYkEZ9BM6ALOpROAfyqI%2FDBQudgidBETXuqRIooz4DV0AV9UV4GsyivkTEyMMmw1UYGdhkuAYjA5sMGMvIwCbDDRgZeAz1TXgcmDy3YeRhk%2BcOjCxsMjyAkYFNhscwMrDJ8BQ2886gXoaRhedQvyTSkDZ7uA6HLLQBI5vGntAbGHugTc53cMxC7%2BE4SKL%2BACOzNpk3YWTWJid%2BiRo5NXIKM3fBItAPW55FdJLY3FeHBDr90606JCIU9Jk%2BMs3%2FY%2F8L8jUq3y79bJ%2F0%2F%2BROoP4v9v%2F4%2Fmj%2Bi7HBXUd0%2FelU6IHfHt8Aj9EPGAAoAvgAAAAB%2F%2F8AAnjaxb0JfBvVtTA%2BdxaN1hltI1m2ZVuSJVneLVlSHCdy9oTEWchqtrBEJRAgCYEsQNhC2EsbWmpI2dqkQBoSYgKlpaQthVL0yusrpW77aEubfq%2Fly%2BujvJampSTW5Dvnzmi1E%2Bjr%2F%2F3%2BXmbu3Llz77nnbuece865DMu0MAy5jGtiOEZkOp8lTNeUwyLP%2FDH%2BrEH41ZTDHAtB5lkOowWMPiwayNiUwwTjE46AI5xwhFrINPXYn%2F7ENY0dbWHfZAiTZbL8ID%2FInAd5xz2NpIH4STpDGonHIJNE3OP1KG4ISaSNeBuITAyRLgIxoiEUhFAnmUpEiXSRSGqAQEw0kuyFUIb0k2gnGSApyBFi0il2SI5YLGb5MdFjXCey4mNHzQ7WwLGEdZiPPgYR64we8THZHAt%2BwnT84D%2Fx8YTpGPgheKH4CMEDVF9xBOIeP3EbQgGH29BGgpGkIxCMTCW9qUTA0Zsir%2BQUP1mt%2BP2KusevwIO6Bx%2FIaj8%2FOD5O0VNrZW2EsqZBWbO1skRiEKE0DdlKKaSVO5VAuRpqk8VQJAqY7ydxaK44YJvrO2EWjOoDBoFYzQbDNkON%2BUbiKoRkywMWWf1j4bEY2iIY1AeMgvmEz%2FkVo9v4FSc%2FaMZMrFbjl4zWLL0%2BY5FlyzNlEVYDudJohg8gPUP7kcB%2Fmn%2BG6cd%2B5PV4Q72dXCgocWJADBgUuDTwiXiGSyZo14HOEQ2lE6k0XDIEusexDzZOMXwt1Dutz%2BtqmxTvlskNWXXUQIbhaurum9GrePqm9Yaeabjkiqf%2BbUvzDOvb2Y1E%2BEX2DnemcTP%2FzLcuu7xjQXdAtjR0Lo5n4%2FHs%2FGtntMlysHt%2B29NXbH6se%2F%2FWbFcyu%2Br28H0MwzI30DYeYTLMXIA2EG8QlHpAsyS0EfEToR0a3utIxFPJ3kiIHCCrZ66b0e2xEmL1dM9YN%2FMwS5p01N5jMX%2FBLKt%2F1R83l0LyC29M6%2BiYxo%2FUNg%2FEF7c2WyyW5tYl8WnhWg2%2FhyySbD5UhnDyS7OcU0dnrFw%2BDfGdI7v4QfYIIzOMq9hFtY55gmvC7jZ2FK7sEdrn6IXBuucYhjsGdQ8z0yEbWkkczjjsE5hNAIZrPx2zOLZDmKNXcXtg7EMqidAEEWg%2BSJCBBNwxvxJfc%2FbZa%2BKKf%2BxoKZybnq5vaqpPTye7CiF%2BZFjxZ8%2F7Qij0hfOG%2FcowPA1rT1l4ymWnrKmxxqfErTVrpgwPlz1kC%2BOy8NMDz6c%2BIO38K%2Fx0xkPnLW8Kx6qGAoQdL%2BTD9V9rb%2B%2Fctn%2F%2Ftrxz8dUrZrD%2Fzk%2FferF0cNt1BzctmX2FZPXt%2FjnFCQNz4Ah%2FiKllGiCMs1w5Lkg0kiEwj6VTXCDKsX9rMpnvIj9pcDecXAIXMnqn2dTUbN6w0XQ9ue6FV%2FnnXCH7S3lPWGltVcLsH75ub3ab7A8M28caNrIeOr3o5Q0yFsYL80xaa0EY%2FUEczV7icUMY5pnelAkmUAXmHYjvFWFGxuqlSaow3OM%2B%2FiYY7%2Fl%2FhVELF4EjRqNR%2FbvRbOY%2BDUGzGR%2FOh3EqmE%2FugIQQguGt%2FeMYz%2F%2BL0cimjeZfQDI3phXMbMQsqH%2BCjwVz%2Fhf4idHovgVmB8gLvjbicDcC%2FNypP536E%2F9N%2FpuMibExdohBmNwyiaZdJGoigos7GpF222xrfnZhML%2F7Z%2BylaqP63Hr%2Bm7bdUkQ6%2F2cXqdfmvwixY%2Bs2ksXFeXcE%2BiX0Z%2BIow76DBNgjJ7TOdUK18iPsPflfQD%2BDPsZG2Aj9VmKMMJ4fYRrhIaxhTDR0Elh2vA6h%2FAE6xUb29mj3sjmL72petXjejPy%2Boel60M99tFduCI59N3221xe7apOvxs6aHs7vab1IqY2tv7q2xsHeHGml%2FcV06u%2F8S%2FxTjJ%2BJYc0bWEX0ukW6YmIbGkJRMdjJ9mYIH5QIdJF4hvRGyK7cC7ctImQRcUET99fGXOoft35GYLMQu%2Bg2smnkgZUrH8AL%2F9Si217IssJ916nv14ZrJrvdxLkQvrvtBcjgPC0NXOicO8Qf4mcxPqh3hgUw3DDfdvLJXngg7N3dN2zbPJSaed3OfZnMU7dvmznp3C3bruO%2BNmue0LFsy7S%2B6265%2BfCKFYdvvuW6vmlblnUI8xCXp37CrOZv4B9gauDBlYp7adcUXB5DNCwYImlXOJJKkAdvExXxVvKEYnCo%2B3eIskP9qrrfIYs71CccBjfXRC52udTHHdaP1A1ui%2FVvH1otbrLrpNXBsGX5B89QghDyimlvNB2KfkxZ5C9%2Fem3%2Bd1%2Bd%2F%2FIfFp2%2B2Oxn%2Fs%2B9n%2F79p39S3s8idN6g0yZObwJOgKUpNB3GyU0Ls0PbRzIRq4lcarLKOJBkLRzJQD4j2090XrbA7DW8K3jNF5hlGS5e4V2D17zgss4T20egOJte5iD0bReM9yjTxnQxCRj3c5kFzGJmGbNKmwGw39IJDJcXJZGMkaAB4jyJAKw0jt5IAuIE%2BA%2BU3cVAZZrq9zhDyBrU8oosuxcGNTzCKJfla7JjNVmuSb%2F%2BtuzN2H%2BX4vlB%2BPpdfMXXmuVsNiub1T34SFbjYw5itEvVi0K0Nt9pNJUMI7SLGRhf2xipfCYf8z5OdlGKayOucFeVPeS%2Fdbo3lBrbSMmwUiQN5%2Fed7g0Ds1s17IuZC5kNzM3MZ6EWCa0DtekdJfAxz%2BR%2FOX28sND7yRMTBcf%2B%2Bs8mQCQWHya4qBv%2FufeMoWyslPA9DtMxUknxkH%2FyfTnm2CMYzs%2BCq3r7PxY%2FMXomrvTEsRpfEGHa%2BWN8E1AHjElb7d06ddA7oK%2F%2B5Mdsv9EtPms0jv0Z5kf1FqPxWdFtfFr0kHfgDX0Y%2B5PRSG7RUj0tQr7rmfX8DH4G5W28kKeJLtmQsQkuwMP1pk16EV4sl7vrMJATfyUWo%2FGwEco4rh4XFQgaiUX9qxZHrMQqKnz%2Fc2d8b9TysYrAuXpP%2FRf%2FGr8b1qwwc5a%2BeuLa6S6sneNXToG2XrEJi4R5SGs8Sq2S3d97bsfCRaTdaLwKClRHt37mkudvXbjwVrLhuYeGhh56bvfQkHpk2CwvwClqgWwuBfndC3c8dwmstj81KkagcUgbfPY8Zje0W%2F82VPWJHmSq6pP8hPWpotc%2FEexDOK3qU%2BwngPhOCiO9MJRm8TJefjelrzoKnG2Bn%2B1NCUmPE4gHFmBN9jrTigRIpsACrc9Gstg58ULkp9467%2BGf%2FeFnD5%2F31lNrt2967dhrm7bzI%2BVT5m%2BfzKhvf2MzpICEm79Bopkn07lt1762adNr127LwVqQLdJ5%2BlpQDcvHPQtVY5knhYrK6q8%2FJsiP6EuhGZdFdaNszjvpqvc%2BPI0CdjN0AXsFOC3ZfALDJwr4q2Xq%2BGF%2BGNbsxUg5NLLIEXi8otcDQcUts0D8eQ1iVDRAMBTsYiNdRIxE09EIBJO9A2xqgERTaW86BUFn0OD2xFO97FAgFhF6OoQ7prYt4XwSeUgQHiJyDbeke9IdQntciLQ1FlJMaYcUNvZBg%2BFB1ubjlnRNvl3o6IEU2w7fdNPhm%2Fhh%2BFLysUu6%2B%2BDLHkOkrSHYEjH0tEPe7WdD3uyDgvAgK%2Fm4szFFR7ch0toUgBTdWHr7EpaWru6%2B6dmbbnqWEbV2EtxAsXiZAPTtGPSbHsotI2leoM8TePEqgSQprs7AGFf8kuOkPdZPXGb55POAW1d%2FjLST9v5YflasP6v%2FCO7%2BGNAPC2BMZWmsOjp2NNbfHwMCJD%2BLPVL%2BD%2FOYlWEEI%2F9jpPddOFkB5d1GSuKZYggmCCd7JUxD7EXAzxyirYnNDLdDZoFdx14kivkvGc3579Jm36reTTvDgBnaO6vzyQ6chQmlsMoIkIQ2%2BbBDWBud1Va4pcCn8CPqxlh%2FfgtG8IPaPH8C5wk6%2FnZDv69jurV5QhtwE0x2iqOsj9Mx8B9%2F0EaUdiPfOYYDCi%2Fq9jhWRuupMDEU0%2BCtX0sDFxv07T%2FK5niBPqN9%2BtQjgEc31NGCXFeMcCEuQBIc%2FBK4CO78u7EPYvl3yaEfK3vcb6qP1R2tI7vUjVDDUdKubsSrNjYKY1qBEa2P50SJoaXiksIoLiCwnxS6EBuBde87botNfdEWwYvF%2FR0%2Fu5yCqhGeEOR2ynSeyXjt6ka7neyye8kryBSWE52y%2BRBgogrXPZ8E1yIHoHIFUM%2BAbJhE7lbMtt8ApL%2BxmZW7PwbjAO0fAVoXQOuiSP%2FksIVdFZ0aulsamKUzwPZ%2FNYDMJRBPCxsBqLzqHyneXF6Ej9HlIFo7%2Bpg%2BjUb3unRmGpstGkm6etOuDBGA5wCMefp1gTHcdZlvPBXlOslvYTp1cd8UjYLVd%2FJ5awNrIOKLnIt9MD9qdrKrWCvA6ALm3QV9VrsPm60Q7%2BRHJHP%2B2hqfugo%2FMvI2H%2Fmqr4b9tFnKSRY1Y5Ek80Nm%2FWIhr1ikKnxGz9TWXrokf9xwujfvcOTtNTWnxd0F37Y2W79tteBqZ4G5qLCuomw%2BnSr28QESCRVLTyYKILGJOPfcnaIFOsewhRdvv%2BrWa%2FWih0vlbX6Zb75T5C0qNKVFvH1QL%2FvazSWgC2s6oWXXIuUxQelKiJbowuJDQViatLmLijg9CQBMg8WiPgiw3LEeYRmm5f%2BXdnvkDnxLLjMLxtvX74C3OlwPQqx4xwIdpPx38LrlDphiyWUWHWKAzzxurS%2FxTo%2BP5wGFak62ap1PVFFN4v%2Fy%2BxuR39WnIO7lsWfwgVsK17wxrs9K8ltIKuhkw7f%2F6dhK6gQokFKhWX3urrjk%2FrnI0pgfpGMeuQIUaEM7%2BGF5q2iMkCaMQwxxOzcvU0eXbsnS9XknXvP7Gtw5dwPXlFu2ecvSHEZgNDsU6x%2FGdXBYXyOQjzZReSedeEPY6nEv9gJR4oBQJtFO6Kd0fwC6BO4LNHDeBujB6dSNcUQC9zIv2LnAzGk99bUDrdFY%2B9yGFQtEo0GQPNv6vS2drj4%2B1jHbv3aJSMUWP%2BQTZrmbNTjU8wyG%2FiXNNpskybLcJ3CiTF5Ir%2BJYzmJwE0mSVhlxbtbmvweB3ulB6Til5UuUZydpgiFVeobhU0WaBqpJ198d%2B%2FXeNRTZ9%2F1OPfG7%2B2hwzd5W3D%2BhmyjsRcUg%2F%2BCavb%2B%2BVh2ls3L7zT%2FetOnHNxeerv313vzLVqPai4nJv%2BK1FC6040%2F4udw7sAb3laSg0XCkAAs0npBO6VJabS4Elk%2FU%2BD4gTXW%2Bj0wnrMlqNamq4tMIYB87tE10i0FR3LZNhJsb7%2FR561btmes8YBCRkhYNByRtKd55mqTas9FYhJnbRGHuOh3M4QTdgQSqmgRxuzGdSvZGcbMxNQGk5C3ebLjoXIOFM4l%2BWKHmLTJwRv9E8GWJ6dYvf%2FFmEyEGr%2Bgyrr1p5zrgkz0Cw2j94Hv8Jdx7dIVegBSNtgsqGsRQEYiIBoXwD0LNvQ5d7s5Z00QzwNhqZA0b%2BtMG1tQq5nd84uq8R0zPvX35G8uRaze4jcOHzz0w1%2BQ2BIRvf6J6Kgatnrbiem%2BCFvAxfkrndzD9MFPP1GWTUHclpASUkCNAQkpCCcCgDSUDAhDZ%2BCuEkgn8J7i9nMA7pA4lISappxILKfAeSAbIcSDuN2bJcfZILqeO5rLs0MnngSHYRdrHjmaz7JEsEPw51ZqDJDmUIOZIe34WaQeegNsJn1qz8AIpT3yCjyEih%2FxELkuJ0lEMYTLVCiWpo5oYMleMH6USyYJcD%2BuOe%2BkWKpn1Qns34iyYDjkSLvgnZXcgVQNeqINXr48m3iS7cjm8tedyY0f1QvTnHHdsrKby%2F%2BSSbPY8%2FNH6vpl%2FEsq3Ae4ZU1HC44KFiI9o7CEgab%2FRqHbj7s5KAg06s39ZP%2FzxI%2FmVuF%2FTbTSy%2B3Fb8If9%2Fcv7%2Bwt91yy8RfP1QXtW5RzQn7qIiZyuFM5QfJ5E9uVnqT85TanFx0lkP3ukBAMprvsRyi%2FC8NAJL1xbIIirSvnSj4O5netb4JxmNANHPssHAcHMHsFRgEug816gDBeMbdfiuRcghqYcm0%2BXxx%2F5IAEtN3fqFF3LzAXqwoT0PN0OVTNqxo8sxMkd5Ig6k79Zk7VxxX6gMLOZFQgvpW2RrMW1D0BDihaXQ9wVRoBxPLfpknmkeMtoB%2FqM9cRc9IqmMD2XUmdZ7GSRKPUZvChf8BoykriM2MnKYbOHX8R7cLdNCxSFFVQqoYswnlWtlFS2mNkhswVpZiQW1J%2FUKFfipHGlUkM6UKBhMz1istELIHJLMSctu3ugzfaVSOjKvUgc%2FTHK4Sdg2Wscz69leKIkkrwuuWiOe9yGYKQXRumkC3qbRcMwrvhjNXgdZk3RxAUEhuSPvn3nnd%2B%2BU%2F3vlVOmrJzCD8JLxV1OHRjrZifbcFDOuRNTGqdgQm1tSNJ2OcQ04YiEXuxtII1ECSQRoQGYioEsgCfchB4ghAtw7FfJre4WZ9hkVi9MtjuWqtdNDlpMrfEG9fOT6q21okg%2Be4As38MfGquNt7oUws6Ysarj1%2FefE%2Byst86YUVNvDdts3Pv5c8m%2FaP0C%2Bf8%2FQb%2BIMnGq09BgwN01oIOAnAdagI8mBSrqk1gxTDUBOtk2ousEtBH2z4Ir2d3f6k8PXXVlt2qN9RODxRuoJT%2Fv27wm09jRYVc%2Fe%2B%2Biyx2tyzJb%2Fn3J0htXP87eSsQaf2Ly0s6Zmxela88REy1cf4273mI3iXNJ7KxrZibOm9xm6rl4fqy%2Ft27smU8tOfdW2ucBzg2UfmOIVyLIl3kpYlwphDISTXJXsctmiDtN7fNV6zelgxwnWxsVr83Aj%2FS5ki1jL%2Fa0GC6%2B2L6Um%2BaoddlNFuj%2BbJ8mH%2FiaLh8I0%2FU51NspIEfq0dohwyFXKgm4NggwQ4rRhCOUFtxxo8XnitT4cnGfT93IS8FaT85XE3H5LMY4zIEPL1hw443wz%2B1UmhTJyJGxZzw%2BwsKkKZgUiVtKOKMEb2AKHTv61FNc01PQFwKnvsZ%2F9pPA4RKTASWahmh%2B8MxwzHxKy74IRn5LGRjsPUUwTu64UYNY38caqd7HKucZ%2FtHnODtENw%2F2UfHRMaq1UUPDJQ0OKkWCeet5fYOhII1VRz8%2B%2FElg5j4Gxur3J8o2PJ4rg%2B2d08T%2FfwEzSVbyZ9XPro95T477lRKqUSRXQnauHNsISAl27oWi6Fv9z48JMv8r%2FaMMj8onCP%2FDuDZOuN%2BGPPr%2F%2Bp7bx%2B7JlbYdppcNhzKU%2F1Px5aiaGDn%2Fs1iGMaBcleKUo%2Fv9rcxkZj7DBEKOfrayytXNLYiUdBY%2BpleQXdnscKlQcpzuWluxsieeyuXIK6SdxozitWyGOV3vOHHjguyCQ6fpIYy2JwvrQEF%2FQa9Pdf%2FQqOSqCiE%2FEE1%2FXIVKTc2tzWbHnimrEd%2BVyz311Ml3P0GVTj7PD5aDnsvCvH36alEaPMePcMegXs7x8igTu4B9v7G9vTHvhCu%2FkzIdx%2BBxC0ay9zRSvoS0F2lIxI%2BX7klU63I40gLQ3w5ep5na%2BSFnba3z5D64zv%2BQtM4n4ffG3tq4aNHGRfxgrXPMim%2B5487abL7xhdseIRn1KDl%2B7aINixdv0OD%2BJSPwKf5%2BxoP6aiTeQIDVlIhMcL1H5R9PYXvprs3fv2bO7MOplCmweuiq2JRZ1zz%2B9a%2Fv2PH1Hfz9236w%2BZrPXvWfAxlj4NLLHpq3c%2FPQ3uvmvbrjG7fe%2Bo2y%2FcLdtE6VUlXi0ASb1VLUBVSUWSU4HdvAraTyS8xzM8NxvxFkXV6pUVRiJwcgC5zEeht4rwcp7ki0k41G0qlQhG1Vzlq8alEmnFi58caB5Q9vn988MLhqyVlHvLEWjtQFeupdiocF%2FtkkOGPW2ibWaBTkeZ%2FdvPWazXfOnnvL6jkRXpi85sFzZt%2B55ZptW3bl1cCCHZPD06MhySha7UFzjcjbp8fOecFCirzAG%2FyVjBX6OFIaadSjQq1nNhyIe8tVbaaSdHlXIWKacMeuZA1uxS95zILhyrxAdsXTL6m7kNQlx2P9uZf2qhufePFFbpI6%2FOU0WcP99RrCsrwseVot5mtytpf6Y0gm9sdeyKnPQ7onyK4nXlR%2Frg7H95M1upzu89DH6pgUcikoiihJ6NJKmRxV1x%2BMJiOA3YwhDRQrWU0u%2F0rvq0VYXnyCwsLeTJYBq3dAtJDavuzyoVpzZ99Z0%2Ba0uoiFH%2FxcqgDR7rUFeOrUn6Cywb8ZeNMbhLV5ugP9l0zv9UN5b5mFkjzxUcpPJCn3V402pRxtJd2GrnLdhtVk9ZSZh9W91fCSH5B7ofxPiWL%2Bj3D%2FuwhBRdyAyozeZwvQzs79soi%2BBKSnafLviZCcfrpBpLyimfLfTyJtbyruIQKD01tUwJyKEo%2FybaxkSNFUMdMkhQoJyRBQFhnUkDQSXhTM%2B3NmY0EDM7ffLIjqWEGt8lCO6mLia3PukFnghosJD5p5SIho%2FVDkzQfLE%2BIrYoJXkD19pdP7OwG%2FvoIUtagiWiZ4PAFTHHlTVhRZ7dYmPar%2BNJ%2B8JhmR6DFK5DV1foHoLNO%2FpHrvZfmWZ15RQlwvoVDKhCWNK3CCch9lfFBuAqUgpFSShmNaPj%2Bi5%2B%2BWZfKeViJfW5HnUakVL4UCNVkA4%2BETfIqx4B5xSaP2L1yn0zn2ltPn4%2BOqZGmwwEVCaCSqG53ldtL1oLGAhdMLd09MpCCF6tD6ZnAZBY9hDaYsP0jzZ0j5ZjKsF4i1UmLuhbJMCnYJPt5VwFNvmZawXjEvLJqIH8STonZjq7BZ8gKgR20C9MDFqJAX1H64QW2NEup6qgzLP8cvppL%2FNNTOBTCJABOHeWoXzLhw4Wuy7gaBtjKr9kgKq8ZlRYBS32Lpxc8vIhpNDTfyNXWybMJbn2RyQ5EmWc2QF9wmSZ0KYCE%2BcPuYO6b15Uotj2Kd4MItLS7gtFbkTdrFND6pvEZqv5Yv7jXAus7Pg7avo7KDot50NX3CPkP%2BKps8J9%2F3mGQIteY%2FLGPC%2BL7872SPR2br5fy8MtKBMHedGuM28%2FMZmPJMrGgi3Gb1S%2BSi1%2FL%2FzrZwO9XH1ce%2Fz7ZQ1WSoY%2F%2BpMb5FT4ua0Wm%2BJf%2F298nFmChEQ%2BTi71est4mq9VYI6RsymoRJKYidElT2FGnDTZvqtfhGAFTbeqEw68GqtfmbVa%2F1IFO1%2FjdWr%2F8BDRRtQh9XNjubEm4aWVpVonpTGR7PVGc%2BKJNoBIWF7kYi4gUV3r1U6723i6TxUl3n3%2FtM27aZfKb7THiHW9VzFSwHJ05VfK6Ar7kaB0XgPPE0BSkSFKsBUpaLihEWoA9wBt8qirh2VSOkZwXEwyrxZ5jyt2rJmSo9gX7cg6jsEUGJU9z9xJPOEM3uQQxKgkh35DNATnVyrmJ3mbCNyIB%2Fyox4wH1bg2DwN7q9kov4pFqny8oSm3RQbGgJ1QQTs6ZMLilOVYJ9v6Wha3HcJ9jddsXp9YhGUXLXt%2FqMDnvLpPNTXfNa60z5%2FyjXQOMq%2BlNmwh5egpYrdfZQZV9rI47xlRkuyTjpzsmCBSWNkAXVoK8sgYWqQJWbo1RLo6QH0YW6pxqfCnRgkd%2BRiFjUQUQ7poIaYoakgXxwFd9BuuI38H1xBxXSFb%2FpBDIKQFn7YB3dB36l7sG1FLaKiBdp1KxLvfswap%2F30lnVESgNnvjbUoT6w9N%2BXoio0qcYOIM%2Bheg940YimsucQVvli9NEcft2UZwGQwLuilj1fFr1i3NP94X%2BPE7Hpvtj6lBJfJ4R6NvWiaL6MgzWHxiN66DExa%2BdAdAbMYX6HVF8A%2B7rjEZIXAVbDe7PVI9rmN69JOLV1DOSvRPxWNPZBZf%2FNf%2BNy65BhYxxxV%2B77XJ2wfQ389%2FIQPgajXbwMsuAz%2F0IaQcXJavKbRqR2IqyZruXjVC2%2Bhdee%2F5vdnYOedpmVtR3NGXldxSzDSIiBVpkGb9by89UpEPKrSLZmyFDzMab%2FwXl2CNe7s%2FqCtTvWgG5kpBmCBlSzDS%2Fr8N4uwBwohRW63JTS1y32f0TQsPfXVGEHQrV8%2FNCfiOUVirYcBbIeA2%2BiF68rQIo3B%2FS628vYESr79ehzS7Q9LEL9UXmik9XVHb1yBO3Ngvt5935%2Bk1efkV51mzzrM0LL3%2F20avnwMeKuWyOUZg2TasSqZ%2BKcZQiOn1Iu2Vh497ALUVZiCKt%2Fgh6IvTIj1ZLRjWAkpHKOKovNwp00eqPROiAbiNEKieXwMLcXhVJ1%2FuzmLP4tfxaHR59cBdJVG1kTAgl9ze9QKUEQ946Hkb%2BokJ5JRDyf54Axur1D%2BWS49cLr0tTPEu7UmXrxcSr3XNvumv4yXzInXKH4F7Tc7p17Zt%2Bt%2FqW2%2B93k063X7VW6lALxTY7i1nBXMxcxmzQbabxz%2BtJo%2BwijYaIGMNS8AoSMgAPt84DdHOoMPfjXhF%2BkuH1tZvuFQrRCN07xGcXRX9MYxYchDe5BcHj%2BZ4i%2B42WyPc8Xofi7bbZJN5nJLJ5qr6IqRtzqNlM17SpFsnkEyTWoABEjz4JXOQvzWYuwdnV5LNGOwTM5v9r4RpQ8ZXsYodks3o31JBlzbYtNotisnm22MxiwGFXam5oN1n0TA%2FhRvshvTSDwHff4nNzRo9Dum6PaJbMXzDz%2Bx%2BFkj4L4bFNBb1asqsgH7Dyh4DvbkPtf5yMDKzEwyoaESMSNS9P9gJVA3%2FRTlwoMwZvxECFWxIPNw9gi01nOHjP32esZTtmXHnxvZd8ZtakqQ7ekajbXetpNa6ocTVxJtY%2BuSe69OLz77zh5bDR3xjZMzUz6fxrz1nqrZGcHQHfPVefN%2BfiK86LeXj%2BSc5lPKy%2Bk%2FvCUI%2FDaLFYCWHr6nbXuILTIsb5imNKY%2FrCm28fSMxPhkN1XbNMNZGuqwOBhtTSxWuTk6bw0ZaG86b1hKddePOKuBvmiguYBn4T%2FyOqOyGRBt7bKUI1GjioBC8aUKwF7Q319UgcmtFGIzCJGBqwQij0ynDsfdFGc3TS3BlNfJ25xmzniMkpXXTPvCaD3ZaZvyzjmZdudBostmhb0ORZNN2sJBeed1HXkrUsywueQH%2BL0eCPxmsa5ZpgRJSDZ11yDv%2Bjmbd86vxZfc1WcZJ3UkMq1BOOOVtvu%2F%2BpB%2Ben186d3GTwWAw2jheaJs09%2F%2BLNfZft37DALyrNj1wABMuUKbODyTVnT%2FKYbJ3Tpq8IrNh92dkxOj5P%2FYpZx4%2FycyiVcDYdn4JbEoKdQi9054iBKsygLW46FRGxAb0NPNCm8BSNCPjoKcj6EAus4SuP3rB%2BcV99%2FeTF6294dA8%2BTK6v74MHVpYNRt%2FI30e8QGTOOdfGWzzxcy%2B87a7bLjw37rHw1nPzp0KyyRSeZO%2BQQhInt3dYgvycjrPOv%2BT8s1rptaP84VeywdWX2T4ysr0%2F7TLIs6%2Bx9zib56ye1dM9e%2FXsZmePY3NDs9zlnNVt4%2BWgHJbbz3Livg4P9WWgviOMm4kCRT6I8vw0NbUUEnFvOuFKoxQW1gTsvFirsF5pb7qTUCx4i7VmtToveaDxvK9uOaedVvPRpVOnNz0Q6bry7uiSdQ8t7Vy4JQKVS%2BXPplV2ts4bvCwZu%2BKzgITtxepaPRzWdpv74muvv6RO0SorX6cu%2FdqKn%2FXWnrtp%2FZragz13DUCl5myiFW2Ycvb0PtsXnU%2Btx8pvLFbUspLX68mdegwmOif%2FNPDONajTGoUh6tU56HBJCTBASVvNUB5VIiKpc9kd7kludodSFz7xQbiOmMk5dOYk56gzL6uaf7N8a6MQOHm0ae6snZpFDfuT3%2FjdYzjzwkXXIVHoXNuCfQslQZqBZjTsoHMqrkE4jaYdgkGz2ATOgB3cPkSukD01DnV3ttb1wx%2B6arPqbkcNAHoFPzKUUQ%2BqL0k97pjbZv1I%2FegC9zTFbrrlFpNdmea%2BgIgfWW3wqkcis8ky5FAcRd1If5nNZrl2FFpungc8wpoCl1BpQV%2FScS%2BzjlASyUTVv%2FAJ46gkJI4bHX4lTnloctxPZE1ckS3%2BjG2fKIjkQFyzuo8jvYQG1OrGvJPSTu%2FnSp9PHNTl4z5hK%2F8gtXVKF6gEKiglgcKiRlCESsQCV5QIlKWKpr34lt%2FwkSx%2FJCmP5%2FcBKQfl%2F5gd%2BrOS%2F%2Bp91%2F%2BYCg5CXK2W4M9fu%2B%2F6xxX%2BvnelVuldIDCG0VQTpU9Dw4pRfei%2B6zWx0MLie0gPbyrkmRU7OwT16JGeyXLHqOLqAfVN1GPlBzWtFNzj0TRTCjogtP1NjIvu5habN5Aoa1k66wGpqriVetJgiGdwDZtKhnN0y4n9sXYnsqGmZfDSR15%2B5NLBlhoDaedEm7sxmpqRija6ZEEg2EAnTiAC8IrmFbGz1q08P9PSkjl%2F5bqzYqT9hMmptEXDgTqP3Wiye%2BsD4Wir4jCeoHbbp5hRfpB7BakUIppIlPCD30dR1GtslDz8OsqbXmejFC%2Fv8wu5X2myq7SJ8Avzv9DFUJySf5uNvq4%2BTi7W9D%2FOZrLChdwxmPNiBRqVjnpK%2FaGxRCDspVYKAW9AN1JANoo8wP4BJUlGqdgw6m1qPQ2QW3%2BOfU5%2FieLS%2FNuKpDU3uf8bcAXyBal5jMR2NEAbPAZt0K3hvxHBEDlUxfIGcD%2BN2gNSNx36nfqlAYow0puatNpRz0e4W2oahKzQHsjf2c16ad%2F3t2KTtPobnX6D8C8pd0MDP%2BKx7wnXqGGlLQcvikMErm6TmfsuxJXbSAxqNjOogJLQBLiKEHAE%2BJGTS3JoEhTrz8%2FCB%2B5YlupJ58aOat8Kv4JvregxwcU5Cp8GFAFm1FyOfto6GS2m1NGTS6CPNKkbsTdCBlnN9onMho55BX8IJZtEQ35lk%2BhtwN5A0V3RCPoD%2FyXAcv6pAtbZczRUA64JmcUf4q7Q89ZHLeJVZ5D1Ps%2Ft%2B0iCT3AHVtZC7JDCXfR7OSb%2FXja5H3zQbZL1B%2BULX1BMTEk3AseSpmnKEK4T9ekMIidUCRQFfcbj7z8gNLvzF7mbhQN8h6ZbRset%2BnQWdS%2FZX3k7WpS8P9sfo0iGS64wV516pOhjI6TZ2dApgI5%2BLhxywYoWxKUrykKJsIoDsR4mSrCTg0egMPnLW%2F3Q5Nn8BZEuzqEI7HK3n0%2BzFmuO3TtWQ5WJoG9YqCD6Gc32SxnbnVPfsxvrFXK2dILl7bLthDp6glhcsfp4bYvbSmj%2FmQ94uBTw0E73x2jbNRCvC6VL6GCFDwU7eWQDcC5FY5s0slieRDwtAbRsbLXbaXAuu14e2OJw1dc6jQ3ZdY8v7rv2%2FBWZLqvFWVvvcmwZkK9f5jS4muO9yR5res4kfkRxhV03L1RfPOiPtYi8pd7jNEsOpyTwxpaY%2FyCZu%2FAmd5Or9uS3DYaeqVOhH7gZN%2F8I%2Fwi1fEuLXvyNivibjuKvN%2B1Nc01HF%2F3h%2Bef%2FsOhox8MPd5SFucPjorQwXT%2BytA8EmA5mamHNFDVhBI5pjZbQpugBNkO8MvRub8KVDKST1Wag7D3xlin1ZF7LFP%2F79nbvCXFOY%2BPUjrT7%2FotsPXXZ4exdPzuhZuL5LUXVAn7k7PbhG89uz3b41X01gbjP1xwlu5rrvvf9%2Bpbs6E%2FVu7Nk642%2FPYRaAiUBdrmO6CDTBLPQFA1ur0uXoBR1INDMkypKpoTqnSMx5GiEdTEaSHLs0Alvu%2F19%2F5QW9Rv1U1ridT22i%2B53pzumbs%2BXFFXYC%2B%2BCGsTj5JUT%2FGCgRt3n78i2n71FHG4%2Fu6X%2B%2B9%2Braya7os3ZbDmgWfXun44e%2Bu2NZKuGZ0HiF8M4TlMPR%2BEU6rPKRJ8wOU2RFUFLex3egEsz3YqEAq0cqhAAW19dBZIlVzR61tuIdTnpXH7l%2BuXrbjPUyep%2B8cl6aXKWhPHpDcXl9KiTWDNr4mBQc8Tq%2BNzK%2FOKSbsfl79o9G20R%2BbrBXYvUg0rLHhtrc4TN81TTOWSZ0gL1ZVlOYH2ery%2F7XVUjFMbzYpg7UswcqJPQwBd0LKLabJ8IaCr2otcjSkIrGwootKECaUd4XH1%2BSdazRrfddkBU98t1htvWrbjqSqjaCguxrffM%2F5zDCpBALUycmajhd%2BR6ww4SWafuZ5eU%2BtPid4lgd3gt%2Bb%2FY9rQoZNmiXYPXyRHbRs8zX%2Ff4WIFjWZJtUdSD55AP3xtXH%2BZipC0EqdBGDA4CoYEU6gRLGPU11QhkLTBiEYPiqOeQgwTCl9aok1Qr5pFf71qEeNxjy%2F8F0GoqYPv75Yh9j3x4DuJ%2BuEzHRpAq2lMqb%2BqfTdiq6kGtzfOWsv0c7lSeMXDHBDe1MT%2BLUgx0Pg%2Fp87u2UicdIvqQi8DkxhcUwUXCedMpb4NQjwY3npTmgsURJavLwCRyEcN2HfWsDVGfv%2Fu9ZUWUx%2BPYFueUKwaNvbtu%2BXps3eVWbN1GcgVrdMnWJ7WmJz9SD66EBidag0NF1Ukep0t5A7sFCWdhzvYwHv6L%2FBehXuHqfaBwBEU7hfVLcXvS4VQv%2BT%2FvaSIl7cbeMc7ekv9i8S3e1L5xxpvMGcu1EYPbKyCiijjGXcDKckm43PqU2qNWlXusZMiqF82cuVzolUHN9NNR0HZPxFPV9V0wLtvq%2Bk4DqOwVWDlzuQLVdqFiP08cRX7aRlBVfR8cb55bWe5LExnlcsDp1vAP8Q9BucPMk1Ulh4GnN0SAdxcNHv3q9ohx1Ati4S%2FtkWjIDe3hQdkUGrGRaFBiUdiTSkI41UkMuuQHP%2BEaSQYlPQTFWJF03BNPpTu5KFAdkWgDukzsZKMG0Q1TAQQglScOaP%2FdsZ8%2BfP75D%2F9Uu5Gs3FY%2F2SxPld0DHOciXI9gqjcEidXjE%2B3BLosy0OcX3T7O5g65ROGyzQ2BZs7WbZVnO5ydLe32hMwTQ4wnnKXW6XW5LAa7oaXOIHoUl0FgLQLH2by8wSTWeAx2Y5PDazK3BqZbeJZwXGPaYhX87ZNszoDdaRxotXO1nNlpdvAPFWHDm8PqEE0sZxDEqGzxisFNnuCWetPcGrObN0p23tTZwMuRVodSV8%2BLTrOV3eRvzjQZiSjaLYS1WEJe0kNsJlZu9LFun7%2B%2BwW4gRDRbaxw2nrOGm%2BxOj9cmtbp9ZqeTM1m8UXfQQCSTVSQox6pvtjot%2FFpHvIUjJovFEoYvHYV9C5Y%2FxN9OfcalvII37UEhTbTg%2FAQIaPb4Vz6j5u8%2FaViycMod%2FfkDcpu8QZbZoeBi%2FvbzP3XPsZvOubMtaPHkD9jt6%2BU2O7vqU%2F9C9SMvgrXpQNG%2FE0oJxun%2BCiElUa0IKQSUwERxOntKSV7ekcuh9VBZBBo3VUcB58ofKBHCwLyf9qFosz9Ibf8dGqwaBMjRig4SGOZ2UkWI7UiO9OfUPdxOYFApUZyfpY7mgEc5rtNGGk2H1lPhAk1Hp%2FVAMqQEHEUfEYkkUQq1JMdzsX7kklRrTrUi1wMcDjmu1YYfATj7Y%2BpGpPEBXuoQIj8rR9mgCl4C9yqmF7xnVWxGVniNqtpVmXBvQ6iwni5YQ8a1jYrXtc2J13HvgkvqWxuva1sbr%2BP2S5ceKGyBwDv2DbrToe1u6BkAJV7xnVLUaq0sJB8pFqcUIPi3yuwxi4JuLr%2BP30f3OkPQ72aO0xYo3%2FEsmO3QO5qEF8S0qQH0UsKXv0brnl9%2B8M7jF174%2BDsfvPOl1au%2FRL5%2F9DsbNnwHL2pHR1NTRxMZhJtHktOOxLxErPF6YlLvpC9YP73x%2B4ofw%2B3xVdrHcDE0dQQCmCRgvt9b35xINDf1CDcRSfJ%2BpYl%2BSf8YcurfmXP5F%2Fkj6J82jNsrkWiEuhVlgFfyNkB3S5MUzLhoNiwSCYcxQ7Ui4J0Xh7fmqRbaPa1tzujxkBRlsEHy0%2FOM4pYLPb7g9O6BQJN6l9zQ0OGyCaZz0vMTbHOzXfQ7a2tsterTcqxeInODoemdktw%2B1SbVhKwtW9ffe8VKadK0OVuC3bWzyKm5LeddsWTeorWyY9IMtUFutdu5g%2BRn533qkocdvLs2HmhU75br%2FMmWtD8zA3OP2t1ea636jEzqYxJZGAwFiDEd61oTsrRuW3%2F3pYNi3bS%2BRd%2BGjOfVpAPNd6y64Gsz1GaZleWIPoYL%2Fv9mTeQBENVEguiF1aC4YeXxFETw6QyPfn0m9g8IrMFAvKM1EI11DARnbqibHk%2FIojy5rSdgCyZi06y8sS024PeuO4MfwQ5Y9yKRZCqyYaF30vzeHlmUprR21tR0t0yz8KZY66zWuGvxVQB%2F36kP%2BK38t2Hu6NQ9SFJfw0AdpqPEK2qTMpf2VCqJwqPoJezTL824b8akoL%2Bx03nhh%2BoNo5e77psxg9Q5LzebIKD%2BfsY34f2MtB9fk9v5b8PT6tYrgv4kRPwd0q9z3gdJSJ0653KjCYPwCaR5aUY63eW48O%2Fkdo33yxX9wCiMv2QTrk8eGSI6Ag6moG9t2P%2FF7GRNlDjl0gw7pJ5aOXXqyqn8SENnXBmbSwUYLyqJjv3UmY1nKr4t80no0faXsaIEiF%2FBRaIBnItSce4OUif7W6Vm9T9H1X9Vj71BEm%2BRdmIJQST%2FZfVdudUvh9S%2FqqNvqT98g9SQ3lHibZY0mRVHooyDN%2FFHmTgzjdozKw28NwQ0hwN6BCoPKaEk3YtKwNhwRLXuk076CGoZNXDQcRwZvreTZY9EZi%2Bd0s4%2Bztv8iei04JQl6ZbDD2eHV7X4uHuFVfPrOmcs6m6Kr7hssr%2B1VZFcEZ%2FPdJkn1hOs8SXS%2FNFFgqt94PIZzZ3tdaL6Q5vo6piSzdy737pwsX1VyxUrF15iJ4uNkq%2Brbyg1Z%2BO8VsNC1UmcvORPRfxtPrfRwL2p%2FoA1eZp6Z%2FaGffoewaXcA%2FxBlKlQLfhQL%2FoPgBGP3qsA7IQS8qDVNswHKRSheDUvA3Q7MZoRcJMxlEygujn1QdyzfPfq3dEp%2FbXh5e5YXW2Ngfvza0ZF6UgFL%2FE0fTq4LBlvTE2qb%2FKuuzYSXVnjTfM1osvqMHVbm9950quIZlbqaL6YP7jk3kUtA0GnX2nvq53f3WoSsvEdDRnULgo2fN7lNZJgI8%2FVWi33c3bBZnGY05%2Bdm%2B3qc7fNmj4YGKLj2nfqFP%2Bg7jdDlxEV5XsJQZP6hYrS1l0VQr4c69Xueixp90gnZPmE5OF22j%2BSYEWHlZ0K%2FHgsh%2FZtsbh6h2DNRlvv6jJh9XaJaHCZDiUDKNTMkvb8vsqCyf3ZNdSmO0fa0Y4baJTtpbKzuVzeeSI7fCKr2Z0WypapnXJ4gnoWy3PoUIlIQ1TXdqhQJIXp9Wx5fYdpeWh2TY5D%2BYVyKd0jw3iumwi%2FBC3cEy4o83QlZnW79MrCgCjbhWXBlRZVVZZv4rIKpXC01HFlHdHLoeWVl6UVc%2FJ5uGm6CViW5mulYMk%2BHqNYr0AyUPivLg2oMs2MPqtuhHyRyiwvNJej1Br%2BfcLyoAyu8D9B7bgmzUqfFobF5nKnK4%2Bt8MPJkI%2FxHUNWk117jugWF%2BxazTAALQn6%2BUE9lhoI5ApGA%2FiuJOsrlNP28SVVuBVajXmircLel46w2bJS1Q0Ft0KDuikDFL%2F3pYrid1Q4FvofwRIo4R9h2ftSwc6jHAMqLcCql8YPHtlzGoByNXYN6v8hXnRaOhUvx0sVLCexwupGDR4NOYC7PePa5keIPACnuAdD7dEadRuTIiS6Lb7uskb381My5yjzF8lGCjBRqdwrWJCagfB3yCy7XT1i92hbcZ5Ci1FJkgYMDf6n%2BjspIsHFjJrTOdzSMuOa9DbDcj%2FnH9N9bIoGVgzHPWIQuFuYtaMRaq8eCKI0gEF6lPOZjBz3EEvaaxwSUT9U%2F8JbJZPJJLBLolH1La%2FRbF9AbC8JJjv%2FmMnssKjLRBJyqj9QXxNko0Ux%2FX79epfiXkm6fmKwF%2Fen1HLc6LxloXWKvGa5rVCVL83VuiPcDEX%2FK5pTXOxHfx6HHB0t2FI0qI2rCZFTrvPWU67zVuS%2FkTsLnc7IKhFg30e4FOkqNSfH5PtkmUy6Cpiv%2F36k2sbqCeCFNa%2BURpoY0sZoYmCgCr3qgZz6s8I0gP1bYiR%2BD79H56NOz0EVWCTy2%2FfffvSCCx59W7uRV9995eqrX8GLesOXNm360iZ%2BT%2FEl3uZqL%2BFyzSZ8XxpTiI%2FG0nkT4zznFZ0t4ipMz5v4q9ssqbdKUZt6u82knPCrt6PZwsnn0XySVnyPR1ZXAn72yx48bWJsu7apnI3Hy8bygUK5Js32qcytapqgmn95uexccj205vGgJ%2BeuOeG2SORmKZr%2FqKzcx9SFctMJdwMUFZDJITs7dnOp1EKZCxg304Cevyfya%2BvlKqv6aXK1qIj3imL%2BL6hL%2ByvUlFfE0VKZ7E8gBY3M%2F8VoJCFgizH1W6VyC76nH6b7jiibYVxUmVIEspry%2FLgZIlCeP11Z4zs%2FAwvVwtGFEut5S1JY4lfyT0N%2FevOLo%2BrUEgjcqc9IkGpQbv3iW7Co5b%2BKgjvpzYdH85PLcc4X21ouwEGl%2FS4qnUAvoSlXUUhR1eKr2VWFTB%2BGMl6FsiQsVD1R3urlAAIoSn7JQkmiVVCHSpCwDH%2FqPepXQ0Db77CJOAImohB%2BRPWr31ev5g%2FkE%2BzTa4lbvZo8xdWPffQu9yJTPCNB66s%2BzXoJt%2F0L6hSoCuBIoK8fnBGG87OoRckJpLqyWe4YbpGi50g0%2B3I3UD85Oa0fzubfoXxPLbW3FDWzigmyJeM0tQkax7PqTy80%2BUxfUHPlBZIRVNQ%2Bv0xRm8REKPoLmNr0%2BUo48v9GFbXPKylqQ2IKm00QddgyWGMROCTxdLB9nCY8P7j2DjlsV%2F%2Bmfr0C0r%2FNkeXbbpPlOTBBwT0mVz1zx9S%2FwJecBF9Wgv3p032iP2v4VSgfgW2G%2BHUEdEXU6iq4CtpLJfIN9XQG8dwa1VoO8XC2SrPDDyCOQptXgbcPvlAgBfxBoGwftQKeKFrNTASPt3pGGqDt%2FQRasn2kri%2BH6L80MJRsmVYJrAKyDItpJUy3%2F15WYIJqcJ9Q5N%2FLFJ4c3dc1URpWl9hW6mu50MUIelg4ucTPf15zs5DFo1c0VSp1tKB9jkwIyuM45kb%2BIP8gHed%2B6jO3v0KbIknzLy636E8KPTdCuUpB0wLo9JKnAO6pv0vS31EtBha%2FfJemkgLVVnd8KCk4qBTpQ5m7FbifBKrPJcq0pZAFVG%2FXbOFz%2BTcq2MLrcmV28Nmi%2FOHskh82bau0k8eWCaPijQPWQ5lUvslwVCfHkXBMIehqUgtDNLeauH1huvZTbYmw%2BluPjyWoNGEuxRLR7LK5fSyXFUyK7PURQv2v8D3XOt2NJ6liBbmPGOsakw1kbeOs%2B31Wm5qpH%2BiJWSzqdPr2O7zc2TmtnrzCig6bBd%2FvgQmzOlz0STWIlmZEQfupogOZFHUZ7EkUnMn0RrpIMqAgHRJAOjIJ3yGw1I%2FMAp9q9S3Q%2FclADNm1wEeO%2Bxbwg5OIYHZLY3ehG5lJk2xhco%2B6JWybpEVz2wrR6hZyD0QXZbeDVB%2BonmlimpkWprdAs4WEZDSQppsDlcdCBJJESIYFuAtUnC4GIF2C3Uu2Kv7L1bdz6FxtqxpG4TqQOqOUNAJ2HLvPWA2GgDy4O4vaDrtyl6P%2B1fAll%2BSyFcQ28GHqh7fvvf37udylf0fNwhzgz87Y%2Bcf5x9GnF6ygHu18sAbipWeF0YPBgp2GaKeQduxxdEr3SgbH1kvH7tvqSLhedomOvZyts2dw8acu3dY%2Ff%2BucuMtCuP%2Fe4zC4XnH3OLZ8ZuxTWxy8dJfU5dhDeKPSlJy5pn%2F%2B7u3XrJhmr9C5CuleGflGQocKnlAUaRKp0BAHV0ZwUt9VCqk6zYOgRIuMfePJzdmBdpPJ7%2F6B23%2Bf%2Bsp9NMDZevovvfYHG5dGPISQq1DojqNckchVrCcCYz%2FQ0hI0m3NKDRfkgsrnamo%2Bp0CAq1FyvC3a3Nak%2Fs5VX282x9Ufy3E39VAx6o7LpCvO2wK%2Bch9jNqpJCutcIOooKnYWtDK8gTRVYygRQfwgzKM5%2BjP2jOZdx3r32Py7rQUPOzAnoRs95NvRAR0qLGU11Taqu1bUYSzMcWjMEir067JQQHfIrLBHsrgv00%2FWavd8HRLMEEYFSW3HCSNQehnrHztKqHcDyo4VfZ6gPKCR%2BgufwA8GegxUEo4A%2Bgd0BASHiH6jYMLIsUdQJTs%2FC641KN4oCHWolCMLlMfIdtWKScjx7SM5LD9HnfmhrGI0S139UWfUnxgOXdJFW%2BAMcGjKr6eHAttHF5sUoeArYKDcxMSYcKA%2FxUDhPiEOEAPafSIUFArN0r24ynI91EPARDXvIDYyvqZaWeroBOUABQA%2FE%2BDXC7PWafDLQY2oiwpUEyj4RQtVlUp1GrM7In2p2A7VuiOW6otMiGOo5Mrp05ejVuTy6dNX%2Fk%2F7mybZQ0nUmfrbx3U4KueDnlHm5wdh8FFeKnoaKKh%2FTK18StOPhwG9Xo5mqXAxvw%2F79YQwwDR%2BnAKQQ4izVXioB84qcppWB7IqjU45z4CE17OvF1Dw%2BoTFqxtz8dxwtogBnF9MjIl%2Fin%2BK8s3hM9laIn0TiCbTAXL0T798bPXqx36p3chrv0O%2BGC9Xaj48Ecv8U8UEeBvUEsDlTepiU5OvlpeNGvpnKF0RvUooWhIjnx6GeBapXCQYTw9DNg6%2FOC3gZjp76oNTj9Kz6Jqobxb9NDqc08vcKReOpcsQV2K8InXFaXW3aI6Ofr1k48rp7CX7rx%2Bv1UKPsfvzQU0Kc83i2VdILmd2%2FyX55zT9luN2%2BCu4nKfwPcK%2FCvDVU%2BpHh8%2BLaldIf1fA5h3ndT6Fln9%2FW%2F9Ce1vndfvJtnPVO2xhm3qbafHVCN1X363UXHq9xuVD8OSD29Z8pZ5cZrern9cAdGW%2Fuib%2Fud%2BVK0L9a42r6C90kL8KzxwLQw9NkIQJL0ASU8M%2BVG0KsUdgdvpgP%2F6NqqP0%2FgHZFUfGEijZLHpiIgvV5%2FBltrj8Qd7XQd5p4P%2B7tJo30NMO6VGBwahSPMYiaaBYoLY6uEnciyhhh1Z%2FvvacG%2Frjpsvnpzs0B1Id6fmX8119l88XnOxe%2FuGrzzHcdu7UtY3%2B2vmXN5zUyj3ZcPl8p1sZSs6%2FnGXtwrV7Ka0XZdz83fwjjINpZWYw85lL8BRK4nGyIir2RiOsEyipuEcIakpGjWgBjLiHWOgj0Yi34gW1kKPxHt2Na5q%2Blwg1RdRSpFDNzosb44YJXnAfoEOpZW%2F%2F6u1lhYA6leevezbI26zNHO811M2dc5HFxpk4i1jPC0s21%2FBWW5DnPQbn2X1WK43%2FaM2n18DfSoybbNHijFpamzXI31eRibGUOxSu%2FlT96YZlq1Yt20DaSBuG6knw2eusHs5EPBfNmVvHKdaQzcDfz9ZsXmLDWGXy2U5OsYSsIn8CS12jQIyD12KKqZrLPy7mSPdICmd6WGHG8NDZkkHuE4h9TU8FpmUO%2FVjC%2FEinToFyoNDz2p9XD6g78WgQdPG7Z3R0T%2FZ5dTM9lsL8Ktek7szl2L%2BgQwGgwkZHc2g5Su7NvVqwGy2Ua4KSXUwt1X4PaM5paaEu6jQ5zVFyNabxvUksVt2T%2F4VeamYPlLtffdQsk%2B2sUTY%2FzDXl%2F05W53%2FBz9UK3p7LjapZ2ZxOm%2BUlZXrL3HHGqO8%2BwVroDaCTTnTxitMxmiAAYQzVJQH%2Bnj3oIHnPaN6Zq6sNSLjBl8tKgVr2mj%2F9CWi9dnKca8rBQBsd5R1tzVlgrl5pbnPw6kZclCr2CHxMnHohLz%2B3KRQokzALyeIKFU1TNCiayJdoHvDYe7K6mZLm8S3uJ9dojuaJ62%2FqN%2FtjQxnSnhnKPw%2BLNrLi8ZKyJ3x1YhiI1aNAtP6NzCGzYv3DmaGh%2FLvQZnt0evgIhTFV0kE%2FPYxAnOHhCQUZdCWY5JWJwMzlAGl1mpNbDU7yyGnhRMILsYhH3VRAijrPcBU8%2FCj1Y9NY6cnGVW0CjTLaz7E3epvaT%2FLtTV72Rs%2B0WVVmd0dz%2FMGTI5F0OsIviaqDlbbO5X6xT3PeXbXHRtf%2Fz%2Bfdka%2BeKPr8KF7IF4vBsT9MFPuPJMBTBMq9hQxXelQ%2Bbewnf18ap4Ib%2BmSMrtDU5zqlD8QANa5MBGh%2FOwOvSDfcV2d66mfEWsbGWmIz6nsyZDWQSmqmxDneYyvjHPmRXHZxeueyRGLZzvRioKnGto9nIPkibAJA16adcOZRQr1iAP3bUyBR7T4RgAWTKxhkCYFwshq%2B7iV9r0whk50cmRcTg4fy5x4OmmNkHndIA2%2BYuMbmE9dwGYB4KFTsvnDE6Ah47r%2FfE3AYI%2BoXADpkdlENcZ8OZEEf8FFGZNxMs6ZLpG3SUFLL7Q2kcFU%2FA%2FJsw%2BvWDa%2F7emewLaoeibaF1B9qUNnuqWK3%2BUfXYVL1v%2FomD15xxeDkPnXTOKSVcCbDGtOu0YQNpGAP7U1HU58UrqGu8xIbHtkQ3LVhb7Dx46ET3Ffcm1q0YcOizNmf3bC3VjWfAcpSv3MyTlgJ23FHQgmgvk%2Bgk8pL0mcCDOn08MDAQlf%2B%2FSlTZ1z12fnqntOhbOTL9%2FZdevbAPN%2Byby1f%2FuUtC%2Fixm8ZBo59LTXEW060hGrTDplNprWd58fwB%2Fb%2FE27BdS%2Fs7U%2BrGVCeQ46nzaw9QccnmZerGZZs3Yw9aVHt%2BKh6HN4ti6lxIhT%2FwahnZtWwzlY9QHQ2c79C%2BdxzvVDKy8GqKWQERO9YAKbpsDUTLdWV5dE8PVPjvj9pqw7ah%2FPFVtkit7aj6G5xY9mfJrCz1j1e0BcnPol4UjtrCdbahIVtd2HaURujnFJR8CuOuUUfhrGhgKKgjCYNSvCc1WKlEp8wHUaAYynFNyzZn%2B2MnYv36dbMDBTonl%2FT%2Fma5IKAyEGz%2B4eRnVtaX6tss2o34u8mWorFtuFgm4A6qK%2Fyp%2FgLEBVat5WnPDdKA574ubuFJ%2FIUfZ%2FY2Nt6mN%2BZNNTSTaeI56gKwkXerTe9DDHUw8%2FH35FY3nNN7GGuBKWhrV9ep%2B0k1WjNWVaHkW1yA%2BQHWNu8rtBw2a5YXuE40rs7%2FGA%2Bj09V3hA98yRnFPOGr8ltGlsFdD%2F7tRce3LH6Trcneuiy7K7J3khKu%2B3qUaXPWaX7T6%2FKfj9BX2eZq2XAcZT79u1ClJzUtHUqfqSMWBcZS43Ena0cUGLgpkKxB1QM%2B0Fxz10wgg6r5rltnFpH05pepUq3Y2HfYqeKRntmUFNz%2BXmcOs1H31U6cC6RTVLfCg7RNBF1UF2%2FwBgu0fFQtPEU1sSg3VcNsR7dWq3af87tUFn1l3ltXpaJxpNvtcZkH2WmMst3JqRpxUH%2BWC0E1qOGtP66s1MYv%2BVLu8%2FXFXvV%2FZbunYYBeVN64ls0ur6NzpV9xzlmQwB5qC4Tq70WC0tk8dWJXeHvkD0h9zJOM0vD86%2F1NJMaIAolctvlByferCsqOKDKceOfUu1PsmoFCamV5mCrMUOCi6V6FJosMF22AcrKJgQDVhfYh6tepp%2FlYgvnCEAbJQ1L0rOpajEmRcasMiPfxhgGoVo4rwreQpV6fUJHH2e8fa1s2c13Apl1b89a58ozdoap2sjgLN9uISl7P1DrulyeIkt0zr6JjWocoPOZsaXPb6jtqBblsgsaRre2xHi4nELm0MhG1%2Bx1SXwLpFi53b%2BaHRYo%2FIrbZtuWAKu5cSEXfybnnmUCaXGTpQr0xK2O2WWY76f%2BnAjNVf7nCZHU5XqIkTnpt6VtvsFlPXg1031g%2FVRdpkkyVpD7jnmax88QwDvg%2F66NnMRdRXTcGTmQc3cuINwN5IQqi0yzb%2BYFVHuVqI5s4ADfg5oE4ybDLd28mFSFmYvRoomsWXEdLU2Wl3GJy93ZNb%2Fd5gqmNaqJZSO1l6PVRy0nZIj%2F45EetjLguh1rLqR%2BSK0hO6NrsqcNX8zoUdjQYDJ7tb4os6%2Bi%2BY0qpY2AWlnLRDWdGFTfGY1gV0zNAtJ7pdo24se0D88AwLY%2FgZmE9iuP4V5v7CSR%2FRThaHLh%2BUeBkXwU6BC7lGOevK65udTv%2BtS%2FPfW7qj3ljTcj3b9OkbV85t8xsMj7Ddj7DGpthZKwKPvso%2Fc%2F1K9aLE12fMWLV1y1D9ua8lyJdWXr%2FbG%2BnoCFutf%2FmLILe39ITUV4igr3876fpX5g2zeB52sWnIL4fXHlgeUzOx5QfIvJQyrKQE9wHUqVq%2BPEaOrz0wVvNbJZVSfsuMzxN4l9PkedFzw9V5Dj%2BnzpgoT4ZxCxJfC5RWLc74YVHxKlExCYt0JAOMatREhHBSCAtSfod6x6Ls8HCWECLwXZ9nd5Dz1T24JUdWs6fU3%2B%2BfcnT49Qe%2BkBs%2BwdsMZgPXMp3U5S958snPP%2FEE7bvkOPCuTUDTUQ%2FUzirLhML9yPahoe1D5Fj5jWsaoveyP00PehdUAHk%2FseDVWsvDWXXXsyn%2F4wfpXc2V3%2FQxli3jl%2F5hj%2F83avSCfpTNxOEKLmTjxOEKuxgNlsQn0xgct724mhynupNW1Ph6o3RYS3%2F%2B2TJrzLlkFz%2Bip3qCHKf6eqW02QJLjBYuuj4sobhCWqa%2FYHGEHpcnumuWSOhxeaL7sOakNR6vvmo%2BYcfFA8UFXEPZf9UjyudIOyNwx%2Fi90DdsujS%2FFX2UAwvWSVK4NxaMhAGw3oowp%2Fuc8CTi7D2rBgZWwb%2F60faR7SPsEbjkXy4G0XaqhXPwe2cePjxjxuHD6ssQuR1fq6PF0E%2Bo2t1nePTn8TUmxz%2FA3crMoCc7egESuoTHYc7mYdg6etORoOhR7BBGD%2BqJopELrl4S6cJNRtEAsLP%2FOdvnJq0Wo0GolY2Et9VFB2Kf%2B4bZvVyxfOMz3WdFfSIryj6DwWghre7aQbdiDrkTL3A3vNDuDpk93HqXwam%2BbWmUJZfNn5ozKV5Pmmq8PF%2FjVY%2B2Tlk2M2RzSXKjmbQ4RZcQavEYrN%2F9rlXwtIQqzxQNMzPPfHYLvuPoO9TbT8bpGw5CQPGd%2BSyX%2FCyf0Vxjd2R9NmsunnXYa8xGHzn%2BsSfM5J0y0DZEXWWxkXjcR75KBLNLHi7XvX2G8VOrf4Ykg0AMdBESIpo7MgAfyakA6rkqpI6UjNs0px7cMV%2BD5BF49Tez1VGnYmq0WIijp985m4Sn2gJR9b07riPPFo97OYbUZbxJCpot7H%2FlpZBicglCPN7WOfJkcHqc3ElWqvvz%2F1E6bIQrG%2Btz6WkM1SM9FBTR7FSs8KyBBytSmNEoquJNFN5EQyTiCrnKDx1h58yxCepPHU5nxGoxEQeeOZi2m80DxNxncVhr6BmEfUarxejw%2BWSiHhWk19bSY7aKR5MsteblJpfTLtjimBouXsm3d3djjYM%2BwEW0El9dM%2FueVRWIsXwe43R7SgbVZqrnqoJ1X%2FkuF7pcgf8duv4q6vayV5U9zMV91GxO59UUjW8rHV6u799WzKMT7umRCXbYUKM%2BfoaCcwgaoqZUtmodV3p%2BX7akb4dnU9B9La38RPFUG2SCC90tVA4XwEFhyOpZZrUCsgWYHsczLFBBVGNtstoN1bw0Z%2BO4fYIbvZVt4EUcJEKOhHeincWqONw%2Bq6w5Go%2BWGOSR7LhKV%2BKBqbBPpfUvOf9QqkpDyVhBeyyZQGMsdA5FBUqvFMtUyGq9vjnsAJU4UcrxldP1CCaofyDkSAifoP5QwWx%2BSyUGxp75BzGAvtG7uQ38LehlyEQMeh0TeE6Bm7tYdXqdkt0uOb3kfYlNwmOdDyacOq%2FqlFo1v%2BPTmTi3E%2FglC9W11b34A22zmLzvb231Q0L2Bgg60OTW4YdstO%2BYOJnO38TtpH7zy9ymokWyA79qlVSn38HtpFlImFnhu3b4boNWXklOXV0Iwo7lQ1hrZyPFcwtjwFP7iEKSHSSJw509kh8kj6pr%2BH1jR7km9vcvqN9657vffefkv%2BfKxge1X%2B7RdjYUPIESN7gTvRkB%2FRMYtEkaVkdHApmdBPpnKmz0n1xSWFOyVIuLrinZwpoCRe6kyiVZoHX088F%2BUX4%2BWKS4iBTP0IWxGtZgOdMaV4KTayqHQF%2FVihBwTbgDXTCmKoOBJeNhwJMzEVjtjIFLuU38fPR7hqNG1JS7g%2FqRCuy3vmQ3W9Vu8qbVbP%2BSzazGRJH83MzP90Ck2m31mMjP8TiLn5uwD2Ugr2PFvPQjB5BnSJvQxGQZZEB%2BLopqzGzDbMmbkAPkZVJjeO5FzOSBKCgJze2ZS4Gemc9twrwY6u9H61iUQTcRvtdT9RW3tRxAWwFs2tcuJRnI6xjmBdWjbgFNRHMHiF1uHYBfUR%2Fut5Ug2jXAaT96%2B9RH%2FFToRwIzGbKmVJ1AZQnoabSB1yyIg7ByAridHApPMjyw0OiV6RjSbCuzwLAvFizBliWJua1tsuAgvNPbmljYbpt8lkWam7b3XZiOiKJskMOtmfScnsbPW208knwjuXrXK4Q1iKIgNyYXXDVT9C2Ye%2F78GQ5BEEXfFdde2RwauOysdJNL5AzCy84ard%2FnGAVN8alecnFdgu5Gbd5DJTL%2BhHZK0vApVy3OfU8XTSJg1TlssivsPYUlIqvn66PzrVTymCc4wgF6SDNR0pDf%2B9Gp%2BVnsUH5WtpHYsuhOaey8zdwLN47V8MTbm78g687%2BP3cx6tcAeNpjYGRgYGBk8s0%2FzBIfz2%2FzlUGeZQNQhOFCWfF0GP0%2F8P8c1jusIkAuBwMTSBQAYwQM6HjaY2BkYGAV%2Bd8KJgP%2FXWG9wwAUQQGLAYqPBl942n1TvUoDQRCe1VM8kWARjNrZGIurBAsRBIuA2vkAFsJiKTYW4guIjT5ARMgTxCLoA1hcb5OgDyGHrY7f7M65e8fpLF%2B%2B2W%2FnZ2eTmGfaIJi5I0qGDlZZcD51QzTTJirZPAI9JIwVA%2BwT8L5nOdMaV0AuMJ%2BicRHq8of6LSD18fzq8ds7xjpwBnQiSI9V5QVl6NwPvgM15NXn%2FAtWZyj3W0HjEXitOc%2FdIdbetPdFTZ%2BP6t%2BX7xU0%2Fk6GJtOe1%2FB3arN0%2Fpmz1J4UZc%2BD6ExwjD7vioeGd5HvhvU%2BR%2BDZcGZ6YBPNfAi0G97iBPwFXqph2cW8%2BD7kjMfwtinHb6kLb6Wygk3cZytSEoptGrlScdHtLPeri1JKueACMZfU1ViJG1Sq5E43dIt7SZZFl1zuRhb%2FGOs44xFVDbrJzB5tYs35OmaXTrEmkv0DajnMWQB42mNgYNCCwk0MLxheMPrhgUuY2JiUmOqY2pjWMD1hdmPOY%2B5hPsLCwWLEksSyiOUOawzrLrYiti%2FsCuxJ7Kc45DiSOPZxmnG2cG7jvMelweXDNYXrEbcBdxf3KR4OngheLd443g18fHwZfFv4NfiX8T8TEBIIEZggsEpQS7BMcJsQl5CFUI3QAWEp4RLhCyJaIldEbURXiJ4RYxEzE0sQ2yD2TzxIfJkEk4SeRJbENIkNEg8k%2FklqSGZITpE8InlL8p2UmVSG1A6pb9Jx0ltkjGSmyDySlZF1kc2RnSK7R%2FaZnJ5cmdwB%2BST5SwpuCvsUjRTLFHcoOShNU9qhzKespGyhXKV8SPmBCpOKgUqcyjSVR6omqgmqe9RE1OrUnqkHqO9R%2F6FholGgsUZzgeYZLTUtL60WbS7tKh0OnQydXTpvdGV0O3S%2F6Gnopekt0ruhz6fvpl%2Bnv0n%2Fh4GdQYvBJUMhwwTDdYYvjFSM4oxmGd0zVjK2M84w3mYiYZJgssLkkqmO6TzTF2Z2ZjVmd8ylzP3MJ5lfsRCwcLJoszhhyWXpZdlhecZKxirHapbVPesF1ndsJGwCbBbZ%2FLA1sn1jZ2XXY3fFXsM%2Bz36V%2FS8HD4cGh2OOTI51ThJOK5zeOUs4OzmXOS9wPuUi4JLgss7lm2uU6zY3NrcSty1u39zN3Mvct7l%2F8xDzMPLw88jyaPM44ynkaeEZ59niucqLyUvPKwgAn3OqOQAAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAHjarZK9TgJBEMf%2Fd6CRaAyRhMLqCgsbL4ciglTGRPEjSiSKlnLycXJ86CEniU%2FhM9jYWPgIFkYfwd6nsDD%2Bd1mBIIUx3mZnfzs3MzszuwDCeIYG8UUwQxmAFgxxPeeuyxrmcaNYxzTuFAewi0fFQSTxqXgM11pC8TgS2oPiCUS1d8Uh8ofiSczpYcVT5LjiCPlY8Qui%2BncOr7D02y6%2FBTCrP%2Fm%2Bb5bdTrPi2I26Z9qNGtbRQBMdXMJBGRW0YOCecxEWYoiTCvxrYBunqHPdoX2bLOyrMKlZg8thDETw5K7Itci1TXlGy0124QRZZLDFU%2FexhxztMozlosTpMH6ZPge0L%2BOKGnFKjJ4WRwppHPL0PP3SI2P9jLQwFOu3GRhDfkeyDo%2F%2FG7IHgzllZQxLdquvrdCyBVvat3seJlYo06gxapUxhU2JWnFygR03sSxnEkvcpf5Y5eibGq315TDp7fKWm8zbUVl71Aqq%2FZtNnlkWmLnQtno9ycvXYbA6W2pF3aKfCayyC0Ja7Fr%2FPW70%2FHO4YM0OKxFvzf0C1MyPjwAAeNpt1VWUU2cYRuHsgxenQt1d8%2F3JOUnqAyR1d%2FcCLQVKO22pu7tQd3d3d3d3d3cXmGzumrWy3pWLs%2FNdPDMpZaWu1783l1Lpf14MnfzO6FbqVupfGkD30iR60JNe9KYP09CXfvRnAAMZxGCGMG3pW6ZjemZgKDMyEzMzC7MyG7MzB3MyF3MzD%2FMyH%2FOzAAuyEAuzCIuyGIuzBGWCRIUqOQU16jRYkqVYmmVYluVYng6GMZwRNGmxAiuyEiuzCquyGquzBmuyFmuzDuuyHuuzARuyERuzCZuyGZuzBVuyFVuzDduyHdszklGMZgd2ZAw7MZZxjGdnJrALu9LJbuzOHkxkT%2FZib%2FZhX%2FZjfw7gQA7iYA7hUA7jcI7gSI7iaI7hWI7jeE7gRE7iZE5hEqdyGqdzBmdyFmdzDudyHudzARdyERdzCZdyGZdzBVdyFVdzDddyHddzAzdyEzdzC7dyG7dzB3dyF3dzD%2FdyH%2FfzAA%2FyEA%2FzCI%2FyGI%2FzBE%2FyFE%2FzDM%2FyHM%2FzAi%2FyEi%2FzCq%2FyGq%2FzBm%2FyFm%2FzDu%2FyHu%2FzAR%2FyER%2FzCZ%2FyGZ%2FzBV%2FyFV%2FzDd%2FyHd%2FzAz%2FyEz%2FzC7%2FyG7%2FzB3%2FyF3%2FzD%2F9mpYwsy7pl3bMeWc%2BsV9Y765NNk%2FXN%2BmX9swHZwGxQNjgb0nPkmInjR0V7Uq%2FOsaPL5Y7ylE3l8tQNN7kVt%2BrmbuHW3LrbcDvam1rtzVvdm50TxrU%2FDBvRtZUY1rV5a3jXFn550Wo%2FXDNWK3dFmh7X9LimxzU9qulRTY9qelTTo5rlKLt2wk7YiaprL%2ByFvbAX9pK9ZC%2FZS%2FaSvWQv2Uv2kr1kr2KvYq9ir2KvYq9ir2KvYq9ir2Kvaq9qr2qvaq9qr2qvaq9qr2qvai%2B3l9vL7eX2cnu5vdxebi%2B3l9sr7BV2CjuFncJOYaewU9gp7NTs1LyrZq9mr2avZq9mr2avZq9mr26vbq9ur26vbq9ur26vbq9ur26vYa9hr2GvYa9hr2GvYa%2FR7oXuQ%2Feh%2B2j%2FUU7e3C3cqc%2FV3fYdof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D92H7kP3ofvQfeg%2BdB%2B6D92H7kP3ofvQfRT29B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6j6nuG3Ya7U5q%2F0hN3nCTW3Grbu4Wrs%2FrP%2Bk%2F6T%2FpP%2Bk%2F6T%2FpP%2Bk%2B6T7pPek86TzpPOk86TzpOuk66TrpOuk66TrpOlWmPu%2F36zrpOuk66TrpOuk66TrpOvl%2FPek76TvpO%2Bk76TvpO%2Bk76TvpO%2Bk76TvpO7V9t%2BqtVs%2FOaOURU6bo6PgPt6rZbwAAAAABVFDDFwAA%29%20format%28%27woff%27%29%2Curl%28data%3Aapplication%2Fx%2Dfont%2Dtruetype%3Bbase64%2CAAEAAAAPAIAAAwBwRkZUTW0ql9wAAAD8AAAAHEdERUYBRAAEAAABGAAAACBPUy8yZ7lriQAAATgAAABgY21hcNqt44EAAAGYAAAGcmN2dCAAKAL4AAAIDAAAAARnYXNw%2F%2F8AAwAACBAAAAAIZ2x5Zn1dwm8AAAgYAACUpGhlYWQFTS%2FYAACcvAAAADZoaGVhCkQEEQAAnPQAAAAkaG10eNLHIGAAAJ0YAAADdGxvY2Fv%2B5XOAACgjAAAAjBtYXhwAWoA2AAAorwAAAAgbmFtZbMsoJsAAKLcAAADonBvc3S6o%2BU1AACmgAAACtF3ZWJmwxhUUAAAsVQAAAAGAAAAAQAAAADMPaLPAAAAANB2gXUAAAAA0HZzlwABAAAADgAAABgAAAAAAAIAAQABARYAAQAEAAAAAgAAAAMEiwGQAAUABAMMAtAAAABaAwwC0AAAAaQAMgK4AAAAAAUAAAAAAAAAAAAAAAIAAAAAAAAAAAAAAFVLV04AQAAg%2F%2F8DwP8QAAAFFAB7AAAAAQAAAAAAAAAAAAAAIAABAAAABQAAAAMAAAAsAAAACgAAAdwAAQAAAAAEaAADAAEAAAAsAAMACgAAAdwABAGwAAAAaABAAAUAKAAgACsAoAClIAogLyBfIKwgvSISIxsl%2FCYBJvonCScP4APgCeAZ4CngOeBJ4FngYOBp4HngieCX4QnhGeEp4TnhRuFJ4VnhaeF54YnhleGZ4gbiCeIW4hniIeIn4jniSeJZ4mD4%2F%2F%2F%2FAAAAIAAqAKAApSAAIC8gXyCsIL0iEiMbJfwmASb6JwknD%2BAB4AXgEOAg4DDgQOBQ4GDgYuBw4IDgkOEB4RDhIOEw4UDhSOFQ4WDhcOGA4ZDhl%2BIA4gniEOIY4iHiI%2BIw4kDiUOJg%2BP%2F%2F%2F%2F%2Fj%2F9r%2FZv9i4Ajf5N%2B132nfWd4F3P3aHdoZ2SHZE9kOIB0gHCAWIBAgCiAEH%2F4f%2BB%2F3H%2FEf6x%2FlH3wfdh9wH2ofZB9jH10fVx9RH0sfRR9EHt4e3B7WHtUezh7NHsUevx65HrMIFQABAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADAAAAAACjAAAAAAAAAA1AAAAIAAAACAAAAADAAAAKgAAACsAAAAEAAAAoAAAAKAAAAAGAAAApQAAAKUAAAAHAAAgAAAAIAoAAAAIAAAgLwAAIC8AAAATAAAgXwAAIF8AAAAUAAAgrAAAIKwAAAAVAAAgvQAAIL0AAAAWAAAiEgAAIhIAAAAXAAAjGwAAIxsAAAAYAAAl%2FAAAJfwAAAAZAAAmAQAAJgEAAAAaAAAm%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%2FAADiUAAA4lkAAAEJAADiYAAA4mAAAAETAAD4%2FwAA%2BP8AAAEUAAH1EQAB9REAAAEVAAH2qgAB9qoAAAEWAAYCCgAAAAABAAABAAAAAAAAAAAAAAAAAAAAAQACAAAAAAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAQAAAAAAAwAAAAAAAAAAAAAAAAAAAAAAAAAEAAUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAVAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAKAL4AAAAAf%2F%2FAAIAAgAoAAABaAMgAAMABwAusQEALzyyBwQA7TKxBgXcPLIDAgDtMgCxAwAvPLIFBADtMrIHBgH8PLIBAgDtMjMRIRElMxEjKAFA%2Fujw8AMg%2FOAoAtAAAQBkAGQETARMAFsAAAEyFh8BHgEdATc%2BAR8BFgYPATMyFhcWFRQGDwEOASsBFx4BDwEGJi8BFRQGBwYjIiYvAS4BPQEHDgEvASY2PwEjIiYnJjU0Nj8BPgE7AScuAT8BNhYfATU0Njc2AlgPJgsLCg%2BeBxYIagcCB57gChECBgMCAQIRCuCeBwIHaggWB54PCikiDyYLCwoPngcWCGoHAgee4AoRAgYDAgECEQrgngcCB2oIFgeeDwopBEwDAgECEQrgngcCB2oIFgeeDwopIg8mCwsKD54HFghqBwIHnuAKEQIGAwIBAhEK4J4HAgdqCBYHng8KKSIPJgsLCg%2BeBxYIagcCB57gChECBgAAAAABAAAAAARMBEwAIwAAATMyFhURITIWHQEUBiMhERQGKwEiJjURISImPQE0NjMhETQ2AcLIFR0BXhUdHRX%2Boh0VyBUd%2FqIVHR0VAV4dBEwdFf6iHRXIFR3%2BohUdHRUBXh0VyBUdAV4VHQAAAAABAHAAAARABEwARQAAATMyFgcBBgchMhYPAQ4BKwEVITIWDwEOASsBFRQGKwEiJj0BISImPwE%2BATsBNSEiJj8BPgE7ASYnASY2OwEyHwEWMj8BNgM5%2BgoFCP6UBgUBDAoGBngGGAp9ARMKBgZ4BhgKfQ8LlAsP%2Fu0KBgZ4BhgKff7tCgYGeAYYCnYFBv6UCAUK%2BhkSpAgUCKQSBEwKCP6UBgwMCKAIDGQMCKAIDK4LDw8LrgwIoAgMZAwIoAgMDAYBbAgKEqQICKQSAAABAGQABQSMBK4AOwAAATIXFhcjNC4DIyIOAwchByEGFSEHIR4EMzI%2BAzUzBgcGIyInLgEnIzczNjcjNzM%2BATc2AujycDwGtSM0QDkXEys4MjAPAXtk%2FtQGAZZk%2FtQJMDlCNBUWOUA0I64eYmunznYkQgzZZHABBdpkhhQ%2BH3UErr1oaS1LMCEPCx4uTzJkMjJkSnRCKw8PIjBKK6trdZ4wqndkLzVkV4UljQAAAgB7AAAETASwAD4ARwAAASEyHgUVHAEVFA4FKwEHITIWDwEOASsBFRQGKwEiJj0BISImPwE%2BATsBNSEiJj8BPgE7ARE0NhcRMzI2NTQmIwGsAV5DakIwFgwBAQwWMEJqQ7ICASAKBgZ4BhgKigsKlQoP%2FvUKBgZ4BhgKdf71CgYGeAYYCnUPtstALS1ABLAaJD8yTyokCwsLJCpQMkAlGmQMCKAIDK8LDg8KrwwIoAgMZAwIoAgMAdsKD8j%2B1EJWVEAAAAEAyAGQBEwCvAAPAAATITIWHQEUBiMhIiY9ATQ2%2BgMgFR0dFfzgFR0dArwdFcgVHR0VyBUdAAAAAgDIAAAD6ASwACUAQQAAARUUBisBFRQGBx4BHQEzMhYdASE1NDY7ATU0NjcuAT0BIyImPQEXFRQWFx4BFAYHDgEdASE1NCYnLgE0Njc%2BAT0BA%2BgdFTJjUVFjMhUd%2FOAdFTJjUVFjMhUdyEE3HCAgHDdBAZBBNxwgIBw3QQSwlhUdZFuVIyOVW5YdFZaWFR2WW5UjI5VbZB0VlshkPGMYDDI8MgwYYzyWljxjGAwyPDIMGGM8ZAAAAAEAAAAAAAAAAAAAAAAxAAAB%2F%2FIBLATCBEEAFgAAATIWFzYzMhYVFAYjISImNTQ2NyY1NDYB9261LCwueKqqeP0ST3FVQgLYBEF3YQ6teHmtclBFaw4MGZnXAAAAAgAAAGQEsASvABoAHgAAAB4BDwEBMzIWHQEhNTQ2OwEBJyY%2BARYfATc2AyEnAwL2IAkKiAHTHhQe%2B1AeFB4B1IcKCSAkCm9wCXoBebbDBLMTIxC7%2FRYlFSoqFSUC6rcQJBQJEJSWEPwecAIWAAAAAAQAAABkBLAETAALABcAIwA3AAATITIWBwEGIicBJjYXARYUBwEGJjURNDYJATYWFREUBicBJjQHARYGIyEiJjcBNjIfARYyPwE2MhkEfgoFCP3MCBQI%2FcwIBQMBCAgI%2FvgICgoDjAEICAoKCP74CFwBbAgFCvuCCgUIAWwIFAikCBQIpAgUBEwKCP3JCAgCNwgK2v74CBQI%2FvgIBQoCJgoF%2FvABCAgFCv3aCgUIAQgIFID%2BlAgKCggBbAgIpAgIpAgAAAAD%2F%2FD%2F8AS6BLoACQANABAAAAAyHwEWFA8BJzcTAScJAQUTA%2BAmDpkNDWPWXyL9mdYCZv4f%2FrNuBLoNmQ4mDlzWYP50%2FZrWAmb8anABTwAAAAEAAAAABLAEsAAPAAABETMyFh0BITU0NjsBEQEhArz6FR384B0V%2Bv4MBLACiv3aHRUyMhUdAiYCJgAAAAEADgAIBEwEnAAfAAABJTYWFREUBgcGLgE2NzYXEQURFAYHBi4BNjc2FxE0NgFwAoUnMFNGT4gkV09IQv2oWEFPiCRXT0hCHQP5ow8eIvzBN1EXGSltchkYEAIJm%2F2iKmAVGilucRoYEQJ%2FJioAAAACAAn%2F%2BAS7BKcAHQApAAAAMh4CFQcXFAcBFgYPAQYiJwEGIycHIi4CND4BBCIOARQeATI%2BATQmAZDItoNOAQFOARMXARY7GikT%2Fu13jgUCZLaDTk6DAXKwlFZWlLCUVlYEp06DtmQCBY15%2Fu4aJRg6FBQBEk0BAU6Dtsi2g1tWlLCUVlaUsJQAAQBkAFgErwREABkAAAE%2BAh4CFRQOAwcuBDU0PgIeAQKJMHt4dVg2Q3mEqD4%2Bp4V4Qzhadnh5A7VESAUtU3ZAOXmAf7JVVbJ%2FgHk5QHZTLQVIAAAAAf%2FTAF4EewSUABgAAAETNjIXEyEyFgcFExYGJyUFBiY3EyUmNjMBl4MHFQeBAaUVBhH%2BqoIHDxH%2Bqf6qEQ8Hgv6lEQYUAyABYRMT%2Fp8RDPn%2BbxQLDPb3DAsUAZD7DBEAAv%2FTAF4EewSUABgAIgAAARM2MhcTITIWBwUTFgYnJQUGJjcTJSY2MwUjFwc3Fyc3IycBl4MHFQeBAaUVBhH%2BqoIHDxH%2Bqf6qEQ8Hgv6lEQYUAfPwxUrBw0rA6k4DIAFhExP%2BnxEM%2Bf5vFAsM9vcMCxQBkPsMEWSO4ouM5YzTAAABAAAAAASwBLAAJgAAATIWHQEUBiMVFBYXBR4BHQEUBiMhIiY9ATQ2NyU%2BAT0BIiY9ATQ2Alh8sD4mDAkBZgkMDwr7ggoPDAkBZgkMJj6wBLCwfPouaEsKFwbmBRcKXQoPDwpdChcF5gYXCktoLvp8sAAAAA0AAAAABLAETAAPABMAIwAnACsALwAzADcARwBLAE8AUwBXAAATITIWFREUBiMhIiY1ETQ2FxUzNSkBIgYVERQWMyEyNjURNCYzFTM1BRUzNSEVMzUFFTM1IRUzNQchIgYVERQWMyEyNjURNCYFFTM1IRUzNQUVMzUhFTM1GQR%2BCg8PCvuCCg8PVWQCo%2F3aCg8PCgImCg8Pc2T8GGQDIGT8GGQDIGTh%2FdoKDw8KAiYKDw%2F872QDIGT8GGQDIGQETA8K%2B%2BYKDw8KBBoKD2RkZA8K%2FqIKDw8KAV4KD2RkyGRkZGTIZGRkZGQPCv6iCg8PCgFeCg9kZGRkZMhkZGRkAAAEAAAAAARMBEwADwAfAC8APwAAEyEyFhURFAYjISImNRE0NikBMhYVERQGIyEiJjURNDYBITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NjIBkBUdHRX%2BcBUdHQJtAZAVHR0V%2FnAVHR39vQGQFR0dFf5wFR0dAm0BkBUdHRX%2BcBUdHQRMHRX%2BcBUdHRUBkBUdHRX%2BcBUdHRUBkBUd%2FagdFf5wFR0dFQGQFR0dFf5wFR0dFQGQFR0AAAkAAAAABEwETAAPAB8ALwA%2FAE8AXwBvAH8AjwAAEzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2MsgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR0ETB0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHf5wHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUd%2FnAdFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0ABgAAAAAEsARMAA8AHwAvAD8ATwBfAAATMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYyyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHQRMHRXIFR0dFcgVHR0VyBUdHRXIFR3%2BcB0VyBUdHRXIFR0dFcgVHR0VyBUd%2FnAdFcgVHR0VyBUdHRXIFR0dFcgVHQAAAAABACYALAToBCAAFwAACQE2Mh8BFhQHAQYiJwEmND8BNjIfARYyAdECOwgUB7EICPzxBxUH%2FoAICLEHFAirBxYB3QI7CAixBxQI%2FPAICAGACBQHsQgIqwcAAQBuAG4EQgRCACMAAAEXFhQHCQEWFA8BBiInCQEGIi8BJjQ3CQEmND8BNjIXCQE2MgOIsggI%2FvUBCwgIsggVB%2F70%2FvQHFQiyCAgBC%2F71CAiyCBUHAQwBDAcVBDuzCBUH%2FvT%2B9AcVCLIICAEL%2FvUICLIIFQcBDAEMBxUIsggI%2FvUBDAcAAwAX%2F%2BsExQSZABkAJQBJAAAAMh4CFRQHARYUDwEGIicBBiMiLgI0PgEEIg4BFB4BMj4BNCYFMzIWHQEzMhYdARQGKwEVFAYrASImPQEjIiY9ATQ2OwE1NDYBmcSzgk1OASwICG0HFQj%2B1HeOYrSBTU2BAW%2BzmFhYmLOZWFj%2BvJYKD0sKDw8KSw8KlgoPSwoPDwpLDwSZTYKzYo15%2FtUIFQhsCAgBK01NgbTEs4JNWJmzmFhYmLOZIw8KSw8KlgoPSwoPDwpLDwqWCg9LCg8AAAMAF%2F%2FrBMUEmQAZACUANQAAADIeAhUUBwEWFA8BBiInAQYjIi4CND4BBCIOARQeATI%2BATQmBSEyFh0BFAYjISImPQE0NgGZxLOCTU4BLAgIbQcVCP7Ud45itIFNTYEBb7OYWFiYs5lYWP5YAV4KDw8K%2FqIKDw8EmU2Cs2KNef7VCBUIbAgIAStNTYG0xLOCTViZs5hYWJizmYcPCpYKDw8KlgoPAAAAAAIAFwAXBJkEsAAPAC0AAAEzMhYVERQGKwEiJjURNDYFNRYSFRQOAiIuAjU0EjcVDgEVFB4BMj4BNTQmAiZkFR0dFWQVHR0BD6fSW5vW6tabW9KnZ3xyxejFcnwEsB0V%2FnAVHR0VAZAVHeGmPv7ZuHXWm1tbm9Z1uAEnPqY3yHh0xXJyxXR4yAAEAGQAAASwBLAADwAfAC8APwAAATMyFhURFAYrASImNRE0NgEzMhYVERQGKwEiJjURNDYBMzIWFREUBisBIiY1ETQ2BTMyFh0BFAYrASImPQE0NgQBlgoPDwqWCg8P%2Ft6WCg8PCpYKDw%2F%2B3pYKDw8KlgoPD%2F7elgoPDwqWCg8PBLAPCvuCCg8PCgR%2BCg%2F%2BcA8K%2FRIKDw8KAu4KD%2F7UDwr%2BPgoPDwoBwgoPyA8K%2BgoPDwr6Cg8AAAAAAgAaABsElgSWAEcATwAAATIfAhYfATcWFwcXFh8CFhUUDwIGDwEXBgcnBwYPAgYjIi8CJi8BByYnNycmLwImNTQ%2FAjY%2FASc2Nxc3Nj8CNhIiBhQWMjY0AlghKSYFMS0Fhj0rUAMZDgGYBQWYAQ8YA1AwOIYFLDIFJisfISkmBTEtBYY8LFADGQ0ClwYGlwINGQNQLzqFBS0xBSYreLJ%2BfrJ%2BBJYFmAEOGQJQMDmGBSwxBiYrHiIoJgYxLAWGPSxRAxkOApcFBZcCDhkDUTA5hgUtMAYmKiAhKCYGMC0Fhj0sUAIZDgGYBf6ZfrF%2BfrEABwBkAAAEsAUUABMAFwAhACUAKQAtADEAAAEhMhYdASEyFh0BITU0NjMhNTQ2FxUhNQERFAYjISImNREXETMRMxEzETMRMxEzETMRAfQBLCk7ARMKD%2Fu0DwoBEzspASwBLDsp%2FUQpO2RkZGRkZGRkBRQ7KWQPCktLCg9kKTtkZGT%2B1PzgKTs7KQMgZP1EArz9RAK8%2FUQCvP1EArwAAQAMAAAFCATRAB8AABMBNjIXARYGKwERFAYrASImNREhERQGKwEiJjURIyImEgJsCBUHAmAIBQqvDwr6Cg%2F%2B1A8K%2BgoPrwoFAmoCYAcH%2FaAICv3BCg8PCgF3%2FokKDw8KAj8KAAIAZAAAA%2BgEsAARABcAAAERFBYzIREUBiMhIiY1ETQ2MwEjIiY9AQJYOykBLB0V%2FOAVHR0VA1L6FR0EsP5wKTv9dhUdHRUETBUd%2FnAdFfoAAwAXABcEmQSZAA8AGwAwAAAAMh4CFA4CIi4CND4BBCIOARQeATI%2BATQmBTMyFhURMzIWHQEUBisBIiY1ETQ2AePq1ptbW5vW6tabW1ubAb%2FoxXJyxejFcnL%2BfDIKD68KDw8K%2BgoPDwSZW5vW6tabW1ub1urWmztyxejFcnLF6MUNDwr%2B7Q8KMgoPDwoBXgoPAAAAAAL%2FnAAABRQEsAALAA8AACkBAyMDIQEzAzMDMwEDMwMFFP3mKfIp%2FeYBr9EVohTQ%2Fp4b4BsBkP5wBLD%2B1AEs%2FnD%2B1AEsAAAAAAIAZAAABLAEsAAVAC8AAAEzMhYVETMyFgcBBiInASY2OwERNDYBMzIWFREUBiMhIiY1ETQ2OwEyFh0BITU0NgImyBUdvxQLDf65DSYN%2FrkNCxS%2FHQJUMgoPDwr75goPDwoyCg8DhA8EsB0V%2Fj4XEP5wEBABkBAXAcIVHfzgDwr%2BogoPDwoBXgoPDwqvrwoPAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgUzMhYVETMyFgcDBiInAyY2OwERNDYB4%2BrWm1tbm9bq1ptbW5sBv%2BjFcnLF6MVycv58lgoPiRUKDd8NJg3fDQoViQ8EmVub1urWm1tbm9bq1ps7csXoxXJyxejFDQ8K%2Fu0XEP7tEBABExAXARMKDwAAAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JiUTFgYrAREUBisBIiY1ESMiJjcTNjIB4%2BrWm1tbm9bq1ptbW5sBv%2BjFcnLF6MVycv7n3w0KFYkPCpYKD4kVCg3fDSYEmVub1urWm1tbm9bq1ps7csXoxXJyxejFAf7tEBf%2B7QoPDwoBExcQARMQAAAAAAIAAAAABLAEsAAZADkAABMhMhYXExYVERQGBwYjISImJyY1EzQ3Ez4BBSEiBgcDBhY7ATIWHwEeATsBMjY%2FAT4BOwEyNicDLgHhAu4KEwO6BwgFDBn7tAweAgYBB7kDEwKX%2FdQKEgJXAgwKlgoTAiYCEwr6ChMCJgITCpYKDAJXAhIEsA4K%2FXQYGf5XDB4CBggEDRkBqRkYAowKDsgOC%2F4%2BCw4OCpgKDg4KmAoODgsBwgsOAAMAFwAXBJkEmQAPABsAJwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgUXFhQPAQYmNRE0NgHj6tabW1ub1urWm1tbmwG%2F6MVycsXoxXJy%2Fov9ERH9EBgYBJlbm9bq1ptbW5vW6tabO3LF6MVycsXoxV2%2BDCQMvgwLFQGQFQsAAQAXABcEmQSwACgAAAE3NhYVERQGIyEiJj8BJiMiDgEUHgEyPgE1MxQOAiIuAjQ%2BAjMyA7OHBwsPCv6WCwQHhW2BdMVycsXoxXKWW5vW6tabW1ub1nXABCSHBwQL%2FpYKDwsHhUxyxejFcnLFdHXWm1tbm9bq1ptbAAAAAAIAFwABBJkEsAAaADUAAAE3NhYVERQGIyEiJj8BJiMiDgEVIzQ%2BAjMyEzMUDgIjIicHBiY1ETQ2MyEyFg8BFjMyPgEDs4cHCw8L%2FpcLBAeGboF0xXKWW5vWdcDrllub1nXAnIYHCw8LAWgKBQiFboJ0xXIEJIcHBAv%2BlwsPCweGS3LFdHXWm1v9v3XWm1t2hggFCgFoCw8LB4VMcsUAAAAKAGQAAASwBLAADwAfAC8APwBPAF8AbwB%2FAI8AnwAAEyEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0NgczMhYdARQGKwEiJj0BNDYzITIWHQEUBiMhIiY9ATQ2BzMyFh0BFAYrASImPQE0NjMhMhYdARQGIyEiJj0BNDYHMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0Nn0EGgoPDwr75goPDwPA%2FK4KDw8KA1IKDw%2F9CDIKDw8KMgoPD9IBwgoPDwr%2BPgoPD74yCg8PCjIKDw%2FSAcIKDw8K%2Fj4KDw%2B%2BMgoPDwoyCg8P0gHCCg8PCv4%2BCg8PvjIKDw8KMgoPD9IBwgoPDwr%2BPgoPDwSwDwr7ggoPDwoEfgoPyA8K%2FK4KDw8KA1IKD2QPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKDwAAAAACAAAAAARMBLAAGQAjAAABNTQmIyEiBh0BIyIGFREUFjMhMjY1ETQmIyE1NDY7ATIWHQEDhHVT%2FtRSdmQpOzspA4QpOzsp%2FageFMgUHgMgyFN1dlLIOyn9qCk7OykCWCk7lhUdHRWWAAIAZAAABEwETAAJADcAABMzMhYVESMRNDYFMhcWFREUBw4DIyIuAScuAiMiBwYjIicmNRE%2BATc2HgMXHgIzMjc2fTIKD2QPA8AEBRADIUNAMRwaPyonKSxHHlVLBwgGBQ4WeDsXKC4TOQQpLUUdZ1AHBEwPCvvNBDMKDzACBhH%2BWwYGO1AkDQ0ODg8PDzkFAwcPAbY3VwMCAwsGFAEODg5XCAAAAwAAAAAEsASXACEAMQBBAAAAMh4CFREUBisBIiY1ETQuASAOARURFAYrASImNRE0PgEDMzIWFREUBisBIiY1ETQ2ITMyFhURFAYrASImNRE0NgHk6N6jYw8KMgoPjeT%2B%2BuSNDwoyCg9joyqgCAwMCKAIDAwCYKAIDAwIoAgMDASXY6PedP7UCg8PCgEsf9FyctF%2F%2FtQKDw8KASx03qP9wAwI%2FjQIDAwIAcwIDAwI%2FjQIDAwIAcwIDAAAAAACAAAA0wRHA90AFQA5AAABJTYWFREUBiclJisBIiY1ETQ2OwEyBTc2Mh8BFhQPARcWFA8BBiIvAQcGIi8BJjQ%2FAScmND8BNjIXAUEBAgkMDAn%2B%2FhUZ%2BgoPDwr6GQJYeAcUByIHB3h4BwciBxQHeHgHFAciBwd3dwcHIgcUBwMurAYHCv0SCgcGrA4PCgFeCg%2BEeAcHIgcUB3h4BxQHIgcHd3cHByIHFAd4eAcUByIICAAAAAACAAAA0wNyA90AFQAvAAABJTYWFREUBiclJisBIiY1ETQ2OwEyJTMWFxYVFAcGDwEiLwEuATc2NTQnJjY%2FATYBQQECCQwMCf7%2BFRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcDLqwGBwr9EgoHBqwODwoBXgoPZAEJgaGafwkBAQYXBxMIZ36EaggUBxYFAAAAAAMAAADEBGID7AAbADEASwAAATMWFxYVFAYHBgcjIi8BLgE3NjU0JicmNj8BNgUlNhYVERQGJyUmKwEiJjURNDY7ATIlMxYXFhUUBwYPASIvAS4BNzY1NCcmNj8BNgPHAwsGh0RABwoDCQcqCAIGbzs3BgIJKgf9ggECCQwMCf7%2BFRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcD7AEJs9lpy1QJAQYiBhQIlrJarEcJFAYhBb6sBgcK%2FRIKBwasDg8KAV4KD2QBCYGhmn8JAQEGFwcTCGd%2BhGoIFQYWBQAAAAANAAAAAASwBLAACQAVABkAHQAhACUALQA7AD8AQwBHAEsATwAAATMVIxUhFSMRIQEjFTMVIREjESM1IQURIREhESERBSM1MwUjNTMBMxEhETM1MwEzFSMVIzUjNTM1IzUhBREhEQcjNTMFIzUzASM1MwUhNSEB9GRk%2FnBkAfQCvMjI%2FtTIZAJY%2B7QBLAGQASz84GRkArxkZP1EyP4MyGQB9MhkyGRkyAEs%2FUQBLGRkZAOEZGT%2BDGRkAfT%2B1AEsA4RkZGQCWP4MZMgBLAEsyGT%2B1AEs%2FtQBLMhkZGT%2BDP4MAfRk%2FtRkZGRkyGTI%2FtQBLMhkZGT%2B1GRkZAAAAAAJAAAAAASwBLAAAwAHAAsADwATABcAGwAfACMAADcjETMTIxEzASMRMxMjETMBIxEzASE1IRcjNTMXIzUzBSM1M2RkZMhkZAGQyMjIZGQBLMjI%2FOD%2B1AEsyGRkyGRkASzIyMgD6PwYA%2Bj8GAPo%2FBgD6PwYA%2Bj7UGRkW1tbW1sAAAIAAAAKBKYEsAANABUAAAkBFhQHAQYiJwETNDYzBCYiBhQWMjYB9AKqCAj%2BMAgUCP1WAQ8KAUM7Uzs7UzsEsP1WCBQI%2FjAICAKqAdsKD807O1Q7OwAAAAADAAAACgXSBLAADQAZACEAAAkBFhQHAQYiJwETNDYzIQEWFAcBBiIvAQkBBCYiBhQWMjYB9AKqCAj%2BMAgUCP1WAQ8KAwYCqggI%2FjAIFAg4Aaj9RP7TO1M7O1M7BLD9VggUCP4wCAgCqgHbCg%2F9VggUCP4wCAg4AaoCvM07O1Q7OwAAAAABAGQAAASwBLAAJgAAASEyFREUDwEGJjURNCYjISIPAQYWMyEyFhURFAYjISImNRE0PwE2ASwDOUsSQAgKDwr9RBkSQAgFCgK8Cg8PCvyuCg8SixIEsEv8fBkSQAgFCgO2Cg8SQAgKDwr8SgoPDwoDzxkSixIAAAABAMj%2F%2FwRMBLAACgAAEyEyFhURCQERNDb6AyAVHf4%2B%2Fj4dBLAdFfuCAbz%2BQwR%2FFR0AAAAAAwAAAAAEsASwABUARQBVAAABISIGBwMGHwEeATMhMjY%2FATYnAy4BASMiBg8BDgEjISImLwEuASsBIgYVERQWOwEyNj0BNDYzITIWHQEUFjsBMjY1ETQmASEiBg8BBhYzITI2LwEuAQM2%2FkQLEAFOBw45BhcKAcIKFwY%2BDgdTARABVpYKFgROBBYK%2FdoKFgROBBYKlgoPDwqWCg8PCgLuCg8PCpYKDw%2F%2Bsf4MChMCJgILCgJYCgsCJgITBLAPCv7TGBVsCQwMCWwVGAEtCg%2F%2BcA0JnAkNDQmcCQ0PCv12Cg8PCpYKDw8KlgoPDwoCigoP%2FagOCpgKDg4KmAoOAAAAAAQAAABkBLAETAAdACEAKQAxAAABMzIeAh8BMzIWFREUBiMhIiY1ETQ2OwE%2BBAEVMzUEIgYUFjI2NCQyFhQGIiY0AfTIOF00JAcGlik7Oyn8GCk7OymWAgknM10ByGT%2Bz76Hh76H%2Fu9WPDxWPARMKTs7FRQ7Kf2oKTs7KQJYKTsIG0U1K%2F7UZGRGh76Hh74IPFY8PFYAAAAAAgA1AAAEsASvACAAIwAACQEWFx4BHwEVITUyNi8BIQYHBh4CMxUhNTY3PgE%2FAQEDIQMCqQGBFCgSJQkK%2Fl81LBFS%2Fnk6IgsJKjIe%2FpM4HAwaBwcBj6wBVKIEr%2FwaMioTFQECQkJXLd6RWSIuHAxCQhgcDCUNDQPu%2FVoByQAAAAADAGQAAAPwBLAAJwAyADsAAAEeBhUUDgMjITU%2BATURNC4EJzUFMh4CFRQOAgclMzI2NTQuAisBETMyNjU0JisBAvEFEzUwOyodN1htbDD%2BDCk7AQYLFyEaAdc5dWM%2BHy0tEP6Pi05pESpTPnbYUFJ9Xp8CgQEHGB0zOlIuQ3VONxpZBzMoAzsYFBwLEAkHRwEpSXNDM1s6KwkxYUopOzQb%2FK5lUFqBAAABAMgAAANvBLAAGQAAARcOAQcDBhYXFSE1NjcTNjQuBCcmJzUDbQJTQgeECSxK%2Fgy6Dq0DAw8MHxUXDQYEsDkTNSj8uTEoBmFhEFIDQBEaExAJCwYHAwI5AAAAAAL%2FtQAABRQEsAAlAC8AAAEjNC4FKwERFBYfARUhNTI%2BAzURIyIOBRUjESEFIxEzByczESM3BRQyCAsZEyYYGcgyGRn%2BcAQOIhoWyBkYJhMZCwgyA%2Bj7m0tLfX1LS30DhBUgFQ4IAwH8rhYZAQJkZAEFCRUOA1IBAwgOFSAVASzI%2FOCnpwMgpwACACH%2FtQSPBLAAJQAvAAABIzQuBSsBERQWHwEVITUyPgM1ESMiDgUVIxEhEwc1IRUnNxUhNQRMMggLGRMmGBnIMhkZ%2FnAEDiIaFsgZGCYTGQsIMgPoQ6f84KenAyADhBUgFQ4IAwH9dhYZAQJkZAEFCRUOAooBAwgOFSAVASz7gn1LS319S0sABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyAlgVHR0V%2FagVHR0VA%2BgVHR0V%2FBgVHR0VAyAVHR0V%2FOAVHR0VBEwVHR0V%2B7QVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYDITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NgMhMhYdARQGIyEiJj0BNDb6ArwVHR0V%2FUQVHR2zBEwVHR0V%2B7QVHR3dArwVHR0V%2FUQVHR2zBEwVHR0V%2B7QVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AAAE1NDYzITIWHQEUBiMhIiYBNTQ2MyEyFh0BFAYjISImEzU0NjMhMhYdARQGIyEiJgE1NDYzITIWHQEUBiMhIiYB9B0VAlgVHR0V%2FagVHf5wHRUD6BUdHRX8GBUdyB0VAyAVHR0V%2FOAVHf7UHRUETBUdHRX7tBUdA7ZkFR0dFWQVHR3%2B6WQVHR0VZBUdHf7pZBUdHRVkFR0d%2FulkFR0dFWQVHR0AAAQAAAAABLAETAAPAB8ALwA%2FAAATITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2MgRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dBEwdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdAAgAAAAABLAETAAPAB8ALwA%2FAE8AXwBvAH8AABMzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2MmQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR0ETB0VZBUdHRVkFR0dFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdHRVkFR0dFWQVHf7UHRVkFR0dFWQVHR0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0dFWQVHR0VZBUdAAAG%2F5wAAASwBEwAAwATACMAKgA6AEoAACEjETsCMhYdARQGKwEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2BQc1IzUzNQUhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2AZBkZJZkFR0dFWQVHR0VAfQVHR0V%2FgwVHR3%2B%2BqfIyAHCASwVHR0V%2FtQVHR0VAlgVHR0V%2FagVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR36fUtkS68dFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdAAAABgAAAAAFFARMAA8AEwAjACoAOgBKAAATMzIWHQEUBisBIiY9ATQ2ASMRMwEhMhYdARQGIyEiJj0BNDYFMxUjFSc3BSEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyZBUdHRVkFR0dA2dkZPyuAfQVHR0V%2FgwVHR0EL8jIp6f75gEsFR0dFf7UFR0dFQJYFR0dFf2oFR0dBEwdFWQVHR0VZBUd%2B7QETP7UHRVkFR0dFWQVHchkS319rx0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0AAAAAAgAAAMgEsAPoAA8AEgAAEyEyFhURFAYjISImNRE0NgkCSwLuHywsH%2F0SHywsBIT%2B1AEsA%2BgsH%2F12HywsHwKKHyz9RAEsASwAAwAAAAAEsARMAA8AFwAfAAATITIWFREUBiMhIiY1ETQ2FxE3BScBExEEMhYUBiImNCwEWBIaGhL7qBIaGkr3ASpKASXs%2FNJwTk5wTgRMGhL8DBIaGhID9BIaZP0ftoOcAT7%2B4AH0dE5vT09vAAAAAAIA2wAFBDYEkQAWAB4AAAEyHgEVFAcOAQ8BLgQnJjU0PgIWIgYUFjI2NAKIdcZzRkWyNjYJIV5YbSk8RHOft7eCgreCBJF4ynVzj23pPz4IIWZomEiEdVijeUjDgriBgbgAAAACABcAFwSZBJkADwAXAAAAMh4CFA4CIi4CND4BAREiDgEUHgEB4%2BrWm1tbm9bq1ptbW5sBS3TFcnLFBJlbm9bq1ptbW5vW6tab%2FG8DVnLF6MVyAAACAHUAAwPfBQ8AGgA1AAABHgYVFA4DBy4DNTQ%2BBQMOAhceBBcWNj8BNiYnLgInJjc2IyYCKhVJT1dOPiUzVnB9P1SbfEokP0xXUEm8FykoAwEbITEcExUWAgYCCQkFEikMGiACCAgFD0iPdXdzdYdFR4BeRiYEBTpjl1lFh3ZzeHaQ%2Ff4hS4I6JUEnIw4IBwwQIgoYBwQQQSlZtgsBAAAAAwAAAAAEywRsAAwAKgAvAAABNz4CHgEXHgEPAiUhMhcHISIGFREUFjMhMjY9ATcRFAYjISImNRE0NgkBBzcBA%2BhsAgYUFR0OFgoFBmz9BQGQMje7%2FpApOzspAfQpO8i7o%2F5wpbm5Azj%2BlqE3AWMD9XMBAgIEDw4WKgsKc8gNuzsp%2FgwpOzsptsj%2BtKW5uaUBkKW5%2Ftf%2BljKqAWMAAgAAAAAEkwRMABsANgAAASEGByMiBhURFBYzITI2NTcVFAYjISImNRE0NgUBFhQHAQYmJzUmDgMHPgY3NT4BAV4BaaQ0wyk7OykB9Ck7yLml%2FnClubkCfwFTCAj%2BrAcLARo5ZFRYGgouOUlARioTAQsETJI2Oyn%2BDCk7OymZZ6W5uaUBkKW5G%2F7TBxUH%2Fs4GBAnLAQINFjAhO2JBNB0UBwHSCgUAAAAAAgAAAAAEnQRMAB0ANQAAASEyFwchIgYVERQWMyEyNj0BNxUUBiMhIiY1ETQ2CQE2Mh8BFhQHAQYiLwEmND8BNjIfARYyAV4BXjxDsv6jKTs7KQH0KTvIuaX%2BcKW5uQHKAYsHFQdlBwf97QcVB%2FgHB2UHFQdvCBQETBexOyn%2BDCk7OylFyNulubmlAZCluf4zAYsHB2UHFQf97AcH%2BAcVB2UHB28HAAAAAQAKAAoEpgSmADsAAAkBNjIXARYGKwEVMzU0NhcBFhQHAQYmPQEjFTMyFgcBBiInASY2OwE1IxUUBicBJjQ3ATYWHQEzNSMiJgE%2BAQgIFAgBBAcFCqrICggBCAgI%2FvgICsiqCgUH%2FvwIFAj%2B%2BAgFCq%2FICgj%2B%2BAgIAQgICsivCgUDlgEICAj%2B%2BAgKyK0KBAf%2B%2FAcVB%2F73BwQKrcgKCP74CAgBCAgKyK0KBAcBCQcVBwEEBwQKrcgKAAEAyAAAA4QETAAZAAATMzIWFREBNhYVERQGJwERFAYrASImNRE0NvpkFR0B0A8VFQ%2F%2BMB0VZBUdHQRMHRX%2BSgHFDggV%2FBgVCA4Bxf5KFR0dFQPoFR0AAAABAAAAAASwBEwAIwAAEzMyFhURATYWFREBNhYVERQGJwERFAYnAREUBisBIiY1ETQ2MmQVHQHQDxUB0A8VFQ%2F%2BMBUP%2FjAdFWQVHR0ETB0V%2FkoBxQ4IFf5KAcUOCBX8GBUIDgHF%2FkoVCA4Bxf5KFR0dFQPoFR0AAAABAJ0AGQSwBDMAFQAAAREUBicBERQGJwEmNDcBNhYVEQE2FgSwFQ%2F%2BMBUP%2FhQPDwHsDxUB0A8VBBr8GBUIDgHF%2FkoVCA4B4A4qDgHgDggV%2FkoBxQ4IAAAAAQDIABYEMwQ2AAsAABMBFhQHAQYmNRE0NvMDLhIS%2FNISGRkEMv4OCx4L%2Fg4LDhUD6BUOAAIAyABkA4QD6AAPAB8AABMzMhYVERQGKwEiJjURNDYhMzIWFREUBisBIiY1ETQ2%2BsgVHR0VyBUdHQGlyBUdHRXIFR0dA%2BgdFfzgFR0dFQMgFR0dFfzgFR0dFQMgFR0AAAEAyABkBEwD6AAPAAABERQGIyEiJjURNDYzITIWBEwdFfzgFR0dFQMgFR0DtvzgFR0dFQMgFR0dAAAAAAEAAAAZBBMEMwAVAAABETQ2FwEWFAcBBiY1EQEGJjURNDYXAfQVDwHsDw%2F%2BFA8V%2FjAPFRUPAmQBthUIDv4gDioO%2FiAOCBUBtv47DggVA%2BgVCA4AAAH%2F%2FgACBLMETwAjAAABNzIWFRMUBiMHIiY1AwEGJjUDAQYmNQM0NhcBAzQ2FwEDNDYEGGQUHgUdFWQVHQL%2BMQ4VAv4yDxUFFQ8B0gIVDwHSAh0ETgEdFfwYFR0BHRUBtf46DwkVAbX%2BOQ4JFAPoFQkP%2Fj4BthQJDv49AbYVHQAAAQEsAAAD6ARMABkAAAEzMhYVERQGKwEiJjURAQYmNRE0NhcBETQ2A1JkFR0dFWQVHf4wDxUVDwHQHQRMHRX8GBUdHRUBtv47DggVA%2BgVCA7%2BOwG2FR0AAAIAZADIBLAESAALABsAAAkBFgYjISImNwE2MgEhMhYdARQGIyEiJj0BNDYCrgH1DwkW%2B%2B4WCQ8B9Q8q%2FfcD6BUdHRX8GBUdHQQ5%2FeQPFhYPAhwP%2FUgdFWQVHR0VZBUdAAEAiP%2F8A3UESgAFAAAJAgcJAQN1%2FqABYMX92AIoA4T%2Bn%2F6fxgIoAiYAAAAAAQE7%2F%2FwEKARKAAUAAAkBJwkBNwQo%2FdnGAWH%2Bn8YCI%2F3ZxgFhAWHGAAIAFwAXBJkEmQAPADMAAAAyHgIUDgIiLgI0PgEFIyIGHQEjIgYdARQWOwEVFBY7ATI2PQEzMjY9ATQmKwE1NCYB4%2BrWm1tbm9bq1ptbW5sBfWQVHZYVHR0Vlh0VZBUdlhUdHRWWHQSZW5vW6tabW1ub1urWm7odFZYdFWQVHZYVHR0Vlh0VZBUdlhUdAAAAAAIAFwAXBJkEmQAPAB8AAAAyHgIUDgIiLgI0PgEBISIGHQEUFjMhMjY9ATQmAePq1ptbW5vW6tabW1ubAkX%2BDBUdHRUB9BUdHQSZW5vW6tabW1ub1urWm%2F5%2BHRVkFR0dFWQVHQACABcAFwSZBJkADwAzAAAAMh4CFA4CIi4CND4BBCIPAScmIg8BBhQfAQcGFB8BFjI%2FARcWMj8BNjQvATc2NC8BAePq1ptbW5vW6tabW1ubAeUZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0JCXh4CQmNBJlbm9bq1ptbW5vW6tabrQl4eAkJjQkZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0AAgAXABcEmQSZAA8AJAAAADIeAhQOAiIuAjQ%2BAQEnJiIPAQYUHwEWMjcBNjQvASYiBwHj6tabW1ub1urWm1tbmwEVVAcVCIsHB%2FIHFQcBdwcHiwcVBwSZW5vW6tabW1ub1urWm%2F4xVQcHiwgUCPEICAF3BxUIiwcHAAAAAAMAFwAXBJkEmQAPADsASwAAADIeAhQOAiIuAjQ%2BAQUiDgMVFDsBFjc%2BATMyFhUUBgciDgUHBhY7ATI%2BAzU0LgMTIyIGHQEUFjsBMjY9ATQmAePq1ptbW5vW6tabW1ubAT8dPEIyIRSDHgUGHR8UFw4TARkOGhITDAIBDQ6tBx4oIxgiM0Q8OpYKDw8KlgoPDwSZW5vW6tabW1ub1urWm5ELHi9PMhkFEBQQFRIXFgcIBw4UHCoZCBEQKDhcNi9IKhsJ%2FeMPCpYKDw8KlgoPAAADABcAFwSZBJkADwAfAD4AAAAyHgIUDgIiLgI0PgEFIyIGHQEUFjsBMjY9ATQmAyMiBh0BFBY7ARUjIgYdARQWMyEyNj0BNCYrARE0JgHj6tabW1ub1urWm1tbmwGWlgoPDwqWCg8PCvoKDw8KS0sKDw8KAV4KDw8KSw8EmVub1urWm1tbm9bq1ptWDwqWCg8PCpYKD%2F7UDwoyCg%2FIDwoyCg8PCjIKDwETCg8AAgAAAAAEsASwAC8AXwAAATMyFh0BHgEXMzIWHQEUBisBDgEHFRQGKwEiJj0BLgEnIyImPQE0NjsBPgE3NTQ2ExUUBisBIiY9AQ4BBzMyFh0BFAYrAR4BFzU0NjsBMhYdAT4BNyMiJj0BNDY7AS4BAg2WCg9nlxvCCg8PCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw%2B5DwqWCg9EZheoCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmBLAPCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw8KlgoPZ5cbwgoP%2Fs2oCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmRA8KlgoPRGYAAwAXABcEmQSZAA8AGwA%2FAAAAMh4CFA4CIi4CND4BBCIOARQeATI%2BATQmBxcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyAePq1ptbW5vW6tabW1ubAb%2FoxXJyxejFcnKaQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwdABxUHfHwHFQSZW5vW6tabW1ub1urWmztyxejFcnLF6MVaQAcVB3x8BxUHQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwAAAAMAFwAXBJkEmQAPABsAMAAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgcXFhQHAQYiLwEmND8BNjIfATc2MgHj6tabW1ub1urWm1tbmwG%2F6MVycsXoxXJyg2oHB%2F7ACBQIyggIagcVB0%2FFBxUEmVub1urWm1tbm9bq1ps7csXoxXJyxejFfWoHFQf%2BvwcHywcVB2oICE%2FFBwAAAAMAFwAXBJkEmQAPABgAIQAAADIeAhQOAiIuAjQ%2BAQUiDgEVFBcBJhcBFjMyPgE1NAHj6tabW1ub1urWm1tbmwFLdMVyQQJLafX9uGhzdMVyBJlbm9bq1ptbW5vW6tabO3LFdHhpAktB0P24PnLFdHMAAAAAAQAXAFMEsAP5ABUAABMBNhYVESEyFh0BFAYjIREUBicBJjQnAgoQFwImFR0dFf3aFxD99hACRgGrDQoV%2Ft0dFcgVHf7dFQoNAasNJgAAAAABAAAAUwSZA%2FkAFQAACQEWFAcBBiY1ESEiJj0BNDYzIRE0NgJ%2FAgoQEP32EBf92hUdHRUCJhcD8f5VDSYN%2FlUNChUBIx0VyBUdASMVCgAAAAEAtwAABF0EmQAVAAAJARYGIyERFAYrASImNREhIiY3ATYyAqoBqw0KFf7dHRXIFR3%2B3RUKDQGrDSYEif32EBf92hUdHRUCJhcQAgoQAAAAAQC3ABcEXQSwABUAAAEzMhYVESEyFgcBBiInASY2MyERNDYCJsgVHQEjFQoN%2FlUNJg3%2BVQ0KFQEjHQSwHRX92hcQ%2FfYQEAIKEBcCJhUdAAABAAAAtwSZBF0AFwAACQEWFAcBBiY1EQ4DBz4ENxE0NgJ%2FAgoQEP32EBdesKWBJAUsW4fHfhcEVf5VDSYN%2FlUNChUBIwIkRHVNabGdcUYHAQYVCgACAAAAAASwBLAAFQArAAABITIWFREUBi8BBwYiLwEmND8BJyY2ASEiJjURNDYfATc2Mh8BFhQPARcWBgNSASwVHRUOXvkIFAhqBwf5Xg4I%2FiH%2B1BUdFQ5e%2BQgUCGoHB%2FleDggEsB0V%2FtQVCA5e%2BQcHaggUCPleDhX7UB0VASwVCA5e%2BQcHaggUCPleDhUAAAACAEkASQRnBGcAFQArAAABFxYUDwEXFgYjISImNRE0Nh8BNzYyASEyFhURFAYvAQcGIi8BJjQ%2FAScmNgP2agcH%2BV4OCBX%2B1BUdFQ5e%2BQgU%2FQwBLBUdFQ5e%2BQgUCGoHB%2FleDggEYGoIFAj5Xg4VHRUBLBUIDl75B%2F3xHRX%2B1BUIDl75BwdqCBQI%2BV4OFQAAAAADABcAFwSZBJkADwAfAC8AAAAyHgIUDgIiLgI0PgEFIyIGFxMeATsBMjY3EzYmAyMiBh0BFBY7ATI2PQE0JgHj6tabW1ub1urWm1tbmwGz0BQYBDoEIxQ2FCMEOgQYMZYKDw8KlgoPDwSZW5vW6tabW1ub1urWm7odFP7SFB0dFAEuFB3%2BDA8KlgoPDwqWCg8AAAAABQAAAAAEsASwAEkAVQBhAGgAbwAAATIWHwEWHwEWFxY3Nj8BNjc2MzIWHwEWHwIeATsBMhYdARQGKwEiBh0BIREjESE1NCYrASImPQE0NjsBMjY1ND8BNjc%2BBAUHBhY7ATI2LwEuAQUnJgYPAQYWOwEyNhMhIiY1ESkBERQGIyERAQQJFAUFFhbEFQ8dCAsmxBYXERUXMA0NDgQZCAEPCj0KDw8KMgoP%2FnDI%2FnAPCjIKDw8KPQsOCRkFDgIGFRYfAp2mBwQK2woKAzMDEP41sQgQAzMDCgrnCwMe%2FokKDwGQAlgPCv6JBLAEAgIKDXYNCxUJDRZ2DQoHIREQFRh7LAkLDwoyCg8PCq8BLP7UrwoPDwoyCg8GBQQwgBkUAwgWEQ55ogcKDgqVCgSqnQcECo8KDgr8cg8KAXf%2BiQoPAZAAAAAAAgAAAAwErwSmACsASQAAATYWFQYCDgQuAScmByYOAQ8BBiY1NDc%2BATc%2BAScuAT4BNz4GFyYGBw4BDwEOBAcOARY2Nz4CNz4DNz4BBI0IGgItQmxhi2KORDg9EQQRMxuZGhYqCFUYEyADCQIQOjEnUmFch3vAJQgdHyaiPT44XHRZUhcYDhItIRmKcVtGYWtbKRYEBKYDEwiy%2Ft3IlVgxEQgLCwwBAQIbG5kYEyJAJghKFRE8Hzdff4U%2FM0o1JSMbL0QJGCYvcSEhHjZST2c1ODwEJygeW0AxJUBff1UyFAABAF0AHgRyBM8ATwAAAQ4BHgQXLgc%2BATceAwYHDgQHBicmNzY3PgQuAScWDgMmJy4BJyY%2BBDcGHgM3PgEuAicmPgMCjScfCic4R0IgBBsKGAoQAwEJEg5gikggBhANPkpTPhZINx8SBgsNJysiCRZOQQoVNU1bYC9QZwICBAUWITsoCAYdJzIYHw8YIiYHDyJJYlkEz0OAZVxEOSQMBzgXOB42IzElKRIqg5Gnl0o3Z0c6IAYWCwYNAwQFIDhHXGF1OWiqb0sdBxUknF0XNTQ8PEUiNWNROBYJDS5AQVUhVZloUSkAAAAAA%2F%2FcAGoE1ARGABsAPwBRAAAAMh4FFA4FIi4FND4EBSYGFxYVFAYiJjU0NzYmBwYHDgEXHgQyPgM3NiYnJgUHDgEXFhcWNj8BNiYnJicuAQIGpJ17bk85HBw6T257naKde25POhwcOU9uewIPDwYIGbD4sBcIBw5GWg0ECxYyWl%2BDiINfWjIWCwQMWv3%2FIw8JCSU4EC0OIw4DDywtCyIERi1JXGJcSSpJXGJcSS0tSVxiXEkqSVxiXEncDwYTOT58sLB8OzcTBg9FcxAxEiRGXkQxMEVeRSQSMRF1HiQPLxJEMA0EDyIPJQ8sSRIEAAAABP%2FcAAAE1ASwABQAJwA7AEwAACEjNy4ENTQ%2BBTMyFzczEzceARUUDgMHNz4BNzYmJyYlBgcOARceBBc3LgE1NDc2JhcHDgEXFhcWNj8CJyYnLgECUJQfW6l2WSwcOU9ue51SPUEglCYvbIknUGqYUi5NdiYLBAw2%2FVFGWg0ECxIqSExoNSlrjxcIB3wjDwkJJTgQLQ4MFgMsLQsieBRhdHpiGxVJXGJcSS0Pef5StVXWNBpacm5jGq0xiD8SMRFGckVzEDESHjxRQTkNmhKnbjs3EwZwJA8vEkQwDQQPC1YELEkSBAAAAAP%2FngAABRIEqwALABgAKAAAJwE2FhcBFgYjISImJSE1NDY7ATIWHQEhAQczMhYPAQ4BKwEiJi8BJjZaAoIUOBQCghUbJfryJRsBCgFZDwqWCg8BWf5DaNAUGAQ6BCMUNhQjBDoEGGQEKh8FIfvgIEdEhEsKDw8KSwLT3x0U%2FBQdHRT8FB0AAAABAGQAFQSwBLAAKAAAADIWFREBHgEdARQGJyURFh0BFAYvAQcGJj0BNDcRBQYmPQE0NjcBETQCTHxYAWsPFhgR%2FplkGhPNzRMaZP6ZERgWDwFrBLBYPv6t%2FrsOMRQpFA0M%2Bf75XRRAFRAJgIAJEBVAFF0BB%2FkMDRQpFDEOAUUBUz4AAAARAAAAAARMBLAAHQAnACsALwAzADcAOwA%2FAEMARwBLAE8AUwBXAFsAXwBjAAABMzIWHQEzMhYdASE1NDY7ATU0NjsBMhYdASE1NDYBERQGIyEiJjURFxUzNTMVMzUzFTM1MxUzNTMVMzUFFTM1MxUzNTMVMzUzFTM1MxUzNQUVMzUzFTM1MxUzNTMVMzUzFTM1A1JkFR0yFR37tB0VMh0VZBUdAfQdAQ8dFfwYFR1kZGRkZGRkZGRk%2FHxkZGRkZGRkZGT8fGRkZGRkZGRkZASwHRUyHRWWlhUdMhUdHRUyMhUd%2FnD9EhUdHRUC7shkZGRkZGRkZGRkyGRkZGRkZGRkZGTIZGRkZGRkZGRkZAAAAAMAAAAZBXcElwAZACUANwAAARcWFA8BBiY9ASMBISImPQE0NjsBATM1NDYBBycjIiY9ATQ2MyEBFxYUDwEGJj0BIyc3FzM1NDYEb%2FkPD%2FkOFZ%2F9qP7dFR0dFdECWPEV%2FamNetEVHR0VASMDGvkPD%2FkOFfG1jXqfFQSN5g4qDuYOCBWW%2FagdFWQVHQJYlhUI%2FpiNeh0VZBUd%2Fk3mDioO5g4IFZa1jXqWFQgAAAABAAAAAASwBEwAEgAAEyEyFhURFAYjIQERIyImNRE0NmQD6Ck7Oyn9rP7QZCk7OwRMOyn9qCk7%2FtQBLDspAlgpOwAAAAMAZAAABEwEsAAJABMAPwAAEzMyFh0BITU0NiEzMhYdASE1NDYBERQOBSIuBTURIRUUFRwBHgYyPgYmNTQ9AZbIFR3%2B1B0C0cgVHf7UHQEPBhgoTGacwJxmTCgYBgEsAwcNFB8nNkI2Jx8TDwUFAQSwHRX6%2BhUdHRX6%2BhUd%2FnD%2B1ClJalZcPigoPlxWakkpASz6CRIVKyclIRsWEAgJEBccISUnKhURCPoAAAAB%2F%2F8A1ARMA8IABQAAAQcJAScBBEzG%2Fp%2F%2Bn8UCJwGbxwFh%2Fp%2FHAicAAQAAAO4ETQPcAAUAAAkCNwkBBE392v3ZxgFhAWEDFf3ZAifH%2Fp8BYQAAAAAC%2F1EAZAVfA%2BgAFAApAAABITIWFREzMhYPAQYiLwEmNjsBESElFxYGKwERIRchIiY1ESMiJj8BNjIBlALqFR2WFQgO5g4qDuYOCBWW%2FoP%2BHOYOCBWWAYHX%2FRIVHZYVCA7mDioD6B0V%2FdkVDvkPD%2FkOFQGRuPkOFf5wyB0VAiYVDvkPAAABAAYAAASeBLAAMAAAEzMyFh8BITIWBwMOASMhFyEyFhQGKwEVFAYiJj0BIRUUBiImPQEjIiYvAQMjIiY0NjheERwEJgOAGB4FZAUsIf2HMAIXFR0dFTIdKh3%2B1B0qHR8SHQYFyTYUHh4EsBYQoiUY%2FiUVK8gdKh0yFR0dFTIyFR0dFTIUCQoDwR0qHQAAAAACAAAAAASwBEwACwAPAAABFSE1MzQ2MyEyFhUFIREhBLD7UMg7KQEsKTv9RASw%2B1AD6GRkKTs7Kcj84AACAAAAAAXcBEwADAAQAAATAxEzNDYzITIWFSEVBQEhAcjIyDspASwqOgH0ASz%2B1PtQASwDIP5wAlgpOzspyGT9RAK8AAEBRQAAA2sErwAbAAABFxYGKwERMzIWDwEGIi8BJjY7AREjIiY%2FATYyAnvmDggVlpYVCA7mDioO5g4IFZaWFQgO5g4qBKD5DhX9pxUO%2BQ8P%2BQ4VAlkVDvkPAAAAAQABAUQErwNrABsAAAEXFhQPAQYmPQEhFRQGLwEmND8BNhYdASE1NDYDqPkODvkPFf2oFQ%2F5Dg75DxUCWBUDYOUPKQ%2FlDwkUl5cUCQ%2FlDykP5Q8JFZWVFQkAAAAEAAAAAASwBLAACQAZAB0AIQAAAQMuASMhIgYHAwUhIgYdARQWMyEyNj0BNCYFNTMVMzUzFQSRrAUkFP1gFCQFrAQt%2FBgpOzspA%2BgpOzv%2Bq2RkZAGQAtwXLSgV%2FR1kOylkKTs7KWQpO8hkZGRkAAAAA%2F%2BcAGQEsARMAAsAIwAxAAAAMhYVERQGIiY1ETQDJSMTFgYjIisBIiYnAj0BNDU0PgE7ASUBFSIuAz0BND4CNwRpKh0dKh1k%2FV0mLwMRFQUCVBQdBDcCCwzIAqP8GAQOIhoWFR0dCwRMHRX8rhUdHRUDUhX8mcj%2B7BAIHBUBUQ76AgQQDw36%2FtT6AQsTKRwyGigUDAEAAAACAEoAAARmBLAALAA1AAABMzIWDwEeARcTFzMyFhQGBw4EIyIuBC8BLgE0NjsBNxM%2BATcnJjYDFjMyNw4BIiYCKV4UEgYSU3oPP3YRExwaEggeZGqfTzl0XFU%2BLwwLEhocExF2Pw96UxIGEyQyNDUxDDdGOASwFRMlE39N%2FrmtHSkoBwQLHBYSCg4REg4FBAgoKR2tAUdNfhQgExr7vgYGMT09AAEAFAAUBJwEnAAXAAABNwcXBxcHFycHJwcnBzcnNyc3Jxc3FzcDIOBO6rS06k7gLZubLeBO6rS06k7gLZubA7JO4C2bmy3gTuq0tOpO4C2bmy3gTuq0tAADAAAAZASwBLAAIQAtAD0AAAEzMhYdAQchMhYdARQHAw4BKwEiJi8BIyImNRE0PwI%2BARcPAREzFzMTNSE3NQEzMhYVERQGKwEiJjURNDYCijIoPBwBSCg8He4QLBf6B0YfHz0tNxSRYA0xG2SWZIjW%2Bv4%2BMv12ZBUdHRVkFR0dBLBRLJZ9USxkLR3%2BqBghMhkZJCcBkCQbxMYcKGTU1f6JZAF3feGv%2FtQdFf4MFR0dFQH0FR0AAAAAAwAAAAAEsARMACAAMAA8AAABMzIWFxMWHQEUBiMhFh0BFAYrASImLwImNRE0NjsBNgUzMhYVERQGKwEiJjURNDYhByMRHwEzNSchNQMCWPoXLBDuHTwo%2FrgcPCgyGzENYJEUNy09fP3pZBUdHRVkFR0dAl%2BIZJZkMjIBwvoETCEY%2FqgdLWQsUXYHlixRKBzGxBskAZAnJGRkHRX%2BDBUdHRUB9BUdZP6J1dSv4X0BdwADAAAAZAUOBE8AGwA3AEcAAAElNh8BHgEPASEyFhQGKwEDDgEjISImNRE0NjcXERchEz4BOwEyNiYjISoDLgQnJj8BJwUzMhYVERQGKwEiJjURNDYBZAFrHxZuDQEMVAEuVGxuVGqDBhsP%2FqoHphwOOmQBJYMGGw%2FLFRMSFv44AgoCCQMHAwUDAQwRklb9T2QVHR0VZBUdHQNp5hAWcA0mD3lMkE7%2BrRUoog0CDRElCkj%2BCVkBUxUoMjIBAgIDBQIZFrdT5B0V%2FgwVHR0VAfQVHQAAAAP%2FnABkBLAETwAdADYARgAAAQUeBBURFAYjISImJwMjIiY0NjMhJyY2PwE2BxcWBw4FKgIjIRUzMhYXEyE3ESUFMzIWFREUBisBIiY1ETQ2AdsBbgIIFBANrAf%2Bqg8bBoNqVW1sVAEuVQsBDW4WSpIRDAIDBQMHAwkDCgH%2BJd0PHAaCASZq%2FqoCUGQVHR0VZBUdHQRP5gEFEBEXC%2F3zDaIoFQFTTpBMeQ8mDXAWrrcWGQIFAwICAWQoFf6tWQH37OQdFf4MFR0dFQH0FR0AAAADAGEAAARMBQ4AGwA3AEcAAAAyFh0BBR4BFREUBiMhIiYvAQMmPwE%2BAR8BETQXNTQmBhURHAMOBAcGLwEHEyE3ESUuAQMhMhYdARQGIyEiJj0BNDYB3pBOAVMVKKIN%2FfMRJQoJ5hAWcA0mD3nGMjIBAgIDBQIZFrdT7AH3Wf6tFSiWAfQVHR0V%2FgwVHR0FDm5UaoMGGw%2F%2BqgemHA4OAWsfFm4NAQxUAS5U1ssVExIW%2FjgCCgIJAwcDBQMBDBGSVv6tZAElgwYb%2FQsdFWQVHR0VZBUdAAP%2F%2FQAGA%2BgFFAAPAC0ASQAAASEyNj0BNCYjISIGHQEUFgEVFAYiJjURBwYmLwEmNxM%2BBDMhMhYVERQGBwEDFzc2Fx4FHAIVERQWNj0BNDY3JREnAV4B9BUdHRX%2BDBUdHQEPTpBMeQ8mDXAWEOYBBRARFwsCDQ2iKBX9iexTtxYZAgUDAgIBMjIoFQFTWQRMHRVkFR0dFWQVHfzmalRubFQBLlQMAQ1uFh8BawIIEw8Mpgf%2Bqg8bBgHP%2Fq1WkhEMAQMFAwcDCQIKAv44FhITFcsPGwaDASVkAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBJSYGHQEhIgYdARQWMyEVFBY3JTY0AeLs1ptbW5vW7NabW1ubAob%2B7RAX%2Fu0KDw8KARMXEAETEASaW5vW7NabW1ub1uzWm%2F453w0KFYkPCpYKD4kVCg3fDSYAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgENAQYUFwUWNj0BITI2PQE0JiMhNTQmAeLs1ptbW5vW7NabW1ubASX%2B7RAQARMQFwETCg8PCv7tFwSaW5vW7NabW1ub1uzWm%2BjfDSYN3w0KFYkPCpYKD4kVCgAAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBAyYiBwMGFjsBERQWOwEyNjURMzI2AeLs1ptbW5vW7NabW1ubAkvfDSYN3w0KFYkPCpYKD4kVCgSaW5vW7NabW1ub1uzWm%2F5AARMQEP7tEBf%2B7QoPDwoBExcAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEFIyIGFREjIgYXExYyNxM2JisBETQmAeLs1ptbW5vW7NabW1ubAZeWCg%2BJFQoN3w0mDd8NChWJDwSaW5vW7NabW1ub1uzWm7sPCv7tFxD%2B7RAQARMQFwETCg8AAAMAGAAYBJgEmAAPAJYApgAAADIeAhQOAiIuAjQ%2BASUOAwcGJgcOAQcGFgcOAQcGFgcUFgcyHgEXHgIXHgI3Fg4BFx4CFxQGFBcWNz4CNy4BJy4BJyIOAgcGJyY2NS4BJzYuAQYHBicmNzY3HgIXHgMfAT4CJyY%2BATc%2BAzcmNzIWMjY3LgMnND4CJiceAT8BNi4CJwYHFB4BFS4CJz4BNxYyPgEB5OjVm1xcm9Xo1ZtcXJsBZA8rHDoKDz0PFD8DAxMBAzEFCRwGIgEMFhkHECIvCxU%2FOR0HFBkDDRQjEwcFaHUeISQDDTAMD0UREi4oLBAzDwQBBikEAQMLGhIXExMLBhAGKBsGBxYVEwYFAgsFAwMNFwQGCQcYFgYQCCARFwkKKiFBCwQCAQMDHzcLDAUdLDgNEiEQEgg%2FKhADGgMKEgoRBJhcm9Xo1ZtcXJvV6NWbEQwRBwkCAwYFBycPCxcHInIWInYcCUcYChQECA4QBAkuHgQPJioRFRscBAcSCgwCch0kPiAIAQcHEAsBAgsLIxcBMQENCQIPHxkCFBkdHB4QBgEBBwoMGBENBAMMJSAQEhYXDQ4qFBkKEhIDCQsXJxQiBgEOCQwHAQ0DBAUcJAwSCwRnETIoAwEJCwsLJQcKDBEAAAAAAQAAAAIErwSFABYAAAE2FwUXNxYGBw4BJwEGIi8BJjQ3ASY2AvSkjv79kfsGUE08hjv9rA8rD28PDwJYIk8EhVxliuh%2BWYcrIgsW%2FawQEG4PKxACV2XJAAYAAABgBLAErAAPABMAIwAnADcAOwAAEyEyFh0BFAYjISImPQE0NgUjFTMFITIWHQEUBiMhIiY9ATQ2BSEVIQUhMhYdARQGIyEiJj0BNDYFIRUhZAPoKTs7KfwYKTs7BBHIyPwYA%2BgpOzsp%2FBgpOzsEEf4MAfT8GAPoKTs7KfwYKTs7BBH%2B1AEsBKw7KWQpOzspZCk7ZGTIOylkKTs7KWQpO2RkyDspZCk7OylkKTtkZAAAAAIAZAAABEwEsAALABEAABMhMhYUBiMhIiY0NgERBxEBIZYDhBUdHRX8fBUdHQI7yP6iA4QEsB0qHR0qHf1E%2FtTIAfQB9AAAAAMAAABkBLAEsAAXABsAJQAAATMyFh0BITIWFREhNSMVIRE0NjMhNTQ2FxUzNQEVFAYjISImPQEB9MgpOwEsKTv%2BDMj%2BDDspASw7KcgB9Dsp%2FBgpOwSwOylkOyn%2BcGRkAZApO2QpO2RkZP1EyCk7OynIAAAABAAAAAAEsASwABUAKwBBAFcAABMhMhYPARcWFA8BBiIvAQcGJjURNDYpATIWFREUBi8BBwYiLwEmND8BJyY2ARcWFA8BFxYGIyEiJjURNDYfATc2MgU3NhYVERQGIyEiJj8BJyY0PwE2MhcyASwVCA5exwcHaggUCMdeDhUdAzUBLBUdFQ5exwgUCGoHB8deDgj%2BL2oHB8deDggV%2FtQVHRUOXscIFALLXg4VHRX%2B1BUIDl7HBwdqCBQIBLAVDl7HCBQIagcHx14OCBUBLBUdHRX%2B1BUIDl7HBwdqCBQIx14OFf0maggUCMdeDhUdFQEsFQgOXscHzl4OCBX%2B1BUdFQ5exwgUCGoHBwAAAAYAAAAABKgEqAAPABsAIwA7AEMASwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JiQyFhQGIiY0JDIWFAYjIicHFhUUBiImNTQ2PwImNTQEMhYUBiImNCQyFhQGIiY0Advy3Z9fX5%2Fd8t2gXl6gAcbgv29vv%2BC%2Fb2%2F%2BLS0gIC0gAUwtICAWDg83ETNIMykfegEJ%2FoctICAtIAIdLSAgLSAEqF%2Bf3fLdoF5eoN3y3Z9Xb7%2Fgv29vv%2BC%2FBiAtISEtICAtIQqRFxwkMzMkIDEFfgEODhekIC0gIC0gIC0gIC0AAf%2FYAFoEuQS8AFsAACUBNjc2JicmIyIOAwcABw4EFx4BMzI3ATYnLgEjIgcGBwEOASY0NwA3PgEzMhceARcWBgcOBgcGIyImJyY2NwE2NzYzMhceARcWBgcBDgEnLgECIgHVWwgHdl8WGSJBMD8hIP6IDx4eLRMNBQlZN0ozAiQkEAcdEhoYDRr%2Bqw8pHA4BRyIjQS4ODyw9DQ4YIwwod26La1YOOEBGdiIwGkQB%2F0coW2tQSE5nDxE4Qv4eDyoQEAOtAdZbZWKbEQQUGjIhH%2F6JDxsdNSg3HT5CMwIkJCcQFBcMGv6uDwEcKQ4BTSIjIQEINykvYyMLKnhuiWZMBxtAOU6%2BRAH%2FSBg3ISSGV121Qv4kDwIPDyYAAAACAGQAWASvBEQAGQBEAAABPgIeAhUUDgMHLgQ1ND4CHgEFIg4DIi4DIyIGFRQeAhcWFx4EMj4DNzY3PgQ1NCYCiTB7eHVYNkN5hKg%2BPqeFeEM4WnZ4eQEjIT8yLSohJyktPyJDbxtBMjMPBw86KzEhDSIzKUAMBAgrKT8dF2oDtURIBS1TdkA5eYB%2FslVVsn%2BAeTlAdlMtBUgtJjY1JiY1NiZvTRc4SjQxDwcOPCouGBgwKEALBAkpKkQqMhNPbQACADn%2F8gR3BL4AFwAuAAAAMh8BFhUUBg8BJi8BNycBFwcvASY0NwEDNxYfARYUBwEGIi8BJjQ%2FARYfAQcXAQKru0KNQjgiHR8uEl%2F3%2FnvUaRONQkIBGxJpCgmNQkL%2B5UK6Qo1CQjcdLhJf9wGFBL5CjUJeKmsiHTUuEl%2F4%2FnvUahKNQrpCARv%2BRmkICY1CukL%2B5UJCjUK7Qjc3LxFf%2BAGFAAAAAAMAyAAAA%2BgEsAARABUAHQAAADIeAhURFAYjISImNRE0PgEHESERACIGFBYyNjQCBqqaZDo7Kf2oKTs8Zj4CWP7%2FVj09Vj0EsB4uMhX8Ryk7OykDuRUzLar9RAK8%2FRY9Vj09VgABAAAAAASwBLAAFgAACQEWFAYiLwEBEScBBRMBJyEBJyY0NjIDhgEbDx0qDiT%2B6dT%2BzP7oywEz0gEsAQsjDx0qBKH%2B5g8qHQ8j%2FvX%2B1NL%2BzcsBGAE01AEXJA4qHQAAAAADAScAEQQJBOAAMgBAAEsAAAEVHgQXIy4DJxEXHgQVFAYHFSM1JicuASczHgEXEScuBDU0PgI3NRkBDgMVFB4DFxYXET4ENC4CArwmRVI8LAKfBA0dMydAIjxQNyiym2SWVygZA4sFV0obLkJOMCAyVWg6HSoqFQ4TJhkZCWgWKTEiGBkzNwTgTgUTLD9pQiQuLBsH%2Fs0NBxMtPGQ%2Bi6oMTU8QVyhrVk1iEAFPCA4ZLzlYNkZwSCoGTf4SARIEDh02Jh0rGRQIBgPQ%2FsoCCRYgNEM0JRkAAAABAGQAZgOUBK0ASgAAATIeARUjNC4CIyIGBwYVFB4BFxYXMxUjFgYHBgc%2BATM2FjMyNxcOAyMiLgEHDgEPASc%2BBTc%2BAScjNTMmJy4CPgE3NgIxVJlemSc8OxolVBQpGxoYBgPxxQgVFS02ImIWIIwiUzUyHzY4HCAXanQmJ1YYFzcEGAcTDBEJMAwk3aYXFQcKAg4tJGEErVCLTig%2FIhIdFSw5GkowKgkFZDKCHj4yCg8BIh6TExcIASIfBAMaDAuRAxAFDQsRCjePR2QvORQrREFMIVgAAAACABn%2F%2FwSXBLAADwAfAAABMzIWDwEGIi8BJjY7AREzBRcWBisBESMRIyImPwE2MgGQlhUIDuYOKg7mDggVlsgCF%2BYOCBWWyJYVCA7mDioBLBYO%2Bg8P%2Bg4WA4QQ%2BQ4V%2FHwDhBUO%2BQ8AAAQAGf%2F%2FA%2BgEsAAHABcAGwAlAAABIzUjFSMRIQEzMhYPAQYiLwEmNjsBETMFFTM1EwczFSE1NyM1IQPoZGRkASz9qJYVCA7mDioO5g4IFZbIAZFkY8jI%2FtTIyAEsArxkZAH0%2FHwWDvoPD%2FoOFgOEZMjI%2FRL6ZJb6ZAAAAAAEABn%2F%2FwPoBLAADwAZACEAJQAAATMyFg8BBiIvASY2OwERMwUHMxUhNTcjNSERIzUjFSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAljIyP7UyMgBLGRkZAEsx2QBLBYO%2Bg8P%2Bg4WA4SW%2BmSW%2BmT7UGRkAfRkyMgAAAAEABn%2F%2FwRMBLAADwAVABsAHwAAATMyFg8BBiIvASY2OwERMwEjESM1MxMjNSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAlhkZMhkZMgBLMdkASwWDvoPD%2FoOFgOE%2FgwBkGT7UGQBkGTIyAAAAAAEABn%2F%2FwRMBLAADwAVABkAHwAAATMyFg8BBiIvASY2OwERMwEjNSMRIQcVMzUDIxEjNTMBkJYVCA7mDioO5g4IFZbIArxkyAEsx2QBZGTIASwWDvoPD%2FoOFgOE%2FgxkAZBkyMj7tAGQZAAAAAAFABn%2F%2FwSwBLAADwATABcAGwAfAAABMzIWDwEGIi8BJjY7AREzBSM1MxMhNSETITUhEyE1IQGQlhUIDuYOKg7mDggVlsgB9MjIZP7UASxk%2FnABkGT%2BDAH0ASwWDvoPD%2FoOFgOEyMj%2BDMj%2BDMj%2BDMgABQAZ%2F%2F8EsASwAA8AEwAXABsAHwAAATMyFg8BBiIvASY2OwERMwUhNSEDITUhAyE1IQMjNTMBkJYVCA7mDioO5g4IFZbIAyD%2BDAH0ZP5wAZBk%2FtQBLGTIyAEsFg76Dw%2F6DhYDhMjI%2FgzI%2FgzI%2FgzIAAIAAAAABEwETAAPAB8AAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmAV4BkKK8u6P%2BcKW5uQJn%2FgwpOzspAfQpOzsETLuj%2FnClubmlAZClucg7Kf4MKTs7KQH0KTsAAAAAAwAAAAAETARMAA8AHwArAAABITIWFREUBiMhIiY1ETQ2BSEiBhURFBYzITI2NRE0JgUXFhQPAQYmNRE0NgFeAZClubml%2FnCju7wCZP4MKTs7KQH0KTs7%2Fm%2F9ERH9EBgYBEy5pf5wpbm5pQGQo7vIOyn%2BDCk7OykB9Ck7gr4MJAy%2BDAsVAZAVCwAAAAADAAAAAARMBEwADwAfACsAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFg8BBiIvASY2AV4BkKO7uaX%2BcKW5uQJn%2FgwpOzspAfQpOzv%2BFQGQFQsMvgwkDL4MCwRMvKL%2BcKW5uaUBkKO7yDsp%2FgwpOzspAfQpO8gYEP0REf0QGAAAAAMAAAAABEwETAAPAB8AKwAAASEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFFxYGIyEiJj8BNjIBXgGQpbm5pf5wo7u5Amf%2BDCk7OykB9Ck7O%2F77vgwLFf5wFQsMvgwkBEy5pf5wo7u8ogGQpbnIOyn%2BDCk7OykB9Ck7z%2F0QGBgQ%2FREAAAAAAgAAAAAFFARMAB8ANQAAASEyFhURFAYjISImPQE0NjMhMjY1ETQmIyEiJj0BNDYHARYUBwEGJj0BIyImPQE0NjsBNTQ2AiYBkKW5uaX%2BcBUdHRUBwik7Oyn%2BPhUdHb8BRBAQ%2FrwQFvoVHR0V%2BhYETLml%2FnCluR0VZBUdOykB9Ck7HRVkFR3p%2FuQOJg7%2B5A4KFZYdFcgVHZYVCgAAAQDZAAID1wSeACMAAAEXFgcGAgclMhYHIggBBwYrAScmNz4BPwEhIicmNzYANjc2MwMZCQgDA5gCASwYEQ4B%2Fvf%2B8wQMDgkJCQUCUCcn%2FtIXCAoQSwENuwUJEASeCQoRC%2F5TBwEjEv7K%2FsUFDwgLFQnlbm4TFRRWAS%2FTBhAAAAACAAAAAAT%2BBEwAHwA1AAABITIWHQEUBiMhIgYVERQWMyEyFh0BFAYjISImNRE0NgUBFhQHAQYmPQEjIiY9ATQ2OwE1NDYBXgGQFR0dFf4%2BKTs7KQHCFR0dFf5wpbm5AvEBRBAQ%2FrwQFvoVHR0V%2BhYETB0VZBUdOyn%2BDCk7HRVkFR25pQGQpbnp%2FuQOJg7%2B5A4KFZYdFcgVHZYVCgACAAAAAASwBLAAFQAxAAABITIWFREUBi8BAQYiLwEmNDcBJyY2ASMiBhURFBYzITI2PQE3ERQGIyEiJjURNDYzIQLuAZAVHRUObf7IDykPjQ8PAThtDgj%2B75wpOzspAfQpO8i7o%2F5wpbm5pQEsBLAdFf5wFQgObf7IDw%2BNDykPAThtDhX%2B1Dsp%2FgwpOzsplMj%2B1qW5uaUBkKW5AAADAA4ADgSiBKIADwAbACMAAAAyHgIUDgIiLgI0PgEEIg4BFB4BMj4BNCYEMhYUBiImNAHh7tmdXV2d2e7ZnV1dnQHD5sJxccLmwnFx%2FnugcnKgcgSiXZ3Z7tmdXV2d2e7ZnUdxwubCcXHC5sJzcqBycqAAAAMAAAAABEwEsAAVAB8AIwAAATMyFhURMzIWBwEGIicBJjY7ARE0NgEhMhYdASE1NDYFFTM1AcLIFR31FAoO%2FoEOJw3%2BhQ0JFfod%2FoUD6BUd%2B7QdA2dkBLAdFf6iFg%2F%2BVg8PAaoPFgFeFR38fB0V%2BvoVHWQyMgAAAAMAAAAABEwErAAVAB8AIwAACQEWBisBFRQGKwEiJj0BIyImNwE%2BAQEhMhYdASE1NDYFFTM1AkcBeg4KFfQiFsgUGPoUCw4Bfw4n%2FfkD6BUd%2B7QdA2dkBJ7%2BTQ8g%2BhQeHRX6IQ8BrxAC%2FH8dFfr6FR1kMjIAAwAAAAAETARLABQAHgAiAAAJATYyHwEWFAcBBiInASY0PwE2MhcDITIWHQEhNTQ2BRUzNQGMAXEHFQeLBwf98wcVB%2F7cBweLCBUH1APoFR37tB0DZ2QC0wFxBweLCBUH%2FfMICAEjCBQIiwcH%2FdIdFfr6FR1kMjIABAAAAAAETASbAAkAGQAjACcAABM3NjIfAQcnJjQFNzYWFQMOASMFIiY%2FASc3ASEyFh0BITU0NgUVMzWHjg4qDk3UTQ4CFtIOFQIBHRX9qxUIDtCa1P49A%2BgVHfu0HQNnZAP%2Fjg4OTdRMDyqa0g4IFf2pFB4BFQ7Qm9T9Oh0V%2BvoVHWQyMgAAAAQAAAAABEwEsAAPABkAIwAnAAABBR4BFRMUBi8BByc3JyY2EwcGIi8BJjQ%2FAQEhMhYdASE1NDYFFTM1AV4CVxQeARUO0JvUm9IOCMNMDyoOjg4OTf76A%2BgVHfu0HQNnZASwAgEdFf2rFQgO0JrUmtIOFf1QTQ4Ojg4qDk3%2BWB0V%2BvoVHWQyMgACAAT%2F7ASwBK8ABQAIAAAlCQERIQkBFQEEsP4d%2Fsb%2BcQSs%2FTMCq2cBFP5xAacDHPz55gO5AAAAAAIAAABkBEwEsAAVABkAAAERFAYrAREhESMiJjURNDY7AREhETMHIzUzBEwdFZb9RJYVHR0V%2BgH0ZMhkZAPo%2FK4VHQGQ%2FnAdFQPoFB7%2B1AEsyMgAAAMAAABFBN0EsAAWABoALwAAAQcBJyYiDwEhESMiJjURNDY7AREhETMHIzUzARcWFAcBBiIvASY0PwE2Mh8BATYyBEwC%2FtVfCRkJlf7IlhUdHRX6AfRkyGRkAbBqBwf%2BXAgUCMoICGoHFQdPASkHFQPolf7VXwkJk%2F5wHRUD6BQe%2FtQBLMjI%2Fc5qBxUH%2FlsHB8sHFQdqCAhPASkHAAMAAAANBQcEsAAWABoAPgAAAREHJy4BBwEhESMiJjURNDY7AREhETMHIzUzARcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyBExnhg8lEP72%2FreWFR0dFfoB9GTIZGQB9kYPD4ODDw9GDykPg4MPKQ9GDw%2BDgw8PRg8pD4ODDykD6P7zZ4YPAw7%2B9v5wHRUD6BQe%2FtQBLMjI%2FYxGDykPg4MPKQ9GDw%2BDgw8PRg8pD4ODDykPRg8Pg4MPAAADAAAAFQSXBLAAFQAZAC8AAAERISIGHQEhESMiJjURNDY7AREhETMHIzUzEzMyFh0BMzIWDwEGIi8BJjY7ATU0NgRM%2FqIVHf4MlhUdHRX6AfRkyGRklmQVHZYVCA7mDioO5g4IFZYdA%2Bj%2B1B0Vlv5wHRUD6BQe%2FtQBLMjI%2FagdFfoVDuYODuYOFfoVHQAAAAADAAAAAASXBLAAFQAZAC8AAAERJyYiBwEhESMiJjURNDY7AREhETMHIzUzExcWBisBFRQGKwEiJj0BIyImPwE2MgRMpQ4qDv75%2Fm6WFR0dFfoB9GTIZGTr5g4IFZYdFWQVHZYVCA7mDioD6P5wpQ8P%2Fvf%2BcB0VA%2BgUHv7UASzIyP2F5Q8V%2BhQeHhT6FQ%2FlDwADAAAAyASwBEwACQATABcAABMhMhYdASE1NDYBERQGIyEiJjURExUhNTIETBUd%2B1AdBJMdFfu0FR1kAZAETB0VlpYVHf7U%2FdoVHR0VAib%2B1MjIAAAGAAMAfQStBJcADwAZAB0ALQAxADsAAAEXFhQPAQYmPQEhNSE1NDYBIyImPQE0NjsBFyM1MwE3NhYdASEVIRUUBi8BJjQFIzU7AjIWHQEUBisBA6f4Dg74DhX%2BcAGQFf0vMhUdHRUyyGRk%2FoL3DhUBkP5wFQ73DwOBZGRkMxQdHRQzBI3mDioO5g4IFZbIlhUI%2FoUdFWQVHcjI%2FcvmDggVlsiWFQgO5g4qecgdFWQVHQAAAAACAGQAAASwBLAAFgBRAAABJTYWFREUBisBIiY1ES4ENRE0NiUyFh8BERQOAg8BERQGKwEiJjURLgQ1ETQ%2BAzMyFh8BETMRPAE%2BAjMyFh8BETMRND4DA14BFBklHRXIFR0EDiIaFiX%2B4RYZAgEVHR0LCh0VyBUdBA4iGhYBBwoTDRQZAgNkBQkVDxcZAQFkAQUJFQQxdBIUH%2FuuFR0dFQGNAQgbHzUeAWcfRJEZDA3%2BPhw%2FMSkLC%2F5BFR0dFQG%2FBA8uLkAcAcICBxENCxkMDf6iAV4CBxENCxkMDf6iAV4CBxENCwABAGQAAASwBEwAMwAAARUiDgMVERQWHwEVITUyNjURIREUFjMVITUyPgM1ETQmLwE1IRUiBhURIRE0JiM1BLAEDiIaFjIZGf5wSxn%2BDBlL%2FnAEDiIaFjIZGQGQSxkB9BlLBEw4AQUKFA78iBYZAQI4OA0lAYr%2BdiUNODgBBQoUDgN4FhkBAjg4DSX%2BdgGKJQ04AAAABgAAAAAETARMAAwAHAAgACQAKAA0AAABITIWHQEjBTUnITchBSEyFhURFAYjISImNRE0NhcVITUBBTUlBRUhNQUVFAYjIQchJyE3MwKjAXcVHWn%2B2cj%2BcGQBd%2F4lASwpOzsp%2FtQpOzspASwCvP5wAZD8GAEsArwdFf6JZP6JZAGQyGkD6B0VlmJiyGTIOyn%2BDCk7OykB9Ck7ZMjI%2FveFo4XGyMhm%2BBUdZGTIAAEAEAAQBJ8EnwAmAAATNzYWHwEWBg8BHgEXNz4BHwEeAQ8BBiIuBicuBTcRohEuDosOBhF3ZvyNdxEzE8ATBxGjAw0uMUxPZWZ4O0p3RjITCwED76IRBhPCFDERdo78ZXYRBA6IDi8RogEECBUgNUNjO0qZfHNVQBAAAAACAAAAAASwBEwAIwBBAAAAMh4EHwEVFAYvAS4BPQEmIAcVFAYPAQYmPQE%2BBRIyHgIfARUBHgEdARQGIyEiJj0BNDY3ATU0PgIB%2FLimdWQ%2FLAkJHRTKFB2N%2FsKNHRTKFB0DDTE7ZnTKcFImFgEBAW0OFR0V%2B7QVHRUOAW0CFiYETBUhKCgiCgrIFRgDIgMiFZIYGJIVIgMiAxgVyAQNJyQrIP7kExwcCgoy%2FtEPMhTUFR0dFdQUMg8BLzIEDSEZAAADAAAAAASwBLAADQAdACcAAAEHIScRMxUzNTMVMzUzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYETMj9qMjIyMjIyPyuArwVHR0VDIn8SokMFR0dswRMFR37UB0CvMjIAfTIyMjI%2FOAdKh1kZB0qHf7UHRUyMhUdAAAAAwBkAAAEsARMAAkAEwAdAAABIyIGFREhETQmASMiBhURIRE0JgEhETQ2OwEyFhUCvGQpOwEsOwFnZCk7ASw7%2FRv%2B1DspZCk7BEw7KfwYA%2BgpO%2F7UOyn9RAK8KTv84AGQKTs7KQAAAAAF%2F5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQURByMRMwcRMxHIArx8sLB8%2FUR8sLAYA4T%2BDMjI%2FtTIyAEsAZBkyMhkZARMsHz%2BDHywsHwB9HywyP1EArzIZP7UZGQBLGT%2B1GQB9GT%2B1AEsAAAABf%2BcAAAEsARMAA8AEwAfACUAKQAAEyEyFhURFAYjISImNRE0NhcRIREBIzUjFSMRMxUzNTMFEQcjETMHETMRyAK8fLCwfP1EfLCwGAOE%2FgxkZGRkZGQBkGTIyGRkBEywfP4MfLCwfAH0fLDI%2FUQCvP2oyMgB9MjIZP7UZAH0ZP7UASwABP%2BcAAAEsARMAA8AEwAbACMAABMhMhYVERQGIyEiJjURNDYXESERBSMRMxUhESEFIxEzFSERIcgCvHywsHz9RHywsBgDhP4MyMj%2B1AEsAZDIyP7UASwETLB8%2Fgx8sLB8AfR8sMj9RAK8yP7UZAH0ZP7UZAH0AAAABP%2BcAAAEsARMAA8AEwAWABkAABMhMhYVERQGIyEiJjURNDYXESERAS0BDQERyAK8fLCwfP1EfLCwGAOE%2Fgz%2B1AEsAZD%2B1ARMsHz%2BDHywsHwB9HywyP1EArz%2BDJaWlpYBLAAAAAX%2FnAAABLAETAAPABMAFwAgACkAABMhMhYVERQGIyEiJjURNDYXESERAyERIQcjIgYVFBY7AQERMzI2NTQmI8gCvHywsHz9RHywsBgDhGT9RAK8ZIImOTYpgv4Mgik2OSYETLB8%2Fgx8sLB8AfR8sMj9RAK8%2FagB9GRWQUFUASz%2B1FRBQVYAAAAF%2F5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQEjESM1MwMjNTPIArx8sLB8%2FUR8sLAYA4T%2BDMjI%2FtTIyAEsAZBkZMjIZGQETLB8%2Fgx8sLB8AfR8sMj9RAK8yGT%2B1GRkASz%2BDAGQZP4MZAAG%2F5wAAASwBEwADwATABkAHwAjACcAABMhMhYVERQGIyEiJjURNDYXESERBTMRIREzASMRIzUzBRUzNQEjNTPIArx8sLB8%2FUR8sLAYA4T9RMj%2B1GQCWGRkyP2oZAEsZGQETLB8%2Fgx8sLB8AfR8sMj9RAK8yP5wAfT%2BDAGQZMjIyP7UZAAF%2F5wAAASwBEwADwATABwAIgAmAAATITIWFREUBiMhIiY1ETQ2FxEhEQEHIzU3NSM1IQEjESM1MwMjNTPIArx8sLB8%2FUR8sLAYA4T%2BDMdkx8gBLAGQZGTIx2RkBEywfP4MfLCwfAH0fLDI%2FUQCvP5wyDLIlmT%2BDAGQZP4MZAAAAAMACQAJBKcEpwAPABsAJQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgchFSEVISc1NyEB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWz%2B1AEs%2FtRkZAEsBKdentvw255eXp7b8NueTHHC5MJxccLkwtDIZGTIZAAAAAAEAAkACQSnBKcADwAbACcAKwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgcVBxcVIycjFSMRIQcVMzUB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWwyZGRklmQBLMjIBKdentvw255eXp7b8NueTHHC5MJxccLkwtBkMmQyZGQBkGRkZAAAAv%2Fy%2F50EwgRBACAANgAAATIWFzYzMhYUBisBNTQmIyEiBh0BIyImNTQ2NyY1ND4BEzMyFhURMzIWDwEGIi8BJjY7ARE0NgH3brUsLC54qqp4gB0V%2FtQVHd5QcFZBAmKqepYKD4kVCg3fDSYN3w0KFYkPBEF3YQ6t8a36FR0dFfpzT0VrDhMSZKpi%2FbMPCv7tFxD0EBD0EBcBEwoPAAAAAAL%2F8v%2BcBMMEQQAcADMAAAEyFhc2MzIWFxQGBwEmIgcBIyImNTQ2NyY1ND4BExcWBisBERQGKwEiJjURIyImNzY3NjIB9m62LCsueaoBeFr%2Bhg0lDf6DCU9xVkECYqnm3w0KFYkPCpYKD4kVCg3HGBMZBEF3YQ%2BteGOkHAFoEBD%2Bk3NPRWsOExNkqWP9kuQQF%2F7tCg8PCgETFxDMGBMAAAABAGQAAARMBG0AGAAAJTUhATMBMwkBMwEzASEVIyIGHQEhNTQmIwK8AZD%2B8qr%2B8qr%2B1P7Uqv7yqv7yAZAyFR0BkB0VZGQBLAEsAU3%2Bs%2F7U%2FtRkHRUyMhUdAAAAAAEAeQAABDcEmwAvAAABMhYXHgEVFAYHFhUUBiMiJxUyFh0BITU0NjM1BiMiJjU0Ny4BNTQ2MzIXNCY1NDYCWF6TGll7OzIJaUo3LRUd%2FtQdFS03SmkELzlpSgUSAqMEm3FZBoNaPWcfHRpKaR77HRUyMhUd%2Bx5pShIUFVg1SmkCAhAFdKMAAAAGACcAFASJBJwAEQAqAEIASgBiAHsAAAEWEgIHDgEiJicmAhI3PgEyFgUiBw4BBwYWHwEWMzI3Njc2Nz4BLwEmJyYXIgcOAQcGFh8BFjMyNz4BNz4BLwEmJyYWJiIGFBYyNjciBw4BBw4BHwEWFxYzMjc%2BATc2Ji8BJhciBwYHBgcOAR8BFhcWMzI3PgE3NiYvASYD8m9PT29T2dzZU29PT29T2dzZ%2Fj0EBHmxIgQNDCQDBBcGG0dGYAsNAwkDCwccBAVQdRgEDA0iBAQWBhJROQwMAwkDCwf5Y4xjY4xjVhYGElE6CwwDCQMLBwgEBVB1GAQNDCIEjRcGG0dGYAsNAwkDCwcIBAR5sSIEDQwkAwPyb%2F7V%2FtVvU1dXU28BKwErb1NXVxwBIrF5DBYDCQEWYEZHGwMVDCMNBgSRAhh1UA0WAwkBFTpREgMVCyMMBwT6Y2OMY2MVFTpREQQVCyMMBwQCGHVQDRYDCQEkFmBGRxsDFQwjDQYEASKxeQwWAwkBAAAABQBkAAAD6ASwAAwADwAWABwAIgAAASERIzUhFSERNDYzIQEjNQMzByczNTMDISImNREFFRQGKwECvAEstP6s%2FoQPCgI%2FASzIZKLU1KJktP51Cg8DhA8KwwMg%2FoTIyALzCg%2F%2B1Mj84NTUyP4MDwoBi8jDCg8AAAAABQBkAAAD6ASwAAkADAATABoAIQAAASERCQERNDYzIQEjNRMjFSM1IzcDISImPQEpARUUBisBNQK8ASz%2Bov3aDwoCPwEsyD6iZKLUqv6dCg8BfAIIDwqbAyD9%2BAFe%2FdoERwoP%2FtTI%2FHzIyNT%2BZA8KNzcKD1AAAAAAAwAAAAAEsAP0AAgAGQAfAAABIxUzFyERIzcFMzIeAhUhFSEDETM0PgIBMwMhASEEiqJkZP7UotT9EsgbGiEOASz9qMhkDiEaAnPw8PzgASwB9AMgyGQBLNTUBBErJGT%2BogHCJCsRBP5w%2FnAB9AAAAAMAAAAABEwETAAZADIAOQAAATMyFh0BMzIWHQEUBiMhIiY9ATQ2OwE1NDYFNTIWFREUBiMhIic3ARE0NjMVFBYzITI2AQc1IzUzNQKKZBUdMhUdHRX%2B1BUdHRUyHQFzKTs7Kf2oARP2%2Fro7KVg%2BASw%2BWP201MjIBEwdFTIdFWQVHR0VZBUdMhUd%2BpY7KfzgKTsE9gFGAUQpO5Y%2BWFj95tSiZKIAAwBkAAAEvARMABkANgA9AAABMzIWHQEzMhYdARQGIyEiJj0BNDY7ATU0NgU1MhYVESMRMxQOAiMhIiY1ETQ2MxUUFjMhMjYBBzUjNTM1AcJkFR0yFR0dFf7UFR0dFTIdAXMpO8jIDiEaG%2F2oKTs7KVg%2BASw%2BWAGc1MjIBEwdFTIdFWQVHR0VZBUdMhUd%2BpY7Kf4M%2FtQkKxEEOykDICk7lj5YWP3m1KJkogAAAAP%2FogAABRYE1AALABsAHwAACQEWBiMhIiY3ATYyEyMiBhcTHgE7ATI2NxM2JgMVMzUCkgJ9FyAs%2BwQsIBcCfRZARNAUGAQ6BCMUNhQjBDoEGODIBK37sCY3NyYEUCf%2BTB0U%2FtIUHR0UAS4UHf4MZGQAAAAACQAAAAAETARMAA8AHwAvAD8ATwBfAG8AfwCPAAABMzIWHQEUBisBIiY9ATQ2EzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBqfoKDw8K%2BgoPDwr6Cg8PCvoKDw8BmvoKDw8K%2BgoPD%2Fzq%2BgoPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K%2BgoPD%2Fzq%2BgoPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K%2BgoPDwRMDwqWCg8PCpYKD%2F7UDwqWCg8PCpYKDw8KlgoPDwqWCg%2F%2B1A8KlgoPDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKD%2F7UDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKDw8KlgoPAAAAAwAAAAAEsAUUABkAKQAzAAABMxUjFSEyFg8BBgchJi8BJjYzITUjNTM1MwEhMhYUBisBFyE3IyImNDYDITIWHQEhNTQ2ArxkZAFePjEcQiko%2FPwoKUIcMT4BXmRkyP4%2BArwVHR0VDIn8SooNFR0dswRMFR37UB0EsMhkTzeEUzMzU4Q3T2TIZPx8HSodZGQdKh3%2B1B0VMjIVHQAABAAAAAAEsAUUAAUAGQArADUAAAAyFhUjNAchFhUUByEyFg8BIScmNjMhJjU0AyEyFhQGKwEVBSElNSMiJjQ2AyEyFh0BITU0NgIwUDnCPAE6EgMBSCkHIq%2F9WrIiCikBSAOvArwVHR0VlgET%2FEoBE5YVHR2zBEwVHftQHQUUOykpjSUmCBEhFpGRFiERCCb%2BlR0qHcjIyMgdKh39qB0VMjIVHQAEAAAAAASwBJ0ABwAUACQALgAAADIWFAYiJjQTMzIWFRQXITY1NDYzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYCDZZqapZqty4iKyf%2BvCcrI%2F7NArwVHR0VDYr8SokMFR0dswRMFR37UB0EnWqWamqW%2Fus5Okxra0w6Of5yHSodZGQdKh3%2B1B0VMjIVHQAEAAAAAASwBRQADwAcACwANgAAATIeARUUBiImNTQ3FzcnNhMzMhYVFBchNjU0NjMBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYL1szb5xvIpBvoyIfLiIrJ%2F68Jysj%2Fs0CvBUdHRUNivxKiQwVHR2zBEwVHftQHQUUa4s2Tm9vTj5Rj2%2BjGv4KOTpMa2tMOjn%2Bch0qHWRkHSod%2FtQdFTIyFR0AAAADAAAAAASwBRIAEgAiACwAAAEFFSEUHgMXIS4BNTQ%2BAjcBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYASz%2B1CU%2FP00T%2Fe48PUJtj0r%2BogK8FR0dFQ2K%2FEqJDBUdHbMETBUd%2B1AdBLChizlmUT9IGVO9VFShdksE%2FH4dKh1kZB0qHf7UHRUyMhUdAAIAyAAAA%2BgFFAAPACkAAAAyFh0BHgEdASE1NDY3NTQDITIWFyMVMxUjFTMVIxUzFAYjISImNRE0NgIvUjsuNv5wNi5kAZA2XBqsyMjIyMh1U%2F5wU3V1BRQ7KU4aXDYyMjZcGk4p%2Fkc2LmRkZGRkU3V1UwGQU3UAAAMAZP%2F%2FBEwETAAPAC8AMwAAEyEyFhURFAYjISImNRE0NgMhMhYdARQGIyEXFhQGIi8BIQcGIiY0PwEhIiY9ATQ2BQchJ5YDhBUdHRX8fBUdHQQDtgoPDwr%2B5eANGiUNWP30Vw0mGg3g%2Ft8KDw8BqmQBRGQETB0V%2FgwVHR0VAfQVHf1EDwoyCg%2FgDSUbDVhYDRslDeAPCjIKD2RkZAAAAAAEAAAAAASwBEwAGQAjAC0ANwAAEyEyFh0BIzQmKwEiBhUjNCYrASIGFSM1NDYDITIWFREhETQ2ExUUBisBIiY9ASEVFAYrASImPQHIAyBTdWQ7KfopO2Q7KfopO2R1EQPoKTv7UDvxHRVkFR0D6B0VZBUdBEx1U8gpOzspKTs7KchTdf4MOyn%2B1AEsKTv%2BDDIVHR0VMjIVHR0VMgADAAEAAASpBKwADQARABsAAAkBFhQPASEBJjQ3ATYyCQMDITIWHQEhNTQ2AeACqh8fg%2F4f%2FfsgIAEnH1n%2BrAFWAS%2F%2Bq6IDIBUd%2FHwdBI39VR9ZH4MCBh9ZHwEoH%2F5u%2FqoBMAFV%2FBsdFTIyFR0AAAAAAgCPAAAEIQSwABcALwAAAQMuASMhIgYHAwYWMyEVFBYyNj0BMzI2AyE1NDY7ATU0NjsBETMRMzIWHQEzMhYVBCG9CCcV%2FnAVJwi9CBMVAnEdKh19FROo%2Fa0dFTIdFTDILxUdMhUdAocB%2BhMcHBP%2BBhMclhUdHRWWHP2MMhUdMhUdASz%2B1B0VMh0VAAAEAAAAAASwBLAADQAQAB8AIgAAASERFAYjIREBNTQ2MyEBIzUBIREUBiMhIiY1ETQ2MyEBIzUDhAEsDwr%2Bif7UDwoBdwEsyP2oASwPCv12Cg8PCgF3ASzIAyD9wQoPAk8BLFQKD%2F7UyP4M%2FcEKDw8KA7YKD%2F7UyAAC%2F5wAZAUUBEcARgBWAAABMzIeAhcWFxY2NzYnJjc%2BARYXFgcOASsBDgEPAQ4BKwEiJj8BBisBIicHDgErASImPwEmLwEuAT0BNDY7ATY3JyY2OwE2BSMiBh0BFBY7ATI2PQE0JgHkw0uOakkMEhEfQwoKGRMKBQ8XDCkCA1Y9Pgc4HCcDIhVkFRgDDDEqwxgpCwMiFWQVGAMaVCyfExwdFXwLLW8QBxXLdAFF%2BgoPDwr6Cg8PBEdBa4pJDgYKISAiJRsQCAYIDCw9P1c3fCbqFB0dFEYOCEAUHR0UnUplNQcmFTIVHVdPXw4TZV8PCjIKDw8KMgoPAAb%2FnP%2FmBRQEfgAJACQANAA8AFIAYgAAASU2Fh8BFgYPASUzMhYfASEyFh0BFAYHBQYmJyYjISImPQE0NhcjIgYdARQ7ATI2NTQmJyYEIgYUFjI2NAE3PgEeARceAT8BFxYGDwEGJi8BJjYlBwYfAR4BPwE2Jy4BJy4BAoEBpxMuDiAOAxCL%2FCtqQ0geZgM3FR0cE%2F0fFyIJKjr%2B1D5YWLlQExIqhhALIAsSAYBALS1ALf4PmBIgHhMQHC0aPzANITNQL3wpgigJASlmHyElDR0RPRMFAhQHCxADhPcICxAmDyoNeMgiNtQdFTIVJgeEBBQPQ1g%2ByD5YrBwVODMQEAtEERzJLUAtLUD%2B24ITChESEyMgAwWzPUkrRSgJL5cvfRxYGyYrDwkLNRAhFEgJDAQAAAAAAwBkAAAEOQSwAFEAYABvAAABMzIWHQEeARcWDgIPATIeBRUUDgUjFRQGKwEiJj0BIxUUBisBIiY9ASMiJj0BNDY7AREjIiY9ATQ2OwE1NDY7ATIWHQEzNTQ2AxUhMj4CNTc0LgMjARUhMj4CNTc0LgMjAnGWCg9PaAEBIC4uEBEGEjQwOiodFyI2LUAjGg8KlgoPZA8KlgoPrwoPDwpLSwoPDwqvDwqWCg9kD9cBBxwpEwsBAQsTKRz%2B%2BQFrHCkTCwEBCxMpHASwDwptIW1KLk0tHwYGAw8UKDJOLTtdPCoVCwJLCg8PCktLCg8PCksPCpYKDwJYDwqWCg9LCg8PCktLCg%2F%2B1MgVHR0LCgQOIhoW%2FnDIFR0dCwoEDiIaFgAAAwAEAAIEsASuABcAKQAsAAATITIWFREUBg8BDgEjISImJy4CNRE0NgQiDgQPARchNy4FAyMT1AMMVnokEhIdgVL9xFKCHAgYKHoCIIx9VkcrHQYGnAIwnAIIIClJVSGdwwSuelb%2BYDO3QkJXd3ZYHFrFMwGgVnqZFyYtLSUMDPPzBQ8sKDEj%2FsIBBQACAMgAAAOEBRQADwAZAAABMzIWFREUBiMhIiY1ETQ2ARUUBisBIiY9AQHblmesVCn%2BPilUrAFINhWWFTYFFKxn%2FgwpVFQpAfRnrPwY4RU2NhXhAAACAMgAAAOEBRQADwAZAAABMxQWMxEUBiMhIiY1ETQ2ARUUBisBIiY9AQHbYLOWVCn%2BPilUrAFINhWWFTYFFJaz%2FkIpVFQpAfRnrPwY4RU2NhXhAAACAAAAFAUOBBoAFAAaAAAJASUHFRcVJwc1NzU0Jj4CPwEnCQEFJTUFJQUO%2FYL%2Bhk5klpZkAQEBBQQvkwKCAVz%2Bov6iAV4BXgL%2F%2FuWqPOCWx5SVyJb6BA0GCgYDKEEBG%2F1ipqaTpaUAAAMAZAH0BLADIAAHAA8AFwAAEjIWFAYiJjQkMhYUBiImNCQyFhQGIiY0vHxYWHxYAeh8WFh8WAHofFhYfFgDIFh8WFh8WFh8WFh8WFh8WFh8AAAAAAMBkAAAArwETAAHAA8AFwAAADIWFAYiJjQSMhYUBiImNBIyFhQGIiY0Aeh8WFh8WFh8WFh8WFh8WFh8WARMWHxYWHz%2ByFh8WFh8%2FshYfFhYfAAAAAMAZABkBEwETAAPAB8ALwAAEyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2fQO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PBEwPCpYKDw8KlgoP%2FnAPCpYKDw8KlgoP%2FnAPCpYKDw8KlgoPAAAABAAAAAAEsASwAA8AHwAvADMAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFhURFAYjISImNRE0NhcVITUBXgH0ory7o%2F4Mpbm5Asv9qCk7OykCWCk7O%2F2xAfQVHR0V%2FgwVHR1HAZAEsLuj%2FgylubmlAfSlucg7Kf2oKTs7KQJYKTtkHRX%2B1BUdHRUBLBUdZMjIAAAAAAEAZABkBLAETAA7AAATITIWFAYrARUzMhYUBisBFTMyFhQGKwEVMzIWFAYjISImNDY7ATUjIiY0NjsBNSMiJjQ2OwE1IyImNDaWA%2BgVHR0VMjIVHR0VMjIVHR0VMjIVHR0V%2FBgVHR0VMjIVHR0VMjIVHR0VMjIVHR0ETB0qHcgdKh3IHSodyB0qHR0qHcgdKh3IHSodyB0qHQAAAAYBLAAFA%2BgEowAHAA0AEwAZAB8AKgAAAR4BBgcuATYBMhYVIiYlFAYjNDYBMhYVIiYlFAYjNDYDFRQGIiY9ARYzMgKKVz8%2FV1c%2FP%2F75fLB8sAK8sHyw%2FcB8sHywArywfLCwHSodKAMRBKNDsrJCQrKy%2FsCwfLB8fLB8sP7UsHywfHywfLD%2B05AVHR0VjgQAAAH%2FtQDIBJQDgQBCAAABNzYXAR4BBw4BKwEyFRQOBCsBIhE0NyYiBxYVECsBIi4DNTQzIyImJyY2NwE2HwEeAQ4BLwEHIScHBi4BNgLpRRkUASoLCAYFGg8IAQQNGyc%2FKZK4ChRUFQu4jjBJJxkHAgcPGQYGCAsBKhQaTBQVCiMUM7YDe7YsFCMKFgNuEwYS%2FtkLHw8OEw0dNkY4MhwBIBgXBAQYF%2F7gKjxTQyMNEw4PHwoBKBIHEwUjKBYGDMHBDAUWKCMAAAAAAgAAAAAEsASwACUAQwAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjNC4DKwERFBYXMxUjNTI1ESMiDgMVIzUhBLAyCAsZEyYYGcgyGRn%2BcAQOIhoWyBkYJhMZCwgyA%2Bj9RBkIChgQEWQZDQzIMmQREBgKCBkB9AOEFSAVDggDAfyuFhkBAmRkAQUJFQ4DUgEDCA4VIBUBLP0SDxMKBQH%2BVwsNATIyGQGpAQUKEw%2BWAAAAAAMAAAAABEwErgAdACAAMAAAATUiJy4BLwEBIwEGBw4BDwEVITUiJj8BIRcWBiMVARsBARUUBiMhIiY9ATQ2MyEyFgPoGR4OFgUE%2Ft9F%2FtQSFQkfCwsBETE7EkUBJT0NISf%2B7IZ5AbEdFfwYFR0dFQPoFR0BLDIgDiIKCwLr%2FQ4jFQkTBQUyMisusKYiQTIBhwFW%2Fqr942QVHR0VZBUdHQADAAAAAASwBLAADwBHAEoAABMhMhYVERQGIyEiJjURNDYFIyIHAQYHBgcGHQEUFjMhMjY9ATQmIyInJj8BIRcWBwYjIgYdARQWMyEyNj0BNCYnIicmJyMBJhMjEzIETBUdHRX7tBUdHQJGRg0F%2FtUREhImDAsJAREIDAwINxAKCj8BCjkLEQwYCAwMCAE5CAwLCBEZGQ8B%2FuAFDsVnBLAdFfu0FR0dFQRMFR1SDP0PIBMSEAUNMggMDAgyCAwXDhmjmR8YEQwIMggMDAgyBwwBGRskAuwM%2FgUBCAAABAAAAAAEsASwAAMAEwAjACcAAAEhNSEFITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NhcRIREEsPtQBLD7ggGQFR0dFf5wFR0dAm0BkBUdHRX%2BcBUdHUcBLARMZMgdFfx8FR0dFQOEFR0dFf5wFR0dFQGQFR1k%2FtQBLAAEAAAAAASwBLAADwAfACMAJwAAEyEyFhURFAYjISImNRE0NgEhMhYVERQGIyEiJjURNDYXESEREyE1ITIBkBUdHRX%2BcBUdHQJtAZAVHR0V%2FnAVHR1HASzI%2B1AEsASwHRX8fBUdHRUDhBUd%2FgwdFf5wFR0dFQGQFR1k%2FtQBLP2oZAAAAAACAAAAZASwA%2BgAJwArAAATITIWFREzNTQ2MyEyFh0BMxUjFRQGIyEiJj0BIxEUBiMhIiY1ETQ2AREhETIBkBUdZB0VAZAVHWRkHRX%2BcBUdZB0V%2FnAVHR0CnwEsA%2BgdFf6ilhUdHRWWZJYVHR0Vlv6iFR0dFQMgFR3%2B1P7UASwAAAQAAAAABLAEsAADABMAFwAnAAAzIxEzFyEyFhURFAYjISImNRE0NhcRIREBITIWFREUBiMhIiY1ETQ2ZGRklgGQFR0dFf5wFR0dRwEs%2FqIDhBUdHRX8fBUdHQSwZB0V%2FnAVHR0VAZAVHWT%2B1AEs%2FgwdFf5wFR0dFQGQFR0AAAAAAgBkAAAETASwACcAKwAAATMyFhURFAYrARUhMhYVERQGIyEiJjURNDYzITUjIiY1ETQ2OwE1MwcRIRECWJYVHR0VlgHCFR0dFfx8FR0dFQFelhUdHRWWZMgBLARMHRX%2BcBUdZB0V%2FnAVHR0VAZAVHWQdFQGQFR1kyP7UASwAAAAEAAAAAASwBLAAAwATABcAJwAAISMRMwUhMhYVERQGIyEiJjURNDYXESERASEyFhURFAYjISImNRE0NgSwZGT9dgGQFR0dFf5wFR0dRwEs%2FK4DhBUdHRX8fBUdHQSwZB0V%2FnAVHR0VAZAVHWT%2B1AEs%2FgwdFf5wFR0dFQGQFR0AAAEBLAAwA28EgAAPAAAJAQYjIiY1ETQ2MzIXARYUA2H%2BEhcSDhAQDhIXAe4OAjX%2BEhcbGQPoGRsX%2FhIOKgAAAAABAUEAMgOEBH4ACwAACQE2FhURFAYnASY0AU8B7h0qKh3%2BEg4CewHuHREp%2FBgpER0B7g4qAAAAAAEAMgFBBH4DhAALAAATITIWBwEGIicBJjZkA%2BgpER3%2BEg4qDv4SHREDhCod%2FhIODgHuHSoAAAAAAQAyASwEfgNvAAsAAAkBFgYjISImNwE2MgJ7Ae4dESn8GCkRHQHuDioDYf4SHSoqHQHuDgAAAAACAAgAAASwBCgABgAKAAABFQE1LQE1ASE1IQK8%2FUwBnf5jBKj84AMgAuW2%2Fr3dwcHd%2B9jIAAAAAAIAAABkBLAEsAALADEAAAEjFTMVIREzNSM1IQEzND4FOwERFAYPARUhNSIuAzURMzIeBRUzESEEsMjI%2FtTIyAEs%2B1AyCAsZEyYYGWQyGRkBkAQOIhoWZBkYJhMZCwgy%2FOADhGRkASxkZP4MFSAVDggDAf3aFhkBAmRkAQUJFQ4CJgEDCA4VIBUBLAAAAgAAAAAETAPoACUAMQAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjFTMVIREzNSM1IQMgMggLGRMmGBlkMhkZ%2FnAEDiIaFmQZGCYTGQsIMgMgASzIyP7UyMgBLAK8FSAVDggDAf3aFhkCAWRkAQUJFQ4CJgEDCA4VIBUBLPzgZGQBLGRkAAABAMgAZgNyBEoAEgAAATMyFgcJARYGKwEiJwEmNDcBNgK9oBAKDP4wAdAMChCgDQr%2BKQcHAdcKBEoWDP4w%2FjAMFgkB1wgUCAHXCQAAAQE%2BAGYD6ARKABIAAAEzMhcBFhQHAQYrASImNwkBJjYBU6ANCgHXBwf%2BKQoNoBAKDAHQ%2FjAMCgRKCf4pCBQI%2FikJFgwB0AHQDBYAAAEAZgDIBEoDcgASAAAAFh0BFAcBBiInASY9ATQ2FwkBBDQWCf4pCBQI%2FikJFgwB0AHQA3cKEKANCv4pBwcB1woNoBAKDP4wAdAAAAABAGYBPgRKA%2BgAEgAACQEWHQEUBicJAQYmPQE0NwE2MgJqAdcJFgz%2BMP4wDBYJAdcIFAPh%2FikKDaAQCgwB0P4wDAoQoA0KAdcHAAAAAgDZ%2F%2FkEPQSwAAUAOgAAARQGIzQ2BTMyFh8BNjc%2BAh4EBgcOBgcGIiYjIgYiJy4DLwEuAT4EHgEXJyY2A%2BiwfLD%2BVmQVJgdPBQsiKFAzRyorDwURAQQSFyozTSwNOkkLDkc3EDlfNyYHBw8GDyUqPjdGMR%2BTDA0EsHywfLDIHBPCAQIGBwcFDx81S21DBxlLR1xKQhEFBQcHGWt0bCQjP2hJNyATBwMGBcASGAAAAAACAMgAFQOEBLAAFgAaAAATITIWFREUBisBEQcGJjURIyImNRE0NhcVITX6AlgVHR0Vlv8TGpYVHR2rASwEsB0V%2FnAVHf4MsgkQFQKKHRUBkBUdZGRkAAAAAgDIABkETASwAA4AEgAAEyEyFhURBRElIREjETQ2ARU3NfoC7ic9%2FUQCWP1EZB8BDWQEsFEs%2FFt1A7Z9%2FBgEARc0%2FV1kFGQAAQAAAAECTW%2FDBF9fDzz1AB8EsAAAAADQdnOXAAAAANB2c5f%2FUf%2BcBdwFFAAAAAgAAgAAAAAAAAABAAAFFP%2BFAAAFFP9R%2FtQF3AABAAAAAAAAAAAAAAAAAAAAowG4ACgAAAAAAZAAAASwAAAEsABkBLAAAASwAAAEsABwAooAAAUUAAACigAABRQAAAGxAAABRQAAANgAAADYAAAAogAAAQQAAABIAAABBAAAAUUAAASwAGQEsAB7BLAAyASwAMgB9AAABLD%2F8gSwAAAEsAAABLD%2F8ASwAAAEsAAOBLAACQSwAGQEsP%2FTBLD%2F0wSwAAAEsAAABLAAAASwAAAEsAAABLAAJgSwAG4EsAAXBLAAFwSwABcEsABkBLAAGgSwAGQEsAAMBLAAZASwABcEsP%2BcBLAAZASwABcEsAAXBLAAAASwABcEsAAXBLAAFwSwAGQEsAAABLAAZASwAAAEsAAABLAAAASwAAAEsAAABLAAAASwAAAEsAAABLAAZASwAMgEsAAABLAAAASwADUEsABkBLAAyASw%2F7UEsAAhBLAAAASwAAAEsAAABLAAAASwAAAEsP%2BcBLAAAASwAAAEsAAABLAA2wSwABcEsAB1BLAAAASwAAAEsAAABLAACgSwAMgEsAAABLAAnQSwAMgEsADIBLAAyASwAAAEsP%2F%2BBLABLASwAGQEsACIBLABOwSwABcEsAAXBLAAFwSwABcEsAAXBLAAFwSwAAAEsAAXBLAAFwSwABcEsAAXBLAAAASwALcEsAC3BLAAAASwAAAEsABJBLAAFwSwAAAEsAAABLAAXQSw%2F9wEsP%2FcBLD%2FnwSwAGQEsAAABLAAAASwAAAEsABkBLD%2F%2FwSwAAAEsP9RBLAABgSwAAAEsAAABLABRQSwAAEEsAAABLD%2FnASwAEoEsAAUBLAAAASwAAAEsAAABLD%2FnASwAGEEsP%2F9BLAAFgSwABYEsAAWBLAAFgSwABgEsAAABMQAAASwAGQAAAAAAAD%2F2ABkADkAyAAAAScAZAAZABkAGQAZABkAGQAZAAAAAAAAAAAAAADZAAAAAAAOAAAAAAAAAAAAAAAEAAAAAAAAAAAAAAAAAAMAZABkAAAAEAAAAAAAZP%2Bc%2F5z%2FnP%2Bc%2F5z%2FnP%2Bc%2F5wACQAJ%2F%2FL%2F8gBkAHkAJwBkAGQAAAAAAGT%2FogAAAAAAAAAAAAAAAADIAGQAAAABAI8AAP%2Bc%2F5wAZAAEAMgAyAAAAGQBkABkAAAAZAEs%2F7UAAAAAAAAAAAAAAAAAAABkAAABLAFBADIAMgAIAAAAAADIAT4AZgBmANkAyADIAAAAKgAqACoAKgCyAOgA6AFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BpAIGAiICfgKGAqwC5ANGA24DjAPEBAgEMgRiBKIE3AVcBboGcgb0ByAHYgfKCB4IYgi%2BCTYJhAm2Cd4KKApMCpQK4gswC4oLygwIDFgNKg1eDbAODg5oDrQPKA%2BmD%2BYQEhBUEJAQqhEqEXYRthIKEjgSfBLAExoTdBPQFCoU1BU8FagVzBYEFjYWYBawFv4XUhemGAIYLhhqGJYYsBjgGP4ZKBloGZQZxBnaGe4aNhpoGrga9hteG7QcMhyUHOIdHB1EHWwdlB28HeYeLh52HsAfYh%2FSIEYgviEyIXYhuCJAIpYiuCMOIyIjOCN6I8Ij4CQCJDAkXiSWJOIlNCVgJbwmFCZ%2BJuYnUCe8J%2FgoNChwKKwpoCnMKiYqSiqEKworeiwILGgsuizsLRwtiC30LiguZi6iLtgvDi9GL34vsi%2F4MD4whDDSMRIxYDGuMegyJDJeMpoy3jMiMz4zaDO2NBg0YDSoNNI1LDWeNeg2PjZ8Ntw3GjdON5I31DgQOEI4hjjIOQo5SjmIOcw6HDpsOpo63jugO9w8GDxQPKI8%2BD0yPew%2BOj6MPtQ%2FKD9uP6o%2F%2BkBIQIBAxkECQX5CGEKoQu5DGENCQ3ZDoEPKRBBEYESuRPZFWkW2RgZGdEa0RvZHNkd2R7ZH9kgWSDJITkhqSIZIzEkSSThJXkmESapKAkouSlIAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAAAAABAAxgABAAAAAAATABIAAAADAAEECQAAAGoAEgADAAEECQABACgAfAADAAEECQACAA4ApAADAAEECQADAEwAsgADAAEECQAEADgA%2FgADAAEECQAFAHgBNgADAAEECQAGADYBrgADAAEECQAIABYB5AADAAEECQAJABYB%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%2FtQAyAAAAAAAAAAAAAAAAAAAAAAAAAAABFwAAAQIBAwADAA0ADgEEAJYBBQEGAQcBCAEJAQoBCwEMAQ0BDgEPARABEQESARMA7wEUARUBFgEXARgBGQEaARsBHAEdAR4BHwEgASEBIgEjASQBJQEmAScBKAEpASoBKwEsAS0BLgEvATABMQEyATMBNAE1ATYBNwE4ATkBOgE7ATwBPQE%2BAT8BQAFBAUIBQwFEAUUBRgFHAUgBSQFKAUsBTAFNAU4BTwFQAVEBUgFTAVQBVQFWAVcBWAFZAVoBWwFcAV0BXgFfAWABYQFiAWMBZAFlAWYBZwFoAWkBagFrAWwBbQFuAW8BcAFxAXIBcwF0AXUBdgF3AXgBeQF6AXsBfAF9AX4BfwGAAYEBggGDAYQBhQGGAYcBiAGJAYoBiwGMAY0BjgGPAZABkQGSAZMBlAGVAZYBlwGYAZkBmgGbAZwBnQGeAZ8BoAGhAaIBowGkAaUBpgGnAagBqQGqAasBrAGtAa4BrwGwAbEBsgGzAbQBtQG2AbcBuAG5AboBuwG8Ab0BvgG%2FAcABwQHCAcMBxAHFAcYBxwHIAckBygHLAcwBzQHOAc8B0AHRAdIB0wHUAdUB1gHXAdgB2QHaAdsB3AHdAd4B3wHgAeEB4gHjAeQB5QHmAecB6AHpAeoB6wHsAe0B7gHvAfAB8QHyAfMB9AH1AfYB9wH4AfkB%2BgH7AfwB%2FQH%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%3D%29%20format%28%27truetype%27%29%2Curl%28data%3Aimage%2Fsvg%2Bxml%3Bbase64%2CPD94bWwgdmVyc2lvbj0iMS4wIiBzdGFuZGFsb25lPSJubyI%2FPgo8IURPQ1RZUEUgc3ZnIFBVQkxJQyAiLS8vVzNDLy9EVEQgU1ZHIDEuMS8vRU4iICJodHRwOi8vd3d3LnczLm9yZy9HcmFwaGljcy9TVkcvMS4xL0RURC9zdmcxMS5kdGQiID4KPHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPgo8bWV0YWRhdGE%2BPC9tZXRhZGF0YT4KPGRlZnM%2BCjxmb250IGlkPSJnbHlwaGljb25zX2hhbGZsaW5nc3JlZ3VsYXIiIGhvcml6LWFkdi14PSIxMjAwIiA%2BCjxmb250LWZhY2UgdW5pdHMtcGVyLWVtPSIxMjAwIiBhc2NlbnQ9Ijk2MCIgZGVzY2VudD0iLTI0MCIgLz4KPG1pc3NpbmctZ2x5cGggaG9yaXotYWR2LXg9IjUwMCIgLz4KPGdseXBoIGhvcml6LWFkdi14PSIwIiAvPgo8Z2x5cGggaG9yaXotYWR2LXg9IjQwMCIgLz4KPGdseXBoIHVuaWNvZGU9IiAiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDAzOyIgaG9yaXotYWR2LXg9IjEzMDAiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDA0OyIgaG9yaXotYWR2LXg9IjQzMyIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDIwMDU7IiBob3Jpei1hZHYteD0iMzI1IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwNjsiIGhvcml6LWFkdi14PSIyMTYiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDA3OyIgaG9yaXotYWR2LXg9IjIxNiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDIwMDg7IiBob3Jpei1hZHYteD0iMTYyIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwOTsiIGhvcml6LWFkdi14PSIyNjAiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDBhOyIgaG9yaXotYWR2LXg9IjcyIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAyZjsiIGhvcml6LWFkdi14PSIyNjAiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3gyNmZhOyIgZD0iTTc3NCAxMTkzLjVxMTYgLTkuNSAyMC41IC0yN3QtNS41IC0zMy41bC0xMzYgLTE4N2w0NjcgLTc0NmgzMHEyMCAwIDM1IC0xOC41dDE1IC0zOS41di00MmgtMTIwMHY0MnEwIDIxIDE1IDM5LjV0MzUgMTguNWgzMGw0NjggNzQ2bC0xMzUgMTgzcS0xMCAxNiAtNS41IDM0dDIwLjUgMjh0MzQgNS41dDI4IC0yMC41bDExMSAtMTQ4bDExMiAxNTBxOSAxNiAyNyAyMC41dDM0IC01ek02MDAgMjAwaDM3N2wtMTgyIDExMmwtMTk1IDUzNHYtNjQ2eiAiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDI0OyIgZD0iTTEzMDAgMGgtNTM4bC00MSA0MDBoLTI0MmwtNDEgLTQwMGgtNTM4bDQzMSAxMjAwaDIwOWwtMjEgLTMwMGgxNjJsLTIwIDMwMGgyMDh6TTUxNSA4MDBsLTI3IC0zMDBoMjI0bC0yNyAzMDBoLTE3MHoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDI4OyIgZD0iTTIyNSAxMjAwaDc1MHExMCAwIDE5LjUgLTd0MTIuNSAtMTdsMTg2IC02NTJxNyAtMjQgNyAtNDl2LTQyNXEwIC0xMiAtNCAtMjd0LTkgLTE3cS0xMiAtNiAtMzcgLTZoLTExMDBxLTEyIDAgLTI3IDR0LTE3IDhxLTYgMTMgLTYgMzhsMSA0MjVxMCAyNSA3IDQ5bDE4NSA2NTJxMyAxMCAxMi41IDE3dDE5LjUgN3pNODc4IDEwMDBoLTU1NnEtMTAgMCAtMTkgLTd0LTExIC0xOGwtODcgLTQ1MHEtMiAtMTEgNCAtMTh0MTYgLTdoMTUwIHExMCAwIDE5LjUgLTd0MTEuNSAtMTdsMzggLTE1MnEyIC0xMCAxMS41IC0xN3QxOS41IC03aDI1MHExMCAwIDE5LjUgN3QxMS41IDE3bDM4IDE1MnEyIDEwIDExLjUgMTd0MTkuNSA3aDE1MHExMCAwIDE2IDd0NCAxOGwtODcgNDUwcS0yIDExIC0xMSAxOHQtMTkgN3oiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDM1OyIgZD0iTTYwMCAxMTc1cTExNiAwIDIyNyAtNDkuNXQxOTIuNSAtMTMxdDEzMSAtMTkyLjV0NDkuNSAtMjI3di0zMDBxMCAtMTAgLTcuNSAtMTcuNXQtMTcuNSAtNy41aC01MHEtMTAgMCAtMTcuNSA3LjV0LTcuNSAxNy41djMwMHEwIDEyNyAtNzAuNSAyMzEuNXQtMTg0LjUgMTYxLjV0LTI0NSA1N3QtMjQ1IC01N3QtMTg0LjUgLTE2MS41dC03MC41IC0yMzEuNXYtMzAwcTAgLTEwIC03LjUgLTE3LjV0LTE3LjUgLTcuNWgtNTAgcS0xMCAwIC0xNy41IDcuNXQtNy41IDE3LjV2MzAwcTAgMTE2IDQ5LjUgMjI3dDEzMSAxOTIuNXQxOTIuNSAxMzF0MjI3IDQ5LjV6TTIyMCA1MDBoMTYwcTggMCAxNCAtNnQ2IC0xNHYtNDYwcTAgLTggLTYgLTE0dC0xNCAtNmgtMTYwcS04IDAgLTE0IDZ0LTYgMTR2NDYwcTAgOCA2IDE0dDE0IDZ6TTgyMCA1MDBoMTYwcTggMCAxNCAtNnQ2IC0xNHYtNDYwcTAgLTggLTYgLTE0dC0xNCAtNmgtMTYwcS04IDAgLTE0IDZ0LTYgMTR2NDYwIHEwIDggNiAxNHQxNCA2eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUwMzY7IiBkPSJNMzIxIDgxNGwyNTggMTcycTkgNiAxNSAyLjV0NiAtMTMuNXYtNzUwcTAgLTEwIC02IC0xMy41dC0xNSAyLjVsLTI1OCAxNzJxLTIxIDE0IC00NiAxNGgtMjUwcS0xMCAwIC0xNy41IDcuNXQtNy41IDE3LjV2MzUwcTAgMTAgNy41IDE3LjV0MTcuNSA3LjVoMjUwcTI1IDAgNDYgMTR6TTkwMCA2NjhsMTIwIDEyMHE3IDcgMTcgN3QxNyAtN2wzNCAtMzRxNyAtNyA3IC0xN3QtNyAtMTdsLTEyMCAtMTIwbDEyMCAtMTIwcTcgLTcgNyAtMTcgdC03IC0xN2wtMzQgLTM0cS03IC03IC0xNyAtN3QtMTcgN2wtMTIwIDExOWwtMTIwIC0xMTlxLTcgLTcgLTE3IC03dC0xNyA3bC0zNCAzNHEtNyA3IC03IDE3dDcgMTdsMTE5IDEyMGwtMTE5IDEyMHEtNyA3IC03IDE3dDcgMTdsMzQgMzRxNyA4IDE3IDh0MTcgLTh6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTAzNzsiIGQ9Ik0zMjEgODE0bDI1OCAxNzJxOSA2IDE1IDIuNXQ2IC0xMy41di03NTBxMCAtMTAgLTYgLTEzLjV0LTE1IDIuNWwtMjU4IDE3MnEtMjEgMTQgLTQ2IDE0aC0yNTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXYzNTBxMCAxMCA3LjUgMTcuNXQxNy41IDcuNWgyNTBxMjUgMCA0NiAxNHpNNzY2IDkwMGg0cTEwIC0xIDE2IC0xMHE5NiAtMTI5IDk2IC0yOTBxMCAtMTU0IC05MCAtMjgxcS02IC05IC0xNyAtMTBsLTMgLTFxLTkgMCAtMTYgNiBsLTI5IDIzcS03IDcgLTguNSAxNi41dDQuNSAxNy41cTcyIDEwMyA3MiAyMjlxMCAxMzIgLTc4IDIzOHEtNiA4IC00LjUgMTh0OS41IDE3bDI5IDIycTcgNSAxNSA1eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUwMzg7IiBkPSJNOTY3IDEwMDRoM3ExMSAtMSAxNyAtMTBxMTM1IC0xNzkgMTM1IC0zOTZxMCAtMTA1IC0zNCAtMjA2LjV0LTk4IC0xODUuNXEtNyAtOSAtMTcgLTEwaC0zcS05IDAgLTE2IDZsLTQyIDM0cS04IDYgLTkgMTZ0NSAxOHExMTEgMTUwIDExMSAzMjhxMCA5MCAtMjkuNSAxNzZ0LTg0LjUgMTU3cS02IDkgLTUgMTl0MTAgMTZsNDIgMzNxNyA1IDE1IDV6TTMyMSA4MTRsMjU4IDE3MnE5IDYgMTUgMi41dDYgLTEzLjV2LTc1MHEwIC0xMCAtNiAtMTMuNSB0LTE1IDIuNWwtMjU4IDE3MnEtMjEgMTQgLTQ2IDE0aC0yNTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXYzNTBxMCAxMCA3LjUgMTcuNXQxNy41IDcuNWgyNTBxMjUgMCA0NiAxNHpNNzY2IDkwMGg0cTEwIC0xIDE2IC0xMHE5NiAtMTI5IDk2IC0yOTBxMCAtMTU0IC05MCAtMjgxcS02IC05IC0xNyAtMTBsLTMgLTFxLTkgMCAtMTYgNmwtMjkgMjNxLTcgNyAtOC41IDE2LjV0NC41IDE3LjVxNzIgMTAzIDcyIDIyOXEwIDEzMiAtNzggMjM4IHEtNiA4IC00LjUgMTguNXQ5LjUgMTYuNWwyOSAyMnE3IDUgMTUgNXoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQyOyIgZD0iTTUwMCAxMjAwbDY4MiAtNjgycTggLTggOCAtMTh0LTggLTE4bC00NjQgLTQ2NHEtOCAtOCAtMTggLTh0LTE4IDhsLTY4MiA2ODJsMSA0NzVxMCAxMCA3LjUgMTcuNXQxNy41IDcuNWg0NzR6TTgwMCAxMjAwbDY4MiAtNjgycTggLTggOCAtMTh0LTggLTE4bC00NjQgLTQ2NHEtOCAtOCAtMTggLTh0LTE4IDhsLTU2IDU2bDQyNCA0MjZsLTcwMCA3MDBoMTUwek0zMTkuNSAxMDI0LjVxLTI5LjUgMjkuNSAtNzEgMjkuNXQtNzEgLTI5LjUgdC0yOS41IC03MS41dDI5LjUgLTcxLjV0NzEgLTI5LjV0NzEgMjkuNXQyOS41IDcxLjV0LTI5LjUgNzEuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQzOyIgZD0iTTMwMCAxMjAwaDgyNXE3NSAwIDc1IC03NXYtOTAwcTAgLTI1IC0xOCAtNDNsLTY0IC02NHEtOCAtOCAtMTMgLTUuNXQtNSAxMi41djk1MHEwIDEwIC03LjUgMTcuNXQtMTcuNSA3LjVoLTcwMHEtMjUgMCAtNDMgLTE4bC02NCAtNjRxLTggLTggLTUuNSAtMTN0MTIuNSAtNWg3MDBxMTAgMCAxNy41IC03LjV0Ny41IC0xNy41di05NTBxMCAtMTAgLTcuNSAtMTcuNXQtMTcuNSAtNy41aC04NTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXY5NzUgcTAgMjUgMTggNDNsMTM5IDEzOXExOCAxOCA0MyAxOHoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQ5OyIgZD0iTTg3NyAxMjAwbDIgLTU3cS04MyAtMTkgLTExNiAtNDUuNXQtNDAgLTY2LjVsLTEzMiAtODM5cS05IC00OSAxMyAtNjl0OTYgLTI2di05N2gtNTAwdjk3cTE4NiAxNiAyMDAgOThsMTczIDgzMnEzIDE3IDMgMzB0LTEuNSAyMi41dC05IDE3LjV0LTEzLjUgMTIuNXQtMjEuNSAxMHQtMjYgOC41dC0zMy41IDEwcS0xMyAzIC0xOSA1djU3aDQyNXoiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDY2OyIgZD0iTTM1MCAxMTAwaDM2MXEtMTY0IC0xNDYgLTIxNiAtMjAwaC0xOTVxLTQxIDAgLTcwLjUgLTI5LjV0LTI5LjUgLTcwLjV2LTUwMHEwIC00MSAyOS41IC03MC41dDcwLjUgLTI5LjVoNTAwcTQxIDAgNzAuNSAyOS41dDI5LjUgNzAuNWwyMDAgMTUzdi0xMDNxMCAtMTY1IC05Mi41IC0yNTcuNXQtMjU3LjUgLTkyLjVoLTQwMHEtMTY1IDAgLTI1Ny41IDkyLjV0LTkyLjUgMjU3LjV2NDAwcTAgMTY1IDkyLjUgMjU3LjV0MjU3LjUgOTIuNXogTTgyNCAxMDczbDMzOSAtMzAxcTggLTcgOCAtMTcuNXQtOCAtMTcuNWwtMzQwIC0zMDZxLTcgLTYgLTEyLjUgLTR0LTYuNSAxMXYyMDNxLTI2IDEgLTU0LjUgMHQtNzguNSAtNy41dC05MiAtMTcuNXQtODYgLTM1dC03MCAtNTdxMTAgNTkgMzMgMTA4dDUxLjUgODEuNXQ2NSA1OC41dDY4LjUgNDAuNXQ2NyAyNC41dDU2IDEzLjV0NDAgNC41djIxMHExIDEwIDYuNSAxMi41dDEzLjUgLTQuNXoiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDY5OyIgZD0iTTI1MCAxMTAwaDEwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtNDM4bDQ2NCA0NTNxMTUgMTQgMjUuNSAxMHQxMC41IC0yNXYtMTAwMHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ2NCA0NTN2LTQzOHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtMTAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXYxMDAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDcwOyIgZD0iTTUwIDExMDBoMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di00MzhsNDY0IDQ1M3ExNSAxNCAyNS41IDEwdDEwLjUgLTI1di00MzhsNDY0IDQ1M3ExNSAxNCAyNS41IDEwdDEwLjUgLTI1di0xMDAwcTAgLTIxIC0xMC41IC0yNXQtMjUuNSAxMGwtNDY0IDQ1M3YtNDM4cTAgLTIxIC0xMC41IC0yNXQtMjUuNSAxMGwtNDY0IDQ1M3YtNDM4cTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMDBxLTIxIDAgLTM1LjUgMTQuNSB0LTE0LjUgMzUuNXYxMDAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDcxOyIgZD0iTTEyMDAgMTA1MHYtMTAwMHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ2NCA0NTN2LTQzOHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ5MiA0ODBxLTE1IDE0IC0xNSAzNXQxNSAzNWw0OTIgNDgwcTE1IDE0IDI1LjUgMTB0MTAuNSAtMjV2LTQzOGw0NjQgNDUzcTE1IDE0IDI1LjUgMTB0MTAuNSAtMjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTA3MjsiIGQ9Ik0yNDMgMTA3NGw4MTQgLTQ5OHExOCAtMTEgMTggLTI2dC0xOCAtMjZsLTgxNCAtNDk4cS0xOCAtMTEgLTMwLjUgLTR0LTEyLjUgMjh2MTAwMHEwIDIxIDEyLjUgMjh0MzAuNSAtNHoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDc5OyIgZD0iTTg4NSA5MDBsLTM1MiAtMzUzbDM1MiAtMzUzbC0xOTcgLTE5OGwtNTUyIDU1Mmw1NTIgNTUweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUwODA7IiBkPSJNMTA2NCA1NDdsLTU1MSAtNTUxbC0xOTggMTk4bDM1MyAzNTNsLTM1MyAzNTNsMTk4IDE5OHoiIC8%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDk0OyIgZD0iTTU1MCAxMjAwaDIwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtNTUwaDI5MXEyMSAwIDI2IC0xMS41dC04IC0yNy41bC00MjcgLTUyMnEtMTMgLTE2IC0zMiAtMTZ0LTMyIDE2bC00MjcgNTIycS0xMyAxNiAtOCAyNy41dDI2IDExLjVoMjkxdjU1MHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTA5NTsiIGQ9Ik02MzkgMTEwOWw1MjIgLTQyN3ExNiAtMTMgMTYgLTMydC0xNiAtMzJsLTUyMiAtNDI3cS0xNiAtMTMgLTI3LjUgLTh0LTExLjUgMjZ2MjkxcS05NCAtMiAtMTgyIC0yMHQtMTcwLjUgLTUydC0xNDcgLTkyLjV0LTEwMC41IC0xMzUuNXE1IDEwNSAyNyAxOTMuNXQ2Ny41IDE2N3QxMTMgMTM1dDE2NyA5MS41dDIyNS41IDQydjI2MnEwIDIxIDExLjUgMjZ0MjcuNSAtOHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDk2OyIgZD0iTTg1MCAxMjAwaDMwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtMzAwcTAgLTIxIC0xMC41IC0yNXQtMjQuNSAxMGwtOTQgOTRsLTI0OSAtMjQ5cS04IC03IC0xOCAtN3QtMTggN2wtMTA2IDEwNnEtNyA4IC03IDE4dDcgMThsMjQ5IDI0OWwtOTQgOTRxLTE0IDE0IC0xMCAyNC41dDI1IDEwLjV6TTM1MCAwaC0zMDBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djMwMHEwIDIxIDEwLjUgMjV0MjQuNSAtMTBsOTQgLTk0bDI0OSAyNDkgcTggNyAxOCA3dDE4IC03bDEwNiAtMTA2cTcgLTggNyAtMTh0LTcgLTE4bC0yNDkgLTI0OWw5NCAtOTRxMTQgLTE0IDEwIC0yNC41dC0yNSAtMTAuNXoiIC8%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%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%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%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%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%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%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTQzOyIgZD0iTTY0OSA5NDlxNDggNjggMTA5LjUgMTA0dDEyMS41IDM4LjV0MTE4LjUgLTIwdDEwMi41IC02NHQ3MSAtMTAwLjV0MjcgLTEyM3EwIC01NyAtMzMuNSAtMTE3LjV0LTk0IC0xMjQuNXQtMTI2LjUgLTEyNy41dC0xNTAgLTE1Mi41dC0xNDYgLTE3NHEtNjIgODUgLTE0NS41IDE3NHQtMTUwIDE1Mi41dC0xMjYuNSAxMjcuNXQtOTMuNSAxMjQuNXQtMzMuNSAxMTcuNXEwIDY0IDI4IDEyM3Q3MyAxMDAuNXQxMDQgNjR0MTE5IDIwIHQxMjAuNSAtMzguNXQxMDQuNSAtMTA0ek04OTYgOTcycS0zMyAwIC02NC41IC0xOXQtNTYuNSAtNDZ0LTQ3LjUgLTUzLjV0LTQzLjUgLTQ1LjV0LTM3LjUgLTE5dC0zNiAxOXQtNDAgNDUuNXQtNDMgNTMuNXQtNTQgNDZ0LTY1LjUgMTlxLTY3IDAgLTEyMi41IC01NS41dC01NS41IC0xMzIuNXEwIC0yMyAxMy41IC01MXQ0NiAtNjV0NTcuNSAtNjN0NzYgLTc1bDIyIC0yMnExNSAtMTQgNDQgLTQ0dDUwLjUgLTUxdDQ2IC00NHQ0MSAtMzV0MjMgLTEyIHQyMy41IDEydDQyLjUgMzZ0NDYgNDR0NTIuNSA1MnQ0NCA0M3E0IDQgMTIgMTNxNDMgNDEgNjMuNSA2MnQ1MiA1NXQ0NiA1NXQyNiA0NnQxMS41IDQ0cTAgNzkgLTUzIDEzMy41dC0xMjAgNTQuNXoiIC8%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTYyOyIgZD0iTTc5MyAxMTgybDkgLTlxOCAtMTAgNSAtMjdxLTMgLTExIC03OSAtMjI1LjV0LTc4IC0yMjEuNWwzMDAgMXEyNCAwIDMyLjUgLTE3LjV0LTUuNSAtMzUuNXEtMSAwIC0xMzMuNSAtMTU1dC0yNjcgLTMxMi41dC0xMzguNSAtMTYyLjVxLTEyIC0xNSAtMjYgLTE1aC05bC05IDhxLTkgMTEgLTQgMzJxMiA5IDQyIDEyMy41dDc5IDIyNC41bDM5IDExMGgtMzAycS0yMyAwIC0zMSAxOXEtMTAgMjEgNiA0MXE3NSA4NiAyMDkuNSAyMzcuNSB0MjI4IDI1N3Q5OC41IDExMS41cTkgMTYgMjUgMTZoOXoiIC8%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%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%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%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%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjE5OyIgZD0iTTIwMCAxMTAwaDgwMHE4MyAwIDE0MS41IC01OC41dDU4LjUgLTE0MS41di0yMDBoLTEwMHEwIDQxIC0yOS41IDcwLjV0LTcwLjUgMjkuNWgtMjUwcS00MSAwIC03MC41IC0yOS41dC0yOS41IC03MC41aC0xMDBxMCA0MSAtMjkuNSA3MC41dC03MC41IDI5LjVoLTI1MHEtNDEgMCAtNzAuNSAtMjkuNXQtMjkuNSAtNzAuNWgtMTAwdjIwMHEwIDgzIDU4LjUgMTQxLjV0MTQxLjUgNTguNXpNMTAwIDYwMGgxMDAwcTQxIDAgNzAuNSAtMjkuNSB0MjkuNSAtNzAuNXYtMzAwaC0xMjAwdjMwMHEwIDQxIDI5LjUgNzAuNXQ3MC41IDI5LjV6TTMwMCAxMDB2LTUwcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMDBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djUwaDIwMHpNMTEwMCAxMDB2LTUwcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMDBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djUwaDIwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjIxOyIgZD0iTTQ4MCAxMTY1bDY4MiAtNjgzcTMxIC0zMSAzMSAtNzUuNXQtMzEgLTc1LjVsLTEzMSAtMTMxaC00ODFsLTUxNyA1MThxLTMyIDMxIC0zMiA3NS41dDMyIDc1LjVsMjk1IDI5NnEzMSAzMSA3NS41IDMxdDc2LjUgLTMxek0xMDggNzk0bDM0MiAtMzQybDMwMyAzMDRsLTM0MSAzNDF6TTI1MCAxMDBoODAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di01MGgtOTAwdjUwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUwOyIgZD0iTTg2NSA1NjVsLTQ5NCAtNDk0cS0yMyAtMjMgLTQxIC0yM3EtMTQgMCAtMjIgMTMuNXQtOCAzOC41djEwMDBxMCAyNSA4IDM4LjV0MjIgMTMuNXExOCAwIDQxIC0yM2w0OTQgLTQ5NHExNCAtMTQgMTQgLTM1dC0xNCAtMzV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTI1MTsiIGQ9Ik0zMzUgNjM1bDQ5NCA0OTRxMjkgMjkgNTAgMjAuNXQyMSAtNDkuNXYtMTAwMHEwIC00MSAtMjEgLTQ5LjV0LTUwIDIwLjVsLTQ5NCA0OTRxLTE0IDE0IC0xNCAzNXQxNCAzNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUyOyIgZD0iTTEwMCA5MDBoMTAwMHE0MSAwIDQ5LjUgLTIxdC0yMC41IC01MGwtNDk0IC00OTRxLTE0IC0xNCAtMzUgLTE0dC0zNSAxNGwtNDk0IDQ5NHEtMjkgMjkgLTIwLjUgNTB0NDkuNSAyMXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUzOyIgZD0iTTYzNSA4NjVsNDk0IC00OTRxMjkgLTI5IDIwLjUgLTUwdC00OS41IC0yMWgtMTAwMHEtNDEgMCAtNDkuNSAyMXQyMC41IDUwbDQ5NCA0OTRxMTQgMTQgMzUgMTR0MzUgLTE0eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyNTQ7IiBkPSJNNzAwIDc0MXYtMTgybC02OTIgLTMyM3YyMjFsNDEzIDE5M2wtNDEzIDE5M3YyMjF6TTEyMDAgMGgtODAwdjIwMGg4MDB2LTIwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU1OyIgZD0iTTEyMDAgOTAwaC0yMDB2LTEwMGgyMDB2LTEwMGgtMzAwdjMwMGgyMDB2MTAwaC0yMDB2MTAwaDMwMHYtMzAwek0wIDcwMGg1MHEwIDIxIDQgMzd0OS41IDI2LjV0MTggMTcuNXQyMiAxMXQyOC41IDUuNXQzMSAydDM3IDAuNWgxMDB2LTU1MHEwIC0yMiAtMjUgLTM0LjV0LTUwIC0xMy41bC0yNSAtMnYtMTAwaDQwMHYxMDBxLTQgMCAtMTEgMC41dC0yNCAzdC0zMCA3dC0yNCAxNXQtMTEgMjQuNXY1NTBoMTAwcTI1IDAgMzcgLTAuNXQzMSAtMiB0MjguNSAtNS41dDIyIC0xMXQxOCAtMTcuNXQ5LjUgLTI2LjV0NCAtMzdoNTB2MzAwaC04MDB2LTMwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU2OyIgZD0iTTgwMCA3MDBoLTUwcTAgMjEgLTQgMzd0LTkuNSAyNi41dC0xOCAxNy41dC0yMiAxMXQtMjguNSA1LjV0LTMxIDJ0LTM3IDAuNWgtMTAwdi01NTBxMCAtMjIgMjUgLTM0LjV0NTAgLTE0LjVsMjUgLTF2LTEwMGgtNDAwdjEwMHE0IDAgMTEgMC41dDI0IDN0MzAgN3QyNCAxNXQxMSAyNC41djU1MGgtMTAwcS0yNSAwIC0zNyAtMC41dC0zMSAtMnQtMjguNSAtNS41dC0yMiAtMTF0LTE4IC0xNy41dC05LjUgLTI2LjV0LTQgLTM3aC01MHYzMDAgaDgwMHYtMzAwek0xMTAwIDIwMGgtMjAwdi0xMDBoMjAwdi0xMDBoLTMwMHYzMDBoMjAwdjEwMGgtMjAwdjEwMGgzMDB2LTMwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU3OyIgZD0iTTcwMSAxMDk4aDE2MHExNiAwIDIxIC0xMXQtNyAtMjNsLTQ2NCAtNDY0bDQ2NCAtNDY0cTEyIC0xMiA3IC0yM3QtMjEgLTExaC0xNjBxLTEzIDAgLTIzIDlsLTQ3MSA0NzFxLTcgOCAtNyAxOHQ3IDE4bDQ3MSA0NzFxMTAgOSAyMyA5eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyNTg7IiBkPSJNMzM5IDEwOThoMTYwcTEzIDAgMjMgLTlsNDcxIC00NzFxNyAtOCA3IC0xOHQtNyAtMThsLTQ3MSAtNDcxcS0xMCAtOSAtMjMgLTloLTE2MHEtMTYgMCAtMjEgMTF0NyAyM2w0NjQgNDY0bC00NjQgNDY0cS0xMiAxMiAtNyAyM3QyMSAxMXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU5OyIgZD0iTTEwODcgODgycTExIC01IDExIC0yMXYtMTYwcTAgLTEzIC05IC0yM2wtNDcxIC00NzFxLTggLTcgLTE4IC03dC0xOCA3bC00NzEgNDcxcS05IDEwIC05IDIzdjE2MHEwIDE2IDExIDIxdDIzIC03bDQ2NCAtNDY0bDQ2NCA0NjRxMTIgMTIgMjMgN3oiIC8%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%2BCjwvZGVmcz48L3N2Zz4g%29%20format%28%27svg%27%29%7D%2Eglyphicon%7Bposition%3Arelative%3Btop%3A1px%3Bdisplay%3Ainline%2Dblock%3Bfont%2Dfamily%3A%27Glyphicons%20Halflings%27%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3B%2Dwebkit%2Dfont%2Dsmoothing%3Aantialiased%3B%2Dmoz%2Dosx%2Dfont%2Dsmoothing%3Agrayscale%7D%2Eglyphicon%2Dasterisk%3Abefore%7Bcontent%3A%22%5C2a%22%7D%2Eglyphicon%2Dplus%3Abefore%7Bcontent%3A%22%5C2b%22%7D%2Eglyphicon%2Deur%3Abefore%2C%2Eglyphicon%2Deuro%3Abefore%7Bcontent%3A%22%5C20ac%22%7D%2Eglyphicon%2Dminus%3Abefore%7Bcontent%3A%22%5C2212%22%7D%2Eglyphicon%2Dcloud%3Abefore%7Bcontent%3A%22%5C2601%22%7D%2Eglyphicon%2Denvelope%3Abefore%7Bcontent%3A%22%5C2709%22%7D%2Eglyphicon%2Dpencil%3Abefore%7Bcontent%3A%22%5C270f%22%7D%2Eglyphicon%2Dglass%3Abefore%7Bcontent%3A%22%5Ce001%22%7D%2Eglyphicon%2Dmusic%3Abefore%7Bcontent%3A%22%5Ce002%22%7D%2Eglyphicon%2Dsearch%3Abefore%7Bcontent%3A%22%5Ce003%22%7D%2Eglyphicon%2Dheart%3Abefore%7Bcontent%3A%22%5Ce005%22%7D%2Eglyphicon%2Dstar%3Abefore%7Bcontent%3A%22%5Ce006%22%7D%2Eglyphicon%2Dstar%2Dempty%3Abefore%7Bcontent%3A%22%5Ce007%22%7D%2Eglyphicon%2Duser%3Abefore%7Bcontent%3A%22%5Ce008%22%7D%2Eglyphicon%2Dfilm%3Abefore%7Bcontent%3A%22%5Ce009%22%7D%2Eglyphicon%2Dth%2Dlarge%3Abefore%7Bcontent%3A%22%5Ce010%22%7D%2Eglyphicon%2Dth%3Abefore%7Bcontent%3A%22%5Ce011%22%7D%2Eglyphicon%2Dth%2Dlist%3Abefore%7Bcontent%3A%22%5Ce012%22%7D%2Eglyphicon%2Dok%3Abefore%7Bcontent%3A%22%5Ce013%22%7D%2Eglyphicon%2Dremove%3Abefore%7Bcontent%3A%22%5Ce014%22%7D%2Eglyphicon%2Dzoom%2Din%3Abefore%7Bcontent%3A%22%5Ce015%22%7D%2Eglyphicon%2Dzoom%2Dout%3Abefore%7Bcontent%3A%22%5Ce016%22%7D%2Eglyphicon%2Doff%3Abefore%7Bcontent%3A%22%5Ce017%22%7D%2Eglyphicon%2Dsignal%3Abefore%7Bcontent%3A%22%5Ce018%22%7D%2Eglyphicon%2Dcog%3Abefore%7Bcontent%3A%22%5Ce019%22%7D%2Eglyphicon%2Dtrash%3Abefore%7Bcontent%3A%22%5Ce020%22%7D%2Eglyphicon%2Dhome%3Abefore%7Bcontent%3A%22%5Ce021%22%7D%2Eglyphicon%2Dfile%3Abefore%7Bcontent%3A%22%5Ce022%22%7D%2Eglyphicon%2Dtime%3Abefore%7Bcontent%3A%22%5Ce023%22%7D%2Eglyphicon%2Droad%3Abefore%7Bcontent%3A%22%5Ce024%22%7D%2Eglyphicon%2Ddownload%2Dalt%3Abefore%7Bcontent%3A%22%5Ce025%22%7D%2Eglyphicon%2Ddownload%3Abefore%7Bcontent%3A%22%5Ce026%22%7D%2Eglyphicon%2Dupload%3Abefore%7Bcontent%3A%22%5Ce027%22%7D%2Eglyphicon%2Dinbox%3Abefore%7Bcontent%3A%22%5Ce028%22%7D%2Eglyphicon%2Dplay%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce029%22%7D%2Eglyphicon%2Drepeat%3Abefore%7Bcontent%3A%22%5Ce030%22%7D%2Eglyphicon%2Drefresh%3Abefore%7Bcontent%3A%22%5Ce031%22%7D%2Eglyphicon%2Dlist%2Dalt%3Abefore%7Bcontent%3A%22%5Ce032%22%7D%2Eglyphicon%2Dlock%3Abefore%7Bcontent%3A%22%5Ce033%22%7D%2Eglyphicon%2Dflag%3Abefore%7Bcontent%3A%22%5Ce034%22%7D%2Eglyphicon%2Dheadphones%3Abefore%7Bcontent%3A%22%5Ce035%22%7D%2Eglyphicon%2Dvolume%2Doff%3Abefore%7Bcontent%3A%22%5Ce036%22%7D%2Eglyphicon%2Dvolume%2Ddown%3Abefore%7Bcontent%3A%22%5Ce037%22%7D%2Eglyphicon%2Dvolume%2Dup%3Abefore%7Bcontent%3A%22%5Ce038%22%7D%2Eglyphicon%2Dqrcode%3Abefore%7Bcontent%3A%22%5Ce039%22%7D%2Eglyphicon%2Dbarcode%3Abefore%7Bcontent%3A%22%5Ce040%22%7D%2Eglyphicon%2Dtag%3Abefore%7Bcontent%3A%22%5Ce041%22%7D%2Eglyphicon%2Dtags%3Abefore%7Bcontent%3A%22%5Ce042%22%7D%2Eglyphicon%2Dbook%3Abefore%7Bcontent%3A%22%5Ce043%22%7D%2Eglyphicon%2Dbookmark%3Abefore%7Bcontent%3A%22%5Ce044%22%7D%2Eglyphicon%2Dprint%3Abefore%7Bcontent%3A%22%5Ce045%22%7D%2Eglyphicon%2Dcamera%3Abefore%7Bcontent%3A%22%5Ce046%22%7D%2Eglyphicon%2Dfont%3Abefore%7Bcontent%3A%22%5Ce047%22%7D%2Eglyphicon%2Dbold%3Abefore%7Bcontent%3A%22%5Ce048%22%7D%2Eglyphicon%2Ditalic%3Abefore%7Bcontent%3A%22%5Ce049%22%7D%2Eglyphicon%2Dtext%2Dheight%3Abefore%7Bcontent%3A%22%5Ce050%22%7D%2Eglyphicon%2Dtext%2Dwidth%3Abefore%7Bcontent%3A%22%5Ce051%22%7D%2Eglyphicon%2Dalign%2Dleft%3Abefore%7Bcontent%3A%22%5Ce052%22%7D%2Eglyphicon%2Dalign%2Dcenter%3Abefore%7Bcontent%3A%22%5Ce053%22%7D%2Eglyphicon%2Dalign%2Dright%3Abefore%7Bcontent%3A%22%5Ce054%22%7D%2Eglyphicon%2Dalign%2Djustify%3Abefore%7Bcontent%3A%22%5Ce055%22%7D%2Eglyphicon%2Dlist%3Abefore%7Bcontent%3A%22%5Ce056%22%7D%2Eglyphicon%2Dindent%2Dleft%3Abefore%7Bcontent%3A%22%5Ce057%22%7D%2Eglyphicon%2Dindent%2Dright%3Abefore%7Bcontent%3A%22%5Ce058%22%7D%2Eglyphicon%2Dfacetime%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce059%22%7D%2Eglyphicon%2Dpicture%3Abefore%7Bcontent%3A%22%5Ce060%22%7D%2Eglyphicon%2Dmap%2Dmarker%3Abefore%7Bcontent%3A%22%5Ce062%22%7D%2Eglyphicon%2Dadjust%3Abefore%7Bcontent%3A%22%5Ce063%22%7D%2Eglyphicon%2Dtint%3Abefore%7Bcontent%3A%22%5Ce064%22%7D%2Eglyphicon%2Dedit%3Abefore%7Bcontent%3A%22%5Ce065%22%7D%2Eglyphicon%2Dshare%3Abefore%7Bcontent%3A%22%5Ce066%22%7D%2Eglyphicon%2Dcheck%3Abefore%7Bcontent%3A%22%5Ce067%22%7D%2Eglyphicon%2Dmove%3Abefore%7Bcontent%3A%22%5Ce068%22%7D%2Eglyphicon%2Dstep%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce069%22%7D%2Eglyphicon%2Dfast%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce070%22%7D%2Eglyphicon%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce071%22%7D%2Eglyphicon%2Dplay%3Abefore%7Bcontent%3A%22%5Ce072%22%7D%2Eglyphicon%2Dpause%3Abefore%7Bcontent%3A%22%5Ce073%22%7D%2Eglyphicon%2Dstop%3Abefore%7Bcontent%3A%22%5Ce074%22%7D%2Eglyphicon%2Dforward%3Abefore%7Bcontent%3A%22%5Ce075%22%7D%2Eglyphicon%2Dfast%2Dforward%3Abefore%7Bcontent%3A%22%5Ce076%22%7D%2Eglyphicon%2Dstep%2Dforward%3Abefore%7Bcontent%3A%22%5Ce077%22%7D%2Eglyphicon%2Deject%3Abefore%7Bcontent%3A%22%5Ce078%22%7D%2Eglyphicon%2Dchevron%2Dleft%3Abefore%7Bcontent%3A%22%5Ce079%22%7D%2Eglyphicon%2Dchevron%2Dright%3Abefore%7Bcontent%3A%22%5Ce080%22%7D%2Eglyphicon%2Dplus%2Dsign%3Abefore%7Bcontent%3A%22%5Ce081%22%7D%2Eglyphicon%2Dminus%2Dsign%3Abefore%7Bcontent%3A%22%5Ce082%22%7D%2Eglyphicon%2Dremove%2Dsign%3Abefore%7Bcontent%3A%22%5Ce083%22%7D%2Eglyphicon%2Dok%2Dsign%3Abefore%7Bcontent%3A%22%5Ce084%22%7D%2Eglyphicon%2Dquestion%2Dsign%3Abefore%7Bcontent%3A%22%5Ce085%22%7D%2Eglyphicon%2Dinfo%2Dsign%3Abefore%7Bcontent%3A%22%5Ce086%22%7D%2Eglyphicon%2Dscreenshot%3Abefore%7Bcontent%3A%22%5Ce087%22%7D%2Eglyphicon%2Dremove%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce088%22%7D%2Eglyphicon%2Dok%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce089%22%7D%2Eglyphicon%2Dban%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce090%22%7D%2Eglyphicon%2Darrow%2Dleft%3Abefore%7Bcontent%3A%22%5Ce091%22%7D%2Eglyphicon%2Darrow%2Dright%3Abefore%7Bcontent%3A%22%5Ce092%22%7D%2Eglyphicon%2Darrow%2Dup%3Abefore%7Bcontent%3A%22%5Ce093%22%7D%2Eglyphicon%2Darrow%2Ddown%3Abefore%7Bcontent%3A%22%5Ce094%22%7D%2Eglyphicon%2Dshare%2Dalt%3Abefore%7Bcontent%3A%22%5Ce095%22%7D%2Eglyphicon%2Dresize%2Dfull%3Abefore%7Bcontent%3A%22%5Ce096%22%7D%2Eglyphicon%2Dresize%2Dsmall%3Abefore%7Bcontent%3A%22%5Ce097%22%7D%2Eglyphicon%2Dexclamation%2Dsign%3Abefore%7Bcontent%3A%22%5Ce101%22%7D%2Eglyphicon%2Dgift%3Abefore%7Bcontent%3A%22%5Ce102%22%7D%2Eglyphicon%2Dleaf%3Abefore%7Bcontent%3A%22%5Ce103%22%7D%2Eglyphicon%2Dfire%3Abefore%7Bcontent%3A%22%5Ce104%22%7D%2Eglyphicon%2Deye%2Dopen%3Abefore%7Bcontent%3A%22%5Ce105%22%7D%2Eglyphicon%2Deye%2Dclose%3Abefore%7Bcontent%3A%22%5Ce106%22%7D%2Eglyphicon%2Dwarning%2Dsign%3Abefore%7Bcontent%3A%22%5Ce107%22%7D%2Eglyphicon%2Dplane%3Abefore%7Bcontent%3A%22%5Ce108%22%7D%2Eglyphicon%2Dcalendar%3Abefore%7Bcontent%3A%22%5Ce109%22%7D%2Eglyphicon%2Drandom%3Abefore%7Bcontent%3A%22%5Ce110%22%7D%2Eglyphicon%2Dcomment%3Abefore%7Bcontent%3A%22%5Ce111%22%7D%2Eglyphicon%2Dmagnet%3Abefore%7Bcontent%3A%22%5Ce112%22%7D%2Eglyphicon%2Dchevron%2Dup%3Abefore%7Bcontent%3A%22%5Ce113%22%7D%2Eglyphicon%2Dchevron%2Ddown%3Abefore%7Bcontent%3A%22%5Ce114%22%7D%2Eglyphicon%2Dretweet%3Abefore%7Bcontent%3A%22%5Ce115%22%7D%2Eglyphicon%2Dshopping%2Dcart%3Abefore%7Bcontent%3A%22%5Ce116%22%7D%2Eglyphicon%2Dfolder%2Dclose%3Abefore%7Bcontent%3A%22%5Ce117%22%7D%2Eglyphicon%2Dfolder%2Dopen%3Abefore%7Bcontent%3A%22%5Ce118%22%7D%2Eglyphicon%2Dresize%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce119%22%7D%2Eglyphicon%2Dresize%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce120%22%7D%2Eglyphicon%2Dhdd%3Abefore%7Bcontent%3A%22%5Ce121%22%7D%2Eglyphicon%2Dbullhorn%3Abefore%7Bcontent%3A%22%5Ce122%22%7D%2Eglyphicon%2Dbell%3Abefore%7Bcontent%3A%22%5Ce123%22%7D%2Eglyphicon%2Dcertificate%3Abefore%7Bcontent%3A%22%5Ce124%22%7D%2Eglyphicon%2Dthumbs%2Dup%3Abefore%7Bcontent%3A%22%5Ce125%22%7D%2Eglyphicon%2Dthumbs%2Ddown%3Abefore%7Bcontent%3A%22%5Ce126%22%7D%2Eglyphicon%2Dhand%2Dright%3Abefore%7Bcontent%3A%22%5Ce127%22%7D%2Eglyphicon%2Dhand%2Dleft%3Abefore%7Bcontent%3A%22%5Ce128%22%7D%2Eglyphicon%2Dhand%2Dup%3Abefore%7Bcontent%3A%22%5Ce129%22%7D%2Eglyphicon%2Dhand%2Ddown%3Abefore%7Bcontent%3A%22%5Ce130%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dright%3Abefore%7Bcontent%3A%22%5Ce131%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dleft%3Abefore%7Bcontent%3A%22%5Ce132%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dup%3Abefore%7Bcontent%3A%22%5Ce133%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Ddown%3Abefore%7Bcontent%3A%22%5Ce134%22%7D%2Eglyphicon%2Dglobe%3Abefore%7Bcontent%3A%22%5Ce135%22%7D%2Eglyphicon%2Dwrench%3Abefore%7Bcontent%3A%22%5Ce136%22%7D%2Eglyphicon%2Dtasks%3Abefore%7Bcontent%3A%22%5Ce137%22%7D%2Eglyphicon%2Dfilter%3Abefore%7Bcontent%3A%22%5Ce138%22%7D%2Eglyphicon%2Dbriefcase%3Abefore%7Bcontent%3A%22%5Ce139%22%7D%2Eglyphicon%2Dfullscreen%3Abefore%7Bcontent%3A%22%5Ce140%22%7D%2Eglyphicon%2Ddashboard%3Abefore%7Bcontent%3A%22%5Ce141%22%7D%2Eglyphicon%2Dpaperclip%3Abefore%7Bcontent%3A%22%5Ce142%22%7D%2Eglyphicon%2Dheart%2Dempty%3Abefore%7Bcontent%3A%22%5Ce143%22%7D%2Eglyphicon%2Dlink%3Abefore%7Bcontent%3A%22%5Ce144%22%7D%2Eglyphicon%2Dphone%3Abefore%7Bcontent%3A%22%5Ce145%22%7D%2Eglyphicon%2Dpushpin%3Abefore%7Bcontent%3A%22%5Ce146%22%7D%2Eglyphicon%2Dusd%3Abefore%7Bcontent%3A%22%5Ce148%22%7D%2Eglyphicon%2Dgbp%3Abefore%7Bcontent%3A%22%5Ce149%22%7D%2Eglyphicon%2Dsort%3Abefore%7Bcontent%3A%22%5Ce150%22%7D%2Eglyphicon%2Dsort%2Dby%2Dalphabet%3Abefore%7Bcontent%3A%22%5Ce151%22%7D%2Eglyphicon%2Dsort%2Dby%2Dalphabet%2Dalt%3Abefore%7Bcontent%3A%22%5Ce152%22%7D%2Eglyphicon%2Dsort%2Dby%2Dorder%3Abefore%7Bcontent%3A%22%5Ce153%22%7D%2Eglyphicon%2Dsort%2Dby%2Dorder%2Dalt%3Abefore%7Bcontent%3A%22%5Ce154%22%7D%2Eglyphicon%2Dsort%2Dby%2Dattributes%3Abefore%7Bcontent%3A%22%5Ce155%22%7D%2Eglyphicon%2Dsort%2Dby%2Dattributes%2Dalt%3Abefore%7Bcontent%3A%22%5Ce156%22%7D%2Eglyphicon%2Dunchecked%3Abefore%7Bcontent%3A%22%5Ce157%22%7D%2Eglyphicon%2Dexpand%3Abefore%7Bcontent%3A%22%5Ce158%22%7D%2Eglyphicon%2Dcollapse%2Ddown%3Abefore%7Bcontent%3A%22%5Ce159%22%7D%2Eglyphicon%2Dcollapse%2Dup%3Abefore%7Bcontent%3A%22%5Ce160%22%7D%2Eglyphicon%2Dlog%2Din%3Abefore%7Bcontent%3A%22%5Ce161%22%7D%2Eglyphicon%2Dflash%3Abefore%7Bcontent%3A%22%5Ce162%22%7D%2Eglyphicon%2Dlog%2Dout%3Abefore%7Bcontent%3A%22%5Ce163%22%7D%2Eglyphicon%2Dnew%2Dwindow%3Abefore%7Bcontent%3A%22%5Ce164%22%7D%2Eglyphicon%2Drecord%3Abefore%7Bcontent%3A%22%5Ce165%22%7D%2Eglyphicon%2Dsave%3Abefore%7Bcontent%3A%22%5Ce166%22%7D%2Eglyphicon%2Dopen%3Abefore%7Bcontent%3A%22%5Ce167%22%7D%2Eglyphicon%2Dsaved%3Abefore%7Bcontent%3A%22%5Ce168%22%7D%2Eglyphicon%2Dimport%3Abefore%7Bcontent%3A%22%5Ce169%22%7D%2Eglyphicon%2Dexport%3Abefore%7Bcontent%3A%22%5Ce170%22%7D%2Eglyphicon%2Dsend%3Abefore%7Bcontent%3A%22%5Ce171%22%7D%2Eglyphicon%2Dfloppy%2Ddisk%3Abefore%7Bcontent%3A%22%5Ce172%22%7D%2Eglyphicon%2Dfloppy%2Dsaved%3Abefore%7Bcontent%3A%22%5Ce173%22%7D%2Eglyphicon%2Dfloppy%2Dremove%3Abefore%7Bcontent%3A%22%5Ce174%22%7D%2Eglyphicon%2Dfloppy%2Dsave%3Abefore%7Bcontent%3A%22%5Ce175%22%7D%2Eglyphicon%2Dfloppy%2Dopen%3Abefore%7Bcontent%3A%22%5Ce176%22%7D%2Eglyphicon%2Dcredit%2Dcard%3Abefore%7Bcontent%3A%22%5Ce177%22%7D%2Eglyphicon%2Dtransfer%3Abefore%7Bcontent%3A%22%5Ce178%22%7D%2Eglyphicon%2Dcutlery%3Abefore%7Bcontent%3A%22%5Ce179%22%7D%2Eglyphicon%2Dheader%3Abefore%7Bcontent%3A%22%5Ce180%22%7D%2Eglyphicon%2Dcompressed%3Abefore%7Bcontent%3A%22%5Ce181%22%7D%2Eglyphicon%2Dearphone%3Abefore%7Bcontent%3A%22%5Ce182%22%7D%2Eglyphicon%2Dphone%2Dalt%3Abefore%7Bcontent%3A%22%5Ce183%22%7D%2Eglyphicon%2Dtower%3Abefore%7Bcontent%3A%22%5Ce184%22%7D%2Eglyphicon%2Dstats%3Abefore%7Bcontent%3A%22%5Ce185%22%7D%2Eglyphicon%2Dsd%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce186%22%7D%2Eglyphicon%2Dhd%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce187%22%7D%2Eglyphicon%2Dsubtitles%3Abefore%7Bcontent%3A%22%5Ce188%22%7D%2Eglyphicon%2Dsound%2Dstereo%3Abefore%7Bcontent%3A%22%5Ce189%22%7D%2Eglyphicon%2Dsound%2Ddolby%3Abefore%7Bcontent%3A%22%5Ce190%22%7D%2Eglyphicon%2Dsound%2D5%2D1%3Abefore%7Bcontent%3A%22%5Ce191%22%7D%2Eglyphicon%2Dsound%2D6%2D1%3Abefore%7Bcontent%3A%22%5Ce192%22%7D%2Eglyphicon%2Dsound%2D7%2D1%3Abefore%7Bcontent%3A%22%5Ce193%22%7D%2Eglyphicon%2Dcopyright%2Dmark%3Abefore%7Bcontent%3A%22%5Ce194%22%7D%2Eglyphicon%2Dregistration%2Dmark%3Abefore%7Bcontent%3A%22%5Ce195%22%7D%2Eglyphicon%2Dcloud%2Ddownload%3Abefore%7Bcontent%3A%22%5Ce197%22%7D%2Eglyphicon%2Dcloud%2Dupload%3Abefore%7Bcontent%3A%22%5Ce198%22%7D%2Eglyphicon%2Dtree%2Dconifer%3Abefore%7Bcontent%3A%22%5Ce199%22%7D%2Eglyphicon%2Dtree%2Ddeciduous%3Abefore%7Bcontent%3A%22%5Ce200%22%7D%2Eglyphicon%2Dcd%3Abefore%7Bcontent%3A%22%5Ce201%22%7D%2Eglyphicon%2Dsave%2Dfile%3Abefore%7Bcontent%3A%22%5Ce202%22%7D%2Eglyphicon%2Dopen%2Dfile%3Abefore%7Bcontent%3A%22%5Ce203%22%7D%2Eglyphicon%2Dlevel%2Dup%3Abefore%7Bcontent%3A%22%5Ce204%22%7D%2Eglyphicon%2Dcopy%3Abefore%7Bcontent%3A%22%5Ce205%22%7D%2Eglyphicon%2Dpaste%3Abefore%7Bcontent%3A%22%5Ce206%22%7D%2Eglyphicon%2Dalert%3Abefore%7Bcontent%3A%22%5Ce209%22%7D%2Eglyphicon%2Dequalizer%3Abefore%7Bcontent%3A%22%5Ce210%22%7D%2Eglyphicon%2Dking%3Abefore%7Bcontent%3A%22%5Ce211%22%7D%2Eglyphicon%2Dqueen%3Abefore%7Bcontent%3A%22%5Ce212%22%7D%2Eglyphicon%2Dpawn%3Abefore%7Bcontent%3A%22%5Ce213%22%7D%2Eglyphicon%2Dbishop%3Abefore%7Bcontent%3A%22%5Ce214%22%7D%2Eglyphicon%2Dknight%3Abefore%7Bcontent%3A%22%5Ce215%22%7D%2Eglyphicon%2Dbaby%2Dformula%3Abefore%7Bcontent%3A%22%5Ce216%22%7D%2Eglyphicon%2Dtent%3Abefore%7Bcontent%3A%22%5C26fa%22%7D%2Eglyphicon%2Dblackboard%3Abefore%7Bcontent%3A%22%5Ce218%22%7D%2Eglyphicon%2Dbed%3Abefore%7Bcontent%3A%22%5Ce219%22%7D%2Eglyphicon%2Dapple%3Abefore%7Bcontent%3A%22%5Cf8ff%22%7D%2Eglyphicon%2Derase%3Abefore%7Bcontent%3A%22%5Ce221%22%7D%2Eglyphicon%2Dhourglass%3Abefore%7Bcontent%3A%22%5C231b%22%7D%2Eglyphicon%2Dlamp%3Abefore%7Bcontent%3A%22%5Ce223%22%7D%2Eglyphicon%2Dduplicate%3Abefore%7Bcontent%3A%22%5Ce224%22%7D%2Eglyphicon%2Dpiggy%2Dbank%3Abefore%7Bcontent%3A%22%5Ce225%22%7D%2Eglyphicon%2Dscissors%3Abefore%7Bcontent%3A%22%5Ce226%22%7D%2Eglyphicon%2Dbitcoin%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dbtc%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dxbt%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dyen%3Abefore%7Bcontent%3A%22%5C00a5%22%7D%2Eglyphicon%2Djpy%3Abefore%7Bcontent%3A%22%5C00a5%22%7D%2Eglyphicon%2Druble%3Abefore%7Bcontent%3A%22%5C20bd%22%7D%2Eglyphicon%2Drub%3Abefore%7Bcontent%3A%22%5C20bd%22%7D%2Eglyphicon%2Dscale%3Abefore%7Bcontent%3A%22%5Ce230%22%7D%2Eglyphicon%2Dice%2Dlolly%3Abefore%7Bcontent%3A%22%5Ce231%22%7D%2Eglyphicon%2Dice%2Dlolly%2Dtasted%3Abefore%7Bcontent%3A%22%5Ce232%22%7D%2Eglyphicon%2Deducation%3Abefore%7Bcontent%3A%22%5Ce233%22%7D%2Eglyphicon%2Doption%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce234%22%7D%2Eglyphicon%2Doption%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce235%22%7D%2Eglyphicon%2Dmenu%2Dhamburger%3Abefore%7Bcontent%3A%22%5Ce236%22%7D%2Eglyphicon%2Dmodal%2Dwindow%3Abefore%7Bcontent%3A%22%5Ce237%22%7D%2Eglyphicon%2Doil%3Abefore%7Bcontent%3A%22%5Ce238%22%7D%2Eglyphicon%2Dgrain%3Abefore%7Bcontent%3A%22%5Ce239%22%7D%2Eglyphicon%2Dsunglasses%3Abefore%7Bcontent%3A%22%5Ce240%22%7D%2Eglyphicon%2Dtext%2Dsize%3Abefore%7Bcontent%3A%22%5Ce241%22%7D%2Eglyphicon%2Dtext%2Dcolor%3Abefore%7Bcontent%3A%22%5Ce242%22%7D%2Eglyphicon%2Dtext%2Dbackground%3Abefore%7Bcontent%3A%22%5Ce243%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dtop%3Abefore%7Bcontent%3A%22%5Ce244%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dbottom%3Abefore%7Bcontent%3A%22%5Ce245%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce246%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dleft%3Abefore%7Bcontent%3A%22%5Ce247%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce248%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dright%3Abefore%7Bcontent%3A%22%5Ce249%22%7D%2Eglyphicon%2Dtriangle%2Dright%3Abefore%7Bcontent%3A%22%5Ce250%22%7D%2Eglyphicon%2Dtriangle%2Dleft%3Abefore%7Bcontent%3A%22%5Ce251%22%7D%2Eglyphicon%2Dtriangle%2Dbottom%3Abefore%7Bcontent%3A%22%5Ce252%22%7D%2Eglyphicon%2Dtriangle%2Dtop%3Abefore%7Bcontent%3A%22%5Ce253%22%7D%2Eglyphicon%2Dconsole%3Abefore%7Bcontent%3A%22%5Ce254%22%7D%2Eglyphicon%2Dsuperscript%3Abefore%7Bcontent%3A%22%5Ce255%22%7D%2Eglyphicon%2Dsubscript%3Abefore%7Bcontent%3A%22%5Ce256%22%7D%2Eglyphicon%2Dmenu%2Dleft%3Abefore%7Bcontent%3A%22%5Ce257%22%7D%2Eglyphicon%2Dmenu%2Dright%3Abefore%7Bcontent%3A%22%5Ce258%22%7D%2Eglyphicon%2Dmenu%2Ddown%3Abefore%7Bcontent%3A%22%5Ce259%22%7D%2Eglyphicon%2Dmenu%2Dup%3Abefore%7Bcontent%3A%22%5Ce260%22%7D%2A%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7D%3Aafter%2C%3Abefore%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7Dhtml%7Bfont%2Dsize%3A10px%3B%2Dwebkit%2Dtap%2Dhighlight%2Dcolor%3Argba%280%2C0%2C0%2C0%29%7Dbody%7Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23fff%7Dbutton%2Cinput%2Cselect%2Ctextarea%7Bfont%2Dfamily%3Ainherit%3Bfont%2Dsize%3Ainherit%3Bline%2Dheight%3Ainherit%7Da%7Bcolor%3A%23337ab7%3Btext%2Ddecoration%3Anone%7Da%3Afocus%2Ca%3Ahover%7Bcolor%3A%2323527c%3Btext%2Ddecoration%3Aunderline%7Da%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7Dfigure%7Bmargin%3A0%7Dimg%7Bvertical%2Dalign%3Amiddle%7D%2Ecarousel%2Dinner%3E%2Eitem%3Ea%3Eimg%2C%2Ecarousel%2Dinner%3E%2Eitem%3Eimg%2C%2Eimg%2Dresponsive%2C%2Ethumbnail%20a%3Eimg%2C%2Ethumbnail%3Eimg%7Bdisplay%3Ablock%3Bmax%2Dwidth%3A100%25%3Bheight%3Aauto%7D%2Eimg%2Drounded%7Bborder%2Dradius%3A6px%7D%2Eimg%2Dthumbnail%7Bdisplay%3Ainline%2Dblock%3Bmax%2Dwidth%3A100%25%3Bheight%3Aauto%3Bpadding%3A4px%3Bline%2Dheight%3A1%2E42857143%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dtransition%3Aall%20%2E2s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3Aall%20%2E2s%20ease%2Din%2Dout%3Btransition%3Aall%20%2E2s%20ease%2Din%2Dout%7D%2Eimg%2Dcircle%7Bborder%2Dradius%3A50%25%7Dhr%7Bmargin%2Dtop%3A20px%3Bmargin%2Dbottom%3A20px%3Bborder%3A0%3Bborder%2Dtop%3A1px%20solid%20%23eee%7D%2Esr%2Donly%7Bposition%3Aabsolute%3Bwidth%3A1px%3Bheight%3A1px%3Bpadding%3A0%3Bmargin%3A%2D1px%3Boverflow%3Ahidden%3Bclip%3Arect%280%2C0%2C0%2C0%29%3Bborder%3A0%7D%2Esr%2Donly%2Dfocusable%3Aactive%2C%2Esr%2Donly%2Dfocusable%3Afocus%7Bposition%3Astatic%3Bwidth%3Aauto%3Bheight%3Aauto%3Bmargin%3A0%3Boverflow%3Avisible%3Bclip%3Aauto%7D%5Brole%3Dbutton%5D%7Bcursor%3Apointer%7D%2Eh1%2C%2Eh2%2C%2Eh3%2C%2Eh4%2C%2Eh5%2C%2Eh6%2Ch1%2Ch2%2Ch3%2Ch4%2Ch5%2Ch6%7Bfont%2Dfamily%3Ainherit%3Bfont%2Dweight%3A500%3Bline%2Dheight%3A1%2E1%3Bcolor%3Ainherit%7D%2Eh1%20%2Esmall%2C%2Eh1%20small%2C%2Eh2%20%2Esmall%2C%2Eh2%20small%2C%2Eh3%20%2Esmall%2C%2Eh3%20small%2C%2Eh4%20%2Esmall%2C%2Eh4%20small%2C%2Eh5%20%2Esmall%2C%2Eh5%20small%2C%2Eh6%20%2Esmall%2C%2Eh6%20small%2Ch1%20%2Esmall%2Ch1%20small%2Ch2%20%2Esmall%2Ch2%20small%2Ch3%20%2Esmall%2Ch3%20small%2Ch4%20%2Esmall%2Ch4%20small%2Ch5%20%2Esmall%2Ch5%20small%2Ch6%20%2Esmall%2Ch6%20small%7Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3Bcolor%3A%23777%7D%2Eh1%2C%2Eh2%2C%2Eh3%2Ch1%2Ch2%2Ch3%7Bmargin%2Dtop%3A20px%3Bmargin%2Dbottom%3A10px%7D%2Eh1%20%2Esmall%2C%2Eh1%20small%2C%2Eh2%20%2Esmall%2C%2Eh2%20small%2C%2Eh3%20%2Esmall%2C%2Eh3%20small%2Ch1%20%2Esmall%2Ch1%20small%2Ch2%20%2Esmall%2Ch2%20small%2Ch3%20%2Esmall%2Ch3%20small%7Bfont%2Dsize%3A65%25%7D%2Eh4%2C%2Eh5%2C%2Eh6%2Ch4%2Ch5%2Ch6%7Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Eh4%20%2Esmall%2C%2Eh4%20small%2C%2Eh5%20%2Esmall%2C%2Eh5%20small%2C%2Eh6%20%2Esmall%2C%2Eh6%20small%2Ch4%20%2Esmall%2Ch4%20small%2Ch5%20%2Esmall%2Ch5%20small%2Ch6%20%2Esmall%2Ch6%20small%7Bfont%2Dsize%3A75%25%7D%2Eh1%2Ch1%7Bfont%2Dsize%3A36px%7D%2Eh2%2Ch2%7Bfont%2Dsize%3A30px%7D%2Eh3%2Ch3%7Bfont%2Dsize%3A24px%7D%2Eh4%2Ch4%7Bfont%2Dsize%3A18px%7D%2Eh5%2Ch5%7Bfont%2Dsize%3A14px%7D%2Eh6%2Ch6%7Bfont%2Dsize%3A12px%7Dp%7Bmargin%3A0%200%2010px%7D%2Elead%7Bmargin%2Dbottom%3A20px%3Bfont%2Dsize%3A16px%3Bfont%2Dweight%3A300%3Bline%2Dheight%3A1%2E4%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Elead%7Bfont%2Dsize%3A21px%7D%7D%2Esmall%2Csmall%7Bfont%2Dsize%3A85%25%7D%2Emark%2Cmark%7Bpadding%3A%2E2em%3Bbackground%2Dcolor%3A%23fcf8e3%7D%2Etext%2Dleft%7Btext%2Dalign%3Aleft%7D%2Etext%2Dright%7Btext%2Dalign%3Aright%7D%2Etext%2Dcenter%7Btext%2Dalign%3Acenter%7D%2Etext%2Djustify%7Btext%2Dalign%3Ajustify%7D%2Etext%2Dnowrap%7Bwhite%2Dspace%3Anowrap%7D%2Etext%2Dlowercase%7Btext%2Dtransform%3Alowercase%7D%2Etext%2Duppercase%7Btext%2Dtransform%3Auppercase%7D%2Etext%2Dcapitalize%7Btext%2Dtransform%3Acapitalize%7D%2Etext%2Dmuted%7Bcolor%3A%23777%7D%2Etext%2Dprimary%7Bcolor%3A%23337ab7%7Da%2Etext%2Dprimary%3Afocus%2Ca%2Etext%2Dprimary%3Ahover%7Bcolor%3A%23286090%7D%2Etext%2Dsuccess%7Bcolor%3A%233c763d%7Da%2Etext%2Dsuccess%3Afocus%2Ca%2Etext%2Dsuccess%3Ahover%7Bcolor%3A%232b542c%7D%2Etext%2Dinfo%7Bcolor%3A%2331708f%7Da%2Etext%2Dinfo%3Afocus%2Ca%2Etext%2Dinfo%3Ahover%7Bcolor%3A%23245269%7D%2Etext%2Dwarning%7Bcolor%3A%238a6d3b%7Da%2Etext%2Dwarning%3Afocus%2Ca%2Etext%2Dwarning%3Ahover%7Bcolor%3A%2366512c%7D%2Etext%2Ddanger%7Bcolor%3A%23a94442%7Da%2Etext%2Ddanger%3Afocus%2Ca%2Etext%2Ddanger%3Ahover%7Bcolor%3A%23843534%7D%2Ebg%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%7Da%2Ebg%2Dprimary%3Afocus%2Ca%2Ebg%2Dprimary%3Ahover%7Bbackground%2Dcolor%3A%23286090%7D%2Ebg%2Dsuccess%7Bbackground%2Dcolor%3A%23dff0d8%7Da%2Ebg%2Dsuccess%3Afocus%2Ca%2Ebg%2Dsuccess%3Ahover%7Bbackground%2Dcolor%3A%23c1e2b3%7D%2Ebg%2Dinfo%7Bbackground%2Dcolor%3A%23d9edf7%7Da%2Ebg%2Dinfo%3Afocus%2Ca%2Ebg%2Dinfo%3Ahover%7Bbackground%2Dcolor%3A%23afd9ee%7D%2Ebg%2Dwarning%7Bbackground%2Dcolor%3A%23fcf8e3%7Da%2Ebg%2Dwarning%3Afocus%2Ca%2Ebg%2Dwarning%3Ahover%7Bbackground%2Dcolor%3A%23f7ecb5%7D%2Ebg%2Ddanger%7Bbackground%2Dcolor%3A%23f2dede%7Da%2Ebg%2Ddanger%3Afocus%2Ca%2Ebg%2Ddanger%3Ahover%7Bbackground%2Dcolor%3A%23e4b9b9%7D%2Epage%2Dheader%7Bpadding%2Dbottom%3A9px%3Bmargin%3A40px%200%2020px%3Bborder%2Dbottom%3A1px%20solid%20%23eee%7Dol%2Cul%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A10px%7Dol%20ol%2Col%20ul%2Cul%20ol%2Cul%20ul%7Bmargin%2Dbottom%3A0%7D%2Elist%2Dunstyled%7Bpadding%2Dleft%3A0%3Blist%2Dstyle%3Anone%7D%2Elist%2Dinline%7Bpadding%2Dleft%3A0%3Bmargin%2Dleft%3A%2D5px%3Blist%2Dstyle%3Anone%7D%2Elist%2Dinline%3Eli%7Bdisplay%3Ainline%2Dblock%3Bpadding%2Dright%3A5px%3Bpadding%2Dleft%3A5px%7Ddl%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A20px%7Ddd%2Cdt%7Bline%2Dheight%3A1%2E42857143%7Ddt%7Bfont%2Dweight%3A700%7Ddd%7Bmargin%2Dleft%3A0%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Edl%2Dhorizontal%20dt%7Bfloat%3Aleft%3Bwidth%3A160px%3Boverflow%3Ahidden%3Bclear%3Aleft%3Btext%2Dalign%3Aright%3Btext%2Doverflow%3Aellipsis%3Bwhite%2Dspace%3Anowrap%7D%2Edl%2Dhorizontal%20dd%7Bmargin%2Dleft%3A180px%7D%7Dabbr%5Bdata%2Doriginal%2Dtitle%5D%2Cabbr%5Btitle%5D%7Bcursor%3Ahelp%3Bborder%2Dbottom%3A1px%20dotted%20%23777%7D%2Einitialism%7Bfont%2Dsize%3A90%25%3Btext%2Dtransform%3Auppercase%7Dblockquote%7Bpadding%3A10px%2020px%3Bmargin%3A0%200%2020px%3Bfont%2Dsize%3A17%2E5px%3Bborder%2Dleft%3A5px%20solid%20%23eee%7Dblockquote%20ol%3Alast%2Dchild%2Cblockquote%20p%3Alast%2Dchild%2Cblockquote%20ul%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%7Dblockquote%20%2Esmall%2Cblockquote%20footer%2Cblockquote%20small%7Bdisplay%3Ablock%3Bfont%2Dsize%3A80%25%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23777%7Dblockquote%20%2Esmall%3Abefore%2Cblockquote%20footer%3Abefore%2Cblockquote%20small%3Abefore%7Bcontent%3A%27%5C2014%20%5C00A0%27%7D%2Eblockquote%2Dreverse%2Cblockquote%2Epull%2Dright%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A0%3Btext%2Dalign%3Aright%3Bborder%2Dright%3A5px%20solid%20%23eee%3Bborder%2Dleft%3A0%7D%2Eblockquote%2Dreverse%20%2Esmall%3Abefore%2C%2Eblockquote%2Dreverse%20footer%3Abefore%2C%2Eblockquote%2Dreverse%20small%3Abefore%2Cblockquote%2Epull%2Dright%20%2Esmall%3Abefore%2Cblockquote%2Epull%2Dright%20footer%3Abefore%2Cblockquote%2Epull%2Dright%20small%3Abefore%7Bcontent%3A%27%27%7D%2Eblockquote%2Dreverse%20%2Esmall%3Aafter%2C%2Eblockquote%2Dreverse%20footer%3Aafter%2C%2Eblockquote%2Dreverse%20small%3Aafter%2Cblockquote%2Epull%2Dright%20%2Esmall%3Aafter%2Cblockquote%2Epull%2Dright%20footer%3Aafter%2Cblockquote%2Epull%2Dright%20small%3Aafter%7Bcontent%3A%27%5C00A0%20%5C2014%27%7Daddress%7Bmargin%2Dbottom%3A20px%3Bfont%2Dstyle%3Anormal%3Bline%2Dheight%3A1%2E42857143%7Dcode%2Ckbd%2Cpre%2Csamp%7Bfont%2Dfamily%3Amonospace%7Dcode%7Bpadding%3A2px%204px%3Bfont%2Dsize%3A90%25%3Bcolor%3A%23c7254e%3Bbackground%2Dcolor%3A%23f9f2f4%3Bborder%2Dradius%3A4px%7Dkbd%7Bpadding%3A2px%204px%3Bfont%2Dsize%3A90%25%3Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23333%3Bborder%2Dradius%3A3px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E25%29%3Bbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E25%29%7Dkbd%20kbd%7Bpadding%3A0%3Bfont%2Dsize%3A100%25%3Bfont%2Dweight%3A700%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7Dpre%7Bdisplay%3Ablock%3Bpadding%3A9%2E5px%3Bmargin%3A0%200%2010px%3Bfont%2Dsize%3A13px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bword%2Dbreak%3Abreak%2Dall%3Bword%2Dwrap%3Abreak%2Dword%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%7Dpre%20code%7Bpadding%3A0%3Bfont%2Dsize%3Ainherit%3Bcolor%3Ainherit%3Bwhite%2Dspace%3Apre%2Dwrap%3Bbackground%2Dcolor%3Atransparent%3Bborder%2Dradius%3A0%7D%2Epre%2Dscrollable%7Bmax%2Dheight%3A340px%3Boverflow%2Dy%3Ascroll%7D%2Econtainer%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Econtainer%7Bwidth%3A750px%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Econtainer%7Bwidth%3A970px%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Econtainer%7Bwidth%3A1170px%7D%7D%2Econtainer%2Dfluid%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%2Erow%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%2Ecol%2Dlg%2D1%2C%2Ecol%2Dlg%2D10%2C%2Ecol%2Dlg%2D11%2C%2Ecol%2Dlg%2D12%2C%2Ecol%2Dlg%2D2%2C%2Ecol%2Dlg%2D3%2C%2Ecol%2Dlg%2D4%2C%2Ecol%2Dlg%2D5%2C%2Ecol%2Dlg%2D6%2C%2Ecol%2Dlg%2D7%2C%2Ecol%2Dlg%2D8%2C%2Ecol%2Dlg%2D9%2C%2Ecol%2Dmd%2D1%2C%2Ecol%2Dmd%2D10%2C%2Ecol%2Dmd%2D11%2C%2Ecol%2Dmd%2D12%2C%2Ecol%2Dmd%2D2%2C%2Ecol%2Dmd%2D3%2C%2Ecol%2Dmd%2D4%2C%2Ecol%2Dmd%2D5%2C%2Ecol%2Dmd%2D6%2C%2Ecol%2Dmd%2D7%2C%2Ecol%2Dmd%2D8%2C%2Ecol%2Dmd%2D9%2C%2Ecol%2Dsm%2D1%2C%2Ecol%2Dsm%2D10%2C%2Ecol%2Dsm%2D11%2C%2Ecol%2Dsm%2D12%2C%2Ecol%2Dsm%2D2%2C%2Ecol%2Dsm%2D3%2C%2Ecol%2Dsm%2D4%2C%2Ecol%2Dsm%2D5%2C%2Ecol%2Dsm%2D6%2C%2Ecol%2Dsm%2D7%2C%2Ecol%2Dsm%2D8%2C%2Ecol%2Dsm%2D9%2C%2Ecol%2Dxs%2D1%2C%2Ecol%2Dxs%2D10%2C%2Ecol%2Dxs%2D11%2C%2Ecol%2Dxs%2D12%2C%2Ecol%2Dxs%2D2%2C%2Ecol%2Dxs%2D3%2C%2Ecol%2Dxs%2D4%2C%2Ecol%2Dxs%2D5%2C%2Ecol%2Dxs%2D6%2C%2Ecol%2Dxs%2D7%2C%2Ecol%2Dxs%2D8%2C%2Ecol%2Dxs%2D9%7Bposition%3Arelative%3Bmin%2Dheight%3A1px%3Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%7D%2Ecol%2Dxs%2D1%2C%2Ecol%2Dxs%2D10%2C%2Ecol%2Dxs%2D11%2C%2Ecol%2Dxs%2D12%2C%2Ecol%2Dxs%2D2%2C%2Ecol%2Dxs%2D3%2C%2Ecol%2Dxs%2D4%2C%2Ecol%2Dxs%2D5%2C%2Ecol%2Dxs%2D6%2C%2Ecol%2Dxs%2D7%2C%2Ecol%2Dxs%2D8%2C%2Ecol%2Dxs%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dxs%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dxs%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dxs%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dxs%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dxs%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dxs%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dxs%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dxs%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dxs%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dxs%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dxs%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dxs%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dxs%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dxs%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dxs%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dxs%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dxs%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dxs%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dxs%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dxs%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dxs%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dxs%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dxs%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dxs%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dxs%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dxs%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Ecol%2Dsm%2D1%2C%2Ecol%2Dsm%2D10%2C%2Ecol%2Dsm%2D11%2C%2Ecol%2Dsm%2D12%2C%2Ecol%2Dsm%2D2%2C%2Ecol%2Dsm%2D3%2C%2Ecol%2Dsm%2D4%2C%2Ecol%2Dsm%2D5%2C%2Ecol%2Dsm%2D6%2C%2Ecol%2Dsm%2D7%2C%2Ecol%2Dsm%2D8%2C%2Ecol%2Dsm%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dsm%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dsm%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dsm%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dsm%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dsm%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dsm%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dsm%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dsm%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dsm%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dsm%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dsm%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dsm%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dsm%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dsm%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dsm%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dsm%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dsm%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dsm%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dsm%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dsm%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dsm%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dsm%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dsm%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dsm%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dsm%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dsm%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Ecol%2Dmd%2D1%2C%2Ecol%2Dmd%2D10%2C%2Ecol%2Dmd%2D11%2C%2Ecol%2Dmd%2D12%2C%2Ecol%2Dmd%2D2%2C%2Ecol%2Dmd%2D3%2C%2Ecol%2Dmd%2D4%2C%2Ecol%2Dmd%2D5%2C%2Ecol%2Dmd%2D6%2C%2Ecol%2Dmd%2D7%2C%2Ecol%2Dmd%2D8%2C%2Ecol%2Dmd%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dmd%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dmd%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dmd%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dmd%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dmd%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dmd%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dmd%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dmd%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dmd%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dmd%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dmd%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dmd%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dmd%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dmd%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dmd%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dmd%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dmd%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dmd%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dmd%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dmd%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dmd%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dmd%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dmd%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dmd%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dmd%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dmd%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Ecol%2Dlg%2D1%2C%2Ecol%2Dlg%2D10%2C%2Ecol%2Dlg%2D11%2C%2Ecol%2Dlg%2D12%2C%2Ecol%2Dlg%2D2%2C%2Ecol%2Dlg%2D3%2C%2Ecol%2Dlg%2D4%2C%2Ecol%2Dlg%2D5%2C%2Ecol%2Dlg%2D6%2C%2Ecol%2Dlg%2D7%2C%2Ecol%2Dlg%2D8%2C%2Ecol%2Dlg%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dlg%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dlg%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dlg%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dlg%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dlg%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dlg%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dlg%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dlg%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dlg%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dlg%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dlg%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dlg%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dlg%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dlg%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dlg%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dlg%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dlg%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dlg%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dlg%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dlg%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dlg%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dlg%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dlg%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dlg%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dlg%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dlg%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7Dtable%7Bbackground%2Dcolor%3Atransparent%7Dcaption%7Bpadding%2Dtop%3A8px%3Bpadding%2Dbottom%3A8px%3Bcolor%3A%23777%3Btext%2Dalign%3Aleft%7Dth%7B%7D%2Etable%7Bwidth%3A100%25%3Bmax%2Dwidth%3A100%25%3Bmargin%2Dbottom%3A20px%7D%2Etable%3Etbody%3Etr%3Etd%2C%2Etable%3Etbody%3Etr%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2C%2Etable%3Etfoot%3Etr%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2C%2Etable%3Ethead%3Etr%3Eth%7Bpadding%3A8px%3Bline%2Dheight%3A1%2E42857143%3Bvertical%2Dalign%3Atop%3Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Etable%3Ethead%3Etr%3Eth%7Bvertical%2Dalign%3Abottom%3Bborder%2Dbottom%3A2px%20solid%20%23ddd%7D%2Etable%3Ecaption%2Bthead%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ecaption%2Bthead%3Etr%3Afirst%2Dchild%3Eth%2C%2Etable%3Ecolgroup%2Bthead%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ecolgroup%2Bthead%3Etr%3Afirst%2Dchild%3Eth%2C%2Etable%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%3Eth%7Bborder%2Dtop%3A0%7D%2Etable%3Etbody%2Btbody%7Bborder%2Dtop%3A2px%20solid%20%23ddd%7D%2Etable%20%2Etable%7Bbackground%2Dcolor%3A%23fff%7D%2Etable%2Dcondensed%3Etbody%3Etr%3Etd%2C%2Etable%2Dcondensed%3Etbody%3Etr%3Eth%2C%2Etable%2Dcondensed%3Etfoot%3Etr%3Etd%2C%2Etable%2Dcondensed%3Etfoot%3Etr%3Eth%2C%2Etable%2Dcondensed%3Ethead%3Etr%3Etd%2C%2Etable%2Dcondensed%3Ethead%3Etr%3Eth%7Bpadding%3A5px%7D%2Etable%2Dbordered%7Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dbordered%3Etbody%3Etr%3Etd%2C%2Etable%2Dbordered%3Etbody%3Etr%3Eth%2C%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%2C%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%2C%2Etable%2Dbordered%3Ethead%3Etr%3Etd%2C%2Etable%2Dbordered%3Ethead%3Etr%3Eth%7Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dbordered%3Ethead%3Etr%3Etd%2C%2Etable%2Dbordered%3Ethead%3Etr%3Eth%7Bborder%2Dbottom%2Dwidth%3A2px%7D%2Etable%2Dstriped%3Etbody%3Etr%3Anth%2Dof%2Dtype%28odd%29%7Bbackground%2Dcolor%3A%23f9f9f9%7D%2Etable%2Dhover%3Etbody%3Etr%3Ahover%7Bbackground%2Dcolor%3A%23f5f5f5%7Dtable%20col%5Bclass%2A%3Dcol%2D%5D%7Bposition%3Astatic%3Bdisplay%3Atable%2Dcolumn%3Bfloat%3Anone%7Dtable%20td%5Bclass%2A%3Dcol%2D%5D%2Ctable%20th%5Bclass%2A%3Dcol%2D%5D%7Bposition%3Astatic%3Bdisplay%3Atable%2Dcell%3Bfloat%3Anone%7D%2Etable%3Etbody%3Etr%2Eactive%3Etd%2C%2Etable%3Etbody%3Etr%2Eactive%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Eactive%2C%2Etable%3Etbody%3Etr%3Eth%2Eactive%2C%2Etable%3Etfoot%3Etr%2Eactive%3Etd%2C%2Etable%3Etfoot%3Etr%2Eactive%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Eactive%2C%2Etable%3Etfoot%3Etr%3Eth%2Eactive%2C%2Etable%3Ethead%3Etr%2Eactive%3Etd%2C%2Etable%3Ethead%3Etr%2Eactive%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Eactive%2C%2Etable%3Ethead%3Etr%3Eth%2Eactive%7Bbackground%2Dcolor%3A%23f5f5f5%7D%2Etable%2Dhover%3Etbody%3Etr%2Eactive%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Eactive%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Eactive%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Eactive%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Eactive%3Ahover%7Bbackground%2Dcolor%3A%23e8e8e8%7D%2Etable%3Etbody%3Etr%2Esuccess%3Etd%2C%2Etable%3Etbody%3Etr%2Esuccess%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Esuccess%2C%2Etable%3Etbody%3Etr%3Eth%2Esuccess%2C%2Etable%3Etfoot%3Etr%2Esuccess%3Etd%2C%2Etable%3Etfoot%3Etr%2Esuccess%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Esuccess%2C%2Etable%3Etfoot%3Etr%3Eth%2Esuccess%2C%2Etable%3Ethead%3Etr%2Esuccess%3Etd%2C%2Etable%3Ethead%3Etr%2Esuccess%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Esuccess%2C%2Etable%3Ethead%3Etr%3Eth%2Esuccess%7Bbackground%2Dcolor%3A%23dff0d8%7D%2Etable%2Dhover%3Etbody%3Etr%2Esuccess%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Esuccess%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Esuccess%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Esuccess%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Esuccess%3Ahover%7Bbackground%2Dcolor%3A%23d0e9c6%7D%2Etable%3Etbody%3Etr%2Einfo%3Etd%2C%2Etable%3Etbody%3Etr%2Einfo%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Einfo%2C%2Etable%3Etbody%3Etr%3Eth%2Einfo%2C%2Etable%3Etfoot%3Etr%2Einfo%3Etd%2C%2Etable%3Etfoot%3Etr%2Einfo%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Einfo%2C%2Etable%3Etfoot%3Etr%3Eth%2Einfo%2C%2Etable%3Ethead%3Etr%2Einfo%3Etd%2C%2Etable%3Ethead%3Etr%2Einfo%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Einfo%2C%2Etable%3Ethead%3Etr%3Eth%2Einfo%7Bbackground%2Dcolor%3A%23d9edf7%7D%2Etable%2Dhover%3Etbody%3Etr%2Einfo%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Einfo%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Einfo%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Einfo%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Einfo%3Ahover%7Bbackground%2Dcolor%3A%23c4e3f3%7D%2Etable%3Etbody%3Etr%2Ewarning%3Etd%2C%2Etable%3Etbody%3Etr%2Ewarning%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Ewarning%2C%2Etable%3Etbody%3Etr%3Eth%2Ewarning%2C%2Etable%3Etfoot%3Etr%2Ewarning%3Etd%2C%2Etable%3Etfoot%3Etr%2Ewarning%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Ewarning%2C%2Etable%3Etfoot%3Etr%3Eth%2Ewarning%2C%2Etable%3Ethead%3Etr%2Ewarning%3Etd%2C%2Etable%3Ethead%3Etr%2Ewarning%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Ewarning%2C%2Etable%3Ethead%3Etr%3Eth%2Ewarning%7Bbackground%2Dcolor%3A%23fcf8e3%7D%2Etable%2Dhover%3Etbody%3Etr%2Ewarning%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Ewarning%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Ewarning%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Ewarning%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Ewarning%3Ahover%7Bbackground%2Dcolor%3A%23faf2cc%7D%2Etable%3Etbody%3Etr%2Edanger%3Etd%2C%2Etable%3Etbody%3Etr%2Edanger%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Edanger%2C%2Etable%3Etbody%3Etr%3Eth%2Edanger%2C%2Etable%3Etfoot%3Etr%2Edanger%3Etd%2C%2Etable%3Etfoot%3Etr%2Edanger%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Edanger%2C%2Etable%3Etfoot%3Etr%3Eth%2Edanger%2C%2Etable%3Ethead%3Etr%2Edanger%3Etd%2C%2Etable%3Ethead%3Etr%2Edanger%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Edanger%2C%2Etable%3Ethead%3Etr%3Eth%2Edanger%7Bbackground%2Dcolor%3A%23f2dede%7D%2Etable%2Dhover%3Etbody%3Etr%2Edanger%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Edanger%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Edanger%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Edanger%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Edanger%3Ahover%7Bbackground%2Dcolor%3A%23ebcccc%7D%2Etable%2Dresponsive%7Bmin%2Dheight%3A%2E01%25%3Boverflow%2Dx%3Aauto%7D%40media%20screen%20and%20%28max%2Dwidth%3A767px%29%7B%2Etable%2Dresponsive%7Bwidth%3A100%25%3Bmargin%2Dbottom%3A15px%3Boverflow%2Dy%3Ahidden%3B%2Dms%2Doverflow%2Dstyle%3A%2Dms%2Dautohiding%2Dscrollbar%3Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dresponsive%3E%2Etable%7Bmargin%2Dbottom%3A0%7D%2Etable%2Dresponsive%3E%2Etable%3Etbody%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Etbody%3Etr%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%3Etfoot%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Etfoot%3Etr%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%3Ethead%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Ethead%3Etr%3Eth%7Bwhite%2Dspace%3Anowrap%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%7Bborder%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%7Bborder%2Dleft%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%7Bborder%2Dright%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%7Dfieldset%7Bmin%2Dwidth%3A0%3Bpadding%3A0%3Bmargin%3A0%3Bborder%3A0%7Dlegend%7Bdisplay%3Ablock%3Bwidth%3A100%25%3Bpadding%3A0%3Bmargin%2Dbottom%3A20px%3Bfont%2Dsize%3A21px%3Bline%2Dheight%3Ainherit%3Bcolor%3A%23333%3Bborder%3A0%3Bborder%2Dbottom%3A1px%20solid%20%23e5e5e5%7Dlabel%7Bdisplay%3Ainline%2Dblock%3Bmax%2Dwidth%3A100%25%3Bmargin%2Dbottom%3A5px%3Bfont%2Dweight%3A700%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7Dinput%5Btype%3Dcheckbox%5D%2Cinput%5Btype%3Dradio%5D%7Bmargin%3A4px%200%200%3Bmargin%2Dtop%3A1px%5C9%3Bline%2Dheight%3Anormal%7Dinput%5Btype%3Dfile%5D%7Bdisplay%3Ablock%7Dinput%5Btype%3Drange%5D%7Bdisplay%3Ablock%3Bwidth%3A100%25%7Dselect%5Bmultiple%5D%2Cselect%5Bsize%5D%7Bheight%3Aauto%7Dinput%5Btype%3Dfile%5D%3Afocus%2Cinput%5Btype%3Dcheckbox%5D%3Afocus%2Cinput%5Btype%3Dradio%5D%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7Doutput%7Bdisplay%3Ablock%3Bpadding%2Dtop%3A7px%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23555%7D%2Eform%2Dcontrol%7Bdisplay%3Ablock%3Bwidth%3A100%25%3Bheight%3A34px%3Bpadding%3A6px%2012px%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23fff%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3B%2Dwebkit%2Dtransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2C%2Dwebkit%2Dbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%3B%2Do%2Dtransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2Cbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%3Btransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2Cbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%7D%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%2366afe9%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%208px%20rgba%28102%2C175%2C233%2C%2E6%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%208px%20rgba%28102%2C175%2C233%2C%2E6%29%7D%2Eform%2Dcontrol%3A%3A%2Dmoz%2Dplaceholder%7Bcolor%3A%23999%3Bopacity%3A1%7D%2Eform%2Dcontrol%3A%2Dms%2Dinput%2Dplaceholder%7Bcolor%3A%23999%7D%2Eform%2Dcontrol%3A%3A%2Dwebkit%2Dinput%2Dplaceholder%7Bcolor%3A%23999%7D%2Eform%2Dcontrol%5Bdisabled%5D%2C%2Eform%2Dcontrol%5Breadonly%5D%2Cfieldset%5Bdisabled%5D%20%2Eform%2Dcontrol%7Bbackground%2Dcolor%3A%23eee%3Bopacity%3A1%7D%2Eform%2Dcontrol%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Eform%2Dcontrol%7Bcursor%3Anot%2Dallowed%7Dtextarea%2Eform%2Dcontrol%7Bheight%3Aauto%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dappearance%3Anone%7D%40media%20screen%20and%20%28%2Dwebkit%2Dmin%2Ddevice%2Dpixel%2Dratio%3A0%29%7Binput%5Btype%3Ddate%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Dtime%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Dmonth%5D%2Eform%2Dcontrol%7Bline%2Dheight%3A34px%7D%2Einput%2Dgroup%2Dsm%20input%5Btype%3Ddate%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Dtime%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Ddatetime%2Dlocal%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Dmonth%5D%2Cinput%5Btype%3Ddate%5D%2Einput%2Dsm%2Cinput%5Btype%3Dtime%5D%2Einput%2Dsm%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Einput%2Dsm%2Cinput%5Btype%3Dmonth%5D%2Einput%2Dsm%7Bline%2Dheight%3A30px%7D%2Einput%2Dgroup%2Dlg%20input%5Btype%3Ddate%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Dtime%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Ddatetime%2Dlocal%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Dmonth%5D%2Cinput%5Btype%3Ddate%5D%2Einput%2Dlg%2Cinput%5Btype%3Dtime%5D%2Einput%2Dlg%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Einput%2Dlg%2Cinput%5Btype%3Dmonth%5D%2Einput%2Dlg%7Bline%2Dheight%3A46px%7D%7D%2Eform%2Dgroup%7Bmargin%2Dbottom%3A15px%7D%2Echeckbox%2C%2Eradio%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Echeckbox%20label%2C%2Eradio%20label%7Bmin%2Dheight%3A20px%3Bpadding%2Dleft%3A20px%3Bmargin%2Dbottom%3A0%3Bfont%2Dweight%3A400%3Bcursor%3Apointer%7D%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Echeckbox%2Dinline%20input%5Btype%3Dcheckbox%5D%2C%2Eradio%20input%5Btype%3Dradio%5D%2C%2Eradio%2Dinline%20input%5Btype%3Dradio%5D%7Bposition%3Aabsolute%3Bmargin%2Dtop%3A4px%5C9%3Bmargin%2Dleft%3A%2D20px%7D%2Echeckbox%2B%2Echeckbox%2C%2Eradio%2B%2Eradio%7Bmargin%2Dtop%3A%2D5px%7D%2Echeckbox%2Dinline%2C%2Eradio%2Dinline%7Bposition%3Arelative%3Bdisplay%3Ainline%2Dblock%3Bpadding%2Dleft%3A20px%3Bmargin%2Dbottom%3A0%3Bfont%2Dweight%3A400%3Bvertical%2Dalign%3Amiddle%3Bcursor%3Apointer%7D%2Echeckbox%2Dinline%2B%2Echeckbox%2Dinline%2C%2Eradio%2Dinline%2B%2Eradio%2Dinline%7Bmargin%2Dtop%3A0%3Bmargin%2Dleft%3A10px%7Dfieldset%5Bdisabled%5D%20input%5Btype%3Dcheckbox%5D%2Cfieldset%5Bdisabled%5D%20input%5Btype%3Dradio%5D%2Cinput%5Btype%3Dcheckbox%5D%2Edisabled%2Cinput%5Btype%3Dcheckbox%5D%5Bdisabled%5D%2Cinput%5Btype%3Dradio%5D%2Edisabled%2Cinput%5Btype%3Dradio%5D%5Bdisabled%5D%7Bcursor%3Anot%2Dallowed%7D%2Echeckbox%2Dinline%2Edisabled%2C%2Eradio%2Dinline%2Edisabled%2Cfieldset%5Bdisabled%5D%20%2Echeckbox%2Dinline%2Cfieldset%5Bdisabled%5D%20%2Eradio%2Dinline%7Bcursor%3Anot%2Dallowed%7D%2Echeckbox%2Edisabled%20label%2C%2Eradio%2Edisabled%20label%2Cfieldset%5Bdisabled%5D%20%2Echeckbox%20label%2Cfieldset%5Bdisabled%5D%20%2Eradio%20label%7Bcursor%3Anot%2Dallowed%7D%2Eform%2Dcontrol%2Dstatic%7Bmin%2Dheight%3A34px%3Bpadding%2Dtop%3A7px%3Bpadding%2Dbottom%3A7px%3Bmargin%2Dbottom%3A0%7D%2Eform%2Dcontrol%2Dstatic%2Einput%2Dlg%2C%2Eform%2Dcontrol%2Dstatic%2Einput%2Dsm%7Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%2Einput%2Dsm%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7Dselect%2Einput%2Dsm%7Bheight%3A30px%3Bline%2Dheight%3A30px%7Dselect%5Bmultiple%5D%2Einput%2Dsm%2Ctextarea%2Einput%2Dsm%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Eform%2Dgroup%2Dsm%20select%2Eform%2Dcontrol%7Bheight%3A30px%3Bline%2Dheight%3A30px%7D%2Eform%2Dgroup%2Dsm%20select%5Bmultiple%5D%2Eform%2Dcontrol%2C%2Eform%2Dgroup%2Dsm%20textarea%2Eform%2Dcontrol%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%2Dstatic%7Bheight%3A30px%3Bmin%2Dheight%3A32px%3Bpadding%3A6px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%7D%2Einput%2Dlg%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7Dselect%2Einput%2Dlg%7Bheight%3A46px%3Bline%2Dheight%3A46px%7Dselect%5Bmultiple%5D%2Einput%2Dlg%2Ctextarea%2Einput%2Dlg%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7D%2Eform%2Dgroup%2Dlg%20select%2Eform%2Dcontrol%7Bheight%3A46px%3Bline%2Dheight%3A46px%7D%2Eform%2Dgroup%2Dlg%20select%5Bmultiple%5D%2Eform%2Dcontrol%2C%2Eform%2Dgroup%2Dlg%20textarea%2Eform%2Dcontrol%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%2Dstatic%7Bheight%3A46px%3Bmin%2Dheight%3A38px%3Bpadding%3A11px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%7D%2Ehas%2Dfeedback%7Bposition%3Arelative%7D%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%7Bpadding%2Dright%3A42%2E5px%7D%2Eform%2Dcontrol%2Dfeedback%7Bposition%3Aabsolute%3Btop%3A0%3Bright%3A0%3Bz%2Dindex%3A2%3Bdisplay%3Ablock%3Bwidth%3A34px%3Bheight%3A34px%3Bline%2Dheight%3A34px%3Btext%2Dalign%3Acenter%3Bpointer%2Devents%3Anone%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dgroup%2Dlg%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dlg%2B%2Eform%2Dcontrol%2Dfeedback%7Bwidth%3A46px%3Bheight%3A46px%3Bline%2Dheight%3A46px%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dgroup%2Dsm%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dsm%2B%2Eform%2Dcontrol%2Dfeedback%7Bwidth%3A30px%3Bheight%3A30px%3Bline%2Dheight%3A30px%7D%2Ehas%2Dsuccess%20%2Echeckbox%2C%2Ehas%2Dsuccess%20%2Echeckbox%2Dinline%2C%2Ehas%2Dsuccess%20%2Econtrol%2Dlabel%2C%2Ehas%2Dsuccess%20%2Ehelp%2Dblock%2C%2Ehas%2Dsuccess%20%2Eradio%2C%2Ehas%2Dsuccess%20%2Eradio%2Dinline%2C%2Ehas%2Dsuccess%2Echeckbox%20label%2C%2Ehas%2Dsuccess%2Echeckbox%2Dinline%20label%2C%2Ehas%2Dsuccess%2Eradio%20label%2C%2Ehas%2Dsuccess%2Eradio%2Dinline%20label%7Bcolor%3A%233c763d%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%233c763d%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%232b542c%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%2367b168%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%2367b168%7D%2Ehas%2Dsuccess%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%233c763d%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%233c763d%7D%2Ehas%2Dwarning%20%2Echeckbox%2C%2Ehas%2Dwarning%20%2Echeckbox%2Dinline%2C%2Ehas%2Dwarning%20%2Econtrol%2Dlabel%2C%2Ehas%2Dwarning%20%2Ehelp%2Dblock%2C%2Ehas%2Dwarning%20%2Eradio%2C%2Ehas%2Dwarning%20%2Eradio%2Dinline%2C%2Ehas%2Dwarning%2Echeckbox%20label%2C%2Ehas%2Dwarning%2Echeckbox%2Dinline%20label%2C%2Ehas%2Dwarning%2Eradio%20label%2C%2Ehas%2Dwarning%2Eradio%2Dinline%20label%7Bcolor%3A%238a6d3b%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%238a6d3b%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%2366512c%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23c0a16b%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23c0a16b%7D%2Ehas%2Dwarning%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%238a6d3b%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%238a6d3b%7D%2Ehas%2Derror%20%2Echeckbox%2C%2Ehas%2Derror%20%2Echeckbox%2Dinline%2C%2Ehas%2Derror%20%2Econtrol%2Dlabel%2C%2Ehas%2Derror%20%2Ehelp%2Dblock%2C%2Ehas%2Derror%20%2Eradio%2C%2Ehas%2Derror%20%2Eradio%2Dinline%2C%2Ehas%2Derror%2Echeckbox%20label%2C%2Ehas%2Derror%2Echeckbox%2Dinline%20label%2C%2Ehas%2Derror%2Eradio%20label%2C%2Ehas%2Derror%2Eradio%2Dinline%20label%7Bcolor%3A%23a94442%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%23a94442%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%23843534%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23ce8483%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23ce8483%7D%2Ehas%2Derror%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23a94442%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%23a94442%7D%2Ehas%2Dfeedback%20label%7E%2Eform%2Dcontrol%2Dfeedback%7Btop%3A25px%7D%2Ehas%2Dfeedback%20label%2Esr%2Donly%7E%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%2Ehelp%2Dblock%7Bdisplay%3Ablock%3Bmargin%2Dtop%3A5px%3Bmargin%2Dbottom%3A10px%3Bcolor%3A%23737373%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dinline%20%2Eform%2Dgroup%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Eform%2Dcontrol%7Bdisplay%3Ainline%2Dblock%3Bwidth%3Aauto%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Eform%2Dcontrol%2Dstatic%7Bdisplay%3Ainline%2Dblock%7D%2Eform%2Dinline%20%2Einput%2Dgroup%7Bdisplay%3Ainline%2Dtable%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Daddon%2C%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Dbtn%7Bwidth%3Aauto%7D%2Eform%2Dinline%20%2Einput%2Dgroup%3E%2Eform%2Dcontrol%7Bwidth%3A100%25%7D%2Eform%2Dinline%20%2Econtrol%2Dlabel%7Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Echeckbox%2C%2Eform%2Dinline%20%2Eradio%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Echeckbox%20label%2C%2Eform%2Dinline%20%2Eradio%20label%7Bpadding%2Dleft%3A0%7D%2Eform%2Dinline%20%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Eform%2Dinline%20%2Eradio%20input%5Btype%3Dradio%5D%7Bposition%3Arelative%3Bmargin%2Dleft%3A0%7D%2Eform%2Dinline%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%7D%2Eform%2Dhorizontal%20%2Echeckbox%2C%2Eform%2Dhorizontal%20%2Echeckbox%2Dinline%2C%2Eform%2Dhorizontal%20%2Eradio%2C%2Eform%2Dhorizontal%20%2Eradio%2Dinline%7Bpadding%2Dtop%3A7px%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%7D%2Eform%2Dhorizontal%20%2Echeckbox%2C%2Eform%2Dhorizontal%20%2Eradio%7Bmin%2Dheight%3A27px%7D%2Eform%2Dhorizontal%20%2Eform%2Dgroup%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A7px%3Bmargin%2Dbottom%3A0%3Btext%2Dalign%3Aright%7D%7D%2Eform%2Dhorizontal%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Bright%3A15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Eform%2Dgroup%2Dlg%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A14%2E33px%3Bfont%2Dsize%3A18px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Eform%2Dgroup%2Dsm%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A6px%3Bfont%2Dsize%3A12px%7D%7D%2Ebtn%7Bdisplay%3Ainline%2Dblock%3Bpadding%3A6px%2012px%3Bmargin%2Dbottom%3A0%3Bfont%2Dsize%3A14px%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%3B%2Dms%2Dtouch%2Daction%3Amanipulation%3Btouch%2Daction%3Amanipulation%3Bcursor%3Apointer%3B%2Dwebkit%2Duser%2Dselect%3Anone%3B%2Dmoz%2Duser%2Dselect%3Anone%3B%2Dms%2Duser%2Dselect%3Anone%3Buser%2Dselect%3Anone%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Ebtn%2Eactive%2Efocus%2C%2Ebtn%2Eactive%3Afocus%2C%2Ebtn%2Efocus%2C%2Ebtn%3Aactive%2Efocus%2C%2Ebtn%3Aactive%3Afocus%2C%2Ebtn%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7D%2Ebtn%2Efocus%2C%2Ebtn%3Afocus%2C%2Ebtn%3Ahover%7Bcolor%3A%23333%3Btext%2Ddecoration%3Anone%7D%2Ebtn%2Eactive%2C%2Ebtn%3Aactive%7Bbackground%2Dimage%3Anone%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%3Bbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%7D%2Ebtn%2Edisabled%2C%2Ebtn%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Ebtn%7Bcursor%3Anot%2Dallowed%3Bfilter%3Aalpha%28opacity%3D65%29%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%3Bopacity%3A%2E65%7Da%2Ebtn%2Edisabled%2Cfieldset%5Bdisabled%5D%20a%2Ebtn%7Bpointer%2Devents%3Anone%7D%2Ebtn%2Ddefault%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ccc%7D%2Ebtn%2Ddefault%2Efocus%2C%2Ebtn%2Ddefault%3Afocus%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%238c8c8c%7D%2Ebtn%2Ddefault%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%23adadad%7D%2Ebtn%2Ddefault%2Eactive%2C%2Ebtn%2Ddefault%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%23adadad%7D%2Ebtn%2Ddefault%2Eactive%2Efocus%2C%2Ebtn%2Ddefault%2Eactive%3Afocus%2C%2Ebtn%2Ddefault%2Eactive%3Ahover%2C%2Ebtn%2Ddefault%3Aactive%2Efocus%2C%2Ebtn%2Ddefault%3Aactive%3Afocus%2C%2Ebtn%2Ddefault%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23d4d4d4%3Bborder%2Dcolor%3A%238c8c8c%7D%2Ebtn%2Ddefault%2Eactive%2C%2Ebtn%2Ddefault%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Ddefault%2Edisabled%2C%2Ebtn%2Ddefault%2Edisabled%2Eactive%2C%2Ebtn%2Ddefault%2Edisabled%2Efocus%2C%2Ebtn%2Ddefault%2Edisabled%3Aactive%2C%2Ebtn%2Ddefault%2Edisabled%3Afocus%2C%2Ebtn%2Ddefault%2Edisabled%3Ahover%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Ahover%7Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ccc%7D%2Ebtn%2Ddefault%20%2Ebadge%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23333%7D%2Ebtn%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%232e6da4%7D%2Ebtn%2Dprimary%2Efocus%2C%2Ebtn%2Dprimary%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23122b40%7D%2Ebtn%2Dprimary%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23204d74%7D%2Ebtn%2Dprimary%2Eactive%2C%2Ebtn%2Dprimary%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23204d74%7D%2Ebtn%2Dprimary%2Eactive%2Efocus%2C%2Ebtn%2Dprimary%2Eactive%3Afocus%2C%2Ebtn%2Dprimary%2Eactive%3Ahover%2C%2Ebtn%2Dprimary%3Aactive%2Efocus%2C%2Ebtn%2Dprimary%3Aactive%3Afocus%2C%2Ebtn%2Dprimary%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23204d74%3Bborder%2Dcolor%3A%23122b40%7D%2Ebtn%2Dprimary%2Eactive%2C%2Ebtn%2Dprimary%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dprimary%2Edisabled%2C%2Ebtn%2Dprimary%2Edisabled%2Eactive%2C%2Ebtn%2Dprimary%2Edisabled%2Efocus%2C%2Ebtn%2Dprimary%2Edisabled%3Aactive%2C%2Ebtn%2Dprimary%2Edisabled%3Afocus%2C%2Ebtn%2Dprimary%2Edisabled%3Ahover%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Ahover%7Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%232e6da4%7D%2Ebtn%2Dprimary%20%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dsuccess%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%235cb85c%3Bborder%2Dcolor%3A%234cae4c%7D%2Ebtn%2Dsuccess%2Efocus%2C%2Ebtn%2Dsuccess%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23255625%7D%2Ebtn%2Dsuccess%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23398439%7D%2Ebtn%2Dsuccess%2Eactive%2C%2Ebtn%2Dsuccess%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23398439%7D%2Ebtn%2Dsuccess%2Eactive%2Efocus%2C%2Ebtn%2Dsuccess%2Eactive%3Afocus%2C%2Ebtn%2Dsuccess%2Eactive%3Ahover%2C%2Ebtn%2Dsuccess%3Aactive%2Efocus%2C%2Ebtn%2Dsuccess%3Aactive%3Afocus%2C%2Ebtn%2Dsuccess%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23398439%3Bborder%2Dcolor%3A%23255625%7D%2Ebtn%2Dsuccess%2Eactive%2C%2Ebtn%2Dsuccess%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dsuccess%2Edisabled%2C%2Ebtn%2Dsuccess%2Edisabled%2Eactive%2C%2Ebtn%2Dsuccess%2Edisabled%2Efocus%2C%2Ebtn%2Dsuccess%2Edisabled%3Aactive%2C%2Ebtn%2Dsuccess%2Edisabled%3Afocus%2C%2Ebtn%2Dsuccess%2Edisabled%3Ahover%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Ahover%7Bbackground%2Dcolor%3A%235cb85c%3Bborder%2Dcolor%3A%234cae4c%7D%2Ebtn%2Dsuccess%20%2Ebadge%7Bcolor%3A%235cb85c%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dinfo%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%235bc0de%3Bborder%2Dcolor%3A%2346b8da%7D%2Ebtn%2Dinfo%2Efocus%2C%2Ebtn%2Dinfo%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%231b6d85%7D%2Ebtn%2Dinfo%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%23269abc%7D%2Ebtn%2Dinfo%2Eactive%2C%2Ebtn%2Dinfo%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%23269abc%7D%2Ebtn%2Dinfo%2Eactive%2Efocus%2C%2Ebtn%2Dinfo%2Eactive%3Afocus%2C%2Ebtn%2Dinfo%2Eactive%3Ahover%2C%2Ebtn%2Dinfo%3Aactive%2Efocus%2C%2Ebtn%2Dinfo%3Aactive%3Afocus%2C%2Ebtn%2Dinfo%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23269abc%3Bborder%2Dcolor%3A%231b6d85%7D%2Ebtn%2Dinfo%2Eactive%2C%2Ebtn%2Dinfo%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dinfo%2Edisabled%2C%2Ebtn%2Dinfo%2Edisabled%2Eactive%2C%2Ebtn%2Dinfo%2Edisabled%2Efocus%2C%2Ebtn%2Dinfo%2Edisabled%3Aactive%2C%2Ebtn%2Dinfo%2Edisabled%3Afocus%2C%2Ebtn%2Dinfo%2Edisabled%3Ahover%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Ahover%7Bbackground%2Dcolor%3A%235bc0de%3Bborder%2Dcolor%3A%2346b8da%7D%2Ebtn%2Dinfo%20%2Ebadge%7Bcolor%3A%235bc0de%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dwarning%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23f0ad4e%3Bborder%2Dcolor%3A%23eea236%7D%2Ebtn%2Dwarning%2Efocus%2C%2Ebtn%2Dwarning%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23985f0d%7D%2Ebtn%2Dwarning%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23d58512%7D%2Ebtn%2Dwarning%2Eactive%2C%2Ebtn%2Dwarning%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23d58512%7D%2Ebtn%2Dwarning%2Eactive%2Efocus%2C%2Ebtn%2Dwarning%2Eactive%3Afocus%2C%2Ebtn%2Dwarning%2Eactive%3Ahover%2C%2Ebtn%2Dwarning%3Aactive%2Efocus%2C%2Ebtn%2Dwarning%3Aactive%3Afocus%2C%2Ebtn%2Dwarning%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23d58512%3Bborder%2Dcolor%3A%23985f0d%7D%2Ebtn%2Dwarning%2Eactive%2C%2Ebtn%2Dwarning%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dwarning%2Edisabled%2C%2Ebtn%2Dwarning%2Edisabled%2Eactive%2C%2Ebtn%2Dwarning%2Edisabled%2Efocus%2C%2Ebtn%2Dwarning%2Edisabled%3Aactive%2C%2Ebtn%2Dwarning%2Edisabled%3Afocus%2C%2Ebtn%2Dwarning%2Edisabled%3Ahover%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Ahover%7Bbackground%2Dcolor%3A%23f0ad4e%3Bborder%2Dcolor%3A%23eea236%7D%2Ebtn%2Dwarning%20%2Ebadge%7Bcolor%3A%23f0ad4e%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Ddanger%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23d9534f%3Bborder%2Dcolor%3A%23d43f3a%7D%2Ebtn%2Ddanger%2Efocus%2C%2Ebtn%2Ddanger%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23761c19%7D%2Ebtn%2Ddanger%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23ac2925%7D%2Ebtn%2Ddanger%2Eactive%2C%2Ebtn%2Ddanger%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23ac2925%7D%2Ebtn%2Ddanger%2Eactive%2Efocus%2C%2Ebtn%2Ddanger%2Eactive%3Afocus%2C%2Ebtn%2Ddanger%2Eactive%3Ahover%2C%2Ebtn%2Ddanger%3Aactive%2Efocus%2C%2Ebtn%2Ddanger%3Aactive%3Afocus%2C%2Ebtn%2Ddanger%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ac2925%3Bborder%2Dcolor%3A%23761c19%7D%2Ebtn%2Ddanger%2Eactive%2C%2Ebtn%2Ddanger%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Ddanger%2Edisabled%2C%2Ebtn%2Ddanger%2Edisabled%2Eactive%2C%2Ebtn%2Ddanger%2Edisabled%2Efocus%2C%2Ebtn%2Ddanger%2Edisabled%3Aactive%2C%2Ebtn%2Ddanger%2Edisabled%3Afocus%2C%2Ebtn%2Ddanger%2Edisabled%3Ahover%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Ahover%7Bbackground%2Dcolor%3A%23d9534f%3Bborder%2Dcolor%3A%23d43f3a%7D%2Ebtn%2Ddanger%20%2Ebadge%7Bcolor%3A%23d9534f%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dlink%7Bfont%2Dweight%3A400%3Bcolor%3A%23337ab7%3Bborder%2Dradius%3A0%7D%2Ebtn%2Dlink%2C%2Ebtn%2Dlink%2Eactive%2C%2Ebtn%2Dlink%3Aactive%2C%2Ebtn%2Dlink%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%7Bbackground%2Dcolor%3Atransparent%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Ebtn%2Dlink%2C%2Ebtn%2Dlink%3Aactive%2C%2Ebtn%2Dlink%3Afocus%2C%2Ebtn%2Dlink%3Ahover%7Bborder%2Dcolor%3Atransparent%7D%2Ebtn%2Dlink%3Afocus%2C%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%2323527c%3Btext%2Ddecoration%3Aunderline%3Bbackground%2Dcolor%3Atransparent%7D%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23777%3Btext%2Ddecoration%3Anone%7D%2Ebtn%2Dgroup%2Dlg%3E%2Ebtn%2C%2Ebtn%2Dlg%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7D%2Ebtn%2Dgroup%2Dsm%3E%2Ebtn%2C%2Ebtn%2Dsm%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Ebtn%2Dgroup%2Dxs%3E%2Ebtn%2C%2Ebtn%2Dxs%7Bpadding%3A1px%205px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Ebtn%2Dblock%7Bdisplay%3Ablock%3Bwidth%3A100%25%7D%2Ebtn%2Dblock%2B%2Ebtn%2Dblock%7Bmargin%2Dtop%3A5px%7Dinput%5Btype%3Dbutton%5D%2Ebtn%2Dblock%2Cinput%5Btype%3Dreset%5D%2Ebtn%2Dblock%2Cinput%5Btype%3Dsubmit%5D%2Ebtn%2Dblock%7Bwidth%3A100%25%7D%2Efade%7Bopacity%3A0%3B%2Dwebkit%2Dtransition%3Aopacity%20%2E15s%20linear%3B%2Do%2Dtransition%3Aopacity%20%2E15s%20linear%3Btransition%3Aopacity%20%2E15s%20linear%7D%2Efade%2Ein%7Bopacity%3A1%7D%2Ecollapse%7Bdisplay%3Anone%7D%2Ecollapse%2Ein%7Bdisplay%3Ablock%7Dtr%2Ecollapse%2Ein%7Bdisplay%3Atable%2Drow%7Dtbody%2Ecollapse%2Ein%7Bdisplay%3Atable%2Drow%2Dgroup%7D%2Ecollapsing%7Bposition%3Arelative%3Bheight%3A0%3Boverflow%3Ahidden%3B%2Dwebkit%2Dtransition%2Dtiming%2Dfunction%3Aease%3B%2Do%2Dtransition%2Dtiming%2Dfunction%3Aease%3Btransition%2Dtiming%2Dfunction%3Aease%3B%2Dwebkit%2Dtransition%2Dduration%3A%2E35s%3B%2Do%2Dtransition%2Dduration%3A%2E35s%3Btransition%2Dduration%3A%2E35s%3B%2Dwebkit%2Dtransition%2Dproperty%3Aheight%2Cvisibility%3B%2Do%2Dtransition%2Dproperty%3Aheight%2Cvisibility%3Btransition%2Dproperty%3Aheight%2Cvisibility%7D%2Ecaret%7Bdisplay%3Ainline%2Dblock%3Bwidth%3A0%3Bheight%3A0%3Bmargin%2Dleft%3A2px%3Bvertical%2Dalign%3Amiddle%3Bborder%2Dtop%3A4px%20dashed%3Bborder%2Dtop%3A4px%20solid%5C9%3Bborder%2Dright%3A4px%20solid%20transparent%3Bborder%2Dleft%3A4px%20solid%20transparent%7D%2Edropdown%2C%2Edropup%7Bposition%3Arelative%7D%2Edropdown%2Dtoggle%3Afocus%7Boutline%3A0%7D%2Edropdown%2Dmenu%7Bposition%3Aabsolute%3Btop%3A100%25%3Bleft%3A0%3Bz%2Dindex%3A1000%3Bdisplay%3Anone%3Bfloat%3Aleft%3Bmin%2Dwidth%3A160px%3Bpadding%3A5px%200%3Bmargin%3A2px%200%200%3Bfont%2Dsize%3A14px%3Btext%2Dalign%3Aleft%3Blist%2Dstyle%3Anone%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23ccc%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E15%29%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%206px%2012px%20rgba%280%2C0%2C0%2C%2E175%29%3Bbox%2Dshadow%3A0%206px%2012px%20rgba%280%2C0%2C0%2C%2E175%29%7D%2Edropdown%2Dmenu%2Epull%2Dright%7Bright%3A0%3Bleft%3Aauto%7D%2Edropdown%2Dmenu%20%2Edivider%7Bheight%3A1px%3Bmargin%3A9px%200%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23e5e5e5%7D%2Edropdown%2Dmenu%3Eli%3Ea%7Bdisplay%3Ablock%3Bpadding%3A3px%2020px%3Bclear%3Aboth%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bwhite%2Dspace%3Anowrap%7D%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23262626%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%7D%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23337ab7%3Boutline%3A0%7D%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23777%7D%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3Atransparent%3Bbackground%2Dimage%3Anone%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28enabled%3Dfalse%29%7D%2Eopen%3E%2Edropdown%2Dmenu%7Bdisplay%3Ablock%7D%2Eopen%3Ea%7Boutline%3A0%7D%2Edropdown%2Dmenu%2Dright%7Bright%3A0%3Bleft%3Aauto%7D%2Edropdown%2Dmenu%2Dleft%7Bright%3Aauto%3Bleft%3A0%7D%2Edropdown%2Dheader%7Bdisplay%3Ablock%3Bpadding%3A3px%2020px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23777%3Bwhite%2Dspace%3Anowrap%7D%2Edropdown%2Dbackdrop%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A990%7D%2Epull%2Dright%3E%2Edropdown%2Dmenu%7Bright%3A0%3Bleft%3Aauto%7D%2Edropup%20%2Ecaret%2C%2Enavbar%2Dfixed%2Dbottom%20%2Edropdown%20%2Ecaret%7Bcontent%3A%22%22%3Bborder%2Dtop%3A0%3Bborder%2Dbottom%3A4px%20dashed%3Bborder%2Dbottom%3A4px%20solid%5C9%7D%2Edropup%20%2Edropdown%2Dmenu%2C%2Enavbar%2Dfixed%2Dbottom%20%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bbottom%3A100%25%3Bmargin%2Dbottom%3A2px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dright%20%2Edropdown%2Dmenu%7Bright%3A0%3Bleft%3Aauto%7D%2Enavbar%2Dright%20%2Edropdown%2Dmenu%2Dleft%7Bright%3Aauto%3Bleft%3A0%7D%7D%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%7Bposition%3Arelative%3Bdisplay%3Ainline%2Dblock%3Bvertical%2Dalign%3Amiddle%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2C%2Ebtn%2Dgroup%3E%2Ebtn%7Bposition%3Arelative%3Bfloat%3Aleft%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Eactive%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Aactive%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Afocus%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Ahover%2C%2Ebtn%2Dgroup%3E%2Ebtn%2Eactive%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Aactive%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Afocus%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Ahover%7Bz%2Dindex%3A2%7D%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%2C%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%20%2Ebtn%2Dgroup%2B%2Ebtn%2C%2Ebtn%2Dgroup%20%2Ebtn%2Dgroup%2B%2Ebtn%2Dgroup%7Bmargin%2Dleft%3A%2D1px%7D%2Ebtn%2Dtoolbar%7Bmargin%2Dleft%3A%2D5px%7D%2Ebtn%2Dtoolbar%20%2Ebtn%2C%2Ebtn%2Dtoolbar%20%2Ebtn%2Dgroup%2C%2Ebtn%2Dtoolbar%20%2Einput%2Dgroup%7Bfloat%3Aleft%7D%2Ebtn%2Dtoolbar%3E%2Ebtn%2C%2Ebtn%2Dtoolbar%3E%2Ebtn%2Dgroup%2C%2Ebtn%2Dtoolbar%3E%2Einput%2Dgroup%7Bmargin%2Dleft%3A5px%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Afirst%2Dchild%7Bmargin%2Dleft%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%2C%2Ebtn%2Dgroup%3E%2Edropdown%2Dtoggle%3Anot%28%3Afirst%2Dchild%29%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%7Bfloat%3Aleft%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%3Alast%2Dchild%2C%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Edropdown%2Dtoggle%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%20%2Edropdown%2Dtoggle%3Aactive%2C%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%7Boutline%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2B%2Edropdown%2Dtoggle%7Bpadding%2Dright%3A8px%3Bpadding%2Dleft%3A8px%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dlg%2B%2Edropdown%2Dtoggle%7Bpadding%2Dright%3A12px%3Bpadding%2Dleft%3A12px%7D%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%7B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%3Bbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%7D%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%2Ebtn%2Dlink%7B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Ebtn%20%2Ecaret%7Bmargin%2Dleft%3A0%7D%2Ebtn%2Dlg%20%2Ecaret%7Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Edropup%20%2Ebtn%2Dlg%20%2Ecaret%7Bborder%2Dwidth%3A0%205px%205px%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3E%2Ebtn%7Bdisplay%3Ablock%3Bfloat%3Anone%3Bwidth%3A100%25%3Bmax%2Dwidth%3A100%25%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3E%2Ebtn%7Bfloat%3Anone%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2B%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2B%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2B%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2B%2Ebtn%2Dgroup%7Bmargin%2Dtop%3A%2D1px%3Bmargin%2Dleft%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%3Alast%2Dchild%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Edropdown%2Dtoggle%7Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Djustified%7Bdisplay%3Atable%3Bwidth%3A100%25%3Btable%2Dlayout%3Afixed%3Bborder%2Dcollapse%3Aseparate%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2C%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%7Bdisplay%3Atable%2Dcell%3Bfloat%3Anone%3Bwidth%3A1%25%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%20%2Ebtn%7Bwidth%3A100%25%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%20%2Edropdown%2Dmenu%7Bleft%3Aauto%7D%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%20input%5Btype%3Dcheckbox%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%20input%5Btype%3Dradio%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%2Dgroup%3E%2Ebtn%20input%5Btype%3Dcheckbox%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%2Dgroup%3E%2Ebtn%20input%5Btype%3Dradio%5D%7Bposition%3Aabsolute%3Bclip%3Arect%280%2C0%2C0%2C0%29%3Bpointer%2Devents%3Anone%7D%2Einput%2Dgroup%7Bposition%3Arelative%3Bdisplay%3Atable%3Bborder%2Dcollapse%3Aseparate%7D%2Einput%2Dgroup%5Bclass%2A%3Dcol%2D%5D%7Bfloat%3Anone%3Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%7Bposition%3Arelative%3Bz%2Dindex%3A2%3Bfloat%3Aleft%3Bwidth%3A100%25%3Bmargin%2Dbottom%3A0%7D%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7Dselect%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Cselect%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Cselect%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A46px%3Bline%2Dheight%3A46px%7Dselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3Aauto%7D%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7Dselect%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Cselect%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Cselect%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A30px%3Bline%2Dheight%3A30px%7Dselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3Aauto%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dbtn%7Bdisplay%3Atable%2Dcell%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%2C%2Einput%2Dgroup%2Daddon%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%2C%2Einput%2Dgroup%2Dbtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dbtn%7Bwidth%3A1%25%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%7D%2Einput%2Dgroup%2Daddon%7Bpadding%3A6px%2012px%3Bfont%2Dsize%3A14px%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3Bcolor%3A%23555%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23eee%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%7D%2Einput%2Dgroup%2Daddon%2Einput%2Dsm%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bborder%2Dradius%3A3px%7D%2Einput%2Dgroup%2Daddon%2Einput%2Dlg%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bborder%2Dradius%3A6px%7D%2Einput%2Dgroup%2Daddon%20input%5Btype%3Dcheckbox%5D%2C%2Einput%2Dgroup%2Daddon%20input%5Btype%3Dradio%5D%7Bmargin%2Dtop%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Afirst%2Dchild%2C%2Einput%2Dgroup%2Daddon%3Afirst%2Dchild%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Edropdown%2Dtoggle%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%3Afirst%2Dchild%7Bborder%2Dright%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Alast%2Dchild%2C%2Einput%2Dgroup%2Daddon%3Alast%2Dchild%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Edropdown%2Dtoggle%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%3Alast%2Dchild%7Bborder%2Dleft%3A0%7D%2Einput%2Dgroup%2Dbtn%7Bposition%3Arelative%3Bfont%2Dsize%3A0%3Bwhite%2Dspace%3Anowrap%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bposition%3Arelative%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2B%2Ebtn%7Bmargin%2Dleft%3A%2D1px%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Aactive%2C%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Afocus%2C%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Ahover%7Bz%2Dindex%3A2%7D%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%7Bmargin%2Dright%3A%2D1px%7D%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%7Bz%2Dindex%3A2%3Bmargin%2Dleft%3A%2D1px%7D%2Enav%7Bpadding%2Dleft%3A0%3Bmargin%2Dbottom%3A0%3Blist%2Dstyle%3Anone%7D%2Enav%3Eli%7Bposition%3Arelative%3Bdisplay%3Ablock%7D%2Enav%3Eli%3Ea%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bpadding%3A10px%2015px%7D%2Enav%3Eli%3Ea%3Afocus%2C%2Enav%3Eli%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23eee%7D%2Enav%3Eli%2Edisabled%3Ea%7Bcolor%3A%23777%7D%2Enav%3Eli%2Edisabled%3Ea%3Afocus%2C%2Enav%3Eli%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23777%3Btext%2Ddecoration%3Anone%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3Atransparent%7D%2Enav%20%2Eopen%3Ea%2C%2Enav%20%2Eopen%3Ea%3Afocus%2C%2Enav%20%2Eopen%3Ea%3Ahover%7Bbackground%2Dcolor%3A%23eee%3Bborder%2Dcolor%3A%23337ab7%7D%2Enav%20%2Enav%2Ddivider%7Bheight%3A1px%3Bmargin%3A9px%200%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23e5e5e5%7D%2Enav%3Eli%3Ea%3Eimg%7Bmax%2Dwidth%3Anone%7D%2Enav%2Dtabs%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%7D%2Enav%2Dtabs%3Eli%7Bfloat%3Aleft%3Bmargin%2Dbottom%3A%2D1px%7D%2Enav%2Dtabs%3Eli%3Ea%7Bmargin%2Dright%3A2px%3Bline%2Dheight%3A1%2E42857143%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%3Eli%3Ea%3Ahover%7Bborder%2Dcolor%3A%23eee%20%23eee%20%23ddd%7D%2Enav%2Dtabs%3Eli%2Eactive%3Ea%2C%2Enav%2Dtabs%3Eli%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%3Eli%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bcursor%3Adefault%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dbottom%2Dcolor%3Atransparent%7D%2Enav%2Dtabs%2Enav%2Djustified%7Bwidth%3A100%25%3Bborder%2Dbottom%3A0%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%7Bfloat%3Anone%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A5px%3Btext%2Dalign%3Acenter%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Enav%2Djustified%3Eli%7Bdisplay%3Atable%2Dcell%3Bwidth%3A1%25%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A0%7D%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dright%3A0%3Bborder%2Dradius%3A4px%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%3A1px%20solid%20%23ddd%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%2Dbottom%2Dcolor%3A%23fff%7D%7D%2Enav%2Dpills%3Eli%7Bfloat%3Aleft%7D%2Enav%2Dpills%3Eli%3Ea%7Bborder%2Dradius%3A4px%7D%2Enav%2Dpills%3Eli%2Bli%7Bmargin%2Dleft%3A2px%7D%2Enav%2Dpills%3Eli%2Eactive%3Ea%2C%2Enav%2Dpills%3Eli%2Eactive%3Ea%3Afocus%2C%2Enav%2Dpills%3Eli%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%7D%2Enav%2Dstacked%3Eli%7Bfloat%3Anone%7D%2Enav%2Dstacked%3Eli%2Bli%7Bmargin%2Dtop%3A2px%3Bmargin%2Dleft%3A0%7D%2Enav%2Djustified%7Bwidth%3A100%25%7D%2Enav%2Djustified%3Eli%7Bfloat%3Anone%7D%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A5px%3Btext%2Dalign%3Acenter%7D%2Enav%2Djustified%3E%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Djustified%3Eli%7Bdisplay%3Atable%2Dcell%3Bwidth%3A1%25%7D%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A0%7D%7D%2Enav%2Dtabs%2Djustified%7Bborder%2Dbottom%3A0%7D%2Enav%2Dtabs%2Djustified%3Eli%3Ea%7Bmargin%2Dright%3A0%3Bborder%2Dradius%3A4px%7D%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%3A1px%20solid%20%23ddd%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Djustified%3Eli%3Ea%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%2Dbottom%2Dcolor%3A%23fff%7D%7D%2Etab%2Dcontent%3E%2Etab%2Dpane%7Bdisplay%3Anone%7D%2Etab%2Dcontent%3E%2Eactive%7Bdisplay%3Ablock%7D%2Enav%2Dtabs%20%2Edropdown%2Dmenu%7Bmargin%2Dtop%3A%2D1px%3Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Enavbar%7Bposition%3Arelative%3Bmin%2Dheight%3A50px%3Bmargin%2Dbottom%3A20px%3Bborder%3A1px%20solid%20transparent%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%7Bborder%2Dradius%3A4px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dheader%7Bfloat%3Aleft%7D%7D%2Enavbar%2Dcollapse%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Boverflow%2Dx%3Avisible%3B%2Dwebkit%2Doverflow%2Dscrolling%3Atouch%3Bborder%2Dtop%3A1px%20solid%20transparent%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%7D%2Enavbar%2Dcollapse%2Ein%7Boverflow%2Dy%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dcollapse%7Bwidth%3Aauto%3Bborder%2Dtop%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Enavbar%2Dcollapse%2Ecollapse%7Bdisplay%3Ablock%21important%3Bheight%3Aauto%21important%3Bpadding%2Dbottom%3A0%3Boverflow%3Avisible%21important%7D%2Enavbar%2Dcollapse%2Ein%7Boverflow%2Dy%3Avisible%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dstatic%2Dtop%20%2Enavbar%2Dcollapse%7Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%7Bmax%2Dheight%3A340px%7D%40media%20%28max%2Ddevice%2Dwidth%3A480px%29%20and%20%28orientation%3Alandscape%29%7B%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%7Bmax%2Dheight%3A200px%7D%7D%2Econtainer%2Dfluid%3E%2Enavbar%2Dcollapse%2C%2Econtainer%2Dfluid%3E%2Enavbar%2Dheader%2C%2Econtainer%3E%2Enavbar%2Dcollapse%2C%2Econtainer%3E%2Enavbar%2Dheader%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Econtainer%2Dfluid%3E%2Enavbar%2Dcollapse%2C%2Econtainer%2Dfluid%3E%2Enavbar%2Dheader%2C%2Econtainer%3E%2Enavbar%2Dcollapse%2C%2Econtainer%3E%2Enavbar%2Dheader%7Bmargin%2Dright%3A0%3Bmargin%2Dleft%3A0%7D%7D%2Enavbar%2Dstatic%2Dtop%7Bz%2Dindex%3A1000%3Bborder%2Dwidth%3A0%200%201px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dstatic%2Dtop%7Bborder%2Dradius%3A0%7D%7D%2Enavbar%2Dfixed%2Dbottom%2C%2Enavbar%2Dfixed%2Dtop%7Bposition%3Afixed%3Bright%3A0%3Bleft%3A0%3Bz%2Dindex%3A1030%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dfixed%2Dbottom%2C%2Enavbar%2Dfixed%2Dtop%7Bborder%2Dradius%3A0%7D%7D%2Enavbar%2Dfixed%2Dtop%7Btop%3A0%3Bborder%2Dwidth%3A0%200%201px%7D%2Enavbar%2Dfixed%2Dbottom%7Bbottom%3A0%3Bmargin%2Dbottom%3A0%3Bborder%2Dwidth%3A1px%200%200%7D%2Enavbar%2Dbrand%7Bfloat%3Aleft%3Bheight%3A50px%3Bpadding%3A15px%2015px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A20px%7D%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Dbrand%3Ahover%7Btext%2Ddecoration%3Anone%7D%2Enavbar%2Dbrand%3Eimg%7Bdisplay%3Ablock%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%3E%2Econtainer%20%2Enavbar%2Dbrand%2C%2Enavbar%3E%2Econtainer%2Dfluid%20%2Enavbar%2Dbrand%7Bmargin%2Dleft%3A%2D15px%7D%7D%2Enavbar%2Dtoggle%7Bposition%3Arelative%3Bfloat%3Aright%3Bpadding%3A9px%2010px%3Bmargin%2Dtop%3A8px%3Bmargin%2Dright%3A15px%3Bmargin%2Dbottom%3A8px%3Bbackground%2Dcolor%3Atransparent%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Enavbar%2Dtoggle%3Afocus%7Boutline%3A0%7D%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bdisplay%3Ablock%3Bwidth%3A22px%3Bheight%3A2px%3Bborder%2Dradius%3A1px%7D%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%2B%2Eicon%2Dbar%7Bmargin%2Dtop%3A4px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dtoggle%7Bdisplay%3Anone%7D%7D%2Enavbar%2Dnav%7Bmargin%3A7%2E5px%20%2D15px%7D%2Enavbar%2Dnav%3Eli%3Ea%7Bpadding%2Dtop%3A10px%3Bpadding%2Dbottom%3A10px%3Bline%2Dheight%3A20px%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%7Bposition%3Astatic%3Bfloat%3Anone%3Bwidth%3Aauto%3Bmargin%2Dtop%3A0%3Bbackground%2Dcolor%3Atransparent%3Bborder%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%20%2Edropdown%2Dheader%2C%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bpadding%3A5px%2015px%205px%2025px%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bline%2Dheight%3A20px%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bbackground%2Dimage%3Anone%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dnav%7Bfloat%3Aleft%3Bmargin%3A0%7D%2Enavbar%2Dnav%3Eli%7Bfloat%3Aleft%7D%2Enavbar%2Dnav%3Eli%3Ea%7Bpadding%2Dtop%3A15px%3Bpadding%2Dbottom%3A15px%7D%7D%2Enavbar%2Dform%7Bpadding%3A10px%2015px%3Bmargin%2Dtop%3A8px%3Bmargin%2Dright%3A%2D15px%3Bmargin%2Dbottom%3A8px%3Bmargin%2Dleft%3A%2D15px%3Bborder%2Dtop%3A1px%20solid%20transparent%3Bborder%2Dbottom%3A1px%20solid%20transparent%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%2C0%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%2C0%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dform%20%2Eform%2Dgroup%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Eform%2Dcontrol%7Bdisplay%3Ainline%2Dblock%3Bwidth%3Aauto%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Eform%2Dcontrol%2Dstatic%7Bdisplay%3Ainline%2Dblock%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%7Bdisplay%3Ainline%2Dtable%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Daddon%2C%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Dbtn%7Bwidth%3Aauto%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%3E%2Eform%2Dcontrol%7Bwidth%3A100%25%7D%2Enavbar%2Dform%20%2Econtrol%2Dlabel%7Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Echeckbox%2C%2Enavbar%2Dform%20%2Eradio%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Echeckbox%20label%2C%2Enavbar%2Dform%20%2Eradio%20label%7Bpadding%2Dleft%3A0%7D%2Enavbar%2Dform%20%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Enavbar%2Dform%20%2Eradio%20input%5Btype%3Dradio%5D%7Bposition%3Arelative%3Bmargin%2Dleft%3A0%7D%2Enavbar%2Dform%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dform%20%2Eform%2Dgroup%7Bmargin%2Dbottom%3A5px%7D%2Enavbar%2Dform%20%2Eform%2Dgroup%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dform%7Bwidth%3Aauto%3Bpadding%2Dtop%3A0%3Bpadding%2Dbottom%3A0%3Bmargin%2Dright%3A0%3Bmargin%2Dleft%3A0%3Bborder%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%7D%2Enavbar%2Dnav%3Eli%3E%2Edropdown%2Dmenu%7Bmargin%2Dtop%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dnav%3Eli%3E%2Edropdown%2Dmenu%7Bmargin%2Dbottom%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Enavbar%2Dbtn%7Bmargin%2Dtop%3A8px%3Bmargin%2Dbottom%3A8px%7D%2Enavbar%2Dbtn%2Ebtn%2Dsm%7Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Enavbar%2Dbtn%2Ebtn%2Dxs%7Bmargin%2Dtop%3A14px%3Bmargin%2Dbottom%3A14px%7D%2Enavbar%2Dtext%7Bmargin%2Dtop%3A15px%3Bmargin%2Dbottom%3A15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dtext%7Bfloat%3Aleft%3Bmargin%2Dright%3A15px%3Bmargin%2Dleft%3A15px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dleft%7Bfloat%3Aleft%21important%7D%2Enavbar%2Dright%7Bfloat%3Aright%21important%3Bmargin%2Dright%3A%2D15px%7D%2Enavbar%2Dright%7E%2Enavbar%2Dright%7Bmargin%2Dright%3A0%7D%7D%2Enavbar%2Ddefault%7Bbackground%2Dcolor%3A%23f8f8f8%3Bborder%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%3Ahover%7Bcolor%3A%235e5e5e%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtext%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23ccc%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%7Bborder%2Dcolor%3A%23ddd%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%3Ahover%7Bbackground%2Dcolor%3A%23ddd%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bbackground%2Dcolor%3A%23888%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dform%7Bborder%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23ccc%3Bbackground%2Dcolor%3Atransparent%7D%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dlink%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dlink%3Ahover%7Bcolor%3A%23333%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Afocus%2C%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23333%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23ccc%7D%2Enavbar%2Dinverse%7Bbackground%2Dcolor%3A%23222%3Bborder%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtext%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23444%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%7Bborder%2Dcolor%3A%23333%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%3Ahover%7Bbackground%2Dcolor%3A%23333%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bbackground%2Dcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dform%7Bborder%2Dcolor%3A%23101010%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edropdown%2Dheader%7Bborder%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%20%2Edivider%7Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23444%3Bbackground%2Dcolor%3Atransparent%7D%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dlink%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dlink%3Ahover%7Bcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Afocus%2C%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23444%7D%2Ebreadcrumb%7Bpadding%3A8px%2015px%3Bmargin%2Dbottom%3A20px%3Blist%2Dstyle%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dradius%3A4px%7D%2Ebreadcrumb%3Eli%7Bdisplay%3Ainline%2Dblock%7D%2Ebreadcrumb%3Eli%2Bli%3Abefore%7Bpadding%3A0%205px%3Bcolor%3A%23ccc%3Bcontent%3A%22%2F%5C00a0%22%7D%2Ebreadcrumb%3E%2Eactive%7Bcolor%3A%23777%7D%2Epagination%7Bdisplay%3Ainline%2Dblock%3Bpadding%2Dleft%3A0%3Bmargin%3A20px%200%3Bborder%2Dradius%3A4px%7D%2Epagination%3Eli%7Bdisplay%3Ainline%7D%2Epagination%3Eli%3Ea%2C%2Epagination%3Eli%3Espan%7Bposition%3Arelative%3Bfloat%3Aleft%3Bpadding%3A6px%2012px%3Bmargin%2Dleft%3A%2D1px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23337ab7%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%7D%2Epagination%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%3Eli%3Afirst%2Dchild%3Espan%7Bmargin%2Dleft%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7D%2Epagination%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A4px%7D%2Epagination%3Eli%3Ea%3Afocus%2C%2Epagination%3Eli%3Ea%3Ahover%2C%2Epagination%3Eli%3Espan%3Afocus%2C%2Epagination%3Eli%3Espan%3Ahover%7Bz%2Dindex%3A3%3Bcolor%3A%2323527c%3Bbackground%2Dcolor%3A%23eee%3Bborder%2Dcolor%3A%23ddd%7D%2Epagination%3E%2Eactive%3Ea%2C%2Epagination%3E%2Eactive%3Ea%3Afocus%2C%2Epagination%3E%2Eactive%3Ea%3Ahover%2C%2Epagination%3E%2Eactive%3Espan%2C%2Epagination%3E%2Eactive%3Espan%3Afocus%2C%2Epagination%3E%2Eactive%3Espan%3Ahover%7Bz%2Dindex%3A2%3Bcolor%3A%23fff%3Bcursor%3Adefault%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Epagination%3E%2Edisabled%3Ea%2C%2Epagination%3E%2Edisabled%3Ea%3Afocus%2C%2Epagination%3E%2Edisabled%3Ea%3Ahover%2C%2Epagination%3E%2Edisabled%3Espan%2C%2Epagination%3E%2Edisabled%3Espan%3Afocus%2C%2Epagination%3E%2Edisabled%3Espan%3Ahover%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ddd%7D%2Epagination%2Dlg%3Eli%3Ea%2C%2Epagination%2Dlg%3Eli%3Espan%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%7D%2Epagination%2Dlg%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%2Dlg%3Eli%3Afirst%2Dchild%3Espan%7Bborder%2Dtop%2Dleft%2Dradius%3A6px%3Bborder%2Dbottom%2Dleft%2Dradius%3A6px%7D%2Epagination%2Dlg%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%2Dlg%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A6px%3Bborder%2Dbottom%2Dright%2Dradius%3A6px%7D%2Epagination%2Dsm%3Eli%3Ea%2C%2Epagination%2Dsm%3Eli%3Espan%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%7D%2Epagination%2Dsm%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%2Dsm%3Eli%3Afirst%2Dchild%3Espan%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epagination%2Dsm%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%2Dsm%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%7D%2Epager%7Bpadding%2Dleft%3A0%3Bmargin%3A20px%200%3Btext%2Dalign%3Acenter%3Blist%2Dstyle%3Anone%7D%2Epager%20li%7Bdisplay%3Ainline%7D%2Epager%20li%3Ea%2C%2Epager%20li%3Espan%7Bdisplay%3Ainline%2Dblock%3Bpadding%3A5px%2014px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A15px%7D%2Epager%20li%3Ea%3Afocus%2C%2Epager%20li%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23eee%7D%2Epager%20%2Enext%3Ea%2C%2Epager%20%2Enext%3Espan%7Bfloat%3Aright%7D%2Epager%20%2Eprevious%3Ea%2C%2Epager%20%2Eprevious%3Espan%7Bfloat%3Aleft%7D%2Epager%20%2Edisabled%3Ea%2C%2Epager%20%2Edisabled%3Ea%3Afocus%2C%2Epager%20%2Edisabled%3Ea%3Ahover%2C%2Epager%20%2Edisabled%3Espan%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23fff%7D%2Elabel%7Bdisplay%3Ainline%3Bpadding%3A%2E2em%20%2E6em%20%2E3em%3Bfont%2Dsize%3A75%25%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Abaseline%3Bborder%2Dradius%3A%2E25em%7Da%2Elabel%3Afocus%2Ca%2Elabel%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%7D%2Elabel%3Aempty%7Bdisplay%3Anone%7D%2Ebtn%20%2Elabel%7Bposition%3Arelative%3Btop%3A%2D1px%7D%2Elabel%2Ddefault%7Bbackground%2Dcolor%3A%23777%7D%2Elabel%2Ddefault%5Bhref%5D%3Afocus%2C%2Elabel%2Ddefault%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%235e5e5e%7D%2Elabel%2Dprimary%7Bbackground%2Dcolor%3A%23337ab7%7D%2Elabel%2Dprimary%5Bhref%5D%3Afocus%2C%2Elabel%2Dprimary%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23286090%7D%2Elabel%2Dsuccess%7Bbackground%2Dcolor%3A%235cb85c%7D%2Elabel%2Dsuccess%5Bhref%5D%3Afocus%2C%2Elabel%2Dsuccess%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23449d44%7D%2Elabel%2Dinfo%7Bbackground%2Dcolor%3A%235bc0de%7D%2Elabel%2Dinfo%5Bhref%5D%3Afocus%2C%2Elabel%2Dinfo%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%2331b0d5%7D%2Elabel%2Dwarning%7Bbackground%2Dcolor%3A%23f0ad4e%7D%2Elabel%2Dwarning%5Bhref%5D%3Afocus%2C%2Elabel%2Dwarning%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23ec971f%7D%2Elabel%2Ddanger%7Bbackground%2Dcolor%3A%23d9534f%7D%2Elabel%2Ddanger%5Bhref%5D%3Afocus%2C%2Elabel%2Ddanger%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23c9302c%7D%2Ebadge%7Bdisplay%3Ainline%2Dblock%3Bmin%2Dwidth%3A10px%3Bpadding%3A3px%207px%3Bfont%2Dsize%3A12px%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%3Bbackground%2Dcolor%3A%23777%3Bborder%2Dradius%3A10px%7D%2Ebadge%3Aempty%7Bdisplay%3Anone%7D%2Ebtn%20%2Ebadge%7Bposition%3Arelative%3Btop%3A%2D1px%7D%2Ebtn%2Dgroup%2Dxs%3E%2Ebtn%20%2Ebadge%2C%2Ebtn%2Dxs%20%2Ebadge%7Btop%3A0%3Bpadding%3A1px%205px%7Da%2Ebadge%3Afocus%2Ca%2Ebadge%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%7D%2Elist%2Dgroup%2Ditem%2Eactive%3E%2Ebadge%2C%2Enav%2Dpills%3E%2Eactive%3Ea%3E%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Elist%2Dgroup%2Ditem%3E%2Ebadge%7Bfloat%3Aright%7D%2Elist%2Dgroup%2Ditem%3E%2Ebadge%2B%2Ebadge%7Bmargin%2Dright%3A5px%7D%2Enav%2Dpills%3Eli%3Ea%3E%2Ebadge%7Bmargin%2Dleft%3A3px%7D%2Ejumbotron%7Bpadding%2Dtop%3A30px%3Bpadding%2Dbottom%3A30px%3Bmargin%2Dbottom%3A30px%3Bcolor%3Ainherit%3Bbackground%2Dcolor%3A%23eee%7D%2Ejumbotron%20%2Eh1%2C%2Ejumbotron%20h1%7Bcolor%3Ainherit%7D%2Ejumbotron%20p%7Bmargin%2Dbottom%3A15px%3Bfont%2Dsize%3A21px%3Bfont%2Dweight%3A200%7D%2Ejumbotron%3Ehr%7Bborder%2Dtop%2Dcolor%3A%23d5d5d5%7D%2Econtainer%20%2Ejumbotron%2C%2Econtainer%2Dfluid%20%2Ejumbotron%7Bborder%2Dradius%3A6px%7D%2Ejumbotron%20%2Econtainer%7Bmax%2Dwidth%3A100%25%7D%40media%20screen%20and%20%28min%2Dwidth%3A768px%29%7B%2Ejumbotron%7Bpadding%2Dtop%3A48px%3Bpadding%2Dbottom%3A48px%7D%2Econtainer%20%2Ejumbotron%2C%2Econtainer%2Dfluid%20%2Ejumbotron%7Bpadding%2Dright%3A60px%3Bpadding%2Dleft%3A60px%7D%2Ejumbotron%20%2Eh1%2C%2Ejumbotron%20h1%7Bfont%2Dsize%3A63px%7D%7D%2Ethumbnail%7Bdisplay%3Ablock%3Bpadding%3A4px%3Bmargin%2Dbottom%3A20px%3Bline%2Dheight%3A1%2E42857143%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dtransition%3Aborder%20%2E2s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3Aborder%20%2E2s%20ease%2Din%2Dout%3Btransition%3Aborder%20%2E2s%20ease%2Din%2Dout%7D%2Ethumbnail%20a%3Eimg%2C%2Ethumbnail%3Eimg%7Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7Da%2Ethumbnail%2Eactive%2Ca%2Ethumbnail%3Afocus%2Ca%2Ethumbnail%3Ahover%7Bborder%2Dcolor%3A%23337ab7%7D%2Ethumbnail%20%2Ecaption%7Bpadding%3A9px%3Bcolor%3A%23333%7D%2Ealert%7Bpadding%3A15px%3Bmargin%2Dbottom%3A20px%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Ealert%20h4%7Bmargin%2Dtop%3A0%3Bcolor%3Ainherit%7D%2Ealert%20%2Ealert%2Dlink%7Bfont%2Dweight%3A700%7D%2Ealert%3Ep%2C%2Ealert%3Eul%7Bmargin%2Dbottom%3A0%7D%2Ealert%3Ep%2Bp%7Bmargin%2Dtop%3A5px%7D%2Ealert%2Ddismissable%2C%2Ealert%2Ddismissible%7Bpadding%2Dright%3A35px%7D%2Ealert%2Ddismissable%20%2Eclose%2C%2Ealert%2Ddismissible%20%2Eclose%7Bposition%3Arelative%3Btop%3A%2D2px%3Bright%3A%2D21px%3Bcolor%3Ainherit%7D%2Ealert%2Dsuccess%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%23d6e9c6%7D%2Ealert%2Dsuccess%20hr%7Bborder%2Dtop%2Dcolor%3A%23c9e2b3%7D%2Ealert%2Dsuccess%20%2Ealert%2Dlink%7Bcolor%3A%232b542c%7D%2Ealert%2Dinfo%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%3Bborder%2Dcolor%3A%23bce8f1%7D%2Ealert%2Dinfo%20hr%7Bborder%2Dtop%2Dcolor%3A%23a6e1ec%7D%2Ealert%2Dinfo%20%2Ealert%2Dlink%7Bcolor%3A%23245269%7D%2Ealert%2Dwarning%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%23faebcc%7D%2Ealert%2Dwarning%20hr%7Bborder%2Dtop%2Dcolor%3A%23f7e1b5%7D%2Ealert%2Dwarning%20%2Ealert%2Dlink%7Bcolor%3A%2366512c%7D%2Ealert%2Ddanger%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23ebccd1%7D%2Ealert%2Ddanger%20hr%7Bborder%2Dtop%2Dcolor%3A%23e4b9c0%7D%2Ealert%2Ddanger%20%2Ealert%2Dlink%7Bcolor%3A%23843534%7D%40%2Dwebkit%2Dkeyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%40%2Do%2Dkeyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%40keyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%2Eprogress%7Bheight%3A20px%3Bmargin%2Dbottom%3A20px%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%202px%20rgba%280%2C0%2C0%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%202px%20rgba%280%2C0%2C0%2C%2E1%29%7D%2Eprogress%2Dbar%7Bfloat%3Aleft%3Bwidth%3A0%3Bheight%3A100%25%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23337ab7%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E15%29%3Bbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E15%29%3B%2Dwebkit%2Dtransition%3Awidth%20%2E6s%20ease%3B%2Do%2Dtransition%3Awidth%20%2E6s%20ease%3Btransition%3Awidth%20%2E6s%20ease%7D%2Eprogress%2Dbar%2Dstriped%2C%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3B%2Dwebkit%2Dbackground%2Dsize%3A40px%2040px%3Bbackground%2Dsize%3A40px%2040px%7D%2Eprogress%2Dbar%2Eactive%2C%2Eprogress%2Eactive%20%2Eprogress%2Dbar%7B%2Dwebkit%2Danimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%3B%2Do%2Danimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%3Banimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%7D%2Eprogress%2Dbar%2Dsuccess%7Bbackground%2Dcolor%3A%235cb85c%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dsuccess%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Dinfo%7Bbackground%2Dcolor%3A%235bc0de%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dinfo%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Dwarning%7Bbackground%2Dcolor%3A%23f0ad4e%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dwarning%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Ddanger%7Bbackground%2Dcolor%3A%23d9534f%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Ddanger%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Emedia%7Bmargin%2Dtop%3A15px%7D%2Emedia%3Afirst%2Dchild%7Bmargin%2Dtop%3A0%7D%2Emedia%2C%2Emedia%2Dbody%7Boverflow%3Ahidden%3Bzoom%3A1%7D%2Emedia%2Dbody%7Bwidth%3A10000px%7D%2Emedia%2Dobject%7Bdisplay%3Ablock%7D%2Emedia%2Dobject%2Eimg%2Dthumbnail%7Bmax%2Dwidth%3Anone%7D%2Emedia%2Dright%2C%2Emedia%3E%2Epull%2Dright%7Bpadding%2Dleft%3A10px%7D%2Emedia%2Dleft%2C%2Emedia%3E%2Epull%2Dleft%7Bpadding%2Dright%3A10px%7D%2Emedia%2Dbody%2C%2Emedia%2Dleft%2C%2Emedia%2Dright%7Bdisplay%3Atable%2Dcell%3Bvertical%2Dalign%3Atop%7D%2Emedia%2Dmiddle%7Bvertical%2Dalign%3Amiddle%7D%2Emedia%2Dbottom%7Bvertical%2Dalign%3Abottom%7D%2Emedia%2Dheading%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A5px%7D%2Emedia%2Dlist%7Bpadding%2Dleft%3A0%3Blist%2Dstyle%3Anone%7D%2Elist%2Dgroup%7Bpadding%2Dleft%3A0%3Bmargin%2Dbottom%3A20px%7D%2Elist%2Dgroup%2Ditem%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bpadding%3A10px%2015px%3Bmargin%2Dbottom%3A%2D1px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%7D%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dtop%2Dright%2Dradius%3A4px%7D%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7Da%2Elist%2Dgroup%2Ditem%2Cbutton%2Elist%2Dgroup%2Ditem%7Bcolor%3A%23555%7Da%2Elist%2Dgroup%2Ditem%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3A%23333%7Da%2Elist%2Dgroup%2Ditem%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%3Ahover%7Bcolor%3A%23555%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%7Dbutton%2Elist%2Dgroup%2Ditem%7Bwidth%3A100%25%3Btext%2Dalign%3Aleft%7D%2Elist%2Dgroup%2Ditem%2Edisabled%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23eee%7D%2Elist%2Dgroup%2Ditem%2Edisabled%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7D%2Elist%2Dgroup%2Ditem%2Edisabled%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dtext%7Bcolor%3A%23777%7D%2Elist%2Dgroup%2Ditem%2Eactive%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%7Bz%2Dindex%3A2%3Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%7Bcolor%3Ainherit%7D%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dtext%7Bcolor%3A%23c7ddef%7D%2Elist%2Dgroup%2Ditem%2Dsuccess%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%7Bcolor%3A%233c763d%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%3Ahover%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23d0e9c6%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%233c763d%3Bborder%2Dcolor%3A%233c763d%7D%2Elist%2Dgroup%2Ditem%2Dinfo%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%7Bcolor%3A%2331708f%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%3Ahover%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23c4e3f3%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331708f%3Bborder%2Dcolor%3A%2331708f%7D%2Elist%2Dgroup%2Ditem%2Dwarning%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%7Bcolor%3A%238a6d3b%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%3Ahover%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23faf2cc%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%238a6d3b%3Bborder%2Dcolor%3A%238a6d3b%7D%2Elist%2Dgroup%2Ditem%2Ddanger%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%7Bcolor%3A%23a94442%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%3Ahover%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23ebcccc%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23a94442%3Bborder%2Dcolor%3A%23a94442%7D%2Elist%2Dgroup%2Ditem%2Dheading%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A5px%7D%2Elist%2Dgroup%2Ditem%2Dtext%7Bmargin%2Dbottom%3A0%3Bline%2Dheight%3A1%2E3%7D%2Epanel%7Bmargin%2Dbottom%3A20px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%3Bbox%2Dshadow%3A0%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%7D%2Epanel%2Dbody%7Bpadding%3A15px%7D%2Epanel%2Dheading%7Bpadding%3A10px%2015px%3Bborder%2Dbottom%3A1px%20solid%20transparent%3Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%2Dheading%3E%2Edropdown%20%2Edropdown%2Dtoggle%7Bcolor%3Ainherit%7D%2Epanel%2Dtitle%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bfont%2Dsize%3A16px%3Bcolor%3Ainherit%7D%2Epanel%2Dtitle%3E%2Esmall%2C%2Epanel%2Dtitle%3E%2Esmall%3Ea%2C%2Epanel%2Dtitle%3Ea%2C%2Epanel%2Dtitle%3Esmall%2C%2Epanel%2Dtitle%3Esmall%3Ea%7Bcolor%3Ainherit%7D%2Epanel%2Dfooter%7Bpadding%3A10px%2015px%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dtop%3A1px%20solid%20%23ddd%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Elist%2Dgroup%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%7Bmargin%2Dbottom%3A0%7D%2Epanel%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%7Bborder%2Dwidth%3A1px%200%3Bborder%2Dradius%3A0%7D%2Epanel%3E%2Elist%2Dgroup%3Afirst%2Dchild%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%3Afirst%2Dchild%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Elist%2Dgroup%3Alast%2Dchild%20%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%3Alast%2Dchild%20%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%7Bborder%2Dbottom%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Epanel%2Dheading%2B%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dwidth%3A0%7D%2Elist%2Dgroup%2B%2Epanel%2Dfooter%7Bborder%2Dtop%2Dwidth%3A0%7D%2Epanel%3E%2Epanel%2Dcollapse%3E%2Etable%2C%2Epanel%3E%2Etable%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%7Bmargin%2Dbottom%3A0%7D%2Epanel%3E%2Epanel%2Dcollapse%3E%2Etable%20caption%2C%2Epanel%3E%2Etable%20caption%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%20caption%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%7Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%7Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Epanel%2Dbody%2B%2Etable%2C%2Epanel%3E%2Epanel%2Dbody%2B%2Etable%2Dresponsive%2C%2Epanel%3E%2Etable%2B%2Epanel%2Dbody%2C%2Epanel%3E%2Etable%2Dresponsive%2B%2Epanel%2Dbody%7Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Epanel%3E%2Etable%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%2C%2Epanel%3E%2Etable%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%7Bborder%2Dtop%3A0%7D%2Epanel%3E%2Etable%2Dbordered%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%7Bborder%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%7Bborder%2Dleft%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%7Bborder%2Dright%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%2Epanel%3E%2Etable%2Dresponsive%7Bmargin%2Dbottom%3A0%3Bborder%3A0%7D%2Epanel%2Dgroup%7Bmargin%2Dbottom%3A20px%7D%2Epanel%2Dgroup%20%2Epanel%7Bmargin%2Dbottom%3A0%3Bborder%2Dradius%3A4px%7D%2Epanel%2Dgroup%20%2Epanel%2B%2Epanel%7Bmargin%2Dtop%3A5px%7D%2Epanel%2Dgroup%20%2Epanel%2Dheading%7Bborder%2Dbottom%3A0%7D%2Epanel%2Dgroup%20%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%2C%2Epanel%2Dgroup%20%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Epanel%2Dgroup%20%2Epanel%2Dfooter%7Bborder%2Dtop%3A0%7D%2Epanel%2Dgroup%20%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%20%2Epanel%2Dbody%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%7D%2Epanel%2Ddefault%7Bborder%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23f5f5f5%3Bbackground%2Dcolor%3A%23333%7D%2Epanel%2Ddefault%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23ddd%7D%2Epanel%2Dprimary%7Bborder%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Epanel%2Dprimary%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23337ab7%7D%2Epanel%2Dsuccess%7Bborder%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23dff0d8%3Bbackground%2Dcolor%3A%233c763d%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dinfo%7Bborder%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%3Bborder%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23d9edf7%3Bbackground%2Dcolor%3A%2331708f%7D%2Epanel%2Dinfo%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dwarning%7Bborder%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23fcf8e3%3Bbackground%2Dcolor%3A%238a6d3b%7D%2Epanel%2Dwarning%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23faebcc%7D%2Epanel%2Ddanger%7Bborder%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23f2dede%3Bbackground%2Dcolor%3A%23a94442%7D%2Epanel%2Ddanger%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23ebccd1%7D%2Eembed%2Dresponsive%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bheight%3A0%3Bpadding%3A0%3Boverflow%3Ahidden%7D%2Eembed%2Dresponsive%20%2Eembed%2Dresponsive%2Ditem%2C%2Eembed%2Dresponsive%20embed%2C%2Eembed%2Dresponsive%20iframe%2C%2Eembed%2Dresponsive%20object%2C%2Eembed%2Dresponsive%20video%7Bposition%3Aabsolute%3Btop%3A0%3Bbottom%3A0%3Bleft%3A0%3Bwidth%3A100%25%3Bheight%3A100%25%3Bborder%3A0%7D%2Eembed%2Dresponsive%2D16by9%7Bpadding%2Dbottom%3A56%2E25%25%7D%2Eembed%2Dresponsive%2D4by3%7Bpadding%2Dbottom%3A75%25%7D%2Ewell%7Bmin%2Dheight%3A20px%3Bpadding%3A19px%3Bmargin%2Dbottom%3A20px%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%3A1px%20solid%20%23e3e3e3%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%7D%2Ewell%20blockquote%7Bborder%2Dcolor%3A%23ddd%3Bborder%2Dcolor%3Argba%280%2C0%2C0%2C%2E15%29%7D%2Ewell%2Dlg%7Bpadding%3A24px%3Bborder%2Dradius%3A6px%7D%2Ewell%2Dsm%7Bpadding%3A9px%3Bborder%2Dradius%3A3px%7D%2Eclose%7Bfloat%3Aright%3Bfont%2Dsize%3A21px%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23000%3Btext%2Dshadow%3A0%201px%200%20%23fff%3Bfilter%3Aalpha%28opacity%3D20%29%3Bopacity%3A%2E2%7D%2Eclose%3Afocus%2C%2Eclose%3Ahover%7Bcolor%3A%23000%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%3Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7Dbutton%2Eclose%7B%2Dwebkit%2Dappearance%3Anone%3Bpadding%3A0%3Bcursor%3Apointer%3Bbackground%3A0%200%3Bborder%3A0%7D%2Emodal%2Dopen%7Boverflow%3Ahidden%7D%2Emodal%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A1050%3Bdisplay%3Anone%3Boverflow%3Ahidden%3B%2Dwebkit%2Doverflow%2Dscrolling%3Atouch%3Boutline%3A0%7D%2Emodal%2Efade%20%2Emodal%2Ddialog%7B%2Dwebkit%2Dtransition%3A%2Dwebkit%2Dtransform%20%2E3s%20ease%2Dout%3B%2Do%2Dtransition%3A%2Do%2Dtransform%20%2E3s%20ease%2Dout%3Btransition%3Atransform%20%2E3s%20ease%2Dout%3B%2Dwebkit%2Dtransform%3Atranslate%280%2C%2D25%25%29%3B%2Dms%2Dtransform%3Atranslate%280%2C%2D25%25%29%3B%2Do%2Dtransform%3Atranslate%280%2C%2D25%25%29%3Btransform%3Atranslate%280%2C%2D25%25%29%7D%2Emodal%2Ein%20%2Emodal%2Ddialog%7B%2Dwebkit%2Dtransform%3Atranslate%280%2C0%29%3B%2Dms%2Dtransform%3Atranslate%280%2C0%29%3B%2Do%2Dtransform%3Atranslate%280%2C0%29%3Btransform%3Atranslate%280%2C0%29%7D%2Emodal%2Dopen%20%2Emodal%7Boverflow%2Dx%3Ahidden%3Boverflow%2Dy%3Aauto%7D%2Emodal%2Ddialog%7Bposition%3Arelative%3Bwidth%3Aauto%3Bmargin%3A10px%7D%2Emodal%2Dcontent%7Bposition%3Arelative%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23999%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E2%29%3Bborder%2Dradius%3A6px%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3A0%203px%209px%20rgba%280%2C0%2C0%2C%2E5%29%3Bbox%2Dshadow%3A0%203px%209px%20rgba%280%2C0%2C0%2C%2E5%29%7D%2Emodal%2Dbackdrop%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A1040%3Bbackground%2Dcolor%3A%23000%7D%2Emodal%2Dbackdrop%2Efade%7Bfilter%3Aalpha%28opacity%3D0%29%3Bopacity%3A0%7D%2Emodal%2Dbackdrop%2Ein%7Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7D%2Emodal%2Dheader%7Bmin%2Dheight%3A16%2E43px%3Bpadding%3A15px%3Bborder%2Dbottom%3A1px%20solid%20%23e5e5e5%7D%2Emodal%2Dheader%20%2Eclose%7Bmargin%2Dtop%3A%2D2px%7D%2Emodal%2Dtitle%7Bmargin%3A0%3Bline%2Dheight%3A1%2E42857143%7D%2Emodal%2Dbody%7Bposition%3Arelative%3Bpadding%3A15px%7D%2Emodal%2Dfooter%7Bpadding%3A15px%3Btext%2Dalign%3Aright%3Bborder%2Dtop%3A1px%20solid%20%23e5e5e5%7D%2Emodal%2Dfooter%20%2Ebtn%2B%2Ebtn%7Bmargin%2Dbottom%3A0%3Bmargin%2Dleft%3A5px%7D%2Emodal%2Dfooter%20%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%7Bmargin%2Dleft%3A%2D1px%7D%2Emodal%2Dfooter%20%2Ebtn%2Dblock%2B%2Ebtn%2Dblock%7Bmargin%2Dleft%3A0%7D%2Emodal%2Dscrollbar%2Dmeasure%7Bposition%3Aabsolute%3Btop%3A%2D9999px%3Bwidth%3A50px%3Bheight%3A50px%3Boverflow%3Ascroll%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Emodal%2Ddialog%7Bwidth%3A600px%3Bmargin%3A30px%20auto%7D%2Emodal%2Dcontent%7B%2Dwebkit%2Dbox%2Dshadow%3A0%205px%2015px%20rgba%280%2C0%2C0%2C%2E5%29%3Bbox%2Dshadow%3A0%205px%2015px%20rgba%280%2C0%2C0%2C%2E5%29%7D%2Emodal%2Dsm%7Bwidth%3A300px%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Emodal%2Dlg%7Bwidth%3A900px%7D%7D%2Etooltip%7Bposition%3Aabsolute%3Bz%2Dindex%3A1070%3Bdisplay%3Ablock%3Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A12px%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Aleft%3Btext%2Dalign%3Astart%3Btext%2Ddecoration%3Anone%3Btext%2Dshadow%3Anone%3Btext%2Dtransform%3Anone%3Bletter%2Dspacing%3Anormal%3Bword%2Dbreak%3Anormal%3Bword%2Dspacing%3Anormal%3Bword%2Dwrap%3Anormal%3Bwhite%2Dspace%3Anormal%3Bfilter%3Aalpha%28opacity%3D0%29%3Bopacity%3A0%3Bline%2Dbreak%3Aauto%7D%2Etooltip%2Ein%7Bfilter%3Aalpha%28opacity%3D90%29%3Bopacity%3A%2E9%7D%2Etooltip%2Etop%7Bpadding%3A5px%200%3Bmargin%2Dtop%3A%2D3px%7D%2Etooltip%2Eright%7Bpadding%3A0%205px%3Bmargin%2Dleft%3A3px%7D%2Etooltip%2Ebottom%7Bpadding%3A5px%200%3Bmargin%2Dtop%3A3px%7D%2Etooltip%2Eleft%7Bpadding%3A0%205px%3Bmargin%2Dleft%3A%2D3px%7D%2Etooltip%2Dinner%7Bmax%2Dwidth%3A200px%3Bpadding%3A3px%208px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23000%3Bborder%2Dradius%3A4px%7D%2Etooltip%2Darrow%7Bposition%3Aabsolute%3Bwidth%3A0%3Bheight%3A0%3Bborder%2Dcolor%3Atransparent%3Bborder%2Dstyle%3Asolid%7D%2Etooltip%2Etop%20%2Etooltip%2Darrow%7Bbottom%3A0%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Etop%2Dleft%20%2Etooltip%2Darrow%7Bright%3A5px%3Bbottom%3A0%3Bmargin%2Dbottom%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Etop%2Dright%20%2Etooltip%2Darrow%7Bbottom%3A0%3Bleft%3A5px%3Bmargin%2Dbottom%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Eright%20%2Etooltip%2Darrow%7Btop%3A50%25%3Bleft%3A0%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%205px%200%3Bborder%2Dright%2Dcolor%3A%23000%7D%2Etooltip%2Eleft%20%2Etooltip%2Darrow%7Btop%3A50%25%3Bright%3A0%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A5px%200%205px%205px%3Bborder%2Dleft%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%20%2Etooltip%2Darrow%7Btop%3A0%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%2Dleft%20%2Etooltip%2Darrow%7Btop%3A0%3Bright%3A5px%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%2Dright%20%2Etooltip%2Darrow%7Btop%3A0%3Bleft%3A5px%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Epopover%7Bposition%3Aabsolute%3Btop%3A0%3Bleft%3A0%3Bz%2Dindex%3A1060%3Bdisplay%3Anone%3Bmax%2Dwidth%3A276px%3Bpadding%3A1px%3Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A14px%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Aleft%3Btext%2Dalign%3Astart%3Btext%2Ddecoration%3Anone%3Btext%2Dshadow%3Anone%3Btext%2Dtransform%3Anone%3Bletter%2Dspacing%3Anormal%3Bword%2Dbreak%3Anormal%3Bword%2Dspacing%3Anormal%3Bword%2Dwrap%3Anormal%3Bwhite%2Dspace%3Anormal%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23ccc%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E2%29%3Bborder%2Dradius%3A6px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%205px%2010px%20rgba%280%2C0%2C0%2C%2E2%29%3Bbox%2Dshadow%3A0%205px%2010px%20rgba%280%2C0%2C0%2C%2E2%29%3Bline%2Dbreak%3Aauto%7D%2Epopover%2Etop%7Bmargin%2Dtop%3A%2D10px%7D%2Epopover%2Eright%7Bmargin%2Dleft%3A10px%7D%2Epopover%2Ebottom%7Bmargin%2Dtop%3A10px%7D%2Epopover%2Eleft%7Bmargin%2Dleft%3A%2D10px%7D%2Epopover%2Dtitle%7Bpadding%3A8px%2014px%3Bmargin%3A0%3Bfont%2Dsize%3A14px%3Bbackground%2Dcolor%3A%23f7f7f7%3Bborder%2Dbottom%3A1px%20solid%20%23ebebeb%3Bborder%2Dradius%3A5px%205px%200%200%7D%2Epopover%2Dcontent%7Bpadding%3A9px%2014px%7D%2Epopover%3E%2Earrow%2C%2Epopover%3E%2Earrow%3Aafter%7Bposition%3Aabsolute%3Bdisplay%3Ablock%3Bwidth%3A0%3Bheight%3A0%3Bborder%2Dcolor%3Atransparent%3Bborder%2Dstyle%3Asolid%7D%2Epopover%3E%2Earrow%7Bborder%2Dwidth%3A11px%7D%2Epopover%3E%2Earrow%3Aafter%7Bcontent%3A%22%22%3Bborder%2Dwidth%3A10px%7D%2Epopover%2Etop%3E%2Earrow%7Bbottom%3A%2D11px%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D11px%3Bborder%2Dtop%2Dcolor%3A%23999%3Bborder%2Dtop%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Epopover%2Etop%3E%2Earrow%3Aafter%7Bbottom%3A1px%3Bmargin%2Dleft%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dtop%2Dcolor%3A%23fff%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Epopover%2Eright%3E%2Earrow%7Btop%3A50%25%3Bleft%3A%2D11px%3Bmargin%2Dtop%3A%2D11px%3Bborder%2Dright%2Dcolor%3A%23999%3Bborder%2Dright%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%3Bborder%2Dleft%2Dwidth%3A0%7D%2Epopover%2Eright%3E%2Earrow%3Aafter%7Bbottom%3A%2D10px%3Bleft%3A1px%3Bcontent%3A%22%20%22%3Bborder%2Dright%2Dcolor%3A%23fff%3Bborder%2Dleft%2Dwidth%3A0%7D%2Epopover%2Ebottom%3E%2Earrow%7Btop%3A%2D11px%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D11px%3Bborder%2Dtop%2Dwidth%3A0%3Bborder%2Dbottom%2Dcolor%3A%23999%3Bborder%2Dbottom%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%7D%2Epopover%2Ebottom%3E%2Earrow%3Aafter%7Btop%3A1px%3Bmargin%2Dleft%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dtop%2Dwidth%3A0%3Bborder%2Dbottom%2Dcolor%3A%23fff%7D%2Epopover%2Eleft%3E%2Earrow%7Btop%3A50%25%3Bright%3A%2D11px%3Bmargin%2Dtop%3A%2D11px%3Bborder%2Dright%2Dwidth%3A0%3Bborder%2Dleft%2Dcolor%3A%23999%3Bborder%2Dleft%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%7D%2Epopover%2Eleft%3E%2Earrow%3Aafter%7Bright%3A1px%3Bbottom%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dright%2Dwidth%3A0%3Bborder%2Dleft%2Dcolor%3A%23fff%7D%2Ecarousel%7Bposition%3Arelative%7D%2Ecarousel%2Dinner%7Bposition%3Arelative%3Bwidth%3A100%25%3Boverflow%3Ahidden%7D%2Ecarousel%2Dinner%3E%2Eitem%7Bposition%3Arelative%3Bdisplay%3Anone%3B%2Dwebkit%2Dtransition%3A%2E6s%20ease%2Din%2Dout%20left%3B%2Do%2Dtransition%3A%2E6s%20ease%2Din%2Dout%20left%3Btransition%3A%2E6s%20ease%2Din%2Dout%20left%7D%2Ecarousel%2Dinner%3E%2Eitem%3Ea%3Eimg%2C%2Ecarousel%2Dinner%3E%2Eitem%3Eimg%7Bline%2Dheight%3A1%7D%40media%20all%20and%20%28transform%2D3d%29%2C%28%2Dwebkit%2Dtransform%2D3d%29%7B%2Ecarousel%2Dinner%3E%2Eitem%7B%2Dwebkit%2Dtransition%3A%2Dwebkit%2Dtransform%20%2E6s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3A%2Do%2Dtransform%20%2E6s%20ease%2Din%2Dout%3Btransition%3Atransform%20%2E6s%20ease%2Din%2Dout%3B%2Dwebkit%2Dbackface%2Dvisibility%3Ahidden%3Bbackface%2Dvisibility%3Ahidden%3B%2Dwebkit%2Dperspective%3A1000px%3Bperspective%3A1000px%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2Eright%2C%2Ecarousel%2Dinner%3E%2Eitem%2Enext%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%28100%25%2C0%2C0%29%3Btransform%3Atranslate3d%28100%25%2C0%2C0%29%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eitem%2Eprev%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%28%2D100%25%2C0%2C0%29%3Btransform%3Atranslate3d%28%2D100%25%2C0%2C0%29%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2C%2Ecarousel%2Dinner%3E%2Eitem%2Enext%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eitem%2Eprev%2Eright%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%280%2C0%2C0%29%3Btransform%3Atranslate3d%280%2C0%2C0%29%7D%7D%2Ecarousel%2Dinner%3E%2Eactive%2C%2Ecarousel%2Dinner%3E%2Enext%2C%2Ecarousel%2Dinner%3E%2Eprev%7Bdisplay%3Ablock%7D%2Ecarousel%2Dinner%3E%2Eactive%7Bleft%3A0%7D%2Ecarousel%2Dinner%3E%2Enext%2C%2Ecarousel%2Dinner%3E%2Eprev%7Bposition%3Aabsolute%3Btop%3A0%3Bwidth%3A100%25%7D%2Ecarousel%2Dinner%3E%2Enext%7Bleft%3A100%25%7D%2Ecarousel%2Dinner%3E%2Eprev%7Bleft%3A%2D100%25%7D%2Ecarousel%2Dinner%3E%2Enext%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eprev%2Eright%7Bleft%3A0%7D%2Ecarousel%2Dinner%3E%2Eactive%2Eleft%7Bleft%3A%2D100%25%7D%2Ecarousel%2Dinner%3E%2Eactive%2Eright%7Bleft%3A100%25%7D%2Ecarousel%2Dcontrol%7Bposition%3Aabsolute%3Btop%3A0%3Bbottom%3A0%3Bleft%3A0%3Bwidth%3A15%25%3Bfont%2Dsize%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Btext%2Dshadow%3A0%201px%202px%20rgba%280%2C0%2C0%2C%2E6%29%3Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7D%2Ecarousel%2Dcontrol%2Eleft%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bbackground%2Dimage%3A%2Dwebkit%2Dgradient%28linear%2Cleft%20top%2Cright%20top%2Cfrom%28rgba%280%2C0%2C0%2C%2E5%29%29%2Cto%28rgba%280%2C0%2C0%2C%2E0001%29%29%29%3Bbackground%2Dimage%3Alinear%2Dgradient%28to%20right%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28startColorstr%3D%27%2380000000%27%2C%20endColorstr%3D%27%2300000000%27%2C%20GradientType%3D1%29%3Bbackground%2Drepeat%3Arepeat%2Dx%7D%2Ecarousel%2Dcontrol%2Eright%7Bright%3A0%3Bleft%3Aauto%3Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bbackground%2Dimage%3A%2Dwebkit%2Dgradient%28linear%2Cleft%20top%2Cright%20top%2Cfrom%28rgba%280%2C0%2C0%2C%2E0001%29%29%2Cto%28rgba%280%2C0%2C0%2C%2E5%29%29%29%3Bbackground%2Dimage%3Alinear%2Dgradient%28to%20right%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28startColorstr%3D%27%2300000000%27%2C%20endColorstr%3D%27%2380000000%27%2C%20GradientType%3D1%29%3Bbackground%2Drepeat%3Arepeat%2Dx%7D%2Ecarousel%2Dcontrol%3Afocus%2C%2Ecarousel%2Dcontrol%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bfilter%3Aalpha%28opacity%3D90%29%3Boutline%3A0%3Bopacity%3A%2E9%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bposition%3Aabsolute%3Btop%3A50%25%3Bz%2Dindex%3A5%3Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bleft%3A50%25%3Bmargin%2Dleft%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%7Bright%3A50%25%3Bmargin%2Dright%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bwidth%3A20px%3Bheight%3A20px%3Bfont%2Dfamily%3Aserif%3Bline%2Dheight%3A1%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%3Abefore%7Bcontent%3A%27%5C2039%27%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%3Abefore%7Bcontent%3A%27%5C203a%27%7D%2Ecarousel%2Dindicators%7Bposition%3Aabsolute%3Bbottom%3A10px%3Bleft%3A50%25%3Bz%2Dindex%3A15%3Bwidth%3A60%25%3Bpadding%2Dleft%3A0%3Bmargin%2Dleft%3A%2D30%25%3Btext%2Dalign%3Acenter%3Blist%2Dstyle%3Anone%7D%2Ecarousel%2Dindicators%20li%7Bdisplay%3Ainline%2Dblock%3Bwidth%3A10px%3Bheight%3A10px%3Bmargin%3A1px%3Btext%2Dindent%3A%2D999px%3Bcursor%3Apointer%3Bbackground%2Dcolor%3A%23000%5C9%3Bbackground%2Dcolor%3Argba%280%2C0%2C0%2C0%29%3Bborder%3A1px%20solid%20%23fff%3Bborder%2Dradius%3A10px%7D%2Ecarousel%2Dindicators%20%2Eactive%7Bwidth%3A12px%3Bheight%3A12px%3Bmargin%3A0%3Bbackground%2Dcolor%3A%23fff%7D%2Ecarousel%2Dcaption%7Bposition%3Aabsolute%3Bright%3A15%25%3Bbottom%3A20px%3Bleft%3A15%25%3Bz%2Dindex%3A10%3Bpadding%2Dtop%3A20px%3Bpadding%2Dbottom%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Btext%2Dshadow%3A0%201px%202px%20rgba%280%2C0%2C0%2C%2E6%29%7D%2Ecarousel%2Dcaption%20%2Ebtn%7Btext%2Dshadow%3Anone%7D%40media%20screen%20and%20%28min%2Dwidth%3A768px%29%7B%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bwidth%3A30px%3Bheight%3A30px%3Bmargin%2Dtop%3A%2D15px%3Bfont%2Dsize%3A30px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bmargin%2Dleft%3A%2D15px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%7Bmargin%2Dright%3A%2D15px%7D%2Ecarousel%2Dcaption%7Bright%3A20%25%3Bleft%3A20%25%3Bpadding%2Dbottom%3A30px%7D%2Ecarousel%2Dindicators%7Bbottom%3A20px%7D%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Aafter%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Abefore%2C%2Ebtn%2Dtoolbar%3Aafter%2C%2Ebtn%2Dtoolbar%3Abefore%2C%2Eclearfix%3Aafter%2C%2Eclearfix%3Abefore%2C%2Econtainer%2Dfluid%3Aafter%2C%2Econtainer%2Dfluid%3Abefore%2C%2Econtainer%3Aafter%2C%2Econtainer%3Abefore%2C%2Edl%2Dhorizontal%20dd%3Aafter%2C%2Edl%2Dhorizontal%20dd%3Abefore%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Aafter%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Abefore%2C%2Emodal%2Dfooter%3Aafter%2C%2Emodal%2Dfooter%3Abefore%2C%2Enav%3Aafter%2C%2Enav%3Abefore%2C%2Enavbar%2Dcollapse%3Aafter%2C%2Enavbar%2Dcollapse%3Abefore%2C%2Enavbar%2Dheader%3Aafter%2C%2Enavbar%2Dheader%3Abefore%2C%2Enavbar%3Aafter%2C%2Enavbar%3Abefore%2C%2Epager%3Aafter%2C%2Epager%3Abefore%2C%2Epanel%2Dbody%3Aafter%2C%2Epanel%2Dbody%3Abefore%2C%2Erow%3Aafter%2C%2Erow%3Abefore%7Bdisplay%3Atable%3Bcontent%3A%22%20%22%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Aafter%2C%2Ebtn%2Dtoolbar%3Aafter%2C%2Eclearfix%3Aafter%2C%2Econtainer%2Dfluid%3Aafter%2C%2Econtainer%3Aafter%2C%2Edl%2Dhorizontal%20dd%3Aafter%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Aafter%2C%2Emodal%2Dfooter%3Aafter%2C%2Enav%3Aafter%2C%2Enavbar%2Dcollapse%3Aafter%2C%2Enavbar%2Dheader%3Aafter%2C%2Enavbar%3Aafter%2C%2Epager%3Aafter%2C%2Epanel%2Dbody%3Aafter%2C%2Erow%3Aafter%7Bclear%3Aboth%7D%2Ecenter%2Dblock%7Bdisplay%3Ablock%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%2Epull%2Dright%7Bfloat%3Aright%21important%7D%2Epull%2Dleft%7Bfloat%3Aleft%21important%7D%2Ehide%7Bdisplay%3Anone%21important%7D%2Eshow%7Bdisplay%3Ablock%21important%7D%2Einvisible%7Bvisibility%3Ahidden%7D%2Etext%2Dhide%7Bfont%3A0%2F0%20a%3Bcolor%3Atransparent%3Btext%2Dshadow%3Anone%3Bbackground%2Dcolor%3Atransparent%3Bborder%3A0%7D%2Ehidden%7Bdisplay%3Anone%21important%7D%2Eaffix%7Bposition%3Afixed%7D%40%2Dms%2Dviewport%7Bwidth%3Adevice%2Dwidth%7D%2Evisible%2Dlg%2C%2Evisible%2Dmd%2C%2Evisible%2Dsm%2C%2Evisible%2Dxs%7Bdisplay%3Anone%21important%7D%2Evisible%2Dlg%2Dblock%2C%2Evisible%2Dlg%2Dinline%2C%2Evisible%2Dlg%2Dinline%2Dblock%2C%2Evisible%2Dmd%2Dblock%2C%2Evisible%2Dmd%2Dinline%2C%2Evisible%2Dmd%2Dinline%2Dblock%2C%2Evisible%2Dsm%2Dblock%2C%2Evisible%2Dsm%2Dinline%2C%2Evisible%2Dsm%2Dinline%2Dblock%2C%2Evisible%2Dxs%2Dblock%2C%2Evisible%2Dxs%2Dinline%2C%2Evisible%2Dxs%2Dinline%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dxs%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dxs%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dxs%2Cth%2Evisible%2Dxs%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dsm%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dsm%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dsm%2Cth%2Evisible%2Dsm%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dmd%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dmd%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dmd%2Cth%2Evisible%2Dmd%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dlg%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dlg%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dlg%2Cth%2Evisible%2Dlg%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Ehidden%2Dxs%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Ehidden%2Dsm%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Ehidden%2Dmd%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Ehidden%2Dlg%7Bdisplay%3Anone%21important%7D%7D%2Evisible%2Dprint%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dprint%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dprint%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dprint%2Cth%2Evisible%2Dprint%7Bdisplay%3Atable%2Dcell%21important%7D%7D%2Evisible%2Dprint%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%2Evisible%2Dprint%2Dinline%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%2Evisible%2Dprint%2Dinline%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20print%7B%2Ehidden%2Dprint%7Bdisplay%3Anone%21important%7D%7D%0A" rel="stylesheet" />
<script src="data:application/x-javascript;base64,/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);"></script>
<script src="data:application/x-javascript;base64,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"></script>
<script src="data:application/x-javascript;base64,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"></script>
<script src="data:application/x-javascript;base64,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"></script>
<link href="data:text/css;charset=utf-8,%2Ehljs%2Dliteral%20%7B%0Acolor%3A%20%23990073%3B%0A%7D%0A%2Ehljs%2Dnumber%20%7B%0Acolor%3A%20%23099%3B%0A%7D%0A%2Ehljs%2Dcomment%20%7B%0Acolor%3A%20%23998%3B%0Afont%2Dstyle%3A%20italic%3B%0A%7D%0A%2Ehljs%2Dkeyword%20%7B%0Acolor%3A%20%23900%3B%0Afont%2Dweight%3A%20bold%3B%0A%7D%0A%2Ehljs%2Dstring%20%7B%0Acolor%3A%20%23d14%3B%0A%7D%0A" rel="stylesheet" />
<script src="data:application/x-javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>

<style type="text/css">code{white-space: pre;}</style>
<style type="text/css">
  pre:not([class]) {
    background-color: white;
  }
</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>



<style type="text/css">
h1 {
  font-size: 34px;
}
h1.title {
  font-size: 38px;
}
h2 {
  font-size: 30px;
}
h3 {
  font-size: 24px;
}
h4 {
  font-size: 18px;
}
h5 {
  font-size: 16px;
}
h6 {
  font-size: 12px;
}
.table th:not([align]) {
  text-align: left;
}
</style>


</head>

<body>

<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
code {
  color: inherit;
  background-color: rgba(0, 0, 0, 0.04);
}
img {
  max-width:100%;
  height: auto;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
</style>



<div class="container-fluid main-container">

<!-- tabsets -->
<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});
</script>

<!-- code folding -->






<div class="fluid-row" id="header">



<h1 class="title toc-ignore">Clean script</h1>

</div>


<pre class="r"><code>library(ggplot2)</code></pre>
<pre><code>## Warning: package 'ggplot2' was built under R version 3.5.1</code></pre>
<pre class="r"><code>library(stringr)</code></pre>
<pre><code>## Warning: package 'stringr' was built under R version 3.5.1</code></pre>
<pre class="r"><code>library(gplots)</code></pre>
<pre><code>## Warning: package 'gplots' was built under R version 3.5.1</code></pre>
<pre><code>## 
## Attaching package: 'gplots'</code></pre>
<pre><code>## The following object is masked from 'package:stats':
## 
##     lowess</code></pre>
<div id="loading-the-two-datasets" class="section level4">
<h4>Loading the two datasets:</h4>
<pre class="r"><code>load('MR_data.RData')#Load the Mendelian Randomization data frame
load('DrugBank_data.RData')#Load the Drugbank data frame</code></pre>
<p>Overview:</p>
<pre class="r"><code>View(head(DB))
cbind(DB$drugbank.id,DB$name,DB$targets)[1:10,]#Here we bind the 3 columns that provide some </code></pre>
<pre><code>##       [,1]      [,2]                   
##  [1,] &quot;DB00001&quot; &quot;Lepirudin&quot;            
##  [2,] &quot;DB00002&quot; &quot;Cetuximab&quot;            
##  [3,] &quot;DB00003&quot; &quot;Dornase alfa&quot;         
##  [4,] &quot;DB00004&quot; &quot;Denileukin diftitox&quot;  
##  [5,] &quot;DB00005&quot; &quot;Etanercept&quot;           
##  [6,] &quot;DB00006&quot; &quot;Bivalirudin&quot;          
##  [7,] &quot;DB00007&quot; &quot;Leuprolide&quot;           
##  [8,] &quot;DB00008&quot; &quot;Peginterferon alfa-2a&quot;
##  [9,] &quot;DB00009&quot; &quot;Alteplase&quot;            
## [10,] &quot;DB00010&quot; &quot;Sermorelin&quot;           
##       [,3]                                                                               
##  [1,] &quot;F2&quot;                                                                               
##  [2,] &quot;EGFR/FCGR3B/C1R/C1QA/C1QB/C1QC/FCGR3A/C1S/FCGR1A/FCGR2A/FCGR2B/FCGR2C&quot;            
##  [3,] &quot;&quot;                                                                                 
##  [4,] &quot;IL2RA/IL2RB/IL2RG&quot;                                                                
##  [5,] &quot;TNF/TNFRSF1B/FCGR1A/FCGR3A/FCGR2A/FCGR2B/FCGR2C/LTA/FCGR3B/C1S/C1R/C1QA/C1QB/C1QC&quot;
##  [6,] &quot;F2&quot;                                                                               
##  [7,] &quot;GNRHR&quot;                                                                            
##  [8,] &quot;IFNAR2/IFNAR1&quot;                                                                    
##  [9,] &quot;PLG/FGA/PLAUR/SERPINE1&quot;                                                           
## [10,] &quot;GHRHR&quot;</code></pre>
<pre class="r"><code>                                               #information about the 10 first drugs </code></pre>
<pre class="r"><code>head(MR)</code></pre>
<pre><code>##      gene_id       pvalue trait
## 1 AC010335.1 1.151219e-15    AD
## 2        ELL 1.151219e-15    AD
## 3      PTK2B 6.922158e-15    AD
## 4       SSR1 4.001775e-13    AD
## 5      AP3M1 1.764334e-12    AD
## 6    ARHGEF3 7.393724e-12    AD</code></pre>
</div>
<div id="filtering-missing-values" class="section level4">
<h4>Filtering missing values:</h4>
<p>In the overview of the drugbank data we notice that drugs have missing gene targets.Here we filter the data by removing them:</p>
<pre class="r"><code>DB=DB[complete.cases(DB$targets),]#remove rows that have NA targets
rmrow=which(DB$targets==&quot;&quot;)#vector containing the indexes of rows with empty values
DB=DB[-rmrow,] #Remove rows containing ''</code></pre>
<p>As shown in the overview, gene names are seperated with ‘/’. A function was created in order to seperate strings of characters according to ‘/’ (useful to access targets one by one):</p>
<pre class="r"><code>unlisttarget=function(vec){
  vec=unlist(str_split(vec,pattern = '/'))
}
DB$targets=tapply(DB$targets,DB$drugbank.id,unlisttarget)</code></pre>
</div>
<div id="creating-a-matrix-p-containing-traits-and-their-p.values" class="section level4">
<h4>Creating a matrix P containing Traits and their P.values:</h4>
<p>Matrix P contains the p.values of each causal gene according to the disease or trait:</p>
<pre class="r"><code>Genes=unique(MR$gene_id)#List containing all the gene names

Traits=unique(MR$trait)#List of all the traits studied

P=matrix(1,nrow = length(Genes),ncol=length(Traits),dimnames = list(Genes,Traits))


#The matrix will be filled by columns
#For each trait, all the p-values of the causal genes will be extracted


for (i in 1:length(Traits)){
c1=MR$trait==Traits[i]#Vector containing TRUE when the desired 
                      #trait is present in a row   
pos=which(c1)#Positions of the row
p.v=MR$pvalue[pos]#P-values of the trait
gen=MR$gene_id[pos]#Gene names for each p-value
P[gen,i]=p.v#Fill in the matrix at the desired positions
}
dim(P)</code></pre>
<pre><code>## [1] 15978    42</code></pre>
<pre class="r"><code>head.matrix(P[,1:6],n=10)</code></pre>
<pre><code>##                      AD        ALS         BASO          BMI         CAD
## AC010335.1 1.151219e-15 0.09500669 8.779308e-08 2.001331e-01 0.133984972
## ELL        1.151219e-15 0.09500669 8.779308e-08 2.001331e-01 0.133984972
## PTK2B      6.922158e-15 0.85924407 5.111168e-02 3.487243e-03 0.001621889
## SSR1       4.001775e-13 0.09495719 3.485468e-01 2.931925e-01 0.206949276
## AP3M1      1.764334e-12 0.26942491 1.897301e-01 8.008671e-03 0.011632994
## ARHGEF3    7.393724e-12 0.06717056 8.130884e-01 3.715537e-01 0.054652970
## TP53INP1   8.241628e-12 0.55461095 3.549094e-07 8.085134e-03 0.003461327
## ARL5B      1.001342e-11 0.99224396 2.419640e-02 5.255013e-02 0.984072531
## FNBP4      1.266168e-11 0.14016729 2.685093e-01 3.953607e-05 0.734256541
## MS4A4A     1.490596e-11 0.12852038 2.173400e-03 7.827340e-01 0.211120149
##                      CD
## AC010335.1 1.473200e-09
## ELL        1.473200e-09
## PTK2B      1.239448e-06
## SSR1       3.561979e-02
## AP3M1      1.551524e-01
## ARHGEF3    4.367540e-10
## TP53INP1   2.522284e-01
## ARL5B      6.271887e-01
## FNBP4      3.153598e-01
## MS4A4A     7.516781e-01</code></pre>
<p>The dimensions of P correspond to the number of genes studied in the MR study (rows=16k), and the corresponding traits (columns=42). It should be noted that a column can contain zeros, meaning that at that position the gene is not causal to the trait.</p>
<p>Sanity check for trait 1 (AD):</p>
<pre class="r"><code>pval_AD=MR$pvalue[MR$trait==Traits[1]]
isFALSE(pval_AD%in%P[,1])#Should be correct</code></pre>
<pre><code>## [1] FALSE</code></pre>
</div>
<div id="creating-a-matrix-q-containing-drugstheir-gene-targets" class="section level4">
<h4>Creating a matrix Q containing Drugs+their gene targets:</h4>
<p>Now, i want to create a matrix Q that contains 0 and 1 for each gene and each drug: - 0 if the drug does not target the gene - 1 if the drug targets the gene</p>
<p>-&gt; This will be helpful for determining the number of targets for each drug (for the association matrix)</p>
<pre class="r"><code>Drugs=unique(DB$drugbank.id)
Q=matrix(0,ncol = length(Drugs),nrow = length(Genes),dimnames = list(Genes,Drugs))
for (i in 1:length(Drugs)){
  tl=DB$targets[[i]]#tl contains the target(s) of the drug
  index=which(Genes%in%tl)#index contains the positions of the targets in the gene vector 
  Q[index,i]=1
}
dim(Q)</code></pre>
<pre><code>## [1] 15978  7063</code></pre>
<pre class="r"><code>head.matrix(Q[,1:10],n=10)</code></pre>
<pre><code>##            DB00001 DB00002 DB00004 DB00005 DB00006 DB00007 DB00008 DB00009
## AC010335.1       0       0       0       0       0       0       0       0
## ELL              0       0       0       0       0       0       0       0
## PTK2B            0       0       0       0       0       0       0       0
## SSR1             0       0       0       0       0       0       0       0
## AP3M1            0       0       0       0       0       0       0       0
## ARHGEF3          0       0       0       0       0       0       0       0
## TP53INP1         0       0       0       0       0       0       0       0
## ARL5B            0       0       0       0       0       0       0       0
## FNBP4            0       0       0       0       0       0       0       0
## MS4A4A           0       0       0       0       0       0       0       0
##            DB00010 DB00011
## AC010335.1       0       0
## ELL              0       0
## PTK2B            0       0
## SSR1             0       0
## AP3M1            0       0
## ARHGEF3          0       0
## TP53INP1         0       0
## ARL5B            0       0
## FNBP4            0       0
## MS4A4A           0       0</code></pre>
<p>Rows of Q represent genes (around 16k) Columns of Q represent drugs (around 7k drugs)</p>
<p>We see at first glance that drugs do not have many gene targets (This will be visualized in a later part)</p>
<p>If we sum the columns of Q, we obtain the total number of targets for each drug:</p>
<pre class="r"><code>t=colSums(Q)
t[1:20]</code></pre>
<pre><code>## DB00001 DB00002 DB00004 DB00005 DB00006 DB00007 DB00008 DB00009 DB00010 
##       1       9       2       9       1       0       2       3       1 
## DB00011 DB00012 DB00013 DB00014 DB00015 DB00016 DB00017 DB00018 DB00019 
##       2       1       7       0       3       1       0       2       2 
## DB00020 DB00021 
##       1       0</code></pre>
<p>We see that some drugs have 0 targets. Given that we are interested in drugs having an effect on phenotypes coded by causal genes, we remove them.</p>
<pre class="r"><code>tar=which(t==0)#A vector containing the positions of drugs that have 0 targets
Q_tar=Q[,-tar]
t=colSums(Q_tar)
t[1:20]</code></pre>
<pre><code>## DB00001 DB00002 DB00004 DB00005 DB00006 DB00008 DB00009 DB00010 DB00011 
##       1       9       2       9       1       2       3       1       2 
## DB00012 DB00013 DB00015 DB00016 DB00018 DB00019 DB00020 DB00022 DB00024 
##       1       7       3       1       2       2       1       2       1 
## DB00025 DB00026 
##       7       1</code></pre>
<pre class="r"><code>which(t==0)</code></pre>
<pre><code>## named integer(0)</code></pre>
<p>Drugs, with 0 targets were removed from the matrix. We can subset these drugs from the original data frame aswell:</p>
<pre class="r"><code>DB_tar=subset(DB,DB$drugbank.id%in%colnames(Q_tar))</code></pre>
</div>
<div id="obtaining-the-association-matrix-r" class="section level4">
<h4>Obtaining the association matrix (R) :</h4>
<p>In order to obtain the association between drugs and traits, we multiply Q and R according to this formula: <span class="math display">\[R={\frac{1}{t}}\times{-log10(P)^T}\times{Q}\]</span> Where:</p>
<p>-R is the association matrix</p>
<p>-t is the number of targets for each drug</p>
<p>-P is the matrix containing the p-values for each gene</p>
<p>-Q contains drugs and the number of targets</p>
<p>-&gt; We want to sum the -log10 of P.values for each association</p>
<p>-&gt; We divide by the number of targets (number of genes targeted by the drug) to normalize the strength of the association:</p>
<ul>
<li>If a drug targets only one gene then it will be penalized : Other drugs with weaker association but target multiple genes will have a higher association strength overall (Because we sum the p.values for each gene that is targeted by the drug)</li>
</ul>
<div id="log-transformation-of-p" class="section level5">
<h5>log transformation of P:</h5>
<pre class="r"><code>lP=-log10(P)
max(lP)</code></pre>
<pre><code>## [1] 117.7008</code></pre>
<pre class="r"><code>min(lP)</code></pre>
<pre><code>## [1] 0</code></pre>
<pre class="r"><code>which(is.na(lP))</code></pre>
<pre><code>## integer(0)</code></pre>
<pre class="r"><code>which(is.infinite(lP))</code></pre>
<pre><code>## integer(0)</code></pre>
<p>Here the -log10 transformation did not yield NA or inf values because, in the P matrix, missing genes for a trait were assigned a p-value of 1. This means that when they are -log10 transformed their score will be 0.</p>
<pre class="r"><code>head.matrix(lP[,1:6],n=10)</code></pre>
<pre><code>##                  AD         ALS       BASO       BMI         CAD        CD
## AC010335.1 14.93884 1.022245793 7.05653972 0.6986811 0.872943910 8.8317383
## ELL        14.93884 1.022245793 7.05653972 0.6986811 0.872943910 8.8317383
## PTK2B      14.15976 0.065883458 1.29147982 2.4575178 2.789978930 5.9067715
## SSR1       12.39775 1.022472149 0.45773892 0.5328472 0.684136088 1.4483086
## AP3M1      11.75342 0.569562260 0.72186386 2.0964395 1.934308500 0.8092415
## ARHGEF3    11.13114 1.172821037 0.08986225 0.4299784 1.262386231 9.3597631
## TP53INP1   11.08399 0.256011559 6.44988252 2.0923128 2.460757330 0.5982059
## ARL5B      10.99942 0.003381536 1.61624916 1.2794262 0.006972891 0.2026018
## FNBP4      10.89751 0.853353312 0.57104067 4.4030065 0.134152176 0.5011937
## MS4A4A     10.82664 0.891027991 2.66286043 0.1063858 0.675470317 0.1239681</code></pre>
</div>
<div id="multiplication" class="section level5">
<h5>Multiplication:</h5>
<pre class="r"><code>R=t(lP)%*%Q_tar
head.matrix(R[1:10,1:10])</code></pre>
<pre><code>##          DB00001   DB00002   DB00004   DB00005     DB00006   DB00008
## AD   0.000000000  2.922388 2.2428984  2.627918 0.000000000 0.3628774
## ALS  0.564340359 11.023857 1.3378391 10.830364 0.564340359 2.0473498
## BASO 0.385841318 16.084281 2.7535770 15.777563 0.385841318 0.3751547
## BMI  0.000000000  3.687918 0.1517365  3.758741 0.000000000 1.7034322
## CAD  0.160469842  2.371039 0.5227172  3.269912 0.160469842 1.1813525
## CD   0.009221253  5.675658 1.6657103  5.743531 0.009221253 0.6871317
##       DB00009    DB00010   DB00011    DB00012
## AD   2.187038 0.57260964 0.3628774 0.21437647
## ALS  2.060445 0.02898310 2.0473498 1.94004777
## BASO 6.058007 0.08768897 0.3751547 0.09661587
## BMI  2.464554 0.08767210 1.7034322 0.35288581
## CAD  2.835698 0.53364544 1.1813525 1.60419162
## CD   0.776974 0.20408331 0.6871317 0.05463131</code></pre>
</div>
<div id="normalization" class="section level5">
<h5>Normalization:</h5>
<p>Each row is divided by the number of targets for each drug:</p>
<pre class="r"><code>for (i in 1:dim(R)[1]){
  R[i,]=R[i,]/t#Each row (trait) is divided by t 
                #t is the number of targets for each column (drug)
}
head.matrix(R[1:10,1:10])</code></pre>
<pre><code>##          DB00001   DB00002    DB00004   DB00005     DB00006   DB00008
## AD   0.000000000 0.3247098 1.12144919 0.2919909 0.000000000 0.1814387
## ALS  0.564340359 1.2248730 0.66891956 1.2033738 0.564340359 1.0236749
## BASO 0.385841318 1.7871424 1.37678852 1.7530626 0.385841318 0.1875773
## BMI  0.000000000 0.4097687 0.07586827 0.4176379 0.000000000 0.8517161
## CAD  0.160469842 0.2634488 0.26135862 0.3633236 0.160469842 0.5906763
## CD   0.009221253 0.6306286 0.83285514 0.6381702 0.009221253 0.3435659
##        DB00009    DB00010   DB00011    DB00012
## AD   0.7290128 0.57260964 0.1814387 0.21437647
## ALS  0.6868150 0.02898310 1.0236749 1.94004777
## BASO 2.0193355 0.08768897 0.1875773 0.09661587
## BMI  0.8215180 0.08767210 0.8517161 0.35288581
## CAD  0.9452326 0.53364544 0.5906763 1.60419162
## CD   0.2589913 0.20408331 0.3435659 0.05463131</code></pre>
</div>
</div>
<div id="visualising-the-data" class="section level4">
<h4>Visualising the data:</h4>
<div id="distribution-of-the-p.values-for-the-traits" class="section level5">
<h5>Distribution of the P.values for the traits:</h5>
<p>Baseline scores for each trait:</p>
<pre class="r"><code>#Threshol set at
#(0.05/42)*16000*10^-8
#or
#-log10(1.9*10^-7)
#Round to 7
S=lP&gt;7#Matrix of boolean values. If the P-value is significant then the value is TRUE
df=data.frame(counts=colSums(S),trait=names(colSums(S)))

ggplot(data =df ,  aes(x=reorder(trait,counts),y=counts)) +
  geom_bar(stat='identity')+coord_flip()+labs(x='traits',y='nb significant causal genes')</code></pre>
<p><img src="data:image/png;base64,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" width="672" /> Save figure:</p>
<pre class="r"><code>pdf('Figures/barplot.pdf')
ggplot(data =df ,  aes(x=reorder(trait,counts),y=counts)) +
  geom_bar(stat='identity')+coord_flip()+labs(x='traits',y='nb significant causal genes')
dev.off()</code></pre>
<pre><code>## png 
##   2</code></pre>
<p>Summing up the TRUE values in each column tells us how many genes are significantly causal to the trait</p>
<pre class="r"><code>sort(colSums(S),decreasing = T)</code></pre>
<pre><code>##                 HEIGHT                    PLT                  LYMPH 
##                    367                    216                    198 
##               MENARCHE                    MCV                   MONO 
##                    196                    187                    184 
##                    SCZ                   NEUT                    RBC 
##                    183                    181                    181 
##                    MPV                    RET                     EO 
##                    174                    151                    138 
##                    HGB                    IBD                    HDL 
##                    110                    102                    100 
##                     TG                     TC                     CD 
##                     96                     92                     90 
##                   BASO         EDU_ATTAINMENT                    BMI 
##                     86                     85                     82 
##                    LDL                    T2D                    CAD 
##                     77                     72                     66 
##              MENOPAUSE                     RA                     UC 
##                     66                     62                     60 
##            NEUROTICISM           INTELLIGENCE                     AD 
##                     53                     49                     43 
##                    ALS                    SWB                     FG 
##                     38                     32                     30 
##          CHILDHOOD_BMI                     HR     DEPRESSIVE_SYNTOMS 
##                     29                     26                     23 
##               INSOMNIA                     FI         DIAST_PRESSURE 
##                     15                      9                      8 
##          SYST_PRESSURE MEAN_ARTERIAL_PRESSURE         PULSE_PRESSURE 
##                      7                      5                      4</code></pre>
<p>We see that Height has the most significant causal genes (has the highest scores across traits), it means that this trait is controlled by multiple genes that we know are directly causal for the trait (highly genetic). The least genetic traits are the traits associated with blood pressure, fasting insulin and insomnia.</p>
<p>Investigating the significant genes for the 10 diseases:</p>
<pre class="r"><code>int_dis=c('UC','T2D','IBD','INSOMNIA','TG','HDL','TC','LDL','HR','SCZ')
cand_gen=list()
for (i in 1:length(int_dis)){
  cand_gen[[i]]=names(which(S[,int_dis[i]]==TRUE))
}
names(cand_gen)=int_dis
str(cand_gen)</code></pre>
<pre><code>## List of 10
##  $ UC      : chr [1:60] &quot;DMPK&quot; &quot;TBKBP1&quot; &quot;APOLD1&quot; &quot;THBS3&quot; ...
##  $ T2D     : chr [1:72] &quot;TP53INP1&quot; &quot;PLEKHA1&quot; &quot;RPL8&quot; &quot;SOCS5&quot; ...
##  $ IBD     : chr [1:102] &quot;PTK2B&quot; &quot;DMPK&quot; &quot;TBKBP1&quot; &quot;C8orf40&quot; ...
##  $ INSOMNIA: chr [1:15] &quot;MYBPC3&quot; &quot;CENPV&quot; &quot;S100A13&quot; &quot;PDCD2&quot; ...
##  $ TG      : chr [1:96] &quot;SCARB1&quot; &quot;RAB3IL1&quot; &quot;GSTA1&quot; &quot;XKR6&quot; ...
##  $ HDL     : chr [1:100] &quot;C1QTNF4&quot; &quot;LACTB&quot; &quot;MMAB&quot; &quot;FOXRED1&quot; ...
##  $ TC      : chr [1:92] &quot;C1QTNF4&quot; &quot;TBKBP1&quot; &quot;DAGLB&quot; &quot;ZNF91&quot; ...
##  $ LDL     : chr [1:77] &quot;TBKBP1&quot; &quot;TMEM230&quot; &quot;CORO1B&quot; &quot;ELP5&quot; ...
##  $ HR      : chr [1:26] &quot;EIF4E3&quot; &quot;CDC14A&quot; &quot;ACTN4&quot; &quot;NEDD1&quot; ...
##  $ SCZ     : chr [1:183] &quot;SSR1&quot; &quot;WDR55&quot; &quot;MAPK3&quot; &quot;NDUFA2&quot; ...</code></pre>
<pre class="r"><code>#Cand_gen is a list of candidate genes causal for diseases for functional follow up studies</code></pre>
</div>
<div id="distribution-of-the-scores-for-the-genes" class="section level5">
<h5>Distribution of the scores for the genes:</h5>
<p>Visualising pleiotropic genes:</p>
<pre class="r"><code>hist(rowSums(S),main='Distribution of the Nb genes per trait',ylab='#Genes',xlab='#traits')</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>S_n0=subset(rowSums(S),rowSums(S)&gt;0)
hist(S_n0,main='Distribution of the Nb of significant genes per trait',ylab='#genes',xlab='#traits',breaks=1:21)</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>#(14049 genes were not significant, only 1929 were)
S_n1=subset(rowSums(S),rowSums(S)&gt;1)
hist(S_n1,main='Distribution of the Nb of significant genes for more than 1 trait',ylab='#Genes',xlab='#traits')</code></pre>
<p><img src="data:image/png;base64,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" width="672" /> The histograms represent the distribution of the genes that are significantly causal to a number of traits We saw in the non-log transformed plot that the majority of genes are not significantly causal to any trait. The aim of this histogram is to identify the pleiotropic genes that control multiple traits. If these genes are identified, it would be unwise to target them, as their pleiotropy makes it difficult to isolate the treatment for a spceific disease –&gt; the strategy would be to target genes that are causal to only one trait ideally.</p>
<p>Saving one figure (ggplot format):</p>
<pre class="r"><code>pdf('Figures/genes_trait_hist.pdf')
hist(S_n0,main='Distribution of the nb of significant genes per trait',ylab='#genes',xlab='#traits',breaks=1:21)
dev.off()</code></pre>
<pre><code>## png 
##   2</code></pre>
<pre class="r"><code>sum(rowSums(S)&gt;0)#number of genes significant for at least one trait</code></pre>
<pre><code>## [1] 1929</code></pre>
<pre class="r"><code>sort(rowSums(S),decreasing = T)[1:30]</code></pre>
<pre><code>##           BLK          XKR6       TMEM258 RP11-467L20.9       FAM167A 
##            21            18            18            17            15 
##          MSRA         FADS1         LIME1        SEC16A    AC087269.1 
##            13            13            12            12            12 
##        CLDN23          GGT7       SULT1A1        FAM43A         MAPK3 
##            12            11            11            11            10 
##         THBS3       CCDC101         FDFT1         MTMR9         APOBR 
##            10            10            10            10            10 
##        GLYCTK         ABCB9         PPP4C        DCAF12           CKB 
##            10             9             9             9             9 
##          PLTP RP11-264B17.3       ALDH8A1          BRD3         KLRC1 
##             9             9             9             9             8</code></pre>
<p>These are the most pleiotropic genes, these maybe not worth to target with drugs:</p>
<ul>
<li><p>The first gene, BLK, codes for a tyrosin-protein kinase involved in B-lymphocyte development differentiation and signalling. Mutations in this gene causes maturity-onset diabetes of the young. <a href="https://www.ncbi.nlm.nih.gov/pubmed/19667185" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/19667185</a></p></li>
<li><p>XKR6 codes for a protein related to the Xk-family domain, involved in sodium dependent transport of neutral amino acids. These proteins are responsible for the Kx blood group system, and defects results in McLeod syndrome (late onset abnormalities in the neuromuscular and hematopoeitic systems).</p></li>
<li><p>TMEM258 codes for a subunit of oligosaccharyl transferase (OST) complex. It is involved in the pathway protein glycosilation</p></li>
</ul>
</div>
<div id="distribution-of-the-number-of-gene-targets-per-drug" class="section level5">
<h5>Distribution of the number of gene targets per drug:</h5>
<pre class="r"><code>df=data.frame(targets=colSums(Q_tar))
ggplot(data = df,aes(x=targets))+geom_histogram(binwidth=10)+labs(title='Distribution of #drugs per #targets',y='#drugs',x='#targets')</code></pre>
<p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAABUAAAAPACAMAAADDuCPrAAABYlBMVEUAAAAAADoAAGYAOjoAOmYAOpAAZrYzMzM6AAA6OgA6Ojo6OmY6OpA6ZmY6ZpA6ZrY6kLY6kNtNTU1NTW5NTY5Nbo5NbqtNjshZWVlmAABmADpmOgBmOjpmZgBmZjpmZmZmZpBmkJBmkLZmkNtmtrZmtttmtv9uTU1ubm5ubo5ujqtujshuq+SOTU2Obk2Obm6Oq6uOq8iOq+SOyOSOyP+QOgCQZgCQZjqQZmaQZpCQkDqQkGaQkLaQkNuQtraQttuQtv+Q29uQ2/+rbk2rbm6rjm6ryOSr5P+2ZgC2Zjq2kDq2kGa2kJC2tpC2tra2ttu229u22/+2/9u2///Ijk3Ijm7IyKvI5P/I///bkDrbkGbbtmbbtpDbtrbb25Db27bb29vb2//b/7bb///kq27kyI7kyKvk///r6+v/tmb/yI7/25D/27b/29v/5Kv/5Mj/5OT//7b//8j//9v//+T///9B286QAAAACXBIWXMAAB2HAAAdhwGP5fFlAAAgAElEQVR4nO2d+4NchX3dR+ZhIWqIRyBKocGmDWoxctrG1KRJ7cYq8WI32NRyYQsuISimEkiqkOb/79x57b3zWN293zlnZ48/5wekkXbncz+7Zw/zuDMaTQghhAzK6LwPgBBCLmoYUEIIGRgGlBBCBoYBJYSQgWFACSFkYBhQQggZGAaUEEIGhgElhJCBYUAJIWRgGFBCCBkYBpQQQgaGASWEkIFhQAkhZGAYUEIIGRgGlBBCBuZ8BvTry6NVrnzv56s/f/jq6NIv+l/N4sMfvTsavXUG+hkpp+bTK1OFp/5b9w/vLI7nePSd33X/5mg0+v6eyPvL7sMlhJya8x/QaS79xeLPT5u2z17f+JuzDujiKvY4oB/Mj3/t2pZLdDR65svu3xzkgG4c7pYv9fDs9coIOawcxICORi/O/3z3tE1HcvNvzjagq6vY34DemR/95u3M2RJNOc9O1v/mAAd07XC3fqmHZq9XRsih5dwGdHnb7NHnP2026Emzctro9RzQfd5zX+R4euvz5xt/ulyiqeW61iEO6Prh7vXrJPiiE3I4OfcBnV964k/ZYQ7odA/Xb2NOTpbozibvEAd0/XAZUEL65hAGdLagW4aonYMd0C17uFyiLU/KHOKArh8uA0pI3xzEgM7uCp/+Y3aRBnSxRNPDWn8O6SAHdP1wGVBC+uYwBnT6YzYblpMft29++lxzftALv11+/Orp7unYvvXog8ujS8//ovMk0uevT/9+8fGdpTqe3bxtXUXrh/rz15uHD1746OSz3pqip3/21Jvr27fx4atnwk5uZzYea5k/L/NZc3Avfrk6rJbE5qHOPqM5P6r9Getfklbm/t9MEaPnW3858zhxayNPOdz2l3qaz5ormX41vth2JVsOskvtXtlOAUIuag5jQJsJaJZjOW2PPlj9RD/90WRzQI/mF9oDerz4+Bfm19trQJtPXJwFsPqst5bozRtOax/ef0C/eW15le0BXUhsHdDNz1j/kqwd11t3uv6tj1+4tZGnHG5n85aHMb341uaVbB7kOrV9ZacIEHJRcxgD2vxgNn+wnLaj1o90M09rA3plduGZL1sD+sbq4+dX3GdA2/ux+qwra390kvUP7z2gJydtfedfnwzoUmLbgJ5cz+oz1r8krTT+P1wx5od9MvbLTW4jTznc9pe6/ffLx0lPrmTLQa5T21d2igAhFzWHM6DND9Vi2pqfuxebO433fjUarZ9bM7up+WdfTu590T4PdPoj/dHiNtFyb7asUvdp5uZHurmv+Xn7s+Z/NLuitcdVNz98+0OaxwvM0WInZofX6Hw2u8W2HNClxLZDbVDNTbhPLy8/Y8uXZJW5/9O/bR/a8YJ574NtyNMOt/WlPmpe4zA9jEe/vrz9uNcOcgt1dWWnCRByUXMgA3qnM6AnDwVurt/sh3Tx89ce0PknPDpa3LzpMaBfX17d8Wx91uKPlo/Kdo55/cO3D+jR6kmZZ1efOH+p1exAV0vz/dXHrx/qyWd88+riA7d8SVaZ+3/ZPrTm8N/qfGk7yNMOt/N1al3J7BvWupItB7mFurqy0wQIuag51AF9eu1OXmdAl4/itQZ0eadw+TPcY0CPTu7Ntj5reUUbp3hu+fCtA7pcoukHrW6mLq/p69YtudVDkZuH2lqYOycDuv4laRPX/dsbdTQ/2B1nOmwc7snX6U7HeDmgyyvZfpDr1PaA7hQg5KLmIAd09oTI937Wvq/ZGdDWj/VyQFc7tpijJw9o5+Snxcgd7b6ZtO3Dtw7ocomWb9Gx/onLAV19ATYOtf0Zy1vCW74knUNb8z9qMe+s1m3jrKoth7v9zKPpny1vxi6uZNtBbqG213inACEXNQcyoN3HQFfPRTz/t8uP6gzos90/7EzU8WoKnzCgnZ1Y3NjaekbR+gGcfPjWAT15b6MtL+w5PhnQ9m21LrTzGYu/3fIlWWXTv/1kzvIJnR13nNcPd3NAH/3jP7x3+eRxgPU7+icHuY26ecbDFgFCLmoOZECPus/Ct34Un56/1vwJA9rZtvMb0G1Pay9vvC0/sdeAnnzG6jSmjS/JKpv+61PWHOyWAd1+0kDb9PPZqZuzbA7o+kFuo55c2SkChFzUHMaArp8H2px0vfpx23wW/rQBPddboMIB3fyStL96a/57GtCT00D3MKCnCBByUXMYA9o8udJ5yqHJvf/x+uwEmeU5m8q78Ls/a5ltH953QPdwF37Ll2SV7Xfh11/cevYBXfz1le/98Df/9GrPu/Dr1LXHA7YLEHJRcxgDerx+0ssyj5YnDT5pQE95Eulo+4DueBJp14D2fRJp462Ydj2JtG1AjzaeROq4db8knUPbfBJp/cC2Pwa65Z2j2k+cz04DnXSeRFq+1nTLQW6hbnlGalOAkIuagxjQ1bsxbZ+2PgO6vLrpVS1Pkm/9pG89jel462lMuwZ024dvW4zNt2Ja+8RtA7p2qJtnCG1d4WW2+Lefcj/ePMfotMM9+Tq1OHc27sLvOI1pndp+VHunACEXNYcwoCfvB7o5bcsbN08a0OU57u+enPG9WITj0ZlOpN85oD1PpN98K6buJ24O6Oahnpyj/vDVzW3auFG6xf+EufpfyvYB3fLOUe3Na500vz6gWw5yC7V9c3anACEXNec+oPf+MHtqYX7rpDVtT/+8+YDmtYnLn/DFD92OAT15seTsqpobRU//3fKJi9knrK7i1Jdy7hzQfi/lXC7Rw1c7NzFPPnFzQLcc6vJVkicv/tzyJWkz24TlbePZiztnr8J8drvQjsNdfZ2Wr+ScvTBzY0C3HOQW6urKThMg5KLmQP5NpLUXwRxv/N3iGd63dg3oG2tX1XpG+IeXT36WZ1expLSfQ9nxFiTtbH74lgF9ePLvY6zusZ4cy6U/3zKgWw61++zO6sWf61+u1hVcWfu79jPi87XaOqCnHO5ba9+ljZuxWw5yk9r5vu0SIOSi5iAGdHVe4OoO3/9efcDyX+y8s/zB2/Es/PHaj+bD5XutvfX1YpVWV3FyX351ms6LG4O47Unr9Q/fMqDLJer8cx7LXbn01rZn4bcd6uoEohf+8xKx+SVpX/3yXfgu/ZvlH67OGVq8edzWAd16uO0v9eJa/+27q9eDnlzJloPcoJ5c2SkChFzUnP+AXvnByRvsnjzSee/Xs9tUz/989VDpp80p3X+2+zSm2XsWr94+ePluv9M/WK3S8ipazwx/1pxV81T7DZVPGdCND98yoHdWT8B07qV+Pnu344+2nsa09VBnfzTVb708cvNLsvz0uf9rrTc+njFn74X8/PJ/TluFth/u8ku9eHfkhni87eVMWw5yndq6st0ChFzUnM+Akr7p88+V9PwnTXQ59wMg5JzCgB5gWjdst72zx3rOZ7/OeJCEJIYBPcCcnNi06z2UOjmfAT3jQRKSGAb0ADM7sal5ZPjzn/Z5xvp8BvSMB0lIYhjQQ8xR6xSFJ9+2O6eHIM92kIQkhgE9xJycDbQ6Y+q0jz6fAT3bQRKSGAb0MLP4N9R/+NGTP/T8ngQ/y0ESkhgGlBBCBoYBJYSQgWFACSFkYBhQQggZGAaUEEIGhgElhJCBYUAJIWRgGFBCCBkYBpQQQgaGASWEkIFhQAkhZGAYUEIIGRgGlBBCBuY8BvT/7jN7vrp+TD8RSxXTT8RSxbRAGNA600/EUsX0E7FUMS0QBrTO9BOxVDH9RCxVTAuEAa0z/UQsVUw/EUsV0wJhQOtMPxFLFdNPxFLFtEAY0DrTT8RSxfQTsVQxLRAGtM70E7FUMf1ELFVMC4QBrTP9RCxVTD8RSxXTAmFA60w/EUsV00/EUsW0QBjQOtNPxFLF9BOxVDEtEAa0zvQTsVQx/UQsVUwLhAGtM/1ELFVMPxFLFdMCYUDrTD8RSxXTT8RSxbRAGNA600/EUsX0E7FUMS0QBrTO9BOxVDH9RCxVTAuEAa0z/UQsVUw/EUsV0wJhQOtMPxFLFdNPxFLFtEAY0DrTT8RSxfQTsVQxLRAGtM70E7FUMf1ELFVMC4QBrTP9RCxVTD8RSxXTAmFA60w/EUsV00/EUsW0QBjQOtNPxFLF9BOxVDEtEAa0zvQTsVQx/UQsVUwLhAGtM/1ELFVMPxFLFdMCYUDrTD8RSxXTT8RSxbRAGNA600/EUsX0E7FUMS0QBrTO9BOxVDH9RCxVTAuEAa0z/UQsVUw/EUsV0wJhQOtMPxFLFdNPxFLFtEAY0DrTT8RSxfQTsVQxLRAGtM70E7FUMf1ELFVMC4QBrTP9RCxVTD8RSxXTAmFA60w/EUsV00/EUsW0QBjQOtNPxFLF9BOxVDEtEAa0zvQTsVQx/UQsVUwLhAGtM/1ELFVMPxFLFdMCYUDrTD8RSxXTT8RSxbRALuyA/sszZa9ftLVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamW+xrQ+9evfTX7zeP3r4/Hb388ecIFBrRETK1jl4iliuknplruaUAf3xzPB/TbG+MmL31y+gUGtEZMrWOXiKWK6SemWu5pQG+PFwN6a3zt48mDxZzuvsCA1oipdewSsVQx/cRUy/0M6P3riwG9f312C/PbG1d/edoFBrRITK1jl4iliuknplruZUCnd+D/w/wx0NvjV2Z/cnv8zmkXGNAiMbWOXSKWKqafmGq5lwG9NX5l8STSrfFPZn9yt5nL3RcY0CIxtY5dIpYqpp+YarmPAb07vfs+H9DHNxd30JuLuy/MP+27iwxBTnO2AR0IIYSQ3hkyoLOHNRlQQsifeoYM6K3mUc2NAX3pk90Xup8/8Lbz2QZ0rzfb18IdIhERSxXTT0y1rA/o7dnz7wNugTKgw4mpdewSsVQx/cRUy/KA3r8+W0YG1JnYOnaJWKqYfmKqZXlAb49Xmd4351l4S2Lr2CViqWL6iamWex7Q5Vmei1M/d11gQIvE1Dp2iViqmH5iqmV5QBdZ3DPnlUiWxNaxS8RSxfQTUy33PKCPb45fXr3iffcFBrRITK1jl4iliuknplrueUAnD9rvubT7AgNaI6bWsUvEUsX0E1Mt9z2gkwfvT1fy7cWtzN0XGNASMbWOXSKWKqafmGq5rwEtZOCRM6Bmpp+IpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgcwoANztgE976MlhOSHW6ADwv/PRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YarmPAf3jj8fjq//xq/mFx+9fH4/f/vhJFxjQEjG1jl0iliqmn5hquYcBvT2e5eVPmgvf3phdeOkJFxjQGjG1jl0iliqmn5hqWR/Q+9ev/tVk8uDH41eaS7fG1z6ePLg5vvbVqRcY0BoxtY5dIpYqpp+Yalkf0Fvjd+Y72ty2nP93emvz6i9Pu8CAFompdewSsVQx/cRUy/qALvLtjWYgb89vh05/fee0CwxokZhaxy4RSxXTT0y13NuA3r/e3De/Nf7J7NLdZi53X2BAi8TUOnaJWKqYfmKq5b4G9J+vNwP5+ObiDnozp7svzD/lu4sMJJ5tQId6EUJI3wwc0Fvj8dW/nzCghJA/5Qwb0Mf//d9dH1/9T50BfemT3Re6nz3wtvPZBnSvN9vXwh0iERFLFdNPTLXcy4A2+WNzH/5Mt0AZ0OHE1Dp2iViqmH5iquXeBnRyd3zaZjKgeyWm1rFLxFLF9BNTLfc3oLNl5Fl4S2Lr2CViqWL6iamW5QF9fHOxjLMBXZ7luTj1c9cFBrRITK1jl4iliuknplqWB3R60/KVk195JZIlsXXsErFUMf3EVMv6gN6/Pv7RV5PHvx83yzi9Pfry6hXvuy8woEViah27RCxVTD8x1bI+oJO783djujq7J/+g/Z5Luy8woDViah27RCxVTD8x1XIPAzp58JfT+Vy+0eeD96cr+fZXT7rAgJaIqXXsErFUMf3EVMt9DGgxA4+cATUz/UQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1PIABHZizDeh5Hy0hJD/cAh0Q/n8uImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1fJsA/roDx/+hgFdD3UUEbFUMf3EVMu+A/rNX385mTx8bTQaPYEYXuEAACAASURBVP0LBrQb6igiYqli+omplj0H9Hj0nd9NJkejJs3vGNBWqKOIiKWK6SemWvYb0Duz2fz68uiZL795dfR9BrQT6igiYqli+omplv0G9Gi6nM2MXvpF89/m9wzoSaijiIiliuknplr2GtBH7zbLuZjRh6/u+T78wCNnQM1MPxFLFdNPTLXsNaDzzXz46ujZCQO6GeooImKpYvqJqZZnGNCvL4/eYkC3hDqKiFiqmH5iqmWvAZ3fhT+ePQTKY6AboY4iIpYqpp+YatlrQCdHo2ebp9+b5eRZ+I1QRxERSxXTT0y17Degd2YngE7vwT/66Wh+O5QBPQl1FBGxVDH9xFTLfgM6vfs+zbOzJ5IuvbXf/WRABxBT69glYqli+omplj0HdPLNez/4+fSXh//qhY/2vJ8M6ABiah27RCxVTD8x1bLvgAoz8MgZUDPTT8RSxfQTUy0Z0Hqoo4iIpYrpJ6Za9hvQe//YDgPaDXUUEbFUMf3EVMteA/rw1VE3T725x1NBBx45A2pm+olYqph+YqrlsAHd67lMA4+cATUz/UQsVUw/MdWy14A++sOvppP5gw8//PC9y6NLb374N6/v811BBx45A2pm+olYqph+YqplrwFtboIuX3706Ww69/l6pIFHzoCamX4iliqmn5hq2W9Aj1pzeTx7T6Y9viJ+4JEzoGamn4iliuknplr2GtDF+4HO8/XlZjq/vry3+/ADj5wBNTP9RCxVTD8x1bLXgHbewW755qAM6DLUUUTEUsX0E1Mtew5o5xYoA9oNdRQRsVQx/cRUy14D2ryd3drveQz0JNRRRMRSxfQTUy37Deid0ejF+V4++qB5V7vJp5d5Fn4V6igiYqli+omplv0GdPYvwj//xhtvXJm9q11zYv3+zqQfeOQMqJnpJ2KpYvqJqZY9B7S54bnIn32553cFHXjkDKiZ6SdiqWL6iamWPQd0Mrn36yuzF8F/0czpe3/La+FPQh1FRCxVTD8x1bL3gOoy8MgZUDPTT8RSxfQTUy0Z0Hqoo4iIpYrpJ6Za9hvQ7vuBfsGAdkIdRUQsVUw/MdWy14CuvZ3d/t6IiQEdSEytY5eIpYrpJ6ZaMqD1UEcREUsV009Mtew1oI/+8OEif/Pa6NLPfrPHp+AZ0EHE1Dp2iViqmH5iqmWvAW1n/mZMDGgr1FFExFLF9BNTLc88oJPj/b2IkwEdSkytY5eIpYrpJ6Zann1A934TdOCRM6Bmpp+IpYrpJ6Zann1A9/hGdgzoUGJqHbtELFVMPzHV8uwDusf3omdAhxJT69glYqli+omplmce0EdH+3snUAZ0KDG1jl0iliqmn5hq2WtAH733xjJ/fnnEk0hroY4iIpYqpp+YatlrQLsn0nMa01qoo4iIpYrpJ6ZannlAn3pzz/vJgA4gptaxS8RSxfQTUy17Dag2A4+cATUz/UQsVUw/MdWSAa2HOoqIWKqYfmKqZb8BPXrhIwZ0Z6ijiIiliuknplr2GtCHr472908gMaB7IKbWsUvEUsX0E1Mtew7ons+dZ0CLxNQ6dolYqph+YqplrwF99O7+/hFjBnQfxNQ6dolYqph+YqplrwGdHI+eOeVB0D/+5Xh89e2P5xcev399PH7yBQa0REytY5eIpYrpJ6Za9hvQe78ajZ763vLVSD/ongn6+/EsV3/ZXPj2xuzCS5+cfoEBrRFT69glYqli+omplr0G9NR/0uPu+OpfTSYPbs6n8db42sfNhWtfnXqBAa0RU+vYJWKpYvqJqZblAX18c/yTxQ3M6a/3r89m9Nsbze3R3RcY0CIxtY5dIpYqpp+YatlrQE/LtzcWd8pvjd+ZTG6PX5lduH36BQa0SEytY5eIpYrpJ6Zalgd0ldmA3prfHJ3er3/ltAsMaJGYWscuEUsV009MtdzbgM7umz++ubiDfv/6ta92X5h/xncXGQg824AO9iKEkJ7ZGNB7/7iZL7Z95uwuOgNKCPnTzfqArj19tO1Z+Hnuzk5jas3kS5/svtD91IG3nc82oHu92b4W7hCJiFiqmH5iquWeBvTu9avNQ5xnugXKgA4nptaxS8RSxfQTUy2fMKCP/vDhLL8ajS794Gcffvg3z40uvfmbjbdUvr04jZ4B9SS2jl0iliqmn5hq+YQBXWR6Q3T5DyF9uuUG6O/Hy5M7eRbektg6dolYqph+YqplvwE9av1DcsejZ7t/+fjW+OXlw5rLszwXp37uusCAFompdewSsVQx/cRUy14D2nk3pq8vr/2rcrdar87klUiWxNaxS8RSxfQTUy17DWjn/UDX3xz0dvvV7Y9vjl9eveJ99wUGtEhMrWOXiKWK6SemWvYc0M4t0M6ALt5kqUnz4OaD9nsu7b7AgNaIqXXsErFUMf3EVMteAzo5aj3uedR9DPTuuDOgkwfvT3/39uJW5u4LDGiJmFrHLhFLFdNPTLXsN6B3RqMX5w98PvpgtO9/H2ngkTOgZqafiKWK6SemWvYb0OnNztHo+TfeeOO56a8v7nc/GdABxNQ6dolYqph+YqplzwFtbngu8v0dH8KA+hJbxy4RSxXTT0y17Dmgk8m9Xze3Pp96c+s7iTCg3sTWsUvEUsX0E1Mtew+oLgOPnAE1M/1ELFVMPzHVss+APnz9yvO/a/3KgHZDHUVELFVMPzHV8gkD+ugPX8xeCT879XP5KwPaDXUUEbFUMf3EVMsnDGjzdnZX3rjMgJ4W6igiYqli+omplk8Y0Ec/vTx/7v3pH/72SwZ0e6ijiIiliuknplo+YUCbfP7ry6e+GT0Dqrzy7cTUOnaJWKqYfmKqZY8Bnd11/9nfvD6f0Evf+9mez2QaeOQMqJnpJ2KpYvqJqZZ9B3TxGKjiZujAI2dAzUw/EUsV009MtTzjgH7nd/f+4b09n8s08MgZUDPTT8RSxfQTUy2fMKAP35veYec0ptNDHUVELFVMPzHV8kkD2txrf27EgJ4W6igiYqli+omplk8Y0Eef/flz8wc+r/zwN//EgG4NdRQRsVQx/cRUyycM6Cz/5+Q0pkt/t/FPGjOg1FFExFLF9BNTLfsMaHPX/X9+/uvXLy/OY/qv+x3RgUfOgJqZfiKWKqafmGrZd0AXj4FeusJpTBuhjiIiliqmn5hqecYBnf567w9/zS3QTqijiIiliuknplqefUD3noFHzoCamX4iliqmn5hq2WdAxRl45AyomeknYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0PYEAH5mwDet5HSwjJD7dAB4T/n4uIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdWSAa2HOoqIWKqYfmKqJQNaD3UUEbFUMf3EVEsGtB7qKCJiqWL6iamWDGg91FFExFLF9BNTLRnQeqijiIiliuknployoPVQRxERSxXTT0y1ZEDroY4iIpYqpp+YasmA1kMdRUQsVUw/MdVyTwP67Y1XFr97/P718fjtj590gQEtEVPr2CViqWL6iamWexrQW+NXlks6bvLSJ6dfYEBrxNQ6dolYqph+YqrlXgb08a3xckBvja99PHlwc3ztq1MvMKA1Ymodu0QsVUw/MdVyHwP6xx+PlwN6//rsFua3N67+8rQLDGiRmFrHLhFLFdNPTLXcw4DeHo9/9M+LAb29+vWd0y4woEViah27RCxVTD8x1XIfA/ry30/uLubx1vgns19nl3dfYECLxNQ6dolYqph+YqrlHga0NYuPby7uoN+/fu2r3Rfmn/PdRQYizzagAyGEENI7DCghhAzM/gb0pU92X+h+7sDbzmcb0L3ebF8Ld4hERCxVTD8x1VI2oE++BcqADiem1rFLxFLF9BNTLRnQeqijiIiliuknplrud0B5Ft6T2Dp2iViqmH5iquWeB3R5lufi1M9dFxjQIjG1jl0iliqmn5hquecB5ZVIlsTWsUvEUsX0E1Mt9zygj2+OX1694n33BQa0SEytY5eIpYrpJ6Za7nlAJw/a77m0+wIDWiOm1rFLxFLF9BNTLfc9oJMH709X8u2vnnSBAS0RU+vYJWKpYvqJqZZ7GtBKBh45A2pm+olYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqyYDWQx1FRCxVTD8x1ZIBrYc6iohYqph+YqolA1oPdRQRsVQx/cRUSwa0HuooImKpYvqJqZYMaD3UUUTEUsX0E1MtGdB6qKOIiKWK6SemWjKg9VBHERFLFdNPTLVkQOuhjiIiliqmn5hqeQADOjBnG9DzPlpCSH64BTog/P9cRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+omplgxoPdRRRMRSxfQTUy0Z0Hqoo4iIpYrpJ6ZaMqD1UEcREUsV009MtWRA66GOIiKWKqafmGrJgNZDHUVELFVMPzHVkgGthzqKiFiqmH5iqiUDWg91FBGxVDH9xFRLBrQe6igiYqli+ompln8qA6qcW+ooImKpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplgwoA9qT6SdiqWL6iamWDCgD2pPpJ2KpYvqJqZYMKAPak+knYqli+omplsYBffz+9fH47Y8Z0Hpi69glYqli+omplr4B/fbGuMlLn1yAAT1bqKOIiKWK6SemWvoG9Nb42seTBzfH175iQKuJrWOXiKWK6SemWtoG9P712W3Pb29c/SUDWk1sHbtELFVMPzHV0jagt8evLH59hwGtJraOXSKWKqafmGppG9Bb45/Mfr27GFIGtJDYOnaJWKqYfmKqpWtAH99c3HW/f335IOh3Fxl4jec9m4eY/XyvDv3rrbQkOTmPVl2gASWEkMOKY0DXT2Ta8y3qvV5dP6afiKWK6SdiqWJaIP4BXT+Pac8+e726fkw/EUsV00/EUsW0QBjQOtNPxFLF9BOxVDEtENOA7v9Z+F0+e726fkw/EUsV00/EUsW0QFwDujz/c2/nge7y2evV9WP6iViqmH4iliqmBeIa0L2/EmmXz16vrh/TT8RSxfQTsVQxLRDXgD6+OX55r6+F3+Wz16vrx/QTsVQx/UQsVUwLxDWgkwd7fjemXT57vbp+TD8RSxXTT8RSxbRAbAM6efD+dD/fXr/9yYAOIWKpYvqJWKqYFohvQHdlzz57vbp+TD8RSxXTT8RSxbRAGNA600/EUsX0E7FUMS0QBrTO9BOxVDH9RCxVTAuEAa0z/UQsVUw/EUsV0wJhQOtMPxFLFdNPxFLFtEAY0DrTT8RSxfQTsVQxLRAGtM70E7FUMf1ELFVMC4QBrTP9RCxVTD8RSxXTAmFA60w/EUsV00/EUsW0QBjQOtNPxFLF9BOxVDEtEAa0zvQTsVQx/UQsVUwLhAGtM/1ELFVMPxFLFdMCYUDrTD8RSxXTT8RSxbRAGNA600/EUsX0E7FUMS0QBrTO9BOxVDH9RCxVTAuEAa0z/UQsVUw/EUsV0wJhQOtMPxFLFdNPxFLFtEAY0DrTT8RSxfQTsVQxLRAGtM70E7FUMf1ELFVMC4QBrTP9RCxVTD8RSxXTAmFA60w/EUsV00/EUsW0QBjQOtNPxFLF9BOxVDEtEAa0zvQTsVQx/UQsVUwLhAGtM/1ELFVMPxFLFdMCYUDrTD8RSxXTT8RSxbRAGNA600/EUsX0E7FUMS2Q8x/Qvea73z3vI3AEy5xgmRQG9EIEy5xgmRQG9EIEy5xgmRQG9EIEy5xgmRQG9EIEy5xgmRQG9EIEy5xgmRQG9EIEy5xgmRQG9EIEy5xgmZQLP6CEEHJeYUAJIWRgGFBCCBkYBpQQQgaGASWEkIFhQAkhZGAYUEIIGRgGlBBCBuZiD+jj96+Px29/fN6Hocq3N8azvPRJcylS9tsbryx+19ELc11Z5n5H//iX4/HVrd++JMvNXOgBXdRx3sbA3L/e+nHLlL017k7LXC/NdWUZ+x39/dzr6i+bC9Hfy7Vc6AG9Nb728eTBzfG1r877SDS5u/y5a5Io+/jWeKnY0ctybVmmfkfvjq/+1aRxme1k8PdyIxd5QO9fX/yPfP7/vbzcGr+z+n2i7B9/PF5OS0cvy7VlmfodfXxz/JPm1+mtzZ9Efy83c5EH9PailrdbrUzK45ut0gXK3h6Pf/TPK62WXpRr2zL1O/rtjcU99Fsb374gy625yAN6a/6/ve79oqB8e+Pa/5reevn3s8ffA2Vvv/z3K52OXpRr2zL9Ozof0Nzv5ZZc4AFd/e/8/vXMx1eWzzg0FUyVXfxcdfTyXO+uHqjI/o7O7qiHfy/XwoAebu5O7/x9Nfl/74/XW3nOx7XP/GkNaPp3dHZ/Pfx7uZaMAc08R+L26u7tO7GymwP60id5rnfXHukN/Y7enZ3GFP69XEvGgGb+z22Zu+Pc/5P/ad0CPbkcaXn9avN4Z/j3ci0M6OFnJ3c92AAABT1JREFU7f/kUbJ/mgMa+R29vTiNPvx7uZYLPKDxT/AtM+teqGz+s/BNNgc07zv6+/HyFK3s7+VaLvKALk8tCz3FbHl28rx7obInjw629OJcV7ezY7+jj2+NX14+xpn9vVzLRR7Q9Bc53Gr/2IXKnpzgk/zqlZPb2anf0Vutl2pmfy/XcpEHdNrDl5NfZnv/enPSy4Mfz/xCZZfT0tGLc22dB5r5Hb3dlsj+Xq7lIg/o5EH2G700rwKc+c1euJIpu3porKOX5rqyDP2OLt+lb/Gi/+jv5Vou9IBOHrw//da8nfm/tiYPmjdZ/NHCL1L25LmFjl6Ya8sy8jt6d9wZ0Ojv5Vou9oASQsg5hgElhJCBYUAJIWRgGFBCCBkYBpQQQgaGASWEkIFhQAkhZGAYUEIIGRgGlBBCBoYBJYSQgWFACSFkYBhQQggZGAaUEEIGhgElhJCBYUDJged49Oz0v4/eHb113kdCyHoYUHLgOZot58NXv/O75tKn/+LL4vXVr4GQZRhQcth59O6lX0x/+fryM83uHY2eKc5f/RoIWYUBJYedxU3PO7M78gwoOawwoOSwc2e0uOn5/cmEASUHFgaUHGwevjrq5FkGlBxYGFBysNkY0OP5r7Pbop//9PL0t1fenK1h8xz9Z6+NRk81D5d+9vpodOnFL49H86edJt80H3nphY+a37euYfbHo+d/fk5yJCIMKDnYnDKgjz5Y/uHTzUpOB/SN5sJ0Mqe/neU7P10M6PHyI1+ctAf0084VEDIoDCg56Hx9eTaD85NBT+6AT4fwxelvvnlttDxLdHTpF5Nvft58RPM3s4FdfOaoufF574P5gi6v4evLo2emf/zoV6PFNRMyIAwoOeisnn2fn0a/mL/pbdP57E1/0/xBM6DzD5gO4+wefjOczYBOLy8G8ng0Ox9qcQ2rO/hHy98QcvYwoOSgczzbw8XJoKv5uzNaXJ4uZ7N/i18mrWGcTmvzu9Xl5mOenbQGdHENhBTCgJKDTvd1SJvPoR8tB/SZ5bNJz7b/pnV58bmrCR5deuG3FgUSHAaUHHIevjq7oXhnuZvtAb33+YfvPTdaDujqLv33F389u+3ZfR6q+dDlNcyfhXrqzS+8QiQrDCg52Jx2Huinz7VXccCAzs52mj0Lz4lMZHAYUHKw2T2g83OVrrzxt18cbQzo8i77ckDXnmRv34b9/L3ZDPM2T2RoGFBysNk9oIuzmCatx0DnO7nlMdCNB007f9Ccx8RLk8jQMKDkgLN4F9DFyaCT5fydzOLiufaT3Vx/Fv5o9Wz74pNW19AZWkIGhQElB5zuWzFNNgf0eO0x0G3ngS4+9M78vvr6aUybt1EJ6R0GlBxwFu8Cetx6ZujSLx59sbwL//lro9krkNo3KI83X4nUPE20uqu+uIbpDdRLf9G8luldHgMlw8OAkgPO2uuQZjcjm8dCH762eFj0hV/N9q81oI+OFk+u/5f118LPb2gurqG5aTpavTCekGFhQMkBZ/4uoIuTQWf5dLp7z05vYf76ufmZ8POn2dvny295N6bmufbV2y4trmF6FVeaE0Ff5ERQMjwMKAkNb/xJ9GFASVRWz6l3bpQSogkDSqJyvPG2TITowoCSqEx389JfTG9/fnqZ0zuJPgwoycqd5bPrT3903odC8sOAkrDc+2D+pDvPIBF9GFBCCBkYBpQQQgaGASWEkIFhQAkhZGAYUEIIGRgGlBBCBoYBJYSQgWFACSFkYBhQQggZGAaUEEIGhgElhJCBYUAJIWRgGFBCCBkYBpQQQgbm/wN+X1ryxb8M0wAAAABJRU5ErkJggg==" width="672" /></p>
<pre class="r"><code>hist(colSums(Q_tar),main='Distribution of nb drug per #targets',ylab='#drugs',xlab='#targets')</code></pre>
<p><img src="data:image/png;base64,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" width="672" /> log10 scale:</p>
<pre class="r"><code>ggplot(data = df,aes(x=targets))+geom_histogram(bins=20)+labs(title='Distribution of the nb of drugs per target',y='#drugs',x='#targets')+scale_x_continuous(trans = 'log10',breaks=c(1,2,3,4,5,10,20,50,100,200))</code></pre>
<p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAABUAAAAPACAMAAADDuCPrAAABYlBMVEUAAAAAADoAAGYAOjoAOmYAOpAAZrYzMzM6AAA6OgA6Ojo6OmY6OpA6ZmY6ZpA6ZrY6kLY6kNtNTU1NTW5NTY5Nbo5NbqtNjshZWVlmAABmADpmOgBmOjpmZgBmZjpmZmZmZpBmkJBmkLZmkNtmtrZmtttmtv9uTU1ubm5ubo5ujqtujshuq+SOTU2Obk2Obm6Oq6uOq8iOq+SOyOSOyP+QOgCQZgCQZjqQZmaQZpCQkDqQkGaQkLaQkNuQtraQttuQtv+Q29uQ2/+rbk2rbm6rjm6ryOSr5P+2ZgC2Zjq2kDq2kGa2kJC2tpC2tra2ttu229u22/+2/9u2///Ijk3Ijm7IyKvI5P/I///bkDrbkGbbtmbbtpDbtrbb25Db27bb29vb2//b/7bb///kq27kyI7kyKvk///r6+v/tmb/yI7/25D/27b/29v/5Kv/5Mj/5OT//7b//8j//9v//+T///9B286QAAAACXBIWXMAAB2HAAAdhwGP5fFlAAAgAElEQVR4nO2d/YOb5Zmd5fARAw1sxnyUhi4JbfCWhGx3Nylss026YUlM0iWhcQoupCwLCbXBuGDP/19JI2n0dWae9350S7oP1/khZsYz13t03neuSCPNeHRKCCEklNGhCxBCSNUgUEIICQaBEkJIMAiUEEKCQaCEEBIMAiWEkGAQKCGEBINACSEkGARKCCHBIFBCCAkGgRJCSDAIlBBCgkGghBASDAIlhJBgECghhARzGIF+dnW0yOPf+vni/V8+P7ryi3bM7MPv/2Q0ennA0Qce5cK8//j4Jjz037f91Y3R6Ntd7KG36+I6/X0IIWs5vEDHufL92fsvUtsHL2z8zVCBzhA7FOhbZ/1XaPOiBxDotjqLHKFAt5zTI4ER0pSjEOho9NTZ+7XaxjLZ/JthAl0gdifQ22ftv/H7bUX3L9AtdZZydALdek6PAkZIYw4m0Ec+PvvP+x++Nvmiv+xL+yLpNYpml4/cZ7k1vrv389V3nR9l/wLdUmcpRyfQnZ6QhLNLyKU5uEDP3rr04j9OgY6d9Kg8yv4FuqXO6t8iUEJ2mmMQ6NSgF3zlT3K0Al130oEFesERESghu85RCHT62PPiqx+Bxuo0/+0BgkBJ+RyHQMdX//SL+/yr4PPXHpu8IOfJ380/fvH88li2L99/6+royhO/WHkS6cMXxn8/+/gVW9ya3r1dQix9rX34wuTbB0++c/5ZL48PPX7fQy8t95tn5cMXz4QtPWmzXHRaYQM2fcf5Ec+zeextt2tYnSnlgwngqY8XkywNuDnT9DMmL4Za/oz107FMn3b8fHyI0RNLf7l2K5cPuW2qcT6YfMb4pn+07TO2NFo9xBqMkD3lOAQ6+TKcfPXO1Xb/rcXz8w+/c7op0BtnbywL9Nbs45884zYJdPKJs1cBLD7r5fmhN78W1z68RaDvX126FSs37Kl1QW8ee9vtGlZnnM+/M0cuC3Q24FaBbn7G+ulYK/Hy7bWOG7dy+ZDbplocc/zmy5ufsdlo/RAIlBwmxyHQydfL5B1ztd0YnWfigzWBPj5945GPlwT64uLjz8AtAp3c7934rMfX3nWe9Q9vEOg67Nx5m9/03fzwbbdrWJ3lF4x949+fC3Q+4DaBnnMXn7F+OpYy6fi9xTHUrVw+5Laplm/LmQOXP2NLo/VDIFBymByPQCdfmTO1Tb4cnpo8lrv769HsK+b8Yff0LtlffHx696Pl14GOv9Lemd1VmX/NbzHD6utAJ16YPAT8cPmzzt41Ba19/3Hzwy/9Hug6bNJ9csPuvjXa+MzND992uwbWmSImR/xgeiduLtD5gNtmmnAn9+rO7jx/+3Tr6Vg9wOjh3y332LyVy4cUU135/viY939zdXvJtUZbDsH3QMkhciQCvb0i0PNvx23ab/q1M/siXhbo2SfcvzG7j9Qg0M+uLh4PLn3W7F3z78qudF7/8MsFugqb/Pnyyg1eyuaHb7tdA+tMPursx7ymsIV85h+2OdP5Z3z+/OwDt5yORc46frzcY8utvLUh3pWpVj9jemUsfcaWRlsOgUDJIXKsAn147adpVgQ6/0pZEujcLvMvrQaB3jh/RLn0WXPQxmsqt3z4pQJdgy3r58b6PdzND992uwbWWboVC+Muv+Rhc6aljrfPBbp+OhbZ0nHLrdz+KovFVLdXbstcoPPP2N5o/RAIlBwiRynQ6ZMS3/rZ8uO9FYEufbXNBboQx0wJlwt05UVCM9Hc0Pe1tn34pQJdgy1L8/b6p25++LbbNazO+kfNBboYf2Om5c+Y3xPecjpWjrDWccutvLX5LdzT7c4bv29+n/WR5dcirDbacggESg6RIxHo6vdAF08RPPEP849aEeijq+9c0cS5qy4R6MpX3Ow+0NZX9awXOP/w5teBnstpORv3cNeOve12Dauz8lG3zgW6fPdt9aArn3Fj6VsJq6djkc2O227lxiP/zXYT1r/88+tXzx/0P7rlo84abTsEAiWHyJEI9Mbqs/BLXyEPn/1w9yUCXZFJFYFuTLAp0I3bNazO/P7c/KOaBHr+GYuXMW2cjkU2O267lZcL9MPpC02n2RToeqNth0Cg5BA5DoGuvw508jLpxZfH5rPwFwm00D3QQQKN3gPdhUA3T8cimx0jAj1/GSgCJaVyHAKdPMGx8UzA3f/xwvR1K/PXbGY+hNefNc+2Dw8IVP9oZsdDeFlnNw/hz7JyOhbZ/hB+/VZeItDZCz0f/9b3fvuvzzc+hF8/BAIlh8hxCPSWei3K/fkrDy8T6AVPIt3YLlDxJJISaOhJpDXYlg8/z3aB5jyJtE2gNzYkv3L8s/dsvBB0+5NI67fyEoHemr0M9HTlSaRHN2/D/GgX7k7I/nIUAl38NqbtamsR6Bw3Rs1fJL/0Bbj1ZUy3tr6MSQl024cPFejyk9G31j91u0DXb9fAOmsftU2gazNtvmhoq4Xn2dJxy628RKBL0NsbD+HFy5jWD4FAySFyDAI9/32gm2qb3+e4TKDzF5XPv55vLV6eeGs06IX0UqCRF9JveZH6+avD177etwt0/XYNrLP6UZsC3Zzp/GXrXz6/qauNO6VbOm65lRcLdAn62eaz8NsabTkEAiWHyMEFeveP0+cnzu7iLKnt4Z9PPmDy84HTL6jzLzIh0PMfWJyiJvdVHv7H+bMf009YIOZfaxOlbPwopxRo449ynhfdApsgJj/2OP2RxU38NoGu3a6hdVY+alOgW2aafMbkByfPf/hzy+lYublLR5jfEV67ldsFupjqxuwh/PQHMzcEuqXRlkNsfr+BkPwcyb+JNLv052q7tfF3sydeX1YCfXENtfRE7feunn+JTRHzo8yeu1g8kXuJQDc/XAn0rOgW2PLTx+v/ctF2ga7frmCdca785RaBbplpmXv+GRunagnw+Nrfbd5KLdDpVKuXw8Z91i2NNg9xvjsh+8tRCHTx4sLF47D/vfiA+b/YeXv+1SOehZ9/kc+/vr+c/wq0lz+bmWGBOH8sv3j1zFMbBtryNb/x4VufFVoU3Qa7v3g50PrvhVPPwq/frqF15qq58vK2Z+G3zbR4TdGT/2XO2zwdy/j5b+G78h/m71y/ldsFunJOZ4j/+JPFD3+ef8aWRptDLmCE7C+HF+jj3z3/Rbzn38i6+5vp/Zonfr74xt/7k1da/4V+GdP09wYv/aLis1/CO37HwgxzxNK3yz6YvDTnoeVfqHyBQDc+fPvT6vOi22EfvnZ1ers2Pk29jGn9dg2tM/2NzKMn3tn6MqatM03fNal4Y3GPbvN0zD/9rON3ln4X8pZbKQS6mGr225En+PPn29ZLrjbaHHIBI2RvOYxASYW0/JMig//Zka7s92iEXBoESlaydC+25YntPShtYCNC9hgESlZy/sIm8TuUVrMHgQ5sRMgeg0DJSqYvbJp8V/rD11qek9mDQAc2ImSPQaBkNTfOn99ruLu3j+9KDmtEyB6DQMlqzl8gtPkvh2756D0IdFgjQvYYBErWM/tH4L+39aVTa9nP8+JDGhGyxyBQQggJBoESQkgwCJQQQoJBoIQQEgwCJYSQYBAoIYQEg0AJISQYBEoIIcEgUEIICQaBEkJIMAiUEEKCQaCEEBIMAiWEkGAOIdD/u5r1t4dnAxlh7K1F64dd8HEX/dX2v9v23lqzHX8LQU7C2sxWrAUCFYy9tUCgpi0EOQlrM1uxFghUMPbWAoGathDkJKzNbMVaIFDB2FsLBGraQpCTsDazFWuBQAVjby0QqGkLQU7C2sxWrAUCFYy9tUCgpi0EOQlrM1uxFghUMPbWAoGathDkJKzNbMVaIFDB2FsLBGraQpCTsDazFWuBQAVjby0QqGkLQU7C2sxWrAUCFYy9tUCgpi0EOQlrM1uxFghUMPbWAoGathDkJKzNbMVaIFDB2FsLBGraQpCTsDazFWuBQAVjby0QqGkLQU7C2sxWrAUCFYy9tUCgpi0EOQlrM1uxFrsQ6J9/dHJy7W8+PXvjwZvXT05eefeyNxDowCMh0GotBDkJazNbsRY7EOgnJ9M8897kja9enb7x9CVvINChR0Kg1VoIchLWZrZiLfoF+sX1a393enrvRyfPTd66efLsu6f33jh59tML30CgQ4+EQKu1EOQkrM1sxVr0C/TmyQ/PPDq5b3n2v+N7m9d+ddEbCHTwkRBotRaCnIS1ma1Yi36BzvLVqxNBfnJ2P3T85w8vegOBDj4SAq3WQpCTsDazFWuxM4F+cX3y2PzmyY+nb92Z6FK/gUAHHwmBVmshyElYm9mKtdiVQP90fSLIB2/MHqBPdKrfOPuUb84SPSQhhBxVggK9eXJy7ZenCJQQ8nVOTKAP/umvrp9c+9sVgT79nn5j9bOjd54vuFfdjeAhfCxft5MXICdhbWYr1mInAp3kz5PH8IPugSLQIUdCoNVaCHIS1ma2Yi12JtDTOycXOROBdh4JgVZrIchJWJvZirXYnUCnZuRZ+MEtEKhpC0FOwtrMVqxFt0AfvDEz41Sg81d5zl76qd5AoIOPhECrtRDkJKzNbMVadAt0fNfyufM/+UmkwS0QqGkLQU7C2sxWrEW/QL+4fvKDT08f/OFkYsbx/dFnFj/xrt9AoIOPhECrtRDkJKzNbMVa9Av09M7Zb2O6Nn0kf2/5dy7pNxDo0CMh0GotBDkJazNbsRY7EOjpvb8e63P+iz7vvTm25CufXvYGAh14JARarYUgJ2FtZivWYhcC7Uy0+gW3qRuBQGP5up28ADkJazNbsRYIVDD21gKBmrYQ5CSszWzFWiBQwdhbCwRq2kKQk7A2sxVrgUAFY28tEKhpC0FOwtrMVqwFAhWMvbVAoKYtBDkJazNbsRYIVDD21gKBmrYQ5CSszWzFWtQV6L+NZdcDagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItjkCgwQQFeujahBDbcA906P8DaQL3QEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1mIXAv3zX5+cXHvl3bM3Hrx5/eTk8jcQ6MAjIdBqLQQ5CWszW7EWOxDoH06mufaryRtfvTp94+n3Ln4DgQ49EgKt1kKQk7A2sxVr0S/QOyfX/u709N4bZ2q8efLsu5M3nv30wjcQ6NAjIdBqLQQ5CWszW7EW3QJ98MbJjyd/ju9gjv/84vpUo1+9Ork/qt9AoIOPhECrtRDkJKzNbMVadAv0q1dnD8pvnvzw9PSTk+emb3xy8RsIdPCREGi1FoKchLWZrViLboEuMhXozbO7o+PH9c9d9AYCHXwkBFqthSAnYW1mK9ZiZwKdPjZ/8MbsAfoX15/9VL9x9hnfnCV4wKBAwzeQEEIuTlyg04foCJQQ8vVNWKB3pi9jWvhpHsAAACAASURBVNLk0+/pN1Y/NXjnOSjQXd+F1wQewocINi0EOQlrM1uxFjsS6J3r1ybf4hx0DxSBDjkSAq3WQpCTsDazFWuxG4F+MnsZPQJdIiDQEMGmhSAnYW1mK9ZiJwL9w8n8xZ08C39OQKAhgk0LQU7C2sxWrMUOBPrg5skz829rzl/lOXvpp3oDgQ4+EgKt1kKQk7A2sxVrsQOB3lz66Ux+EumcgEBDBJsWgpyEtZmtWIt+gX6y/NPtD944eWbxE+/6DQQ6+EgItFoLQU7C2sxWrEW3QGe/ZGmSyTc37y3/ziX9BgIdeiQEWq2FICdhbWYr1qJboHdOVgR6eu/N8X+9MruXqd9AoAOPhECrtRDkJKzNbMVadAu0P8HqCLQFgUAP1kKQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrgUA7B9QEBBoi2LQQ5CSszWzFWiDQzgE1AYGGCDYtBDkJazNbsRYItHNATUCgIYJNC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVrMUyg9//49m8RaCMBgYYINi0EOQlrM1uxFq0C/fzvPz49/fI7o9Ho4V8g0CYCAg0RbFoIchLWZrZiLRoFemv0jd+fnt4YTTL5LwR6OQGBhgg2LQQ5CWszW7EWbQK9PdXmZ1dHj3z8+fOjbyPQFgICDRFsWghyEtZmtmIt2gR6Y2zOiUav/GLyv5P/RqCXEhBoiGDTQpCTsDazFWvRJND7P5mYc6bRL5/f8WP4YHUE2oJAoAdrIchJWJvZirVoEuiZM798fvToKQJtDQKNEWxaCHIS1ma2Yi0GCPSzq6OXEWhzEGiMYNNCkJOwNrMVa9Ek0LOH8Lem3wLle6CtBAQaIti0EOQkrM1sxVo0CfT0xujRydPvE3PyLHwrAYGGCDYtBDkJazNbsRZtAr09fQHo+BH8/ddGZ/dDEeilBAQaIti0EOQkrM1sxVq0CXT88H2cR6dPJF15ebf+RKDdOAR6jC0EOQlrM1uxFo0CPf389e/+fPzHl//uyXd27E8E2o1DoMfYQpCTsDazFWvRKtDEBKsj0BYEAj1YC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVr0SbQu/+yHATaRECgIYJNC0FOwtrMVqxFk0C/fH60mode2uFLQYPVEWgLAoEerIUgJ2FtZivWIibQnb6WKVgdgbYgEOjBWghyEtZmtmItmgR6/4+/Hivzu2+//fbrV0dXXnr7py/s8reCBqsj0BYEAj1YC0FOwtrMVqxFk0And0HnP370/lSdu/x5pGB1BNqCQKAHayHISVib2Yq1aBPojSVd3pr+TqYd/kR8sDoCbUEg0IO1EOQkrM1sxVo0CXT2+0DP8tnViTo/u7qzx/DB6gi0BYFAD9ZCkJOwNrMVa9Ek0JXfYDf/5aAI9BICAg0RbFoIchLWZrZiLRoFunIPFIE2ERBoiGDTQpCTsDazFWvRJNDJr7Nb+2++B3opAYGGCDYtBDkJazNbsRZtAr09Gj115sv7b01+q93p+1d5Fv4yAgINEWxaCHIS1ma2Yi3aBDr9F+GfePHFFx+f/la7yQvrd/dK+mB1BNqCQKAHayHISVib2Yq1aBTo5I7nLH/x8Y5/K2iwOgJtQSDQg7UQ5CSszWzFWjQK9PT07m8en/4Q/EcTnb7+D/ws/KUEBBoi2LQQ5CSszWzFWjQLNC/B6gi0BYFAD9ZCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVq0CXT194F+hEBbCAg0RLBpIchJWJvZirVoEujar7Pb3S9iQqAI1LaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVoEuj9P749y0+/M7rys9/u8Cl4BIpATVsIchLWZrZiLZoEupyzX8Z0BAkK9NC1CSG2aXgW/tbufojzLEH3cw+0BcE90IO1EOQkrM1sxVoMF+jO74IGqyPQFgQCPVgLQU7C2sxWrMVwge7wF9kh0PYjIdBqLQQ5CWszW7EWwwW6w99Fj0Dbj4RAq7UQ5CSszWzFWgwW6P0bu/tNoAi0/UgItFoLQU7C2sxWrEWTQO+//uI8f3l1xJNIbQQEGiLYtBDkJKzNbMVaNAl09YX0u34ZU7A6Am1BINCDtRDkJKzNbMVaDBboQy/t+mWgweoItAWBQA/WQpCTsDazFWvRJNDcBKsj0BYEAj1YC0FOwtrMVqwFAu0cUBMQaIhg00KQk7A2sxVr0SbQG0++g0AHBoHGCDYtBDkJazNbsRZNAv3y+dHu/gkkBBo6EgKt1kKQk7A2sxVr0SjQHb92HoEOPhICrdZCkJOwNrMVa9Ek0Ps/2d0/YoxAY0dCoNVaCHIS1ma2Yi2aBHp6a/RI3jdBg9URaAsCgR6shSAnYW1mK9aiTaB3fz0aPfSt+U8jfZcf5WwhINAQwaaFICdhbWYr1qJJoPyTHoEg0BjBpoUgJ2FtZivWAoF2DqgJCDREsGkhyElYm9mKtWgSaG6C1RFoCwKBHqyFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItLhPo3X/ZzEcItIWAQEMEmxaCnIS1ma1Yi0sEuvb0EU8itQeBxgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasxSUCvf/Ht6f59Wh05bs/e/vtnz42uvLSb3khfQsBgYYINi0EOQlrM1uxFpcIdJbxHdH5P4T0/q7vgCLQbhwCPcYWgpyEtZmtWIs2gd5Y+ofkbo0eRaAtBAQaIti0EOQkrM1sxVo0CXTltzF9dpV/1riJgEBDBJsWgpyEtZmtWIsmga78PtCd/3LQYHUE2oJAoAdrIchJWJvZirVoFOjKPVAE2kRAoCGCTQtBTsLazFasRZNAT28sfd/zBt8DbSMg0BDBpoUgJ2FtZivWok2gt0ejp86+8Xn/rdGu/32kYHUE2oJAoAdrIchJWJvZirVoE+j4budo9MSLL7742PjPp3brTwTajUOgx9hCkJOwNrMVa9Eo0Mkdz1m+LT4Ega4REGiIYNNCkJOwNrMVa9Eo0NPTu7+Z3Pt86KUd/yYRBIpATVsIchLWZrZiLZoFmpdgdQTagkCgB2shyElYm9mKtWgR6JcvPP7E75f+RKBNBAQaIti0EOQkrM1sxVpcItD7f/xo+pPw05d+zv9EoE0EBBoi2LQQ5CSszWzFWlwi0Mmvs3v8xasIdHgQaIxg00KQk7A2sxVrcYlA77929ey594e/97uPEeiQINAYwaaFICdhbWYr1uISgU7y4W+uZv0uZQSKQG1bCHIS1ma2Yi0aBDp96P6zn75wptAr3/oZ/yZSEwGBhgg2LQQ5CWszW7EWrQKdfQ+Uf9KjOQg0RrBpIchJWJvZirUYKNBv/P7uP7++49cyBasj0BYEAj1YC0FOwtrMVqzFJQL98vXxA3ZexhQJAo0RbFoIchLWZrZiLS4T6ORR+2MjBDo8CDRGsGkhyElYm9mKtbhEoPc/+MvHzr7x+fj3fvuvCHRAEGiMYNNCkJOwNrMVa3GJQKf5P+cvY7ryj7v995AQKAJ1bSHISVib2Yq1aBHo5KH7//zwNy9cnb2O6b/xj8q1EBBoiGDTQpCTsDazFWvRKtDZ90CvPM7LmFoJCDREsGkhyElYm9mKtRgo0PGfd//499wDbSEg0BDBpoUgJ2FtZivWYrhAd55gdQTagkCgB2shyElYm9mKtWgRaHKC1RFoCwKBHqyFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirVAoJ0DagICDRFsWghyEtZmtmItEGjngJqAQEMEmxaCnIS1ma1YCwTaOaAmINAQwaaFICdhbWYr1mJHAv3q1edm//XgzesnJ6+8e9kbCHTgkRBotRaCnIS1ma1Yix0J9ObJc3OTnkzy9HsXv4FAhx4JgVZrIchJWJvZirXYiUAf3DyZC/TmybPvnt574+TZTy98A4EOPRICrdZCkJOwNrMVa7ELgf75RydzgX5xfXoP86tXr/3qojcQ6OAjIdBqLQQ5CWszW7EWOxDoJycnP/jTTKCfLP784UVvINDBR0Kg1VoIchLWZrZiLXYh0Gd+eXpnpsebJz+e/jl9W7+BQAcfCYFWayHISVib2Yq12IFAl7T44I3ZA/Qvrj/7qX7j7HO+OUvwkEGBBo9GCCGXBYESQkgwuxPo0+/pN1Y/N3jnOSjQXd+F1wQewocINi0EOQlrM1uxFmkCvfweKAIdciQEWq2FICdhbWYr1gKBdg6oCQg0RLBpIchJWJvZirXYrUB5Fn6JgEBDBJsWgpyEtZmtWIsdC3T+Ks/ZSz/VGwh08JEQaLUWgpyEtZmtWIsdC5SfRDonINAQwaaFICdhbWYr1mLHAn3wxskzi594128g0MFHQqDVWghyEtZmtmItdizQ03vLv3NJv4FAhx4JgVZrIchJWJvZirXYtUBP7705tuQrn172BgIdeCQEWq2FICdhbWYr1mJHAu1JsDoCbUEg0IO1EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRzQE1AoCGCTQtBTsLazFasBQLtHFATEGiIYNNCkJOwNrMVa4FAOwfUBAQaIti0EOQkrM1sxVog0M4BNQGBhgg2LQQ5CWszW7EWCLRtwLyjIVDTFoKchLWZrVgLBNo2IAJtSrGrP7WFICdhbWYr1gKBtg2IQJtS7OpPbSHISVib2Yq1QKBtAyLQphS7+lNbCHIS1ma2Yi0QaNuACLQpxa7+1BaCnIS1ma1YCwTaNiACbUqxqz+1hSAnYW1mK9YCgbYNiECbUuzqT20hyElYm9mKtUCgbQMi0KYUu/pTWwhyEtZmtmItEGjbgAi0KcWu/tQWgpyEtZmtWAsE2jYgAm1Ksas/tYUgJ2FtZivWAoG2DYhAm1Ls6k9tIchJWJvZirVAoG0DItCmFLv6U1sIchLWZrZiLRBo24AItCnFrv7UFoKchLWZrVgLBNo2IAJtSrGrP7WFICdhbWYr1gKBtg2IQJtS7OpPbSHISVib2Yq1QKBtAyLQphS7+lNbCHIS1ma2Yi0QaNuACLQpxa7+1BaCnIS1ma1YCwTaNiACbUqxqz+1hSAnYW1mK9YCgbYNiECbUuzqT20hyElYm9mKtUCgbQMi0KYUu/pTWwhyEtZmtmItEGjbgAi0KcWu/tQWgpyEtZmtWAsE2jYgAm1Ksas/tYUgJ2FtZivWAoG2DYhAm1Ls6k9tIchJWJvZirVAoG0DItCmFLv6U1sIchLWZrZiLRBo24AItCnFrv7UFoKchLWZrVgLBNo2IAJtSrGrP7WFICdhbWYr1gKBtg2IQJtS7OpPbSHISVib2Yq1QKBtAyLQphS7+lNbCHIS1ma2Yi0QaNuACLQpxa7+1BaCnIS1ma1YCwTaNiACbUqxqz+1hSAnYW1mK9YCgbYNiECbUuzqT20hyElYm9mKtUCgbQMi0KYUu/pTWwhyEtZmtmItEGjbgAi0KcWu/tQWgpyEtZmtWAsE2jYgAm1Ksas/tYUgJ2FtZivWAoG2DYhAm1Ls6k9tIchJWJvZirVAoG0DItCmFLv6U1sIchLWZrZiLRBo24AItCnFrv7UFoKchLWZrVgLBNo2IAJtSrGrP7WFICdhbWYr1gKBtg2IQJtS7OpPbSHISVib2Yq1QKBtAyLQphS7+lNbCHIS1ma2Yi0QaNuACLQpxa7+1BaCnIS1ma1YCwTaNiACbUqxqz+1hSAnYW1mK9YCgbYNiECbUuzqT20hyElYm9mKtUCgbQMi0KYUu/pTWwhyEtZmtmItEGjbgAi0KcWu/tQWgpyEtZmtWAsE2jYgAm1Ksas/tYUgJ2FtZivW4ggEGkxQaSWORgipGO6BihZ5R+MeqGkLQU7C2sxWrAUCbRsQgTal2NWf2kKQk7A2sxVrgUDbBkSgTSl29ae2EOQkrM1sxVog0LYBEWhTil39qS0EQQuOIQAAFV1JREFUOQlrM1uxFgi0bUAE2pRiV39qC0FOwtrMVqwFAm0bEIE2pdjVn9pCkJOwNrMVa4FA2wZEoE0pdvWnthDkJKzNbMVaINC2ARFoU4pd/aktBDkJazNbsRYItG1ABNqUYld/agtBTsLazFasBQJtGxCBNqXY1Z/aQpCTsDazFWuBQNsGRKBNKXb1p7YQ5CSszWzFWiDQtgERaFOKXf2pLQQ5CWszW7EWCLRtQATalGJXf2oLQU7C2sxWrAUCbRsQgTal2NWf2kKQk7A2sxVrgUDbBkSgTSl29ae2EOQkrM1sxVog0LYBEWhTil39qS0EOQlrM1uxFgi0bUAE2pRiV39qC0FOwtrMVqwFAm0bEIE2pdjVn9pCkJOwNrMVa4FA2wZEoE0pdvWnthDkJKzNbMVaINC2ARFoU4pd/aktBDkJazNbsRYItG1ABNqUYld/agtBTsLazFasBQJtGxCBNqXY1Z/aQpCTsDazFWuBQNsGRKBNKXb1p7YQ5CSszWzFWiDQtgERaFOKXf2pLQQ5CWszW7EWCLRtQATalGJXf2oLQU7C2sxWrAUCbRsQgTal2NWf2kKQk7A2sxVrgUDbBkSgTSl29ae2EOQkrM1sxVog0LYBEWhTil39qS0EOQlrM1uxFgi0bUAE2pRiV39qC0FOwtrMVqwFAm0bEIE2pdjVn9pCkJOwNrMVa4FA2wZEoE0pdvWnthDkJKzNbMVaINC2ARFoU4pd/aktBDkJazNbsRYItG1ABNqUYld/agtBTsLazFasBQJtGxCBNqXY1Z/aQpCTsDazFWuBQNsGRKBNKXb1p7YQ5CSszWzFWiDQtgERaFOKXf2pLQQ5CWszW7EWCLRtQATalGJXf2oLQU7C2sxWrAUCbRsQgTal2NWf2kKQk7A2sxVrgUDbBkSgTSl29ae2EOQkrM1sxVog0LYBEWhTil39qS0EOQlrM1uxFgi0bUAE2pRiV39qC0FOwtrMVqwFAm0bEIE2pdjVn9pCkJOwNrMVa4FA2wZEoE0pdvWnthDkJKzNbMVaINC2ARFoU4pd/aktBDkJazNbsRYItG1ABNqUYld/agtBTsLazFasBQJtGxCBNqXY1Z/aQpCTsDazFWuBQNsGRKBNKXb1p7YQ5CSszWzFWiDQtgERaFOKXf2pLQQ5CWszW7EWCLRtQATalGJXf2oLQU7C2sxWrAUCbRsQgTal2NWf2kKQk7A2sxVrgUDbBkSgTSl29ae2EOQkrM1sxVog0LYBEWhTil39qS0EOQlrM1uxFgi0bcA9C3Rnh0OgB2shyElYm9mKtUCgbQPmHQ2BmrYQ5CSszWzFWiDQtgHzjoZATVsIchLWZrZiLRBo24B5R0Ogpi0EOQlrM1uxFgi0bcC8oyFQ0xaCnIS1ma1YCwTaNmDe0RCoaQtBTsLazFasBQJtGzDvaAjUtIUgJ2FtZivWAoG2DZh3NARq2kKQk7A2sxVrgUDbBsw7GgI1bSHISVib2Yq1QKBtA+YdDYGathDkJKzNbMVaINC2AfOOhkBNWwhyEtZmtmItEGjbgHlHQ6CmLQQ5CWszW7EWCLRtwLyjIVDTFoKchLWZrVgLBNo2YN7REKhpC0FOwtrMVqwFAm0bMO9oCNS0hSAnYW1mK9YCgbYNmHc0BGraQpCTsDazFWuBQNsGzDsaAjVtIchJWJvZirVAoG0D5h0NgZq2EOQkrM1sxVog0LYB846GQE1bCHIS1ma2Yi0QaNuAeUdDoKYtBDkJazNbsRYItG3AvKMhUNMWgpyEtZmtWAsE2jZg3tEQqGkLQU7C2sxWrAUCbRsw72gI1LSFICdhbWYr1gKBtg2YdzQEatpCkJOwNrMVa4FA2wbMOxoCNW0hyElYm9mKtUCgbQPmHQ2BmrYQ5CSszWzFWiDQtgHzjoZATVsIchLWZrZiLRBo24B5RzsCge7uxhW7+lNbCHIS1ma2Yi0QaNuAeUdDoC2FhzGOooUgJ2FtZivWAoG2DZh3NATaUngY4yhaCHIS1ma2Yi0QaNuAeUdDoC2FhzGOooUgJ2FtZivWAoG2DZh3NATaUngY4yhaCHIS1ma2Yi0QaNuAeUdDoC2FhzGOooUgJ2FtZivWAoG2DZh3NATaUngY4yhaCHIS1ma2Yi0QaNuAeUdDoC2FhzGOooUgJ2FtZivWAoG2DZh3NATaUngY4yhaCHIS1ma2Yi0QaNuAeUfbpUD3m9YbMyg+X4OCnIS1ma1YCwTaNmDe0RDoKsHma1CQk7A2sxVrgUDbBsw7GgJdJdh8DQpyEtZmtmItEGjbgHlHQ6CrBJuvQUFOwtrMVqwFAm0bMO9oCHSVYPM1KMhJWJvZirVAoG0D5h0Nga4SbL4GBTkJazNbsRYItG3AvKMh0FWCzdegICdhbWYr1gKBtg2YdzQEukqw+RoU5CSszWzFWiDQtgHzjoZAVwk2X4OCnIS1ma1YCwTaNmDe0RDoKsHma1CQk7A2sxVrgUDbBsw7GgJdJdh8DQpyEtZmtmItEGjbgHlHQ6CrBJuvQUFOwtrMVqwFAm0bMO9oCHSVYPM1KMhJWJvZirVAoG0D5h2trkCDuWQOm69BQU7C2sxWrAUCbRsw72gIdHUOm69BQU7C2sxWrAUCbRsw72gIdHUOm69BQU7C2sxWrAUCbRsw72gIdHUOm69BQU7C2sxWrAUCbRsw72hfO4FG03jm1KSDgkBp0XowBNoyYN7REGhjGs+cmnRQECgtWg+GQFsGzDsaAm1M45lTkw4KAqVF68EQaMuAeUdDoI1pPHNq0kFBoLRoPRgCbRkw72gItDGNZ05NOigIlBatB0OgLQPmHQ2BNqbxzKlJBwWB0qL1YAi0ZcC8oyHQxjSeOTXpoCBQWrQeDIG2DJh3NATamMYzpyYdFARKi9aDIdCWAfOOhkAb03jm1KSDgkBp0XowBNoyYN7REGhjGs+cmnRQECgtWg+GQFsGzDsaAm1M45lTkw4KAqVF68EQaMuAeUdDoI1pPHNq0kFBoLRoPRgCbRkw72gINDeNJ3ztpCBQWjQebG8CffDm9ZOTV95FoA23N3g4spnGE752UhAoLRoPti+BfvXqySRPv4dAL7+9wcORnaXxOhkcBOrVYn8CvXny7Lun9944efZTBHrp7Q0ejuwsjdfJ4CBQrxZ7E+gX16f3Pb969dqvEOiltzd4OLKzNF4ng4NAvVrsTaCfnDw3+/OHCPTS2xs8HNlZGq+TwUGgXi32JtCbJz+e/nlnJlIEetHtDR6OHDqx092fr6G6jqPFvgT64I3ZQ/cvrs+/CfrNWYLE4BVe4mjRwxFyfIl+Eez3S2c3Ry8kUEIIOa7sQ6DrL2SK3nm+4F51N2KPLVo/7IKPu+ivtv/dtvfWmu34WwhyEtZmtmItDiDQ9dcxRatfcJu6EQg0lq/byQuQk7A2sxVrgUAFY28tEKhpC0FOwtrMVqzFvgS6+2fhL7pN3QgEGsvX7eQFyElYm9mKtdibQOev/9zZ60Avuk3dCAQay9ft5AXISVib2Yq12JtAd/6TSBfdpm4EAo3l63byAuQkrM1sxVrsTaAP3jh5Zqc/C3/RbepGINBYvm4nL0BOwtrMVqzF3gR6em/Hv43potvUjUCgsXzdTl6AnIS1ma1Yi/0J9PTem2N/vrJ+/xOB9uMQ6DG2EOQkrM1sxVrsUaAq0eoX3KZuBAKN5et28gLkJKzNbMVaIFDB2FsLBGraQpCTsDazFWuBQAVjby0QqGkLQU7C2sxWrAUCFYy9tUCgpi0EOQlrM1uxFghUMPbWAoGathDkJKzNbMVaIFDB2FsLBGraQpCTsDazFWuBQAVjby0QqGkLQU7C2sxWrAUCFYy9tUCgpi0EOQlrM1uxFghUMPbWAoGathDkJKzNbMVaIFDB2FsLBGraQpCTsDazFWuBQAVjby0QqGkLQU7C2sxWrAUCFYy9tUCgpi0EOQlrM1uxFghUMPbWAoGathDkJKzNbMVaIFDB2FsLBGraQpCTsDazFWuBQAVjby0QqGkLQU7C2sxWrAUCFYy9tUCgpi0EOQlrM1uxFghUMPbWAoGathDkJKzNbMVaIFDB2FsLBGraQpCTsDazFWuBQAVjby0QqGkLQU7C2sxWrAUCFYy9tUCgpi0EOQlrM1uxFghUMPbWAoGathDkJKzNbMVaIFDB2FsLBGraQpCTsDazFWuBQAVjby0QqGkLQU7C2sxWrAUCFYy9tUCgpi0EOQlrM1uxFghUMPbWAoGathDkJKzNbMVaIFDB2FsLBGraQpCTsDazFWtxBALdeb75zUM3mGTHLYK4AZ9mOVswx9FiQI6jMC0Q6M6CQEOhRSjHUZgWCHRnQaCh0CKU4yhMCwS6syDQUGgRynEUpgUC3VkQaCi0COU4CtMCge4sCDQUWoRyHIVpgUB3FgQaCi1COY7CtECgOwsCDYUWoRxHYVpYCJQQQg4RBEoIIcEgUEIICQaBEkJIMAiUEEKCQaCEEBIMAiWEkGAQKCGEBGMh0K9efe7QFf781ycn1155d2e4H41xf/Np5FO/uP5sw+d99erJNE+/FznGbnJ+2h68ef3kZHfrtWfltB2sRXtWT9tBCouzts8u+qztfxELgd48ObRA/3B2XV/71W5wn5zhngnY7cEbJy0C/eL64QW6OG0zLey/y8ppO1iLAVk5bYcpvP2s7bOLPmsHWMRAoA9unhxaoHdOrv3d6em9N3Z06r64PsX9KHKzxu5tEeidQ0+2fNpunjz77mS9luK7zOppO1SLIVk5bYcorM7aHrtccNYOsEh9gU4e7R7YBuN7fT+e/Dn+P8Af74J38+SHkz++uD7cx5O7KC2Xz+wQh8vSaZvdzq9e3dUd+MasnrZDtRiU5dN2iMLqrO2xywVn7RCLlBfo+B7XD/50YIF+9erMdLvV0gLbnvHV9Z9bvgf64I0Da2L5tH2y+HO/Ul89bYdqMSQrp+0AheVZ22OXC87aIU5hfYE+88sjeDw6y24F2vZ00FqB55o+66tXn/1f4zsT/+lgz5gsn7abs/vtBzuN09N28BYNWTltBygsz9ohxts8a4doUV6gkxzLNb/bxw5/uj74GwJ3xg/fmwQ6fzJiN99yCGZ22hZ3qwL/h7GTTE/bwVu0ZPm0HarwtrN2iC6bZ+0giyDQHeaTHfa4eXJy7ZcDP2d6TTVdPXfGj8U+Pf1/b+7sdQORHItAp6ft4C1asnzavu4C3TxrCDSaIxHonR3q6ME//dX1k2t/O+yTpg9qmq6eTxaPww74Db/NL8WDvITo7LQdukVTlk/boQpvO2sH6LLlrB1kEQS6s9y5fm23D4j/PPAx/CfT598H/d/vnUO+aOc47oHOTluJe6DzTE7b1/se6Lazxj3QaI5CoJ/s/uHwML19cX1aYNDVc9C7W0ch0PlpKyXQtftbXz+Bbj1rCDSaYxDoHxK+nTjsQpj9+NKgH8U4qC2O4Vn489NW4Vn4eaan7UCFj+FZeHHWeBY+mMNf8w9uhn7uUsBmLxXOE+jiCAddbn7w+cv29v8KzOXTdrgWzVk9bQcqvPWs7bWLPGuHWASB7iQ3d/q9xJuL/5MP3K4m696cPw475OuY5qftcD8DtHzaKvwk0sppO1DhrWdtr13kWeMnkYI5uEA/2e1zMV9cn7xa5UHsuwKtrwMdH+Hejw76g9/z0zb2wTMH+Sn0ldN2sBYDsnLaDlR461nbZxd91g6xCALdQea/ZGxnP5R/Z/b7ZiJ3D9se988e7z99yF/etjht9w7ze5DWTtuBWgzKymk7TOHtZ21/XS46awdYBIHu5Pg7FujpvfivF238xun0CD846J2t89N2783xdK/su8z6aTtMi2FZOW0HKSzO2t66XHjW9r+IhUAJIeQQQaCEEBIMAiWEkGAQKCGEBINACSEkGARKCCHBIFBCCAkGgRJCSDAIlBBCgkGghBASDAIlhJBgECghhASDQAkhJBgESgghwSBQcuS5NXp0/L/3fzJ6+dBNCFkPAiVHnhtTc375/Dd+P3nr/X/zcSevn0DIPAiUHHfu/+TKL8Z/fHb1kYn3bowe6dRfP4GQRRAoOe7M7nrenj6QR6DkuIJAyXHn9mh21/Pbp6cIlBxZECg52nz5/GgljyJQcmRBoORosyHQW2d/Tu+Lfvja1fF/Pv7S1IaT5+g/+M5o9NDk26UfvDAaXXnq41ujs6edTj+ffOSVJ9+Z/PcSYfru0RM/P9CNIxZBoORoc4FA7781f+fDE0uOBfri5I2xMsf/Oc03XpsJ9Nb8I586XRbo+ysAQkJBoOSo89nVqQbPXgx6/gB8LMKnxv/x+XdG81eJjq784vTzn08+YvI3U8HOPnM0ufN5960zg84Jn10dPTJ+9/1fj2ZkQgJBoOSos3j2/exl9DP9je+bnmlv/B+Td0wEevYBYzFOH+FPxDkR6PjtmSBvjaavh5oRFg/wb8z/g5DhQaDkqHNr6sPZi0EX+rs9mr09NufEf7M/TpfEOFbr5L8Wb08+5tHTJYHOCIR0BIGSo87qzyFtPod+Yy7QR+bPJj26/DdLb88+d6Hg0ZUnf7eXm0CMg0DJMefL56d3FG/Pvbks0Lsfvv36Y6O5QBcP6b89++vpfc/V56EmHzonnD0L9dBLH+33BhGvIFBytLnodaDvP7ZsxYBAp692mj4LzwuZSDgIlBxttEDPXqv0+Iv/8NGNDYHOH7LPBbr2JPvyfdgPX59qmF/zRKJBoORoowU6exXT6dL3QM88ueV7oBvfNF15x+R1TPxoEokGgZIjzuy3gM5eDHo619+5FmfPtZ97c/1Z+BuLZ9tnn7QgrIiWkFAQKDnirP4qptNNgd5a+x7otteBzj709tlj9fWXMW3eRyWkOQiUHHFmvwX01tIzQ1d+cf+j+UP4D78zmv4E0vIdylubP4k0eZpo8VB9RhjfQb3y/cnPMv2E74GSeBAoOeKs/RzS9G7k5HuhX35n9m3RJ3899d+SQO/fmD25/l/Xfxb+7I7mjDC5azpa/GA8IbEgUHLEOfstoLMXg07z/th7j47vYf7msbNXwp89zb78evktv41p8lz74tcuzQhjxOOTF4I+xQtBSTwIlJiGX/xJ8oNAiVUWz6mv3CklJCcIlFjl1savZSIkLwiUWGXszSvfH9//fP8qL+8k+UGgxCu358+uP/zOoasQ/yBQYpa7b5096c4zSCQ/CJQQQoJBoIQQEgwCJYSQYBAoIYQEg0AJISQYBEoIIcEgUEIICQaBEkJIMAiUEEKCQaCEEBIMAiWEkGAQKCGEBINACSEkGARKCCHB/H8VhOjy5dXhGgAAAABJRU5ErkJggg==" width="672" /> Proportion of drugs that have more than 1 target:</p>
<pre class="r"><code>sum(df$targets&gt;1)/length(df$targets)</code></pre>
<pre><code>## [1] 0.3442733</code></pre>
<p>save it:</p>
<pre class="r"><code>pdf('Figures/drugs_targets_hist.pdf')
ggplot(data = df,aes(x=targets))+geom_histogram(bins=20)+labs(title='Distribution of the nb of drugs per target',y='#drugs',x='#targets')+scale_x_continuous(trans = 'log10',breaks=c(1,2,3,4,5,10,20,50,100,200))
dev.off()</code></pre>
<pre><code>## png 
##   2</code></pre>
</div>
</div>
<div id="visualizing-the-drug-trait-matrix" class="section level4">
<h4>Visualizing the drug trait matrix:</h4>
<p>Histogram:</p>
<pre class="r"><code>lR=-log10(R)
max(lR)</code></pre>
<pre><code>## [1] Inf</code></pre>
<pre class="r"><code>max(lR[!is.infinite(lR)])</code></pre>
<pre><code>## [1] 5.583209</code></pre>
<pre class="r"><code>lR[is.infinite(lR)]=max(lR[!is.infinite(lR)])
max(lR)</code></pre>
<pre><code>## [1] 5.583209</code></pre>
<pre class="r"><code>hist(lR,main='Trait/Drug association scores distribution',xlab='scores')</code></pre>
<p><img src="data:image/png;base64,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" width="672" /> We see that few drugs have a high association score with diseases.</p>
<pre class="r"><code>pdf('Figures/scores_hist.pdf')
hist(lR,main='Trait/Drug association scores distribution',xlab='scores')
dev.off()</code></pre>
<pre><code>## png 
##   2</code></pre>
<p>The heatmap:</p>
<pre class="r"><code>heatmap.2(lR,trace = 'none',margins=c(12,12),col=colorRampPalette(c('blue','White','red')))</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<p>Subsetting the cluster of high scores:</p>
<pre class="r"><code>hm=heatmap.2(lR,trace = 'none',margins=c(12,12),col=colorRampPalette(c('blue','White','red')))</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre class="r"><code>m=t(hm$carpet)#Get the matrix as clustered in the heatmap
nam=colnames(m[1:21,1:1000])</code></pre>
<p>Saving it:</p>
<pre class="r"><code>pdf(file = 'Figures/heatmap.pdf',height = 16,width =20)
heatmap.2(lR,trace = 'none',margins=c(12,14),col=colorRampPalette(c('blue','White','red')),main='Trait/drug association scores',cexRow=1)
dev.off()</code></pre>
<pre><code>## png 
##   2</code></pre>
</div>
<div id="finding-hits-drugs-for-a-trait-in-the-drugbank-database" class="section level4">
<h4>Finding hits (drugs) for a trait in the Drugbank database:</h4>
<div id="function-that-plots-hits-and-the-rest-of-the-drug-scores-on-a-boxplot-and-returns-the-p-value-of-the-rank-sum-test" class="section level5">
<h5>Function that plots hits, and the rest of the drug scores on a boxplot, and returns the p-value of the rank-sum test:</h5>
<pre class="r"><code>find_hits_to_vis=function(keywords,categories,trait,DB_tar,lR){
  
  des=DB_tar$description
  indi=DB_tar$indication
  cat=DB_tar$categories

hits_indi_des_list=list()
for (i in 1:length(keywords)){

posd=grep(keywords[i],des,ignore.case = T)

hitsd=DB_tar$drugbank.id[posd]
 
posi=grep(keywords[i],indi,ignore.case = T)
hitsi=DB_tar$drugbank.id[posi] 

hits_indi_des=unique(hitsd,hitsi)
hits_indi_des_list[[i]]=hits_indi_des
}


hits_cat_list=list()
for (j in 1:length(categories)){
posc=grep(categories[j],cat,ignore.case = T)
hitsc=DB_tar$drugbank.id[posc]
hits_cat_list[[j]]=hitsc
}


hits_id=unique(unlist(hits_cat_list,hits_indi_des_list))
hits_names=DB_tar$name[DB_tar$drugbank.id%in%hits_id]

hits_ind=which(colnames(lR)%in%hits_id)
hits_scores=lR[paste(trait),hits_ind]

rest_scores=lR[paste(trait),-hits_ind]
rest_scores_names=DB_tar$name[DB_tar$drugbank.id%in%names(rest_scores)]

dat.hits=data.frame(drugs='hits',score=hits_scores,names=hits_names)
dat.rest=data.frame(drugs='rest',score=rest_scores,names=rest_scores_names)
dat.plot=rbind(dat.hits,dat.rest)
plot=ggplot(dat.plot, aes(x=drugs, y=score,label=names))+
  geom_boxplot()+ggtitle(paste('Association scores with ',trait))
plot=plot+theme(plot.title = element_text(size = 20,face = 'bold',hjust = 0.5))
logplot=plot

wilc=wilcox.test(hits_scores,rest_scores)
ttes=t.test(hits_scores,rest_scores)
 
result=list(plot=logplot,ranksum.test=wilc,
            student.test=ttes,hits=hits_names,
            rest_high_score=dat.rest$names[dat.rest$score==max(lR)])

if(max(dat.rest$score)==max(dat.hits$score)){
  result$rest_high_score=dat.rest$names[dat.rest$score==max(dat.hits$score)]
  }


return(result)

}</code></pre>
</div>
<div id="insomnia" class="section level5">
<h5>Insomnia:</h5>
<pre class="r"><code>keywords=c('insomnia','sleep','hypnotic','antidepressant','anti-depressent')
categories=c('Benzodiazepine hypnotics and sedatives','Hypnotics and Sedatives')
trait='INSOMNIA'
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)</code></pre>
<pre><code>## $plot</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre><code>## 
## $ranksum.test
## 
##  Wilcoxon rank sum test with continuity correction
## 
## data:  hits_scores and rest_scores
## W = 118320, p-value = 0.9125
## alternative hypothesis: true location shift is not equal to 0
## 
## 
## $student.test
## 
##  Welch Two Sample t-test
## 
## data:  hits_scores and rest_scores
## t = -3.4576, df = 74.778, p-value = 0.0009026
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
##  -0.12533592 -0.03370158
## sample estimates:
## mean of x mean of y 
## 0.5372942 0.6168130 
## 
## 
## $hits
##  [1] &quot;Lorazepam&quot;           &quot;Ethchlorvynol&quot;       &quot;Temazepam&quot;          
##  [4] &quot;Butabarbital&quot;        &quot;Butalbital&quot;          &quot;Etomidate&quot;          
##  [7] &quot;Talbutal&quot;            &quot;Pentobarbital&quot;       &quot;Meprobamate&quot;        
## [10] &quot;Eszopiclone&quot;         &quot;Alprazolam&quot;          &quot;Secobarbital&quot;       
## [13] &quot;Zolpidem&quot;            &quot;Methohexital&quot;        &quot;Chlordiazepoxide&quot;   
## [16] &quot;Thiopental&quot;          &quot;Midazolam&quot;           &quot;Flurazepam&quot;         
## [19] &quot;Scopolamine&quot;         &quot;Propiomazine&quot;        &quot;Primidone&quot;          
## [22] &quot;Propofol&quot;            &quot;Diazepam&quot;            &quot;Oxazepam&quot;           
## [25] &quot;Methylphenobarbital&quot; &quot;Triazolam&quot;           &quot;Remifentanil&quot;       
## [28] &quot;Zaleplon&quot;            &quot;Ramelteon&quot;           &quot;Melatonin&quot;          
## [31] &quot;Diphenhydramine&quot;     &quot;Methyprylon&quot;         &quot;Thiamylal&quot;          
## [34] &quot;Phenobarbital&quot;       &quot;Zopiclone&quot;           &quot;Estazolam&quot;          
## [37] &quot;Amobarbital&quot;         &quot;Aprobarbital&quot;        &quot;Butethal&quot;           
## [40] &quot;Heptabarbital&quot;       &quot;Hexobarbital&quot;        &quot;Glutethimide&quot;       
## [43] &quot;Barbital&quot;            &quot;Flunitrazepam&quot;       &quot;Bromazepam&quot;         
## [46] &quot;Quazepam&quot;            &quot;Cinolazepam&quot;         &quot;Nitrazepam&quot;         
## [49] &quot;clomethiazole&quot;       &quot;Fospropofol&quot;         &quot;Tasimelteon&quot;        
## [52] &quot;Etizolam&quot;            &quot;Lormetazepam&quot;       
## 
## $rest_high_score
##  [1] Griseofulvin                                                                                  
##  [2] Metocurine Iodide                                                                             
##  [3] Brimonidine                                                                                   
##  [4] Cisatracurium                                                                                 
##  [5] Chloroquine                                                                                   
##  [6] Bacitracin                                                                                    
##  [7] Atracurium besylate                                                                           
##  [8] Vecuronium                                                                                    
##  [9] Phosphoaminophosphonic Acid Guanylate Ester                                                   
## [10] Galiximab                                                                                     
## [11] Dapagliflozin                                                                                 
## [12] (2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol
## [13] N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine          
## [14] 3,7,3',4'-TETRAHYDROXYFLAVONE                                                                 
## [15] 4,4'-BIS([H]METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL                                     
## [16] Gabapentin Enacarbil                                                                          
## [17] Hexamethonium                                                                                 
## [18] Empagliflozin                                                                                 
## [19] Alirocumab                                                                                    
## [20] Potassium perchlorate                                                                         
## [21] Ertugliflozin                                                                                 
## 4426 Levels: '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine ...</code></pre>
</div>
<div id="inflammatory-bowel-diseaseibd" class="section level5">
<h5>Inflammatory Bowel Disease(IBD):</h5>
<pre class="r"><code>keywords=c('inflammatory bowel disease','gastroenteritis')
categories=c('Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents')
trait='IBD'
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)</code></pre>
<pre><code>## $plot</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre><code>## 
## $ranksum.test
## 
##  Wilcoxon rank sum test with continuity correction
## 
## data:  hits_scores and rest_scores
## W = 38638, p-value = 0.3023
## alternative hypothesis: true location shift is not equal to 0
## 
## 
## $student.test
## 
##  Welch Two Sample t-test
## 
## data:  hits_scores and rest_scores
## t = -1.9255, df = 19.445, p-value = 0.06892
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
##  -0.43459902  0.01777962
## sample estimates:
## mean of x mean of y 
## 0.3155586 0.5239683 
## 
## 
## $hits
##  [1] &quot;Mesalazine&quot;                  &quot;Morphine&quot;                   
##  [3] &quot;Beclomethasone dipropionate&quot; &quot;Betamethasone&quot;              
##  [5] &quot;Prednisone&quot;                  &quot;Hydrocortisone&quot;             
##  [7] &quot;Sulfasalazine&quot;               &quot;Loperamide&quot;                 
##  [9] &quot;Prednisolone&quot;                &quot;Neomycin&quot;                   
## [11] &quot;Cromoglicic acid&quot;            &quot;Balsalazide&quot;                
## [13] &quot;Diphenoxylate&quot;               &quot;Streptomycin&quot;               
## [15] &quot;Miconazole&quot;                  &quot;Rifaximin&quot;                  
## [17] &quot;Budesonide&quot;                  &quot;Olsalazine&quot;                 
## [19] &quot;Tixocortol&quot;                  &quot;Opium&quot;                      
## 
## $rest_high_score
##  [1] Levothyroxine                                                                                                                 
##  [2] Chloroquine                                                                                                                   
##  [3] Liotrix                                                                                                                       
##  [4] Ethylmercurithiosalicylic acid                                                                                                
##  [5] KB-141                                                                                                                        
##  [6] Galiximab                                                                                                                     
##  [7] Eprotirome                                                                                                                    
##  [8] XL844                                                                                                                         
##  [9] XL019                                                                                                                         
## [10] 4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE                                 
## [11] N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE                                            
## [12] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE                                                 
## [13] 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID                                                           
## [14] (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL                                                                       
## [15] 2-(cyclohexylamino)benzoic acid                                                                                               
## [16] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE                                        
## [17] (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE                                     
## [18] 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE                                                                 
## [19] 5-phenyl-1H-indazol-3-amine                                                                                                   
## [20] 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide                                                                    
## [21] (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL                                
## [22] 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA                                         
## [23] (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE                                         
## [24] 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE                          
## [25] 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA                                                                  
## [26] 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID                                    
## [27] 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL                                                                  
## [28] (2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol                                
## [29] (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL                                                       
## [30] (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL                            
## [31] N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE                                                                              
## [32] (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC                                                                          
## [33] 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                          
## [34] 3,7,3',4'-TETRAHYDROXYFLAVONE                                                                                                 
## [35] 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE                                                                                          
## [36] 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM                           
## [37] 4,4'-BIS([H]METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL                                                                     
## [38] 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL                                                         
## [39] 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL                                                                       
## [40] REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE
## [41] 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine                                                 
## [42] N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE                                                      
## [43] 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE                                                                    
## [44] [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone                                                               
## [45] 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol                                                                   
## [46] 6-MORPHOLIN-4-YL-9H-PURINE                                                                                                    
## [47] 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE                                                  
## [48] Gabapentin Enacarbil                                                                                                          
## [49] Alirocumab                                                                                                                    
## [50] Potassium perchlorate                                                                                                         
## 4459 Levels: '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine ...</code></pre>
</div>
<div id="type-2-diabetes" class="section level5">
<h5>Type 2 Diabetes:</h5>
<pre class="r"><code>keywords=c('anti-diabetic','insulin receptor','glucose','type 2 diabetes','type II diabetes','antihyperglycemic','anti-hyperglycemic','hypoglycemic','anti-diabetic drug','insulin resistance')
categories=c('Blood Glucose Lowering Agents','Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors','Drugs Used in Diabetes','Sodium-Glucose Transporter 2 Inhibitors')
trait='T2D'
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)</code></pre>
<pre><code>## $plot</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre><code>## 
## $ranksum.test
## 
##  Wilcoxon rank sum test with continuity correction
## 
## data:  hits_scores and rest_scores
## W = 93525, p-value = 0.003158
## alternative hypothesis: true location shift is not equal to 0
## 
## 
## $student.test
## 
##  Welch Two Sample t-test
## 
## data:  hits_scores and rest_scores
## t = -2.756, df = 55.115, p-value = 0.007918
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
##  -0.42854843 -0.06770591
## sample estimates:
## mean of x mean of y 
## 0.1976653 0.4457924 
## 
## 
## $hits
##  [1] &quot;Insulin Human&quot;     &quot;Insulin Lispro&quot;    &quot;Insulin Glargine&quot; 
##  [4] &quot;Insulin Pork&quot;      &quot;Troglitazone&quot;      &quot;Glimepiride&quot;      
##  [7] &quot;Disopyramide&quot;      &quot;Acarbose&quot;          &quot;Metformin&quot;        
## [10] &quot;Rosiglitazone&quot;     &quot;Acetohexamide&quot;     &quot;Quinine&quot;          
## [13] &quot;Miglitol&quot;          &quot;Simvastatin&quot;       &quot;Chlorpropamide&quot;   
## [16] &quot;Nateglinide&quot;       &quot;Pentamidine&quot;       &quot;Mifepristone&quot;     
## [19] &quot;Tolazamide&quot;        &quot;Repaglinide&quot;       &quot;Phenformin&quot;       
## [22] &quot;Sulfamethoxazole&quot;  &quot;Glyburide&quot;         &quot;Glipizide&quot;        
## [25] &quot;Gliclazide&quot;        &quot;Tolbutamide&quot;       &quot;Pioglitazone&quot;     
## [28] &quot;Bromocriptine&quot;     &quot;Gliquidone&quot;        &quot;Mitiglinide&quot;      
## [31] &quot;Sitagliptin&quot;       &quot;Sunitinib&quot;         &quot;Mecasermin&quot;       
## [34] &quot;Pramlintide&quot;       &quot;Insulin Aspart&quot;    &quot;Insulin Detemir&quot;  
## [37] &quot;Insulin Glulisine&quot; &quot;Glycodiazine&quot;      &quot;Tolrestat&quot;        
## [40] &quot;Vildagliptin&quot;      &quot;Voglibose&quot;         &quot;NN344&quot;            
## [43] &quot;AMG-222&quot;           &quot;KRP-104&quot;           &quot;Alogliptin&quot;       
## [46] &quot;Dapagliflozin&quot;     &quot;Saxagliptin&quot;       &quot;Gosogliptin&quot;      
## [49] &quot;Linagliptin&quot;       &quot;Canagliflozin&quot;     &quot;Empagliflozin&quot;    
## [52] &quot;Lobeglitazone&quot;     &quot;Ciglitazone&quot;       &quot;Insulin Degludec&quot; 
## [55] &quot;Dutogliptin&quot;      
## 
## $rest_high_score
##  [1] Chloroquine                                                                                                                                                                            
##  [2] Farnesol                                                                                                                                                                               
##  [3] Fexaramine                                                                                                                                                                             
##  [4] Biopterin                                                                                                                                                                              
##  [5] 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE
##  [6] Galiximab                                                                                                                                                                              
##  [7] Obinepitide                                                                                                                                                                            
##  [8] Obeticholic acid                                                                                                                                                                       
##  [9] (2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol                                                                                         
## [10] 3,7,3',4'-TETRAHYDROXYFLAVONE                                                                                                                                                          
## [11] 4,4'-BIS([H]METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL                                                                                                                              
## [12] Gabapentin Enacarbil                                                                                                                                                                   
## [13] Alirocumab                                                                                                                                                                             
## [14] Oxetacaine                                                                                                                                                                             
## 4424 Levels: '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine ...</code></pre>
<pre class="r"><code>pdf('Figures/T2D_boxplot.pdf')
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)$plot
dev.off()</code></pre>
<pre><code>## png 
##   2</code></pre>
</div>
<div id="ulcerative-colitis" class="section level5">
<h5>Ulcerative Colitis:</h5>
<pre class="r"><code>keywords=c('ulcerative colitis','corticosteroids','glucocorticoid')
categories=c('Intestinal Antiinflammatory Agents','Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents')
trait='UC'
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)</code></pre>
<pre><code>## $plot</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre><code>## 
## $ranksum.test
## 
##  Wilcoxon rank sum test with continuity correction
## 
## data:  hits_scores and rest_scores
## W = 37682, p-value = 0.2312
## alternative hypothesis: true location shift is not equal to 0
## 
## 
## $student.test
## 
##  Welch Two Sample t-test
## 
## data:  hits_scores and rest_scores
## t = -2.6553, df = 19.701, p-value = 0.01531
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
##  -0.40496991 -0.04843849
## sample estimates:
## mean of x mean of y 
## 0.3875466 0.6142508 
## 
## 
## $hits
##  [1] &quot;Mesalazine&quot;                  &quot;Morphine&quot;                   
##  [3] &quot;Beclomethasone dipropionate&quot; &quot;Betamethasone&quot;              
##  [5] &quot;Prednisone&quot;                  &quot;Hydrocortisone&quot;             
##  [7] &quot;Sulfasalazine&quot;               &quot;Loperamide&quot;                 
##  [9] &quot;Prednisolone&quot;                &quot;Neomycin&quot;                   
## [11] &quot;Cromoglicic acid&quot;            &quot;Balsalazide&quot;                
## [13] &quot;Diphenoxylate&quot;               &quot;Streptomycin&quot;               
## [15] &quot;Miconazole&quot;                  &quot;Rifaximin&quot;                  
## [17] &quot;Budesonide&quot;                  &quot;Olsalazine&quot;                 
## [19] &quot;Tixocortol&quot;                  &quot;Opium&quot;                      
## 
## $rest_high_score
##  [1] Chloroquine                                                                                                                   
##  [2] Phenacemide                                                                                                                   
##  [3] Phenazopyridine                                                                                                               
##  [4] Ethylmercurithiosalicylic acid                                                                                                
##  [5] Galiximab                                                                                                                     
##  [6] XL844                                                                                                                         
##  [7] Brivaracetam                                                                                                                  
##  [8] 4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE                                 
##  [9] N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE                                            
## [10] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE                                                 
## [11] 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID                                                           
## [12] (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL                                                                       
## [13] 2-(cyclohexylamino)benzoic acid                                                                                               
## [14] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE                                        
## [15] (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE                                     
## [16] 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE                                                                 
## [17] (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL                                
## [18] 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA                                         
## [19] (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE                                         
## [20] 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE                          
## [21] 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA                                                                  
## [22] 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID                                    
## [23] 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL                                                                  
## [24] (2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol                                
## [25] (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL                                                       
## [26] (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL                            
## [27] N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE                                                                              
## [28] (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC                                                                          
## [29] 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                          
## [30] 3,7,3',4'-TETRAHYDROXYFLAVONE                                                                                                 
## [31] 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE                                                                                          
## [32] 4,4'-BIS([H]METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL                                                                     
## [33] 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL                                                         
## [34] 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL                                                                       
## [35] REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE
## [36] 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine                                                 
## [37] N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE                                                      
## [38] 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE                                                                    
## [39] [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone                                                               
## [40] 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol                                                                   
## [41] 6-MORPHOLIN-4-YL-9H-PURINE                                                                                                    
## [42] 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE                                                  
## [43] Gabapentin Enacarbil                                                                                                          
## [44] Alirocumab                                                                                                                    
## [45] Potassium perchlorate                                                                                                         
## [46] Dichlorobenzyl alcohol                                                                                                        
## 4459 Levels: '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine ...</code></pre>
</div>
<div id="schizophrenia" class="section level5">
<h5>Schizophrenia:</h5>
<pre class="r"><code>keywords=c('schizophrenia','antipsychotic','antidepressant','psychoses')
categories=c('Antipsychotic Agents','Antipsychotic Agents (Second Generation [Atypical])')
trait='SCZ'

find_hits_to_vis(keywords,categories,trait,DB_tar,lR)</code></pre>
<pre><code>## $plot</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre><code>## 
## $ranksum.test
## 
##  Wilcoxon rank sum test with continuity correction
## 
## data:  hits_scores and rest_scores
## W = 183070, p-value = 1.601e-05
## alternative hypothesis: true location shift is not equal to 0
## 
## 
## $student.test
## 
##  Welch Two Sample t-test
## 
## data:  hits_scores and rest_scores
## t = -0.46353, df = 135.52, p-value = 0.6437
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
##  -0.08161035  0.05061762
## sample estimates:
## mean of x mean of y 
## 0.7432930 0.7587894 
## 
## 
## $hits
##  [1] &quot;Reserpine&quot;           &quot;Ziprasidone&quot;         &quot;Dapiprazole&quot;        
##  [4] &quot;Olanzapine&quot;          &quot;Clozapine&quot;           &quot;Thiethylperazine&quot;   
##  [7] &quot;Sulpiride&quot;           &quot;Loxapine&quot;            &quot;Remoxipride&quot;        
## [10] &quot;Promazine&quot;           &quot;Prochlorperazine&quot;    &quot;Droperidol&quot;         
## [13] &quot;Chlorpromazine&quot;      &quot;Haloperidol&quot;         &quot;Triflupromazine&quot;    
## [16] &quot;Amoxapine&quot;           &quot;Fluphenazine&quot;        &quot;Thioridazine&quot;       
## [19] &quot;Moricizine&quot;          &quot;Risperidone&quot;         &quot;Trifluoperazine&quot;    
## [22] &quot;Perphenazine&quot;        &quot;Flupentixol&quot;         &quot;Mesoridazine&quot;       
## [25] &quot;Acetophenazine&quot;      &quot;Promethazine&quot;        &quot;Pimozide&quot;           
## [28] &quot;Quetiapine&quot;          &quot;Aripiprazole&quot;        &quot;Chlorprothixene&quot;    
## [31] &quot;Paliperidone&quot;        &quot;Lithium&quot;             &quot;Methotrimeprazine&quot;  
## [34] &quot;Propericiazine&quot;      &quot;Acepromazine&quot;        &quot;Molindone&quot;          
## [37] &quot;Pipotiazine&quot;         &quot;Thioproperazine&quot;     &quot;Thiothixene&quot;        
## [40] &quot;Zuclopenthixol&quot;      &quot;Fluspirilene&quot;        &quot;Bifeprunox&quot;         
## [43] &quot;Iloperidone&quot;         &quot;Pimavanserin&quot;        &quot;BL-1020&quot;            
## [46] &quot;Cariprazine&quot;         &quot;Lumateperone&quot;        &quot;Sertindole&quot;         
## [49] &quot;Asenapine&quot;           &quot;Amisulpride&quot;         &quot;Lurasidone&quot;         
## [52] &quot;Perospirone&quot;         &quot;Amperozide&quot;          &quot;Brexpiprazole&quot;      
## [55] &quot;Blonanserin&quot;         &quot;Melperone&quot;           &quot;Zotepine&quot;           
## [58] &quot;Methylene blue&quot;      &quot;Pipamperone&quot;         &quot;Tetrahydropalmatine&quot;
## [61] &quot;Raclopride&quot;          &quot;Ritanserin&quot;          &quot;Tiapride&quot;           
## 
## $rest_high_score
##   [1] Lepirudin                                                                                                                                     
##   [2] Bivalirudin                                                                                                                                   
##   [3] Valsartan                                                                                                                                     
##   [4] Oseltamivir                                                                                                                                   
##   [5] Milrinone                                                                                                                                     
##   [6] Anagrelide                                                                                                                                    
##   [7] Olmesartan                                                                                                                                    
##   [8] Argatroban                                                                                                                                    
##   [9] Brimonidine                                                                                                                                   
##  [10] Aminocaproic Acid                                                                                                                             
##  [11] Azelaic Acid                                                                                                                                  
##  [12] Acetohydroxamic Acid                                                                                                                          
##  [13] Zanamivir                                                                                                                                     
##  [14] Chloroquine                                                                                                                                   
##  [15] Losartan                                                                                                                                      
##  [16] Candesartan cilexetil                                                                                                                         
##  [17] Eprosartan                                                                                                                                    
##  [18] Phenacemide                                                                                                                                   
##  [19] Proflavine                                                                                                                                    
##  [20] Dutasteride                                                                                                                                   
##  [21] Cilostazol                                                                                                                                    
##  [22] Finasteride                                                                                                                                   
##  [23] Forasartan                                                                                                                                    
##  [24] Saprisartan                                                                                                                                   
##  [25] Tasosartan                                                                                                                                    
##  [26] Phenazopyridine                                                                                                                               
##  [27] Hemi-Babim                                                                                                                                    
##  [28] M-Cresol                                                                                                                                      
##  [29] 1-{2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy}-4-(1,1,3,3-Tetramethylbutyl)Benzene                                                                   
##  [30] Phosphoaminophosphonic Acid Guanylate Ester                                                                                                   
##  [31] CP-271485                                                                                                                                     
##  [32] (5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione                                                                                                 
##  [33] N-Tridecanoic Acid                                                                                                                            
##  [34] [3-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Propyl-]-Phosphonic Acid                                                            
##  [35] 4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide      
##  [36] Ethylmercurithiosalicylic acid                                                                                                                
##  [37] 4-(1-Benzyl-3-Carbamoylmethyl-2-Methyl-1h-Indol-5-Yloxy)-Butyric Acid                                                                         
##  [38] 6-Carboxymethyluracil                                                                                                                         
##  [39] (1-Benzyl-5-methoxy-2-methyl-1H-indol-3-yl)acetic acid                                                                                        
##  [40] 3-Oxiran-2ylalanine                                                                                                                           
##  [41] PF-00356231                                                                                                                                   
##  [42] 6-Phenyl-4(R)-(7-Phenyl-Heptanoylamino)-Hexanoic Acid                                                                                         
##  [43] 5-Iodouracil                                                                                                                                  
##  [44] L-2-amino-4-methoxy-cis-but-3-enoic acid                                                                                                      
##  [45] Morpholine-4-Carboxylic Acid [1s-(2-Benzyloxy-1r-Cyano-Ethylcarbamoyl)-3-Methyl-Butyl]Amide                                                   
##  [46] Elaidoylamide                                                                                                                                 
##  [47] Morpholine-4-Carboxylic Acid (1-(3-Benzenesulfonyl-1-Phenethylallylcarbamoyl)-3-Methylbutyl)-Amide                                            
##  [48] Morpholine-4-Carboxylic Acid [1-(2-Benzylsulfanyl-1-Formyl-Ethylcarbamoyl)-2-Phenyl-Ethyl]-Amide                                              
##  [49] 2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid                                                                                                  
##  [50] 1-Octadecyl-2-Acetamido-2-Deoxy-Sn-Glycerol-3-Phosphoethylmethyl Sulfide                                                                      
##  [51] Lysophosphotidylserine                                                                                                                        
##  [52] (S)-5-(4-Benzyloxy-Phenyl)-4-(7-Phenyl-Heptanoylamino)-Pentanoic Acid                                                                         
##  [53] 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid                                       
##  [54] N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE                           
##  [55] TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE                               
##  [56] 2-(3-CHLORO-6-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-1-OXIDOPYRIDIN-2-YL)-N-[1-(3-CHLOROPHENYL)ETHYL]ACETAMIDE                    
##  [57] N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA                            
##  [58] 1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                             
##  [59] 1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                          
##  [60] Cediranib                                                                                                                                     
##  [61] Enoximone                                                                                                                                     
##  [62] Vapreotide                                                                                                                                    
##  [63] Ximelagatran                                                                                                                                  
##  [64] Galiximab                                                                                                                                     
##  [65] ND7001                                                                                                                                        
##  [66] XL844                                                                                                                                         
##  [67] Tetrodotoxin                                                                                                                                  
##  [68] Brivaracetam                                                                                                                                  
##  [69] Ramucirumab                                                                                                                                   
##  [70] FX06                                                                                                                                          
##  [71] Flovagatran                                                                                                                                   
##  [72] Varespladib methyl                                                                                                                            
##  [73] CYT006-AngQb                                                                                                                                  
##  [74] Abiraterone                                                                                                                                   
##  [75] Pegdinetanib                                                                                                                                  
##  [76] RAF-265                                                                                                                                       
##  [77] Semaxanib                                                                                                                                     
##  [78] Dabigatran etexilate                                                                                                                          
##  [79] Lanreotide                                                                                                                                    
##  [80] methyl L-phenylalaninate                                                                                                                      
##  [81] D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-prolinamide                                                    
##  [82] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide                                                       
##  [83] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide                                                        
##  [84] 4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE                                                 
##  [85] N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                   
##  [86] N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                    
##  [87] N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE                                                                           
##  [88] 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE                                                                                                 
##  [89] 6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                   
##  [90] 6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                   
##  [91] N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                        
##  [92] 1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE                                
##  [93] N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE                                                            
##  [94] N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE                                                                            
##  [95] 1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide                                                                                     
##  [96] D-leucyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                     
##  [97] D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                               
##  [98] 1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                            
##  [99] N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                 
## [100] 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide                                   
## [101] N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide                                                                                 
## [102] 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                              
## [103] D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                              
## [104] D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide                                                                                
## [105] (3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline                                                                                 
## [106] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE                                                                 
## [107] (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE                                      
## [108] D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide                                                                                               
## [109] 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID                                                                           
## [110] (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL                                                                                       
## [111] 2-(cyclohexylamino)benzoic acid                                                                                                               
## [112] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE                                                        
## [113] (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE                                                     
## [114] beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide                                                                                             
## [115] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                         
## [116] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                          
## [117] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide                                                             
## [118] 2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE                                                               
## [119] N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE                                                                                                     
## [120] N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE                                                    
## [121] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide                                                              
## [122] D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide                                                                                               
## [123] D-phenylalanyl-N-benzyl-L-prolinamide                                                                                                         
## [124] 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE                                                                                 
## [125] N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE                             
## [126] N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide                                                                                 
## [127] 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                        
## [128] (2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE                  
## [129] (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL                                                
## [130] 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA                                                         
## [131] (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE                                                         
## [132] (S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE                            
## [133] N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide                                                                    
## [134] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE                           
## [135] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE                           
## [136] N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE                                                               
## [137] 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE                                          
## [138] 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA                                                                                  
## [139] 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID                                                    
## [140] 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide                                                
## [141] N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE                                    
## [142] N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE                                                            
## [143] 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL                                                                                  
## [144] 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL                                                                                                       
## [145] 2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER                                                           
## [146] (2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol                                                
## [147] N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine                                                          
## [148] 1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE                                                                                           
## [149] 4-TERT-BUTYLBENZENESULFONIC ACID                                                                                                              
## [150] N-(biphenyl-4-ylsulfonyl)-D-leucine                                                                                                           
## [151] 3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                             
## [152] 4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE                                                                   
## [153] 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one                                                             
## [154] 1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL         
## [155] N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(MORPHOLIN-4-YLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE                   
## [156] 6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL                        
## [157] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE                                                                          
## [158] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE                                                       
## [159] 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one                                                            
## [160] N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide                                                            
## [161] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE                     
## [162] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE            
## [163] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE                   
## [164] N-(1-CYANOCYCLOPROPYL)-3-({[(2S)-5-OXOPYRROLIDIN-2-YL]METHYL}SULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE      
## [165] N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(BENZYLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-HYDROXYPHENYL)ETHYL]-L-ALANINAMIDE                          
## [166] 3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER                                                                                
## [167] (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL                                                                       
## [168] (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL                                            
## [169] N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE                                                                                              
## [170] (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC                                                                                          
## [171] 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                                          
## [172] AC-(D)PHE-PRO-BOROLYS-OH                                                                                                                      
## [173] AC-(D)PHE-PRO-BOROHOMOLYS-OH                                                                                                                  
## [174] AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH                                                                                                            
## [175] N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide                               
## [176] N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine                                                                                                
## [177] 3-(4-HYDROXY-PHENYL)PYRUVIC ACID                                                                                                              
## [178] 4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE                            
## [179] (3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE                        
## [180] 5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE                                                                   
## [181] 3,7,3',4'-TETRAHYDROXYFLAVONE                                                                                                                 
## [182] (3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE                                      
## [183] 4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE                                                                      
## [184] N~2~-1,3-BENZOXAZOL-2-YL-3-CYCLOHEXYL-N-{2-[(4-METHOXYPHENYL)AMINO]ETHYL}-L-ALANINAMIDE                                                       
## [185] N-[(1S)-1-{1-[(1R,3E)-1-ACETYLPENT-3-EN-1-YL]-1H-1,2,3-TRIAZOL-4-YL}-1,2-DIMETHYLPROPYL]BENZAMIDE                                             
## [186] 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE                                                                                                    
## [187] (1aR,8S,13S,14S,15aR)-5,13,14-trihydroxy-3-methoxy-8-methyl-8,9,13,14,15,15a-hexahydro-6H-oxireno[k][2]benzoxacyclotetradecine-6,12(1aH)-dione
## [188] N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide                                                                                             
## [189] 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide                                                                                            
## [190] N-oxo-2-(phenylsulfonylamino)ethanamide                                                                                                       
## [191] [[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE                                                                    
## [192] N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE                                                                       
## [193] N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide                        
## [194] 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE                                                                                                          
## [195] 5-ACETAMIDO-5,6-DIHYDRO-4-HYDROXY-6-ISOBUTOXY-4H-PYRAN-2-CARBOXYLIC ACID                                                                      
## [196] N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                               
## [197] 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE                                                                                              
## [198] 3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE                                                                                           
## [199] {(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate                                                         
## [200] METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE                                                                                                        
## [201] (1R)-2-[(CYANOMETHYL)AMINO]-1-({[2-(DIFLUOROMETHOXY)BENZYL]SULFONYL}METHYL)-2-OXOETHYL MORPHOLINE-4-CARBOXYLATE                               
## [202] 2-NAPHTHALENESULFONIC ACID                                                                                                                    
## [203] 4,4'-BIS([H]METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL                                                                                     
## [204] 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL                                                                         
## [205] 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL                                                                                       
## [206] [PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE                                                                                 
## [207] N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                                           
## [208] 4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE        
## [209] N-[(4-methoxyphenyl)sulfonyl]-D-alanine                                                                                                       
## [210] 2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL                                                                                               
## [211] REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE                
## [212] N-[(1S)-2-[(4-cyano-1-methylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide                                    
## [213] N-[(1S)-2-{[(1R)-2-(benzyloxy)-1-cyano-1-methylethyl]amino}-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide                          
## [214] 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine                                                                 
## [215] N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE                                                                      
## [216] 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE                                                                                    
## [217] [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone                                                                               
## [218] 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol                                                                                   
## [219] 6-MORPHOLIN-4-YL-9H-PURINE                                                                                                                    
## [220] 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE                                                                  
## [221] Azilsartan medoxomil                                                                                                                          
## [222] Gabapentin Enacarbil                                                                                                                          
## [223] Linaclotide                                                                                                                                   
## [224] Turoctocog alfa                                                                                                                               
## [225] Nicorandil                                                                                                                                    
## [226] Gimeracil                                                                                                                                     
## [227] Fimasartan                                                                                                                                    
## [228] Alirocumab                                                                                                                                    
## [229] Tipiracil                                                                                                                                     
## [230] Potassium perchlorate                                                                                                                         
## [231] Turpentine                                                                                                                                    
## [232] Antithrombin Alfa                                                                                                                             
## [233] Angiotensin II                                                                                                                                
## [234] Dichlorobenzyl alcohol                                                                                                                        
## [235] Metergoline                                                                                                                                   
## [236] Candesartan                                                                                                                                   
## 4416 Levels: '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine ...</code></pre>
<pre class="r"><code>pdf('Figures/SCZ_boxplot.pdf')
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)$plot
dev.off()</code></pre>
<pre><code>## png 
##   2</code></pre>
</div>
<div id="high-density-lipids-hdl-cholesterol" class="section level5">
<h5>High density lipids (HDL cholesterol):</h5>
<pre class="r"><code>keywords=c('cholesterol ','HDL','lipids','statins','hypercholesterolaemia','HMG-CoA')
categories=c('Anticholesteremic Agents','Hypolipidemic Agents','Lipid Modifying Agents')
trait='HDL'
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)</code></pre>
<pre><code>## $plot</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre><code>## 
## $ranksum.test
## 
##  Wilcoxon rank sum test with continuity correction
## 
## data:  hits_scores and rest_scores
## W = 81772, p-value = 0.1447
## alternative hypothesis: true location shift is not equal to 0
## 
## 
## $student.test
## 
##  Welch Two Sample t-test
## 
## data:  hits_scores and rest_scores
## t = 0.58786, df = 31.467, p-value = 0.5608
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
##  -0.4572088  0.8278202
## sample estimates:
## mean of x mean of y 
##  1.355396  1.170090 
## 
## 
## $hits
##  [1] &quot;Choline&quot;              &quot;Icosapent&quot;            &quot;Pravastatin&quot;         
##  [4] &quot;Valsartan&quot;            &quot;Ramipril&quot;             &quot;Lovastatin&quot;          
##  [7] &quot;Amlodipine&quot;           &quot;Cerivastatin&quot;         &quot;Dextrothyroxine&quot;     
## [10] &quot;Niacin&quot;               &quot;Clofibrate&quot;           &quot;Simvastatin&quot;         
## [13] &quot;Lisinopril&quot;           &quot;Perindopril&quot;          &quot;Acetylsalicylic acid&quot;
## [16] &quot;Isoniazid&quot;            &quot;Ezetimibe&quot;            &quot;Fenofibrate&quot;         
## [19] &quot;Atorvastatin&quot;         &quot;Fluvastatin&quot;          &quot;Rosuvastatin&quot;        
## [22] &quot;Gemfibrozil&quot;          &quot;Bezafibrate&quot;          &quot;Probucol&quot;            
## [25] &quot;Sulodexide&quot;           &quot;Torcetrapib&quot;          &quot;Mevastatin&quot;          
## [28] &quot;Glycine betaine&quot;      &quot;Triclosan&quot;            &quot;Pitavastatin&quot;        
## [31] &quot;Ciprofibrate&quot;         &quot;Fenofibric acid&quot;     
## 
## $rest_high_score
##   [1] Lepirudin                                                                                                                                                                              
##   [2] Bivalirudin                                                                                                                                                                            
##   [3] Glucagon recombinant                                                                                                                                                                   
##   [4] Hyaluronidase                                                                                                                                                                          
##   [5] Baclofen                                                                                                                                                                               
##   [6] Esmolol                                                                                                                                                                                
##   [7] Oseltamivir                                                                                                                                                                            
##   [8] Bethanidine                                                                                                                                                                            
##   [9] Glimepiride                                                                                                                                                                            
##  [10] Guanadrel                                                                                                                                                                              
##  [11] Pregabalin                                                                                                                                                                             
##  [12] Reboxetine                                                                                                                                                                             
##  [13] Milrinone                                                                                                                                                                              
##  [14] Anagrelide                                                                                                                                                                             
##  [15] Olmesartan                                                                                                                                                                             
##  [16] Argatroban                                                                                                                                                                             
##  [17] Ropivacaine                                                                                                                                                                            
##  [18] Bupivacaine                                                                                                                                                                            
##  [19] Gefitinib                                                                                                                                                                              
##  [20] Nitroprusside                                                                                                                                                                          
##  [21] Griseofulvin                                                                                                                                                                           
##  [22] Acetohexamide                                                                                                                                                                          
##  [23] Metocurine Iodide                                                                                                                                                                      
##  [24] Methocarbamol                                                                                                                                                                          
##  [25] Streptozocin                                                                                                                                                                           
##  [26] Brimonidine                                                                                                                                                                            
##  [27] Fosinopril                                                                                                                                                                             
##  [28] Zidovudine                                                                                                                                                                             
##  [29] Aminocaproic Acid                                                                                                                                                                      
##  [30] Trandolapril                                                                                                                                                                           
##  [31] Bentiromide                                                                                                                                                                            
##  [32] Benazepril                                                                                                                                                                             
##  [33] Azelaic Acid                                                                                                                                                                           
##  [34] Acetohydroxamic Acid                                                                                                                                                                   
##  [35] Zanamivir                                                                                                                                                                              
##  [36] Cisatracurium                                                                                                                                                                          
##  [37] Enalapril                                                                                                                                                                              
##  [38] Piperazine                                                                                                                                                                             
##  [39] Chloroquine                                                                                                                                                                            
##  [40] Dyclonine                                                                                                                                                                              
##  [41] Mecamylamine                                                                                                                                                                           
##  [42] Chlorpropamide                                                                                                                                                                         
##  [43] Losartan                                                                                                                                                                               
##  [44] Pentosan Polysulfate                                                                                                                                                                   
##  [45] Moexipril                                                                                                                                                                              
##  [46] Porfimer sodium                                                                                                                                                                        
##  [47] Nitroglycerin                                                                                                                                                                          
##  [48] Diphemanil Methylsulfate                                                                                                                                                               
##  [49] Atracurium besylate                                                                                                                                                                    
##  [50] Modafinil                                                                                                                                                                              
##  [51] Metyrosine                                                                                                                                                                             
##  [52] Tirofiban                                                                                                                                                                              
##  [53] Candesartan cilexetil                                                                                                                                                                  
##  [54] Proparacaine                                                                                                                                                                           
##  [55] Phenmetrazine                                                                                                                                                                          
##  [56] Tolazamide                                                                                                                                                                             
##  [57] Eprosartan                                                                                                                                                                             
##  [58] Quinapril                                                                                                                                                                              
##  [59] Isosorbide Dinitrate                                                                                                                                                                   
##  [60] Oxybuprocaine                                                                                                                                                                          
##  [61] Diethylpropion                                                                                                                                                                         
##  [62] Mepivacaine                                                                                                                                                                            
##  [63] Levobupivacaine                                                                                                                                                                        
##  [64] Benzocaine                                                                                                                                                                             
##  [65] Levocabastine                                                                                                                                                                          
##  [66] Phenacemide                                                                                                                                                                            
##  [67] Proflavine                                                                                                                                                                             
##  [68] Tolbutamide                                                                                                                                                                            
##  [69] Dutasteride                                                                                                                                                                            
##  [70] Diphenylpyraline                                                                                                                                                                       
##  [71] Cilostazol                                                                                                                                                                             
##  [72] Guanethidine                                                                                                                                                                           
##  [73] Rescinnamine                                                                                                                                                                           
##  [74] Levetiracetam                                                                                                                                                                          
##  [75] Lomustine                                                                                                                                                                              
##  [76] Finasteride                                                                                                                                                                            
##  [77] Gliquidone                                                                                                                                                                             
##  [78] Lisdexamfetamine                                                                                                                                                                       
##  [79] Panitumumab                                                                                                                                                                            
##  [80] Hydralazine                                                                                                                                                                            
##  [81] Corticotropin                                                                                                                                                                          
##  [82] Practolol                                                                                                                                                                              
##  [83] Insulin Aspart                                                                                                                                                                         
##  [84] Insulin Detemir                                                                                                                                                                        
##  [85] Insulin Glulisine                                                                                                                                                                      
##  [86] Vecuronium                                                                                                                                                                             
##  [87] Cilazapril                                                                                                                                                                             
##  [88] Forasartan                                                                                                                                                                             
##  [89] Saprisartan                                                                                                                                                                            
##  [90] Spirapril                                                                                                                                                                              
##  [91] Tasosartan                                                                                                                                                                             
##  [92] Glycodiazine                                                                                                                                                                           
##  [93] Phenazopyridine                                                                                                                                                                        
##  [94] Fencamfamine                                                                                                                                                                           
##  [95] Androstanedione                                                                                                                                                                        
##  [96] Cilastatin                                                                                                                                                                             
##  [97] Amyl Nitrite                                                                                                                                                                           
##  [98] Erythrityl Tetranitrate                                                                                                                                                                
##  [99] Alverine                                                                                                                                                                               
## [100] Isopropamide                                                                                                                                                                           
## [101] L-Phospholactate                                                                                                                                                                       
## [102] Hemi-Babim                                                                                                                                                                             
## [103] M-Cresol                                                                                                                                                                               
## [104] Beta-D-Glucopyranose Spirohydantoin                                                                                                                                                    
## [105] 3-Amino-8,9,10-Trihydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                   
## [106] N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide                                                                                                 
## [107] 2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride                                                                                                             
## [108] Sucrosofate                                                                                                                                                                            
## [109] Pentanal                                                                                                                                                                               
## [110] Dcka, 5,7-Dichlorokynurenic Acid                                                                                                                                                       
## [111] Balanol Analog 2                                                                                                                                                                       
## [112] Carbobenzoxy-Pro-Lys-Phe-Y(Po2)-Ala-Pro-Ome                                                                                                                                            
## [113] 1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine                                                                                                                         
## [114] 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid                                                                                                                        
## [115] S-Acetyl-Cysteine                                                                                                                                                                      
## [116] Phosphoaminophosphonic Acid Guanylate Ester                                                                                                                                            
## [117] A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor                                                                                                                         
## [118] Leucine - Reduced Carbonyl                                                                                                                                                             
## [119] CP-271485                                                                                                                                                                              
## [120] 4-Carboxycinnamic Acid                                                                                                                                                                 
## [121] Balanol Analog 8                                                                                                                                                                       
## [122] SR11254                                                                                                                                                                                
## [123] EM-1745                                                                                                                                                                                
## [124] Fluoro-Phosphite Ion                                                                                                                                                                   
## [125] N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide                                                                                        
## [126] (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine                                                                                          
## [127] 2-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Ethanesulfonic Acid                                                                                                                       
## [128] D-gluconhydroximo-1,5-lactam                                                                                                                                                           
## [129] 12-Bromododecanoic Acid                                                                                                                                                                
## [130] (R,R)-2,3-Butanediol                                                                                                                                                                   
## [131] 3,8,9,10-Tetrahydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                       
## [132] 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid                                                                                                  
## [133] 4-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic Acid                                                                                             
## [134] Farnesol                                                                                                                                                                               
## [135] Indirubin-5-Sulphonate                                                                                                                                                                 
## [136] (4s)-5-Fluoro-L-Leucine                                                                                                                                                                
## [137] Fexaramine                                                                                                                                                                             
## [138] Quinonoid 7,8-Tetrahydrobiopterin                                                                                                                                                      
## [139] 2-Deoxy-Glucose-6-Phosphate                                                                                                                                                            
## [140] Balanol Analog 1                                                                                                                                                                       
## [141] 4-Deoxy-Alpha-D-Glucose                                                                                                                                                                
## [142] C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide                                                                                                                                         
## [143] Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide                                                                                                                                         
## [144] 4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide                                               
## [145] CD564                                                                                                                                                                                  
## [146] alpha-D-glucose-1-phosphate                                                                                                                                                            
## [147] Domoic Acid                                                                                                                                                                            
## [148] Arotinoid acid                                                                                                                                                                         
## [149] Alpha-Aminoisobutyric Acid                                                                                                                                                             
## [150] 8,9,10-Trihydroxy-7-Hydroxymethyl-2-Thioxo-6-Oxa-1,3-Diaza-Spiro[4.5]Decan-4-One                                                                                                       
## [151] Quisqualate                                                                                                                                                                            
## [152] 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid                                                                                                                                 
## [153] N-Acetyl-D-Allosamine                                                                                                                                                                  
## [154] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole                                                                                                                                 
## [155] 3-Oxiran-2ylalanine                                                                                                                                                                    
## [156] N-Acetyl-N'-Beta-D-Glucopyranosyl Urea                                                                                                                                                 
## [157] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole                                                                                                                                 
## [158] 1-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine                                                                                                                                    
## [159] Dodecyl-Alpha-D-Maltoside                                                                                                                                                              
## [160] C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide                                                                                                                                           
## [161] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole                                                                                                                                    
## [162] PF-00356231                                                                                                                                                                            
## [163] 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione                                                                                                                                  
## [164] 5-Chloro-1h-Indole-2-Carboxylic Acid [1-(4-Fluorobenzyl)-2-(4-Hydroxypiperidin-1yl)-2-Oxoethyl]Amide                                                                                   
## [165] alpha-D-Xylopyranose                                                                                                                                                                   
## [166] (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester                                                                                            
## [167] 2s,4r-4-Methylglutamate                                                                                                                                                                
## [168] BMS184394                                                                                                                                                                              
## [169] 8,9,10-Trihydroxy-7-Hydroxymethyl-3-Methyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                  
## [170] 2-(Acetylamino)-2-Deoxy-6-O-Methyl-Alpha-D-Allopyranose                                                                                                                                
## [171] 3-Tyrosine                                                                                                                                                                             
## [172] L-2-amino-4-methoxy-cis-but-3-enoic acid                                                                                                                                               
## [173] Ribostamycin                                                                                                                                                                           
## [174] Argifin                                                                                                                                                                                
## [175] CRA_1144                                                                                                                                                                               
## [176] 1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose                                                                                                                                        
## [177] Beta(2-Thienyl)Alanine                                                                                                                                                                 
## [178] Vanoxerine                                                                                                                                                                             
## [179] 12-Hydroxydodecanoic Acid                                                                                                                                                              
## [180] Phosphomethylphosphonic Acid-Guanylate Ester                                                                                                                                           
## [181] Dihydrolipoic Acid                                                                                                                                                                     
## [182] N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide                                                                         
## [183] N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide                                
## [184] (2r,3r,4s,5r)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium                                                                                                                   
## [185] 5-Alpha-Androstane-3-Beta,17beta-Diol                                                                                                                                                  
## [186] Biopterin                                                                                                                                                                              
## [187] 2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid                                                                                                                                           
## [188] 1-Deoxy-1-Methoxycarbamido-Beta-D-Gluco-2-Heptulopyranosonamide                                                                                                                        
## [189] 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol                                                                                  
## [190] 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid                                                                                                                                      
## [191] 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium                                                                                                     
## [192] Balanol                                                                                                                                                                                
## [193] Lysophosphotidylserine                                                                                                                                                                 
## [194] 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide                                                                                       
## [195] S-Hydroxymethyl Glutathione                                                                                                                                                            
## [196] Heptulose-2-Phosphate                                                                                                                                                                  
## [197] N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide                                                                                                     
## [198] 4-(1-Amino-1-Carboxy-Ethyl)-Benzoic Acid                                                                                                                                               
## [199] 2-deoxy-2-fluoro-a-D-glucose                                                                                                                                                           
## [200] N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea                                                                                                                                                
## [201] 6-hydroxydopa quinone                                                                                                                                                                  
## [202] Argadin                                                                                                                                                                                
## [203] Allosamizoline                                                                                                                                                                         
## [204] 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid                                                                                
## [205] Naphthalene Trisulfonate                                                                                                                                                               
## [206] R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid                                                                                                      
## [207] 4'-Hydroxyflavanone                                                                                                                                                                    
## [208] Mercuric iodide                                                                                                                                                                        
## [209] 1-Deoxy-1-Acetylamino-Beta-D-Gluco-2-Heptulopyranosonamide                                                                                                                             
## [210] Gluconolactone                                                                                                                                                                         
## [211] (2R)-({4-[AMINO(IMINO)METHYL]PHENYL}AMINO){5-ETHOXY-2-FLUORO-3-[(3R)-TETRAHYDROFURAN-3-YLOXY]PHENYL}ACETICACID                                                                         
## [212] N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE                                                                    
## [213] 3-({1-[3-CARBAMIMIDOYL-1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-PROPYLCARBAMOYL]-2-METHYL-BUTYLSULFAMOYL}-METHYL)-BENZOIC ACID                                                              
## [214] 2-[2-ETHANESULFONYLAMINO-3-(5-PROPOXY-1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIMIDOYL-BENZYLAMIDE)                                                         
## [215] Cycloleucine                                                                                                                                                                           
## [216] 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID                                                                                                                
## [217] 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID                                                                                                                  
## [218] 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID                                                                                                              
## [219] 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID                                                                                                                
## [220] (1S,2S,3R,4S,5S)-2,3,4-TRIHYDROXY-5-(HYDROXYMETHYL)CYCLOHEXYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE                                                                              
## [221] Coumarin                                                                                                                                                                               
## [222] TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE                                                                        
## [223] 2-(3-CHLORO-6-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-1-OXIDOPYRIDIN-2-YL)-N-[1-(3-CHLOROPHENYL)ETHYL]ACETAMIDE                                                             
## [224] N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA                                                                     
## [225] 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE
## [226] 2-[2-ETHANESULFONYLAMINO-3-(1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIM IDOYL-BENZYLAMIDE)                                                                  
## [227] N-[1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-3-METHYLSULFANYL-PROPYL]-3-HYDROXY-2-PROPOXYAMINO-BUTYRAMID                                                                                     
## [228] 1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                                                                      
## [229] 1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                                                                   
## [230] ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE                                                                                                                                      
## [231] Debrisoquin                                                                                                                                                                            
## [232] Cediranib                                                                                                                                                                              
## [233] Lefradafiban                                                                                                                                                                           
## [234] Enoximone                                                                                                                                                                              
## [235] Dapoxetine                                                                                                                                                                             
## [236] Vapreotide                                                                                                                                                                             
## [237] Ximelagatran                                                                                                                                                                           
## [238] Nesiritide                                                                                                                                                                             
## [239] Altropane                                                                                                                                                                              
## [240] Lesopitron                                                                                                                                                                             
## [241] SGS-742                                                                                                                                                                                
## [242] XEN2174                                                                                                                                                                                
## [243] REV131                                                                                                                                                                                 
## [244] Ularitide                                                                                                                                                                              
## [245] SGS518                                                                                                                                                                                 
## [246] MF101                                                                                                                                                                                  
## [247] Matuzumab                                                                                                                                                                              
## [248] NN344                                                                                                                                                                                  
## [249] AT1391                                                                                                                                                                                 
## [250] XL844                                                                                                                                                                                  
## [251] GMX1777                                                                                                                                                                                
## [252] Tetrodotoxin                                                                                                                                                                           
## [253] TP-508                                                                                                                                                                                 
## [254] MN-305                                                                                                                                                                                 
## [255] Rindopepimut                                                                                                                                                                           
## [256] Amibegron                                                                                                                                                                              
## [257] Tifuvirtide                                                                                                                                                                            
## [258] Canertinib                                                                                                                                                                             
## [259] AVI-4557                                                                                                                                                                               
## [260] Pozanicline                                                                                                                                                                            
## [261] R667                                                                                                                                                                                   
## [262] Pradefovir Mesylate                                                                                                                                                                    
## [263] Pelitinib                                                                                                                                                                              
## [264] Brivaracetam                                                                                                                                                                           
## [265] Naluzotan                                                                                                                                                                              
## [266] Ramucirumab                                                                                                                                                                            
## [267] Farletuzumab                                                                                                                                                                           
## [268] FX06                                                                                                                                                                                   
## [269] Flovagatran                                                                                                                                                                            
## [270] CYT006-AngQb                                                                                                                                                                           
## [271] CNS-5161                                                                                                                                                                               
## [272] RI 624                                                                                                                                                                                 
## [273] Pegdinetanib                                                                                                                                                                           
## [274] Contulakin-G                                                                                                                                                                           
## [275] RAF-265                                                                                                                                                                                
## [276] Obeticholic acid                                                                                                                                                                       
## [277] PRX-07034                                                                                                                                                                              
## [278] Olaratumab                                                                                                                                                                             
## [279] SUVN-502                                                                                                                                                                               
## [280] Pentaerythritol Tetranitrate                                                                                                                                                           
## [281] Solabegron                                                                                                                                                                             
## [282] Hyaluronidase (Human Recombinant)                                                                                                                                                      
## [283] Dapagliflozin                                                                                                                                                                          
## [284] Tezampanel                                                                                                                                                                             
## [285] CHGN111                                                                                                                                                                                
## [286] Xaliproden                                                                                                                                                                             
## [287] Armodafinil                                                                                                                                                                            
## [288] Semaxanib                                                                                                                                                                              
## [289] Tyloxapol                                                                                                                                                                              
## [290] Fradafiban                                                                                                                                                                             
## [291] Repinotan                                                                                                                                                                              
## [292] Robalzotan                                                                                                                                                                             
## [293] Reslizumab                                                                                                                                                                             
## [294] Mepolizumab                                                                                                                                                                            
## [295] Casopitant                                                                                                                                                                             
## [296] Denosumab                                                                                                                                                                              
## [297] Vilazodone                                                                                                                                                                             
## [298] Dabigatran etexilate                                                                                                                                                                   
## [299] Methacholine                                                                                                                                                                           
## [300] Fospropofol                                                                                                                                                                            
## [301] Bufuralol                                                                                                                                                                              
## [302] Gavestinel                                                                                                                                                                             
## [303] Lanreotide                                                                                                                                                                             
## [304] methyl L-phenylalaninate                                                                                                                                                               
## [305] D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-prolinamide                                                                                             
## [306] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide                                                                                                
## [307] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide                                                                                                 
## [308] 4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE                                                                                          
## [309] N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                            
## [310] N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                             
## [311] N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE                                                                                                                    
## [312] 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE                                                                                                                                          
## [313] 6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                                                            
## [314] 6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                                                            
## [315] N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                                                                 
## [316] 1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE                                                                         
## [317] N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE                                                                                                     
## [318] 1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                              
## [319] 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol                                                                                            
## [320] 1-[4-(hydroxymethyl)phenyl]guanidine                                                                                                                                                   
## [321] D-leucyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                              
## [322] D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                        
## [323] 1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                                     
## [324] N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                                                          
## [325] 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL                                                                                                                                    
## [326] 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide                                                                            
## [327] N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide                                                                                                                          
## [328] 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                       
## [329] 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide                                                                                         
## [330] (2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine                                                                                                         
## [331] 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                                                         
## [332] D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                                       
## [333] D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide                                                                                                                         
## [334] (3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline                                                                                                                          
## [335] 3-Hydroxypropyl 3-[(7-carbamimidoyl-1-naphthyl)carbamoyl]benzenesulfonate                                                                                                              
## [336] (1R)-2-{[AMINO(IMINO)METHYL]AMINO}-1-{4-[(4R)-4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL]PHENYL}ETHYL NICOTINATE                                                                        
## [337] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE                                                                                                          
## [338] (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE                                                                               
## [339] D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide                                                                                                                                        
## [340] 3-Fluoro-4-{[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino}benzoic acid                                                                         
## [341] 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL                                                                                                                                                    
## [342] 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID                                                                                                                    
## [343] (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol                                                                       
## [344] (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL                                                                                                                                
## [345] 2-(cyclohexylamino)benzoic acid                                                                                                                                                        
## [346] 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                                                          
## [347] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE                                                                                                                
## [348] 6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER                                                                                         
## [349] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE                                                                                                 
## [350] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE                                                                                                                   
## [351] (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE                                                                                              
## [352] beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide                                                                                                                                      
## [353] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                                                                  
## [354] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                                                                   
## [355] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide                                                                                                      
## [356] 2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE                                                                                                        
## [357] 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID                                                                                                                                              
## [358] N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE                                                                                                                                              
## [359] (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE                                                                                           
## [360] N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE                                                                                             
## [361] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide                                                                                                       
## [362] D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide                                                                                                                                        
## [363] D-phenylalanyl-N-benzyl-L-prolinamide                                                                                                                                                  
## [364] 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE                                                                                                                          
## [365] N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE                                                                      
## [366] [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile                                                                                  
## [367] N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide                                                                                                                          
## [368] 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                 
## [369] 2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE                                                                                                               
## [370] (2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE                                                           
## [371] N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE                                                                                                                       
## [372] (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL                                                                                         
## [373] 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA                                                                                                  
## [374] N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE                                                                                  
## [375] (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE                                                                                                  
## [376] [2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA                                                                                                               
## [377] N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide                                                                                                             
## [378] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE                                                                    
## [379] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE                                                                    
## [380] N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE                                                                                                        
## [381] 3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid                                                                             
## [382] 4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE                                                                                 
## [383] 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE                                                                                   
## [384] 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA                                                                                                                           
## [385] 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID                                                                                             
## [386] 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide                                                                                         
## [387] N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE                                                                             
## [388] N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE                                                                                                     
## [389] 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL                                                                                                                           
## [390] 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL                                                                                                                                                
## [391] 2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER                                                                                                    
## [392] 5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID)                                                                                                                              
## [393] (2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol                                                                                         
## [394] N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine                                                                                                   
## [395] 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE                                                                                                        
## [396] 1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE                                                                                                                                    
## [397] 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine                                                                                                                                          
## [398] 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine                                                                                                                                          
## [399] 4-TERT-BUTYLBENZENESULFONIC ACID                                                                                                                                                       
## [400] N-(biphenyl-4-ylsulfonyl)-D-leucine                                                                                                                                                    
## [401] 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione                                                                                          
## [402] 3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                                                                      
## [403] 4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE                                                                                                            
## [404] 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one                                                                                                      
## [405] 1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL                                                  
## [406] 6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL                                                                 
## [407] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE                                                                                                                   
## [408] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE                                                                                                
## [409] 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one                                                                                                     
## [410] N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide                                                                                                     
## [411] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE                                                              
## [412] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE                                                     
## [413] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE                                                            
## [414] N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE                                                                                          
## [415] S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE                                                                                                                         
## [416] N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                    
## [417] 3-phenyl-5-(1H-pyrazol-3-yl)isoxazole                                                                                                                                                  
## [418] PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-THIAZOLE                                                                                                                                                
## [419] Tranilast                                                                                                                                                                              
## [420] 4-{[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino}-2-hydroxybenzoic acid                                                                                                          
## [421] N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                        
## [422] (5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                                
## [423] 4,4'-DIPYRIDYL DISULFIDE                                                                                                                                                               
## [424] 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one                                                                                          
## [425] 3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER                                                                                                                         
## [426] SEBACIC ACID                                                                                                                                                                           
## [427] (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL                                                                                                                
## [428] (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL                                                                                     
## [429] N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE                                                                                                                                       
## [430] (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC                                                                                                                                   
## [431] 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                                                                                   
## [432] AC-(D)PHE-PRO-BOROLYS-OH                                                                                                                                                               
## [433] AC-(D)PHE-PRO-BOROHOMOLYS-OH                                                                                                                                                           
## [434] AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH                                                                                                                                                     
## [435] N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide                                                                        
## [436] N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine                                                                                                                                         
## [437] 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine                                                                                                
## [438] 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine                                                                                                   
## [439] 3-(4-HYDROXY-PHENYL)PYRUVIC ACID                                                                                                                                                       
## [440] 4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE                                                                     
## [441] (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one                                                                                                                  
## [442] 1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea                                     
## [443] (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                    
## [444] (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                              
## [445] 3,7,3',4'-TETRAHYDROXYFLAVONE                                                                                                                                                          
## [446] (3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE                                                                               
## [447] (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL                                                                                                                     
## [448] 4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE                                                                                                               
## [449] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)BENZYL)GUANIDINE                                                                                                                   
## [450] 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE                                                                                                                                             
## [451] 7-HYDROXY-4-METHYL-3-(2-HYDROXY-ETHYL)COUMARIN                                                                                                                                         
## [452] 4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE                                                                                                                            
## [453] N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide                                                                                                                                      
## [454] 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide                                                                                                                                     
## [455] N-oxo-2-(phenylsulfonylamino)ethanamide                                                                                                                                                
## [456] N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE                                                                                                    
## [457] [[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE                                                                                                             
## [458] N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE                                                                                                                
## [459] N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide                                                                 
## [460] ({[(3E)-2'-OXO-2',7'-DIHYDRO-2,3'-BIINDOL-3(7H)-YLIDENE]AMINO}OXY)ACETIC ACID                                                                                                          
## [461] 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE                                                                                                                                                   
## [462] 5-ACETAMIDO-5,6-DIHYDRO-4-HYDROXY-6-ISOBUTOXY-4H-PYRAN-2-CARBOXYLIC ACID                                                                                                               
## [463] [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID                                                                                                                         
## [464] [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER                                                                                             
## [465] 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE                                                                                              
## [466] N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide                                                                                                                
## [467] 3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide                                                                                                                                    
## [468] L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide                                                                                                                            
## [469] N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                                                                        
## [470] 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE                                                                                                                                       
## [471] 3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE                                                                                                                                    
## [472] 2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID                                                                                                       
## [473] (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol                                                                                           
## [474] {(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate                                                                                                  
## [475] METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE                                                                                                                                                 
## [476] [5-(5-Amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acid                                                                                                 
## [477] 5-AMINO-NAPHTALENE-2-MONOSULFONATE                                                                                                                                                     
## [478] 2-NAPHTHALENESULFONIC ACID                                                                                                                                                             
## [479] 2,6-dicarboxynaphthalene                                                                                                                                                               
## [480] nocodazole                                                                                                                                                                             
## [481] 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID                                                                                                                 
## [482] 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile                                                                                                             
## [483] 4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazole                                                                                                                                  
## [484] 2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline                                                                                                                 
## [485] 2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline                                                                                                                         
## [486] 2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline                                                                                                                
## [487] 6,7-DIMETHOXY-4-[(3R)-3-(2-NAPHTHYLOXY)PYRROLIDIN-1-YL]QUINAZOLINE                                                                                                                     
## [488] 6,7-DIMETHOXY-4-[(3R)-3-(QUINOXALIN-2-YLOXY)PYRROLIDIN-1-YL]QUINAZOLINE                                                                                                                
## [489] 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL                                                                                                                  
## [490] 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL                                                                                                                                
## [491] METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID                                                                                                                                        
## [492] [PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE                                                                                                                          
## [493] [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER                                                                                                      
## [494] Efaproxiral                                                                                                                                                                            
## [495] N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE                                                                                                            
## [496] (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol                                                                                     
## [497] (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol                                                                                 
## [498] N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID                                                                                                   
## [499] N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                                                                                    
## [500] 4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE                                                 
## [501] 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL                                                                                                                           
## [502] N-[(4-methoxyphenyl)sulfonyl]-D-alanine                                                                                                                                                
## [503] 1,3,5-BENZENETRICARBOXYLIC ACID                                                                                                                                                        
## [504] 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER                                                                       
## [505] REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE                                                         
## [506] ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate                                                                                                     
## [507] 3-(4-nitrophenyl)-1H-pyrazole                                                                                                                                                          
## [508] 12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one                                                                                    
## [509] 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine                                                                                                          
## [510] N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE                                                                                                               
## [511] 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE                                                                                                                             
## [512] [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone                                                                                                                        
## [513] 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol                                                                                                                            
## [514] 6-MORPHOLIN-4-YL-9H-PURINE                                                                                                                                                             
## [515] 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE                                                                                                           
## [516] 1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID                                                                                                                                                 
## [517] Azilsartan medoxomil                                                                                                                                                                   
## [518] Temocapril                                                                                                                                                                             
## [519] Gabapentin Enacarbil                                                                                                                                                                   
## [520] Linaclotide                                                                                                                                                                            
## [521] Arbaclofen                                                                                                                                                                             
## [522] Arbaclofen Placarbil                                                                                                                                                                   
## [523] Mirabegron                                                                                                                                                                             
## [524] Teduglutide                                                                                                                                                                            
## [525] Canagliflozin                                                                                                                                                                          
## [526] Hexamethonium                                                                                                                                                                          
## [527] Empagliflozin                                                                                                                                                                          
## [528] Palbociclib                                                                                                                                                                            
## [529] Turoctocog alfa                                                                                                                                                                        
## [530] Chromic chloride                                                                                                                                                                       
## [531] Oxygen                                                                                                                                                                                 
## [532] Ferric pyrophosphate                                                                                                                                                                   
## [533] Viloxazine                                                                                                                                                                             
## [534] Nicorandil                                                                                                                                                                             
## [535] Azelnidipine                                                                                                                                                                           
## [536] Pirlindole                                                                                                                                                                             
## [537] Fimasartan                                                                                                                                                                             
## [538] Trapidil                                                                                                                                                                               
## [539] Alirocumab                                                                                                                                                                             
## [540] Setiptiline                                                                                                                                                                            
## [541] Osimertinib                                                                                                                                                                            
## [542] Levobetaxolol                                                                                                                                                                          
## [543] Magnesium acetate tetrahydrate                                                                                                                                                         
## [544] Potassium perchlorate                                                                                                                                                                  
## [545] Enalaprilat                                                                                                                                                                            
## [546] Magnesium carbonate                                                                                                                                                                    
## [547] Sodium ferric gluconate complex                                                                                                                                                        
## [548] Necitumumab                                                                                                                                                                            
## [549] Insulin Degludec                                                                                                                                                                       
## [550] Butamben                                                                                                                                                                               
## [551] Antithrombin Alfa                                                                                                                                                                      
## [552] Dioxybenzone                                                                                                                                                                           
## [553] Rupatadine                                                                                                                                                                             
## [554] Amifampridine                                                                                                                                                                          
## [555] Equol                                                                                                                                                                                  
## [556] Ribociclib                                                                                                                                                                             
## [557] Depatuxizumab mafodotin                                                                                                                                                                
## [558] Icotinib                                                                                                                                                                               
## [559] Ertugliflozin                                                                                                                                                                          
## [560] Neratinib                                                                                                                                                                              
## [561] Angiotensin II                                                                                                                                                                         
## [562] Abemaciclib                                                                                                                                                                            
## [563] Ulimorelin                                                                                                                                                                             
## [564] Zalutumumab                                                                                                                                                                            
## [565] Oxetacaine                                                                                                                                                                             
## [566] Sparsentan                                                                                                                                                                             
## [567] Daporinad                                                                                                                                                                              
## [568] Tertomotide                                                                                                                                                                            
## [569] Gossypol                                                                                                                                                                               
## [570] Macimorelin                                                                                                                                                                            
## [571] Olmutinib                                                                                                                                                                              
## [572] Zofenopril                                                                                                                                                                             
## [573] Dichlorobenzyl alcohol                                                                                                                                                                 
## [574] Metergoline                                                                                                                                                                            
## [575] Xamoterol                                                                                                                                                                              
## [576] Candesartan                                                                                                                                                                            
## [577] Nonacog beta pegol                                                                                                                                                                     
## [578] Burosumab                                                                                                                                                                              
## [579] Eptinezumab                                                                                                                                                                            
## [580] Fremanezumab                                                                                                                                                                           
## [581] Galcanezumab                                                                                                                                                                           
## 4447 Levels: '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine ...</code></pre>
<pre class="r"><code>pdf('Figures/HDL_boxplot.pdf')
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)$plot
dev.off()</code></pre>
<pre><code>## png 
##   2</code></pre>
</div>
<div id="low-density-lipids-ldl-cholesterol" class="section level5">
<h5>Low density lipids (LDL cholesterol):</h5>
<pre class="r"><code>keywords=c('cholesterol ','LDL','lipids','statins','hypercholesterolaemia','HMG-CoA')
categories=c('Anticholesteremic Agents','Hypolipidemic Agents','Lipid Modifying Agents')
trait='LDL'
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)</code></pre>
<pre><code>## $plot</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre><code>## 
## $ranksum.test
## 
##  Wilcoxon rank sum test with continuity correction
## 
## data:  hits_scores and rest_scores
## W = 42862, p-value = 0.0001021
## alternative hypothesis: true location shift is not equal to 0
## 
## 
## $student.test
## 
##  Welch Two Sample t-test
## 
## data:  hits_scores and rest_scores
## t = -2.1721, df = 31.457, p-value = 0.0375
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
##  -1.32815353 -0.04221799
## sample estimates:
## mean of x mean of y 
## 0.4877235 1.1729093 
## 
## 
## $hits
##  [1] &quot;Choline&quot;              &quot;Icosapent&quot;            &quot;Pravastatin&quot;         
##  [4] &quot;Valsartan&quot;            &quot;Ramipril&quot;             &quot;Lovastatin&quot;          
##  [7] &quot;Amlodipine&quot;           &quot;Cerivastatin&quot;         &quot;Dextrothyroxine&quot;     
## [10] &quot;Niacin&quot;               &quot;Clofibrate&quot;           &quot;Simvastatin&quot;         
## [13] &quot;Lisinopril&quot;           &quot;Perindopril&quot;          &quot;Acetylsalicylic acid&quot;
## [16] &quot;Isoniazid&quot;            &quot;Ezetimibe&quot;            &quot;Fenofibrate&quot;         
## [19] &quot;Atorvastatin&quot;         &quot;Fluvastatin&quot;          &quot;Rosuvastatin&quot;        
## [22] &quot;Gemfibrozil&quot;          &quot;Bezafibrate&quot;          &quot;Probucol&quot;            
## [25] &quot;Sulodexide&quot;           &quot;Torcetrapib&quot;          &quot;Mevastatin&quot;          
## [28] &quot;Glycine betaine&quot;      &quot;Triclosan&quot;            &quot;Pitavastatin&quot;        
## [31] &quot;Ciprofibrate&quot;         &quot;Fenofibric acid&quot;     
## 
## $rest_high_score
##   [1] Lepirudin                                                                                                                                                                              
##   [2] Bivalirudin                                                                                                                                                                            
##   [3] Glucagon recombinant                                                                                                                                                                   
##   [4] Hyaluronidase                                                                                                                                                                          
##   [5] Baclofen                                                                                                                                                                               
##   [6] Esmolol                                                                                                                                                                                
##   [7] Oseltamivir                                                                                                                                                                            
##   [8] Bethanidine                                                                                                                                                                            
##   [9] Glimepiride                                                                                                                                                                            
##  [10] Guanadrel                                                                                                                                                                              
##  [11] Pregabalin                                                                                                                                                                             
##  [12] Reboxetine                                                                                                                                                                             
##  [13] Milrinone                                                                                                                                                                              
##  [14] Anagrelide                                                                                                                                                                             
##  [15] Olmesartan                                                                                                                                                                             
##  [16] Argatroban                                                                                                                                                                             
##  [17] Ropivacaine                                                                                                                                                                            
##  [18] Bupivacaine                                                                                                                                                                            
##  [19] Gefitinib                                                                                                                                                                              
##  [20] Nitroprusside                                                                                                                                                                          
##  [21] Griseofulvin                                                                                                                                                                           
##  [22] Acetohexamide                                                                                                                                                                          
##  [23] Metocurine Iodide                                                                                                                                                                      
##  [24] Methocarbamol                                                                                                                                                                          
##  [25] Streptozocin                                                                                                                                                                           
##  [26] Brimonidine                                                                                                                                                                            
##  [27] Fosinopril                                                                                                                                                                             
##  [28] Zidovudine                                                                                                                                                                             
##  [29] Aminocaproic Acid                                                                                                                                                                      
##  [30] Trandolapril                                                                                                                                                                           
##  [31] Bentiromide                                                                                                                                                                            
##  [32] Benazepril                                                                                                                                                                             
##  [33] Azelaic Acid                                                                                                                                                                           
##  [34] Acetohydroxamic Acid                                                                                                                                                                   
##  [35] Zanamivir                                                                                                                                                                              
##  [36] Cisatracurium                                                                                                                                                                          
##  [37] Enalapril                                                                                                                                                                              
##  [38] Piperazine                                                                                                                                                                             
##  [39] Chloroquine                                                                                                                                                                            
##  [40] Dyclonine                                                                                                                                                                              
##  [41] Mecamylamine                                                                                                                                                                           
##  [42] Chlorpropamide                                                                                                                                                                         
##  [43] Losartan                                                                                                                                                                               
##  [44] Pentosan Polysulfate                                                                                                                                                                   
##  [45] Moexipril                                                                                                                                                                              
##  [46] Porfimer sodium                                                                                                                                                                        
##  [47] Nitroglycerin                                                                                                                                                                          
##  [48] Diphemanil Methylsulfate                                                                                                                                                               
##  [49] Atracurium besylate                                                                                                                                                                    
##  [50] Modafinil                                                                                                                                                                              
##  [51] Metyrosine                                                                                                                                                                             
##  [52] Tirofiban                                                                                                                                                                              
##  [53] Candesartan cilexetil                                                                                                                                                                  
##  [54] Proparacaine                                                                                                                                                                           
##  [55] Phenmetrazine                                                                                                                                                                          
##  [56] Tolazamide                                                                                                                                                                             
##  [57] Eprosartan                                                                                                                                                                             
##  [58] Quinapril                                                                                                                                                                              
##  [59] Isosorbide Dinitrate                                                                                                                                                                   
##  [60] Oxybuprocaine                                                                                                                                                                          
##  [61] Diethylpropion                                                                                                                                                                         
##  [62] Mepivacaine                                                                                                                                                                            
##  [63] Levobupivacaine                                                                                                                                                                        
##  [64] Benzocaine                                                                                                                                                                             
##  [65] Levocabastine                                                                                                                                                                          
##  [66] Phenacemide                                                                                                                                                                            
##  [67] Proflavine                                                                                                                                                                             
##  [68] Tolbutamide                                                                                                                                                                            
##  [69] Dutasteride                                                                                                                                                                            
##  [70] Diphenylpyraline                                                                                                                                                                       
##  [71] Cilostazol                                                                                                                                                                             
##  [72] Guanethidine                                                                                                                                                                           
##  [73] Rescinnamine                                                                                                                                                                           
##  [74] Levetiracetam                                                                                                                                                                          
##  [75] Lomustine                                                                                                                                                                              
##  [76] Finasteride                                                                                                                                                                            
##  [77] Gliquidone                                                                                                                                                                             
##  [78] Lisdexamfetamine                                                                                                                                                                       
##  [79] Panitumumab                                                                                                                                                                            
##  [80] Hydralazine                                                                                                                                                                            
##  [81] Corticotropin                                                                                                                                                                          
##  [82] Practolol                                                                                                                                                                              
##  [83] Insulin Aspart                                                                                                                                                                         
##  [84] Insulin Detemir                                                                                                                                                                        
##  [85] Insulin Glulisine                                                                                                                                                                      
##  [86] Vecuronium                                                                                                                                                                             
##  [87] Cilazapril                                                                                                                                                                             
##  [88] Forasartan                                                                                                                                                                             
##  [89] Saprisartan                                                                                                                                                                            
##  [90] Spirapril                                                                                                                                                                              
##  [91] Tasosartan                                                                                                                                                                             
##  [92] Glycodiazine                                                                                                                                                                           
##  [93] Phenazopyridine                                                                                                                                                                        
##  [94] Fencamfamine                                                                                                                                                                           
##  [95] Androstanedione                                                                                                                                                                        
##  [96] Cilastatin                                                                                                                                                                             
##  [97] Amyl Nitrite                                                                                                                                                                           
##  [98] Erythrityl Tetranitrate                                                                                                                                                                
##  [99] Alverine                                                                                                                                                                               
## [100] Isopropamide                                                                                                                                                                           
## [101] L-Phospholactate                                                                                                                                                                       
## [102] Hemi-Babim                                                                                                                                                                             
## [103] M-Cresol                                                                                                                                                                               
## [104] Beta-D-Glucopyranose Spirohydantoin                                                                                                                                                    
## [105] 3-Amino-8,9,10-Trihydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                   
## [106] N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide                                                                                                 
## [107] 2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride                                                                                                             
## [108] Sucrosofate                                                                                                                                                                            
## [109] Pentanal                                                                                                                                                                               
## [110] Dcka, 5,7-Dichlorokynurenic Acid                                                                                                                                                       
## [111] Balanol Analog 2                                                                                                                                                                       
## [112] Carbobenzoxy-Pro-Lys-Phe-Y(Po2)-Ala-Pro-Ome                                                                                                                                            
## [113] 1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine                                                                                                                         
## [114] 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid                                                                                                                        
## [115] S-Acetyl-Cysteine                                                                                                                                                                      
## [116] Phosphoaminophosphonic Acid Guanylate Ester                                                                                                                                            
## [117] A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor                                                                                                                         
## [118] Leucine - Reduced Carbonyl                                                                                                                                                             
## [119] CP-271485                                                                                                                                                                              
## [120] 4-Carboxycinnamic Acid                                                                                                                                                                 
## [121] Balanol Analog 8                                                                                                                                                                       
## [122] Zinc Trihydroxide                                                                                                                                                                      
## [123] SR11254                                                                                                                                                                                
## [124] EM-1745                                                                                                                                                                                
## [125] Fluoro-Phosphite Ion                                                                                                                                                                   
## [126] N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide                                                                                        
## [127] (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine                                                                                          
## [128] 2-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Ethanesulfonic Acid                                                                                                                       
## [129] D-gluconhydroximo-1,5-lactam                                                                                                                                                           
## [130] 12-Bromododecanoic Acid                                                                                                                                                                
## [131] (R,R)-2,3-Butanediol                                                                                                                                                                   
## [132] 3,8,9,10-Tetrahydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                       
## [133] 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid                                                                                                  
## [134] S-(2,4-dinitrophenyl)glutathione                                                                                                                                                       
## [135] 4-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic Acid                                                                                             
## [136] Farnesol                                                                                                                                                                               
## [137] Indirubin-5-Sulphonate                                                                                                                                                                 
## [138] (4s)-5-Fluoro-L-Leucine                                                                                                                                                                
## [139] Fexaramine                                                                                                                                                                             
## [140] Quinonoid 7,8-Tetrahydrobiopterin                                                                                                                                                      
## [141] 2-Deoxy-Glucose-6-Phosphate                                                                                                                                                            
## [142] Balanol Analog 1                                                                                                                                                                       
## [143] 4-Deoxy-Alpha-D-Glucose                                                                                                                                                                
## [144] C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide                                                                                                                                         
## [145] Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide                                                                                                                                         
## [146] 4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide                                               
## [147] CD564                                                                                                                                                                                  
## [148] alpha-D-glucose-1-phosphate                                                                                                                                                            
## [149] Domoic Acid                                                                                                                                                                            
## [150] Arotinoid acid                                                                                                                                                                         
## [151] Alpha-Aminoisobutyric Acid                                                                                                                                                             
## [152] 8,9,10-Trihydroxy-7-Hydroxymethyl-2-Thioxo-6-Oxa-1,3-Diaza-Spiro[4.5]Decan-4-One                                                                                                       
## [153] Quisqualate                                                                                                                                                                            
## [154] S-Octylglutathione                                                                                                                                                                     
## [155] 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid                                                                                                                                 
## [156] N-Acetyl-D-Allosamine                                                                                                                                                                  
## [157] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole                                                                                                                                 
## [158] 3-Oxiran-2ylalanine                                                                                                                                                                    
## [159] N-Acetyl-N'-Beta-D-Glucopyranosyl Urea                                                                                                                                                 
## [160] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole                                                                                                                                 
## [161] 1-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine                                                                                                                                    
## [162] Dodecyl-Alpha-D-Maltoside                                                                                                                                                              
## [163] C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide                                                                                                                                           
## [164] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole                                                                                                                                    
## [165] PF-00356231                                                                                                                                                                            
## [166] 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione                                                                                                                                  
## [167] 5-Chloro-1h-Indole-2-Carboxylic Acid [1-(4-Fluorobenzyl)-2-(4-Hydroxypiperidin-1yl)-2-Oxoethyl]Amide                                                                                   
## [168] alpha-D-Xylopyranose                                                                                                                                                                   
## [169] (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester                                                                                            
## [170] 2s,4r-4-Methylglutamate                                                                                                                                                                
## [171] BMS184394                                                                                                                                                                              
## [172] 8,9,10-Trihydroxy-7-Hydroxymethyl-3-Methyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                  
## [173] 2-(Acetylamino)-2-Deoxy-6-O-Methyl-Alpha-D-Allopyranose                                                                                                                                
## [174] 3-Tyrosine                                                                                                                                                                             
## [175] L-2-amino-4-methoxy-cis-but-3-enoic acid                                                                                                                                               
## [176] Ribostamycin                                                                                                                                                                           
## [177] Argifin                                                                                                                                                                                
## [178] CRA_1144                                                                                                                                                                               
## [179] 1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose                                                                                                                                        
## [180] Beta(2-Thienyl)Alanine                                                                                                                                                                 
## [181] Vanoxerine                                                                                                                                                                             
## [182] 12-Hydroxydodecanoic Acid                                                                                                                                                              
## [183] 1-Hydroxy-2-S-Glutathionyl-3-Para-Nitrophenoxy-Propane                                                                                                                                 
## [184] Phosphomethylphosphonic Acid-Guanylate Ester                                                                                                                                           
## [185] Dihydrolipoic Acid                                                                                                                                                                     
## [186] N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide                                                                         
## [187] N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide                                
## [188] (2r,3r,4s,5r)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium                                                                                                                   
## [189] 5-Alpha-Androstane-3-Beta,17beta-Diol                                                                                                                                                  
## [190] Biopterin                                                                                                                                                                              
## [191] 2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid                                                                                                                                           
## [192] 1-Deoxy-1-Methoxycarbamido-Beta-D-Gluco-2-Heptulopyranosonamide                                                                                                                        
## [193] 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol                                                                                  
## [194] 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid                                                                                                                                      
## [195] 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium                                                                                                     
## [196] Balanol                                                                                                                                                                                
## [197] Lysophosphotidylserine                                                                                                                                                                 
## [198] 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide                                                                                       
## [199] S-Hydroxymethyl Glutathione                                                                                                                                                            
## [200] (9S,10S)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene                                                                                                                        
## [201] Heptulose-2-Phosphate                                                                                                                                                                  
## [202] N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide                                                                                                     
## [203] 4-(1-Amino-1-Carboxy-Ethyl)-Benzoic Acid                                                                                                                                               
## [204] 2-deoxy-2-fluoro-a-D-glucose                                                                                                                                                           
## [205] N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea                                                                                                                                                
## [206] 6-hydroxydopa quinone                                                                                                                                                                  
## [207] Argadin                                                                                                                                                                                
## [208] Allosamizoline                                                                                                                                                                         
## [209] 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid                                                                                
## [210] Naphthalene Trisulfonate                                                                                                                                                               
## [211] R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid                                                                                                      
## [212] 4'-Hydroxyflavanone                                                                                                                                                                    
## [213] Mercuric iodide                                                                                                                                                                        
## [214] 1-Deoxy-1-Acetylamino-Beta-D-Gluco-2-Heptulopyranosonamide                                                                                                                             
## [215] Gluconolactone                                                                                                                                                                         
## [216] (2R)-({4-[AMINO(IMINO)METHYL]PHENYL}AMINO){5-ETHOXY-2-FLUORO-3-[(3R)-TETRAHYDROFURAN-3-YLOXY]PHENYL}ACETICACID                                                                         
## [217] N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE                                                                    
## [218] 3-({1-[3-CARBAMIMIDOYL-1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-PROPYLCARBAMOYL]-2-METHYL-BUTYLSULFAMOYL}-METHYL)-BENZOIC ACID                                                              
## [219] 2-[2-ETHANESULFONYLAMINO-3-(5-PROPOXY-1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIMIDOYL-BENZYLAMIDE)                                                         
## [220] Cycloleucine                                                                                                                                                                           
## [221] 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID                                                                                                                
## [222] 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID                                                                                                                  
## [223] 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID                                                                                                              
## [224] 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID                                                                                                                
## [225] (1S,2S,3R,4S,5S)-2,3,4-TRIHYDROXY-5-(HYDROXYMETHYL)CYCLOHEXYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE                                                                              
## [226] Coumarin                                                                                                                                                                               
## [227] TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE                                                                        
## [228] S-METHYL-GLUTATHIONE                                                                                                                                                                   
## [229] 2-(3-CHLORO-6-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-1-OXIDOPYRIDIN-2-YL)-N-[1-(3-CHLOROPHENYL)ETHYL]ACETAMIDE                                                             
## [230] N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA                                                                     
## [231] 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE
## [232] 2-[2-ETHANESULFONYLAMINO-3-(1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIM IDOYL-BENZYLAMIDE)                                                                  
## [233] N-[1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-3-METHYLSULFANYL-PROPYL]-3-HYDROXY-2-PROPOXYAMINO-BUTYRAMID                                                                                     
## [234] 1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                                                                      
## [235] 1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                                                                   
## [236] ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE                                                                                                                                      
## [237] Debrisoquin                                                                                                                                                                            
## [238] Cediranib                                                                                                                                                                              
## [239] Lefradafiban                                                                                                                                                                           
## [240] Enoximone                                                                                                                                                                              
## [241] Dapoxetine                                                                                                                                                                             
## [242] Vapreotide                                                                                                                                                                             
## [243] Ximelagatran                                                                                                                                                                           
## [244] Nesiritide                                                                                                                                                                             
## [245] Altropane                                                                                                                                                                              
## [246] Lesopitron                                                                                                                                                                             
## [247] SGS-742                                                                                                                                                                                
## [248] XEN2174                                                                                                                                                                                
## [249] REV131                                                                                                                                                                                 
## [250] Ularitide                                                                                                                                                                              
## [251] SGS518                                                                                                                                                                                 
## [252] MF101                                                                                                                                                                                  
## [253] Matuzumab                                                                                                                                                                              
## [254] NN344                                                                                                                                                                                  
## [255] AT1391                                                                                                                                                                                 
## [256] XL844                                                                                                                                                                                  
## [257] AT2220                                                                                                                                                                                 
## [258] GMX1777                                                                                                                                                                                
## [259] Tetrodotoxin                                                                                                                                                                           
## [260] TP-508                                                                                                                                                                                 
## [261] MN-305                                                                                                                                                                                 
## [262] Rindopepimut                                                                                                                                                                           
## [263] Amibegron                                                                                                                                                                              
## [264] Tifuvirtide                                                                                                                                                                            
## [265] Canertinib                                                                                                                                                                             
## [266] AVI-4557                                                                                                                                                                               
## [267] Pozanicline                                                                                                                                                                            
## [268] R667                                                                                                                                                                                   
## [269] Pradefovir Mesylate                                                                                                                                                                    
## [270] Pelitinib                                                                                                                                                                              
## [271] Brivaracetam                                                                                                                                                                           
## [272] Naluzotan                                                                                                                                                                              
## [273] Ramucirumab                                                                                                                                                                            
## [274] FX06                                                                                                                                                                                   
## [275] Flovagatran                                                                                                                                                                            
## [276] CYT006-AngQb                                                                                                                                                                           
## [277] CNS-5161                                                                                                                                                                               
## [278] RI 624                                                                                                                                                                                 
## [279] Pegdinetanib                                                                                                                                                                           
## [280] Contulakin-G                                                                                                                                                                           
## [281] RAF-265                                                                                                                                                                                
## [282] Obeticholic acid                                                                                                                                                                       
## [283] PRX-07034                                                                                                                                                                              
## [284] Olaratumab                                                                                                                                                                             
## [285] SUVN-502                                                                                                                                                                               
## [286] Pentaerythritol Tetranitrate                                                                                                                                                           
## [287] Solabegron                                                                                                                                                                             
## [288] Hyaluronidase (Human Recombinant)                                                                                                                                                      
## [289] Dapagliflozin                                                                                                                                                                          
## [290] Tezampanel                                                                                                                                                                             
## [291] CHGN111                                                                                                                                                                                
## [292] Xaliproden                                                                                                                                                                             
## [293] Armodafinil                                                                                                                                                                            
## [294] Semaxanib                                                                                                                                                                              
## [295] Fradafiban                                                                                                                                                                             
## [296] Repinotan                                                                                                                                                                              
## [297] Robalzotan                                                                                                                                                                             
## [298] Reslizumab                                                                                                                                                                             
## [299] Mepolizumab                                                                                                                                                                            
## [300] Casopitant                                                                                                                                                                             
## [301] Denosumab                                                                                                                                                                              
## [302] Vilazodone                                                                                                                                                                             
## [303] Dabigatran etexilate                                                                                                                                                                   
## [304] Methacholine                                                                                                                                                                           
## [305] Fospropofol                                                                                                                                                                            
## [306] Bufuralol                                                                                                                                                                              
## [307] Gavestinel                                                                                                                                                                             
## [308] Lanreotide                                                                                                                                                                             
## [309] methyl L-phenylalaninate                                                                                                                                                               
## [310] D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-prolinamide                                                                                             
## [311] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide                                                                                                
## [312] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide                                                                                                 
## [313] 4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE                                                                                          
## [314] N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                            
## [315] N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                             
## [316] N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE                                                                                                                    
## [317] 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE                                                                                                                                          
## [318] 6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                                                            
## [319] 6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                                                            
## [320] N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                                                                 
## [321] 1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE                                                                         
## [322] N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE                                                                                                     
## [323] 1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                              
## [324] 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol                                                                                            
## [325] 1-[4-(hydroxymethyl)phenyl]guanidine                                                                                                                                                   
## [326] D-leucyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                              
## [327] D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                        
## [328] 1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                                     
## [329] N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                                                          
## [330] 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL                                                                                                                                    
## [331] 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide                                                                            
## [332] N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide                                                                                                                          
## [333] 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                       
## [334] 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide                                                                                         
## [335] (2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine                                                                                                         
## [336] 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                                                         
## [337] D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                                       
## [338] D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide                                                                                                                         
## [339] (3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline                                                                                                                          
## [340] 3-Hydroxypropyl 3-[(7-carbamimidoyl-1-naphthyl)carbamoyl]benzenesulfonate                                                                                                              
## [341] (1R)-2-{[AMINO(IMINO)METHYL]AMINO}-1-{4-[(4R)-4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL]PHENYL}ETHYL NICOTINATE                                                                        
## [342] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE                                                                                                          
## [343] (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE                                                                               
## [344] D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide                                                                                                                                        
## [345] 3-Fluoro-4-{[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino}benzoic acid                                                                         
## [346] 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL                                                                                                                                                    
## [347] 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID                                                                                                                    
## [348] (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol                                                                       
## [349] (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL                                                                                                                                
## [350] 2-(cyclohexylamino)benzoic acid                                                                                                                                                        
## [351] 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                                                          
## [352] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE                                                                                                                
## [353] 6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER                                                                                         
## [354] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE                                                                                                 
## [355] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE                                                                                                                   
## [356] (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE                                                                                              
## [357] beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide                                                                                                                                      
## [358] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                                                                  
## [359] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                                                                   
## [360] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide                                                                                                      
## [361] 2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE                                                                                                        
## [362] 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID                                                                                                                                              
## [363] N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE                                                                                                                                              
## [364] (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE                                                                                           
## [365] N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE                                                                                             
## [366] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide                                                                                                       
## [367] D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide                                                                                                                                        
## [368] D-phenylalanyl-N-benzyl-L-prolinamide                                                                                                                                                  
## [369] 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE                                                                                                                          
## [370] N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE                                                                      
## [371] [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile                                                                                  
## [372] N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide                                                                                                                          
## [373] 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                 
## [374] 2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE                                                                                                               
## [375] (2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE                                                           
## [376] N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE                                                                                                                       
## [377] (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL                                                                                         
## [378] 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA                                                                                                  
## [379] N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE                                                                                  
## [380] (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE                                                                                                  
## [381] [2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA                                                                                                               
## [382] N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide                                                                                                             
## [383] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE                                                                    
## [384] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE                                                                    
## [385] N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE                                                                                                        
## [386] 3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid                                                                             
## [387] 4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE                                                                                 
## [388] 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE                                                                                   
## [389] 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA                                                                                                                           
## [390] 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID                                                                                             
## [391] 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide                                                                                         
## [392] N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE                                                                             
## [393] N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE                                                                                                     
## [394] 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL                                                                                                                           
## [395] 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL                                                                                                                                                
## [396] 2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER                                                                                                    
## [397] 5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID)                                                                                                                              
## [398] (2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol                                                                                         
## [399] N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine                                                                                                   
## [400] 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE                                                                                                        
## [401] 1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE                                                                                                                                    
## [402] 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine                                                                                                                                          
## [403] 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine                                                                                                                                          
## [404] 4-TERT-BUTYLBENZENESULFONIC ACID                                                                                                                                                       
## [405] N-(biphenyl-4-ylsulfonyl)-D-leucine                                                                                                                                                    
## [406] 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione                                                                                          
## [407] 3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                                                                      
## [408] 4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE                                                                                                            
## [409] 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one                                                                                                      
## [410] 1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL                                                  
## [411] 6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL                                                                 
## [412] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE                                                                                                                   
## [413] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE                                                                                                
## [414] 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one                                                                                                     
## [415] N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide                                                                                                     
## [416] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE                                                              
## [417] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE                                                     
## [418] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE                                                            
## [419] N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE                                                                                          
## [420] S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE                                                                                                                         
## [421] N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                    
## [422] 3-phenyl-5-(1H-pyrazol-3-yl)isoxazole                                                                                                                                                  
## [423] PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-THIAZOLE                                                                                                                                                
## [424] Tranilast                                                                                                                                                                              
## [425] 4-{[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino}-2-hydroxybenzoic acid                                                                                                          
## [426] N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                        
## [427] (5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                                
## [428] 4,4'-DIPYRIDYL DISULFIDE                                                                                                                                                               
## [429] 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one                                                                                          
## [430] 3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER                                                                                                                         
## [431] SEBACIC ACID                                                                                                                                                                           
## [432] (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL                                                                                                                
## [433] (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL                                                                                     
## [434] N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE                                                                                                                                       
## [435] (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC                                                                                                                                   
## [436] 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                                                                                   
## [437] AC-(D)PHE-PRO-BOROLYS-OH                                                                                                                                                               
## [438] AC-(D)PHE-PRO-BOROHOMOLYS-OH                                                                                                                                                           
## [439] AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH                                                                                                                                                     
## [440] N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide                                                                        
## [441] N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine                                                                                                                                         
## [442] 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine                                                                                                
## [443] 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine                                                                                                   
## [444] 3-(4-HYDROXY-PHENYL)PYRUVIC ACID                                                                                                                                                       
## [445] 4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE                                                                     
## [446] (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one                                                                                                                  
## [447] 1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea                                     
## [448] (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                    
## [449] (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                              
## [450] 3,7,3',4'-TETRAHYDROXYFLAVONE                                                                                                                                                          
## [451] (3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE                                                                               
## [452] (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL                                                                                                                     
## [453] 4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE                                                                                                               
## [454] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)BENZYL)GUANIDINE                                                                                                                   
## [455] 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE                                                                                                                                             
## [456] 7-HYDROXY-4-METHYL-3-(2-HYDROXY-ETHYL)COUMARIN                                                                                                                                         
## [457] 4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE                                                                                                                            
## [458] N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide                                                                                                                                      
## [459] 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide                                                                                                                                     
## [460] N-oxo-2-(phenylsulfonylamino)ethanamide                                                                                                                                                
## [461] N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE                                                                                                    
## [462] [[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE                                                                                                             
## [463] N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE                                                                                                                
## [464] N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide                                                                 
## [465] ({[(3E)-2'-OXO-2',7'-DIHYDRO-2,3'-BIINDOL-3(7H)-YLIDENE]AMINO}OXY)ACETIC ACID                                                                                                          
## [466] 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE                                                                                                                                                   
## [467] 5-ACETAMIDO-5,6-DIHYDRO-4-HYDROXY-6-ISOBUTOXY-4H-PYRAN-2-CARBOXYLIC ACID                                                                                                               
## [468] [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID                                                                                                                         
## [469] [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER                                                                                             
## [470] 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE                                                                                              
## [471] N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide                                                                                                                
## [472] 3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide                                                                                                                                    
## [473] L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide                                                                                                                            
## [474] N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                                                                        
## [475] 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE                                                                                                                                       
## [476] 3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE                                                                                                                                    
## [477] 2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID                                                                                                       
## [478] (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol                                                                                           
## [479] {(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate                                                                                                  
## [480] METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE                                                                                                                                                 
## [481] [5-(5-Amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acid                                                                                                 
## [482] 5-AMINO-NAPHTALENE-2-MONOSULFONATE                                                                                                                                                     
## [483] 2-NAPHTHALENESULFONIC ACID                                                                                                                                                             
## [484] 2,6-dicarboxynaphthalene                                                                                                                                                               
## [485] nocodazole                                                                                                                                                                             
## [486] 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID                                                                                                                 
## [487] 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile                                                                                                             
## [488] 4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazole                                                                                                                                  
## [489] 2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline                                                                                                                 
## [490] 2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline                                                                                                                         
## [491] 2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline                                                                                                                
## [492] 6,7-DIMETHOXY-4-[(3R)-3-(2-NAPHTHYLOXY)PYRROLIDIN-1-YL]QUINAZOLINE                                                                                                                     
## [493] 6,7-DIMETHOXY-4-[(3R)-3-(QUINOXALIN-2-YLOXY)PYRROLIDIN-1-YL]QUINAZOLINE                                                                                                                
## [494] 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL                                                                                                                  
## [495] 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL                                                                                                                                
## [496] METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID                                                                                                                                        
## [497] [PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE                                                                                                                          
## [498] [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER                                                                                                      
## [499] Efaproxiral                                                                                                                                                                            
## [500] N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE                                                                                                            
## [501] (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol                                                                                     
## [502] (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol                                                                                 
## [503] N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID                                                                                                   
## [504] N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                                                                                    
## [505] 4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE                                                 
## [506] 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL                                                                                                                           
## [507] N-[(4-methoxyphenyl)sulfonyl]-D-alanine                                                                                                                                                
## [508] 1,3,5-BENZENETRICARBOXYLIC ACID                                                                                                                                                        
## [509] 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER                                                                       
## [510] REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE                                                         
## [511] ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate                                                                                                     
## [512] 3-(4-nitrophenyl)-1H-pyrazole                                                                                                                                                          
## [513] 12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one                                                                                    
## [514] 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine                                                                                                          
## [515] N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE                                                                                                               
## [516] 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE                                                                                                                             
## [517] [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone                                                                                                                        
## [518] 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol                                                                                                                            
## [519] 6-MORPHOLIN-4-YL-9H-PURINE                                                                                                                                                             
## [520] 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE                                                                                                           
## [521] 1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID                                                                                                                                                 
## [522] Azilsartan medoxomil                                                                                                                                                                   
## [523] Temocapril                                                                                                                                                                             
## [524] Gabapentin Enacarbil                                                                                                                                                                   
## [525] Linaclotide                                                                                                                                                                            
## [526] Arbaclofen                                                                                                                                                                             
## [527] Arbaclofen Placarbil                                                                                                                                                                   
## [528] Mirabegron                                                                                                                                                                             
## [529] Teduglutide                                                                                                                                                                            
## [530] Canagliflozin                                                                                                                                                                          
## [531] Hexamethonium                                                                                                                                                                          
## [532] Empagliflozin                                                                                                                                                                          
## [533] Palbociclib                                                                                                                                                                            
## [534] Turoctocog alfa                                                                                                                                                                        
## [535] Chromic chloride                                                                                                                                                                       
## [536] Oxygen                                                                                                                                                                                 
## [537] Ferric pyrophosphate                                                                                                                                                                   
## [538] Viloxazine                                                                                                                                                                             
## [539] Nicorandil                                                                                                                                                                             
## [540] Azelnidipine                                                                                                                                                                           
## [541] Pirlindole                                                                                                                                                                             
## [542] Fimasartan                                                                                                                                                                             
## [543] Trapidil                                                                                                                                                                               
## [544] Alirocumab                                                                                                                                                                             
## [545] Setiptiline                                                                                                                                                                            
## [546] Osimertinib                                                                                                                                                                            
## [547] Levobetaxolol                                                                                                                                                                          
## [548] Magnesium acetate tetrahydrate                                                                                                                                                         
## [549] Potassium perchlorate                                                                                                                                                                  
## [550] Enalaprilat                                                                                                                                                                            
## [551] Magnesium carbonate                                                                                                                                                                    
## [552] Sodium ferric gluconate complex                                                                                                                                                        
## [553] Necitumumab                                                                                                                                                                            
## [554] Insulin Degludec                                                                                                                                                                       
## [555] Butamben                                                                                                                                                                               
## [556] Antithrombin Alfa                                                                                                                                                                      
## [557] Dioxybenzone                                                                                                                                                                           
## [558] Rupatadine                                                                                                                                                                             
## [559] Amifampridine                                                                                                                                                                          
## [560] Equol                                                                                                                                                                                  
## [561] Ribociclib                                                                                                                                                                             
## [562] Depatuxizumab mafodotin                                                                                                                                                                
## [563] Icotinib                                                                                                                                                                               
## [564] Ertugliflozin                                                                                                                                                                          
## [565] Neratinib                                                                                                                                                                              
## [566] Angiotensin II                                                                                                                                                                         
## [567] Abemaciclib                                                                                                                                                                            
## [568] Ulimorelin                                                                                                                                                                             
## [569] Zalutumumab                                                                                                                                                                            
## [570] Oxetacaine                                                                                                                                                                             
## [571] Sparsentan                                                                                                                                                                             
## [572] Daporinad                                                                                                                                                                              
## [573] Tertomotide                                                                                                                                                                            
## [574] Gossypol                                                                                                                                                                               
## [575] Macimorelin                                                                                                                                                                            
## [576] Olmutinib                                                                                                                                                                              
## [577] Zofenopril                                                                                                                                                                             
## [578] Dichlorobenzyl alcohol                                                                                                                                                                 
## [579] Metergoline                                                                                                                                                                            
## [580] Xamoterol                                                                                                                                                                              
## [581] Candesartan                                                                                                                                                                            
## [582] Nonacog beta pegol                                                                                                                                                                     
## [583] Burosumab                                                                                                                                                                              
## [584] Eptinezumab                                                                                                                                                                            
## [585] Fremanezumab                                                                                                                                                                           
## [586] Galcanezumab                                                                                                                                                                           
## 4447 Levels: '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine ...</code></pre>
</div>
<div id="tc-total-cholesterol" class="section level5">
<h5>TC (total cholesterol):</h5>
<pre class="r"><code>keywords=c('cholesterol ','HDL','LDL','lipids','statins','hypercholesterolaemia','HMG-CoA')
categories=c('Anticholesteremic Agents','Hypolipidemic Agents','Lipid Modifying Agents')
trait='TC'
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)</code></pre>
<pre><code>## $plot</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre><code>## 
## $ranksum.test
## 
##  Wilcoxon rank sum test with continuity correction
## 
## data:  hits_scores and rest_scores
## W = 39764, p-value = 1.624e-05
## alternative hypothesis: true location shift is not equal to 0
## 
## 
## $student.test
## 
##  Welch Two Sample t-test
## 
## data:  hits_scores and rest_scores
## t = -2.3733, df = 31.441, p-value = 0.02392
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
##  -1.4141162 -0.1073693
## sample estimates:
## mean of x mean of y 
##  0.429735  1.190478 
## 
## 
## $hits
##  [1] &quot;Choline&quot;              &quot;Icosapent&quot;            &quot;Pravastatin&quot;         
##  [4] &quot;Valsartan&quot;            &quot;Ramipril&quot;             &quot;Lovastatin&quot;          
##  [7] &quot;Amlodipine&quot;           &quot;Cerivastatin&quot;         &quot;Dextrothyroxine&quot;     
## [10] &quot;Niacin&quot;               &quot;Clofibrate&quot;           &quot;Simvastatin&quot;         
## [13] &quot;Lisinopril&quot;           &quot;Perindopril&quot;          &quot;Acetylsalicylic acid&quot;
## [16] &quot;Isoniazid&quot;            &quot;Ezetimibe&quot;            &quot;Fenofibrate&quot;         
## [19] &quot;Atorvastatin&quot;         &quot;Fluvastatin&quot;          &quot;Rosuvastatin&quot;        
## [22] &quot;Gemfibrozil&quot;          &quot;Bezafibrate&quot;          &quot;Probucol&quot;            
## [25] &quot;Sulodexide&quot;           &quot;Torcetrapib&quot;          &quot;Mevastatin&quot;          
## [28] &quot;Glycine betaine&quot;      &quot;Triclosan&quot;            &quot;Pitavastatin&quot;        
## [31] &quot;Ciprofibrate&quot;         &quot;Fenofibric acid&quot;     
## 
## $rest_high_score
##   [1] Lepirudin                                                                                                                                                                              
##   [2] Bivalirudin                                                                                                                                                                            
##   [3] Glucagon recombinant                                                                                                                                                                   
##   [4] Hyaluronidase                                                                                                                                                                          
##   [5] Baclofen                                                                                                                                                                               
##   [6] Esmolol                                                                                                                                                                                
##   [7] Oseltamivir                                                                                                                                                                            
##   [8] Bethanidine                                                                                                                                                                            
##   [9] Glimepiride                                                                                                                                                                            
##  [10] Guanadrel                                                                                                                                                                              
##  [11] Pregabalin                                                                                                                                                                             
##  [12] Reboxetine                                                                                                                                                                             
##  [13] Milrinone                                                                                                                                                                              
##  [14] Anagrelide                                                                                                                                                                             
##  [15] Olmesartan                                                                                                                                                                             
##  [16] Argatroban                                                                                                                                                                             
##  [17] Ropivacaine                                                                                                                                                                            
##  [18] Bupivacaine                                                                                                                                                                            
##  [19] Gefitinib                                                                                                                                                                              
##  [20] Nitroprusside                                                                                                                                                                          
##  [21] Griseofulvin                                                                                                                                                                           
##  [22] Acetohexamide                                                                                                                                                                          
##  [23] Metocurine Iodide                                                                                                                                                                      
##  [24] Methocarbamol                                                                                                                                                                          
##  [25] Streptozocin                                                                                                                                                                           
##  [26] Brimonidine                                                                                                                                                                            
##  [27] Fosinopril                                                                                                                                                                             
##  [28] Zidovudine                                                                                                                                                                             
##  [29] Aminocaproic Acid                                                                                                                                                                      
##  [30] Trandolapril                                                                                                                                                                           
##  [31] Bentiromide                                                                                                                                                                            
##  [32] Benazepril                                                                                                                                                                             
##  [33] Azelaic Acid                                                                                                                                                                           
##  [34] Acetohydroxamic Acid                                                                                                                                                                   
##  [35] Zanamivir                                                                                                                                                                              
##  [36] Cisatracurium                                                                                                                                                                          
##  [37] Enalapril                                                                                                                                                                              
##  [38] Piperazine                                                                                                                                                                             
##  [39] Chloroquine                                                                                                                                                                            
##  [40] Dyclonine                                                                                                                                                                              
##  [41] Mecamylamine                                                                                                                                                                           
##  [42] Chlorpropamide                                                                                                                                                                         
##  [43] Losartan                                                                                                                                                                               
##  [44] Pentosan Polysulfate                                                                                                                                                                   
##  [45] Moexipril                                                                                                                                                                              
##  [46] Porfimer sodium                                                                                                                                                                        
##  [47] Nitroglycerin                                                                                                                                                                          
##  [48] Diphemanil Methylsulfate                                                                                                                                                               
##  [49] Atracurium besylate                                                                                                                                                                    
##  [50] Modafinil                                                                                                                                                                              
##  [51] Metyrosine                                                                                                                                                                             
##  [52] Tirofiban                                                                                                                                                                              
##  [53] Candesartan cilexetil                                                                                                                                                                  
##  [54] Proparacaine                                                                                                                                                                           
##  [55] Phenmetrazine                                                                                                                                                                          
##  [56] Tolazamide                                                                                                                                                                             
##  [57] Eprosartan                                                                                                                                                                             
##  [58] Quinapril                                                                                                                                                                              
##  [59] Isosorbide Dinitrate                                                                                                                                                                   
##  [60] Oxybuprocaine                                                                                                                                                                          
##  [61] Diethylpropion                                                                                                                                                                         
##  [62] Mepivacaine                                                                                                                                                                            
##  [63] Levobupivacaine                                                                                                                                                                        
##  [64] Benzocaine                                                                                                                                                                             
##  [65] Levocabastine                                                                                                                                                                          
##  [66] Phenacemide                                                                                                                                                                            
##  [67] Proflavine                                                                                                                                                                             
##  [68] Tolbutamide                                                                                                                                                                            
##  [69] Dutasteride                                                                                                                                                                            
##  [70] Diphenylpyraline                                                                                                                                                                       
##  [71] Cilostazol                                                                                                                                                                             
##  [72] Guanethidine                                                                                                                                                                           
##  [73] Rescinnamine                                                                                                                                                                           
##  [74] Levetiracetam                                                                                                                                                                          
##  [75] Lomustine                                                                                                                                                                              
##  [76] Finasteride                                                                                                                                                                            
##  [77] Gliquidone                                                                                                                                                                             
##  [78] Lisdexamfetamine                                                                                                                                                                       
##  [79] Panitumumab                                                                                                                                                                            
##  [80] Hydralazine                                                                                                                                                                            
##  [81] Corticotropin                                                                                                                                                                          
##  [82] Practolol                                                                                                                                                                              
##  [83] Insulin Aspart                                                                                                                                                                         
##  [84] Insulin Detemir                                                                                                                                                                        
##  [85] Insulin Glulisine                                                                                                                                                                      
##  [86] Vecuronium                                                                                                                                                                             
##  [87] Cilazapril                                                                                                                                                                             
##  [88] Forasartan                                                                                                                                                                             
##  [89] Saprisartan                                                                                                                                                                            
##  [90] Spirapril                                                                                                                                                                              
##  [91] Tasosartan                                                                                                                                                                             
##  [92] Glycodiazine                                                                                                                                                                           
##  [93] Phenazopyridine                                                                                                                                                                        
##  [94] Fencamfamine                                                                                                                                                                           
##  [95] Androstanedione                                                                                                                                                                        
##  [96] Cilastatin                                                                                                                                                                             
##  [97] Amyl Nitrite                                                                                                                                                                           
##  [98] Erythrityl Tetranitrate                                                                                                                                                                
##  [99] Alverine                                                                                                                                                                               
## [100] Isopropamide                                                                                                                                                                           
## [101] L-Phospholactate                                                                                                                                                                       
## [102] Hemi-Babim                                                                                                                                                                             
## [103] M-Cresol                                                                                                                                                                               
## [104] Beta-D-Glucopyranose Spirohydantoin                                                                                                                                                    
## [105] 3-Amino-8,9,10-Trihydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                   
## [106] N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide                                                                                                 
## [107] 2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride                                                                                                             
## [108] Sucrosofate                                                                                                                                                                            
## [109] Pentanal                                                                                                                                                                               
## [110] Dcka, 5,7-Dichlorokynurenic Acid                                                                                                                                                       
## [111] Balanol Analog 2                                                                                                                                                                       
## [112] Carbobenzoxy-Pro-Lys-Phe-Y(Po2)-Ala-Pro-Ome                                                                                                                                            
## [113] 1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine                                                                                                                         
## [114] 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid                                                                                                                        
## [115] S-Acetyl-Cysteine                                                                                                                                                                      
## [116] Phosphoaminophosphonic Acid Guanylate Ester                                                                                                                                            
## [117] A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor                                                                                                                         
## [118] Leucine - Reduced Carbonyl                                                                                                                                                             
## [119] CP-271485                                                                                                                                                                              
## [120] 4-Carboxycinnamic Acid                                                                                                                                                                 
## [121] Balanol Analog 8                                                                                                                                                                       
## [122] Zinc Trihydroxide                                                                                                                                                                      
## [123] SR11254                                                                                                                                                                                
## [124] EM-1745                                                                                                                                                                                
## [125] Fluoro-Phosphite Ion                                                                                                                                                                   
## [126] N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide                                                                                        
## [127] (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine                                                                                          
## [128] 2-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Ethanesulfonic Acid                                                                                                                       
## [129] D-gluconhydroximo-1,5-lactam                                                                                                                                                           
## [130] 12-Bromododecanoic Acid                                                                                                                                                                
## [131] (R,R)-2,3-Butanediol                                                                                                                                                                   
## [132] 3,8,9,10-Tetrahydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                       
## [133] 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid                                                                                                  
## [134] 4-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic Acid                                                                                             
## [135] Farnesol                                                                                                                                                                               
## [136] Indirubin-5-Sulphonate                                                                                                                                                                 
## [137] (4s)-5-Fluoro-L-Leucine                                                                                                                                                                
## [138] Fexaramine                                                                                                                                                                             
## [139] Quinonoid 7,8-Tetrahydrobiopterin                                                                                                                                                      
## [140] 2-Deoxy-Glucose-6-Phosphate                                                                                                                                                            
## [141] Balanol Analog 1                                                                                                                                                                       
## [142] 4-Deoxy-Alpha-D-Glucose                                                                                                                                                                
## [143] C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide                                                                                                                                         
## [144] Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide                                                                                                                                         
## [145] 4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide                                               
## [146] CD564                                                                                                                                                                                  
## [147] alpha-D-glucose-1-phosphate                                                                                                                                                            
## [148] Domoic Acid                                                                                                                                                                            
## [149] Arotinoid acid                                                                                                                                                                         
## [150] Alpha-Aminoisobutyric Acid                                                                                                                                                             
## [151] 8,9,10-Trihydroxy-7-Hydroxymethyl-2-Thioxo-6-Oxa-1,3-Diaza-Spiro[4.5]Decan-4-One                                                                                                       
## [152] Quisqualate                                                                                                                                                                            
## [153] S-Octylglutathione                                                                                                                                                                     
## [154] 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid                                                                                                                                 
## [155] N-Acetyl-D-Allosamine                                                                                                                                                                  
## [156] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole                                                                                                                                 
## [157] 3-Oxiran-2ylalanine                                                                                                                                                                    
## [158] N-Acetyl-N'-Beta-D-Glucopyranosyl Urea                                                                                                                                                 
## [159] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole                                                                                                                                 
## [160] 1-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine                                                                                                                                    
## [161] Dodecyl-Alpha-D-Maltoside                                                                                                                                                              
## [162] C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide                                                                                                                                           
## [163] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole                                                                                                                                    
## [164] PF-00356231                                                                                                                                                                            
## [165] 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione                                                                                                                                  
## [166] 5-Chloro-1h-Indole-2-Carboxylic Acid [1-(4-Fluorobenzyl)-2-(4-Hydroxypiperidin-1yl)-2-Oxoethyl]Amide                                                                                   
## [167] alpha-D-Xylopyranose                                                                                                                                                                   
## [168] (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester                                                                                            
## [169] 2s,4r-4-Methylglutamate                                                                                                                                                                
## [170] BMS184394                                                                                                                                                                              
## [171] 8,9,10-Trihydroxy-7-Hydroxymethyl-3-Methyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                  
## [172] 2-(Acetylamino)-2-Deoxy-6-O-Methyl-Alpha-D-Allopyranose                                                                                                                                
## [173] 3-Tyrosine                                                                                                                                                                             
## [174] L-2-amino-4-methoxy-cis-but-3-enoic acid                                                                                                                                               
## [175] Ribostamycin                                                                                                                                                                           
## [176] Argifin                                                                                                                                                                                
## [177] CRA_1144                                                                                                                                                                               
## [178] 1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose                                                                                                                                        
## [179] Beta(2-Thienyl)Alanine                                                                                                                                                                 
## [180] Vanoxerine                                                                                                                                                                             
## [181] 12-Hydroxydodecanoic Acid                                                                                                                                                              
## [182] 1-Hydroxy-2-S-Glutathionyl-3-Para-Nitrophenoxy-Propane                                                                                                                                 
## [183] Phosphomethylphosphonic Acid-Guanylate Ester                                                                                                                                           
## [184] Dihydrolipoic Acid                                                                                                                                                                     
## [185] N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide                                                                         
## [186] N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide                                
## [187] (2r,3r,4s,5r)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium                                                                                                                   
## [188] 5-Alpha-Androstane-3-Beta,17beta-Diol                                                                                                                                                  
## [189] Biopterin                                                                                                                                                                              
## [190] 2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid                                                                                                                                           
## [191] 1-Deoxy-1-Methoxycarbamido-Beta-D-Gluco-2-Heptulopyranosonamide                                                                                                                        
## [192] 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol                                                                                  
## [193] 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid                                                                                                                                      
## [194] 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium                                                                                                     
## [195] Balanol                                                                                                                                                                                
## [196] Lysophosphotidylserine                                                                                                                                                                 
## [197] 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide                                                                                       
## [198] S-Hydroxymethyl Glutathione                                                                                                                                                            
## [199] (9S,10S)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene                                                                                                                        
## [200] Heptulose-2-Phosphate                                                                                                                                                                  
## [201] N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide                                                                                                     
## [202] 4-(1-Amino-1-Carboxy-Ethyl)-Benzoic Acid                                                                                                                                               
## [203] 2-deoxy-2-fluoro-a-D-glucose                                                                                                                                                           
## [204] N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea                                                                                                                                                
## [205] 6-hydroxydopa quinone                                                                                                                                                                  
## [206] Argadin                                                                                                                                                                                
## [207] Allosamizoline                                                                                                                                                                         
## [208] 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid                                                                                
## [209] Naphthalene Trisulfonate                                                                                                                                                               
## [210] R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid                                                                                                      
## [211] 4'-Hydroxyflavanone                                                                                                                                                                    
## [212] Mercuric iodide                                                                                                                                                                        
## [213] 1-Deoxy-1-Acetylamino-Beta-D-Gluco-2-Heptulopyranosonamide                                                                                                                             
## [214] Gluconolactone                                                                                                                                                                         
## [215] (2R)-({4-[AMINO(IMINO)METHYL]PHENYL}AMINO){5-ETHOXY-2-FLUORO-3-[(3R)-TETRAHYDROFURAN-3-YLOXY]PHENYL}ACETICACID                                                                         
## [216] N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE                                                                    
## [217] 3-({1-[3-CARBAMIMIDOYL-1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-PROPYLCARBAMOYL]-2-METHYL-BUTYLSULFAMOYL}-METHYL)-BENZOIC ACID                                                              
## [218] 2-[2-ETHANESULFONYLAMINO-3-(5-PROPOXY-1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIMIDOYL-BENZYLAMIDE)                                                         
## [219] Cycloleucine                                                                                                                                                                           
## [220] 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID                                                                                                                
## [221] 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID                                                                                                                  
## [222] 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID                                                                                                              
## [223] 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID                                                                                                                
## [224] (1S,2S,3R,4S,5S)-2,3,4-TRIHYDROXY-5-(HYDROXYMETHYL)CYCLOHEXYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE                                                                              
## [225] Coumarin                                                                                                                                                                               
## [226] TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE                                                                        
## [227] 2-(3-CHLORO-6-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-1-OXIDOPYRIDIN-2-YL)-N-[1-(3-CHLOROPHENYL)ETHYL]ACETAMIDE                                                             
## [228] N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA                                                                     
## [229] 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE
## [230] 2-[2-ETHANESULFONYLAMINO-3-(1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIM IDOYL-BENZYLAMIDE)                                                                  
## [231] N-[1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-3-METHYLSULFANYL-PROPYL]-3-HYDROXY-2-PROPOXYAMINO-BUTYRAMID                                                                                     
## [232] 1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                                                                      
## [233] 1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                                                                   
## [234] ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE                                                                                                                                      
## [235] Debrisoquin                                                                                                                                                                            
## [236] Cediranib                                                                                                                                                                              
## [237] Lefradafiban                                                                                                                                                                           
## [238] Enoximone                                                                                                                                                                              
## [239] Dapoxetine                                                                                                                                                                             
## [240] Vapreotide                                                                                                                                                                             
## [241] Ximelagatran                                                                                                                                                                           
## [242] Nesiritide                                                                                                                                                                             
## [243] Altropane                                                                                                                                                                              
## [244] Lesopitron                                                                                                                                                                             
## [245] SGS-742                                                                                                                                                                                
## [246] XEN2174                                                                                                                                                                                
## [247] REV131                                                                                                                                                                                 
## [248] Ularitide                                                                                                                                                                              
## [249] SGS518                                                                                                                                                                                 
## [250] MF101                                                                                                                                                                                  
## [251] Matuzumab                                                                                                                                                                              
## [252] NN344                                                                                                                                                                                  
## [253] AT1391                                                                                                                                                                                 
## [254] XL844                                                                                                                                                                                  
## [255] GMX1777                                                                                                                                                                                
## [256] Tetrodotoxin                                                                                                                                                                           
## [257] TP-508                                                                                                                                                                                 
## [258] MN-305                                                                                                                                                                                 
## [259] Rindopepimut                                                                                                                                                                           
## [260] Amibegron                                                                                                                                                                              
## [261] Tifuvirtide                                                                                                                                                                            
## [262] Canertinib                                                                                                                                                                             
## [263] AVI-4557                                                                                                                                                                               
## [264] Pozanicline                                                                                                                                                                            
## [265] R667                                                                                                                                                                                   
## [266] Pradefovir Mesylate                                                                                                                                                                    
## [267] Pelitinib                                                                                                                                                                              
## [268] Brivaracetam                                                                                                                                                                           
## [269] Naluzotan                                                                                                                                                                              
## [270] Ramucirumab                                                                                                                                                                            
## [271] FX06                                                                                                                                                                                   
## [272] Flovagatran                                                                                                                                                                            
## [273] CYT006-AngQb                                                                                                                                                                           
## [274] CNS-5161                                                                                                                                                                               
## [275] RI 624                                                                                                                                                                                 
## [276] Pegdinetanib                                                                                                                                                                           
## [277] Contulakin-G                                                                                                                                                                           
## [278] RAF-265                                                                                                                                                                                
## [279] Obeticholic acid                                                                                                                                                                       
## [280] PRX-07034                                                                                                                                                                              
## [281] Olaratumab                                                                                                                                                                             
## [282] SUVN-502                                                                                                                                                                               
## [283] Pentaerythritol Tetranitrate                                                                                                                                                           
## [284] Solabegron                                                                                                                                                                             
## [285] Hyaluronidase (Human Recombinant)                                                                                                                                                      
## [286] Dapagliflozin                                                                                                                                                                          
## [287] Tezampanel                                                                                                                                                                             
## [288] CHGN111                                                                                                                                                                                
## [289] Xaliproden                                                                                                                                                                             
## [290] Armodafinil                                                                                                                                                                            
## [291] Semaxanib                                                                                                                                                                              
## [292] Fradafiban                                                                                                                                                                             
## [293] Repinotan                                                                                                                                                                              
## [294] Robalzotan                                                                                                                                                                             
## [295] Reslizumab                                                                                                                                                                             
## [296] Mepolizumab                                                                                                                                                                            
## [297] Casopitant                                                                                                                                                                             
## [298] Denosumab                                                                                                                                                                              
## [299] Vilazodone                                                                                                                                                                             
## [300] Dabigatran etexilate                                                                                                                                                                   
## [301] Methacholine                                                                                                                                                                           
## [302] Fospropofol                                                                                                                                                                            
## [303] Bufuralol                                                                                                                                                                              
## [304] Gavestinel                                                                                                                                                                             
## [305] Lanreotide                                                                                                                                                                             
## [306] methyl L-phenylalaninate                                                                                                                                                               
## [307] D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-prolinamide                                                                                             
## [308] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide                                                                                                
## [309] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide                                                                                                 
## [310] 4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE                                                                                          
## [311] N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                            
## [312] N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                             
## [313] N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE                                                                                                                    
## [314] 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE                                                                                                                                          
## [315] 6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                                                            
## [316] 6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                                                            
## [317] N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                                                                 
## [318] 1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE                                                                         
## [319] N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE                                                                                                     
## [320] 1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                              
## [321] 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol                                                                                            
## [322] 1-[4-(hydroxymethyl)phenyl]guanidine                                                                                                                                                   
## [323] D-leucyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                              
## [324] D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                        
## [325] 1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                                     
## [326] N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                                                          
## [327] 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL                                                                                                                                    
## [328] 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide                                                                            
## [329] N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide                                                                                                                          
## [330] 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                       
## [331] 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide                                                                                         
## [332] (2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine                                                                                                         
## [333] 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                                                         
## [334] D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                                       
## [335] D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide                                                                                                                         
## [336] (3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline                                                                                                                          
## [337] 3-Hydroxypropyl 3-[(7-carbamimidoyl-1-naphthyl)carbamoyl]benzenesulfonate                                                                                                              
## [338] (1R)-2-{[AMINO(IMINO)METHYL]AMINO}-1-{4-[(4R)-4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL]PHENYL}ETHYL NICOTINATE                                                                        
## [339] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE                                                                                                          
## [340] (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE                                                                               
## [341] D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide                                                                                                                                        
## [342] 3-Fluoro-4-{[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino}benzoic acid                                                                         
## [343] 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL                                                                                                                                                    
## [344] 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID                                                                                                                    
## [345] (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol                                                                       
## [346] (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL                                                                                                                                
## [347] 2-(cyclohexylamino)benzoic acid                                                                                                                                                        
## [348] 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                                                          
## [349] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE                                                                                                                
## [350] 6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER                                                                                         
## [351] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE                                                                                                 
## [352] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE                                                                                                                   
## [353] (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE                                                                                              
## [354] beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide                                                                                                                                      
## [355] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                                                                  
## [356] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                                                                   
## [357] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide                                                                                                      
## [358] 2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE                                                                                                        
## [359] 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID                                                                                                                                              
## [360] N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE                                                                                                                                              
## [361] (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE                                                                                           
## [362] N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE                                                                                             
## [363] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide                                                                                                       
## [364] D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide                                                                                                                                        
## [365] D-phenylalanyl-N-benzyl-L-prolinamide                                                                                                                                                  
## [366] 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE                                                                                                                          
## [367] N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE                                                                      
## [368] [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile                                                                                  
## [369] N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide                                                                                                                          
## [370] 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                 
## [371] 2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE                                                                                                               
## [372] (2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE                                                           
## [373] N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE                                                                                                                       
## [374] (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL                                                                                         
## [375] 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA                                                                                                  
## [376] N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE                                                                                  
## [377] (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE                                                                                                  
## [378] [2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA                                                                                                               
## [379] N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide                                                                                                             
## [380] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE                                                                    
## [381] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE                                                                    
## [382] N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE                                                                                                        
## [383] 3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid                                                                             
## [384] 4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE                                                                                 
## [385] 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE                                                                                   
## [386] 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA                                                                                                                           
## [387] 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID                                                                                             
## [388] 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide                                                                                         
## [389] N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE                                                                             
## [390] N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE                                                                                                     
## [391] 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL                                                                                                                           
## [392] 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL                                                                                                                                                
## [393] 2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER                                                                                                    
## [394] 5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID)                                                                                                                              
## [395] (2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol                                                                                         
## [396] N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine                                                                                                   
## [397] 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE                                                                                                        
## [398] 1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE                                                                                                                                    
## [399] 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine                                                                                                                                          
## [400] 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine                                                                                                                                          
## [401] 4-TERT-BUTYLBENZENESULFONIC ACID                                                                                                                                                       
## [402] N-(biphenyl-4-ylsulfonyl)-D-leucine                                                                                                                                                    
## [403] 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione                                                                                          
## [404] 3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                                                                      
## [405] 4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE                                                                                                            
## [406] 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one                                                                                                      
## [407] 1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL                                                  
## [408] 6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL                                                                 
## [409] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE                                                                                                                   
## [410] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE                                                                                                
## [411] 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one                                                                                                     
## [412] N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide                                                                                                     
## [413] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE                                                              
## [414] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE                                                     
## [415] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE                                                            
## [416] N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE                                                                                          
## [417] S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE                                                                                                                         
## [418] N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                    
## [419] 3-phenyl-5-(1H-pyrazol-3-yl)isoxazole                                                                                                                                                  
## [420] PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-THIAZOLE                                                                                                                                                
## [421] Tranilast                                                                                                                                                                              
## [422] 4-{[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino}-2-hydroxybenzoic acid                                                                                                          
## [423] N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                        
## [424] (5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                                
## [425] 4,4'-DIPYRIDYL DISULFIDE                                                                                                                                                               
## [426] 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one                                                                                          
## [427] 3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER                                                                                                                         
## [428] SEBACIC ACID                                                                                                                                                                           
## [429] (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL                                                                                                                
## [430] (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL                                                                                     
## [431] N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE                                                                                                                                       
## [432] (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC                                                                                                                                   
## [433] 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                                                                                   
## [434] AC-(D)PHE-PRO-BOROLYS-OH                                                                                                                                                               
## [435] AC-(D)PHE-PRO-BOROHOMOLYS-OH                                                                                                                                                           
## [436] AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH                                                                                                                                                     
## [437] N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide                                                                        
## [438] N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine                                                                                                                                         
## [439] 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine                                                                                                
## [440] 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine                                                                                                   
## [441] 3-(4-HYDROXY-PHENYL)PYRUVIC ACID                                                                                                                                                       
## [442] 4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE                                                                     
## [443] (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one                                                                                                                  
## [444] 1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea                                     
## [445] (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                    
## [446] (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                              
## [447] 3,7,3',4'-TETRAHYDROXYFLAVONE                                                                                                                                                          
## [448] (3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE                                                                               
## [449] (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL                                                                                                                     
## [450] 4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE                                                                                                               
## [451] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)BENZYL)GUANIDINE                                                                                                                   
## [452] 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE                                                                                                                                             
## [453] 7-HYDROXY-4-METHYL-3-(2-HYDROXY-ETHYL)COUMARIN                                                                                                                                         
## [454] 4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE                                                                                                                            
## [455] N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide                                                                                                                                      
## [456] 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide                                                                                                                                     
## [457] N-oxo-2-(phenylsulfonylamino)ethanamide                                                                                                                                                
## [458] N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE                                                                                                    
## [459] [[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE                                                                                                             
## [460] N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE                                                                                                                
## [461] N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide                                                                 
## [462] ({[(3E)-2'-OXO-2',7'-DIHYDRO-2,3'-BIINDOL-3(7H)-YLIDENE]AMINO}OXY)ACETIC ACID                                                                                                          
## [463] 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE                                                                                                                                                   
## [464] 5-ACETAMIDO-5,6-DIHYDRO-4-HYDROXY-6-ISOBUTOXY-4H-PYRAN-2-CARBOXYLIC ACID                                                                                                               
## [465] [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID                                                                                                                         
## [466] [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER                                                                                             
## [467] 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE                                                                                              
## [468] N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide                                                                                                                
## [469] 3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide                                                                                                                                    
## [470] L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide                                                                                                                            
## [471] N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                                                                        
## [472] 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE                                                                                                                                       
## [473] 3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE                                                                                                                                    
## [474] 2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID                                                                                                       
## [475] (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol                                                                                           
## [476] {(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate                                                                                                  
## [477] METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE                                                                                                                                                 
## [478] [5-(5-Amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acid                                                                                                 
## [479] 5-AMINO-NAPHTALENE-2-MONOSULFONATE                                                                                                                                                     
## [480] 2-NAPHTHALENESULFONIC ACID                                                                                                                                                             
## [481] 2,6-dicarboxynaphthalene                                                                                                                                                               
## [482] nocodazole                                                                                                                                                                             
## [483] 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID                                                                                                                 
## [484] 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile                                                                                                             
## [485] 4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazole                                                                                                                                  
## [486] 2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline                                                                                                                 
## [487] 2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline                                                                                                                         
## [488] 2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline                                                                                                                
## [489] 6,7-DIMETHOXY-4-[(3R)-3-(2-NAPHTHYLOXY)PYRROLIDIN-1-YL]QUINAZOLINE                                                                                                                     
## [490] 6,7-DIMETHOXY-4-[(3R)-3-(QUINOXALIN-2-YLOXY)PYRROLIDIN-1-YL]QUINAZOLINE                                                                                                                
## [491] 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL                                                                                                                  
## [492] 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL                                                                                                                                
## [493] METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID                                                                                                                                        
## [494] [PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE                                                                                                                          
## [495] [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER                                                                                                      
## [496] Efaproxiral                                                                                                                                                                            
## [497] N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE                                                                                                            
## [498] (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol                                                                                     
## [499] (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol                                                                                 
## [500] N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID                                                                                                   
## [501] N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                                                                                    
## [502] 4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE                                                 
## [503] 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL                                                                                                                           
## [504] N-[(4-methoxyphenyl)sulfonyl]-D-alanine                                                                                                                                                
## [505] 1,3,5-BENZENETRICARBOXYLIC ACID                                                                                                                                                        
## [506] 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER                                                                       
## [507] REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE                                                         
## [508] ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate                                                                                                     
## [509] 3-(4-nitrophenyl)-1H-pyrazole                                                                                                                                                          
## [510] 12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one                                                                                    
## [511] 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine                                                                                                          
## [512] N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE                                                                                                               
## [513] 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE                                                                                                                             
## [514] [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone                                                                                                                        
## [515] 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol                                                                                                                            
## [516] 6-MORPHOLIN-4-YL-9H-PURINE                                                                                                                                                             
## [517] 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE                                                                                                           
## [518] 1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID                                                                                                                                                 
## [519] Azilsartan medoxomil                                                                                                                                                                   
## [520] Temocapril                                                                                                                                                                             
## [521] Gabapentin Enacarbil                                                                                                                                                                   
## [522] Linaclotide                                                                                                                                                                            
## [523] Arbaclofen                                                                                                                                                                             
## [524] Arbaclofen Placarbil                                                                                                                                                                   
## [525] Mirabegron                                                                                                                                                                             
## [526] Teduglutide                                                                                                                                                                            
## [527] Canagliflozin                                                                                                                                                                          
## [528] Hexamethonium                                                                                                                                                                          
## [529] Empagliflozin                                                                                                                                                                          
## [530] Palbociclib                                                                                                                                                                            
## [531] Turoctocog alfa                                                                                                                                                                        
## [532] Chromic chloride                                                                                                                                                                       
## [533] Oxygen                                                                                                                                                                                 
## [534] Ferric pyrophosphate                                                                                                                                                                   
## [535] Viloxazine                                                                                                                                                                             
## [536] Nicorandil                                                                                                                                                                             
## [537] Azelnidipine                                                                                                                                                                           
## [538] Pirlindole                                                                                                                                                                             
## [539] Fimasartan                                                                                                                                                                             
## [540] Trapidil                                                                                                                                                                               
## [541] Alirocumab                                                                                                                                                                             
## [542] Setiptiline                                                                                                                                                                            
## [543] Osimertinib                                                                                                                                                                            
## [544] Levobetaxolol                                                                                                                                                                          
## [545] Magnesium acetate tetrahydrate                                                                                                                                                         
## [546] Potassium perchlorate                                                                                                                                                                  
## [547] Enalaprilat                                                                                                                                                                            
## [548] Magnesium carbonate                                                                                                                                                                    
## [549] Sodium ferric gluconate complex                                                                                                                                                        
## [550] Necitumumab                                                                                                                                                                            
## [551] Insulin Degludec                                                                                                                                                                       
## [552] Butamben                                                                                                                                                                               
## [553] Antithrombin Alfa                                                                                                                                                                      
## [554] Dioxybenzone                                                                                                                                                                           
## [555] Rupatadine                                                                                                                                                                             
## [556] Amifampridine                                                                                                                                                                          
## [557] Equol                                                                                                                                                                                  
## [558] Ribociclib                                                                                                                                                                             
## [559] Depatuxizumab mafodotin                                                                                                                                                                
## [560] Icotinib                                                                                                                                                                               
## [561] Ertugliflozin                                                                                                                                                                          
## [562] Neratinib                                                                                                                                                                              
## [563] Angiotensin II                                                                                                                                                                         
## [564] Abemaciclib                                                                                                                                                                            
## [565] Ulimorelin                                                                                                                                                                             
## [566] Zalutumumab                                                                                                                                                                            
## [567] Oxetacaine                                                                                                                                                                             
## [568] Sparsentan                                                                                                                                                                             
## [569] Daporinad                                                                                                                                                                              
## [570] Tertomotide                                                                                                                                                                            
## [571] Gossypol                                                                                                                                                                               
## [572] Macimorelin                                                                                                                                                                            
## [573] Olmutinib                                                                                                                                                                              
## [574] Zofenopril                                                                                                                                                                             
## [575] Dichlorobenzyl alcohol                                                                                                                                                                 
## [576] Metergoline                                                                                                                                                                            
## [577] Xamoterol                                                                                                                                                                              
## [578] Candesartan                                                                                                                                                                            
## [579] Nonacog beta pegol                                                                                                                                                                     
## [580] Burosumab                                                                                                                                                                              
## [581] Eptinezumab                                                                                                                                                                            
## [582] Fremanezumab                                                                                                                                                                           
## [583] Galcanezumab                                                                                                                                                                           
## 4447 Levels: '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine ...</code></pre>
</div>
<div id="tg-high-triglycerid" class="section level5">
<h5>TG (High Triglycerid):</h5>
<p>Few drugs are prescribed for this disease (2 in the drugbank database):</p>
<pre class="r"><code>keywords=c('hypertriglyeridemia ','triglyceride')
categories=c('Anticholesteremic Agents')
trait='TG'
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)</code></pre>
<pre><code>## $plot</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre><code>## 
## $ranksum.test
## 
##  Wilcoxon rank sum test with continuity correction
## 
## data:  hits_scores and rest_scores
## W = 18640, p-value = 0.00894
## alternative hypothesis: true location shift is not equal to 0
## 
## 
## $student.test
## 
##  Welch Two Sample t-test
## 
## data:  hits_scores and rest_scores
## t = -8.5488, df = 14.406, p-value = 5.086e-07
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
##  -1.2947462 -0.7764722
## sample estimates:
## mean of x mean of y 
## 0.1631311 1.1987403 
## 
## 
## $hits
##  [1] &quot;Pravastatin&quot;     &quot;Lovastatin&quot;      &quot;Cerivastatin&quot;   
##  [4] &quot;Clofibrate&quot;      &quot;Simvastatin&quot;     &quot;Ezetimibe&quot;      
##  [7] &quot;Atorvastatin&quot;    &quot;Fluvastatin&quot;     &quot;Rosuvastatin&quot;   
## [10] &quot;Probucol&quot;        &quot;Torcetrapib&quot;     &quot;Mevastatin&quot;     
## [13] &quot;Pitavastatin&quot;    &quot;Fenofibric acid&quot;
## 
## $rest_high_score
##   [1] Lepirudin                                                                                                                                                                              
##   [2] Bivalirudin                                                                                                                                                                            
##   [3] Glucagon recombinant                                                                                                                                                                   
##   [4] Hyaluronidase                                                                                                                                                                          
##   [5] Valsartan                                                                                                                                                                              
##   [6] Ramipril                                                                                                                                                                               
##   [7] Baclofen                                                                                                                                                                               
##   [8] Esmolol                                                                                                                                                                                
##   [9] Oseltamivir                                                                                                                                                                            
##  [10] Bethanidine                                                                                                                                                                            
##  [11] Glimepiride                                                                                                                                                                            
##  [12] Guanadrel                                                                                                                                                                              
##  [13] Pregabalin                                                                                                                                                                             
##  [14] Reboxetine                                                                                                                                                                             
##  [15] Milrinone                                                                                                                                                                              
##  [16] Anagrelide                                                                                                                                                                             
##  [17] Olmesartan                                                                                                                                                                             
##  [18] Argatroban                                                                                                                                                                             
##  [19] Ropivacaine                                                                                                                                                                            
##  [20] Bupivacaine                                                                                                                                                                            
##  [21] Gefitinib                                                                                                                                                                              
##  [22] Nitroprusside                                                                                                                                                                          
##  [23] Griseofulvin                                                                                                                                                                           
##  [24] Acetohexamide                                                                                                                                                                          
##  [25] Metocurine Iodide                                                                                                                                                                      
##  [26] Methocarbamol                                                                                                                                                                          
##  [27] Streptozocin                                                                                                                                                                           
##  [28] Brimonidine                                                                                                                                                                            
##  [29] Fosinopril                                                                                                                                                                             
##  [30] Zidovudine                                                                                                                                                                             
##  [31] Aminocaproic Acid                                                                                                                                                                      
##  [32] Trandolapril                                                                                                                                                                           
##  [33] Bentiromide                                                                                                                                                                            
##  [34] Benazepril                                                                                                                                                                             
##  [35] Azelaic Acid                                                                                                                                                                           
##  [36] Acetohydroxamic Acid                                                                                                                                                                   
##  [37] Zanamivir                                                                                                                                                                              
##  [38] Cisatracurium                                                                                                                                                                          
##  [39] Enalapril                                                                                                                                                                              
##  [40] Piperazine                                                                                                                                                                             
##  [41] Chloroquine                                                                                                                                                                            
##  [42] Dyclonine                                                                                                                                                                              
##  [43] Mecamylamine                                                                                                                                                                           
##  [44] Chlorpropamide                                                                                                                                                                         
##  [45] Losartan                                                                                                                                                                               
##  [46] Pentosan Polysulfate                                                                                                                                                                   
##  [47] Moexipril                                                                                                                                                                              
##  [48] Porfimer sodium                                                                                                                                                                        
##  [49] Lisinopril                                                                                                                                                                             
##  [50] Nitroglycerin                                                                                                                                                                          
##  [51] Diphemanil Methylsulfate                                                                                                                                                               
##  [52] Atracurium besylate                                                                                                                                                                    
##  [53] Modafinil                                                                                                                                                                              
##  [54] Metyrosine                                                                                                                                                                             
##  [55] Tirofiban                                                                                                                                                                              
##  [56] Candesartan cilexetil                                                                                                                                                                  
##  [57] Proparacaine                                                                                                                                                                           
##  [58] Phenmetrazine                                                                                                                                                                          
##  [59] Tolazamide                                                                                                                                                                             
##  [60] Eprosartan                                                                                                                                                                             
##  [61] Quinapril                                                                                                                                                                              
##  [62] Isosorbide Dinitrate                                                                                                                                                                   
##  [63] Oxybuprocaine                                                                                                                                                                          
##  [64] Diethylpropion                                                                                                                                                                         
##  [65] Mepivacaine                                                                                                                                                                            
##  [66] Levobupivacaine                                                                                                                                                                        
##  [67] Benzocaine                                                                                                                                                                             
##  [68] Levocabastine                                                                                                                                                                          
##  [69] Phenacemide                                                                                                                                                                            
##  [70] Proflavine                                                                                                                                                                             
##  [71] Tolbutamide                                                                                                                                                                            
##  [72] Dutasteride                                                                                                                                                                            
##  [73] Diphenylpyraline                                                                                                                                                                       
##  [74] Cilostazol                                                                                                                                                                             
##  [75] Guanethidine                                                                                                                                                                           
##  [76] Rescinnamine                                                                                                                                                                           
##  [77] Levetiracetam                                                                                                                                                                          
##  [78] Lomustine                                                                                                                                                                              
##  [79] Finasteride                                                                                                                                                                            
##  [80] Gliquidone                                                                                                                                                                             
##  [81] Lisdexamfetamine                                                                                                                                                                       
##  [82] Panitumumab                                                                                                                                                                            
##  [83] Hydralazine                                                                                                                                                                            
##  [84] Corticotropin                                                                                                                                                                          
##  [85] Practolol                                                                                                                                                                              
##  [86] Insulin Aspart                                                                                                                                                                         
##  [87] Insulin Detemir                                                                                                                                                                        
##  [88] Insulin Glulisine                                                                                                                                                                      
##  [89] Vecuronium                                                                                                                                                                             
##  [90] Cilazapril                                                                                                                                                                             
##  [91] Forasartan                                                                                                                                                                             
##  [92] Saprisartan                                                                                                                                                                            
##  [93] Spirapril                                                                                                                                                                              
##  [94] Tasosartan                                                                                                                                                                             
##  [95] Glycodiazine                                                                                                                                                                           
##  [96] Phenazopyridine                                                                                                                                                                        
##  [97] Fencamfamine                                                                                                                                                                           
##  [98] Androstanedione                                                                                                                                                                        
##  [99] Cilastatin                                                                                                                                                                             
## [100] Amyl Nitrite                                                                                                                                                                           
## [101] Erythrityl Tetranitrate                                                                                                                                                                
## [102] Alverine                                                                                                                                                                               
## [103] Isopropamide                                                                                                                                                                           
## [104] L-Phospholactate                                                                                                                                                                       
## [105] Hemi-Babim                                                                                                                                                                             
## [106] M-Cresol                                                                                                                                                                               
## [107] Beta-D-Glucopyranose Spirohydantoin                                                                                                                                                    
## [108] 3-Amino-8,9,10-Trihydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                   
## [109] N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide                                                                                                 
## [110] 2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride                                                                                                             
## [111] Sucrosofate                                                                                                                                                                            
## [112] Pentanal                                                                                                                                                                               
## [113] Dcka, 5,7-Dichlorokynurenic Acid                                                                                                                                                       
## [114] Balanol Analog 2                                                                                                                                                                       
## [115] Carbobenzoxy-Pro-Lys-Phe-Y(Po2)-Ala-Pro-Ome                                                                                                                                            
## [116] 1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine                                                                                                                         
## [117] 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid                                                                                                                        
## [118] S-Acetyl-Cysteine                                                                                                                                                                      
## [119] Phosphoaminophosphonic Acid Guanylate Ester                                                                                                                                            
## [120] A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor                                                                                                                         
## [121] Leucine - Reduced Carbonyl                                                                                                                                                             
## [122] 2-Aminoethanimidic Acid                                                                                                                                                                
## [123] CP-271485                                                                                                                                                                              
## [124] 4-Carboxycinnamic Acid                                                                                                                                                                 
## [125] 3-Amino-4-Oxybenzyl-2-Butanone                                                                                                                                                         
## [126] Balanol Analog 8                                                                                                                                                                       
## [127] SR11254                                                                                                                                                                                
## [128] EM-1745                                                                                                                                                                                
## [129] Fluoro-Phosphite Ion                                                                                                                                                                   
## [130] N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide                                                                                        
## [131] (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine                                                                                          
## [132] 2-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Ethanesulfonic Acid                                                                                                                       
## [133] D-gluconhydroximo-1,5-lactam                                                                                                                                                           
## [134] 12-Bromododecanoic Acid                                                                                                                                                                
## [135] (R,R)-2,3-Butanediol                                                                                                                                                                   
## [136] 3,8,9,10-Tetrahydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                       
## [137] 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid                                                                                                  
## [138] 4-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic Acid                                                                                             
## [139] Farnesol                                                                                                                                                                               
## [140] Indirubin-5-Sulphonate                                                                                                                                                                 
## [141] (4s)-5-Fluoro-L-Leucine                                                                                                                                                                
## [142] Fexaramine                                                                                                                                                                             
## [143] Quinonoid 7,8-Tetrahydrobiopterin                                                                                                                                                      
## [144] 2-Deoxy-Glucose-6-Phosphate                                                                                                                                                            
## [145] Balanol Analog 1                                                                                                                                                                       
## [146] 4-Deoxy-Alpha-D-Glucose                                                                                                                                                                
## [147] 3-Methylphenylalanine                                                                                                                                                                  
## [148] C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide                                                                                                                                         
## [149] Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide                                                                                                                                         
## [150] 4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide                                               
## [151] CD564                                                                                                                                                                                  
## [152] alpha-D-glucose-1-phosphate                                                                                                                                                            
## [153] Domoic Acid                                                                                                                                                                            
## [154] N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline                                                                                                                              
## [155] Arotinoid acid                                                                                                                                                                         
## [156] Alpha-Aminoisobutyric Acid                                                                                                                                                             
## [157] 8,9,10-Trihydroxy-7-Hydroxymethyl-2-Thioxo-6-Oxa-1,3-Diaza-Spiro[4.5]Decan-4-One                                                                                                       
## [158] Quisqualate                                                                                                                                                                            
## [159] 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid                                                                                                                                 
## [160] N-Acetyl-D-Allosamine                                                                                                                                                                  
## [161] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole                                                                                                                                 
## [162] 3-Oxiran-2ylalanine                                                                                                                                                                    
## [163] N-Acetyl-N'-Beta-D-Glucopyranosyl Urea                                                                                                                                                 
## [164] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole                                                                                                                                 
## [165] 1-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine                                                                                                                                    
## [166] Dodecyl-Alpha-D-Maltoside                                                                                                                                                              
## [167] C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide                                                                                                                                           
## [168] 2-Pyridinethiol                                                                                                                                                                        
## [169] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole                                                                                                                                    
## [170] PF-00356231                                                                                                                                                                            
## [171] 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione                                                                                                                                  
## [172] 5-Chloro-1h-Indole-2-Carboxylic Acid [1-(4-Fluorobenzyl)-2-(4-Hydroxypiperidin-1yl)-2-Oxoethyl]Amide                                                                                   
## [173] alpha-D-Xylopyranose                                                                                                                                                                   
## [174] (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester                                                                                            
## [175] 2s,4r-4-Methylglutamate                                                                                                                                                                
## [176] BMS184394                                                                                                                                                                              
## [177] 8,9,10-Trihydroxy-7-Hydroxymethyl-3-Methyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                  
## [178] 2-(Acetylamino)-2-Deoxy-6-O-Methyl-Alpha-D-Allopyranose                                                                                                                                
## [179] 3-Tyrosine                                                                                                                                                                             
## [180] Diphenylacetic Acid                                                                                                                                                                    
## [181] L-2-amino-4-methoxy-cis-but-3-enoic acid                                                                                                                                               
## [182] Ribostamycin                                                                                                                                                                           
## [183] Argifin                                                                                                                                                                                
## [184] CRA_1144                                                                                                                                                                               
## [185] 1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose                                                                                                                                        
## [186] Beta(2-Thienyl)Alanine                                                                                                                                                                 
## [187] Vanoxerine                                                                                                                                                                             
## [188] 12-Hydroxydodecanoic Acid                                                                                                                                                              
## [189] Phosphomethylphosphonic Acid-Guanylate Ester                                                                                                                                           
## [190] Dihydrolipoic Acid                                                                                                                                                                     
## [191] N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide                                                                         
## [192] N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide                                
## [193] (2r,3r,4s,5r)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium                                                                                                                   
## [194] 5-Alpha-Androstane-3-Beta,17beta-Diol                                                                                                                                                  
## [195] Biopterin                                                                                                                                                                              
## [196] 2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid                                                                                                                                           
## [197] 1-Deoxy-1-Methoxycarbamido-Beta-D-Gluco-2-Heptulopyranosonamide                                                                                                                        
## [198] 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol                                                                                  
## [199] 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid                                                                                                                                      
## [200] 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium                                                                                                     
## [201] Balanol                                                                                                                                                                                
## [202] Lysophosphotidylserine                                                                                                                                                                 
## [203] 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide                                                                                       
## [204] S-Hydroxymethyl Glutathione                                                                                                                                                            
## [205] Heptulose-2-Phosphate                                                                                                                                                                  
## [206] N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide                                                                                                     
## [207] 4-(1-Amino-1-Carboxy-Ethyl)-Benzoic Acid                                                                                                                                               
## [208] 2-deoxy-2-fluoro-a-D-glucose                                                                                                                                                           
## [209] N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea                                                                                                                                                
## [210] 6-hydroxydopa quinone                                                                                                                                                                  
## [211] Argadin                                                                                                                                                                                
## [212] Allosamizoline                                                                                                                                                                         
## [213] 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid                                                                                
## [214] Naphthalene Trisulfonate                                                                                                                                                               
## [215] R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid                                                                                                      
## [216] 4'-Hydroxyflavanone                                                                                                                                                                    
## [217] Mercuric iodide                                                                                                                                                                        
## [218] 1-Deoxy-1-Acetylamino-Beta-D-Gluco-2-Heptulopyranosonamide                                                                                                                             
## [219] Gluconolactone                                                                                                                                                                         
## [220] N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-                                                                                                                                   
## [221] (2R)-({4-[AMINO(IMINO)METHYL]PHENYL}AMINO){5-ETHOXY-2-FLUORO-3-[(3R)-TETRAHYDROFURAN-3-YLOXY]PHENYL}ACETICACID                                                                         
## [222] N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE                                                                    
## [223] 3-({1-[3-CARBAMIMIDOYL-1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-PROPYLCARBAMOYL]-2-METHYL-BUTYLSULFAMOYL}-METHYL)-BENZOIC ACID                                                              
## [224] 2-[2-ETHANESULFONYLAMINO-3-(5-PROPOXY-1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIMIDOYL-BENZYLAMIDE)                                                         
## [225] Cycloleucine                                                                                                                                                                           
## [226] 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID                                                                                                                
## [227] 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID                                                                                                                  
## [228] 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID                                                                                                              
## [229] 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID                                                                                                                
## [230] (1S,2S,3R,4S,5S)-2,3,4-TRIHYDROXY-5-(HYDROXYMETHYL)CYCLOHEXYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE                                                                              
## [231] Coumarin                                                                                                                                                                               
## [232] TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE                                                                        
## [233] 2-(3-CHLORO-6-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-1-OXIDOPYRIDIN-2-YL)-N-[1-(3-CHLOROPHENYL)ETHYL]ACETAMIDE                                                             
## [234] N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA                                                                     
## [235] 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE
## [236] 2-[2-ETHANESULFONYLAMINO-3-(1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIM IDOYL-BENZYLAMIDE)                                                                  
## [237] N-[1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-3-METHYLSULFANYL-PROPYL]-3-HYDROXY-2-PROPOXYAMINO-BUTYRAMID                                                                                     
## [238] 1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                                                                      
## [239] 1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                                                                   
## [240] ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE                                                                                                                                      
## [241] Debrisoquin                                                                                                                                                                            
## [242] Cediranib                                                                                                                                                                              
## [243] Lefradafiban                                                                                                                                                                           
## [244] Enoximone                                                                                                                                                                              
## [245] Dapoxetine                                                                                                                                                                             
## [246] Vapreotide                                                                                                                                                                             
## [247] Ximelagatran                                                                                                                                                                           
## [248] Nesiritide                                                                                                                                                                             
## [249] Altropane                                                                                                                                                                              
## [250] Lesopitron                                                                                                                                                                             
## [251] SGS-742                                                                                                                                                                                
## [252] XEN2174                                                                                                                                                                                
## [253] REV131                                                                                                                                                                                 
## [254] Ularitide                                                                                                                                                                              
## [255] SGS518                                                                                                                                                                                 
## [256] MF101                                                                                                                                                                                  
## [257] Matuzumab                                                                                                                                                                              
## [258] NN344                                                                                                                                                                                  
## [259] AT1391                                                                                                                                                                                 
## [260] XL844                                                                                                                                                                                  
## [261] GMX1777                                                                                                                                                                                
## [262] Tetrodotoxin                                                                                                                                                                           
## [263] TP-508                                                                                                                                                                                 
## [264] MN-305                                                                                                                                                                                 
## [265] Rindopepimut                                                                                                                                                                           
## [266] Amibegron                                                                                                                                                                              
## [267] Tifuvirtide                                                                                                                                                                            
## [268] Canertinib                                                                                                                                                                             
## [269] AVI-4557                                                                                                                                                                               
## [270] Pozanicline                                                                                                                                                                            
## [271] R667                                                                                                                                                                                   
## [272] Pradefovir Mesylate                                                                                                                                                                    
## [273] Pelitinib                                                                                                                                                                              
## [274] Brivaracetam                                                                                                                                                                           
## [275] Naluzotan                                                                                                                                                                              
## [276] Ramucirumab                                                                                                                                                                            
## [277] FX06                                                                                                                                                                                   
## [278] Flovagatran                                                                                                                                                                            
## [279] CYT006-AngQb                                                                                                                                                                           
## [280] CNS-5161                                                                                                                                                                               
## [281] RI 624                                                                                                                                                                                 
## [282] Pegdinetanib                                                                                                                                                                           
## [283] Contulakin-G                                                                                                                                                                           
## [284] RAF-265                                                                                                                                                                                
## [285] Obeticholic acid                                                                                                                                                                       
## [286] PRX-07034                                                                                                                                                                              
## [287] Olaratumab                                                                                                                                                                             
## [288] SUVN-502                                                                                                                                                                               
## [289] Pentaerythritol Tetranitrate                                                                                                                                                           
## [290] Solabegron                                                                                                                                                                             
## [291] Hyaluronidase (Human Recombinant)                                                                                                                                                      
## [292] Dapagliflozin                                                                                                                                                                          
## [293] Tezampanel                                                                                                                                                                             
## [294] CHGN111                                                                                                                                                                                
## [295] Xaliproden                                                                                                                                                                             
## [296] Armodafinil                                                                                                                                                                            
## [297] Semaxanib                                                                                                                                                                              
## [298] Tyloxapol                                                                                                                                                                              
## [299] Fradafiban                                                                                                                                                                             
## [300] Repinotan                                                                                                                                                                              
## [301] Robalzotan                                                                                                                                                                             
## [302] Reslizumab                                                                                                                                                                             
## [303] Mepolizumab                                                                                                                                                                            
## [304] Casopitant                                                                                                                                                                             
## [305] Denosumab                                                                                                                                                                              
## [306] Vilazodone                                                                                                                                                                             
## [307] Dabigatran etexilate                                                                                                                                                                   
## [308] Methacholine                                                                                                                                                                           
## [309] Fospropofol                                                                                                                                                                            
## [310] Bufuralol                                                                                                                                                                              
## [311] Gavestinel                                                                                                                                                                             
## [312] Lanreotide                                                                                                                                                                             
## [313] methyl L-phenylalaninate                                                                                                                                                               
## [314] D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-prolinamide                                                                                             
## [315] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide                                                                                                
## [316] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide                                                                                                 
## [317] 4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE                                                                                          
## [318] N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                            
## [319] N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                             
## [320] N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE                                                                                                                    
## [321] 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE                                                                                                                                          
## [322] 6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                                                            
## [323] 6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                                                            
## [324] N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                                                                 
## [325] 1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE                                                                         
## [326] N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE                                                                                                     
## [327] 1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                              
## [328] 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol                                                                                            
## [329] 1-[4-(hydroxymethyl)phenyl]guanidine                                                                                                                                                   
## [330] D-leucyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                              
## [331] D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                        
## [332] 1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                                     
## [333] N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                                                          
## [334] 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL                                                                                                                                    
## [335] 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide                                                                            
## [336] N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide                                                                                                                          
## [337] 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                       
## [338] 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide                                                                                         
## [339] (2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine                                                                                                         
## [340] 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                                                         
## [341] D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                                       
## [342] D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide                                                                                                                         
## [343] (3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline                                                                                                                          
## [344] 3-Hydroxypropyl 3-[(7-carbamimidoyl-1-naphthyl)carbamoyl]benzenesulfonate                                                                                                              
## [345] (1R)-2-{[AMINO(IMINO)METHYL]AMINO}-1-{4-[(4R)-4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL]PHENYL}ETHYL NICOTINATE                                                                        
## [346] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE                                                                                                          
## [347] (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE                                                                               
## [348] D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide                                                                                                                                        
## [349] 3-Fluoro-4-{[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino}benzoic acid                                                                         
## [350] 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL                                                                                                                                                    
## [351] 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID                                                                                                                    
## [352] (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol                                                                       
## [353] (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL                                                                                                                                
## [354] 2-(cyclohexylamino)benzoic acid                                                                                                                                                        
## [355] 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                                                          
## [356] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE                                                                                                                
## [357] 6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER                                                                                         
## [358] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE                                                                                                 
## [359] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE                                                                                                                   
## [360] (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE                                                                                              
## [361] beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide                                                                                                                                      
## [362] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                                                                  
## [363] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                                                                   
## [364] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide                                                                                                      
## [365] 2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE                                                                                                        
## [366] 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID                                                                                                                                              
## [367] N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE                                                                                                                                              
## [368] (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE                                                                                           
## [369] N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE                                                                                             
## [370] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide                                                                                                       
## [371] D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide                                                                                                                                        
## [372] D-phenylalanyl-N-benzyl-L-prolinamide                                                                                                                                                  
## [373] 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE                                                                                                                          
## [374] N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE                                                                                                                       
## [375] N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE                                                                      
## [376] [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile                                                                                  
## [377] N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide                                                                                                                          
## [378] 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                 
## [379] 2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE                                                                                                               
## [380] (2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE                                                           
## [381] N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE                                                                                                                       
## [382] (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL                                                                                         
## [383] BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE                                                                                              
## [384] METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE                                                                                              
## [385] N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE                                                                                                              
## [386] N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE                                                                                                           
## [387] 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA                                                                                                  
## [388] N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE                                                                                                       
## [389] N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE                                                                                  
## [390] (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE                                                                                                  
## [391] [2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA                                                                                                               
## [392] N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide                                                                                                             
## [393] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE                                                                    
## [394] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE                                                                    
## [395] N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE                                                                                                        
## [396] 3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid                                                                             
## [397] 4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE                                                                                 
## [398] 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE                                                                                   
## [399] 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA                                                                                                                           
## [400] 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID                                                                                             
## [401] 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide                                                                                         
## [402] N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE                                                                             
## [403] N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE                                                                                                     
## [404] 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL                                                                                                                           
## [405] 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL                                                                                                                                                
## [406] 2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER                                                                                                    
## [407] 5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID)                                                                                                                              
## [408] (2S)-2-({6-[(3-amino-5-chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)-3-methylbutan-1-ol                                                                                         
## [409] N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine                                                                                                   
## [410] 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE                                                                                                        
## [411] 1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE                                                                                                                                    
## [412] 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine                                                                                                                                          
## [413] 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine                                                                                                                                          
## [414] 4-TERT-BUTYLBENZENESULFONIC ACID                                                                                                                                                       
## [415] N-(biphenyl-4-ylsulfonyl)-D-leucine                                                                                                                                                    
## [416] 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione                                                                                          
## [417] 3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                                                                      
## [418] 4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE                                                                                                            
## [419] 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one                                                                                                      
## [420] 1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL                                                  
## [421] 6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL                                                                 
## [422] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE                                                                                                                   
## [423] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE                                                                                                
## [424] 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one                                                                                                     
## [425] N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide                                                                                                     
## [426] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE                                                              
## [427] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE                                                     
## [428] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE                                                            
## [429] N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE                                                                                          
## [430] S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE                                                                                                                         
## [431] N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                    
## [432] 3-phenyl-5-(1H-pyrazol-3-yl)isoxazole                                                                                                                                                  
## [433] PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-THIAZOLE                                                                                                                                                
## [434] Tranilast                                                                                                                                                                              
## [435] 4-{[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino}-2-hydroxybenzoic acid                                                                                                          
## [436] N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                        
## [437] (5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                                
## [438] 4,4'-DIPYRIDYL DISULFIDE                                                                                                                                                               
## [439] 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one                                                                                          
## [440] 3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER                                                                                                                         
## [441] SEBACIC ACID                                                                                                                                                                           
## [442] (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL                                                                                                                
## [443] (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL                                                                                     
## [444] N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE                                                                                                                                       
## [445] (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC                                                                                                                                   
## [446] 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                                                                                   
## [447] AC-(D)PHE-PRO-BOROLYS-OH                                                                                                                                                               
## [448] AC-(D)PHE-PRO-BOROHOMOLYS-OH                                                                                                                                                           
## [449] AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH                                                                                                                                                     
## [450] N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide                                                                        
## [451] N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine                                                                                                                                         
## [452] 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine                                                                                                
## [453] 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine                                                                                                   
## [454] 3-(4-HYDROXY-PHENYL)PYRUVIC ACID                                                                                                                                                       
## [455] 4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE                                                                     
## [456] (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one                                                                                                                  
## [457] 1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea                                     
## [458] (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                    
## [459] (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                              
## [460] 3,7,3',4'-TETRAHYDROXYFLAVONE                                                                                                                                                          
## [461] (3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE                                                                               
## [462] (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL                                                                                                                     
## [463] 4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE                                                                                                               
## [464] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)BENZYL)GUANIDINE                                                                                                                   
## [465] 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE                                                                                                                                             
## [466] 7-HYDROXY-4-METHYL-3-(2-HYDROXY-ETHYL)COUMARIN                                                                                                                                         
## [467] 4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE                                                                                                                            
## [468] N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide                                                                                                                                      
## [469] 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide                                                                                                                                     
## [470] N-oxo-2-(phenylsulfonylamino)ethanamide                                                                                                                                                
## [471] N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE                                                                                                    
## [472] [[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE                                                                                                             
## [473] N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE                                                                                                                
## [474] N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide                                                                 
## [475] ({[(3E)-2'-OXO-2',7'-DIHYDRO-2,3'-BIINDOL-3(7H)-YLIDENE]AMINO}OXY)ACETIC ACID                                                                                                          
## [476] 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE                                                                                                                                                   
## [477] 5-ACETAMIDO-5,6-DIHYDRO-4-HYDROXY-6-ISOBUTOXY-4H-PYRAN-2-CARBOXYLIC ACID                                                                                                               
## [478] [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID                                                                                                                         
## [479] [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER                                                                                             
## [480] 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE                                                                                              
## [481] N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide                                                                                                                
## [482] 3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide                                                                                                                                    
## [483] L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide                                                                                                                            
## [484] N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                                                                        
## [485] 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE                                                                                                                                       
## [486] 3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE                                                                                                                                    
## [487] 2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID                                                                                                       
## [488] (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol                                                                                           
## [489] {(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate                                                                                                  
## [490] METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE                                                                                                                                                 
## [491] [5-(5-Amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acid                                                                                                 
## [492] 5-AMINO-NAPHTALENE-2-MONOSULFONATE                                                                                                                                                     
## [493] 2-NAPHTHALENESULFONIC ACID                                                                                                                                                             
## [494] 2,6-dicarboxynaphthalene                                                                                                                                                               
## [495] nocodazole                                                                                                                                                                             
## [496] 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID                                                                                                                 
## [497] 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile                                                                                                             
## [498] 4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazole                                                                                                                                  
## [499] 2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline                                                                                                                 
## [500] 2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline                                                                                                                         
## [501] 2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline                                                                                                                
## [502] 6,7-DIMETHOXY-4-[(3R)-3-(2-NAPHTHYLOXY)PYRROLIDIN-1-YL]QUINAZOLINE                                                                                                                     
## [503] 6,7-DIMETHOXY-4-[(3R)-3-(QUINOXALIN-2-YLOXY)PYRROLIDIN-1-YL]QUINAZOLINE                                                                                                                
## [504] 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL                                                                                                                  
## [505] 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL                                                                                                                                
## [506] METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID                                                                                                                                        
## [507] [PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE                                                                                                                          
## [508] [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER                                                                                                      
## [509] Efaproxiral                                                                                                                                                                            
## [510] N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE                                                                                                            
## [511] (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol                                                                                     
## [512] (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol                                                                                 
## [513] N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID                                                                                                   
## [514] N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                                                                                    
## [515] 4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE                                                 
## [516] 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL                                                                                                                           
## [517] N-[(4-methoxyphenyl)sulfonyl]-D-alanine                                                                                                                                                
## [518] 1,3,5-BENZENETRICARBOXYLIC ACID                                                                                                                                                        
## [519] 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER                                                                       
## [520] REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE                                                         
## [521] ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate                                                                                                     
## [522] 3-(4-nitrophenyl)-1H-pyrazole                                                                                                                                                          
## [523] 12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one                                                                                    
## [524] 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine                                                                                                          
## [525] N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE                                                                                                               
## [526] 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE                                                                                                                             
## [527] [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone                                                                                                                        
## [528] 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol                                                                                                                            
## [529] 6-MORPHOLIN-4-YL-9H-PURINE                                                                                                                                                             
## [530] 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE                                                                                                           
## [531] 1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID                                                                                                                                                 
## [532] Azilsartan medoxomil                                                                                                                                                                   
## [533] Temocapril                                                                                                                                                                             
## [534] Gabapentin Enacarbil                                                                                                                                                                   
## [535] Linaclotide                                                                                                                                                                            
## [536] Arbaclofen                                                                                                                                                                             
## [537] Arbaclofen Placarbil                                                                                                                                                                   
## [538] Mirabegron                                                                                                                                                                             
## [539] Teduglutide                                                                                                                                                                            
## [540] Canagliflozin                                                                                                                                                                          
## [541] Hexamethonium                                                                                                                                                                          
## [542] Empagliflozin                                                                                                                                                                          
## [543] Palbociclib                                                                                                                                                                            
## [544] Turoctocog alfa                                                                                                                                                                        
## [545] Chromic chloride                                                                                                                                                                       
## [546] Oxygen                                                                                                                                                                                 
## [547] Ferric pyrophosphate                                                                                                                                                                   
## [548] Viloxazine                                                                                                                                                                             
## [549] Nicorandil                                                                                                                                                                             
## [550] Azelnidipine                                                                                                                                                                           
## [551] Pirlindole                                                                                                                                                                             
## [552] Fimasartan                                                                                                                                                                             
## [553] Trapidil                                                                                                                                                                               
## [554] Alirocumab                                                                                                                                                                             
## [555] Setiptiline                                                                                                                                                                            
## [556] Osimertinib                                                                                                                                                                            
## [557] Levobetaxolol                                                                                                                                                                          
## [558] Magnesium acetate tetrahydrate                                                                                                                                                         
## [559] Potassium perchlorate                                                                                                                                                                  
## [560] Enalaprilat                                                                                                                                                                            
## [561] Magnesium carbonate                                                                                                                                                                    
## [562] Sodium ferric gluconate complex                                                                                                                                                        
## [563] Necitumumab                                                                                                                                                                            
## [564] Insulin Degludec                                                                                                                                                                       
## [565] Butamben                                                                                                                                                                               
## [566] Antithrombin Alfa                                                                                                                                                                      
## [567] Dioxybenzone                                                                                                                                                                           
## [568] Rupatadine                                                                                                                                                                             
## [569] Amifampridine                                                                                                                                                                          
## [570] Equol                                                                                                                                                                                  
## [571] Ribociclib                                                                                                                                                                             
## [572] Depatuxizumab mafodotin                                                                                                                                                                
## [573] Icotinib                                                                                                                                                                               
## [574] Ertugliflozin                                                                                                                                                                          
## [575] Neratinib                                                                                                                                                                              
## [576] Angiotensin II                                                                                                                                                                         
## [577] Abemaciclib                                                                                                                                                                            
## [578] Ulimorelin                                                                                                                                                                             
## [579] Zalutumumab                                                                                                                                                                            
## [580] Oxetacaine                                                                                                                                                                             
## [581] Sparsentan                                                                                                                                                                             
## [582] Daporinad                                                                                                                                                                              
## [583] Tertomotide                                                                                                                                                                            
## [584] Gossypol                                                                                                                                                                               
## [585] Macimorelin                                                                                                                                                                            
## [586] Olmutinib                                                                                                                                                                              
## [587] Zofenopril                                                                                                                                                                             
## [588] Dichlorobenzyl alcohol                                                                                                                                                                 
## [589] Metergoline                                                                                                                                                                            
## [590] Xamoterol                                                                                                                                                                              
## [591] Candesartan                                                                                                                                                                            
## [592] Nonacog beta pegol                                                                                                                                                                     
## [593] Burosumab                                                                                                                                                                              
## [594] Eptinezumab                                                                                                                                                                            
## [595] Fremanezumab                                                                                                                                                                           
## [596] Galcanezumab                                                                                                                                                                           
## 4465 Levels: '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine ...</code></pre>
</div>
<div id="hr-every-condition-affecting-heart-rate" class="section level5">
<h5>HR (Every condition affecting heart rate):</h5>
<pre class="r"><code>keywords=c('heart failure ','stroke','cardiovascular events','myocardial infarction')
categories=c('Cardiovascular Agents','Hypotensive Agents','Cardiac Therapy','Cardiotonic Agents','Cardiac Stimulants Excl. Cardiac Glycosides')
trait='HR'
find_hits_to_vis(keywords,categories,trait,DB_tar,lR)</code></pre>
<pre><code>## $plot</code></pre>
<p><img src="data:image/png;base64,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" width="672" /></p>
<pre><code>## 
## $ranksum.test
## 
##  Wilcoxon rank sum test with continuity correction
## 
## data:  hits_scores and rest_scores
## W = 781250, p-value = 0.001754
## alternative hypothesis: true location shift is not equal to 0
## 
## 
## $student.test
## 
##  Welch Two Sample t-test
## 
## data:  hits_scores and rest_scores
## t = 2.4123, df = 390.46, p-value = 0.01631
## alternative hypothesis: true difference in means is not equal to 0
## 95 percent confidence interval:
##  0.04915727 0.48233247
## sample estimates:
## mean of x mean of y 
##  1.393745  1.128000 
## 
## 
## $hits
##   [1] &quot;Lepirudin&quot;                                         
##   [2] &quot;Alteplase&quot;                                         
##   [3] &quot;Reteplase&quot;                                         
##   [4] &quot;Anistreplase&quot;                                      
##   [5] &quot;Tenecteplase&quot;                                      
##   [6] &quot;Aldesleukin&quot;                                       
##   [7] &quot;Streptokinase&quot;                                     
##   [8] &quot;Calcitriol&quot;                                        
##   [9] &quot;Valsartan&quot;                                         
##  [10] &quot;Ramipril&quot;                                          
##  [11] &quot;Esmolol&quot;                                           
##  [12] &quot;Bortezomib&quot;                                        
##  [13] &quot;Betaxolol&quot;                                         
##  [14] &quot;Sildenafil&quot;                                        
##  [15] &quot;Dofetilide&quot;                                        
##  [16] &quot;Reserpine&quot;                                         
##  [17] &quot;Ticlopidine&quot;                                       
##  [18] &quot;Midodrine&quot;                                         
##  [19] &quot;Bethanidine&quot;                                       
##  [20] &quot;Glimepiride&quot;                                       
##  [21] &quot;Guanadrel&quot;                                         
##  [22] &quot;Pregabalin&quot;                                        
##  [23] &quot;Methyclothiazide&quot;                                  
##  [24] &quot;Milrinone&quot;                                         
##  [25] &quot;Ranolazine&quot;                                        
##  [26] &quot;Methysergide&quot;                                      
##  [27] &quot;Phenytoin&quot;                                         
##  [28] &quot;Anagrelide&quot;                                        
##  [29] &quot;Metoprolol&quot;                                        
##  [30] &quot;Ropinirole&quot;                                        
##  [31] &quot;Isradipine&quot;                                        
##  [32] &quot;Olmesartan&quot;                                        
##  [33] &quot;Theophylline&quot;                                      
##  [34] &quot;Disopyramide&quot;                                      
##  [35] &quot;Lidocaine&quot;                                         
##  [36] &quot;Travoprost&quot;                                        
##  [37] &quot;Morphine&quot;                                          
##  [38] &quot;Ropivacaine&quot;                                       
##  [39] &quot;Bupivacaine&quot;                                       
##  [40] &quot;Ibutilide&quot;                                         
##  [41] &quot;Ethoxzolamide&quot;                                     
##  [42] &quot;Dihydroergotamine&quot;                                 
##  [43] &quot;Tolcapone&quot;                                         
##  [44] &quot;Nitroprusside&quot;                                     
##  [45] &quot;Indomethacin&quot;                                      
##  [46] &quot;Atenolol&quot;                                          
##  [47] &quot;Minoxidil&quot;                                         
##  [48] &quot;Clozapine&quot;                                         
##  [49] &quot;Norepinephrine&quot;                                    
##  [50] &quot;Timolol&quot;                                           
##  [51] &quot;Treprostinil&quot;                                      
##  [52] &quot;Mexiletine&quot;                                        
##  [53] &quot;Dexrazoxane&quot;                                       
##  [54] &quot;Amlodipine&quot;                                        
##  [55] &quot;Triamterene&quot;                                       
##  [56] &quot;Phenylephrine&quot;                                     
##  [57] &quot;Digoxin&quot;                                           
##  [58] &quot;Nimodipine&quot;                                        
##  [59] &quot;Phenylpropanolamine&quot;                               
##  [60] &quot;Nisoldipine&quot;                                       
##  [61] &quot;Ardeparin&quot;                                         
##  [62] &quot;Carbachol&quot;                                         
##  [63] &quot;Pramipexole&quot;                                       
##  [64] &quot;Spironolactone&quot;                                    
##  [65] &quot;Hyoscyamine&quot;                                       
##  [66] &quot;Nitric Oxide&quot;                                      
##  [67] &quot;Bendroflumethiazide&quot;                               
##  [68] &quot;Prazosin&quot;                                          
##  [69] &quot;Imipramine&quot;                                        
##  [70] &quot;Sodium Tetradecyl Sulfate&quot;                         
##  [71] &quot;Chlorpromazine&quot;                                    
##  [72] &quot;Brimonidine&quot;                                       
##  [73] &quot;Nabilone&quot;                                          
##  [74] &quot;Sotalol&quot;                                           
##  [75] &quot;Fosinopril&quot;                                        
##  [76] &quot;Acetyldigitoxin&quot;                                   
##  [77] &quot;Trandolapril&quot;                                      
##  [78] &quot;Carteolol&quot;                                         
##  [79] &quot;Benazepril&quot;                                        
##  [80] &quot;Lamotrigine&quot;                                       
##  [81] &quot;Bosentan&quot;                                          
##  [82] &quot;Cinnarizine&quot;                                       
##  [83] &quot;Fondaparinux&quot;                                      
##  [84] &quot;Propranolol&quot;                                       
##  [85] &quot;Atropine&quot;                                          
##  [86] &quot;Clonidine&quot;                                         
##  [87] &quot;Enalapril&quot;                                         
##  [88] &quot;Doxazosin&quot;                                         
##  [89] &quot;Amiloride&quot;                                         
##  [90] &quot;Ulobetasol&quot;                                        
##  [91] &quot;Labetalol&quot;                                         
##  [92] &quot;Cyclothiazide&quot;                                     
##  [93] &quot;Metaraminol&quot;                                       
##  [94] &quot;Bisoprolol&quot;                                        
##  [95] &quot;Candoxatril&quot;                                       
##  [96] &quot;Nicardipine&quot;                                       
##  [97] &quot;Niacin&quot;                                            
##  [98] &quot;Clofarabine&quot;                                       
##  [99] &quot;Adenosine&quot;                                         
## [100] &quot;Dyphylline&quot;                                        
## [101] &quot;Magnesium sulfate&quot;                                 
## [102] &quot;Latanoprost&quot;                                       
## [103] &quot;Mecamylamine&quot;                                      
## [104] &quot;Verapamil&quot;                                         
## [105] &quot;Epinephrine&quot;                                       
## [106] &quot;Sumatriptan&quot;                                       
## [107] &quot;Losartan&quot;                                          
## [108] &quot;Thioridazine&quot;                                      
## [109] &quot;Moricizine&quot;                                        
## [110] &quot;Moexipril&quot;                                         
## [111] &quot;Phentolamine&quot;                                      
## [112] &quot;Furosemide&quot;                                        
## [113] &quot;Ergotamine&quot;                                        
## [114] &quot;Tizanidine&quot;                                        
## [115] &quot;Nicergoline&quot;                                       
## [116] &quot;Eplerenone&quot;                                        
## [117] &quot;Methazolamide&quot;                                     
## [118] &quot;Tamsulosin&quot;                                        
## [119] &quot;Sufentanil&quot;                                        
## [120] &quot;Apomorphine&quot;                                       
## [121] &quot;Lisinopril&quot;                                        
## [122] &quot;Methoxamine&quot;                                       
## [123] &quot;Nitroglycerin&quot;                                     
## [124] &quot;Isoflurane&quot;                                        
## [125] &quot;Tretinoin&quot;                                         
## [126] &quot;Alprostadil&quot;                                       
## [127] &quot;Hydroflumethiazide&quot;                                
## [128] &quot;Tirofiban&quot;                                         
## [129] &quot;Oxcarbazepine&quot;                                     
## [130] &quot;Phenelzine&quot;                                        
## [131] &quot;Cryptenamine&quot;                                      
## [132] &quot;Perindopril&quot;                                       
## [133] &quot;Candesartan cilexetil&quot;                             
## [134] &quot;Tolazoline&quot;                                        
## [135] &quot;Fenoldopam&quot;                                        
## [136] &quot;Pentoxifylline&quot;                                    
## [137] &quot;Propofol&quot;                                          
## [138] &quot;Acetazolamide&quot;                                     
## [139] &quot;Tadalafil&quot;                                         
## [140] &quot;Dobutamine&quot;                                        
## [141] &quot;Pseudoephedrine&quot;                                   
## [142] &quot;Vardenafil&quot;                                        
## [143] &quot;Alprenolol&quot;                                        
## [144] &quot;Dorzolamide&quot;                                       
## [145] &quot;Eprosartan&quot;                                        
## [146] &quot;Chlorothiazide&quot;                                    
## [147] &quot;Quinapril&quot;                                         
## [148] &quot;Isosorbide Dinitrate&quot;                              
## [149] &quot;Risedronate&quot;                                       
## [150] &quot;Omapatrilat&quot;                                       
## [151] &quot;Bumetanide&quot;                                        
## [152] &quot;Remifentanil&quot;                                      
## [153] &quot;Etacrynic acid&quot;                                    
## [154] &quot;Bimatoprost&quot;                                       
## [155] &quot;Cocaine&quot;                                           
## [156] &quot;Quinidine&quot;                                         
## [157] &quot;Levosimendan&quot;                                      
## [158] &quot;Phenoxybenzamine&quot;                                  
## [159] &quot;Oxymetazoline&quot;                                     
## [160] &quot;Acetylsalicylic acid&quot;                              
## [161] &quot;Naratriptan&quot;                                       
## [162] &quot;Pindolol&quot;                                          
## [163] &quot;Apraclonidine&quot;                                     
## [164] &quot;Telmisartan&quot;                                       
## [165] &quot;Dipyridamole&quot;                                      
## [166] &quot;Dopamine&quot;                                          
## [167] &quot;Gabapentin&quot;                                        
## [168] &quot;Hydrochlorothiazide&quot;                               
## [169] &quot;Levobupivacaine&quot;                                   
## [170] &quot;Trichlormethiazide&quot;                                
## [171] &quot;Felodipine&quot;                                        
## [172] &quot;Irbesartan&quot;                                        
## [173] &quot;Procainamide&quot;                                      
## [174] &quot;Thalidomide&quot;                                       
## [175] &quot;Ergoloid mesylate&quot;                                 
## [176] &quot;Ibuprofen&quot;                                         
## [177] &quot;Nitrendipine&quot;                                      
## [178] &quot;Tocainide&quot;                                         
## [179] &quot;Isoprenaline&quot;                                      
## [180] &quot;Perhexiline&quot;                                       
## [181] &quot;Deslanoside&quot;                                       
## [182] &quot;Iloprost&quot;                                          
## [183] &quot;Pentolinium&quot;                                       
## [184] &quot;Ouabain&quot;                                           
## [185] &quot;Arbutamine&quot;                                        
## [186] &quot;Heparin&quot;                                           
## [187] &quot;Papaverine&quot;                                        
## [188] &quot;Nifedipine&quot;                                        
## [189] &quot;Trimethaphan&quot;                                      
## [190] &quot;Amiodarone&quot;                                        
## [191] &quot;Diazoxide&quot;                                         
## [192] &quot;Carvedilol&quot;                                        
## [193] &quot;Amifostine&quot;                                        
## [194] &quot;Diclofenamide&quot;                                     
## [195] &quot;Bretylium&quot;                                         
## [196] &quot;Halothane&quot;                                         
## [197] &quot;Terazosin&quot;                                         
## [198] &quot;Cilostazol&quot;                                        
## [199] &quot;Arsenic trioxide&quot;                                  
## [200] &quot;Guanethidine&quot;                                      
## [201] &quot;Propafenone&quot;                                       
## [202] &quot;Desflurane&quot;                                        
## [203] &quot;Acebutolol&quot;                                        
## [204] &quot;Flecainide&quot;                                        
## [205] &quot;Captopril&quot;                                         
## [206] &quot;Bromocriptine&quot;                                     
## [207] &quot;Nadolol&quot;                                           
## [208] &quot;Levobunolol&quot;                                       
## [209] &quot;Metipranolol&quot;                                      
## [210] &quot;Aminophylline&quot;                                     
## [211] &quot;Quetiapine&quot;                                        
## [212] &quot;Enoxaparin&quot;                                        
## [213] &quot;Encainide&quot;                                         
## [214] &quot;Paclitaxel&quot;                                        
## [215] &quot;Levodopa&quot;                                          
## [216] &quot;Sevoflurane&quot;                                       
## [217] &quot;Epoprostenol&quot;                                      
## [218] &quot;Clomipramine&quot;                                      
## [219] &quot;Bepridil&quot;                                          
## [220] &quot;Hydralazine&quot;                                       
## [221] &quot;Carbetocin&quot;                                        
## [222] &quot;Pirbuterol&quot;                                        
## [223] &quot;Practolol&quot;                                         
## [224] &quot;Quinethazone&quot;                                      
## [225] &quot;Cilazapril&quot;                                        
## [226] &quot;Saprisartan&quot;                                       
## [227] &quot;Spirapril&quot;                                         
## [228] &quot;Penbutolol&quot;                                        
## [229] &quot;Ephedrine&quot;                                         
## [230] &quot;Mephentermine&quot;                                     
## [231] &quot;Rasagiline&quot;                                        
## [232] &quot;Mibefradil&quot;                                        
## [233] &quot;Drospirenone&quot;                                      
## [234] &quot;Digitoxin&quot;                                         
## [235] &quot;Theobromine&quot;                                       
## [236] &quot;Ajmaline&quot;                                          
## [237] &quot;Amrinone&quot;                                          
## [238] &quot;Aprindine&quot;                                         
## [239] &quot;Oxprenolol&quot;                                        
## [240] &quot;Amyl Nitrite&quot;                                      
## [241] &quot;Erythrityl Tetranitrate&quot;                           
## [242] &quot;Camphor&quot;                                           
## [243] &quot;Platelet Activating Factor&quot;                        
## [244] &quot;Colforsin&quot;                                         
## [245] &quot;Calyculin A&quot;                                       
## [246] &quot;Acetylcholine&quot;                                     
## [247] &quot;N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide&quot;
## [248] &quot;Prenylamine&quot;                                       
## [249] &quot;Debrisoquin&quot;                                       
## [250] &quot;Flunarizine&quot;                                       
## [251] &quot;Celiprolol&quot;                                        
## [252] &quot;Dronedarone&quot;                                       
## [253] &quot;Nebivolol&quot;                                         
## [254] &quot;Enoximone&quot;                                         
## [255] &quot;Nesiritide&quot;                                        
## [256] &quot;Clevidipine&quot;                                       
## [257] &quot;Defibrotide&quot;                                       
## [258] &quot;Lofexidine&quot;                                        
## [259] &quot;Azimilide&quot;                                         
## [260] &quot;Ularitide&quot;                                         
## [261] &quot;Ancrod&quot;                                            
## [262] &quot;Beraprost&quot;                                         
## [263] &quot;Tetrodotoxin&quot;                                      
## [264] &quot;Fibrinolysin&quot;                                      
## [265] &quot;Ibudilast&quot;                                         
## [266] &quot;Rotigotine&quot;                                        
## [267] &quot;Canertinib&quot;                                        
## [268] &quot;Nylidrin&quot;                                          
## [269] &quot;Pentaerythritol Tetranitrate&quot;                      
## [270] &quot;Regadenoson&quot;                                       
## [271] &quot;Vernakalant&quot;                                       
## [272] &quot;Droxidopa&quot;                                         
## [273] &quot;Sulodexide&quot;                                        
## [274] &quot;Dapagliflozin&quot;                                     
## [275] &quot;Dotarizine&quot;                                        
## [276] &quot;Cariporide&quot;                                        
## [277] &quot;Tezosentan&quot;                                        
## [278] &quot;Dalfampridine&quot;                                     
## [279] &quot;Ethanolamine Oleate&quot;                               
## [280] &quot;Xylometazoline&quot;                                    
## [281] &quot;Naphazoline&quot;                                       
## [282] &quot;Nilvadipine&quot;                                       
## [283] &quot;Drotaverine&quot;                                       
## [284] &quot;Danaparoid&quot;                                        
## [285] &quot;Tetryzoline&quot;                                       
## [286] &quot;Dalteparin&quot;                                        
## [287] &quot;Tinzaparin&quot;                                        
## [288] &quot;Tranilast&quot;                                         
## [289] &quot;Bupranolol&quot;                                        
## [290] &quot;Nadroparin&quot;                                        
## [291] &quot;Azilsartan medoxomil&quot;                              
## [292] &quot;Temocapril&quot;                                        
## [293] &quot;Tetraethylammonium&quot;                                
## [294] &quot;Canagliflozin&quot;                                     
## [295] &quot;Obinutuzumab&quot;                                      
## [296] &quot;Inositol nicotinate&quot;                               
## [297] &quot;Indoramin&quot;                                         
## [298] &quot;Ifenprodil&quot;                                        
## [299] &quot;Hexamethonium&quot;                                     
## [300] &quot;Empagliflozin&quot;                                     
## [301] &quot;Tibolone&quot;                                          
## [302] &quot;Xanthinol&quot;                                         
## [303] &quot;Nitrous acid&quot;                                      
## [304] &quot;Eslicarbazepine acetate&quot;                           
## [305] &quot;Cirazoline&quot;                                        
## [306] &quot;Synephrine&quot;                                        
## [307] &quot;Arotinolol&quot;                                        
## [308] &quot;Moxisylyte&quot;                                        
## [309] &quot;Tolfenamic Acid&quot;                                   
## [310] &quot;Nicorandil&quot;                                        
## [311] &quot;Barnidipine&quot;                                       
## [312] &quot;Benidipine&quot;                                        
## [313] &quot;Cilnidipine&quot;                                       
## [314] &quot;Efonidipine&quot;                                       
## [315] &quot;Lacidipine&quot;                                        
## [316] &quot;Manidipine&quot;                                        
## [317] &quot;Niguldipine&quot;                                       
## [318] &quot;Moxonidine&quot;                                        
## [319] &quot;Ubidecarenone&quot;                                     
## [320] &quot;Fimasartan&quot;                                        
## [321] &quot;Trapidil&quot;                                          
## [322] &quot;Pipamperone&quot;                                       
## [323] &quot;Sacubitril&quot;                                        
## [324] &quot;Isosorbide&quot;                                        
## [325] &quot;Enalaprilat&quot;                                       
## [326] &quot;Racepinephrine&quot;                                    
## [327] &quot;Selexipag&quot;                                         
## [328] &quot;Angiotensin II&quot;                                    
## [329] &quot;Tetrahydropalmatine&quot;                               
## [330] &quot;Sarpogrelate&quot;                                      
## [331] &quot;Nitroaspirin&quot;                                      
## [332] &quot;Ketanserin&quot;                                        
## [333] &quot;Rolofylline&quot;                                       
## [334] &quot;Zofenopril&quot;                                        
## [335] &quot;Phosphocreatine&quot;                                   
## [336] &quot;Dihydroergocristine&quot;                               
## [337] &quot;Xamoterol&quot;                                         
## [338] &quot;Candesartan&quot;                                       
## [339] &quot;Dexverapamil&quot;                                      
## [340] &quot;Emopamil&quot;                                          
## [341] &quot;Lomerizine&quot;                                        
## [342] &quot;Tetrandrine&quot;                                       
## [343] &quot;Dexniguldipine&quot;                                    
## 
## $rest_high_score
##   [1] Bivalirudin                                                                                                                                                                            
##   [2] Glucagon recombinant                                                                                                                                                                   
##   [3] Hyaluronidase                                                                                                                                                                          
##   [4] Baclofen                                                                                                                                                                               
##   [5] Oseltamivir                                                                                                                                                                            
##   [6] Reboxetine                                                                                                                                                                             
##   [7] Betazole                                                                                                                                                                               
##   [8] Argatroban                                                                                                                                                                             
##   [9] Gefitinib                                                                                                                                                                              
##  [10] Griseofulvin                                                                                                                                                                           
##  [11] Acetohexamide                                                                                                                                                                          
##  [12] Metocurine Iodide                                                                                                                                                                      
##  [13] Streptozocin                                                                                                                                                                           
##  [14] Zidovudine                                                                                                                                                                             
##  [15] Cimetidine                                                                                                                                                                             
##  [16] Aminocaproic Acid                                                                                                                                                                      
##  [17] Bentiromide                                                                                                                                                                            
##  [18] Azelaic Acid                                                                                                                                                                           
##  [19] Acetohydroxamic Acid                                                                                                                                                                   
##  [20] Zanamivir                                                                                                                                                                              
##  [21] Cisatracurium                                                                                                                                                                          
##  [22] Nizatidine                                                                                                                                                                             
##  [23] Piperazine                                                                                                                                                                             
##  [24] Chloroquine                                                                                                                                                                            
##  [25] Dyclonine                                                                                                                                                                              
##  [26] Chlorpropamide                                                                                                                                                                         
##  [27] Pentosan Polysulfate                                                                                                                                                                   
##  [28] Porfimer sodium                                                                                                                                                                        
##  [29] Diphemanil Methylsulfate                                                                                                                                                               
##  [30] Atracurium besylate                                                                                                                                                                    
##  [31] Modafinil                                                                                                                                                                              
##  [32] Metyrosine                                                                                                                                                                             
##  [33] Proparacaine                                                                                                                                                                           
##  [34] Phenmetrazine                                                                                                                                                                          
##  [35] Tolazamide                                                                                                                                                                             
##  [36] Oxybuprocaine                                                                                                                                                                          
##  [37] Famotidine                                                                                                                                                                             
##  [38] Diethylpropion                                                                                                                                                                         
##  [39] Mepivacaine                                                                                                                                                                            
##  [40] Orlistat                                                                                                                                                                               
##  [41] Benzocaine                                                                                                                                                                             
##  [42] Levocabastine                                                                                                                                                                          
##  [43] Phenacemide                                                                                                                                                                            
##  [44] Proflavine                                                                                                                                                                             
##  [45] Tolbutamide                                                                                                                                                                            
##  [46] Dutasteride                                                                                                                                                                            
##  [47] Diphenylpyraline                                                                                                                                                                       
##  [48] Rescinnamine                                                                                                                                                                           
##  [49] Levetiracetam                                                                                                                                                                          
##  [50] Lomustine                                                                                                                                                                              
##  [51] Finasteride                                                                                                                                                                            
##  [52] Gliquidone                                                                                                                                                                             
##  [53] Lisdexamfetamine                                                                                                                                                                       
##  [54] Panitumumab                                                                                                                                                                            
##  [55] Corticotropin                                                                                                                                                                          
##  [56] Insulin Aspart                                                                                                                                                                         
##  [57] Insulin Detemir                                                                                                                                                                        
##  [58] Insulin Glulisine                                                                                                                                                                      
##  [59] Vecuronium                                                                                                                                                                             
##  [60] Forasartan                                                                                                                                                                             
##  [61] Tasosartan                                                                                                                                                                             
##  [62] Glycodiazine                                                                                                                                                                           
##  [63] Phenazopyridine                                                                                                                                                                        
##  [64] Fencamfamine                                                                                                                                                                           
##  [65] Androstanedione                                                                                                                                                                        
##  [66] Cilastatin                                                                                                                                                                             
##  [67] Alverine                                                                                                                                                                               
##  [68] Isopropamide                                                                                                                                                                           
##  [69] L-Phospholactate                                                                                                                                                                       
##  [70] Hemi-Babim                                                                                                                                                                             
##  [71] M-Cresol                                                                                                                                                                               
##  [72] Beta-D-Glucopyranose Spirohydantoin                                                                                                                                                    
##  [73] 3-Amino-8,9,10-Trihydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                   
##  [74] N-Hydroxy 1n(4-Methoxyphenyl)Sulfonyl-4-(Z,E-N-Methoxyimino)Pyrrolidine-2r-Carboxamide                                                                                                 
##  [75] 2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride                                                                                                             
##  [76] Sucrosofate                                                                                                                                                                            
##  [77] Pentanal                                                                                                                                                                               
##  [78] Dcka, 5,7-Dichlorokynurenic Acid                                                                                                                                                       
##  [79] 7-Hydroxystaurosporine                                                                                                                                                                 
##  [80] Balanol Analog 2                                                                                                                                                                       
##  [81] Carbobenzoxy-Pro-Lys-Phe-Y(Po2)-Ala-Pro-Ome                                                                                                                                            
##  [82] 1-(2-Fluorobenzyl)-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine                                                                                                                         
##  [83] 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid                                                                                                                        
##  [84] S-Acetyl-Cysteine                                                                                                                                                                      
##  [85] Phosphoaminophosphonic Acid Guanylate Ester                                                                                                                                            
##  [86] A Disubstituted Succinyl Caprolactam Hydroxymate Mmp3inhibitor                                                                                                                         
##  [87] Leucine - Reduced Carbonyl                                                                                                                                                             
##  [88] CP-271485                                                                                                                                                                              
##  [89] 4-Carboxycinnamic Acid                                                                                                                                                                 
##  [90] Balanol Analog 8                                                                                                                                                                       
##  [91] SR11254                                                                                                                                                                                
##  [92] EM-1745                                                                                                                                                                                
##  [93] Fluoro-Phosphite Ion                                                                                                                                                                   
##  [94] N-Hydroxy-4-[(4-Methoxylphenyl)Sulfonyl]-2,2-Dimethyl-Hexahydro-1,4-Thiazepine-3(S)-Carboxamide                                                                                        
##  [95] (1n)-4-N-Butoxyphenylsulfonyl-(2r)-N-Hydroxycarboxamido-(4s)-Methanesulfonylamino-Pyrrolidine                                                                                          
##  [96] 2-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Ethanesulfonic Acid                                                                                                                       
##  [97] D-gluconhydroximo-1,5-lactam                                                                                                                                                           
##  [98] 12-Bromododecanoic Acid                                                                                                                                                                
##  [99] (R,R)-2,3-Butanediol                                                                                                                                                                   
## [100] 3,8,9,10-Tetrahydroxy-7-Hydroxymethyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                       
## [101] 3-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic Acid                                                                                                  
## [102] B-nonylglucoside                                                                                                                                                                       
## [103] 4-[3-Oxo-3-(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-Naphthalen-2-Yl)-Propenyl]-Benzoic Acid                                                                                             
## [104] Farnesol                                                                                                                                                                               
## [105] Indirubin-5-Sulphonate                                                                                                                                                                 
## [106] (4s)-5-Fluoro-L-Leucine                                                                                                                                                                
## [107] Fexaramine                                                                                                                                                                             
## [108] Quinonoid 7,8-Tetrahydrobiopterin                                                                                                                                                      
## [109] 2-Deoxy-Glucose-6-Phosphate                                                                                                                                                            
## [110] Balanol Analog 1                                                                                                                                                                       
## [111] 4-Deoxy-Alpha-D-Glucose                                                                                                                                                                
## [112] C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide                                                                                                                                         
## [113] Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide                                                                                                                                         
## [114] 4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide                                               
## [115] Ethylmercurithiosalicylic acid                                                                                                                                                         
## [116] CD564                                                                                                                                                                                  
## [117] alpha-D-glucose-1-phosphate                                                                                                                                                            
## [118] Domoic Acid                                                                                                                                                                            
## [119] Arotinoid acid                                                                                                                                                                         
## [120] Alpha-Aminoisobutyric Acid                                                                                                                                                             
## [121] 8,9,10-Trihydroxy-7-Hydroxymethyl-2-Thioxo-6-Oxa-1,3-Diaza-Spiro[4.5]Decan-4-One                                                                                                       
## [122] Quisqualate                                                                                                                                                                            
## [123] 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid                                                                                                                                 
## [124] N-Acetyl-D-Allosamine                                                                                                                                                                  
## [125] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole                                                                                                                                 
## [126] 2',3'-Dideoxythymidine-5'-Monophosphate                                                                                                                                                
## [127] 3-Oxiran-2ylalanine                                                                                                                                                                    
## [128] Phosphoric Acid Mono-[3-Fluoro-5-(5-Methyl-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Tetrahyro-Furan-2-Ylmethyl] Ester                                                                  
## [129] N-Acetyl-N'-Beta-D-Glucopyranosyl Urea                                                                                                                                                 
## [130] Phosphoric Acid Mono-[3-Amino-5-(5-Methyl-2,4-Dioxo-3,4-Dihydro-2h-Pyrimidin-1-Yl)-Tetrahydro-Furan-2-Ylmethyl] Ester                                                                  
## [131] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole                                                                                                                                 
## [132] 1-Allyl-3-Butyl-8-(N-Acetyl-4-Aminobenzyl)-Xanthine                                                                                                                                    
## [133] Dodecyl-Alpha-D-Maltoside                                                                                                                                                              
## [134] P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate                                                                                                                                         
## [135] C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide                                                                                                                                           
## [136] 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole                                                                                                                                    
## [137] PF-00356231                                                                                                                                                                            
## [138] 5-Methyl-5-(4-Phenoxy-Phenyl)-Pyrimidine-2,4,6-Trione                                                                                                                                  
## [139] 5-Chloro-1h-Indole-2-Carboxylic Acid [1-(4-Fluorobenzyl)-2-(4-Hydroxypiperidin-1yl)-2-Oxoethyl]Amide                                                                                   
## [140] alpha-D-Xylopyranose                                                                                                                                                                   
## [141] (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester                                                                                            
## [142] 2s,4r-4-Methylglutamate                                                                                                                                                                
## [143] BMS184394                                                                                                                                                                              
## [144] 8,9,10-Trihydroxy-7-Hydroxymethyl-3-Methyl-6-Oxa-1,3-Diaza-Spiro[4.5]Decane-2,4-Dione                                                                                                  
## [145] 2-(Acetylamino)-2-Deoxy-6-O-Methyl-Alpha-D-Allopyranose                                                                                                                                
## [146] 3-Tyrosine                                                                                                                                                                             
## [147] L-2-amino-4-methoxy-cis-but-3-enoic acid                                                                                                                                               
## [148] Ribostamycin                                                                                                                                                                           
## [149] Argifin                                                                                                                                                                                
## [150] CRA_1144                                                                                                                                                                               
## [151] 1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose                                                                                                                                        
## [152] 3'-Azido-3'-Deoxythymidine-5'-Monophosphate                                                                                                                                            
## [153] Beta(2-Thienyl)Alanine                                                                                                                                                                 
## [154] Vanoxerine                                                                                                                                                                             
## [155] 12-Hydroxydodecanoic Acid                                                                                                                                                              
## [156] Phosphomethylphosphonic Acid-Guanylate Ester                                                                                                                                           
## [157] Dihydrolipoic Acid                                                                                                                                                                     
## [158] N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide                                                                         
## [159] P1-(5'-Adenosyl)P5-(5'-(3'azido-3'-Deoxythymidyl))Pentaphosphate                                                                                                                       
## [160] N-Butyl-11-[(7r,8r,9s,13s,14s,17s)-3,17-Dihydroxy-13-Methyl-7,8,9,11,12,13,14,15,16,17-Decahydro-6h-Cyclopenta[a]Phenanthren-7-Yl]-N-Methylundecanamide                                
## [161] (2r,3r,4s,5r)-2-Acetamido-3,4-Dihydroxy-5-Hydroxymethyl-Piperidinium                                                                                                                   
## [162] 5-Alpha-Androstane-3-Beta,17beta-Diol                                                                                                                                                  
## [163] Biopterin                                                                                                                                                                              
## [164] 2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid                                                                                                                                           
## [165] 1-Deoxy-1-Methoxycarbamido-Beta-D-Gluco-2-Heptulopyranosonamide                                                                                                                        
## [166] 4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol                                                                                  
## [167] 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid                                                                                                                                      
## [168] 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium                                                                                                     
## [169] Balanol                                                                                                                                                                                
## [170] Lysophosphotidylserine                                                                                                                                                                 
## [171] 1-Benzyl-3-(4-Methoxy-Benzenesulfonyl)-6-Oxo-Hexahydro-Pyrimidine-4-Carboxylic Acid Hydroxyamide                                                                                       
## [172] S-Hydroxymethyl Glutathione                                                                                                                                                            
## [173] Heptulose-2-Phosphate                                                                                                                                                                  
## [174] N-Hydroxy-1-(4-Methoxyphenyl)Sulfonyl-4-Benzyloxycarbonyl-Piperazine-2-Carboxamide                                                                                                     
## [175] (Hydroxyethyloxy)Tri(Ethyloxy)Octane                                                                                                                                                   
## [176] 4-(1-Amino-1-Carboxy-Ethyl)-Benzoic Acid                                                                                                                                               
## [177] 2-deoxy-2-fluoro-a-D-glucose                                                                                                                                                           
## [178] N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea                                                                                                                                                
## [179] 6-hydroxydopa quinone                                                                                                                                                                  
## [180] Argadin                                                                                                                                                                                
## [181] Allosamizoline                                                                                                                                                                         
## [182] 2-[2-(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)Ethyl]-4-(4'-Ethoxy-1,1'-Biphenyl-4-Yl)-4-Oxobutanoic Acid                                                                                
## [183] Naphthalene Trisulfonate                                                                                                                                                               
## [184] R-2-{[4'-Methoxy-(1,1'-Biphenyl)-4-Yl]-Sulfonyl}-Amino-6-Methoxy-Hex-4-Ynoic Acid                                                                                                      
## [185] 4'-Hydroxyflavanone                                                                                                                                                                    
## [186] Mercuric iodide                                                                                                                                                                        
## [187] 1-Deoxy-1-Acetylamino-Beta-D-Gluco-2-Heptulopyranosonamide                                                                                                                             
## [188] Gluconolactone                                                                                                                                                                         
## [189] (2R)-({4-[AMINO(IMINO)METHYL]PHENYL}AMINO){5-ETHOXY-2-FLUORO-3-[(3R)-TETRAHYDROFURAN-3-YLOXY]PHENYL}ACETICACID                                                                         
## [190] N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE                                                                    
## [191] 3-({1-[3-CARBAMIMIDOYL-1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-PROPYLCARBAMOYL]-2-METHYL-BUTYLSULFAMOYL}-METHYL)-BENZOIC ACID                                                              
## [192] 2-[2-ETHANESULFONYLAMINO-3-(5-PROPOXY-1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIMIDOYL-BENZYLAMIDE)                                                         
## [193] Cycloleucine                                                                                                                                                                           
## [194] 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID                                                                                                                
## [195] 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID                                                                                                                  
## [196] 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID                                                                                                              
## [197] 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID                                                                                                                
## [198] (1S,2S,3R,4S,5S)-2,3,4-TRIHYDROXY-5-(HYDROXYMETHYL)CYCLOHEXYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE                                                                              
## [199] Coumarin                                                                                                                                                                               
## [200] TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE                                                                        
## [201] 2-(3-CHLORO-6-{[2,2-DIFLUORO-2-(1-OXIDOPYRIDIN-2-YL)ETHYL]AMINO}-1-OXIDOPYRIDIN-2-YL)-N-[1-(3-CHLOROPHENYL)ETHYL]ACETAMIDE                                                             
## [202] N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA                                                                     
## [203] 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE(BETA1-4)-2-ACETAMIDO-1,6-ANHYDRO-3-O-[(R)-1-CARBOXYETHYL]-2-DEOXY-BETA-D-GLUCOPYRANOSE-L-ALANYL-GAMMA-D-GLUTAMYL-MESO-DIAMINOPIMELYL-D-ALANINE
## [204] 2-[2-ETHANESULFONYLAMINO-3-(1H-INDOL-3-YL)-PROPIONYLAMINO]-PENTANEDIOIC ACID 5-AMIDE 1-(4-CARBAMIM IDOYL-BENZYLAMIDE)                                                                  
## [205] N-[1-(4-CARBAMIMIDOYL-BENZYLCARBAMOYL)-3-METHYLSULFANYL-PROPYL]-3-HYDROXY-2-PROPOXYAMINO-BUTYRAMID                                                                                     
## [206] 1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                                                                      
## [207] 1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE                                                                                                                   
## [208] ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE                                                                                                                                      
## [209] Cediranib                                                                                                                                                                              
## [210] Lefradafiban                                                                                                                                                                           
## [211] Dapoxetine                                                                                                                                                                             
## [212] Vapreotide                                                                                                                                                                             
## [213] Ximelagatran                                                                                                                                                                           
## [214] Altropane                                                                                                                                                                              
## [215] Lesopitron                                                                                                                                                                             
## [216] SGS-742                                                                                                                                                                                
## [217] XEN2174                                                                                                                                                                                
## [218] REV131                                                                                                                                                                                 
## [219] SGS518                                                                                                                                                                                 
## [220] MF101                                                                                                                                                                                  
## [221] Matuzumab                                                                                                                                                                              
## [222] NN344                                                                                                                                                                                  
## [223] AT1391                                                                                                                                                                                 
## [224] XL844                                                                                                                                                                                  
## [225] GMX1777                                                                                                                                                                                
## [226] TP-508                                                                                                                                                                                 
## [227] MN-305                                                                                                                                                                                 
## [228] HZT-501                                                                                                                                                                                
## [229] Rindopepimut                                                                                                                                                                           
## [230] Amibegron                                                                                                                                                                              
## [231] Tifuvirtide                                                                                                                                                                            
## [232] AVI-4557                                                                                                                                                                               
## [233] Pozanicline                                                                                                                                                                            
## [234] R667                                                                                                                                                                                   
## [235] Pradefovir Mesylate                                                                                                                                                                    
## [236] Pelitinib                                                                                                                                                                              
## [237] Brivaracetam                                                                                                                                                                           
## [238] Naluzotan                                                                                                                                                                              
## [239] Ramucirumab                                                                                                                                                                            
## [240] FX06                                                                                                                                                                                   
## [241] Flovagatran                                                                                                                                                                            
## [242] CYT006-AngQb                                                                                                                                                                           
## [243] CNS-5161                                                                                                                                                                               
## [244] RI 624                                                                                                                                                                                 
## [245] Pegdinetanib                                                                                                                                                                           
## [246] Contulakin-G                                                                                                                                                                           
## [247] RAF-265                                                                                                                                                                                
## [248] Obeticholic acid                                                                                                                                                                       
## [249] PRX-07034                                                                                                                                                                              
## [250] Olaratumab                                                                                                                                                                             
## [251] SUVN-502                                                                                                                                                                               
## [252] Solabegron                                                                                                                                                                             
## [253] Hyaluronidase (Human Recombinant)                                                                                                                                                      
## [254] Tezampanel                                                                                                                                                                             
## [255] CHGN111                                                                                                                                                                                
## [256] Xaliproden                                                                                                                                                                             
## [257] Armodafinil                                                                                                                                                                            
## [258] Semaxanib                                                                                                                                                                              
## [259] Fradafiban                                                                                                                                                                             
## [260] Repinotan                                                                                                                                                                              
## [261] Robalzotan                                                                                                                                                                             
## [262] Cetilistat                                                                                                                                                                             
## [263] Reslizumab                                                                                                                                                                             
## [264] Mepolizumab                                                                                                                                                                            
## [265] Casopitant                                                                                                                                                                             
## [266] Denosumab                                                                                                                                                                              
## [267] Vilazodone                                                                                                                                                                             
## [268] Dabigatran etexilate                                                                                                                                                                   
## [269] Methacholine                                                                                                                                                                           
## [270] Fospropofol                                                                                                                                                                            
## [271] Bufuralol                                                                                                                                                                              
## [272] Gavestinel                                                                                                                                                                             
## [273] Lanreotide                                                                                                                                                                             
## [274] methyl L-phenylalaninate                                                                                                                                                               
## [275] D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}-1-(chloroacetyl)butyl]-L-prolinamide                                                                                             
## [276] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide                                                                                                
## [277] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide                                                                                                 
## [278] 4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YLAMINO]-3-(1H-BENZIMIDAZOL-2-YL)-6-CHLOROQUINOLIN-2(1H)-ONE                                                                                          
## [279] N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                            
## [280] N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                             
## [281] N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE                                                                                                                    
## [282] 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE                                                                                                                                          
## [283] 6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                                                            
## [284] 6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID                                                                                                            
## [285] N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                                                                 
## [286] 1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE                                                                         
## [287] N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE                                                                                                     
## [288] 1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                              
## [289] 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol                                                                                            
## [290] 1-[4-(hydroxymethyl)phenyl]guanidine                                                                                                                                                   
## [291] D-leucyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                              
## [292] D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                        
## [293] 1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                                     
## [294] 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine                                                                                                                     
## [295] N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide                                                                                                                          
## [296] 4-(6-HYDROXY-BENZO[D]ISOXAZOL-3-YL)BENZENE-1,3-DIOL                                                                                                                                    
## [297] 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide                                                                            
## [298] N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide                                                                                                                          
## [299] 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                       
## [300] 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide                                                                                         
## [301] (2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine                                                                                                         
## [302] 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                                                         
## [303] D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide                                                                                                                                       
## [304] D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide                                                                                                                         
## [305] (3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline                                                                                                                          
## [306] 3-Hydroxypropyl 3-[(7-carbamimidoyl-1-naphthyl)carbamoyl]benzenesulfonate                                                                                                              
## [307] (1R)-2-{[AMINO(IMINO)METHYL]AMINO}-1-{4-[(4R)-4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL]PHENYL}ETHYL NICOTINATE                                                                        
## [308] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE                                                                                                          
## [309] (1S,5S,7R)-N~7~-(BIPHENYL-4-YLMETHYL)-N~3~-HYDROXY-6,8-DIOXA-3-AZABICYCLO[3.2.1]OCTANE-3,7-DICARBOXAMIDE                                                                               
## [310] D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide                                                                                                                                        
## [311] 3-Fluoro-4-{[(2R)-2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)acetyl]amino}benzoic acid                                                                         
## [312] 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL                                                                                                                                                    
## [313] 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE                                                                                                                              
## [314] 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID                                                                                                                    
## [315] (3aS,4R,9bR)-2,2-difluoro-4-(4-hydroxyphenyl)-6-(methoxymethyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[c]chromen-8-ol                                                                       
## [316] (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL                                                                                                                                
## [317] 2-(cyclohexylamino)benzoic acid                                                                                                                                                        
## [318] 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                                                          
## [319] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE                                                                                                                
## [320] 6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER                                                                                         
## [321] 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE                                                                                                 
## [322] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE                                                                                                                   
## [323] (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE                                                                                              
## [324] beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide                                                                                                                                      
## [325] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                                                                  
## [326] (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide                                                                                                   
## [327] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide                                                                                                      
## [328] 2-[2-(4-CHLORO-PHENYLSULFANYL)-ACETYLAMINO]-3-(4-GUANIDINO-PHENYL)-PROPIONAMIDE                                                                                                        
## [329] 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID                                                                                                                                              
## [330] N4-(N,N-DIPHENYLCARBAMOYL)-AMINOGUANIDINE                                                                                                                                              
## [331] (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE                                                                                           
## [332] N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE                                                                                             
## [333] (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide                                                                                                       
## [334] 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA                                                                                                                           
## [335] D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide                                                                                                                                        
## [336] D-phenylalanyl-N-benzyl-L-prolinamide                                                                                                                                                  
## [337] 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE                                                                                                                          
## [338] N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE                                                                      
## [339] [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)pyrimidin-2-yl}amino)phenyl]acetonitrile                                                                                  
## [340] N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide                                                                                                                          
## [341] 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide                                                                                                                                 
## [342] 2-(4-HYDROXY-5-PHENYL-1H-PYRAZOL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE                                                                                                               
## [343] (2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE                                                           
## [344] N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE                                                                                                                       
## [345] (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL                                                                                         
## [346] 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA                                                                                                  
## [347] N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE                                                                                  
## [348] (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE                                                                                                  
## [349] [2'-HYDROXY-3'-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-BIPHENYL-3-YLMETHYL]-UREA                                                                                                               
## [350] N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide                                                                                                             
## [351] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE                                                                    
## [352] 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHENESULFONAMIDE                                                                    
## [353] N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE                                                                                                        
## [354] 3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid                                                                             
## [355] 4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE                                                                                 
## [356] 2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine                                                                                                    
## [357] 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE                                                                                   
## [358] 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA                                                                                                                           
## [359] 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID                                                                                             
## [360] 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide                                                                                         
## [361] N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE                                                                             
## [362] N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE                                                                                                     
## [363] 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL                                                                                                                           
## [364] 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL                                                                                                                                                
## [365] 2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER                                                                                                    
## [366] 5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID)                                                                                                                              
## [367] N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine                                                                                                   
## [368] 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YL)-UREIDO]-N-METHYL-3-PHENYL-PROPIONAMIDE                                                                                                        
## [369] 1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE                                                                                                                                    
## [370] 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine                                                                                                                                          
## [371] 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine                                                                                                                                          
## [372] 4-TERT-BUTYLBENZENESULFONIC ACID                                                                                                                                                       
## [373] N-(biphenyl-4-ylsulfonyl)-D-leucine                                                                                                                                                    
## [374] 3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione                                                                                        
## [375] 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE                                                                                                             
## [376] 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione                                                                                          
## [377] 3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                                                                      
## [378] 4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE                                                                                                            
## [379] 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one                                                                                                      
## [380] 1-(2-{[(6-AMINO-2-METHYLPYRIDIN-3-YL)METHYL]AMINO}ETHYL)-6-CHLORO-3-[(2,2-DIFLUORO-2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL                                                  
## [381] 6-CHLORO-1-(2-{[(5-CHLORO-1-BENZOTHIEN-3-YL)METHYL]AMINO}ETHYL)-3-[(2-PYRIDIN-2-YLETHYL)AMINO]-1,4-DIHYDROPYRAZIN-2-OL                                                                 
## [382] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE                                                                                                                   
## [383] N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE                                                                                                
## [384] 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one                                                                                                     
## [385] N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide                                                                                                     
## [386] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-6-PYRIDINYL)METHYL]ACETAMIDE                                                              
## [387] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE                                                     
## [388] 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE                                                            
## [389] N-HYDROXY-2(R)-[[(4-METHOXYPHENYL)SULFONYL](3-PICOLYL)AMINO]-3-METHYLBUTANAMIDE HYDROCHLORIDE                                                                                          
## [390] S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE                                                                                                                         
## [391] N,N-DIMETHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                    
## [392] 3-phenyl-5-(1H-pyrazol-3-yl)isoxazole                                                                                                                                                  
## [393] PHENYL-5-(1H-PYRAZOL-3-YL)-1,3-THIAZOLE                                                                                                                                                
## [394] 4-{[4-(4-fluoro-3-methylphenyl)-1,3-thiazol-2-yl]amino}-2-hydroxybenzoic acid                                                                                                          
## [395] N-METHYL(5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                        
## [396] (5-(PYRIDIN-3-YL)FURAN-2-YL)METHANAMINE                                                                                                                                                
## [397] 4,4'-DIPYRIDYL DISULFIDE                                                                                                                                                               
## [398] 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one                                                                                          
## [399] 3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER                                                                                                                         
## [400] SEBACIC ACID                                                                                                                                                                           
## [401] (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL                                                                                                                
## [402] (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL                                                                                     
## [403] N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE                                                                                                                                       
## [404] (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC                                                                                                                                   
## [405] 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE                                                                                                                                   
## [406] AC-(D)PHE-PRO-BOROLYS-OH                                                                                                                                                               
## [407] AC-(D)PHE-PRO-BOROHOMOLYS-OH                                                                                                                                                           
## [408] AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH                                                                                                                                                     
## [409] N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide                                                                        
## [410] N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine                                                                                                                                         
## [411] 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine                                                                                                
## [412] 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine                                                                                                   
## [413] 3-(4-HYDROXY-PHENYL)PYRUVIC ACID                                                                                                                                                       
## [414] 4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE                                                                     
## [415] (9aS)-4-bromo-9a-butyl-7-hydroxy-1,2,9,9a-tetrahydro-3H-fluoren-3-one                                                                                                                  
## [416] 1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea                                     
## [417] (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                    
## [418] (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE                                                              
## [419] (3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE                                                                               
## [420] (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL                                                                                                                     
## [421] 4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE                                                                                                               
## [422] (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)BENZYL)GUANIDINE                                                                                                                   
## [423] 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE                                                                                                                                             
## [424] 7-HYDROXY-4-METHYL-3-(2-HYDROXY-ETHYL)COUMARIN                                                                                                                                         
## [425] 4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE                                                                                                                            
## [426] N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide                                                                                                                                      
## [427] 2-[(4-fluorophenyl)sulfonylamino]-N-oxo-ethanamide                                                                                                                                     
## [428] N-oxo-2-(phenylsulfonylamino)ethanamide                                                                                                                                                
## [429] N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE                                                                                                    
## [430] [[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE                                                                                                             
## [431] N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE                                                                                                                
## [432] N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide                                                                 
## [433] ({[(3E)-2'-OXO-2',7'-DIHYDRO-2,3'-BIINDOL-3(7H)-YLIDENE]AMINO}OXY)ACETIC ACID                                                                                                          
## [434] 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE                                                                                                                                                   
## [435] 5-ACETAMIDO-5,6-DIHYDRO-4-HYDROXY-6-ISOBUTOXY-4H-PYRAN-2-CARBOXYLIC ACID                                                                                                               
## [436] [4-(4-PHENYL-PIPERIDIN-1-YL)-BENZENESULFONYLAMINO]-ACETIC ACID                                                                                                                         
## [437] [2-(5-MERCAPTO-[1,3,4]THIADIAZOL-2-YLCARBAMOYL)-1-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER                                                                                             
## [438] 2-[3-(5-MERCAPTO-[1,3,4]THIADIAZOL-2YL)-UREIDO]-N-METHYL-3-PENTAFLUOROPHENYL-PROPIONAMIDE                                                                                              
## [439] N~2~-(biphenyl-4-ylsulfonyl)-N-hydroxy-N~2~-(2-hydroxyethyl)glycinamide                                                                                                                
## [440] 3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide                                                                                                                                    
## [441] L-alanyl-N-[(1S,2R)-1-benzyl-2-hydroxypropyl]-L-alaninamide                                                                                                                            
## [442] N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                                                                        
## [443] 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE                                                                                                                                       
## [444] 3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE                                                                                                                                    
## [445] 2-[4-({[(3,5-DICHLOROPHENYL)AMINO]CARBONYL}AMINO)PHENOXY]-2-METHYLPROPANOIC ACID                                                                                                       
## [446] (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol                                                                                           
## [447] {(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate                                                                                                  
## [448] METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE                                                                                                                                                 
## [449] METHOXYUNDECYLPHOSPHINIC ACID                                                                                                                                                          
## [450] [5-(5-Amino-1H-pyrrolo[3,2-b]pyridin-2-yl)-6-hydroxy-3'-nitro-3-biphenylyl]acetic acid                                                                                                 
## [451] 5-AMINO-NAPHTALENE-2-MONOSULFONATE                                                                                                                                                     
## [452] 2-NAPHTHALENESULFONIC ACID                                                                                                                                                             
## [453] 2,6-dicarboxynaphthalene                                                                                                                                                               
## [454] nocodazole                                                                                                                                                                             
## [455] 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID                                                                                                                 
## [456] 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile                                                                                                             
## [457] 4,5-bis(4-methoxyphenyl)-2-thiophen-2-yl-1H-imidazole                                                                                                                                  
## [458] 2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline                                                                                                                 
## [459] 2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline                                                                                                                         
## [460] 2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline                                                                                                                
## [461] 6,7-DIMETHOXY-4-[(3R)-3-(2-NAPHTHYLOXY)PYRROLIDIN-1-YL]QUINAZOLINE                                                                                                                     
## [462] 6,7-DIMETHOXY-4-[(3R)-3-(QUINOXALIN-2-YLOXY)PYRROLIDIN-1-YL]QUINAZOLINE                                                                                                                
## [463] 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL                                                                                                                  
## [464] 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL                                                                                                                                
## [465] METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID                                                                                                                                        
## [466] [PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE                                                                                                                          
## [467] [[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER                                                                                                      
## [468] Efaproxiral                                                                                                                                                                            
## [469] N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE                                                                                                            
## [470] (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol                                                                                     
## [471] (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol                                                                                 
## [472] N-[[2-METHYL-4-HYDROXYCARBAMOYL]BUT-4-YL-N]-BENZYL-P-[PHENYL]-P-[METHYL]PHOSPHINAMID                                                                                                   
## [473] N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine                                                                                                    
## [474] 4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE                                                 
## [475] 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL                                                                                                                           
## [476] N-[(4-methoxyphenyl)sulfonyl]-D-alanine                                                                                                                                                
## [477] 1,3,5-BENZENETRICARBOXYLIC ACID                                                                                                                                                        
## [478] 2-(2-{2-[(BIPHENYL-4-YLMETHYL)-AMINO]-3-MERCAPTO-PENTANOYLAMINO}-ACETYLAMINO)-3-METHYL-BUTYRIC ACID METHYL ESTER                                                                       
## [479] REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE                                                         
## [480] ethyl 3-[(E)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1H-indole-2-carboxylate                                                                                                     
## [481] 3-(4-nitrophenyl)-1H-pyrazole                                                                                                                                                          
## [482] 12-(2-hydroxyethyl)-2-(1-methylethoxy)-13,14-dihydronaphtho[2,1-a]pyrrolo[3,4-c]carbazol-5(12H)-one                                                                                    
## [483] 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine                                                                                                          
## [484] N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE                                                                                                               
## [485] 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE                                                                                                                             
## [486] [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone                                                                                                                        
## [487] 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol                                                                                                                            
## [488] 6-MORPHOLIN-4-YL-9H-PURINE                                                                                                                                                             
## [489] 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE                                                                                                           
## [490] 1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID                                                                                                                                                 
## [491] Metiamide                                                                                                                                                                              
## [492] Roxatidine acetate                                                                                                                                                                     
## [493] Gabapentin Enacarbil                                                                                                                                                                   
## [494] Linaclotide                                                                                                                                                                            
## [495] Arbaclofen                                                                                                                                                                             
## [496] Arbaclofen Placarbil                                                                                                                                                                   
## [497] Mirabegron                                                                                                                                                                             
## [498] Teduglutide                                                                                                                                                                            
## [499] Turoctocog alfa                                                                                                                                                                        
## [500] Chromic chloride                                                                                                                                                                       
## [501] Oxygen                                                                                                                                                                                 
## [502] Ferric pyrophosphate                                                                                                                                                                   
## [503] Viloxazine                                                                                                                                                                             
## [504] Azelnidipine                                                                                                                                                                           
## [505] Pirlindole                                                                                                                                                                             
## [506] Alirocumab                                                                                                                                                                             
## [507] Setiptiline                                                                                                                                                                            
## [508] Osimertinib                                                                                                                                                                            
## [509] Levobetaxolol                                                                                                                                                                          
## [510] Magnesium acetate tetrahydrate                                                                                                                                                         
## [511] Potassium perchlorate                                                                                                                                                                  
## [512] Magnesium carbonate                                                                                                                                                                    
## [513] Sodium ferric gluconate complex                                                                                                                                                        
## [514] Necitumumab                                                                                                                                                                            
## [515] Insulin Degludec                                                                                                                                                                       
## [516] Butamben                                                                                                                                                                               
## [517] Antithrombin Alfa                                                                                                                                                                      
## [518] Dioxybenzone                                                                                                                                                                           
## [519] Rupatadine                                                                                                                                                                             
## [520] Amifampridine                                                                                                                                                                          
## [521] Equol                                                                                                                                                                                  
## [522] Depatuxizumab mafodotin                                                                                                                                                                
## [523] Icotinib                                                                                                                                                                               
## [524] Ertugliflozin                                                                                                                                                                          
## [525] Neratinib                                                                                                                                                                              
## [526] Ulimorelin                                                                                                                                                                             
## [527] Zalutumumab                                                                                                                                                                            
## [528] Oxetacaine                                                                                                                                                                             
## [529] Sparsentan                                                                                                                                                                             
## [530] Daporinad                                                                                                                                                                              
## [531] Tertomotide                                                                                                                                                                            
## [532] Gossypol                                                                                                                                                                               
## [533] Macimorelin                                                                                                                                                                            
## [534] Olmutinib                                                                                                                                                                              
## [535] Dichlorobenzyl alcohol                                                                                                                                                                 
## [536] Metergoline                                                                                                                                                                            
## [537] Nonacog beta pegol                                                                                                                                                                     
## [538] Burosumab                                                                                                                                                                              
## [539] Eptinezumab                                                                                                                                                                            
## [540] Fremanezumab                                                                                                                                                                           
## [541] Galcanezumab                                                                                                                                                                           
## 4136 Levels: '5'-O-(N-(L-Alanyl)-Sulfamoyl)Adenosine ...</code></pre>
</div>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
